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Abstract 
MicroRNAs are non-coding, negative regulators of gene expression which act 
either by repressing protein translation or via mRNA degradation. They have been shown 
to play biologically significant roles in various processes like cell differentiation, 
proliferation, apoptosis and development in humans as well as other model organisms. 
miRNAs direct the wide repertoire of normal biological processes by down-regulating the 
expression of their target genes. Deregulation of miRNAs has been shown to be 
associated with various human diseases such as cancer. Although several oncomirs have 
been identified to date, functional studies to understand their mode of action have been 
hampered by the lack of tools to accurately predict and validate the gene networks 
repressed. This thesis aims to address this issue by using a combination of high-
throughput technologies and subsequent experimental validation using cell based assays.  
Chapter two takes a closer look at miR-182, which at the time this study was 
initiated was shown to be deregulated in several cancers, but its biological role and target 
networks in the context of breast cancer was relatively unknown. We used biotinylated 
synthetic miRNA to pull-down its endogenous mRNA targets to reveal that it disrupts 
key pathways underlying tumorigenesis, and subsequently confirmed its clinical 
relevance in human breast cancers. Chapter three takes a similar approach to identify the 
biologically relevant targets of miR-139, a novel breast cancer oncomir. The role of miR-
139 is more akin to being a potential tumour suppressor supporting our data and 
published datasets where its expression is frequently downregulated in human breast 
cancers. In Chapter four, we take a more global approach where using next-generation 
sequencing technology we identify miRNAs which show dynamic expression across 
various phases of the cell cycle, another biological process typically disrupted during 
tumorigenesis. Using online datasets, we try to identify if there is a significant correlation 
between these oscillating miRNAs and cancer, and also possible regulators of their 
expression. 
These approaches facilitate the identification of novel oncomirs and subsequent 
characterization of their biologically relevant targets using context-dependent cell 
ii
models. In addition these studies show that these miRNAs achieve their functional output 
by targeting multiple genes, which belong to the same pathway, adding to the existing 
notion of concomitant suppression. Together, this leads to a better understanding of the 
miRNA-mediated disruption to specific molecular processes underlying tumorigenesis. 
Such studies are imperative to explore the potential of oncomirs as possible prognostic, 
diagnostic or therapeutic tools. 
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1. Introduction 
1.1 Non-coding RNAs 
 The central dogma of molecular biology is that genetic information, stored in 
DNA is translated through to protein via RNA molecules. Since the 1960s, when studies 
first described the genetic code, it has been assumed that all genes encode proteins and 
collectively they were sufficient to cover all functions related to the cell, organismal 
development and homeostasis [1]. More recently, this theory has been refined to 
accommodate the findings that some genes can encode non-coding functional RNAs as 
an alternative to proteins. [2]. Indeed it is becoming apparent that more complex genomes 
e.g. human and mouse have similar number of proteins as Caenorhabditis elegans 
(C.elegans) and biological complexity correlates more with the size of the non-protein 
coding fraction of the genome [3].  
 Global analysis of the mouse genome revealed over 35000 non-coding transcripts 
mapping to ~10000 distinct loci [4] and ~98% of the human genome could transcribe 
long and short non-protein coding RNAs (ncRNAs) [5]. Several studies have now shown 
the regulatory potential of ncRNAs in key cellular processes underlying normal 
development and diseases in complex organisms [6, 7]. ncRNAs can be classified based 
on their size and functions as outlined in Table 1  
 
Table 1.1: Known sub-classes of ncRNAs and their characteristics 
Name Characteristics References 
Small interfering RNAs 
(siRNAs) 
~21-22nt long, Dicer dependant biogenesis, 
associates with Argonaute (AGO) proteins to 
bring about sequence specific silencing of 
genes. Involved in gene and transposon 
regulation and viral defense 
[8-10] 
microRNAs (miRNAs) Small RNAs ~21nt long (discussed in detail 
later) 
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PIWI-interacting RNAs 
(piRNAs) 
24-30 nt long, Dicer independent, associate 
with the PIWI clade of AGO proteins and 
known functions include silencing transposons 
and DNA methylation 
[9, 10] 
Transcription initiation 
RNAs (tiRNAs) 
~18nt long, map within -60 to +120nt of 
transcription start sites (TSSs), could be 
involved in chromatin modification and 
regulation of protein recruitment in 
transcription initiation 
[11] 
Small nucleolar RNAs 
(snoRNAs) 
Variable length, involved in guiding rRNA 
methylation and pseudouridylation. Targets 
besides rRNAs have recently been discovered, 
suggesting gene regulatory functions  
[12-14] 
Promoter-associated 
small RNAs (PASRs) 
~20-200nt, capped and found at the 5’ regions 
of protein/non-coding genes, strongly 
associated with highly expressed genes and 
regions of RNAPII binding. 
[11, 15] 
Transcription-start site 
associated RNAs 
(TSSa-RNAs) 
~20–90nt, found within -250 to +50 of TSSs, 
strongly associated with highly expressed 
genes and regions of RNAPII binding. 
[11, 16] 
Promoter upstream 
transcripts (PROMPTs) 
<200nts, found within -500 to -5kb of TSSs, 
transcription is bidirectional and is associated 
with gene activity. May have gene regulatory 
functions.  
[17] 
Long non-coding RNAs 
(lncRNAs) 
200nt – 100kb in length with functional roles in 
development through genetic and molecular 
processes including epigenetic regulation, 
cellular differentiation, cell cycle control, 
transcription, splicing and translation 
[18-20] 
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1.2 miRNAs 
 miRNAs are conserved, short non-coding RNAs, ~ 22 nucleotides long with 
regulatory functions across several organisms [21]. lin-4 was the first miRNA to be 
discovered in C. elegans and was thought to be specific to this species [22, 23] . The 
second miRNA let-7 was discovered in C. elegans but was found to be conserved 
amongst worms, flies and humans [24-26]. This discovery led to an extensive search for 
miRNAs across different organisms and in the last decade several studies have addressed 
the questions of miRNA biogenesis, target recognition principles, identification of 
miRNA targets, miRNA expression profiling techniques and their roles in development 
and diseases. An overview of each of these topics will be presented in this introduction 
chapter. Since the focus of the thesis is to study the role of miRNAs in human diseases, 
all subsequent topics are discussed in the context of mammalian miRNAs unless 
otherwise specified. 
 
1.2.1 miRNA biogenesis 
 The canonical biogenesis pathway for most animal miRNAs is summarized in 
Figure 1.1. Precursor molecules (pri-miRNAs) can originate either from full-length 
transcripts or spliced by-products deriving from intronic regions of protein coding genes. 
Multiple pri-miRNAs can be encoded in an individual transcript and are transcribed by 
RNA Polymerase II [8, 27]. miRNA biogenesis begins with the cleavage of the hairpin 
pri-miRNAs at the base by the DiGeorge syndrome critical region gene 8 (DGCR8) 
/Drosha (family of RNAse III) complex. DGCR8 recognizes the proximal 10bp of the 
stem and anchors Drosha, resulting in cleavage of ~55-70nt long pre-miRNA molecules 
[28]. miRNAs of intronic origin bypass this step and undergo normal splicing processes 
or a Drosha-only dependant pathway to produce the pre-miRNA molecules [29, 30].    
 Next, Exportin-5 and Ran-GTP recognizes the pre-miRNA and export them to the 
cytoplasm. Dicer then partners with the Transactivation-responsive (TAR) RNA binding 
protein (TRBP) to cleave the pre-miRNA to ~22nts long small RNA duplexes. Post-
processing, one strand (the mature sequence) of the miRNA duplex gets incorporated into 
miRNA-induced silencing complex (miRISC) and the other (passenger) strand gets 
 5 
degraded. Recent studies have shown that the passenger strands are not always degraded 
and can get loaded into miRISC to function as miRNAs [31-34].  
Certain exceptions to the this ‘canonical biogenesis pathway’ occur in mammals where 
Argonaute 2 (AGO2), which has endonuclease activity, cleaves the 3’ arm of some pre-
miRNAs to generate AGO2-cleaved precursor miRNA (ac-pre-miRNA) [35]. These 
intermediate molecules subsequently get processed by Dicer to form miRNA duplexes 
(Figure 1.1). However in the case of pre-miR-451, the ac-pre-miR-451 has been shown to 
be processed in a Dicer-independent manner to form miR-451 [36]. A more recent study 
has also shown supporting evidence for another 11 miRNAs undergoing this type of 
biogenesis [37].  
 The mature miRNAs in the miRISC interact with AGO proteins and glycine-
tryptophan protein of 182 kDa (GW182) proteins, the key functional and effector 
molecules to mediate target repression [38]. 
 
 
 
 
  
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: miRNA biogenesis pathway: Illustration of miRNA biogenesis pathway showing the primary 
precursor molecules (pri-miRNA) which are processed by Drosha to ~70 nt long precursor hairpins (pre-
miRNA) and get exported to the cytoplasm by Exportin 5. Dicer then cleaves the pre-miRNA hairpins to 
generate ~20 bp long miRNA duplexes, one strand of which gets incorporated into RNAinduced silencing 
complex (RISC) to bind to target mRNAs, leading to gene silencing.  
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1.2.2 Role of AGO proteins in gene silencing 
 Mammals contain four Ago proteins (AGO1-AGO4), which have three conserved 
domains capable of interacting with miRNAs: PAZ, MID and PIWI domains [39, 40]. All 
four AGO proteins are involved in miRNA-mediated gene silencing, however, only 
AGO2 with an enzymatically active RNAse-H like PIWI domain also functions in RNAi 
[41]. The differential expression of individual AGO proteins in a tissue/cell specific 
manner and their ability to repress targets at different efficacy suggests differential roles 
for these proteins [42]. This is strengthened by studies showing a much stronger effect on 
miRNA mediated gene silencing in HEK293 cells with knockdown of AGO2 compared 
to the other AGO proteins [43] and embryonic lethality in AGO2 knockout mice [41]. 
The GW182 proteins act downstream of AGO proteins and are important for miRNA-
mediated gene silencing [44]; there are three known mammalian GW182 proteins 
including TNRC6A, B, and C. The interaction between GW182 and AGO proteins in the 
miRISC is essential for target repression by miRNAs [45, 46].  
 
1.2.3 Mechanism of gene silencing  
 miRNAs in association with the AGO proteins in the miRISC, direct target 
repression by either mRNA degradation, deadenylation or translational repression, due to 
imperfect base-pair complementarity between miRNA and target mRNA. In few cases 
perfect base-pair complementarity has been shown to lead to mRNA cleavage by AGO 
proteins [47-49]. An overview of studies attempting to decode the mechanism employed 
by miRNAs to efficiently silence their targets is given below.  
 
1.2.3.1 Translational repression 
 Translation from mRNA to proteins, in eukaryotes, requires several processes to 
work harmoniously for efficient translation:  (i) initiation (at the correct codon); (ii) 
elongation of the polypeptide chain, and (iii) termination and release from the ribosome. 
These processes require a 5’ capped and 3’ poly-A tailed mRNA; the eukaryotic 
translation initiation factor 4G (eIF4G) which circularizes the mRNA by interacting with 
the cap binding protein eIF4E (associated with the cap); and the cytoplasmic poly(A)-
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binding protein (PABPC, associated with the poly(A) tail). This circularization activates 
the translation initiation process and protects the mRNA from degradation [50, 51]. 
Studies thus far suggest interference of miRNAs on the roles of the eIF4F complex and 
PABPC as possible mechanisms for translational repression.  
 The first studies to investigate miRNA mediated target repression in C.elegans 
showed lin4 (miRNA) to repress translation of its targets lin-14 and lin-28 with no 
apparent change in their mRNA abundance [52, 53]. The mRNA was found to be 
localized in polysomes suggesting translation repression to have occurred post-initiation. 
Later studies in HeLa cells supported this finding and suggested degradation of nascent 
polypeptide chain to be the causal mechanism for translational repression [54]. Petersen 
et. al. suggested repression happened before synthesis of the polypeptide and was due to 
‘ribosome drop-off’ during the elongation process [55].  
 Translational repression at initiation has also been shown to be the case, where the 
mRNA targets do not sediment in larger polysomal fractions of sucrose gradients and are 
instead found in lighter fractions with fewer ribosomes [56]. Replacing the cap structure 
with Internal Ribosome Entry Site (IRES) showed abrogation of translational repression, 
suggesting that the cap and its binding protein eIF4E are key targets of this mechanism 
[56, 57]. Further studies in human and mouse cell extracts support this model where 
using IRES led to efficient translation of target genes [58, 59]. More recently this has 
gained support in model organisms like drosophila [60] and zebrafish [61] where using 
different approaches, the authors concluded that miRNA targeting occurs at  initiation 
rather than post-elongation or as an early termination. These studies have reasonably 
shown that the primary mechanism used by miRNAs to silence their targets is 
translational repression during the initiation process.   
 
1.2.3.2 mRNA deadenylation and degradation  
 Evidence for this type of target repression comes from several transcriptome-wide 
studies showing inverse correlation in the expression of miRNAs and their target mRNAs 
[62-65]. Subsequent studies with depletion of crucial factors, part of the miRNA 
machinery, like Dicer or Ago [43] and models which over-express [62-66] or knock-
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down miRNAs [62, 63, 67] of interest have suggested mRNA degradation as one possible 
mechanism for miRNA mediated gene silencing.  
 Direct cleavage of mRNA targets has been reported [49], however it is a rare 
phenomenon in animal cells where the miRNAs can function with only partial 
complementarity to their mRNA targets. In such instances, they usually employ 
shortening of the poly-A tail followed by a 3’ to 5’ decay activated by the exosome or a 
5’ to 3’ degradation preceded by decapping of the mRNA catalysed by XRN1 [68-71]. In 
Drosophila depletion of key factors from the cellular mRNA decay pathway led to 
increased expression of miRNA targets, emphasizing its widespread role in target 
repression by miRNAs [70, 72-74]. mRNA deadenylation alone can lead to repression by 
interfering with PABPC association with the tail, hence disabling the circularization of 
the mRNA and subsequent translation [59]. Translationally repressed mRNAs can 
localize in cytoplasmic foci called P-bodies, which can act as the destination for the final 
steps involving mRNA degradation, aided by the accumulation of proteins involved in 
deadenylation, decapping and mRNA degradation [75, 76].  
 A study involving miR-223 knockout mice showed much greater correlation 
between mRNA and protein changes, and suggested mRNA degradation to be the 
principle cause of protein reduction [63]. Recently Guo et. al. showed that about 84% of 
target repression at the protein level can be attributed to decrease in mRNA abundance at 
both 12 and 32 hrs post transfection of miRNAs, suggesting a close-link between mRNA 
deadenylation and translational repression [65]. In contrast, a study utilizing both 
microarrays and a proteomic approach to identify targets of miR-143 showed more 
targets regulated through translational repression compared to mRNA decay [77]. It has 
also been shown that depending on the time point chosen for the analysis many targets 
could be regulated only at the protein level [62].  
 Another possible explanation for the widespread reduction of target mRNA in 
response to miRNA expression is the over representation of transcription factors in its 
target cohort [78]. This could lead to a secondary effect of mRNA suppression by the loss 
of activating transcription factors. Another factor confounding these studies is the 
presence of mRNA isoforms with UTRs of different length which may or may not be 
able to undergo miRNA mediated silencing [79]. This is more relevant in the case of 
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cancer cells which show widespread shortening of 3’ UTRS compared to normal cells 
[80]. Recent studies in drosophila [60] and zebrafish [61] have shown reduction in  (a) 
ribosomes bound to miRNA targets or (b) protein expression respectively to occur 2 
hours before any change in the mRNA abundance is seen, again suggesting a miRNA 
mediated translational repression. Taken together, translational control of targets genes is 
the dominant direct-mechanism underlying miRNA mediated gene silencing. However, 
the effects of miRNAs are made far-reaching and efficient by directly targeting 
expression of primary targets e.g. transcription factors which then subsequently leads to 
changes in widespread mRNA abundance, resulting in the desired phenotype. 
 
1.2.4 Target Recognition principles 
 In animals, the majority of miRNAs are partially complementary to their mRNA 
targets. While this increases their ability to target multiple genes, it also makes target 
prediction and identification more complicated. Studies to date have elucidated several 
‘target recognition principles’, which follow certain rules of base-pairing depending on 
locations both in miRNAs and the target genes. The most common type of site is the 
‘seed’ region in the 5’ end of the miRNA involving perfect base pairing between 
nucleotides 2 and 7 (6mer) [21]. This type of site recognition can be sub divided into: 
8mer, 7mer-m8, 7mer- A1 and 6mer sites, where 8mer sites have an adenine at position 1 
of the target site and base pairing at position 8. 7mer-A1 and 7mer-m8 sites either have 
an adenine at position 1 or base-pairing at position 8 respectively [81]. It is speculated 
that a component of RISC recognizes and enables interaction between the adenine on the 
target site and the first base of the miRNA, which in general has been shown to have a 
strong bias towards being a Uracil (U) [82]. This type of site recognition was initially 
thought to be both necessary and sufficient for effective miRNA-mediated silencing [83]. 
 Subsequent studies have since shown other types of site recognition models 
including  ‘3’- supplementary’ or ‘3’- compensatory sites’ to either enhance target 
recognition or to overcome imperfect base-pairing at the seed region [21]. The 3’- 
supplementary sites require at least 3-4 perfect base-pairing from nucleotides 13 to 16 in 
the miRNA and this type of site conservation predict targets with greater specificity [81]. 
Mismatches or bulges in the seed region can also be ‘compensated’ by the 3’-
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complementary sites spanning nucleotides 13 to 17 with at least nine perfect base-pairing 
[21]. However these types of site recognition seem relatively rare and experimental 
evidence to support their functionality in the miRNA-pathway are relatively few [21, 48]. 
Most recently, ‘centered sites’ beginning at position 3,4 or 5 of the miRNA and spanning 
11 nucleotides of perfect base-pairing to the target have been reported [48]. The different 
models of miRNA-mRNA base-pairing are outlined in Figure 1.2. 
 
 
Figure 1.2: mRNA Target Recognition principles: (A) Seed site involving perfect base-pairing at the 5’ 
end of the miRNA (B) 3’ Supplementary and (C) 3’ Compensatory sites involving base-pairing at the 3’ 
end of miRNA to enhance target recognition (D) Centered sites starting at position 3,4 or 5 spanning 11 
nucleotides of perfect base-pairing. Figure adapted from Brennecke et al., (2005) PLoS Biology. 
 
 
1.2.4.1 mRNA Target site location 
  Most studies to date report target sites in the 3’ UTR of the target gene, 
leading to the hypothesis that target genes have longer 3’ UTRs as opposed to house-
keeping genes which avoid miRNA-mediated repression by having shorter 3’ UTRs [84]. 
Target sites are found about 15-20 nts away from the stop codons in short 3’ UTRs [81] 
and are found at both ends in longer (>2000nts) 3’ UTRs [85]. Alternative 
polyadenylation and alternative splicing are classic mechanisms employed by the cell in 
specific contexts (e.g. cancer) to disrupt miRNA-mediated target repression [80, 86, 87]. 
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Although functional miRNA sites are more prevalent in the 3’ UTR, evidence suggesting 
their presence in 5’ UTRs and coding regions leading target repression have been found 
[88-91]. This number would no doubt increase when computational tools evolve to 
account for CDS and 5’ UTRs into their prediction algorithms.  
 
1.2.4.2 Target prediction tools 
 Initial target prediction tools generally yielded non-overlapping targets [21], 
which limited subsequent analysis and biological validations in specific cellular contexts. 
The computational tools have since evolved, predominantly due to the general consensus 
of importance attributed to ‘seed-sites’. Although each tool employs its own method to 
reduce false-positive rates and increase accuracy, the most commonly used tools follow 
certain general guidelines: complementary bases to the miRNA seed sequence, 
evolutionary conservation of the target region, and the thermal stability of the miRNA-
mRNA duplex [63, 92-94]. Some algorithms like Target Scan [82, 95, 96] assign 
‘context’ scores depending on the location of the predicted target site (proximity to stop 
codon) and other features flanking in the mRNA. A table summarizing commonly used 
miRNA target prediction software is shown (Table 2). 
 
Table 1.2: List of commonly used target prediction software and their properties 
No. Name Clades Criteria for prediction Refere
nce 
1 MiRanda Human, 
Drosophila, 
zebrafish 
Sequence match, conservation and 
thermal stability. 
[97] 
2 RNAhybrid Mammals, Fly Analyzing secondary structure of 
miRNA/mRNA duplex 
[98] 
3 TargetScan 
and 
TargetscanS 
Mammals, 
nematodes, fish, 
fly 
Thermodynamic model of RNA 
interaction and sequence alignment 
analysis 
[82, 
95, 96] 
4 DIANA- Mammals, fly Single miRNA-recognition elements [99] 
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microT 
5 PicTar Mammals, fly, 
nematodes 
Stringent seed pairing for at least one 
of the sites for the miRNA, site 
number, overall predicted pairing 
stability 
[100] 
6 Target gene  
prediction 
at EMBL 
Drosophila Sequence search with evaluation of 
the predicted miRNA–target 
heteroduplex structures and energies 
[101] 
7 PITA Top Mammals, 
nematodes, fly 
Sequence search with site 
accessibility and thermodynamic 
model of interaction 
[102] 
8 EIMMo Mammals, fish, 
fly, nematodes 
Seed pairing, likely hood of 
conservation. 
[85] 
9 mirWIP C. elegans Site accessibility, pairing stability, 
total free energy of miRNA-target 
hybridization. 
[103] 
10 RNA22 Mammals, fly, 
nematode 
Matches to sequence patterns, 
sequence stability, does not take 
conservation  
[104] 
11 FASTH  Human, mouse Free energy score thresholds, perfect 
complementarity to the 5’ end of 
miRNA, minimum base pairing at 
the 3’ end, and other optional criteria 
[105] 
 
1.2.4.3 miRNAs target genetic networks 
 It is now becoming increasingly clear that each miRNA has a large number of 
target mRNAs that it can regulate. It has been proposed that a large portion of miRNA 
targets are mRNAs that fall under similar pathways, ablation of which ultimately 
contribute to the outcome [94]. One such miRNA that has been shown to regulate 
different mRNA targets that function along the same pathway is miR-24. This anti-
proliferative miRNA was shown to target a network of genes whose function was highly 
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enriched for DNA repair and cell cycle progression such as MYC, E2F2 and VHL [106]. 
Subsequent studies showed that the miRNA regulated H2AX, a protein that plays a key 
role in the double-strand break response [106]. Hence miR-24 plays a role in the 
regulation of DNA repair and cell cycle progression through the regulation of various 
mRNAs that are key players in these cellular processes.  
 Another such example is miR-34, a p53-regulated miRNA that has been shown to 
be a suppressor of Wnt signaling through the repression of WNT1, WNT3, LRP6, 
AXIN2, β-catenin and LEF1, all of which are components of the canonical Wnt signaling 
cascade [107]. p53 has been shown to inhibit the epithelial-to-mesenchymal transition 
program and subsequent metastasis of cancers [108] whereas Wnt signaling is known to 
promote the process [109]. Hence, p53 presumably exerts its anti-metastatic functions 
through the transactivation of miR-34, which then acts through the inhibition of various 
components of the Wnt signaling cascade, inhibiting their translation. Hence to fully 
understand the role of a particular miRNA, a thorough study of the target gene network 
that it regulates through a robust assay is an essential first step.  
 The mechanism by which a particular miRNA is able to regulate the expression of 
numerous target mRNAs is still poorly understood, perhaps resulting from our inability to 
accurately identify a major portion of targets of a particular miRNA. Lal et al. observe 
that almost all target genes regulated by miR-24 lack the presence of a seed sequence in 
their 3’-UTRs although they do contain sequences that are highly complementary to the 
miRNA, thus resembling non-canonical miRNA response elements (MREs) [106]. 
Moreover, independent studies have demonstrated the presence of complementary 
sequences within the ORFs of genes to be as effective in miRNA repression, with many 
well-known tumor suppressors such as RB1 harbouring such sequences in the coding 
region complementary to miR-181 [110]. Hence, the search for binding sequences in the 
3’UTRs of genes as the sole predictor of miRNA targets could be misleading and provide 
an incomplete picture of miRNA biology. As better algorithms and lab-based protocols 
are developed to identify miRNA targets, a better picture of how miRNAs are able to 
regulate large networks of genes will evolve, enabling better understanding of the 
properties of these molecules. This will also be greatly aided by the techniques used to 
both biologically identify and validate miRNA targets. 
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1.2.4.4 Identification and validation of putative targets 
 Forward and reverse genetics were the first techniques used to identify miRNAs 
and their target genes [111]. Since then, microarray analysis of samples after over-
expression or knock down of a miRNA has widely been used to identify targets whose 
expression are inversely correlated to the miRNA and was first used to show the effect of 
miR-124 in the brain [66]. These studies are typically hampered by limitations due to 
probe-design and are not able to distinguish between direct targets or indirect targets 
(genes down regulated by transcription factors which are direct targets of the miRNA). It 
will also overlook translationally repressed targets, which show no apparent change at the 
transcript level. Immunoprecipitation of AGO followed by assaying the ‘co-precipitated’ 
mRNA targets by microarrays or next-generation sequencing technology has helped 
identify targets potentially regulated at the level of mRNA degradation or translational 
repression [112-116]. This approach is typically specific to one AGO protein and can 
potentially lead to false negatives when other AGO proteins are present in miRISC [117]. 
Another limitation is the non-specific binding of AGO proteins to cognate mRNAs in the 
cell lysis leading to false positives [114]. 
 Proteomic approaches including Stable isotope labelling with amino acids in cell 
culture (SILAC) in combination with mass spectrometry have been used to gauge the 
global changes in protein expression after manipulation of miRNA expression [62, 63], 
which supported the importance of seed sites. Target validations subsequent to these 
large-scale analyses are typically carried out using reporter assays where the predicted 
binding site is cloned downstream of a reporter gene and assayed for the effect of miRNA 
regulation to that site. This method can be labour intensive, expensive and most 
importantly loses context-specificity. 
 To overcome some of these limitations, new approaches are being employed to 
identify direct targets of miRNAs. One such approach is the high-throughput sequencing 
of RNA isolated by crosslinking immunoprecipitation (HITS-CLIP), where to 
recapitulate endogenous interactions, ultraviolet radiation is used to crosslink RNA and 
associated RNA binding proteins prior to immunoprecipitation, followed by sequencing 
to assay the targets [116, 118]. Photoactivatable-ribonucleoside-enhanced crosslinking 
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and immunoprecipitation (PAR-CLIP) has optimized the UV crosslinking by incubating 
cultured cells with a photoactivatable nucleoside such as 4-thiouridine and is capable of 
indicating the site of targeting [112]. Both studies found comparable number of sites in 
the 3’ UTR, CDS and the 5’ UTR [119].  
 Biotinylation, the process of attaching biotin covalently to a protein or nucleic 
acid, has [94] been used extensively in molecular biology owing to its high affinity to 
streptavidin, which can be used to specifically isolate the labeled molecules. Pull-downs 
using biotinylated proteins has been successfully used to identify protein-protein 
interactions [120] and genome-wide binding sites for transcription factors using bioChIP-
seq [121] or to perform DNA mediated chromatin pull-down (Dm-ChP) [122]. Pull-
downs using biotinylated miRNAs followed by microarrays or high-throughput 
sequencing has also been used to identify miRNA targets [37, 123]. Recent studies have 
demonstrated the utility of this technique to specifically identify miRNA targets with 
higher accuracy than routinely used bioinformatics algorithms. The major advantage of 
this system is the highly specific nature of the biotin-streptavidin binding which ensures 
minimal non-specificity and noise [124, 125]. This robustness of the interaction ensures 
higher fidelity compared to other techniques such as HITS-CLIP, which call for the 
availability of a ChIP grade antibody against a miRISC component and a challenging 
multistep protocol [94]. Additionally, such protocols are carried out by pull-down of a 
generic miRISC complex protein in cells that overexpress a particular miRNA with the 
assumption that majority of the miRISC component will be co-localized specifically to 
the miRNA in question. This provides room for non-specificity especially in the case of 
isomirs where distinguishing targets of a miRNA and its isomiR is difficult using these 
approaches. The use of biotinylated miRNA on the other hand ensures the identification 
of targets specifically associated to the miRNA or the isomiR in question [37].  
 
1.2.5 miRNA expression profiling  
  miRNA expression profiling across sample cohorts are essential and have greatly 
aided in elucidating their role in normal developmental processes and disease states. 
Their small size and ability to generate isomiRs (discussed later) pose certain challenges 
in accurate quantification of their abundance; however certain approaches are robust, 
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reproducible and routinely used in global miRNA expression profiling studies. miRBase 
[126, 127] is both the repository and valuable resource for such studies, constantly 
updated when novel miRNAs are identified. Version 18 of miRBase (current at time of 
writing) has a total of 18,226 entries of hairpin precursor miRNAs expressing 21,643 
mature miRNA products derived from a broad range of plant and animal species.  
 Reverse transcription of miRNA to cDNA followed by real time PCR provides 
relative quantification of the specific miRNA interrogated; is highly sensitive and 
requires very small amounts of input RNA. This method cannot be used to identify novel 
miRNAs and scalability is limited [128]. Two most commonly used commercial products 
include ABI’s specific stem-loop primers, used to generate cDNA, subsequently 
amplified by primers specific to mature miRNA, and Exiqon’s LNA based primers which 
adds a polyA tail to the mature miRNA before it is converted to cDNA and amplified 
using miRNA specific primers.    
 Microarrays provide a cost-effective, high-throughput approach to simultaneously 
profile hundreds of miRNAs. Typically this approach involves fluorescent labeling of 
miRNAs in samples, followed by hybridization to DNA probes attached to glass slides or 
in some cases beads [129]. Estimating the fluorescence associated with specific probes 
gives an indication of relative abundance of specific miRNAs.  Limitations include 
inability to identify novel miRNAs, less specificity and lower dynamic range compared 
to qRT-PCR or sequencing [128]. Sequence similarity of more than 75% results in cross 
hybridization leading to noise [130]. The probe design depends on known miRNA 
sequences and generally lags behind new releases from miRBase thereby excluding 
several families of miRNAs. 
 Another popular approach widely used now is next generation sequencing which 
is sensitive, and becoming increasingly very cost-effective. This topic is discussed in 
detail in the book chapter titled “Tag Sequencing” (attached below). Briefly, the 
advantages of this method include its non-reliance on previously known sequences of 
miRNAs, which can be used to identify novel miRNAs. Sequencing based studies have 
shown it to be highly sensitive, reproducible and quantitative [131]. Most importantly it 
can very accurately distinguish between miRNAs of similar sequence or even isomiRs 
[37].  
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1.2.6 miRNA diversity: Isomirs 
 Next-generation sequencing technology has enabled the identification of miRNA 
variants called ‘isomiRs’ [132] or non-canonical miRNAs, which are generated from a 
common hairpin pre-miRNA molecule. When first observed, isomiRs were thought to be 
artifacts of library generation, sequencing or poor alignment [133-135], degraded RNA 
[136] or by products of inefficient processing by Drosha/Dicer [137, 138]. In more recent 
studies however, a more functional role for the variants are emerging; suggesting a model 
where their expression allows a more fine-tuned modulation of target repression [37].  
 IsomiRs differ from their canonical counterparts in a wide variety of ways 
including: substitutions, insertions or deletions, 3' end non-templated additions, and 5' 
and/or 3' cleavage variations [37]. 3’ isomiRs can result from a variation in Drosha/Dicer 
processing [31, 137-140] and have been shown to be developmentally regulated 
suggesting a functional role [141]. 5’ isomiRs potentially represent a new ‘seed region’ 
and hence a new set of targets. Although this could explain the reduced expression of 5’ 
isomiRs relative to 3’ isomiRs in some sequencing data [31, 142] there are contradictory 
reports where 5′ isomiR expression was comparable to the canonical miRNAs [31, 138, 
142]. Research into isomiRs is still at its infancy and requires a more targeted approach to 
unravel their specific biological functions in a context dependent manner. 
 
1.2.7 Role of miRNAs in cancer 
 miRNAs are gene regulators which play key roles in development and 
homeostasis as well as in human diseases. For the purpose of this thesis, an overview of 
miRNAs frequently deregulated in human cancers and their contribution to the 
pathogenesis of the disease is outlined below. 
 Cancer is an accumulation of mutations in the genome and epigenome leading to 
activation of oncogenes or silencing of tumour suppressors. The disease is characterized 
by a multi-step process involving the: (1) Uncontrolled proliferation of aberrant cells 
developing into a primary tumour, (2) Escape of tumour cells into the systemic 
circulation, and (3) Establishment in a distant tissue followed by outgrowth of secondary 
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tumours (metastasis). High-throughput analyses have reported altered miRNA expression 
in almost all tumours investigated till date, signifying the major role they play in 
oncogenesis. The term “oncomir” has been commonly used in reference to miRNAs that 
play a role in tumourigenesis. The following sections will discuss oncogenic and tumour 
suppressive miRNAs and the role they play in the pathogenesis of various cancers, a list 
of well characterized oncomirs is shown in Table 3. 
 
Table 1.3: List of widely studied miRNAs associated with human cancer 
miRNA Activity Cancer Type Reference 
17-92 cluster Oncogene B cell lymphoma; lung cancer; 
colon cancer; multiple myeloma, 
medulloblastoma 
[143-147] 
155 Oncogene CLL, non-Hodgkin’s lymphoma, 
Hodgkin’s disease, Burkitt’s 
lymphoma, breast, lung, colon, 
pancreatic cancers. 
[148-153] 
21 Oncogene Breast, lung, gastric, cervical, 
prostate, colorectal, head and neck 
cancers, glioblastoma 
[154-162] 
221 Oncogene Hepatocarcinoma, CLL, melanoma, 
glioblastoma, breast, thyroid, lung 
and prostate cancer 
[163-171] 
372/373 Oncogene Testicular tumours [172] 
106b-93-25 
cluster 
Oncogene Colon, pancreatic, gastric and 
prostate cancer, multiple myeloma 
[173] 
LIN28 Oncogene CML, hepatocellular carcinoma, 
Wilms tumour 
[174] 
151 Oncogene Hepatocellular carcinoma [175] 
10b Oncogene Breast, pancreatic cancer, glioma [58, 176, 177] 
9 Oncogene Breast cancer, renal cell carcinoma, 
colon cancer 
[178-180] 
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27a Oncogene Breast cancer [181] 
517c, 520g Oncogene Neuro-ectodermal brain tumours [169] 
15a, 16-1 Tumour 
Suppressor 
CLL, DLBCL, prostate, pancreatic 
cancer, multiple myeloma 
[169, 182-187] 
34 Tumour 
Suppressor 
Colon and pancreatic cancers, 
Burkitt’s lymphoma 
[188-191] 
Let-7 Tumour 
Suppressor 
Lung, breast, colon, gastric, prostate 
cancer, CLL 
[192-195] 
29 Tumour 
Suppressor 
Colon, breast, lung cancer, AML, 
cholangiocarcinoma 
[196-198] 
145 Tumour 
Suppressor 
Breast cancer [199] 
221, 222 Tumour 
Suppressor 
Erythroblastic leukemia [200] 
200 Tumour 
Suppressor 
Colon, breast, lung, bladder cancers [201-204] 
148a Tumour 
Suppressor 
Pancreatic and gastric cancer [205, 206] 
124a Tumour 
Suppressor 
Glioblastoma, ALL, gastric cancer [207-209] 
31 Tumour 
Suppressor 
Breast cancer, T-cell leukemia, 
colon carcinoma 
[210-212] 
137 Tumour 
Suppressor 
Glioblastoma, squamous cell 
carcinoma 
[213, 214] 
129-2 Tumour 
Suppressor 
Gastric, endometrial cancer [215, 216] 
 
1.2.7.1 Oncogenic miRNAs 
 One of the main indications of a potential oncogenic role for a miRNA is 
overexpression in tumours. miR-155 and the miR-17-92 cluster were the first set of 
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miRNAs to be causatively associated with human cancer, the coding regions of both 
being amplified in B-cell lymphomas [217, 218]. Using Eμ-miR-155 transgenic mice, 
overexpression of this miRNA was demonstrated to be causative of high-grade 
lymphoma, the first evidence that dysregulation of a single miRNA can lead to cancer 
[219]. Follow up studies have shown that miR-155 is overexpressed in a range of 
haematopoietic malignancies as well as lung and breast cancer [148, 150, 152, 220]. 
More recent studies into its oncogenic nature have revealed that it is a target for 
epigenetic silencing by BRCA1 through the recruitment of HDAC2, which deacetylates 
its promoter [221].  
 The miR-17-92 cluster consists of six miRNA hairpins – miR-17, miR-18a, miR-
19a, miR-20a, miR-19b and miR-92a-1. The cluster has been found to be overexpressed 
in various other solid tumours including those of the breast, colon, lung and prostate 
[152]. Importantly, a causative role for this cluster was established when overexpression 
in B cells was shown to induce a lymphoproliferative disorder in mice. Studying the 
mechanism of tumourigenicity revealed that the cluster can be transactivated by Myc and 
promotes cell cycle progression and cell proliferation through the regulation of the E2F 
transcription factors [222, 223]. A paralog of miR-17-92 is miR-106b-25 cluster, which 
has also been shown to act as an oncogene in gastric, prostate and pancreatic 
neuroendocrine tumours by cooperating with MCM7 in the inhibition of PTEN [173, 224, 
225]. 
 Expression profiling of both tumour and normal tissues has evolved as one of the 
most effective ways of identifying novel miRNAs that could play a role in 
tumourigenesis. miR-31 was found to be overexpressed in malignant lung cancers, its 
knockdown leading to repressed growth of the tumour [226]. Its tumourigenicity was 
attributed to its ability to repress the LATS2 and PPP2R2A tumour suppressors. 
Expression of another miRNA, miR-27a, was found to be elevated in a panel of breast 
cancer cell lines, contributing to their oncogenicity through the regulation of its target 
genes ZBTB10 and Myt-1 [181]. These target genes repress the Sp family of transcription 
factors that contribute to the proliferative and angiogenic phenotype of cancer cells. The 
miR-106b family was also identified through microarray profiling, its expression levels 
being highly correlated with the expression of cell cycle genes [227]. It was shown to 
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directly target CDKN1A (p21), promoting exit from the G1 phase and entry into the S-
phase. A member of the miR-106b family, miR-17-5p, was shown to promote cell cycle 
progression through the modulation of over 20 oncogenes and tumour-suppressor genes, 
including MAPK9/JNK2 [228]. 
 Recent studies have also focused on the role of miRNAs in tumour progression 
and metastasis. miR-10b was identified as an oncomir highly expressed in metastatic 
breast cancer cells, conferring properties of invasiveness and metastasis [58]. It was 
shown to inhibit translation of HOXD10 upon induction by Twist, leading to increased 
expression of RHOC. Further study showed that administration of miR-10b antagomirs to 
mice bearing highly metastatic tumours effectively suppressed lung metastasis, proving 
to be a promising candidate for therapeutic intervention [229]. Similarly miR-9, which is 
upregulated in breast cancer cells, was shown to directly inhibit expression of E-cadherin, 
leading to activation of beta-catenin signaling which results in increased cell motility and 
invasiveness [179]. Activation of beta-catenin also contributed to upregulation of VEGF 
signaling, promoting tumour angiogenesis.  
 
1.2.7.2 Tumour-suppressor miRNAs 
 miR-15a and miR-16-1 were the first miRNAs shown to be lost in human cancer, 
the 13q14 locus being frequently lost in CLL [184]. Further study showed that these two 
miRNAs target the BCL2 oncogene known to be causative of follicular lymphoma [184, 
185]. Let-7, a founding member of the miRNA family identified in C. elegans was also 
the first miRNA shown to target an oncogene, with all three RAS genes harbouring let-7 
complementary sites in their 3’UTRs [192]. Accordingly, expression levels of let-7 were 
reduced in lung tumour tissue, reciprocal to that of RAS expression. Through the above 
two studies it became clear that the loss of miRNAs could contribute to tumourigenesis 
through deregulation of cellular oncogenes. Further study has shown that miR-15a and 
16-1 are also lost in prostate cancer and multiple myeloma [185, 230, 231] whereas the 
let-7 family is lost in lung and breast cancers [193, 232]. 
 The miR-29 family consists of three members: miR-29a, b and c, which are lost in 
various haematological malignancies such as chronic lymphocytic leukemia and acute 
myeloid leukemia, as well as solid tumours such as breast cancers [196, 197, 233]. They 
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were shown to inhibit apoptosis through repression of the anti-apoptotic gene Mcl-1 
[197]. miR-129 is also involved in the activation of p53 (TP53) through the repression of 
p85a, the regulatory subunit of PI3 kinase and CDC42, both of which are negative 
regulators of p53 (TP53) [198]. Through the targeting of DNMT3A and B, miR-29 
relieves epigenetic silencing of tumour suppressor genes such as FHIT and WWOX, 
which are repressed by promoter methylation during the pathogenesis of non-small cell 
lung cancer [234]. Although most studies have revealed a tumour suppressive role for this 
miRNA, it has been shown to act as a context-dependent oncogenic miRNA. Through the 
repression of TTP (tristetraprolin), miR-29a has been shown to promote the epithelial-to-
mesenchymal transition and metastasis in EpRas cells [235].  
 Several miRNAs have been implicated in the inhibition of cancer progression and 
metastasis. Expression of miR-31 was inversely correlated with metastatic potential and 
its overexpression in aggressive breast cancer cells sufficient to suppress metastasis 
[210]. Its effects were shown to be mediated by several targets, including RHOA, integrin 
alpha5 (ITGAV) and radixin (RDX) [236]. The suppression of just these three genes 
could mimic suppression of miR-31. Moreover, activation of miR-31 function in 
established metastasis, even in the form of a brief induction, leads to its regression [237]. 
The previous section addressed the role of miR-31 as an oncogenic miRNA whereas 
other studies discussed here establish it as a tumour suppressive miRNA. This points out 
to a dual, context-dependent role for miR-31 in tumourigenesis. 
 The miR-200 family also plays tumour suppressive roles in various cancers. The 
family consists of miR-200a, miR-200b, miR-200c, miR-141 and miR-429, which were 
shown to inhibit the epithelial-to-mesenchymal transition (EMT) and maintain the 
epithelial state by targeting the transcriptional repressors Zeb1 and Zeb2 [201]. p53 has 
been shown to bind to the miR-200c promoter and transactivate it, preventing the EMT 
program and metastasis [238]. 
 As described above, most studies suggest correlation between miRNAs and 
cancer. This is based on expression profiling in tumour samples but does not always 
imply a causative role in the disease initiation or progression. Such large-scale profiling 
analyses also possess certain inherent limitations including: inter-study variability in 
terms of sample size and variable validation approaches [239]. However it is increasingly 
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becoming evident that miRNAs do have a fundamental role to play in tumorigenesis 
[240, 241], suggesting it is important to tease out the molecular mechanism underlying 
the role of miRNAs in cancer. This can be achieved by identifying deregulation of 
clusters of miRNAs and by identifying the functional network of genes they modulate in 
a given context. Using these approaches we can then decipher the specific mechanism 
underlying the role of the deregulated miRNA in a given cancer type.  
 
1.2.8 Role of miRNAs in breast cancer 
 Breast cancer, a major health burden around the world, is one of the leading 
causes of death amongst women. It has often been referred to as a collection of breast 
diseases with diverse histopathologies, genetic and genomic variations, distinct 
expression profiles and clinical outcomes. This diversity impedes our understanding of its 
biology and is a major barrier to both identifying novel therapies and improving existing 
therapies for treatment and prevention [242]. 
 Contributing to this molecular heterogeneity is the differential expression of 
miRNAs across the various clinical subgroups [199]. The expression signatures of 
miRNAs were also shown to correlate with histopathological features including tumour 
size, nodal involvement, proliferative, and invasive abilities of the cancer cells [199]. 
Shown in Table 4 are known oncomirs of breast cancer and the functional relevance of 
their validated targets. 
 
Table 1.4: Known oncomirs in breast cancer with their validated targets and 
functional relevance 
 
miRNA_name 
 
Function Targets 
 
Related cellular event Reference 
miR-21 
 
Oncogenic 
 
RHOB, PTEN, 
TPM1, 
Cell migration, elongation, 
invasion and apoptosis 
[158, 243-
246] 
miR-10b* 
 
Oncogenic   HOXD10, 
TIAM1  
Metastasis, cell motility, 
invasiveness 
[247, 248] 
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miR-155 
 
Oncogenic RhoA, 
FOXO3a, 
Cell survival, 
chemoresistance, cell 
[249-251] 
miR-373 
 
Oncogenic 
 
  CD44 
 
Invasion, metastasis 
 
[252] 
miR-520c 
 
Oncogenic 
 
CD44 Invasion, metastasis 
 
[252] 
miR-27a 
 
Oncogenic 
 
ZBTB10, 
Myt1, 
†
Cell cycle dysregulation, 
proliferation, angiogenesis, 
[181, 253] 
miR-206 
 
TS ER-alpha Estrogen-receptor mediated 
proliferation 
[254, 255] 
miR17-5p 
 
TS HBP-1, AIB1, 
cyclinD1 
Cell migration, invasion, 
proliferation,  
[256-258] 
miR-125a,b 
 
TS HuR, ERBB2, 
ERBB3 
Anchorage dependant 
growth, migration, invasion 
[259, 260] 
miR-200c 
 
TS TCF-8 (ZEB1) EMT, invasion [261] 
let-7 family 
 
TS ER-alpha, H-
Ras, HMGA2 
Proliferation, apoptosis, 
self-renewal and 
[262, 263] 
miR-31 
 
TS Rho-A, Fzd3, 
ITGA5, RDX 
Metastasis [210] 
miR-335 
 
TS SOX4, 
PTPRN2, 
Metastasis [264] 
miR-27b 
 
TS 
 
CYP1B1 
 
Modulation of anticancer 
drugs 
[265] 
 
miR-126 
 
TS IRS-1 Cell growth 
 
[266] 
miR-185 
 
TS SIX-1 Proliferation, apoptosis 
 
[267] 
miR-145 
 
TS Mucin1, 
RTKN, ER-
Cell invasion, metastasis, 
cell growth, apoptosis 
[268-270] 
 26 
miR-205 
 
TS ERBB3, 
VEGF-A,  
Proliferation, anchorage-
independent growth, 
[271, 272] 
miR101 
 
TS EZH2 Proliferation, invasion, 
H3K27-trimethylation 
[273] 
 
 Several clinical studies reported on the possibility of using miRNAs as prognostic 
markers by highlighting the differential expression of certain miRNAs in large patient 
sample cohorts [274-276]; however given the inherent heterogeneity of the disease this 
has proved to be difficult. This highlights the scope for identification of novel oncomirs 
in breast cancer and the subsequent validation of specific biological processes they 
disrupt.  The following section will focus on three processes that are commonly 
deregulated during tumorigenesis, which are also the focus of the results chapters 
forming part of this thesis.  
 
1.2.8.1 DNA Damage and Repair 
 Maintenance of genome integrity is one of the major cellular functions that 
ensures proper replication of DNA and its transmission across generations, deregulation 
of which can lead to the occurrence of mutations and aberrations that ultimately result in 
tumorigenesis. DNA damage can result from physical agents such as ionizing radiation 
(IR) and ultraviolet light (UV), or by chemical means from alkylating agents, DNA 
crosslinking agents and cigarette smoke, all of which can induce both single-strand 
(SSBs) and double-strand DNA breaks (DSBs). DNA repair mechanisms counteract such 
damage through processes such as homologous recombination (HR) or nonhomologous 
end joining (NHEJ) in the case of DSBs [277] or mismatch repair (MMR) and base 
excision repair (BER) to repair mismatched or damaged bases [278, 279]. This repair is 
carried out by the action of several enzymes including nucleases, ligases, kinases and 
phosphatases, amongst others that are recruited upon sensing of damage, a process known 
as the DNA damage response (DDR). DDR is a signal transduction pathway that senses 
DNA damage and initiates the cascade of signals that sets out to counter the threat to the 
cell, primarily mediated by three kinases, ATM, ATR and DNA-PK and poly (ADP-
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ribose) polymerase (PARP) family members [280]. More recently, miRNAs have also 
been identified to play a major role in this process, as will be described in detail in the 
first results chapter of this thesis. 
 
1.2.8.2 Metastasis 
 Over 90% of cancer-related deaths are a result of metastasis and not the primary 
tumor itself [281], with the ability to form metastasis being an indicator of the prognosis 
of the cancer. The invasion-metastasis cascade is the process by which tumor cells are 
able to escape from the primary tumor site by the acquisition of invasive and migratory 
properties, intravasate into the bloodstream and lodge in distal sites where they would 
ultimately colonize and lead to the outgrowth of metastases [282]. In the case of 
carcinomas, individual cancer cells acquire invasive properties through a change in cell 
state termed the epithelial-to-mesenchymal transition characterized by a loss of epithelial 
properties including cell junctions, accompanied by the gain of mesenchymal properties 
that enables their translocation from the primary tumor [283]. Several signaling pathways 
have been implicated in the ability of an epithelial cell to acquire mesenchymal properties 
that enable it to metastasize including TGFb, Wnt, Hedgehog, NOTCH and NFkB [284-
287]. More recently, several miRNAs have been implicated in processes underlying 
metastasis as will be discussed in the second results chapter. 
 
1.2.8.3 Cell Cycle 
 The cell cycle is a fundamental cellular process that ensures DNA replication and 
cell division. Given its high relevance to cell division and proliferation, its deregulation 
has severe implications for normal cell functions and is one of the hallmarks of cancer 
[288]. It is composed of the initial G1 resting phase where the cell synthesizes proteins 
required for DNA synthesis, regulated by cyclinD1-CDK4/6 complexes [289]. The 
transition between these two phases, known as the G1-S checkpoint ensures that cells 
with damaged DNA do not progress further and is tightly controlled by cyclinE-CDK2 
complexes, which upon entry into S-phase changes to a cyclinA-CDk2 complex. The S-
phase where DNA is replicated is followed by the G2 phase where the cell, through 
 28 
protein synthesis, prepares for mitosis. The transition to the M phase, known as G2-M 
transition is initially regulated by cyclinA-CDK1 and later cyclinB1-CDK1 complexes 
and is a major checkpoint for genotoxic stress ensuring damaged DNA is not passed onto 
the next generation [289]. Cyclin-dependent kinase inhibitors (CKIs; the INK4 and CIP 
family) bind to cyclins or cyclin-CDK complexes and negatively regulate progression of 
the cell cycle and incidentally, happen to be important tumor suppressors that curb the 
process of tumorigenesis that results from uncontrolled cell cycle progression. The 
complexity of this process requires the involvement of a large number of regulators, 
which also includes miRNAs as will be expanded upon in the third results chapter of this 
thesis. 
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Keywords 
Tag sequencing 
The process of generating short fragments of nucleic acid sequence 
derived from longer nucleic acids. Originally performed using 
standard capillary sequencing, most tag sequencing is now per-
formed by massively parallel sequencing. 
 
PCR: Polymerase chain reaction 
A molecular biology technique used to replicate and amplify DNA 
fragments using DNA polymerase, nucleotides, primers, and the 
modulation of reaction temperature. 
 
Library 
In this context, library refers to a collection of DNA fragments, each 
flanked by a pair of defined nucleic acid sequences (adaptors) from 
which molecular biology protocols can be anchored.  
 
Genome 
The full complement of heritable nucleic acids from an organism, 
and includes all genes (protein coding and non-coding genes). In 
most cases the genome is DNA, however some viral genomes are 
RNA based. Unless otherwise specified, the genome contains mito-
chondrial DNA too. 
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Transcriptome 
The full complement of RNA transcripts expressed in a particular 
cell population or a particular tissue, in a particular environment at a 
particular time. While an organism usually has only one genome, it 
may have many transcriptomes. The transcriptome is considered to 
be the active portion of the genome. 
 
Epigenome 
The full complement of heritable material that are is not nucleic ac-
id. This includes modifications to DNA (methylation), and the modi-
fications and positioning of proteins that can affect the stability and 
accessibility of the genome to transcription.  
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Abstract 
Technological advances in sequencing are revolutionizing the 
way genome scale biological research is performed – leading to an 
explosion of applications made possible by the massive scale of data 
generated and a similarly massive decrease in cost. Specific mention 
of throughputs, lengths, or costs will become out of date very quick-
ly as the technology is still rapidly evolving, however the concepts 
and protocols surrounding the technology have largely stabilized. 
This article will explore the technology, analysis, and common ap-
plications of tag sequencing, and how these are impacting the major 
facets of nucleic acid research: genomics, epigenomics, and tran-
scriptomics. 
1 Library construction 
The process of creating libraries for massive scale tag se-
quencing will determine the kinds of information that can be ex-
tracted at the time of analysis. Although each strategy differs in the 
specifics, there are two very general steps for every library construc-
tion (i) fragment the nucleic acids to an appropriate size; (ii) capture 
and amplify the fragments between adaptors of a defined sequence. 
1.1 Fragment libraries 
By far the simplest library preparation protocol is a "fragment" 
library, where DNA is sheared down to fragments that are slightly 
larger than the desired tag length. This strategy provides the best use 
of DNA, as almost the entire DNA used for library generation is 
available for sequencing (Figure 1A). Data from this style of library 
is typically used in applications where an appropriate reference ge-
nome has already been assembled. De novo assembly applications 
using fragment data alone are confounded by repetitive regions 
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longer than the read length, computationally intensive, and are often 
hampered by the high error rates in massive-scale sequencing [1]. 
There are three main approaches to adding adaptors to ge-
nomic fragments: (i) adaptors are added via PCR (Figure 1A); (ii) 
two unique double stranded molecules (designated A and B) are 
ligated to the fragment simultaneously, and only molecules both an 
A and B adaptor are selected by PCR amplification (Figure 1B); or 
(iii) the use of Y shaped adaptors which allow only the generation of 
AB molecules (Figure 1C). There are obvious advantages to the use 
of Y-adaptors, which result in significantly more molecules suitable 
for sequencing (if we assume that both A and B adaptors ligate 
equally, half of the molecules in an AB ligation protocol will be ei-
ther AA or BB) and allow libraries to be generated from smaller 
amounts of material. Most recently, the use of Y shaped adaptors 
that include Taqman probe binding sites have been described for use 
in pyrosequencing (see section 2.2.1), which allows for the specific 
titration of library molecule concentrations required for bead genera-
tion [2]. Generating libraries via PCR is generally considered less 
favorable than ligation due to the difficulty in ensuring even cover-
age across the genome, the difficulty in generating tight insert size 
distributions, and the creation of PCR artifacts which require more 
extensive purification [3]. 
1.2 Paired-end libraries 
"Paired-end" libraries are fragment-style libraries where short 
tags are read from both ends of a single fragment (typically 200-
300nt long). A critical step in this protocol is size selecting the DNA 
fragments, so the physical distance between the paired tags is 
known. Once paired-reads are aligned to a reference genome, the 
distance between the tags can be compared with the expected dis-
tance, and discordant mapping distances identify variations in ge-
nomic structure (see section 4.2 and Figure 7). The vast majority of 
genome re-sequencing data comes from paired-end libraries, due to 
their relatively low requirement for input DNA and the simplicity of 
the library preparation.  
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Figure 1. Sequencing library construction. (A) Chromosomal DNA can be left 
intact, or sheared. PCR primers containing known adaptor sequence and random 
hexamers (depicted as 6 N’s) are used to PCR amplify genomic fragments ready 
for sequencing. Optionally, sequence specific primers can be used, depending on 
the application, although this may require substantial optimization for multiplex 
PCR, or many individual PCR reactions. (B) Standard adaptor libraries are pre-
pared by fragmenting the DNA into small fragments slightly larger than the de-
sired tag length. Adaptors of a known sequence are ligated to each end, which are 
used for subsequent PCR amplification and priming for the sequencing reactions. 
For a simple fragment run, tags are usually sequenced from the 5’ end of the li-
brary (black arrowhead). For a paired-end run, tags are sequenced from the 5’ 
(black arrowhead) and the 3’ (white arrowhead) end of the library. (C) Y-adaptor 
libraries are prepared as in (B), except a single Y adaptor is used rather than two 
distinct double-stranded adaptors. This eliminates the situation where two of the 
same adaptor ligate to the same DNA fragment and not amplified during the PCR 
stage. Additionally, as each strand now contains a forward primer (black arrow-
head), the number of DNA fragments present in the library that can be sequenced 
directly are again increased. (D) Mate-pair libraries are usually constructed from 
much larger fragments than fragment or paired-end libraries (1-10kb vs 50-500nt). 
Adaptors are added, and the longer molecules are then circularized by ligation. 
The ends of the DNA fragments (dotted lines) are then removed from the remain-
ing DNA (by restriction digest or by nick translation) producing a linear molecule 
of each end separated by the first adaptors. Finally, the sequencing adaptors are 
ligated to each end to allow for amplification. To generate mate-pair data, tags are 
generated from the 5’ end (black arrowhead), and the 3’ end (white arrowheads), 
although the direction of the second read will depend on both the protocol and 
sequencing platform employed. 
 
 
1.3 Mate-pair libraries 
The "mate-pair" strategy is less commonly used for large scale 
genomic sequencing, but offers greater sensitivity to detect structural 
variations such as translocations and inversions. The protocol in-
volves breaking the target molecule into large fragments (often be-
tween 1-10kb, allowing tag pairs to straddle repetitive regions) and 
rather than sequence the entire fragment, each end is captured and 
sequenced as a pair of short tags (Figure 1D). Although sensitive, 
this protocol is more complex, and requires substantially more DNA 
- typically 10-50X more than paired-end libraries depending on the 
size of the fragmentation desired. 
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1.4 Transcriptome libraries 
Sequencing can also be used to capture information about gene 
expression levels and RNA editing events. Termed RNA-seq, these 
libraries are conceptually similar to DNA libraries, with the addition 
of a cDNA synthesis step to convert the RNA to DNA. 
Where the RNA from a sample is limited, an effective way to 
prepare RNA libraries for sequencing is to perform cDNA synthesis 
using random-hexamer priming prior to fragmentation and adaptor 
ligation [4]. This step amplifies the amount of starting material 
available for subsequent steps in the protocol, however as it creates 
double stranded molecules, information regarding the originating 
strand is lost. Subsequent analysis of the data is problematic in cases 
of overlapping genes, overlapping anti-sense transcripts, or in exper-
iments where the goal is to identify novel transcriptional events.  
By capturing RNA fragments prior to cDNA synthesis, frag-
ment or paired-end libraries can be created which retain information 
regarding the strand of transcription. Strategies used so far include: 
adaptor tagged random hexamers (Cloonan et al. 2008), serial adap-
tor ligation [6], or simultaneous adaptor ligation [7]. However all 
these approaches require microgram scale reactions to produce high 
quality (high complexity) libraries. 
2 Advanced Sequencing Technologies 
Conventional “Sanger” sequencing [8] requires the isolation of 
individual DNA fragments, which is typically achieved either 
through PCR or molecular cloning into bacteria. The rapid advance 
in sequencing that has been observed in recent years was kick-
started by the miniaturization of the PCR step – a protocol often 
referred to as “emulsion PCR” or ePCR [9]. 
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2.1 Massively parallel PCR 
Emulsion PCR requires a population of DNA fragments that 
have been captured individually between adaptors of known se-
quence (see Section 1.1). This population is diluted in PCR reagents, 
and microscopic beads coated with primers complementary to the 
adaptor sequence are added to the mix. This aqueous mix of PCR 
reactants is then vortexed with oil to produce micro-reactors or ‘mi-
celles’ (water in oil emulsion) which ideally contain a single DNA 
fragment, a single bead, and PCR reagents. This mixture is then 
thermally cycled, and each individual DNA fragment is clonally 
amplified onto a bead (Figure 2). Billions of micelles present in the 
emulsion allow the massive parallelization of the PCR step of se-
quencing, enabling in just hours what would take years to achieve 
using 384 well plates. 
For clonal amplification of individual library molecules, it is 
crucial to ensure that any micelle contains only a single DNA frag-
ment. The probability of any micelle containing exactly N DNA 
fragments given a ratio of DNA fragments to micelles can be mod-
eled by the Poisson distribution: (RN.e-R/N!). For example, using a 
DNA to micelle ratio of 1, the chance of a micelle containing exactly 
1 DNA fragment is 36.8%, and there is 26.4% of containing 2 or 
more DNA fragments. As multiple templates on a single bead will 
lead to mixed signals when sequencing, the optimal ratio of DNA to 
micelle numbers is actually much less than this, usually about 0.1. 
At this ratio, the chance of a micelle containing exactly 1 DNA 
fragment is only 9.1%, however there is only a 0.47% chance of 2 or 
more fragments in the same micelle.  
Also important, but less crucial is ensuring that each micelle 
only contains a single bead. Multiple beads in a micelle can deplete 
the PCR reagents available and lead to lower intensity signals when 
sequencing. However using low ratios of beads can lead to insuffi-
cient yields of amplified material: the probability of a micelle con-
taining exactly 1 DNA fragment and exactly 1 bead is the product of 
the individual probabilities. Using a DNA ratio of 0.1 and a bead 
ratio of 1 we can calculate an overall 3.3% chance of single bead 
and single template micelles. This means that the optimization of 
ratios is a trade-off between specificity and yield, and in practice this 
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leaves the majority of micelles empty, and the majority of beaded 
micelles without DNA. 
 
 
 
 
Figure 2. Emulsion PCR. Oil and PCR reagents (including the reverse primer) 
are mixed to form bubbles of aqueous reactors in an emulsion (micelles). The 
DNA template is amplified on beads coated with primers complimentary to the 
forward adaptor. Only a small fraction of all micelles will contain exactly one 
bead and one DNA fragment. 
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2.2 Advanced sequencing technologies 
2.2.1 Pyrosequencing 
The first commercial second-generation sequencer (Roche’s 
454 GS FLX) utilized pyrosequencing [10,11], a protocol where 
incorporation of a single nucleotide results ultimately in the emis-
sion of light via the firefly enzyme luciferase [12].  
Emulsion PCR (see section 2.1) is used to generate beads with 
amplified template DNA. These beads are arrayed onto a picotiter 
plate (PTP; a fused silica capillary structure), providing a fixed loca-
tion at which the subsequent sequencing reaction can be recorded. 
The reaction is initiated by the addition of a primer and DNA poly-
merase to the PTP followed by a solution of each nucleotide in a 
stepwise fashion. The incorporation of a complementary base in the 
growing DNA strand releases pyrophosphate, and leads to the emis-
sion of light captured by camera. The amount of light emitted is pro-
portional to the number of nucleotides present in the template (Fig-
ure 3).  
Sequencing across a homopolymer fragment (stretches of the 
same nucleotide within a sequence) can sometimes be troublesome 
for this technology due to limitations in the dynamic range of the 
cameras used, or insufficient nucleotides to complete the extension 
of the homopolymer, which can result in insertions or deletions 
when base-calling. By contrast, because each incorporation step is 
nucleotide-specific, substitution errors are rarely encountered in py-
roseqeuncing reads [13]. 
2.2.2 Sequencing by synthesis 
Illumina’s Genome Analyzer (previously Solexa) is based on 
the ‘sequence by synthesis’ concept to generate millions of reads per 
run. Unlike other massive-scale sequencing platforms, the Genome 
Analyzer doesn’t use emulsion PCR to amplify the signal from DNA 
fragments. Instead, this platform uses solid-phase amplification of 
DNA clusters [14]. Template DNA (captured between two different 
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Figure 3. Schematic diagram of Pyrosequencing. Emulsion PCR is used to 
generate beads covered in sequencing template. These are added to individual 
wells along with a cocktail of enzymes and reactants, including DNA polymerase, 
ATP sulfurylase, and Luciferase. The sequential addition of either dATP, dCTP, 
dGTP, or dTTP results in an enzymatic cascade which converts nucleotide incor-
poration into the growing DNA strand to light. This conversion is semi-
quantitative– the light generated is proportional to the number of nucleotides in-
corporated. The signal is then captured by a high performance camera, and digital-
ly converted to a DNA sequence.  
 
 
adaptors of known sequence) is added to a glass flowcell coated with 
covalently attached oligos complementary to the two adaptors. Hy-
bridization of the library molecules to the flowcell is followed by its 
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amplification via bridge PCR to produce randomly distributed, clon-
ally amplified clusters (Figure 4A).  
Each sequencing cycle involves flushing the flowcell with re-
action mixture, including: primers, a nucleotide mix, and DNA pol-
ymerase. The nucleotide mix contains four differently labeled fluo-
rescent nucleotides that are reversibly blocked at the 3′-OH to ensure 
that only a single base is incorporated per cycle by the DNA poly-
merase. The fluorescence at each cluster and its position on theglass 
surface is captured by camera, followed by a chemical step to re-
move the fluorescent group and unblock the 3’ end. The read length 
in each run is dependent on the number of cycles performed (Figure 
4B).  
Since this method reads each base individually, errors are not 
introduced while sequencing homopolymer sequences. The use of a 
modified polymerase and reversible dye terminator nucleotides, 
however, results in base-substitution errors and shorter read lengths 
than compared to pyrosequencing. 
2.2.3 Sequencing by ligation 
The SOLiD system from Applied Biosystems (now Life Tech-
nologies) is based on the hybridization-ligation chemistry, also re-
ferred to as sequencing by ligation [15]. Also utilizing emulsion 
PCR, the beads generated are covalently attached to a glass slide and 
placed into a fluidics cassette within the sequencer (Figure 5A).  
The sequencing process starts with the annealing of a universal 
sequencing primer complementary to the forward adapter on the 
library molecules. Fluorescently labeled nucleic acid probes are in-
troduced to hybridize to the template, and are ligated to the primer 
by DNA ligase. The unbound probes are washed away and fluores-
cent signals are recorded. A cleavage and wash step is performed to 
remove the final 3 bases along with the fluorescent group of the li 
gated probe to enable subsequent rounds of ligation and imaging 
(Figure 5B). 
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Figure 4. Sequencing by synthesis on the Illumina Genome Analyzer. (A) 
Instead of emulsion PCR amplified beads, single library molecules are clonally 
amplified by bridge PCR. Library molecules are hybridized to the flow cell which 
is covered with primers complementary to the library adaptors. PCR occurs 
through the bridging of single-stranded DNA molecules to nearby adaptors, caus-
ing replication to occur in clonal clusters. (B) Sequencing by synthesis is achieved 
through reversible terminator chemistry. The simultaneous addition of fluorescent-
ly labeled dNTPs (colored circles) that cannot extend ensures incorporation of a 
single nucleotide per cycle. The flow cell is washed, imaged, and then the termina-
tor (black triangle) is cleaved from the nucleotide allowing extension for the next 
cycle.  
 
 
 
Rather than directly probing individual nucleotides, SOLiD 
sequencers detect relationship between nucleotides due to the de-
generate design of the probes (di-base encoding). Each probe is an 
octamer consisting of 2 probe-specific bases and 6 universal bases 
with one of 4 fluorescent labels attached to the 5' end. In the first  
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Figure 5. Sequencing by ligation. (A) Emulsion PCR is used to generate beads 
which are subsequently attached to the surface of the slide. (B) DNA ligase is used 
to extend the DNA strand by incorporating fluorescently labeled octamer probes 
(inset). Each probe contains one of 16 possible di-base combinations, and an addi-
tional 5 random nucleotides (for a total of 1024 unique probes). A phosphorothio-
ate cleavage point allows the fluorescent label to be cleaved, and further probes 
can be ligated. (C) Once the full length of the tag has been extended, the DNA 
strands are denatured, and new primers are annealed. These new primers differ in 
their starting positions within the adaptor, which allows the di-base probes to 
interrogate different nucleotides. For primers n-2 onwards, unlabelled “bridge 
probes” are used to push the interrogated area out so that the adaptor sequence is 
not interrogated. After five ligation cycles, every nucleotide would have been 
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interrogated twice (dashed line). The overall length of the tag can be extended by 
performing extra ligation cycles per primer. Additional primer sets using different 
probes can be used to increase the accuracy of the reads. For example, the “Exact 
Call Chemistry” uses a single extension from the n-4 primer with tri-base probes 
containing known nucleotides at nucleotides 1, 2, and 4, which can increase the 
error correcting capabilities according to the manufacturer. The sizes of primers, 
probes, and DNA fragments are not to scale. 
 
 
ligation step, probes consisting one of 16 possible 2-base combina-
tions (eg. TT, AT etc) compete to anneal to the template sequence 
adjacent to the universal primer followed by its ligation. The synthe- 
sized strand is then denatured and washed away, and the process is 
restarted with a different primer, offset from the original. Five 
rounds of primer reset are completed for every sequenced tag – each 
primer is offset from the previous primer by 1nt to ensure that every 
nucleotide in the DNA template gets probed by the di-base twice. 
The number of ligation cycles determines the eventual read length. 
Although slower than the previously discussed technologies, 
di-base encoding results in sequencing every nucleotide twice, lead-
ing to higher system accuracy than single-pass sequencing according 
to the manufacturer (McKernan et al. 2009). However, the output of 
di-base encoding is a string of digits (0, 1, 2, or 3) representing the 
di-nucletotide relationships rather than the familiar strings of A, C, 
G, or T, and presents specific challenges for analysis. This represen-
tation, known as “color-space”, has not been widely adopted by the 
sequencing community, and the development of analysis tools lags 
behind those available for other platforms.  
The most common error reported from SOLiD sequenced tags 
include base-substitutions and sequence bias due to the under-
representation of sequences at the extremes of G/C % content [17].  
2.2.4 Semiconductor sequencing 
A recent development in massive scale sequencing has been 
the release of the Ion Torrent by Life Technologies. Most closely 
analogous to pyrosequencing, the Ion Torrent also arrays beads gen-
erated by emulsion PCR, and sequentially washes the array with 
individual nucleotides and DNA polymerase. However two major 
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advances differentiate these technologies. Firstly, the array is a sem-
iconductor microchip with wells positioned above nano-scale pH 
detectors. Secondly, native (unlabelled) nucleotides are used in the 
sequencing reactions. Nucleotide incorporation is detected as a 
change in pH when protons are released as a byproduct of DNA 
polymerization (Figure 6). This change in process reduces the cost 
of the machines and the reagents considerably, as no specialized 
optics are required. The sequencing runs are also considerably faster 
using native reactants, a typical run (generating up to 200nt) will last 
only two hours.  
The technology is in its infancy, but early reports suggest that 
the homopolymer tract issue is less of a problem than with pyrose-
quencing [18]. However this may not be due to any fundamental 
superiority of the platform, but to the sophistication of the correction 
algorithms used in the primary analysis (see section 3.1).  
Figure 6. Semiconductor sequencing. Emulsion PCR is used to generate beads 
covered in sequencing template. These are added to individual wells along with 
DNA polymerase. The sequential addition of either dATP, dCTP, dGTP, or dTTP 
results in the release of a hydrogen ion (H+), which is detected by the sensitive pH 
meters built into the semiconductor chip. The signal is converted to a sequencing 
read analogous to pyrosequencing, however as the optics are not required, the runs 
are faster, and both the reagents and machines are substantially less expensive 
than other currently available technologies. 
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2.2.5 Massive scale of data generation 
Regardless of the platform used, parallelizing sequencing dra-
matically increases the volume of data produced versus non-parallel 
sequencing. These new sequencers can analyze hundreds of millions 
of DNA fragments per run, compared with 96 to 384 DNA frag-
ments using the traditional method. Although the read-lengths ob-
tained are substantially shorter than with capillary sequencing (50 to 
400 nucleotides versus > 1000 nucleotides), the volume of sequence 
produced is substantially higher. For example, a SOLiD run generat-
ing 500 million mappable 50-mer tags will produce 25 Gb of usable 
sequence in 7 days – almost 1500-fold more than previously possi-
ble using a 384-well capillary sequencing instrument in the same 
time frame.  
3 Data analysis and bioinformatics 
Experiments using deep sequencing platforms require exten-
sive data analysis, normally consisting of three loosely coupled 
phases. 
3.1 Primary analysis 
In the first, primary phase, tag sequence and quality values are 
extracted from original high resolution images of each sequencing 
cycle (or in the case of Ion Torrent, digital signals of the change in 
pH). This analysis (termed base-calling) is normally performed by 
vendor maintained instrument embedded software and hardware. 
When raw intensity signals, normally of optical origin, are trans-
formed into base calls, each base call is ascribed a quality (generally 
a phred score), representing the likelihood that base is correct, and 
are closely linked to the molecular biology featured by that platform 
(see sections 2.3.1 – 2.3.4). Additionally, all platforms suffer from 
deterioration of signal as the read extends, leading to noise towards 
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the end of sequences – high throughput is traded for lower accuracy 
of reads. Although software has been written to improve the base-
calling of 454, Illumina, and SOLiD [19,20], they are often made at 
great computational expense in terms of both disk space for raw data 
storage and CPU time for re-processing it, hence not widely adopt-
ed. 
The extracted data has historically been text (ASCII) files 
which are easy to view, parse, and manipulate, however as the size 
of the output data increases, binary file formats are being adopted to 
better manage data storage issue. The use of binary formats for se-
quencing data will be advantageous as their file size is smaller than 
plain ASCII text, and also allows for more rapid access to individual 
sequencing reads when required. 
3.2 Secondary analysis 
Secondary analysis typically involves aligning the tags to 
some reference genome, if it exists, a process both computationally 
intensive and often strategically challenging [21]. This is due in part 
to systematic error in deep sequencing experiments, the size of the 
data sets being utilised, and the approach of aligning to reference 
sequences derived from different samples to the source data.  
Deep sequencing alignment software packages employ a varie-
ty of algorithms and approaches, often forcing a trade-off between 
accuracy and speed, as well as providing functions to facilitate cer-
tain tertiary analysis requirements. For example, aligners producing 
‘gapped’ alignments tend to perform slower than ‘ungapped’ align-
ers [22], but can detect insertion and deletion events, which may be 
a requirement for experimental analysis. Some aligners adopt a heu-
ristic approach, often with very fast performance, but at the expense 
of potentially missing some alignments. To increase performance, a 
common algorithmic approach is to ‘seed and extend’ an alignment. 
In this approach, small sub-sequences (seeds) of a specified length 
are used to rapidly determine candidate alignments, which can be 
extended to the full length of the read, or partially to include a pa-
rameterised minimum amount (variable length alignments). For ad-
ditional speed and sensitivity, ‘spaced seeds’ are most often used. 
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For highly accurate short read alignments, initial seed hits can be 
extended using computationally expensive algorithms such as 
Smith-Waterman to determine the most accurate local alignment.  
In some applications of deep sequencing methodologies, such 
as mammalian transcriptomics (RNA-seq), the mapped data can be 
subjected to further multiple sequence alignment among the tags to 
produce a reference-based assembly of transcripts. The adoption of 
such assembly approaches can assist in identification of novel se-
quence events. In all cases, the goal of secondary analysis is to iden-
tify biological signal from the data, reduce the data size and com-
plexity, and transform data to a format suitable with the continued 
analysis requirements. 
3.3 Tertiary analysis 
Unlike the previous two phases, the third phase is application 
specific, and the analysis will depend on the experimental design, 
the library protocol employed, and the precise biological question to 
be addressed. Many qualitative and quantitative aspects can be ex-
tracted from the sequencing data: sequence content (eg. mutations or 
RNA editing events), gene expression estimates, structural variation, 
copy number analysis, DNA or RNA footprinting, are but some of 
the applications (see section 4). Crucially, in order to obtain biologi-
cally meaningful results, and reduce experimental noise, this ‘bot-
tom up’ analysis approach imparts heavy reliance on the appropriate 
completion of previous stages for effective tertiary analysis [23]. 
4 Applications of tag sequencing 
4.1 Historical applications  
Although tag sequencing has often been thought of as a recent 
invention made possible by the rapid evolution of sequencing tech-
nology, it has been used since the early 1990s when “Sanger” se-
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quencing became broadly accessible to many laboratories. The de-
sire to increase the throughput of gene discovery and gene expres-
sion studies while lowering the experimental costs led to the adop-
tion of tag sequencing and spawned the field that would later be-
come known as transcriptomics. 
At the heart of this drive were the “Expressed Sequence Tags” 
(ESTs), generated by single stranded sequencing of the extreme ends 
of cloned cDNAs [24]. Large scale EST screens were slow to be 
adopted as the results were seen as incomplete and inaccurate [25]. 
However these tags soon proved to be invaluable, enabling rapid 
gene discovery (both novel genes in the same species [26], or the 
same genes in novel species [27]), exon identification [28], and ge-
netic mapping [29]. By 1995 more than half of the records in Gen-
bank were ESTs, and were being heavily accessed by scientific 
community [25].  
The development of SAGE (Serial Analysis of Gene Expres-
sion) - where transcripts are cleaved by one or more restriction en-
zymes, ligated together, and then sequenced - allowed for the first 
time broad detailed surveying of the mRNA population of cells [30]. 
SAGE had the advantage of not relying on prior knowledge of tran-
script sequences for their detection, and that quantification of tran-
script abundance was possible using the counts of sequenced tags. 
The primary disadvantage was the very short length of tag se-
quenced, typically only 10 – 14 nucleotides long. This short length, 
combined with the redundancy of complex genomes confounded the 
unambiguous detection of transcripts with multiple tag-to-gene 
mappings. This meant that statistically significant detection of dif-
ferentially expressed transcripts was difficult, particularly for those 
transcripts that were very poorly expressed (Lu et al. 2004). While 
improvements to the SAGE protocol extended tag lengths to 21 ba-
ses using LongSAGE [32], and then to 26 bases using SuperSAGE 
[33], these protocols (like EST sequencing) were still limited by 
cost, where it was prohibitively expensive to thoroughly survey mul-
tiple transcriptomes. When lower capillary sequencing costs failed to 
materialize and DNA microarray technology became the predomi-
nant genomic workhorse [34], interest in tag sequencing waned. 
4.2 Whole genome sequencing 
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The first, and arguably the most common application of the 
newer massive-scale sequencing was to perform whole genome se-
quencing or re-sequencing [12]. Full prokaryote de-novo genomic 
sequencing is now possible in single runs, although typically longer 
sequence reads (from capillary or 454 sequencing) are used as scaf-
folds and paired with the shorter massive scale technologies to gen-
erate high levels of sequence coverage for complex eukaryotic ge-
nomes.  
There has also been a widespread adoption of massive scale 
sequencing to detect mutations in cancer genomes. Many different 
kinds of mutations can be discovered by tag sequencing, including: 
simple nucleotide variations (SNVs; substitutions and small inser-
tions or deletions); copy number variations (CNVs; amplification or 
loss); and structural variations (SVs; insertions, deletions, inver-
sions, and translocations) (Figure 7).  
4.3 Targeted genome re-sequencing 
Another popular application of massive-scale tag sequencing 
is the re-sequencing of specific sub-regions of genomes. This in-
cludes “exome” re-sequencing, where genomic libraries are enriched 
by hybridization to arrays of exon sequences, providing a more cost 
effective approach when sequence variations of interest are likely to 
impact the transcriptionally active genome.  
The DNA binding locations of specific proteins can be inter-
rogated using Chromatin ImmunoPrecipitation followed by deep 
sequencing (ChIP-seq) experiments [35]. In such experiments, tran-
scription factor binding sites, RNA polymerase II binding sites and 
other proteins, as well as nucleosome locations can be determined. 
These experiments provide insight into transcriptional regulation and 
the functional organization of the genome. A more general applica-
tion of this idea, DNAse footprinting, can be used to assess genome-
wide positions of all DNA binding proteins simultaneously [36].  
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Figure 7. Detecting structural variations using paired sequencing. Tags from 
“paired-end” or “mate-pair” libraries are aligned to a reference genome, and the 
distance between the two tags is used to detect specific structural variants. Where 
the alignment distance is concordant with the size of the DNA fragments, no struc-
tural variation can be inferred. Discordant mapping distances and orientations 
between the two tags can identify specific molecular events. Deletions: are detec-
ted when the observed alignment distance for paired end reads is much larger than 
what would be expected from the library. Insertions: can be inferred when the 
observed alignment difference is much smaller than the expected alignment dis-
tance. Translocations: Inter-chromosomal translocations can be detected when the 
paired ends of a DNA fragment map to different chromosomes. Intra-
chromosomal events are often seen as pairs of insertion and deletion events. Inver-
sions: are identified when the orientation of the observed tags is different to the 
expected orientation, and depending on the size of the inversion, may also be 
coupled with discordant pairs detecting insertion and deletion events. 
 
 
There are a number of strategies for capturing epigenomic sig-
natures. Antibody based capture protocols, including ChIP-seq and 
MeDIP-seq (Methylated DNA ImmunoPrecipitation sequencing) 
[37], are easily combined with fragment library making strategies to 
profile DNA methylation and histone modification signatures [38]. 
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Similarly, capture using methyl-CpG binding domains (MBDs) [39] 
is also well suited for traditional fragment library sequencing how-
ever neither MeDIP nor MBD strategies are able to precisely deter-
mine the methylation status of each cytosine within the capture 
fragment. Bisulfite sequencing (a protocol that converts unmethylat-
ed cytosines to uracils) [40] provides this resolution, but is difficult 
to combine with short-tag sequencing due to the ambiguity in align-
ing bisulfite converted short tags. However, recent improvements to 
both the experimental protocol and to the computational analysis 
may make this approach more widely adopted [41]. 
Another less commonly applied targeted resequencing proto-
col is Restriction site Associate DNA sequencing (RAD-seq) [42]. 
RAD tags are generated through restriction enzyme digest and liga-
tion of a biotinylated adaptor, followed by DNA shearing and isola-
tion of biotinylated tags using streptavidin beads. Such libraries are 
used for genetic mapping [43], genotyping studies [42], and can also 
be used for targeted enrichment of CpG islands for DNA methyla-
tion studies [44,45] 
4.4 Whole transcriptome sequencing 
Whole transcriptome RNAseq can provide accurate and sensi-
tive gene expression data, but also information on novel exons, ex-
pressed mutations, alternative splicing, and fusion gene identifica-
tion (Figure 8) [46]. RNAseq data can be prepared as fragment or 
paired-end libraries, analogous to those described above - and the 
identification of exons and introns parallels the identification of de-
letions in genomic DNA. Fragment library sequencing can easily 
detect known exon-exon junction sequences, but the sensitivity for 
novel events is low. Paired-end libraries are far more sensitive, as 
they do not rely on a tag to cross an exon-exon boundary, and can 
also detect the relationship between novel exonic sequence and the 
transcriptional framework. Once the framework is assembled, the 
presence of individual transcripts can be modelled and quantified 
[47,48]. The single nucleotide resolution of RNA-seq data also al-
lows for determination of allelic specific expression if the parental 
genotype is known [49].  
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4.5 Targeted transcriptome sequencing 
Strictly speaking, most “whole transcriptome” RNA-seq ex-
periments could already be considered as targeted transcriptome tag 
sequencing. The majority include a step to deplete the very large 
proportion of cellular RNA composed of ribosomal RNA (rRNA) or 
transfer RNA (tRNA), together accounting for >99% of RNA in an 
average eukaryotic cell. Semantics aside though, targeted transcrip-
tome sequencing has revealed a great deal about the structure and 
function of complex transcriptomes.  
 Short-tag sequencing is ideally suited to detecting microRNAs 
(~22nt) and other small RNA populations (siRNAs, piRNAs, tiR-
NAs, snoRNAs, etc), as these molecules do not need to be fragment-
ed prior to library preparation [50]. Such libraries are generally pre-
pared from size selected RNA, either prior to or after the ligation of 
adaptors (see section 1.1). 
SAGE (see section 4.1) and CAGE (Cap Analysis of Gene 
Expression) [51] are tag sequencing strategies that both pre-date 
massive-scale sequencing – but these have been given a new lease of 
life with the dramatically reduced cost of obtaining data. CAGE, 
used to measure the transcriptional start sites of RNAs with a me-
thyl-G cap, has been particularly boosted by the new technology, 
spawning new protocols for comprehensive profiling (deep-CAGE) 
[52], and for applications where only tiny amounts of sample are 
available (nano-CAGE) [53]. 
Cross-Linking Immuno-Precipitation sequencing (CLIP-seq) 
[54] or High-throughput Sequencing CLIP (HITS-CLIP) [55], are 
two names to describe a protocol to profile the specific binding sites 
of RNA-binding proteins. RNA is cross-linked to bound proteins by 
UV irradiation. Unbound RNA is degraded, and the protected RNA 
is isolated and sequenced. It can be applied to all endogenous RNA-
binding proteins (RNA foot-printing), or to specific RNA-binding 
proteins by immuno-precipitaion or other protein tagging approach-
es. This technique is rapidly gaining popularity, as the immense reg-
ulatory potential of RNA-protein interactions becomes apparent. 
Recently, HITS-CLIP has been used to identify miRNA binding 
sites in mRNA [56]. 
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5 Clinical applications of tag sequencing 
Massively-parallel sequencing technology has progressed to 
the point where entire human genomes can be sequenced rapidly and 
comprehensively – and it is only a matter of time until sequencing 
costs fall to the magic $1000 mark, widely thought to be the thresh-
old price for consumer adoption of genome sequencing as a clinical 
test [57]. This is causing much excitement among medical research-
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ers, as it heralds an era of personalized medical genomics where 
genomic analysis is used to take the guesswork out of treatment. 
Such tests could be used to determine what mutations are present 
within an individual’s cancer, and guide chemotherapy choice to 
achieve the best possible outcomes for that patient.  
Despite the hyperbole, there are various non-trivial challenges 
that must be overcome before whole genome sequencing can be 
adopted as a mainstream clinical test. These include issues of start-
ing material availability, availability of 'normal' control samples, and 
the time involved for sample gathering and substantial computation-
al analysis [58]. While not insurmountable, these challenges make it 
far more likely that whole genome sequencing for mutation or pol-
ymorphism detection will not be routinely used as a clinical test in 
the short to medium term, remaining predominantly a research tool 
until these challenges are met.  
Of course the potential of tag sequencing in the clinic goes be-
yond whole tumor interrogation, and there are smaller scale tests 
with less ambitious outcomes that are currently under development. 
For example, Sequenom is developing a test known as MaterniT21 
to detect the aneuploidy that causes Down syndrome. This approach 
uses tag sequencing to detect an over-representation of tags deriving 
from chromosome 21 (indicative of a trisomy) in the maternal 
bloodstream [59]. As single nucleotide resolution of chromosome 21 
derived tags is not required, the analysis and interpretation of this 
test is far simpler and more amenable to routine clinical use. 
Research projects conducted in clinically accredited laborato-
ries to discover the causative mutations of rare disease are also be-
coming more common: Miller syndrome [60], Dopa-responsive dys-
tonia [61], and a rare manifestation of inflammatory bowel disease 
[62] have all had causative mutations identified through the use of 
massive-scale sequencing. While these success stories emphasize the 
potential benefits of tag sequencing in the clinic (although the ma-
jority of efforts to locate causal mutations are not as successful 
[63]), they are not routine genetic tests, and there is still significant 
ethical debate around using whole genome sequencing in the clinic 
[64]. 
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6 Future perspectives 
The prospect of technology improvements is very good with 
all current sequencing platforms continuing to drive higher through-
puts, longer reads, and improved accuracy from their current ap-
proaches. It is predicted that rapidly increasing data outputs from 
these technologies will make all tag sequencing projects more af-
fordable. However, even with current throughputs though, sequenc-
ing is already coming up against its next major challenge – the com-
putational requirements of storage, processing and analysis. What is 
becoming a headache of major genome sequencing centres world-
wide will only become worse as throughputs increase, and larger 
experiments become more common. Major breakthroughs in both 
hardware and software will be required to cope with the onslaught of 
genomic-scale data in the coming years.  
The commercial release of single molecule sequencing tech-
nologies (SMS) will be an area to watch. Early access users of the 
PacBio sequencing platform have demonstrated that with SMS, it is 
possible to generate sequence reads in excess of 1,000 nt, in real 
time, from minute amounts of template [65]. However error rates for 
this technology are substantially higher than the other platforms, and 
this creates substantial analytical challenges and pragmatically limits 
the application of this technology [66]. It is hoped that the likes of 
SMS will complement current sequencing approaches in the short to 
intermediate term but significant improvements in both data genera-
tion and error rates will be required for SMS to overtake current 
sequencing platforms as the technology of choice. 
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1.3 Hypotheses and Aims 
 
The extensive studies on miRNAs described above have revealed that these 
molecules are master regulators of genetic networks, frequently shown to be involved in 
human cancers. To truly understand their biological role in tumour initiation and 
progression it is imperative to characterize their biologically relevant targets using 
context-dependent cell models. This will lead to a better understanding of the miRNA-
mediated disruption to specific molecular processes underlying tumorigenesis, and will 
maximize their potential for medical applications. There are three specific hypotheses 
that will be tested in this thesis: 
1. The role of miRNAs in breast cancer is far from resolved because of the 
molecular heterogeneity of the disease. Identifying miRNAs whose expression is 
recurrently deregulated in human cancer samples will help discover novel 
oncomirs, whose role in the pathogenesis of the human cancer can then be 
elucidated. 
2. The oncogenic potential of miRNAs is driven by the coordinated targeting of 
transcripts in key pathways. Accurately surveying miRNA-mRNA binding events 
by biotinylated miRNA pull-downs in human cells will reveal the biological 
processes and pathways underlying their cancer promoting potential. 
3. Cell cycle is a key process underlying cell survival, proliferation and replication, 
and is frequently disrupted in disease states. Integrating leads from cell cycle 
related miRNA profiling and miRNAs deregulated in human cancers will enrich 
for novel oncomiRs, with either tumor suppressive or an oncogenic potential.  
 
This thesis specifically aims to address these hypotheses by functionally 
characterizing miR-182 and miR-139, both of which are deregulated in human breast 
cancers. To study the miRNA-mRNA interactions we use a biotinylated pull-down 
approach, and perform experimental validations using cell based assays. We also perform 
next generation sequencing technology to identify miRNAs, which show phasic 
expression across the cell cycle and perform an overlap analysis with miRNAs 
deregulated in human cancers to identify novel oncomirs.  
 
 
 
 
 
 
 
CHAPTER TWO 
 
miR-182-5p targets genes underlying the 
DNA Damage Repair pathway in breast 
cancer 
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2 miR-182-5p targets genes underlying the DNA Damage Repair 
pathway in breast cancer 
2.1 Summary 
 The role of microRNAs (miRNAs) in cancer were first discovered in 2002 when 
the miRs-15 and -16 were implicated in the causation of chronic lymphocytic leukemia 
[184]. Since then, hundreds of miRNAs have been identified and a large number of them 
have been linked to tumorigenesis [290]. Acting through the degradation of mRNA or 
inhibition of translation, they are believed to regulate the expression levels of genes 
exerting both oncogenic as well as tumour-suppressive properties, diving them into two 
groups based on their targets. Despite numerous studies reporting a causative role in 
different cancers, very few of these have provided deeper insight by defining the myriad 
of target genes that the miRNA could be acting upon. Identification of miRNA targets 
has been pursued, initially by carrying our miRNA microarrays [291], next-generation 
RNA-sequencing [292] and SILAC to quantitate changes in protein expression [62], 
high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation 
(HITS-CLIP) [116] and biotinylated synthetic tagging [123] have been used more 
recently to directly identify sites on mRNA that the miRNA associates with. Despite 
these technological advances, very few studies on cancer have exploited these tools to 
venture deeper into miRNA targets and their integrative function in tumorigenesis.  
 Chapter two of this thesis, presented in the form of a published manuscript titled 
‘MicroRNA-182-5p targets a network of genes involved in DNA repair’, characterizes 
the role of miR-182-5p in mammary tumorigenesis by identifying its targets using a 
biotinylated pulldown approach. Based on this technique, we were able to identify over a 
thousand putative targets for this miRNA, a significant proportion of which have been 
previously documented to play a role in cancer biology. Targets of this miRNA were 
shown to be involved in the DNA damage repair pathway and to play a role in cell cycle. 
While characterizing the role of miR-182 in tumorigenesis, another study reported its role 
in DNA damage through its target gene BRCA1 and its ability to sensitize cells to PARP 
inhibition [293]. From our study, we identify a significant number of miR-182-5p target 
genes, including BRCA1, which play a role in DNA damage repair such as CHEK2 and 
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TP53BP1. We find that miR-182-5p targets a network of genes involved in DNA damage 
repair and carry out functional assays to show that re-expression of CHEK2 (and BRCA1 
as previously reported) in miR-182 over-expressing cells can overcome their PARP 
sensitivity. Supplementary tables associated with the journal article are included as 
Appendix 1 of this thesis. The details of contributions to the following manuscript can be 
found on page vi under the heading ‘Publications included in this thesis’ 
 This study, while identifying novel target genes for miR-182, also fosters the 
hypothesis that miRNAs act by coordinated repression of a large number of target genes 
that lie in the same pathways to achieve functional outcomes. Not only do these 
hypotheses apply to the case of miR-182-5p, but they will be an overriding theme 
through the following chapters of this thesis. 
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ABSTRACT
MicroRNAs are noncoding regulators of gene expression, which act by repressing protein translation and/or degrading mRNA.
Many have been shown to drive tumorigenesis in cancer, but functional studies to understand their mode of action are
typically limited to single-target genes. In this study, we use synthetic biotinylated miRNA to pull down endogenous targets of
miR-182-5p. We identified more than 1000 genes as potential targets of miR-182-5p, most of which have a known function in
pathways underlying tumor biology. Specifically, functional enrichment analysis identified components of both the DNA
damage response pathway and cell cycle to be highly represented in this target cohort. Experimental validation confirmed that
miR-182-5p-mediated disruption of the homologous recombination (HR) pathway is a consequence of its ability to target
multiple components in that pathway. Although there is a strong enrichment for the cell cycle ontology, we do not see
primary proliferative defects as a consequence of miR-182-5p overexpression. We highlight targets that could be responsible
for miR-182-5p-mediated disruption of other biological processes attributed in the literature so far. Finally, we show that miR-
182-5p is highly expressed in a panel of human breast cancer samples, highlighting its role as a potential oncomir in breast cancer.
Keywords: PARP inhibition; biotin pull-down; miRNA; target identification
INTRODUCTION
MicroRNAs (miRNAs) are short (∼22 nt), single-stranded,
noncoding, negative regulators of gene expression in eukary-
otes. An individual miRNA is capable of targeting hundreds
of distinct mRNAs (Thomas et al. 2010), and together the
1150+ human miRNAs are believed to modulate more than
a third of the mRNA species encoded in the genome (Bartel
2009). miRNAs have been shown to be biologically significant
in various cellular processes such as cell differentiation, pro-
liferation, apoptosis, and development in humans as well as
other model organisms (for review, see Kloosterman and
Plasterk 2006). Thus, deregulation of miRNAs can result in
abnormal growth and development leading to several disor-
ders, including cancer.
Since the first study showing direct evidence of miR-17-92
acting as an oncogene in B-cell lymphomas (He et al. 2005),
the role of miRNAs as oncogenes or tumor suppressors has
been reported in almost every type of cancer. In the case of
breast cancer, miRNA expression profiling of more than 70
primary tumors and cell lines identified five miRNAs
(miR-10b, miR125b, miR-145, miR-21, and miR-155) that
were consistently deregulated (Iorio et al. 2005). miR-10b
has subsequently been shown to play a role in the metastatic
ability of breast cancer, positively regulating cell migration
and invasion (Ma et al. 2007). miR-21, initially shown to
be overexpressed in several human breast cancers (Iorio
et al. 2005; Volinia et al. 2006), was later established to func-
tion as an oncogene (Si et al. 2007) by targeting anti-meta-
static genes TPM1 (Zhu et al. 2007), PDCD4 (Frankel et al.
2008), and Maspin (Zhu et al. 2008). These and other studies
highlighted the importance of identifying miRNAs driving
tumorigenesis and of accurate prediction followed by charac-
terization of their biologically relevant targets. Intriguingly,
some miRNAs (such as miR-17-5p) have been shown to
have a dual role as both oncogenes and tumor suppressors,
depending on the cellular model under investigation (He
et al. 2005; Hossain et al. 2006; Volinia et al. 2006; Zhang
et al. 2006), and this has been due to a combination of the
gene networks targeted by the miRNA and the expression
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levels of target transcripts (Cloonan et al. 2008). These dual-
functioning miRNAs are of particular importance because
they are key biological hubs that could be used to leverage a
therapeutic outcome.
Another miRNA with this potential dual function is miR-
182-5p. This miRNA was first identified and cloned from the
mouse eye (Lagos-Quintana et al. 2003) and has shown to be
tumorigenic in melanoma (Segura et al. 2009) and endome-
trial cancer (Myatt et al. 2010) and is overexpressed in lung
(Cho et al. 2009), prostate (Schaefer et al. 2010), and colon
cancers (Sarver et al. 2009). It is also up-regulated in primary
gliomas and is associated with poor prognosis for patients
with metastasis (Jiang et al. 2010). In contrast, a tumor-sup-
pressive role for miR-182-5p has been established in lung
cancer (Sun et al. 2010; Zhang et al. 2011), and gastric adeno-
carcinoma (Kong et al. 2012), where overexpression of this
miRNA leads to suppression of cell growth. Despite the wide-
spread association of altered miR-182-5p expression across a
range of human cancers, only a few targets have been identi-
fied so far; including FOXO3, MITF (Segura et al. 2009),
FOXO1 (Guttilla and White 2009), BRCA1 (Moskwa et al.
2011), CTTN (Sun et al. 2010), RGS17 (Sun et al. 2010),
and more recently CREB1 (Kong et al. 2012) and MTSS1
(Liu et al. 2012). Recently, miR-182-5p, along with other
miRNAs in its cluster, has been shown to affect apoptosis,
senescence, proliferation, and migration/motility in medul-
loblastoma (Weeraratne et al. 2012). We believe that a
more thorough and systematic screen of miR-182-5p targets
will help elucidate its biological role in tumor biology.
Accurate miRNA target gene prediction has been challeng-
ing due to several reasons, mostly the constantly evolving hy-
potheses surrounding the miRNA–mRNA target recognition
principles. Initial studies showed miRNAs binding to the 3′
UTRs of their target mRNAs by partial complementation
spanning 6–8 nt of the seed sequence in their 5′ end (Lim
et al. 2005), and most computational target-prediction pro-
grams rely on evolutionary conservation of these seed sites
to limit the high false-positive rates for such small sequence
motifs (Brennecke et al. 2005; Krek et al. 2005; Lewis et al.
2005). Even with this limitation, there are typically hundreds
to thousands of targets predicted for a single miRNA, and
many are shown to be false positives when interrogated by lu-
ciferase assays (Bentwich 2005; Rajewsky 2006; Baek et al.
2008; Cloonan et al. 2008). Along with the lack of overlap
between targets predicted by different programs (Saito
and Saetrom 2010), this limits streamlined analysis of biolog-
ically relevant targets and their subsequent experimental
validation.
Our study overcomes these obstacles by using a combina-
tion of biotinylated synthetic miRNA pull-downs (Cloonan
et al. 2011) to capture endogenous mRNA targets of miR-
182-5p, and microarray expression profiling to identify
them. We show that miR-182-5p targets more than 1000
genes including many well-characterized oncogenes and tu-
mor suppressors. Its targets include multiple components of
the BRCA1-dependent DNA damage response pathway and
the downstream G2 cell cycle checkpoint. In the context of
breast cancer, we demonstrate that miR-182-5p’s primary
effect is to mediate the double-stranded DNA damage re-
sponse. Finally, we observe overexpression of miR-182-5p
in a panel of human breast cancer patient samples, estab-
lishing its role as a potential oncomir in human breast
cancer.
RESULTS
Identification of putative miR-182-5p targets using
biotinylated pull-down method
Endogenous targets of miR-182-5p in HEK293T cells were
captured using biotinylated synthetic miRNAs as described
in Cloonan et al. (2011). Transient transfections of biotiny-
lated miR-182-5p molecules and mock transfections, to be
used as negative controls in the subsequent analysis, were car-
ried out simultaneously in the same cell line. Expression pro-
filing was then performed on the pull-down fraction versus
the mock-transfected samples using microarrays (Fig. 1A).
The false discovery rate (FDR) was calculated to account
for multiple testing (Benjamini and Hochberg 1995).
Probes that met the 5% FDR threshold (for one-sided tests)
and with a fold-change >1.25 were considered significantly
enriched in the pull-down (Fig. 1B). This differential expres-
sion analysis (see Materials and Methods) revealed 1235
probes (1091 genes) to be significantly enriched in the pull-
down fractions (Supplemental Table 1).
Previously validated mRNA targets of miR-182-5p,
BRCA1, RGS17, and FOXO3 were significantly enriched in
our pull-down (P-values ∼0.005) (Fig. 1B), confirming the
validity of our approach. Although there is no large-scale ex-
perimental validation of miR-182-5p targets with which to
compare, we would expect to see an enrichment of predicted
targets in our biotin pull-down data. To assess this, we com-
pared the TargetScan (Lewis et al. 2005) predicted targets of
miR-182-5p with our significantly enriched genes from the
biotin pull-down (Fig. 1B,C). We observed an overlap of
113 genes, which was significantly more than we would pre-
dict by chance (χ2 test; P≈ 8 × 10−24; degrees of freedom =
1), indicating that the biotin pull-down is enriched for
predicted targets of miR-182-5p. Finally, we selected four
previously uncharacterized targets (CDKN1B, CHEK2,
SMARCD3, and NFKBIB), which also fall within our strin-
gent significance threshold, and asked whether miR-182-5p
could interact with these mRNAs. We cloned the predicted
binding sites into the 3′ UTR of a luciferase reporter gene,
and cotransfected either miR-182-5p mimic or a negative
mimic control, and measured the luciferase activity 48 h
post-transfection. Using this assay, we validated all four bind-
ing sites tested (Fig. 1B,D). Taken together, these results con-
firm that our pull-downs are enriching for genuine targets of
miR-182-5p.
miR-182-5p targets the DNA repair pathway
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miR-182-5p targets genes involved
in the DNA damage response
pathway
To infer the broad biological process-
es regulated by miR-182-5p, we per-
formed gene set enrichment analysis
(GSEA) on the full set of experimentally
determined targets miR-182-5p (biotin
pull-down) using Ingenuity Pathway
Analysis (IPA, Ingenuity Systems). The
enrichment of ontologies found in this
set was compared with 10 randomly
generated gene lists of equivalent size.
Supplemental Table 2 lists all “Molec-
ular and Cellular Functions” (P-value
< 0.002), and Supplemental Table 3
lists all “Canonical Pathways” (P-value
< 0.02) associated with the miR-182-
5p-predicted targets where the −log(P-
value) of the enrichment was at least
one standard deviation away from the
mean −log(P-value) from random gene
lists. For all subsequent analysis and
validations, we considered an ontology
as significantly enriched if its −log(P-
value) was at least four standard devia-
tions away from the mean of the −log
(P-value) from the random gene sets
(Cloonan et al. 2008).
Only two molecular processes were
identified above our stringent thresh-
old: “Gene Expression” (160 genes; P-
value≈ 1.15 × 10−11), and “Cell Cycle”
(114 genes; P-value≈ 1.46 × 10−10).
Like many miRNAs, transcription fac-
tors are over-represented in miR-182-
5p targets (Cui et al. 2006). The cell
cycle ontology is similarly broad, en-
compassing a variety of proliferative
and regulatory functions from the direct
control of proliferation to checkpoint
control. Like others (Moskwa et al.
2011), we could not identify a prolifera-
tive defect in MDA-MB-231 cells upon
inducing overexpression of miR-182-
5p (Fig. 2A,B). We constructed three
independent cell lines that could over-
express miR-182-5p in response to
doxycycline (Fig. 2A). Using all three
stable cell lines, we examined the rate
of proliferation (Fig. 2B) and the dis-
tribution of cells in each phase of the
cell cycle (Fig. 2C), but were unable to
detect any substantial differences. We
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FIGURE 1. Identifying targets of miR-182-5p via biotin pull-down. (A) Hierarchical clustering
of microarray data was performed using the plotSampleRelations function in the lumi package.
Total vertical distance between samples indicates similarity. (B) A “volcano plot” showing the
log2-transformed fold-change (mock/pull-down) versus the log10-transformed P-value for that
fold-change for every gene detected above background in the microarray. (Blue) Genes that are
targets validated by previous studies; (orange) genes predicted by TargetScan to be targets of
miR-182-5p; (green) genes selected for validation using luciferase assays (D). There is an apparent
enrichment of the targets in the pull-downs compared with the controls. (C) Venn diagram
showing the overlap of genes between TargetScan-predicted targets of miR-182-5p (also ex-
pressed above background in HEK293Ts) and biotinylated miR-182-5p pull-down-predicted tar-
gets. This overlap is significantly more than expected by chance. (D) Dual luciferase assay used to
validate CHEK2, SMARCD3, CDKN1B, and NFKBIB as targets of miR-182-5p. HEK293T cells
were transiently cotransfected with 20 nM miR-182-5p or control mimic with a pmirGlo-lucif-
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activity was normalized to Renilla activity; (∗) P < 0.05 in a Student’s t-test. The data plotted
are the mean and SEM of three independent biological replicates.
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were also unable to find a significant change in the proportion
of cells in each phase of the cell cycle upon miR-182-5p over-
expression in this system (Fig. 2C), and only a small (5%) ac-
cumulation in the G1 phase of transiently transfected HeLa
cells (Fig. 2D,E). Taken together, we conclude that miR-
182-5p is not sufficient to modulate proliferation or cell cycle
progression in the cell lines tested here.
However, this does not exclude a role
for this miRNA in proliferation in other
biological contexts or other aspects of
cell cycle biology, such as checkpoint
regulation.
We next sought to identify the canon-
ical pathways enriched with predicted
miR-182-5p targets. The most signifi-
cantly enriched pathways were all facets
of the DNA damage response (DDR)
(Supplemental Table 3): “Cell Cycle:
G2/M DNA Damage Checkpoint Regu-
lation” (P-value≈ 2.90 × 10−05), “Role
of BRCA1 in DNA Damage Response”
(P-value ≈ 8.50 × 10−05), “Hereditary
Breast Cancer Signaling” (P-value≈
1.1 × 10−04), “Cyclins and Cell Cycle
Regulation” (P-value≈ 1.49 × 10−04),
“Role of CHK Proteins in Cell Cycle
Checkpoint Control” (P-value≈ 5.6 ×
10−04), and “ATM Signaling” (P-val-
ue ≈ 8.20 × 10−04). To confirm that
this enrichment is not occurring in
response to a foreignmolecule being in-
troduced into these cells, we transiently
transfected 20 nM miR-182-5p mimic
(∼3× the concentration of the biotiny-
lated molecule) into MDA-MB-231
cells and evaluated expression levels of
known DNA repair genes. Figure 3A
shows that only ATF1 changed signifi-
cantly between cells transfected with
miR-182-5p or negative mimic control,
but only to a small extent (1.16×). This
confirms that there is no substantial
and widespread DNA-damage response
as a result of introducing an exogenous
molecule into these cells. To further
verify if this response is miR-182-5p
specific, we performed functional en-
richment analysis on biotin pull-down
targets of othermiRNAs (data generated
in-house). Figure 3B shows the canon-
ical pathway “Role of BRCA1 in DNA
Damage Response” to be highly signifi-
cant only in the miR-182-5p pull-down
analysis. As shown in the figure, the lev-
el of enrichment in the miR-182-5p
pull-down is at least four standard deviations away from
the mean of −log(significance) of other miRNA pull-downs,
suggesting that this enrichment is not occurring by chance
and is a specific response to miR-182-5p overexpression.
DDR is a key pathway in cancer, and its disruption leads to
genetic instability and promotes tumorigenesis (Deng 2006).
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FIGURE 2. Overexpression of miR-182-5p does not induce a proliferative defect. (A) Expression
of miR-182-5p as assessed by qRT-PCR in MDA-MB-231 cells (with low endogenous expression
of miR-182-5p) stably transfected with miR-182-5p whose expression is induced in response to
doxycycline. Shown here are three independent cell lines grown in the presence of 0 or 1000 ng/
mL of doxycycline for 48 h. RNU6B was used as an endogenous control for normalization of ex-
pression. (B) MTT cell proliferation assays of MDA-MB-231 cells stably expressing miR-182-5p.
The graph plots the mean and SEM of the previously studied stable cell lines grown with either 0
or 1000 ng/mL doxycycline. The induction of miR-182-5p does not affect the proliferation rates
of MDA-MB-231 cells. (C) DNA profile analysis of MDA-MB-231 cells stably expressing miR-
182-5p. The graph shows the mean and SEM of the percentage of cells in different cell cycle phas-
es, as assessed by FACS. There was no significant difference between MDA-MB-231 cells express-
ing or not expressing miR-182-5p. (D) Expression of miR-182-5p in HeLa cells transiently
transfected with miR-182-5p mimic or negative mimic control as assessed by qRT-PCR.
RNU6B was used as an endogenous control for normalization of expression. (E) A graph showing
the DNA profile analysis of HeLa cells transiently transfected with either miR-182-5p mimic or a
control mimic. Shown is the mean and SEM of three independent biological replicates, each per-
formed in technical triplicates. (∗) P < 0.05 in a Student’s t-test (n = 3).
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Typically, this pathway is activated in response to double-
stranded breaks (DSBs) leading to cell cycle arrest at either
the p53-dependent G1/S-phase checkpoint or the p53-inde-
pendent G2/M-phase DNA damage checkpoint (Moynahan
et al. 1999;Moynahan and Jasin 2010), and regulates a specific
set of gene products involved in DNA repair, such as BRCA1
(Khanna and Jackson 2001). Disruption to this pathway has
been associated with a wide variety of malignancies including
breast, ovarian, and pancreatic cancer (Lord and Ashworth
2012). Figure 4 shows an overview of this pathway and its
downstream effects, with the pull-down-identified targets of
miR-182-5p highlighted in dark gray. Of the 54 genes in
this pathway, we have now identified 36 (66.66%) as likely tar-
gets of miR-182-5p (Fig. 4; Supplemental Table 4).
A majority (32 of 36) of the miR-182-5p targets in this
pathway are proteins that play a major role in the positive reg-
ulation of the response to DNA damage, so their repression
by miR-182-5p could lead to a disruption of the DDR path-
way. There are, however, two classes of proteins that are an
exception to this coherent model. First is the Cyclin-depen-
dent Kinase 6 (CDK6), which, along with CDK4, is known
to phosphorylate and inactivate RB (RB1), leading to the
cell cycle progression (Meyerson and Harlow 1994). How-
ever, in response to DNA damage, this would typically lead
to an accumulation of genomic instability and is therefore
repressed by p53 (TP53), through p21 (CDKN1A) in vitro
(see Fig. 4; Meyerson and Harlow 1994; Harper et al.
1995). Hence, repression of the CDKs by miR-182-5p would
lead to activation of RB and a cell cycle arrest, enabling effi-
cient DNA repair. The second class is the components of the
SCF complex that are responsible for the ubiquitylation of
several proteins that are essential for the DDR, e.g., SKP1
and 2, components of the SCF complex, which are known
to degrade p27KIP1 (CDKN1B), an essential mediator of cell
cycle arrest in response to DNA damage (Cuadrado et al.
2009). Another component of the SCF complex, BTRC, is
also known to ubiquitylate ATF4, which plays a role in main-
taining genomic integrity (Lassot et al. 2001). The repres-
sion of these two classes of proteins by miR-182-5p could
lead to a normal functioning DDR, which may explain the
tumor-suppressive effects of this miRNA observed in lung
cancer (Sun et al. 2010; Zhang et al. 2011), and human gastric
adenocarcinoma (Kong et al. 2012), in a manner analogous
to miR-17-5p’s dual functionality (He et al. 2005; Hossain
et al. 2006; Volinia et al. 2006; Zhang et al. 2006).
miR-182-5p modulates PARP inhibitor sensitivity
by targeting multiple components of the DNA repair
pathway
miR-182-5p has recently been reported to target BRCA1
(Moskwa et al. 2011), a critical component of the homolo-
gous recombination (HR) pathway, in breast cancer cell lines.
Since it has been shown that some miRNAs concurrently tar-
get functionally related genes to drive a specific biological sig-
nal (Cloonan et al. 2008; Tsang et al. 2010; Ulitsky et al. 2010;
Su et al. 2011) and miR-182-5p targets are enriched for genes
involved in DNA damage repair, we hypothesized that miR-
182-5p’s action on the HR pathway extends beyond the tar-
geting of BRCA1. miR-182-5p targeting of CHEK2, an up-
stream regulator of BRCA1, should also alter sensitivity to
the HR-mediated repair. Direct targeting of the predicted
miR-182-5p-binding site in CHEK2 was confirmed by dual
luciferase assay (P < 0.05) (Fig. 1D). We then used the
BRCA1 wild-type MDA-MB-231 cells transiently transfected
with miR-182-5p mimics in PARP inhibition assays, using
different concentrations of ANI (PARP1 inhibitor 4-amino-
1,8-naphthalimide) ranging from 0 to 10 μM. These cells
were also shown to have an ∼1000-fold increase in the ex-
pression of miR-182-5p relative to the negative control mim-
ic in the MDA-MB-231 cells (Fig. 5B). PARP inhibitors are
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FIGURE 3. Enrichment of targets in the DNA damage response is spe-
cific to miR-182-5p overexpression. (A) Real-time PCR analysis to eval-
uate the relative mRNA levels of known DNA repair genes was
performed in MDA-MB-231 cells transiently transfected with 20 nM
miR-182-5p mimic or negative mimic. (∗) Significant changes (P <
0.05). Data were normalized using HPRT as the internal control. The re-
sults shown are from three independent biological replicates, each per-
formed in technical quadruplicates. (B) Functional enrichment analysis
was performed using biotin-enriched targets of several miRNAs includ-
ing miR-182-5p. As shown, the canonical pathway “Role of BRCA1 in
DNA Damage Response” is highly significant in the miR-182-5p pull-
down with its −log(significance) at least four standard deviations
away (top arrow) from the mean −log(significance) (lower arrow) of
the other miRNAs. This confirms that the enrichment seen for targets
in the DNA damage response is miR-182-5p specific and not occurring
by chance.
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cytotoxic in cells deficient in HR-mediated repair, because
the inhibitors suppress base excision repair (BER), which
would normally compensate an HR deficiency. Increased
sensitivity to PARP inhibitors would therefore indicate a re-
duction in HR function, and reintroduction of a miR-182-5p
target ORF should rescue the phenotype (Fig. 5A).
As previously reported (Moskwa et al. 2011), overexpres-
sion of miR-182-5p sensitized the cells to PARP inhibition,
as measured by clonogenic survival assays. We confirmed
that reintroduction of the BRCA1 ORF could rescue this phe-
notype (Fig. 5C) with a P-value < 0.05 at 0.01 μM and 0.1 μM
showing 10%–20% increase in rescue of the cells. Our results
also demonstrate that the phenotype can be rescued by
CHEK2, where similar results were obtained with 20%–
30% increase in survival at the 0.1 and 1 μMconcentrations of
the PARP inhibitor (P-value < 0.05), indicating that CHEK2
is another target of miR-182-5p that contributes to this
phenotype.
Validation of predicted binding sites
in MDA-MB-231 cells
Since the original target identification analysis was performed
in the nonmalignant HEK293T cell lines, we sought to vali-
date the interaction between miR-182-5p and some of the
genes enriched in the biotin pull-down using MDA-MB-
231 breast cancer cells. We selected genes for which there
was a single predicted binding site, for validation in luciferase
assays. The predicted binding sites (and ∼60 nt of surround-
ing sequence) were cloned into the 3′ UTR of the Dual
Luciferase pmiRGlo vector and transiently transfected into
cells. Luciferase activity, indicative of translation from the
plasmid, was measured in the presence of miR-182-5p mimic
or negative control mimic and normalized using Renilla ac-
tivity. Using this approach, we were able to validate seven
out of eight of the targets picked (87.5%) (Fig. 6), including
ATF1, RAD17, CHEK2, SMARD3, CREB5, TP53BP1, and
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CDKN1B. These data further strengthen our hypothesis that
miR-182-5p targets the DNA repair pathway through a net-
work of functionally related genes. Additionally, the high
rate of validation seen here contrasts favorably with valida-
tion rates based on TargetScan predictions alone (40%)
(Cloonan et al. 2008), and confirms the ability of the biotin
pull-down approach to enrich for genuine biological targets.
miR-182-5p is frequently up-regulated in human
breast cancer
Although miR-182-5p has been shown to be important for
development of breast cancer in cell lines andmice, no screens
have been performed to determine its relevance to human
breast cancer subtypes. We extended the analysis of miR-
182-5p expression to a cohort of human breast cancer patient
samples (from the Brisbane Breast Bank, The University of
QueenslandCentre forClinical Research,UQCCR). The sam-
ple cohort (n = 40) included “Invasive Ductal Carcinomas–
No Special Type” (IDC-NST) of different molecular subtypes
including triple negative (n = 18); Her2+ (n = 4), ER+/PR+ (n
= 9); Invasive Lobular Carcinomas (ILC) (n = 3); and normal
breast tissue (n = 6) (Supplemental Table 5). We included
several molecular subtypes of breast cancer and assayed the
expression levels of miR-182-5p relative to an endogenous
controlRNU6B, using qRT-PCR.As shown inFigure 7 (upper
panel), miR-182-5p is highly expressed (log10 fold-change
[tumor/normal] >1.5) in 32/40 tumor samples (∼80%) as-
sayed relative to the normal controls, and all but one sample
had higher expression in the tumors than any of the normal
controls. The average expression of miR-182-5p in every tu-
mor subtype is significantly higher (P < 0.0001) than the av-
erage expression across the normal breast tissue (Fig. 7,
upper panel). Expression of miR-182-5p is highest across
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the ER+/PR+ luminal subtype; however, the expression of
miR-182-5p is highly variable across the triple negative tu-
mors, perhaps indicative of the heterogeneitywithin this class.
To confirm the relevance of miR-182-5p in an indepen-
dent cohort of human breast cancers, we downloaded
miRNA-seq data from the Cancer Genome Atlas (TCGA)
data portal (https://tcga-data.nci.nih.gov/tcga/), which in-
cluded both tumor (n = 741) and normal tissues (n = 99).
The relative abundance of miRNAs was counted, and shown
in Figure 7 (lower panel) is the reads per million of miR-182-
5p across both the tumor and normal cohort, where we find a
significant difference (P < 0.0001) in its level of expression.
These results confirm that miR-182-5p is an important
miRNA relevant to human cancer and that further study is
warranted to clearly delineate its role in the pathogenesis
and progression in specific breast cancer subtypes.
DISCUSSION
In this study, we have characterized transcriptome-wide
mRNA targets of miR-182-5p using the affinity copurifica-
tion of mRNA bound to biotin-labeled miRNAs (Cloonan
et al. 2011). Gene set enrichment analysis (GSEA) of miR-
182-5p targets revealed that the DNA damage response was
a core molecular pathway regulated by this miRNA. This
pathway is critical in the normal functioning and replication
of cells, and disruption can cause cellular transformation.
PARP plays a key role in DNA repair via the base excision re-
pair (BER) pathway. When PARP is inhibited, single-strand
breaks (SSBs) degenerate to lethal DSBs, which, in the case
of BRCA-negative cells or cells deficient in HR, leads to
cell death (Bryant et al. 2005; McCabe et al. 2006).
Importantly, we were able to partially rescue miR-182-5p-
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FIGURE 7. Expression analysis of miR-182-5p across tumor subtypes
and normal tissue from human breast cancer patient samples. (Upper
panel) Real-time PCR was performed in breast cancer patient samples
of various subtypes to assess miR-182-5p expression, where lines and er-
ror bars represent the mean and SEM of miR-182-5p expression (nor-
malized to RNU6B) across sample subtypes: Invasive Ductal
Carcinoma of Triple Negative (n− 19); Her2+ (n = 4) or ER+/PR+
(n = 9) phenotype; Invasive Lobular Carcinomas (n = 3); and normal
breast tissue (n = 6). (▪) Expression levels for individual patients; (∗) in-
dicate where the difference in the means subtype was (P < 0.0001) when
compared with the normal samples. (Lower panel) Expression of miR-
182-5p across several breast cancer patient samples as assessed by
miRNA-seq. Shown in the x-axis is reads per million of miR-182-5p
in data downloaded from the TCGAweb portal, which included tumors
(n = 741) and normal tissue (n = 99). (∗) Where the difference in the
means was (P < 0.0001) when compared with the normal samples.
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induced sensitivity to PARP inhibitors by restoring either
BRCA1 or CHEK2 expression. Moskwa et al. (2011) previ-
ously concluded that BRCA1 was the key gene responsible
for the miR-182-5p-induced sensitivity for PARP inhibitors,
because 100% reversal of the sensitivity was observed upon
reintroduction of BRCA1. However, the overexpression of
BRCA1 under a strong promoter could easily compensate
for the relatively weaker disruption to the pathway achieved
by induction of an miRNA, and hence mask the contribution
of other pathway members. Our results directly demonstrate
that CHEK2 contributes to the miR-182-5p-induced sensi-
tivity to PARP inhibition, but also suggest that other mem-
bers of the pathway could contribute as well, confirmed by
the luciferase assay validation in the breast cancer cells (Fig.
6). Together, repression of DNA damage repair could lead
to genomic instability followed by cellular transformation
(Fig. 8).
One of the well-studied consequences of suppressing the
repair of DNA damage is the activation of apoptotic path-
ways, and this seems counterintuitive for a potential driver
of tumorigenesis. There are two hypotheses that could ex-
plain this apparent contradiction. The first is that the com-
bined effect of miR-182-5p targeting across a broad range
of genes involved in DNA damage repair would manifest as
a reduction in the fidelity of DNA repair, rather than a failure
of this pathway. This would increase the burden of mutation
in these cells, possibly quite slowly, allowing the cells to ac-
commodate and adapt to a modestly increasing mutation
load. Such a hypothesis, while plausible, has not been directly
tested in this study. The second (but not mutually exclusive)
hypothesis is that miR-182-5p also directly suppresses the
apoptotic pathway triggered by DNA damage. CDKN1B
(p27KIP1) was a target of miR-182-5p identified by the biotin
pull-down and validated using luciferase assay. This gene reg-
ulates G0-to-S phase transitions by interacting with cyclin-
dependent kinases (CDKs) (Hengst and Reed 1998; Sherr
and Roberts 1999), and overexpression of this gene has
been shown to trigger apoptosis in the MDA-MB-231 cell
line (Katayose et al. 1997) with pro-apoptotic properties in
other cancers (Fujieda et al. 1999; Wu et al. 1999; Tenjo
et al. 2000). Apoptosis has recently been identified as one
of the deregulated pathways by the miR-182-5p cluster in
medulloblastoma (Weeraratne et al. 2012), and suppression
of CDKN1B by miR-182-5p, along with other pro-apoptotic
genes like BAK and BAX (Supplemental Table 1), suggests
that apoptosis triggered by DNA damage could be deregulat-
ed by this miRNA.
Not all targets of miR-182-5p easily fit into the model pro-
posed here (Fig. 8). Some targets—like BTRC, SKP1, SKP2,
and the components of the SCF complex—are suppressors
of DNA damage repair, andmiR-182-5p suppression of these
proteins would act to ensure genome fidelity. Relevant to this
point are the conflicting reports regarding miR-182-5p’s mo-
lecular role in tumorigenesis. Whereas there appears to be an
oncogenic role for this miRNA in some cancers including
melanoma (Segura et al. 2009), endometrioid endometrial
cancer (Myatt et al. 2010), and glioma (Jiang et al. 2010);
in others, such as lung adenocarcinoma (Sun et al. 2010;
Zhang et al. 2011) and human gastric adenocarcinoma
(Kong et al. 2012), its role is more akin to that of a tumor sup-
pressor. Such dual-function miRNAs have been previously
reported: miR-26a (Sander et al. 2008; Huse et al. 2009;
Kota et al. 2009; Kim et al. 2010), miR-205 (Iorio et al.
2007, 2009; Gandellini et al. 2009; Wu et al. 2009), and
miR-17-5p (Hossain et al. 2006; Mraz et al. 2009; Yu et al.
2010; Li et al. 2011) are all characterized examples. In the
latter case, the molecular mechanism underlying the dual
phenotype was uncovered through systematic screening of
predicted targets through luciferase assays (Cloonan et al.
2008). Targeting both inhibitors and activators of DNA dam-
age repair could either promote or inhibit genomic stability
depending on the relative expression levels of those targets
—and this could explain the conflicting reports of miR-
182-5p’s role in tumorigenesis. For a firm conclusion to be
made, independent validation of each target would be re-
quired. While the biotin pull-down has been optimized for
high specificity, the presence of false-positive targets in the
enrichment analysis should be considered while interpreting
these results. Ongoing work suggests that the rate of false pos-
itives is ≤5% (data not shown), which would not be high
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FIGURE 8. Model showing the effect of miR-182-5p on the DNA re-
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sor” genes activate a signaling cascade including transducer and effector
genes that leads to an efficient repair of the DNA damage. Under this
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enough to interfere with GSEA but may become critical when
considering individual targets.
Many of the key genes involved in DNA repair also have
annotated roles in the cell cycle, and GSEA correctly identi-
fied the cell cycle as an important molecular function of
miR-182-5p targets. Although we found that ectopic expres-
sion of miR-182-5p was not sufficient to drive proliferation
(confirming earlier reports) (Moskwa et al. 2011), we did
observe minor cell cycle effects consistent with a DNA dam-
age response. The HR-mediated repair is restricted to the
S and G2 phases of the cell cycle (Moynahan et al. 1999;
Moynahan and Jasin 2010) by several factors and detection
of double-strand breaks would typically result in a G2 arrest.
In our analysis with overexpression of miR-182-5p in HeLa
cells (which would suppress this checkpoint), we see fewer
cells in both the S and G2 phases with increased accumulation
in the G1 phase. This could be a result of a disrupted G2 arrest
as a result of the deregulated HR-mediated repair pathway
(Fig. 8). Other studies have shown the miR-182-5p in con-
junction with miR-96 and miR-27a (Guttilla and White
2009) can alter proliferation rates in MCF-7 breast cancer
cells; hence, it could be that concomitant targeting of genes
by all members of the miR-182-5p cluster and other mature
miRNAs is essential to drive this phenotype.
We confirm the relevance of miR-182-5p dysregulation to
human breast cancer by showing that this miRNA is overex-
pressed across a panel of human breast cancer samples, which
belong to several molecular and pathological subtypes. Al-
though overexpressed in the triple negative subtype, the var-
iability of miR-182-5p expression within this subtype was
substantially more than seen in any other classification. Tri-
ple negative tumors are typically characterized by BRCA defi-
ciency and a disrupted HR pathway. Given miR-182-5p’s role
in HR-mediated DNA repair, it is possible that transcription
factors that typically dysregulate protein components of this
pathway are also dysregulating miR-182-5p transcription. In
melanoma, miR-182-5p has been associated with the inva-
sion/metastatic signaling cascade (Segura et al. 2009). We
did not find a strong association betweenmiR-182-5p and the
metastatic lymph node status of samples, suggesting that its
role in breast cancer is more likely tumorigenesis than tumor
progression. However, further studies using matched prima-
ry and distant metastatic samples followed by functional val-
idations are required to elucidate miR-182-5p’s molecular
role in each cancer subtype.
Of particular relevance to therapeutic biomarkers is miR-
182-5p’s ability to induce sensitivity to PARP inhibitors
through multiple effectors. This result could be of immense
therapeutic value, potentially widening the opportunity to
expand treatment from breast cancers with mutations in
BRCA1/2 to tumors with miR-182-5p disrupted HR-mediat-
ed pathways. It is currently not clear what percentage of the
sporadic breast tumor patients with a functional HR pathway
would respond to treatment with PARP inhibitors. We have
now shown miR-182-5p as a potential regulator of the HR-
mediated DNA repair pathway, which is the major determi-
nant of a cell’s sensitivity to PARP inhibition. Further studies
are required to address if the status of BRCA mutation and
overexpression of miR-182-5p are mutually exclusive and if
either one is sufficient to make cells PARP-inhibition sensi-
tive. This could include nonbreast cancer tumors, such as
ovarian cancer, where several sporadic cancer types display
a “BRCA-like” phenotype (Turner et al. 2004). Intriguingly,
overexpression of miR-182-5p has recently been shown to
target BRCA1 in ovarian papillary serous carcinoma (Liu
et al. 2012). An important subject of future studies would
be to determine how well miR-182-5p performs as a prog-
nostic or therapeutic biomarker.
MATERIALS AND METHODS
Cell culture
HEK293T, MDA-MB-231, and HeLa cells were maintained in
DMEM (Life Technologies) with 10% FBS and 1% Penicillin–
Streptomycin (Life Technologies) and grown in a 5% CO2 atmo-
sphere at 37°C. MDA-MB-231 and HeLa cell lines were purchased
from Cell Bank; the HEK293T cell line was purchased from ATCC.
Biotin pull-downs, microarray hybridizations,
and analysis
Pull-downs of miR-182-5p targets were carried out as previously de-
scribed (Cloonan et al. 2011), using biotin-labeled oligonucleotides
specific for miR-182-5p (Supplemental Table 6). Briefly, 50 pmol of
biotin-labeled oligos (IDT) was transiently transfected into
HEK293T cells and cultured for 24 h. This was followed by cell lysis
and binding of 50 μL (Streptavidin), myOne C1 Dynabeads
(Invitrogen) to the RNA fraction for enrichment. Fifty nanograms
of captured mRNA fractions (three independent biological repli-
cates) was amplified and labeled using the Illumina Total Prep
RNA amplification kit (Ambion) as per the manufacturer’s instruc-
tions. Samples were profiled on Illumina HumanHT-12 chips along
with control RNA from mock-transfected cells.
Microarray data were normalized using the lumi package (Du
et al. 2008) by applying background adjustment, variance-stabilizing
transformation (Lin et al. 2008), and robust spline normalization
(Workman et al. 2002) successively. The lmFit and eBayes functions
in the limma package (Smyth 2004) were used to test differential ex-
pression between the pull-down samples and the controls (Cloonan
et al. 2011). The false discovery rate (FDR) was calculated to account
for multiple testing (Benjamini and Hochberg 1995). Probes that
met the 5% FDR threshold (for one-sided tests) were considered sig-
nificantly enriched in the pull-down. The transcripts (ENSEMBL
V62) to which theymatched exactly were considered putative targets
of that miRNA. The targets enriched using the biotin pull-downs
were analyzed using Ingenuity Pathway Analysis as previously de-
scribed (Cloonan et al. 2008).
Stable cell line generation
MDA-MB-231 cells stably expressing miR-182-5p were generated
using the Mir-X Inducible miRNA Systems (Clontech). Briefly,
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MDA-MB-231 cells were transfected with the pTet-on Advanced
Vector using Lipofectamine 2000 (Life Technologies Australia, Invi-
trogen Division), and cells stably expressing the plasmid were select-
ed using 800 μg/mL G418 (Life Technologies); maintenance
concentration: 400 μg/mL G418. Primers (Supplemental Table 6)
were used to amplify the miR-182-5p hairpin from human genomic
DNA and cloned into the pmRI-ZsGreen I vector plasmid
supplied and subsequently transfected into the 231-pTet-on parent
line. Cells stably expressing pmRi-Zsgreen-miR-182-5p were select-
ed using 1 μg/mL puromycin and further maintained in 0.5 μg/mL
puromycin. Stable expression of miR-182-5p was confirmed using
the miRNA Taqman Assay (Applied Biosystems) specific for miR-
182-5p (Fig. 2A).
Clonogenic cell survival assay
MDA-MB-231 cells were seeded overnight (2 × 105 cells/well in a
12-well plate) and transfected with 10 nM miRNA mimics
(Ambion). In rescue experiments, miR-182-5p or control mimics
were cotransfected with 0.5 μg of BRCA1 or CHEK2 cDNA clones.
After 48 h, 500 cells in 2 mL of DMEM media (10% FBS, v/v)
were seeded on six-well plates in triplicate and incubated overnight
before treatment. PARP inhibitors (4-amino-1, 8-naphthalimide
[Sigma-Aldrich] in DMSO) were added to the growth media at 0
μM, 0.01 μM, 0.1 μM, 1 μM, and 10 μM concentrations. Cells in
the presence of PARP inhibitor were allowed to form colonies for
14 d. For evaluation, formed colonies were stained with Crystal Vio-
let and surviving colonies containing more than 50 cells were count-
ed. The plating efficiency was 20%–35%.
Flow cytometry for cell cycle analysis
HeLa cells were transiently transfected using 50 nM miR-182-5p
mirVana mimic (Life Technologies) using Lipofectamine 2000
(Invitrogen) as per the manufacturer’s instructions. All cells were
harvested and fixed in 70% ethanol overnight at −20°C. DNA was
stained using 10 μg/mL propidium iodide (Sigma-Aldrich), and
RNA was removed using 200 μg/mL RNase A (Sigma-Aldrich).
Cells were filtered through a 35-μm cell strainer mesh
(BectonDickinson) and analyzed on Becton Dickinson LSR II flow
cytometer fitted with a 488-nm laser. Cell data were gated and ana-
lyzed using FlowJo 7.2.2 (Tree Star, Inc.). The same fixing and
FACS protocol was applied to MDA-MB-231 cells stably overex-
pressing miR-182-5p.
Dual luciferase assay to validate predicted binding sites
Predicted target sites of miR-182-5p were cloned into the Nhe1 and
SalI sites of pmirGLO Dual-Luciferase miRNA Target Expression
Vector (Promega). Synthetic oligos (Supplemental Table 6) corre-
sponding to 60 nucleotides surrounding the target sequence were
annealed before ligation into the pmirGlo plasmid. All constructs
were verified by sequencing. HEK293T or MDA-MB-231 cells
were cotransfected with 50 ng of a pmirGlo construct and miR-
182-5p or negative mimic (Ambion) to a final concentration of
20 nM. Post-transfection, cells were incubated for 48 h prior to as-
saying. Luciferase activity was assayed using the Dual Luciferase
Reporter Assay System (Promega) and detected on a Wallac 1420
luminometer (PerkinElmer). Luciferase activity was normalized to
the internal control, Renilla activity in each well. Assays were con-
ducted in triplicate and independently repeated three times.
MTT proliferation assays
Stable pmRi-MDA-MB-231 cell lines overexpressing miR-182-5p
(1000 ng/mL doxycycline) and parent stables (with no doxycycline)
were plated at 1 × 104 cells per well. MTT (3-[4,5-dimethylthiazol-
2-yl]-2,5-diphenyl tetrazolium bromide) activity was assayed using
a Cell Growth Determination Kit (Sigma-Aldrich) according to the
manufacturer’s instructions and detected on a PowerWave XS spec-
trophotometer (BioTek).
Clinical samples, RNA purification, and qRT-PCR
analyses
Human breast tumors were derived from the Brisbane Breast Bank,
collected from consenting patients and with ethical approval from
the research ethics committees of the Royal Brisbane & Women’s
Hospital and the University of Queensland. Histological type, tumor
grade, tumor size, lymph node status, and ER, PR, and HER2 status
were obtained from the pathology reports. ER, PR, and HER2 bio-
markers were used to infer molecular subtype as luminal, HER2, or
triple negative. Total RNA from human tumor samples was extract-
ed using tumor homogenization followed by TRIzol extraction
(Invitrogen).
Total RNA was purified from cell lines using the miRNeasy Mini
Kit (QIAGEN), and RNA integrity was assessed using an Agilent
Bioanalyzer 2100. For mature miRNA, cDNA (5–10 ng of total
RNA) was synthesized using a Taqman MicroRNA RT Kit
(Applied Biosystems), and qRT-PCR was performed using a miR-
182-5p MicroRNA Taqman assay (Applied Biosystems). For
mRNA expression analysis, 500 ng of total RNA was reverse-tran-
scribed using SuperScript III (Invitrogen), and a 1:50 dilution of
the cDNA was used in the real-time PCR reaction. All RT-PCR
was performed on an Applied Biosystems 7000 Sequence
Detection System. For small RNA expression analysis, RNU6B was
used as an endogenous control to normalize the data.
DATA DEPOSITION
The raw microarray data used in this study are available from
the Gene Expression Omnibus (GEO) under accession number
GSE38593.
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3 miR-139-5p is a potential tumour suppressor of breast cancer by targeting 
genes underlying metastasis related pathways 
3.1 Summary 
As discussed in the previous chapter, miRNAs exert their functions through the 
regulation of a multitude of targets, many of which are components of the same pathway. 
Through the coordinate repression of these targets genes, they are able to induce global changes 
to gene expression resulting in the alteration of cellular and organismal phenotypes. In the case 
of miR-182, identification of its target genes led to uncovering its function in DNA damage 
repair, which, although alluded to in previous publications from its target BRCA1 [293], was not 
a complete representation of its function. The following chapter will discuss the role of another 
miRNA, miR-139-5p, whose function was previously poorly defined based on a few identified 
targets. 
Carcinomas that result from malignant transformation of epithelial cells are the most 
common types of cancers in humans. 90% of mortalities from this form of cancer are a result of 
the spreading of the disease to other organs and tissue sites of the body through the process of 
metastasis [281]. Although the mechanisms involved in this process are poorly understood, there 
are a series of steps that cancer cells undergo before being able to metastasize to distant tissue, 
commonly known as the invasion-metastasis cascade [294]. Briefly, the carcinoma cells acquire 
migratory and invasive properties that enable them to renounce their cell-cell adhesion junctions 
as well as adherence to the basement membrane at their orthotopic site. This enables them to 
invade local tissues and intravasate into the bloodstream where they can travel to distant sites. 
Following this, they extravasate and colonize foreign tissue where they form macrometastases. 
The mechanisms that govern the initial acquisition of migratory and invasive properties have 
been under intense investigation, with many potential players identified [295]. 
 The following chapter will discuss the role of miR-139-5p in the suppression of 
migratory and invasive properties of human breast cancer cells. From data presented in this 
chapter, miR-139-5p is shown to be downregulated in the most invasive subtypes of human 
breast cancers that fall under the triple-negative subgroup. Moreover, mining of two other studies 
uncover its downregulation in aggressive forms of breast cancer. To better understand the role of 
 82 
miR-139-5p in breast cancer progression and metastasis, we carried out biotin pull-downs to 
identify its target genes. We found its targets to be closely associated with pathways involved in 
metastases, specifically the TGFbeta and Wnt signaling cascades. Other pathways that were 
enriched were the PRKC, PI3Kinase and MAP kinase signaling cascades, all of which have been 
shown to play a role in cancer cell invasion and migration. To functionally test its role in the 
acquisition of properties required for breast cancer metastasis, we tested the ability of the breast 
cancer cell line MDA-MB-231 to migrate through a transwell membrane and to invade through a 
matrigel extracellular matrix layer. We found a significant reduction in the ability of these cells 
to both migrate and invade, showing the ability of this miRNA to play a major role in the 
metastatic ability of breast cancer cells. Supplementary tables associated with the journal article 
are included as Appendix 2 of this thesis. The details of contributions to the following 
manuscript can be found on page vii under the heading ‘Publications included in this thesis’ 
This chapter recapitulates the previously known functions of miR-139-5p (from other 
cancer types) in breast cancer and extends its network of target cohort. Also, miR-139-5p is not 
only shown to regulate multiple targets but can alter multiple pathways underlying the invasive 
phenotype, providing another framework as part of the miRNA targeting mechanisms. 
miR-139-5p is a regulator of metastatic pathways
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ABSTRACT
Metastasis is a complex,multistep process involved in the progression of cancer from a localized primary tissue to distant sites, often
characteristic of themore aggressive forms of this disease. Despite being studied in great detail in recent years, themechanisms that
govern this process remain poorly understood. In this study, we identify a novel role for miR-139-5p in the inhibition of breast
cancer progression. We highlight its clinical relevance by reviewing miR-139-5p expression across a wide variety of breast
cancer subtypes using in-house generated and online data sets to show that it is most frequently lost in invasive tumors. A biotin
pull-down approach was then used to identify the mRNA targets of miR-139-5p in the breast cancer cell line MCF7. Functional
enrichment analysis of the pulled-down targets showed significant enrichment of genes in pathways previously implicated in
breast cancer metastasis (P < 0.05). Further bioinformatic analysis revealed a predicted disruption to the TGFβ, Wnt, Rho, and
MAPK/PI3K signaling cascades, implying a potential role for miR-139-5p in regulating the ability of cells to invade and migrate.
To corroborate this finding, using the MDA-MB-231 breast cancer cell line, we show that overexpression of miR-139-5p results
in suppression of these cellular phenotypes. Furthermore, we validate the interaction between miR-139-5p and predicted
targets involved in these pathways. Collectively, these results suggest a significant functional role for miR-139-5p in breast
cancer cell motility and invasion and its potential to be used as a prognostic marker for the aggressive forms of breast cancer.
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INTRODUCTION
Breast cancer is the most commonly diagnosed cancer in
women and a leading cause of cancer mortality. One of the
major determinants of breast cancer mortality is the stage
of disease at diagnosis; patients who present with metastatic
disease have a 5-year survival rate of 21% (Cardoso and
Castiglione 2009). The progression of primary tumors to
metastatic disease is known to involve (1) invasion of extra-
cellular matrix and stromal layers by the tumor cells, (2)
intravasation into the bloodstream to travel to a distant or-
gan, (3) extravasation into the parenchyma of distant tissues,
and (4) colonization and outgrowth of tumors in the distant
site (for review, see Fidler 2003). The molecular mechanisms
underlying metastatic migration and invasion are only par-
tially understood, despite several signaling pathways being
implicated (Blanco and Kang 2011). Interaction between car-
cinoma cells and their neighboring stroma has also been
shown to play a critical role (Bhowmick et al. 2004).
Recently,miRNAs have also been found to play a key role in
metastases (Ma et al. 2007; Valastyan et al. 2009). miRNAs are
short noncoding RNAs that suppress target gene activity pre-
dominantly through binding to target mRNAs and inhibiting
their translation. miRNAs have also been shown to promote
target gene degradation (for review, see Fabian et al. 2010;
Huntzinger and Izaurralde 2011). Several miRNAs have
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causative or correlative links with metastasis. In the case of
breast cancer, miR-21 overexpression has been shown to pro-
mote metastasis (Asangani et al. 2008; Zhu et al. 2008). miR-
31 regulates the expression of the key metastatic genes integ-
rin-α5, radixin, and RhoA (Valastyan et al. 2009). miR-200
has also been shown to increase metastatic potential of mam-
mary carcinoma cell lines (Korpal et al. 2011), while other
studies have observed an inverse correlation between miR-
200 expression and tumor invasion and metastasis (Gregory
et al. 2008; Korpal et al. 2008). Overexpression of miR-139-
5pwas recently shown to correlatewith reducedmetastatic ac-
tivity in hepatocellular carcinoma and gastric cancer cells
(Bao et al. 2011; Wong et al. 2011; Li et al. 2013) and down-
regulated in glioblastoma (Li et al. 2013). Furthermore, in pa-
tients with invasive squamous cell carcinoma, loss of miR-
139-5p expression is associated with increased metastatic dis-
ease (Mascaux et al. 2009).
Although a strong association between miR-139-5p and
metastasis exists, there is little knowledge of the mechanisms
by which it contributes to this process or of the gene networks
it regulates; the specific pathways that are disrupted are still
poorly understood. Only five targets of miR-139-5p have
been identified and validated so far: FoxO1 (Hasseine et al.
2009), Rho-kinase2 (Wong et al. 2011), CXCR4 (Bao et al.
2011), RAP1B (Guo et al. 2012), and Type I Insulin-like GF
(Shen et al. 2012). However, its role in breast cancer has not
been studied so far.
miRNAs have the potential to be oncogenes or tumor sup-
pressors in a given cellular context. Depending on the specific
tissues or cancer type they are expressed in, miRNAs achieve
functional specificity by targeting a core network of genes
that belong to the same pathway. This interaction is highly
dependent on the relative abundance of multiple mRNA tar-
gets. For instance, miR-17-5p is oncogenic in hepatocellular
and colorectal carcinomas (Ma et al. 2012; Shan et al. 2013)
and, in contrast, has been shown to have tumor-suppressive
properties in cervical cancer cells (Wei et al. 2012). Similarly,
miR-182-5p was shown to have oncogenic properties in blad-
der, ovarian, and breast cancers (Hirata et al. 2012; Liu et al.
2012; Krishnan et al. 2013), whereas it acts as a tumor sup-
pressor in lung cancer (Sun et al. 2010). Given this molecular
and context specificity of miRNAs, we wished to explore
whether miR-139-5p was a potential oncomir of breast can-
cer and what the output of its functional repression was, and
identify the network of genes possibly regulating its functions
in the context of breast cancer.
RESULTS
miR-139-5p is de-regulated in human triple negative
breast cancer samples
To assess the clinical relevance of miR-139-5p in human
breast cancer, wemeasured its expression in a cohort of breast
cancer patient samples (n = 40) that included the following
molecular subtypes of invasive ductal carcinomas–no special
type (IDC-NST): triple negative (n = 18), Her2+ (n = 4), ER+/
PR+ (n = 9); invasive lobular carcinomas (ILC) (n = 3);
and normal breast tissue (n = 6) (Supplemental Table 1).
The expression levels of miR-139-5p were assayed by qRT-
PCR relative to an endogenous control RNU6B (Fig. 1A).
We observe an increase in the levels of miR-139-5p in normal
mammary tissue and several subtypes, but the triple negative
subtype showed a marked variable pattern where 38% of the
samples had lower expression compared to the normal con-
trols. Since this subtype is heterogeneous at clinical, morpho-
logical, and molecular levels, it is possible that the low miR-
139-5p expressing subgroup is one with a very different prog-
nosis (Cheang et al. 2008), and further studies are warranted
to try to validate this. Although the difference in the popula-
tion average did not reach statistical significance, the loss of
miR-139-5p expression may help to identify a new molecular
subtype important for the biological understanding of disease
and for clinical management within this invasive subgroup
of breast cancer.
miR-139-5p is frequently down-regulated in invasive
breast carcinoma
Next, we reviewed miR-139-5p expression in previously pub-
lished data using TaqMan Low-Density Arrays to analyze 29
breast tumors and 21 normal adjacent controls (Romero-
Cordoba et al. 2012). This sample cohort included inva-
sive ductal carcinomas (n = 26), invasive lobular carcinomas
(n = 1), invasive mucinous carcinomas (IMC) (n = 1), and
ductal carcinoma in situ (DCIS) (n = 1). Of the IDCs, only
five samples were triple negative. As shown in Figure 1B,
miR-139-5p is significantly (P value < 0.0001) down-regulat-
ed in the tumor cohort compared to normal controls. To
strengthen the validity of this expression profile, we also
looked for changes in expression of knownmetastasis-associ-
ated miRNAs in breast cancer. Importantly, miR-139-5p ex-
pression positively correlates with miR-31 (r = 0.44) and
miR-200b (r = 0.36), which are well-characterized anti-meta-
static miRNAs in breast cancer (Korpal et al. 2008; Valastyan
et al. 2009). This result suggested that miR-139-5p could be
another marker for metastatic breast cancer besides the asso-
ciation with triple negative tumors.
To further investigate the expression of miR-139-5p across
a larger cohort of patient samples, we chose to analyze a
miRNA-seq data set (Farazi et al. 2011) consisting of normal
breast tissue (n = 16) and various types of breast cancer in-
cluding: adenoid cystic carcinoma ((n = 2), apocrine carcino-
ma (n = 4), atypical medullary carcinoma (n = 9), metaplastic
carcinoma (n = 11), mucinous carcinoma (n = 1), ductal car-
cinoma in situ (n = 21), and invasive ductal carcinoma (n =
174). Although the adenoid cystic carcinoma, a proportion
of apocrine carcinomas, atypical medullary, and metaplastic
carcinomas can be classified as basal-like molecular subtypes,
they differ in theirmorphology, aggressiveness, and prognosis
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(Yerushalmi et al. 2009; Marchio et al. 2010; Park et al. 2010).
Metaplastic carcinomas are a heterogeneous group of tumors
characterized by the presence of epithelial cells (spindle,
squamous) with or without metaplastic elements such as
bone, cartilage, and muscle. They are aggressive tumors with
a poor prognosis (Park et al. 2010). Medullary carcinoma is a
controversial entity defined by Ridolfi and, despite the high
grade, is said to have a good prognosis. In contrast, tumors
that do not fulfill the criteria for typical medullary carcinomas
have been designated as atypical medullary carcinomas
(Ridolfi et al. 1977). These are more aggressive and have mor-
phological features and prognosis that overlapwith high grade
IDC (Ridolfi et al. 1977). Adenoid cystic carcinoma, despite
falling into the basal-like category, is an indolent tumor in
the breast compared to its salivary gland counterpart.
Carcinomas with apocrine differentiation are heterogeneous,
and the behavior is dependent on grade and stage (Yerushalmi
et al. 2009; Marchio et al. 2010). Interestingly, as shown in
Figure 1C, the subtypes that have the worst prognosis and
the highest propensity to form distantmetastases (metaplastic
carcinomas, atypical medullary, and the high grade TN IDCs)
exhibit the lowest levels ofmiR-139-5p expression.Within the
IDCs, those patients with a triple negative phenotype show
a more significant (P < 0.001) down-regulation compared
to those that express either ER/PR or Her2 (P∼ 0.007).
However, not all triple negative patient samples show a
down-regulation of miR-139-5p expression as seen in Figure
1A and in some subtypes in Figure 1C, but the common fea-
ture among these results is that miR-139-5p is frequently
lost in the most aggressive subtypes of breast cancer, suggest-
ing that itmayplay a key role in themetastatic cascade of breast
cancer.
Identification of direct targets of miR-139-5p using a
biotinylated miRNA duplex
It is well established that the function of microRNAs depends
on the expression of their targets (Sood et al. 2006) and that
the differing expression of these targets in different cellular
states can lead to opposing phenotypic outcomes—for exam-
ple, overexpression of miR-17-5p acts as either an oncogene
or a tumor suppressor depending on what tissue it is ex-
pressed in (Cloonan et al. 2008). Therefore, it is critical to ro-
bustly identify the direct targets of miR-139-5p in breast
cancer cells. Given that target prediction programs are noisy
and have high false-positive rates (Bentwich 2005; Sood et al.
2006), we resorted to an experimental identification of tar-
gets. We used the recently reported miRNA pull-down ap-
proach (Cloonan et al. 2011) that involves transfecting
synthetic biotinylated miR-139-5p duplexes (Fig. 2A) into
cells (in our case, MCF7 cells) and surveying the captured
target mRNAs using microarrays. Figure 2B shows sample
clustering of cells transfected with biotinylated miR-139-5p
and the total lysates where total distance between samples in-
dicates similarity, highlighting the reproducibility of the pull-
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along the x-axis). Triangles represent the expression levels for individual
patients. Asterisks indicate significant difference between the expression
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spectively. Asterisks indicate significant difference between the
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the normal tissue. (∗∗) P < 0.0001, (∗) P∼ 0.007, Student’s t-test.
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down approach between biological replicates. We identified
mRNAs significantly enriched in the biotin fraction com-
pared to the input RNA at a 5% false discovery rate (FDR)
threshold, with a fold-change > 2 (Fig. 2C). Using this ap-
proach, 884 probes (targeting 879 genes) were found to be sig-
nificantly enriched in the pull-down fractions (Supplemental
Table 2).
Next, we compared the miR-139-5p pull-down targets to
TargetScan predicted targets and saw an overlap between
the experimentally determined and the predicted targets
which was significantly more than expected by chance (P≈
5.5 × 10−7) (Fig. 2D), supporting the notion that we are en-
riching for biologically relevant targets of miR-139-5p. As ex-
pected, some targets identified in other pathologies are either
not expressed in MCF7 cells (2/5) or do not meet our strin-
gent threshold for target identification (Fig. 2C). Figure 2C
highlights (in green) the significantly enriched genes that
are associated with the metastatic cascade, specifically in the
context of breast cancer. miRNAs regulate cellular processes
by concomitant suppression of a network of genes, so we in-
cluded genes which do not pass our stringent threshold cutoff
for target identification, since they belong to closely connect-
ed pathways associatedwith the invasive ability of cancer cells.
Together, these results demonstrate that the pull-down has
enriched for miR-139-5p’s biological targets.
miR-139-5p targets genes involved in pathways
associated with metastasis
A gene set enrichment analysis (GSEA) was performed using
ingenuity pathway analysis (IPA) on the miR-139-5p targets
significantly enriched in the biotin pull-down. The list of
pull-down-enriched 879 genes (Supplemental Table 2) was
compared to 10 other random gene lists of the same size to
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confirm specificity. A functional ontology was only consid-
ered significant if its −log(P-value) was at least four standard
deviations away from the mean −log(P-value) of the 10 ran-
dom gene lists. Supplemental Table 3 lists all canonical path-
ways (IPA) showing significant enrichment (P-value < 0.05)
for miR-139-5p pull-down targets. As predicted, several sig-
nificantly enriched pathways have been previously implicated
in metastatic biology (Table 1), with confirmed roles for all
but one in breast cancer.
Functional enrichment analysis identified several canonical
pathways previously implicated in the metastatic cascade, but
the specific mechanism by which miR-139-5p modulates key
signaling pathways underlying these processes is still un-
known. To explore this, we analyzed the list of significantly
enriched targets from the pull-down approach and explored
the literature for their known role specifically in cellular pro-
cesses underlying metastasis, including cell proliferation, mi-
gration, and invasion. Shown in Figure 3 are key signaling
cascades underlying these processes, with targets of miR-
139-5p highlighted in dark gray (log2 FC > 1) and light gray
(log2 FC > 0.5) and targets previously validated in other stud-
ies. The signaling molecules identified from this analysis were
found to be part of three major pathways: (1) Wnt signaling
which consists of canonical and noncanonical arms, depend-
ing on the ligand; canonical Wnt signaling occurs upon re-
cruitment of β-catenin to the nucleus (Clevers and Nusse
2012), whereas the noncanonical streams work through
downstream activation of molecules such as PRKC and
RHO (Schlessinger et al. 2009), both of which are known
players in breast cancer progression (Scheel et al. 2011); (2)
receptor tyrosine kinases (RTK) signal through several path-
ways including RAS–MAPK and PI3 kinase, activating several
downstream signal transducers, such as RAF1 and RAC1, and
transcription factors such as MAPK3/1 (ERK1/2), NFKB,
CEBPB, and TWIST1, all of which play important roles in
breast cancer progression (Chaudhary et al. 2000; Bundy
and Sealy 2003; Buchholz et al. 2005; Kim et al. 2008; Hong
et al. 2011); (3) TGFB signaling which plays an important
role in breast cancer (Buck and Knabbe 2006), epithelial
to mesenchymal transition (EMT) (Zavadil and Bottinger
2005), and breast cancer metastasis (Padua et al. 2008).
Interestingly, TGFB also cross-talks with several other path-
ways, including estrogen receptor signaling (Matsuda et al.
2001), which have also been identified as miR-139-5p targets
from our analyses. Also interestingly, proteins underlying this
pathway were identified to be potentially regulated by miR-
139-5p using target prediction software (Lee et al. 2013).
This analysis outlines the complex set of targets that ap-
pear to be regulated by miR-139-5p, a major proportion of
them being involved in tumor progression and metastasis.
It suggests possible mechanistic targets of miR-139-5p in
the regulation of metastasis, warranting further functional
characterization of its role in suppressing these functional
phenotypes.
miR-139-5p does not alter proliferation or DNA profile
in MDA-MB-231 cells
The pathways analysis suggested a role formiR-139-5p in pro-
moting breast cancer metastasis. To confirm its relevance in
processes underlying malignancy of tumor cells, we under-
took a series of cell-based assays. Previous studies have report-
ed a prognostic role for cell proliferation in the metastatic
ability of tumors (Maeda et al. 1996; Panizo-Santos et al.
2000).Moreover, cell proliferation has been reported to be al-
tered bymiR-139-5p in human colorectal carcinoma through
regulating the expression of RAP1B (Guo et al. 2012).
To test whether this phenotype was relevant in breast
cancer, we generated four stable cell lines with inducible
expressionofmiR-139-5p inMDA-MB-231 cells, awell-char-
acterized invasive breast cancer cell line.Doxycycline-induced
expression ofmiR-139-5p for each cell line was confirmed us-
ing TaqMan real time PCR (Fig. 4A). The four stable cell lines
showbetween20- and200-foldhigher expressionofmiR-139-
5p in the presence of 1000 ng/mL doxycycline, which is also
comparable to the difference in expression seen between nor-
mal breast tissues relative to tumor patient samples (Fig. 1C).
Sequencing the small RNA population of the MDA-MB-231
TABLE 1. miR-139-5p target enriched canonical pathways and their association with tumor progression
Pathway P-value
Associated with
metastasis? Cancer type References
Protein ubiquitination pathway 1.00 × 10−5 Yes Breast Kim et al. (2011)
ERK5 signaling 2.95 × 10−5 Yes Breast, prostate Cronan et al. (2011); Ramsay et al. (2011)
Aminoacyl-tRNA biosynthesis 1.95 × 10−4 Maybe (tumorigenesis) Lung, colon Kim et al. (2011)
N-Glycan biosynthesis 2.90 × 10−4 Yes Breast Lau and Dennis (2008)
Glucocorticoid receptor
signaling
3.55 × 10−4 Maybe (tumorigenesis) Breast Moutsatsou and Papavassiliou (2008)
NGF signaling 3.90 × 10−4 Yes Breast Adriaenssens et al. (2008)
Xenobiotic metabolism
signaling
5.80 × 10−4 Maybe (tumorigenesis) Breast Aust et al. (2005); Naushad et al. (2011)
HGF signaling 6.50 × 10−4 Yes Breast, melanoma Maroni et al. (2007); Previdi et al. (2010)
PI3K/AKT signaling 1.15 × 10−3 Yes Breast, lung, thyroid Smirnova et al. (2012); Xue et al. (2012)
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cells (Supplemental Table 4) shows miR-139-5p to be ex-
pressed at ∼300 transcripts per million (tpm), where the top
10% of miRNAs are expressed (miRNAs with <100 tpm ex-
cluded) with >1000 tpm. The highest expressed miRNA in
the cell line had ∼74,000 tpm (a difference of ∼240-fold be-
tween miR-139-5p and the highest expressed miRNA). This
suggestedour stableoverexpressionofmiR-139-5pwaswithin
physiologically relevant levels. Additionally, an analysis of the
data downloaded from The Cancer Genome Atlas (TCGA)
that contains data from 893 breast invasive carcinomas and
normal patient samples show expression of miRNAs in nor-
mal breast tissue to be between 100 tpm and 300,000 tpm
with the top 10% of miRNAs with >10,000 tpm. These find-
ings suggest our levels of expression are within the realms of
normal copy numbers per cell. At this low level of overexpres-
sion, we did not observe any gross morphological changes or
changes in cellular integrity.
All four cell lines were used in the subsequent cell-based
assays. We performed MTT assays to measure the rate of pro-
liferation over a time course of four days. Figure 4B shows no
significant difference in the proliferation rates of the parental
(uninduced) cell lines versus the induced cell lines overex-
pressing miR-139-5p. We also performed FACS analysis of
the PI-stained cells to measure any change in the DNA profile
of MDA-MB-231 cells in response to miR-139-5p expres-
sion. As shown in Figure 4C, there was no statistically signifi-
cant change in DNA profile. Together, these results suggest
that overexpression of miR-139-5p has no effect on cell pro-
liferation or progression through the cell cycle in MDA-MB-
231 cells. This result also suggests that miR-139-5p may tar-
get different gene networks in other cancer types where alter-
ations in proliferation rates have been shown to result from
miR-139-5p overexpression.
miR-139-5p suppresses both invasion and migration
in MDA-MB-231 cells
Cellular migration and invasion are key processes under-
lying metastasis. To test the hypothesis that miR-139-5p
overexpression can suppress these phenotypes in breast
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cancer cells, we used the stable cell lineswith inducible expres-
sion of miR-139-5p in MDA-MB-231 cells. The migratory
ability of the stable cell lines was tested by quantifying their
ability to traverse a transwell membrane in the presence
(1000 ng/mL) or absence of doxycycline. The parent cell
line stably expressing an empty vector without the miR-
139-5p construct was included in the assay to identify poten-
tial side effects of the doxycycline treatment. Cells were plated
on the top of a transwell insert containing 8-μMpores in basal
medium and placed in a well containing medium enriched
with EGF. After 6 h, cells that migrated to the bottom of the
insert were stained with crystal violet and counted.
Induction of miR-139-5p expression, upon addition of doxy-
cycline, significantly decreased the migratory ability of the
MDA-MD-231 cells to between 40% and 70% (P < 0.05)
(Fig. 5A,B) of their original levels in the four stable cell lines
tested.
The invasive ability of the cells was tested using a similar
procedure as outlined above using transwells that contained
a layer of matrigel to mimic the basement membrane. Cells
were plated on top of the matrigel and invading cells were
stained and counted 24 h after plating. Overexpression of
miR-139-5p decreased the ability of the MBA-MB-231 cells
to invade to 40%–70% (Fig. 5C,D) of the original levels in
all four stable cell lines (reached significance in two of them
[P < 0.05]). These assays reveal a novel role for miR-139-5p
in the inhibition of properties that account for the metastatic
potential of breast cancer cells. Similar effects of anti-invasive
and anti-migratory roles for miR-139-5p have also been
shown in other cancer types, like human hepatocellular carci-
noma (Wong et al. 2011; Fan et al. 2012) and colorectal cancer
cells (Shen et al. 2012).
Validation of miR-139-5p target-binding sites and
change in protein expression in MDA-MB-231 cells
The initial pull-down analysis was performed in MCF7 cells,
which is a breast cancer cell line, albeit less invasive than the
MDA-MB-231 cells. Since these cellswereused in all function-
al assays, we sought to validate the interaction between miR-
139-5p and some of the genes enriched in the biotin pull-
down using MDA-MB-231 breast cancer cells. The predicted
binding sites (and ∼60 nt of surrounding sequence) were
cloned into the 3′ UTRof the pMIR-REPORTLuciferase con-
struct and transiently transfected into cells. Luciferase activity,
indicative of translation from the plasmid, was measured in
the presence of amiR-139-5pmimic or negative controlmim-
ic and normalized using β-galactosidase activity. Using this
approach, we were able to validate five of seven genes selected
(Fig. 6A), including HRAS, NFKB1, PIK3CA, RAF, and
RHOT1. These genes are keymodulators of the pathways pre-
viously discussed (Fig. 3). These data further strengthen our
hypothesis thatmiR-139-5p targets a network of genes under-
lying cellular processes involved in metastasis. The validation
of target binding in the MDA-MB-231 cells also suggests that
these targets are possibly themediators ofmiR-139-5p’s influ-
ence on invasion and migration (Fig. 5). The high rate of val-
idation is further evidence of the ability of the biotin pull-
down approach to enrich for biologically relevant targets of
the miRNA.
We further tested if regulation of these target genes by
miR-139-5p could result in observable changes in their pro-
tein expression. Western blotting carried out with lysates
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MDA-MB-231 cells (with low endogenous expression of miR-139-5p)
stably transfected with miR-139-5p whose expression is induced in re-
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(B) MTT cell proliferation assays of MDA-MB-231 cells stably express-
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from stably transfectedMDA-MB-231 cells in the presence or
absence of doxycycline showed reduction in the protein levels
of NFKB1/p50 and PIK3CA and a dramatic loss in the levels
of HRAS when miR-139-5p is overexpressed (Fig. 6B,C).
Quantification of the levels of protein expression showed
statistical significance in the reduction of HRAS and
PIK3CA levels across all four stable cell lines, whereas the av-
erage 65% reduction of NFKB1/p50 was not statistically sig-
nificant when including the increase in protein observed in
one cell line. This difference could be attributed to the inher-
ent differences in expression of miR-139-5p across the differ-
ent stable cell lines and the rate of transcription, which might
alter protein levels at different time points. These observa-
tions further substantiate our initial findings, showing that
miR-139-5p does have a substantial effect on the levels of tar-
get genes that are relevant to tumorigenesis, cell migration,
and invasion.
DISCUSSION
In prior studies, miR-139-5p has been shown to have anti-
invasive, anti-migratory, and in some cases, anti-proliferative
effects on cancer cells. However, studies focusing on its target
cohort have been limited to FoxO1 (Hasseine et al. 2009),
Rho-kinase2 (Wong et al. 2011), and
c-Fos (Fan et al. 2012) in hepatocellular
carcinoma, CXCR4 (Bao et al. 2011) in
gastric cancer cells, RAP1B (Guo et al.
2012), and Type I insulin-like growth fac-
tor (Shen et al. 2012) in colorectal cancer.
In this study, we show miR-139-5p to be
associated with human breast cancer,
where its expression is frequently down-
regulated in themore aggressive subtypes.
Using the biotin pull-down method,
followed by GSEA, we experimentally
identified a large cohort of miR-139-5p
targets in breast cancer cells, with known
functions in pathways underlying the
cellular migration and invasion pro-
cesses. Overexpressing miR-139-5p in
MDA-MB-231 cells reduced their inva-
sive and migratory abilities. Together,
these findings support the hypothesis
that miR-139-5p is a potential anti-meta-
static oncomir of solid tumors.
There are certain caveats to be consid-
ered when interpreting our results. For
instance, although we did not observe
gross morphological changes or changes
in the cell cycle (Fig. 4B,C), it is possi-
ble that the introduction of an exogenous
molecule could lead to changes in mRNA
expression affecting our ability to detect
miRNA targets. Reduced or absence of
target expression in the cell line being studied could lead to
false negatives, and thus the targets identified in this study
should not be considered to be a definitive list of all possible
targets in all possible cell types. Similarly, overexpression of
an exogenous miRNA (even at the low levels used in this
study) could also lead to competition for gene targets with
endogenous miRNAs, leading to false positives in our assay.
Although we do not observe major disruption to the tran-
scriptional landscape either here or in previous studies
(Cloonan et al. 2011; Krishnan et al. 2013), this potential
requires that studies of individual miRNA targets will need
to be individually validated (Fig. 6). However, the inclusion
of a small proportion of false positives is unlikely to affect
the functional enrichment analysis performed here (Supple-
mental Table 3). This style of analyses has shown reliable re-
sults with a 0.25 FDR (Subramanian et al. 2005), and for
strong biological signals, even a false-positive rate of 50%
can yield accurate results (Cloonan et al. 2008). The accuracy
of the analyses in this study is highlighted by our recapitula-
tion of known biological functions for miR-139-5p (Wong
et al. 2011; Fan et al. 2012; Shen et al. 2012).
miRNAs achieve specific regulation of cellular processes by
concomitant suppression of a network of genes underlying
the same function and/or pathways (Cloonan et al. 2008,
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2011; Shirdel et al. 2011; Gennarino et al. 2012). In this study,
we have shown miR-139-5p to be able to target several path-
ways underlying the invasive and migratory phenotypes of
cancer cells. The Wnt signaling pathway activation has been
shown in several cancers and more specifically in breast can-
cer (Schlange et al. 2007; Khalil et al. 2012). Schepeler et al.
have shown that disruption of Wnt signaling leads to an in-
crease in the levels of miR-139-5p, among other miRNAs,
in colorectal carcinoma cells (Schepeler et al. 2012). In our
study, we observe components of theWnt pathway being tar-
gets of miR-139-5p. If disruption ofWnt in breast cancer cells
also leads to increase in levels ofmiR-139-5p, it is possible that
this miRNA could be part of a regulatory feedback loop that
could keep theWnt pathway in check in normal cells. The in-
vasive and migratory capacity of cells can also be attributed to
MAPK signaling, which can occur downstream from PRKC
signaling through the Wnt-calcium pathway (Sheldahl et al.
1999) or through RTK-induced downstream Ras and PI3K
signaling (Huang et al. 2004; Du et al. 2010).
Through luciferase assays and Western blotting, we were
able to confirm Ras and PI3Kmembers to be directly regulat-
ed by miR-139-5p, suggesting that the miRNA is likely inhib-
iting the invasive phenotypes through regulation of RTK-
mediated downstream signaling. Additionally, NFkB, which
can also be regulated by PI3K (Romashkova and Makarov
1999), has been shown to be a direct target of miR-139-5p,
which is capable of conferring anti-apoptotic properties on
metastatic cancer cells (Buchholz et al. 2005). Ras activates
the canonical MAPK pathway (RAF→MEK→ ERK),
through which they regulate Rho GTPases, which are key
players in cell migration and invasion (Vega and Ridley
2008; Makrodouli et al. 2011). Interaction of PI3K with Rho
GTPase members Rac1 and Cdc42 has also been shown to
regulate downstream actin reorganization (Tolias et al. 1995)
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andcancercellmigration (BarberandWelch2006), suggesting
that both validated targets of miR-139-5p could be mediating
anti-migratory and anti-invasive properties through the same
effectors, the RhoGTPases. These properties are classical hall-
marks of aggressive breast tumors, suggesting miR-139-5p to
be anti-metastatic.
In this study, we show loss of miR-139-5p across the inva-
sive subtypes in three different data sets. However, this loss
does not always correlate with other molecular markers usu-
ally employed to classify breast cancers, e.g., the triple nega-
tive phenotype has been routinely used to classify aggressive
breast cancers. More recently, the heterogeneity underlying
this subgroup has been noted, warranting more detailed
prognostic tools (Metzger-Filho et al. 2012). Consistent
with this view, we observe a wide distribution in the expres-
sion of miR-139-5p in the triple negative breast cancers ana-
lyzed (Fig. 1A). Moreover, analysis of this and the Farazi et al.
data sets (Fig. 1A,C) suggests that loss of miR-139-5p could
help identify an aggressive subgroup of triple negative can-
cers. However, a comprehensive screen of a large number
of patient samples, including those from relatively rare sub-
types, is required to further understand the potential of
miR-139-5p as a biomarker for aggressive breast cancer.
Experimental validations as performed in this study across
other breast cancer cell lines and subtypes would help to
identify its potential as a prognostic marker for the invasive
property.
Being widely implicated in the progression of various can-
cers would indicate a common mode of action by miR-139-
5p, presumably through the inhibition of signaling pathways
underlying the metastatic traits of a wide range of carcinomas
(Fig. 7). Metastatic properties of different carcinoma cells
have been attributed to the pathways described in this study,
among others, suggesting that inhibition of these pathways
would be the initial step in reversing the aggressive nature of
late stage tumors. Our study now shows experimental evi-
dence for regulation of these pathways by a single miRNA.
Future studies in the characterization of these downstream
signaling pathways and the mode of miR-139-5p silencing
in human cancers would provide further information for its
potential use as a therapeutic in the reversal of the metastatic
phenotype of breast and other cancers.
MATERIALS AND METHODS
Cell culture
MDA-MB-231 cells were maintained in DMEM (Life Technologies
Australia) with 10% FBS and 1% Pen-strep and grown in a 5% CO2
atmosphere at 37°C. MCF7 cells were maintained in similar condi-
tions with the exception of 10 μg/mL bovine insulin (SigmaAldrich)
added to the growthmedia. MDA-MB-231 andMCF7 cell lines were
purchased from Cell Bank Australia.
Clinical samples, RNA purification, and qRT-PCR
analyses
Human breast tumors were derived from the Brisbane Breast Bank,
collected from consenting patients and with ethical approval from
the research ethics committees of The Royal Brisbane & Women’s
Hospital andTheUniversity ofQueensland.Histological type, tumor
grade, tumor size, lymph node status, and ER, PR, and HER2 status
were obtained from the pathology reports. ER, PR, and HER2 bio-
markers were used to infer molecular subtype as luminal, HER2,
or triple negative. Total RNA from human tumor samples was ex-
tracted using tumor homogenization followed by TRIzol extraction
(Invitrogen).
Total RNA was purified from cell lines using the miRNeasy Mini
Kit (Qiagen), and RNA integrity was assessed using an Agilent
Bioanalyzer 2100. For mature miRNA, cDNA (5–10 ng total RNA)
was synthesized using a TaqMan MicroRNA RT Kit (Applied
Biosystems), and qRT-PCR was performed using a miR-139-5p
MicroRNA TaqMan Assay (Applied Biosystems). All RT-PCR was
performed on an Applied Biosystems 7000 SequenceDetection
System. For small RNA expression analysis, RNU6B was used as an
endogenous control to normalize the data.
Biotin pull-downs, microarray hybridizations
Pull-downs of miR-139-5p targets were carried out as previously de-
scribed (Cloonan et al. 2011), using biotin-labeled oligonucleotides
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FIGURE 7. Model showing effect of miR-139-5p on tumor progres-
sion. Primary tumors, upon receiving autocrine and paracrine signals,
respond by downstream activation of key signaling pathways such
as TGF-β, Wnt, MAPK, and PI3K that are responsible for promoting
their migratory, invasive, proliferative, and anti-apoptotic properties.
Combined acquisition of these phenotypes enables the cells to become
metastatic and seed distant organs. Shown in the figure is a potential
model where miR-139-5p-mediated inhibition of these pathways can
abrogate the onset of metastatic traits, potentially making them more
susceptible for currently employed chemotherapeutic regimes.
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specific for miR-139-5p (Fig. 2A). Briefly, the 50 pmol of biotin-
labeled oligos (IDT) were transiently transfected into MCF7 cells,
cultured for 24 h, followed by cell lysis and binding of 50 μL
myOne C1 Streptavidin Dynabeads (Invitrogen) to the RNA frac-
tion for enrichment. Fifty nanograms of captured mRNA fractions
(three independent biological replicates) were amplified and labeled
using the Illumina Total Prep RNA Amplification Kit (Ambion) as
per the manufacturer’s instructions. Samples were profiled on
Illumina Human HT-12 chips along with input total RNA from
the same cells as negative controls. Microarray data have been
deposited to the Gene Expression Omnibus and can be accessed
with accession number GSE40411.
Bioinformatic analysis of pulldown
microarray data
Microarray data were normalized using the lumi package (Du et al.
2008) by applying background adjustment, variance-stabilizing
transformation (Lin et al. 2008), and robust spline normalization
(Workman et al. 2002) successively. The lmFit and eBayes functions
in the limma package (Smyth 2004) were used to test differential ex-
pression between the pull-down samples and the controls (Cloonan
et al. 2011). The false discovery rate was calculated to account for
multiple testing (Benjamini and Hochberg 1995). Probes that met
the 5% FDR threshold (for one-sided tests) with a fold-change > 2
were considered significantly enriched in the pull-down. The tran-
scripts (ENSEMBLV62) to which theymatched exactly were consid-
ered putative targets of that miRNA. The targets enriched using the
biotin pull-downs were analyzed using ingenuity pathway analysis as
previously described (Cloonan et al. 2008).
Stable cell line generation
MDA-MB-231 cells stably expressing miR-139-5p were generated
using the Mir-X Inducible miRNA Systems (Clontech). Briefly,
MDA-MB-231 cells were transfected with the pTet-on Advanced
Vector using Lipofectamine 2000 (Life Technologies Australia,
Invitrogen Division), and cells stably expressing the plasmid were
selected using 800 μg/mLG418 (Life Technologies Australia) (main-
tenance concentration: 400 μg/mL G418). Primers (Supplemental
Table 5) were used to amplify the miR-139-5p hairpin from human
genomic DNA and cloned into the pmRI-Zsgreen vector plasmid
supplied and subsequently transfected into the 231-pTet-on parent
line. Cells stably expressing the pmRi-Zsgreen-miR-139-5p were se-
lected using 1 μg/mL puromycin and further maintained in 0.5 μg/
mL puromycin. Stable expression of miR-139-5p was confirmed us-
ing TaqMan MicroRNA Assay (Applied Biosystems) specific for
miR-139-5p (Fig. 4A).
MTT proliferation assays
Stable pmRi-MDA-MB-231 cell lines overexpressing miR-139-5p
(1000 ng/mL dox) and parent stables (with no doxycycline) were
plated at 1 × 104 cells per well. MTT (3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyl tetrazolium bromide) activity was assayed using a Cell
Growth Determination Kit (SigmaAldrich) according to the manu-
facturer’s instructions and detected on a PowerWave XS spectropho-
tometer (BioTek).
Flow cytometry for cell-cycle analysis
MDA-MB-231 cells stably expressing miR-139-5p were harvested
and fixed in 70% ethanol at −20°C overnight. DNA was stained
using 10 μg/mL propidium iodide (SigmaAldrich), and RNA was
removed using 200 μg/mL RNase A (SigmaAldrich). Cells were fil-
tered through 35-μm cell strainer mesh (BectonDickinson) and an-
alyzed on a Becton Dickinson LSR II flow cytometer fitted with a
488-nm laser. Cell data were gated and analyzed using FlowJo
7.2.2 (Tree Star).
Cell invasion assay
MDA-MB-231 cells stably overexpressing miR-139-5p and parent
stables (in the presence or absence of doxycycline) were counted
and resuspended in serum-free media. Cell were plated at a density
of 2 × 105 cells/well in the upper chamber of a matrigel (200 μg)-
coated transwell filter (8.0-μmpore) fromCorning. To the reservoir,
650 μL of serum-free media with 0.1% BSA, 1% tet-FCS, and 10 ng/
mLEGFwas added. At 24 h, noninvaded cells on the upper side of the
matrigel were removed carefully with a cotton swab. The cells bound
to the lower side of the filter were washed twice with PBS and fixed
with 5% gluteraldehyde at room temperature for 10 min. Fixed cells
were washed twice with PBS and stained using 1% crystal violet.
Excess stain was removed by washing with water, and the filters
were dried overnight. Migrated cells were counted in six random
fields and images obtained using light microscopy and camera.
Cell migration assay
MDA-MB-231 cells stably overexpressing miR-139-5p and parent
stables (in the presence or absence of doxycycline) were counted
and resuspended in serum-free media. Cells were plated at a density
of 2 × 105 cells/well in the upper chamber of a transwell filter (8.0-
μm pore) from Corning. To the reservoir, 650 μL of serum-free me-
dia with 0.1% BSA, 1% tet-FCS, and 10 ng/mL EGF was added. At
6 h, nonmigrated cells on the upper side of the filter were removed
carefully with a cotton swab. The cells bound to the lower side of the
filter were washed twice with PBS and fixed with 5% gluteraldehyde
at room temperature for 10 min. Fixed cells were washed twice with
PBS and stained using 1% crystal violet. Excess stain was removed by
washing with water, and the filters were dried overnight. Migrated
cells were counted in six random fields and images obtained using
light microscopy and camera.
Luciferase assay to validate predicted binding sites
Predicted target sites of miR-139-5p were cloned into the HindIII
and SpeI sites of the pMIR-REPORT Luciferase vector. Synthetic
oligos (Supplemental Table 5) corresponding to 60 nt surround-
ing the target sequence were annealed before ligation into the
pMIR-REPORT Luciferase vector. All constructs were verified by
sequencing. MDA-MB-231 cells were cotransfected with 50 ng of a
pMIR-REPORT Luciferase construct and 50 ng of pMIR-REPORT
β-galactosidase Reporter Control Vector (Ambion) along with
miR-139-5p or a negative mimic (Ambion) to a final concentration
of 20 nM. Post-transfection, cells were incubated for 48 h prior to as-
saying. Luciferase activity was assayed using the Luciferase Assay
System (Promega Corporation) and detected on a Wallac
miR-139-5p and breast cancer
www.rnajournal.org 1777
Cold Spring Harbor Laboratory Press on April 13, 2014 - Published by rnajournal.cshlp.orgDownloaded from 
1420 luminometer (PerkinElmer). β-galactosidase activity was de-
termined using the β-Galactosidase Enzyme Assay System (Prom-
ega) and detected on a PowerWave XS spectrophotometer
(BioTek). Luciferase activitywasnormalized to β-galactosidase activ-
ity in eachwell. Assayswere conducted in triplicate and independent-
ly repeated at least twice.
Western blotting
MDA-MB-231 cells stably overexpressing miR-139-5p (in the pres-
ence or absence of 1000 ng/mL doxycycline) grown in 10-cm dishes
for 24 h were washed gently in 5 mL of ice cold PBS and then lysed
using 300 μL of ice-cold aqueous lysis buffer (50 mM Tris, pH 7.5,
150 mM NaCl, 10 mM EDTA, pH 8.0, 0.2% sodium azide, 50 mM
NaF, 0.5% NP40) containing protease (Cat.# P8340, SigmaAldrich)
and phosphatase inhibitors (Cat.# P5726 and P0044, SigmaAldrich).
Lysates were spun at 12,000g for 30 min and the supernatants col-
lected and stored at −80°C. Estimation of protein concentration
was performed using Bradford reagent (Cat.# 500-0001, Biorad) us-
ing a standard curve created with known concentrations of BSA.
Optical density measurements were carried out on an Ultrospec
6300 pro (Amersham Biosciences). Thirty micrograms of protein
containing lysate were loaded onto each well of a NuPAGE SDS-
PAGE gel (Invitrogen) and run for 1.5 h at 130V. Protein from
the gel was transferred onto PVDF membrane (Millipore) using
NuPAGE transfer buffer at 20V for 2 h. Following transfer, mem-
branes were blocked in TBS-T containing 5% skim milk powder
for 1 h at room temperature, after which they were incubated
with primary antibody (1:500)-containing solution (in 5% BSA)
overnight rocking at 4°C. Primary antibodies used were: rabbit
anti-p50/p105 antibody (Cat.# 3035P, Cell Signaling), rabbit anti-
HRAS (Cat.# SC520, Santa Cruz Biotechnology), rabbit anti-
PIK3CA p110 antibody (Cat.# 4249S, Cell Signaling), and rabbit
anti-histone H3 (Cat.# 9715, Cell Signaling). Membranes were
then washed in TBS-T three times (30 min each), followed by incu-
bation with anti-rabbit HRP secondary antibody (Cat.# 7074, Cell
Signaling) at 1:5000 in TBS-T containing 5% skim milk powder
for 1 h at room temperature. Membranes were then washed in
TBS-T and developed using the SuperSignal West Dura
Chemiluminescent Substrate (Cat.# 34076, ThermoScientific) on
a Konica Minolta film processor (SRX 201A, Konica Minolta).
DATA DEPOSITION
Microarray data have been deposited to the Gene Expression
Omnibus under accession number GSE40411.
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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4 Exploration of cell cycle associated miRNAs 
4.1 Introduction 
MicroRNAs (miRNAs) are non-coding RNAs, predominantly 22 nucleotides, 
long that act to regulate protein production through either repression of translation [296] 
or (more rarely) mRNA degradation [297]. An individual miRNA is capable of directly 
targeting hundreds to thousands of distinct mRNAs [94, 123, 298-302], but achieve their 
functional specificity by coordinate suppression of a network of genes involved in 
specific cellular processes [101, 298, 299, 303, 304], and by the cooperative targeting of 
isomiRs [305]. As the biological role of a miRNA depends on the presence of specific 
mRNA targets, the pathways targeted by individual miRNAs may differ in different cell 
types. This results in some miRNAs behaving as either oncogenes or tumor suppressors 
depending on the cell type they are expressed in [183, 298, 299].  
One of the most crucial processes underlying cell biology is the cell cycle, which 
goes through three phases followed by mitosis. The G1 phase is where, in response to 
signals from the environment, the cell synthesizes proteins required for its division [306]. 
This is followed by the S (synthesis)-phase where the DNA is replicated, and enters the 
second gap phase (the G2 pre-mitotic phase). During this phase rapid increase in cell 
mass occurs owing to increased protein synthesis [289]. Finally, mitosis occurs in several 
stages that include chromatin condensation and segregation, ultimately resulting in cell 
division [307]. This process is tightly controlled by a host of proteins including cyclins, 
cyclin-dependent kinases (CDK) and cyclin-dependent kinase inhibitors (CDKi) that 
regulate the transition through each phase, ensuring that only cells with undamaged DNA 
proceed to division [289]. In addition to regulation by these proteins, miRNAs and 
proteins that belong to the miRNA machinery such as Dicer and Argonaute also regulate 
the cell cycle. 
Dicer, an endoribonuclease which catalyzes the excision of double-stranded 
RNAs into short 21-22bp fragments during miRNA biogenesis [308], has been shown 
through knockout studies to induce a G1 arrest in response to nitrogen limiting conditions 
in fission yeast [309, 310]. In a chicken-human hybrid cell line, loss of Dicer leads to 
accumulation of cells in the G2-M phase [311]. Knockout of Dicer 1 leads to 
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accumulation in the G1-S phase in germ line stem cells of Drosophila melanogaster [312], 
also recapitulated in mouse embryonic stem cells where depletion of DGCR8 leads to an 
extended G1-S phase [313]. Knockdown of AGO2, which constitute catalytic units of the 
RNA-induced silencing complex (RISC) [40], leads to inhibition of cell proliferation by 
inducing apoptosis in myeloma cell lines [314]. Several miRNAs have also been shown 
to play an important role in the different stages of the cell cycle, including the G1-S 
transition and entry and progression through mitosis by controlling the actions of several 
key regulators. For example, the miR-15a-16 cluster regulates the cell cycle through its 
targets that include CDK1, CDK2 and CDK6 and cyclins D1, D3 and E1 [315-318]. A 
summary of miRNAs that regulate various phases of the cell cycle is shown in Appendix 
3.1, and the dysregulation of these miRNAs in cancer has been recently reviewed [319]. 
Together, these studies provide strong evidence that miRNAs play a significant role in 
regulation of the cell cycle. 
miRNAs with dynamic expression across the cell cycle phases and their potential 
functions have been difficult to study. Zhou et. al [320] previously used synchronized 
HeLa cells to identify 25 miRNAs as differentially expressed across the cell cycle phases, 
however the study was limited to ~700 human miRNAs, and suffered from a lower level 
of synchronization. In this report we expand this study using miRNA-seq to characterize 
cell cycle expression patterns from synchronized HeLa and MCF7 cells, with data 
mapped back to miRBase V19 with ~2000 precursor human miRNAs. We integrate this 
data with ENCODE regulatory factor profiling, and TCGA tumor expression data to 
determine the relationship between miRNAs with differential expression in the cell cycle 
and their expression across human cancers.  
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4.2 Materials and Methods 
4.2.1 Cell Culture 
HeLa and MCF7 cells were maintained in DMEM (Life Technologies) with 10% FBS 
and 1% Penicillin–Streptomycin (Life Technologies) and grown in a 5% CO2 
atmosphere at 37°C. HeLa cell lines were purchased from Cell Bank. 
4.2.2 Synchronization of cells 
HeLa cells were synchronized by incubation for 18 h with 2.5 mM thymidine (Sigma-
Aldrich), released into fresh media for 8 h, and treated again with 2.5 mM thymidine for 
another 18 h. To obtain synchronized populations, these cells were then released for 0 h 
(S phase), 8 h (G2-M), and 14 h (G0-G1). Chemically synchronized populations were 
verified by flow cytometry. MCF7 cells were synchronized by culture in the absence of 
beta-estradiol for 48 hours followed by its re-addition when cells were in G-0-G1 at 6h, S 
phase at 22h and G2-M at 26h. Brian Gabrielli provided synchronized HeLa cells and 
Elizabeth Musgrove provided synchronized MCF7 cells along with data for the Figures 
4.1b and c.  
4.2.3 Cell cycle analysis by flow cytometry 
All cells were harvested and fixed in 70% ethanol at -20°C overnight, then resuspended 
in buffer (5 mM EDTA, PBS, pH 7.4) approximately 1 h prior to analysis. DNA was 
stained using 40 μg/ml propidium iodide (Sigma-Aldrich), and RNA was removed using 
400 μg/ml RNase A (Sigma-Aldrich). Cells were filtered through 35 μm cell strainer 
mesh (Becton Dickinson, North Ryde, NSW, Australia) and analyzed on Becton 
Dickinson LSR II flow cytometer fitted with 488 nm laser. Cell data were gated using 
WinList v6.0 and analyzed in Modfit LT v3.0, both programs from Verity Software 
House (Topsham, ME, USA). Melissa Brown performed FACS analysis for Figure 4.1a.  
4.2.4 RNA Purification and microarray analysis 
Total RNA was purified from cell pellets using either an RNeasy Mini Kit (Qiagen), or a 
miRNeasy Mini Kit (Qiagen), and in both cases RNA integrity was assessed using an 
Agilent Bioanalyzer 2100. Total RNA samples were profiled on Illumina Human HT-12 
chips along with control RNA from mock-transfected cells. Microarray data were 
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normalized using the lumi package (Du et al. 2008) by applying background adjustment, 
variance-stabilizing transformation (Lin et al. 2008), and robust spline normalization 
(Workman et al. 2002) successively. Shivangi Wani and Katia Nones performed RNA 
purification and microarray data generation respectively.  
4.2.5 Library preparation and sequencing 
Construction of small RNA libraries was performed using the Small RNA Expression Kit 
(SREK, Ambion, Austin, TX, USA), according to the manufacturer's instructions. 
Briefly, small RNA purified using the miRNeasy kit (Qiagen) was combined with a 
mixture of both 5' and 3' adaptors and ligated in a single reaction. cDNA was synthesized, 
and PCR amplified. During the PCR, sequencing adaptors were incorporated along with a 
unique six-nucleotide barcode sequence. Following library construction and purification, 
barcoded libraries were pooled and sequenced together using the Applied Biosystems 
(Beverly, MA, USA) SOLiD system.  Shivangi Wani and Keerthana Krishnan generated 
small RNA sequencing libraries. Ehsan Nourbaksh sequenced all libraries. 
4.2.6 Bioinformatic Analysis of small RNA sequencing data 
Sequenced data was de-barcoded and small RNA reads for individual samples were 
mapped back to human hairpin sequences from miRBase V19, allowing up to 2 
mismatches. Mature names for mapped miRNAs were derived from miRBase if there 
was a seed length of at least 20 with up to 2 mismatches, with another stipulation being at 
least 8 consecutive bases should map before a mismatch is found. The expression of the 
mature miRNAs were quantified using the sum of all reads mapping to the isoforms 
arising from the same arm of the hairpin. The mapped data was scaled using a limma 
based Trimmed Mean of M-values (TMM) and quantile normalized. The miRNAs were 
called ‘dynamically expressed’ if the expression values were >2 fold different between 
any two phases of the cell cycle. To remove potentially cross-hybridizing miRNAs to the 
probes used on the Ncode miRNA microarray from Zhou et.al’s study, we used the probe 
sequences to map against mature miRNA sequences from miRBase v19. Microarray 
probes can potentially cross-hybridize with targets with ~80% similarity in sequence. To 
account for this in a ~22 nucleotide long miRNA, we allowed up to 4 mismatches to 
generate the list of potential cross-hybridizing miRNAs (Appendix 3.6).  
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4.2.7 Bioinformatic Analysis of transcription factor binding  
Analysis was performed using the UCSC genome browser, where the promoter regions of 
the specific miRNAs were scanned for binding regions of transcription factors that play a 
role in the cell cycle. These binding regions were obtained from ChIP-seq data generated 
by ENCODE and can be viewed on the genome browser. To ensure that we cover both 
promoters and enhancer regions, we scanned upto 10kb upstream of the transcription start 
site of each miRNA in the presence of the H3K27Ac and H3K4me3 marks. The analysis 
was performed for well-characterized cell cycle associated transcription factors such as c-
Myc, FOXM1, NRF1, GATA3, STAT1, E2F4 and E2F6 amongst others. 
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4.3 RESULTS 
4.3.1 Synchronization of cancer cell lines and verification of cell populations in different 
phases  
 To identify miRNAs with dynamic expression across cell cycle phases, we used 
HeLa and MCF7 cells. We chose these two cell lines, representing two cancer types and 
the two cell lines were synchronized using different methods. This would overcome 
biases based on cell specificity and the methodologies used for synchronization to 
identify a broad set of potential cell cycle associated miRNAs. HeLa cells were 
synchronized using a double-thymidine block protocol, following which synchrony was 
assessed by flow cytometry of propidium iodide (PI) stained cells, these cells have been 
previously used and described (Cloonan, Brown et al. 2008). As shown in Figure 4.1A, at 
0hrs all the cells were cycling in S-phase (>97% synchrony), 8 hrs after addition of 
thymidine majority of cells are in the G2-M phase (>93% synchrony), whereas after 14 
hrs cells were in the G0-G1 phase (>74% synchrony). MCF7 cells are estrogen-dependent 
and undergo growth arrest in its absence. These cells were arrested in the G0 phase by 
withdrawal of estrogen for 48hrs. A modified version of previously used synchronization 
protocols was employed [321], resulting in >80% of cells accumulating in the G0-G1 
phase after 6hrs of estrogen re-addition, >60% of cells residing in S-phase at 22hrs and 
40%, of cells passing through the G2-M phase at 27hrs (Fig 4.1B). Validation of these 
phases was carried out by immunoblotting for the expression of representative markers 
i.e. expression of cyclin E2 and cyclin A, whose expression is at its peak during the G1-S 
transition [322], showed high levels of expression at 18-24hrs following estrogen 
addition, with cyclin E2 undergoing a time-dependent decrease after 24hrs (Fig 4.1C). 
From 24-30 hrs following estrogen addition, there was a concomitant increase in the 
expression of Cyclin B1, known for its role in the G2-M transition and mitosis [323] (Fig 
4.1C). Biological replicates were generated of HeLa and MCF7 cells, which were 
harvested at the above mentioned time points for extraction of total RNA for sequencing 
(miRNA) analysis. One replicate of the cell line at each time point was then used in gene 
expression profiling to estimate the relative expression of known cell cycle markers 
across the three cell cycle phases. 
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Figure 4.1: Synchronization and cell cycle analysis of HeLa and MCF-7 cells: (A) HeLa cells were 
synchronized by a double-thymidine block protocol and cells harvested at 0 hrs to represent S-phase, 8 hrs 
following thymidine addition to represent G2-M phase and 14 hrs post-addition for the G0-G1 time point. 
This figure panel is reproduced from a previously published study (Cloonan, Brown et al. 2008 (Ref. 228)). 
(B) MCF-7 cells were synchronized by estrogen withdrawal for 48 hrs followed by its re-addition, with 
>80% of cells in the G0-G1 phase after 6 hrs of re-addition, >60% of cells in S-phase at 22hrs and >20% of 
cells in G2-M at 27hrs. (C) Cell cycle phase of synchronized MCF-7 cells was validated by 
immunoblotting of protein extracts for Cyclin E2 and Cyclin B1 that show maximal expression in the G1-S 
and G2-M phases respectively. 
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Expression levels of cell cycle markers were analyzed from the microarray data as 
a means of synchronization validation. Typically, genes such as CDKN2A (p16) decrease 
at the late G1 stage to allow progression into the S-phase whereas CCND1, CCNE1 and 
CCNE2 (Cyclins D1, E1 and E2) are expressed maximally during the G1-S transition, 
with levels decreasing after entry into S-phase [322]. As shown in Figure 4.2, the 
expression of CDKN2A decreased in S phase in HeLa cells. Markers of G1-S transition 
such as CCNE1, CCNE2, CDK2 and CDC25A [322] all showed a decrease in expression 
after S phase in both cell lines, except CCNE1 and CDK2 whose fold-change in MCF7 
and HeLa, respectively, was <2-fold. Markers of G2-M transition such as CCNB1, CDC2, 
CDC25B and CDC25C [323] showed maximal expression at this stage in both cell lines 
(Fig 4.2). These results demonstrate efficient synchronization of HeLa and MCF7 cells 
and are an accurate representation of cell populations in the specific phases of the cell 
cycle.  
4.3.2 Small RNA sequencing of synchronized cancer cell lines for identification of 
miRNAs with dynamic expression across cell cycle 
miRNA sequencing was performed on small RNA populations from G1, S and 
G2/M phases of the two synchronized cancer cell lines (Appendix 3.2). Data was mapped 
to miRBase V19, scaled using a limma based Trimmed Mean of M-Values (TMM) 
method and quantile normalized. We first filtered out potential cross-mappers within our 
sequencing dataset by aligning the mature miRNA sequences from miRBase v19 to the 
hairpin sequences, with the same parameters as the data (see M&M). This list (Appendix 
3.3) was then cross-referenced with the sequencing data and potential cross-mapping 
miRNAs were excluded from further analysis. A fold change of > 2 between any two 
phases of the cell cycle was used to identify miRNAs with dynamic expression across the 
cell cycle phases (Appendix 3.4). 
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Figure 4.2: Expression of cell cycle markers in synchronized HeLa and MCF-7 cells: Microarray data 
obtained from the synchronized cells was analyzed for expression of markers of cell cycle progression in 
(A) HeLa and (B) MCF-7 cells. Expression of markers shown is relative to their levels in the G1 phase. 
Yellow bars indicate expression levels in the G1, light blue bars indicate relative levels in the S, and dark  
blue bars in the G2M phase.
A
B
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We looked for miRNAs with known association to cell cycle (Appendix 3.1) in our 
dataset and found 7/37 miRNAs (Appendix 3.5) to have dynamic expression; five across 
HeLa (hsa-miR-145-5p, hsa-miR-15a-5p, hsa-miR-195-5p, hsa-miR-331-3p and hsa-
miR-424-5p) and two across the MCF7 data (hsa-miR-200b-5p and hsa-miR-503-5p). 
Surprisingly, although we had previously identified miR-17-5p as dynamic by qRT-PCR 
of the mature and hairpin sequences [298], we did not identify it to be dynamic across our 
sequenced dataset. One possible reason for this anomaly is the presence of isomiRs [37]; 
indeed, separating isomiR reads from the mature miRNA highlighted a different pattern 
of expression (Appendix 3.5). The mature hsa-miR-17-5p did not show differential 
expression across the phases whereas the sum of reads mapping back to isomiRs were 
more representative of results from Cloonan et. al [228]. They showed highest expression 
in the G2M phase followed by G1G0, whereas the S phase had almost half the number of 
reads. The TaqMan based qRT-PCR assay relies on a target specific stem-loop primer 
which then extends the 3’ end for quantitation of the target, suggesting a higher 
sensitivity to differences in that region. As expected, when we split the reads mapping 
back to the shorter versions of the miRNA (stop position <37) and the longer versions 
(stop positions >37), there was a larger variation between the cell cycle phases. This was 
not found to be the case in MCF7 cells, where neither the mature nor the isomiRs forms 
had any phase specific distribution, suggesting it was specific to the HeLa cells. Analysis 
of isomiRs was able to reproduce the expression pattern of miR-17-5p in the same sample 
set as Cloonan et. al [228], highlighting the importance to understand the measurement 
bias across technologies and its application to accurate interpretation of the data. These 
suggest the low overlap between dynamically expressed miRNAs in our dataset and 
known cell cycle associated miRNAs can be attributed to tissue specificity where 
expression patterns are highly specific to the cell type, and limitation and differences due 
the technology used. More importantly, not all cell cycle associated miRNAs are 
dynamically expressed across the phases; they could exert their influence across the cell 
cycle phases by modulating specific targets’ expression. 
 
As an additional quality control we examined the expression of the 25 HeLa 
cyclic miRNAs identified by Zhou et al using array-based miR profiling and our dataset 
108 
(Appendix 3.5). Three miRNAs have expression below our threshold (>100 transcripts 
per million (tpm) in at least one phase). Eleven miRNAs were discounted after it was 
deduced that they are likely false positives arising from cross-hybrization of miRNAs 
with >80% homology to target probes on the array (Appendix 3.6). Four of the remaining 
11 cell cycle related miRNAs were common to both studies (hsa-miR-126, hsa-miR-582, 
hsa-miR-34a and hsa-miR-221) with concordance in pattern of fold change (Fig 4.3). The 
disparity arising due to cross-hybridization and lower sensitivity suggests that the major 
differences between the two studies are likely due to technical variations in protocol.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: Comparison of dynamically expressed miRNAs to previous study: Comparison of miRNAs 
that show dynamic expression across the cell cycle in HeLa cells between our current study (red line) and 
Zhou et al., (blue line) where after filtering for cross-mappers and cross-hybridizing miRNAs, an overlap of 
4 dynamic miRNAs was observed. (A) miR-34a (B) miR-126 (C) miR-221 (D) miR-582 shows the 
concordance in pattern of relative fold change Data is represented as fold change ratios between phases 
since this was the only available data format from Zhou et al.  
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C
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Finally, to shortlist miRNAs for further analysis, we applied a stringent threshold 
of expression greater than 100 tpm in at least one phase of the cell cycle to ensure that the 
miRNA was robustly expressed in at least one sample. Using this criterion we identified 
9 miRNAs to be dynamically expressed across both cell lines, with an additional 12 
miRNAs only in HeLa cells, and 8 miRNAs only in MCF7 cells (Table 4.1), which were 
used in all subsequent analyses. 
Table 4.1: List of miRNA with >100tpm in at least one sample and >2 fold difference 
between two cell cycle phases in MCF7 and HeLa cells 
  MCF7 HeLa >100 tpm* 
miRNA G1G0  S  G2M G1G0 S  G2M MCF7 Hela 
mir-451a-5p 464.4 1160.4 776.9 539.6 435.4 8463.4 Yes Yes 
mir-421-3p 1902.9 792.5 1160.4 1084.4 1204.5 504.4 Yes Yes 
mir-3975-3p 7.4 55.1 133.7 29.3 3364.7 1587.1 Yes Yes 
mir-3607-5p 455.0 455.0 2238.3 776.9 3443.9 1033.9 Yes Yes 
mir-185-5p 1778.7 2387.2 629.5 109.4 49.3 78.3 Yes Yes 
mir-15b-3p 88.9 427.0 341.4 365.9 85.7 326.1 Yes Yes 
mir-1234-5p 6576.0 2699.7 5160.1 1033.9 1186.6 497.5 Yes Yes 
mir-106b-3p 273.2 140.5 301.7 381.1 589.4 275.7 Yes Yes 
let-7d-5p 1445.1 2323.8 575.4 192.0 85.7 154.4 Yes Yes 
mir-5095-3p 5.6 12.5 12.4 161.7 479.3 175.0   Yes 
mir-4485 12.1 17.0 28.7 501.0 2959.1 722.6   Yes 
mir-3940-3p 1.4 10.6 19.4 222.9 182.5 90.6   Yes 
mir-3609-3p 21.6 12.5 26.9 149.3 683.6 144.5   Yes 
mir-338-3p 35.0 22.8 15.7 163.0 78.5 208.2   Yes 
mir-1468-3p 12.1 5.2 7.2 35.8 121.8 23.0   Yes 
mir-3159-3p 7.4 21.9 26.9 423.5 890.6 316.8   Yes 
mir-143-3p 3.5 10.6 9.2 45.6 60.7 1058.4   Yes 
mir-1248-5p 21.6 49.7 49.1 15.0 186.4 8.9   Yes 
mir-1247-5p 45.0 86.1 96.7 21.9 116.4 29.1   Yes 
mir-1246-5p 13.9 19.3 32.4 35.8 226.4 15.1   Yes 
mir-1180-3p 5.6 22.8 22.9 57.8 153.4 51.5   Yes 
mir-503-5p 144.5 346.4 232.3 21.9 27.8 61.9 Yes   
mir-4263-3p 331.2 86.1 166.4 25.3 12.8 3.5 Yes   
mir-3908-5p 672.1 742.1 1397.8 15.0 32.3 9.5 Yes   
mir-3196-5p 121.8 36.3 216.9 45.6 2.4 5.4 Yes   
mir-3195-5p 184.6 42.9 101.2 12.8 9.4 3.5 Yes   
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mir-3195-3p 306.5 156.4 358.3 21.9 0.0 3.5 Yes   
mir-15a-3p 52.8 173.9 195.8 48.9 23.8 57.9 Yes   
let-7d-3p 205.8 216.9 82.5 48.9 70.9 12.2 Yes   
 
*>100 transcripts per million in atleast one cell cycle phase 
 
4.3.3 Cell cycle associated transcription factors are not significantly enriched in the 
promoter regions of miRNAs that are dynamic across the cell cycle phases 
To explore the possible upstream transcription factors that could regulate the 
dynamic expression of miRNAs, we used data from the ENCODE project [324]. We 
asked if there was evidence for binding of transcription factors previously reported to 
regulate the cell cycle in the promoter regions of our shortlisted miRNAs. The ENCODE 
Chip-Seq analysis was also performed in HeLa and MCF7 cells, which helps to 
accurately capture the biological relevance of the presence of such binding sites, since the 
miRNA-seq was performed in the same cell lines.  
Defining the transcriptional start sites of the transcripts giving rise to miRNAs is 
challenging. Studies have reported transcription start sites for miRNAs can be between 2-
10kb upstream, within their promoter regions [325, 326]. To strengthen the promoter 
analysis, we used the presence of the H3K27Ac and H3K4me3 marks to support the 
location of proximal promoters and enhancers. H3K27Ac is found near active regulatory 
elements and active enhancers [327], whereas H3K4me3 marks active promoters [328]. 
The majority of transcription factor binding sites (TFBS) in the promoter regions of the 
miRNAs were in regions that contained both these marks (Appendix 3.7), reinforcing the 
validity of the binding sites. As summarized in Appendix 3.7, we observe that 8 out of 
these 9 miRNAs (except hsa-let-7d-5p) have binding of transcription factors with a 
known role in cell cycle, as demonstrated by ChIP-seq such as E2F4, ELK4, FOXM1, 
NRF1, c-Myc amongst others.  
To determine if the presence of these TF binding sites occur by chance or are 
actual effectors of the miRNAs’ dynamic expression across the phases, we looked 
upstream of an equal number of matched stationary miRNAs, whose expression levels 
had the same distribution as the miRNAs with dynamic expression across the cell cycle 
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phases (Appendix 3.7). There was no statistically significant difference (p=1.57E-01; 
degrees of freedom=1), when we used a chi-squared test between the two sets, suggesting 
the presence of the TFBS could be occurring by chance. Although a significant 
association was not found between cell cycle related TFs and dynamic miRNAs, we 
wondered if any cell cycle related TF was bound to only dynamic miRNAs and not the 
stationary miRNAs. On visual inspection and comparing the TFs (Appendix 3.7), we 
identified a subset of 5 TFs (FOXM1 in MCF7 and NRF1, E2F4, E2F6 and ELK4 in 
HeLa) exclusively bound to promoter regions of the cell cycle associated miRNAs. We 
restricted further analysis to this subset of TFs, to explore if they could potentially 
regulate the expression of the miRNAs.  
4.3.4 Expression analysis of associated transcription factors in the matching microarray 
data 
If the transcription factors, uniquely bound to dynamically regulated miRNAs, are 
indeed regulators of miRNA expression, then the expression of the TFs could also be 
dynamic across the cell cycle. To determine whether this is the case, the expression levels 
of the TFs with the potential to regulate our miRNAs of interest (Appendix 3.7) were 
analysed using microarray data. The expression of NRF1 was dynamic across the cell 
cycle in HeLa cells, showing an increase in the G2-M phase, whereas FOXM1 was 
elevated in the S-phase of MCF7 cells (Fig 4.4A). E2F4, E2F6 and ELK4 were not 
differentially expressed across the cell cycle in HeLa. This suggests that the expression of 
certain TFs may be different across the different phases of the cell cycle, possibly 
resulting in differences in their target miRNA expression and inducing phenotypic effects 
such as changes in the cell cycle.  
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Figure 4.4: Correlation between transcription factors and miRNA expression: (A) Expression of 
NRF1 and FOXM1 were dynamic in HeLa and MCF7 cells, respectively. NRF1 is maximally expressed in 
the G2-M phase whereas FOXM1 is maximally expressed in the S-phase. E2F4, E2F6 and ELK4 do not 
show dynamic expression across the HeLa cell cycle (B) Expression pattern of NRF1 correlates with 
increased expression of miR-15b-3p in G2M but a relative downregulation in S phase, with an inverse 
pattern of expression for miR-1234-5p across the phase of HeLa cells (C) Expression pattern of FOXM1 
correlates with increased expression of miR-15b-3p in the S and G2M phases with reduced expression of  
miR-1234-5p and miR-106b-3p in the S-phase of MCF7 cells.
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 Next, we compared the expression patterns of the transcription factors (Fig 4.4A, 
Appendix 3.7) to those of the miRNAs (Appendix 3.7) that they possibly regulate. NRF1 
is bound to the promoters of miR-1234-5p and miR-15b-3p and its expression is maximal 
in the G2-M phase in HeLa cells. The expression of miR-1234-5p decreases whereas that 
of miR-15b-3p increases in the G2-M phase (Fig 4.4B). Similarly, FOXM1 is expressed 
maximally in the S-phase of MCF7 cells and is bound to the promoters of miR-1234-5p, 
miR-106b-3p and miR-15b-3p. The expression of miR-1234-5p and miR-106b-3p 
decrease in the S-phase in MCF7 cells, whereas that of miR-15b-3p increases during this 
phase (Fig 4.4C). This brings about an interesting possibility that transcription factors 
such as NRF1 and FOXM1 could not only activate miRNAs but also repress their 
transcription. NRF1 has previously been shown to repress the DSPP gene in odontoblasts 
[329] whereas FOXM1 has been shown to act as a repressor of GATA3 in luminal 
mammary epithelial cells [330]. Although these findings make it tempting to infer a 
direct relationship between the expression of the miRNA and TF and their functional 
output, there are confounding factors like the lag time between transcription and 
expression of active mature miRNAs. This duration represents about a fourth of the time 
for the entire cell cycle process (HeLa has doubling time of ~24 hrs and MCF7 has 
doubling time of ~29hrs), during which changes in level of TF may not be able to alter 
miRNA transcription levels. Moreover, other aspects such as phosphorylation state can 
have a major effect on the activity of transcription factors as has been demonstrated for 
both FOXM1 and NRF1 [331, 332]. Given the small number of samples and many 
variables not addressed using experimental evidence, this data must be interpreted with 
caution. Large-scale analysis combined with further downstream validations is warranted, 
for instance TF-binding data through ChIP may provide a clearer picture of the dynamics 
of miRNA regulation. 
4.3.5 Expression of cell cycle dynamic miRNAs in human cancer samples 
As regulation of the cell cycle is one of the 10 hallmarks for cancer initiation and 
progression [288], we hypothesized that the cell cycle-associated miRNAs identified in 
this study may also be involved in cancer. Six of the nine miRNAs have previously 
known associations with at least one cancer type (Table 4.2). To determine if these 
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miRNAs are dysregulated in multiple cancer types, we examined their expression across 
12 cancers from The Cancer Genome Atlas (TCGA) database (https://tcga-
data.nci.nih.gov/tcga/). We used stringent criteria to define differential expression: (i) 
miRNAs must be expressed more than 100tpm on average in either tumour or normal; (ii) 
at least 2 fold difference in expression between normal and tumour samples; and (iii) a 
significance value  <0.05 with bonferonni FDR correction. Supporting the known 
association of cell-cycle with cancer, 7 out of 9 cell cycle-associated miRNAs were 
differentially expressed in ≥ 50% of tumor types analyzed, when compared to normal 
samples of the same tissue type (Table 4.2 and Fig 4.5).  For the remaining two 
microRNAs, (miR-3975-3p and miR-1234-5p), data was not present. In most cases, their 
over or under expression was concordant with their predicted role as oncogenic or tumour 
suppressive in the relevant cancer types (Table 4.2). The contradictory finding for some 
miRNAs (miR-185-5p in colon and breast cancer; let-7d-5p in prostate and breast cancer) 
and their previously shown role may be attributed to the presence of molecular subtypes 
within the cancer where the miRNAs could have distinct roles to play. Of the 7 miRNAs 
with data in TCGA, five miRNAs (miR-421-3p, miR-15b-3p, mir-451a-5p, let-7d-tp and 
miR-185-5p) were significantly over- expressed in both breast and cervical carcinomas 
that were represented by the two cell lines used in our study, suggesting their biological 
relevance. 
Table 4.2: Dynamically expressed miRNAs in HeLa and MCF7 and their expression 
across human cancers in The Cancer Genome Atlas dataset 

miRNA Literature TCGA  
Cancer  Role Cancer* Expression Up Down 
miR-421 Gastric  Onc [333] STAD Up 6 0 
Hepatocellular  Onc [334] LIHC Up   
miR-185 Prostate  TS [335, 
336] 
PRAD n.s. 6 0 
Colon  TS [337] COAD Up   
Breast  TS [338] BRCA Up   
Let-7d Head and Neck 
Single Cell 
TS [339] HNSC Up 7 1 
Breast  TS [340] BRCA Up   
Prostate  TS [341] PRAD Up   
miR-106b Hepatocellular  Onc [342] LIHC Up 3 0 
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Breast  Onc [343] BRCA n.s.   
Prostate  Onc [344] PRAD Up   
Head and Neck 
Single Cell 
Onc [345] HNSC Up   
miR-451a Lung  TS [346] LUAD Down 2 6 
Hepatocellular  TS [347] LIHC n.s.   
Colorectal  Onc [348] COAD Up   
Breast  TS [349] BRCA Down   
Lung  TS [350] LUAD Down   
miR-15b Cervical  Onc [351] CESC Up 8 1 
Hepatocellular  TS [352] LIHC Up   
mir-3607-5p None    5 1 
miR-1234-5p None    n/a n/a 
miR-3975 None    n/a n/a 
 
*BRCA – Breast adenocarcinoma; CESC – Cervical squamous cell carcinoma and endocervical 
adenocarcinoma; COAD – Colon adenocarcinoma; HNSC – Head and Neck squamous cell carcinoma; 
LIHC – Liver hepatocellular carcinoma; LUAD – Lung adenocarcinoma; PRAD – Prostate 
adenocarcinoma; STAD – Stomach adenocarcinoma; n.s. – not significant; n/a – not available. 
 
We also identified a novel potential oncomiR, e.g. miR-3607-5p with dynamic 
expression across both cell lines, which does not have a previously reported role in 
human cancer, but is significantly over-expressed in 5 cancer types and down-regulated 
in one (Fig 4.5). This apparently contradictory role is seen with at least 3 other miRNAs, 
miR-451a-5p, miR-15b-3p and lte-7d-5p (Table 4.2), which show both up and down 
regulation across the different cancer types. Previously, miRNAs like miR-17-5p [218, 
353] and miR-182-5p [299, 302, 354-359] have been shown to act as potential tumour 
suppressors or oncogenes depending on cancer cell type and the target mRNAs expressed 
in those cells. We have now identified four other miRNAs, which have the potential to be 
dual functioning in cancer. Further functional characterization of these miRNAs is 
essential to elucidate their specific role in each of the cancer types. 
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Figure 4.5: Analysis of miR-3607 in TCGA tumour samples: Expression of miR-3607 across a range of 
tumours from publicly available TCGA data showing significant overexpression (as marked by asterisk) in 
5 tumour types and down-regulation in one. *represents p-value < 0.05 (unpaired t-test). 
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4.3.6 miR-3607-5p and its predicted target cohort with a potential role in cell cycle and 
cancer 
Very little is known about miR-3607-5p, apart from its expression upon exposure 
to ionizing radiation in lymphoblast cells [360]. To further assess its role in cell cycle 
regulation and disease, we analyzed TargetScan predicted targets of miR-3607-5p [82] 
for functional enrichment using Ingenuity Pathway Analysis. We also included predicted 
targets of miR-3975-3p and miR-1234-5p, about which there is little published evidence 
supporting biological functions. To identify cellular and molecular functions over 
represented within these targets, we performed gene set enrichment analysis with these 
predicted targets and 10 random gene lists of the same size. Appendix 3.8 lists the 
molecular and cellular functions associated with targets of miR-3607-5p. A category was 
considered significant if its –log (p-value) was at least 3 standard deviations away from 
the significance of the mean of the random gene lists. Figure 4.6 shows ontological 
categories passing these criteria. We find cellular growth and proliferation, DNA 
Replication, Recombination & Repair, and Tumour Morphology as significantly (p-value 
< 0.05) over represented within these predicted targets of miR-3607-5p. The enriched 
targets include well-characterized genes underlying tumorigenesis such as FGF2, 
FOXO1, FZD7, MMP24, BMP2 amongst others (Appendix 3.8). However we didn’t find 
such significant associations with either miR3975-3p or miR-1234-5p. Although the 
predicted targets need experimental validation, it is plausible for miR-3607-5p to have a 
role in tumorigenesis. 
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Figure 4.6: Ingenuity Pathway Analysis of predicted targets of phasic miRNAs: Graph displaying the 
significance of functional enrichment for TargetScan predicted targets of miR-3607-5p, miR-3975-3p and 
miR-1234-5p cyclic miRNAs. Black arrows indicate the mean significance of randomly selected gene sets 
of equivalent size, and the grey boxes show +3 standard deviations (grey arrows) away from the mean. 
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4.4 DISCUSSION 
Understanding the cell cycle is important to gain insights into its dysregulation in 
diseases such as cancer. In this study we used synchronized HeLa and MCF7 cells at each 
phase of the cell cycle and profiled their miRNA expression using deep sequencing, to 
globally survey miRNAs whose expression is dynamic across the phases, and to identify 
potential regulators of cell cycle. We carried out FACS analysis in HeLa cells and 
immunoblotting for classic cell cycle markers in MCF7 cells to ensure proper 
synchronization of cells. We also examined the expression of well-known regulators of 
the cell cycle to determine their dynamics in our cells as a validation of the individual cell 
cycle phases in both cell lines. From these data, we identify 9 miRNAs whose expression 
is dynamic in both HeLa and MCF7 cells. Analysis of upstream regulators using data 
from the ENCODE consortium on the same cancer cell lines, showed the presence of 
binding sites for cell cycle regulating transcription factors, some of which are also 
dynamic in matching mRNA data. The differential expression of about 80% of the 
oscillating miRNAs in the TCGA cancer dataset potentially suggests that this property 
might impart a tendency to be either driving or being a passenger in tumorigenesis. For 
the first time we now show dynamic expression of miR-3607-5p in cell cycle phases and 
dysregulation in cancer using online datasets, with gene set enrichment analysis of its 
predicted targets supporting a role for it in cell cycle and tumorigenesis.  
Only one previous study has looked at expression of miRNAs across different 
phases of the cell cycle in HeLa cells using microarrays [320]. Recognizing that 
identifying miRNAs with dynamic changes across the cell cycle of HeLa cells might not 
be representative of all epithelial cells, we chose to perform synchronization of another 
epithelial cancer line, MCF7, an estrogen receptor-positive breast cancer cell line. 
Although this might still not eliminate cell type-specific idiosyncrasies, miRNAs which 
show differential expression in both cells lines would be a better representation of those 
that play a broad role in the cell cycle. To improve on the previous study, we have also 
performed miRNA-seq. This technology is not bound by known miRNAs, and can 
identify miRNAs more accurately and with higher sensitivity than microarrays [128, 
361], providing a good resource for the community studying miRNAs in cell cycle. We 
have also expanded our studies to look for an association between these miRNAs and 
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their expression levels across various tumor types and also begun to explore their 
upstream regulation. 
A caveat of the study is that the method of synchronization might have introduced 
bias in the data, especially in MCF7 cells where estrogen withdrawal and re-addition was 
used. The ability of estrogen to lead to c-Myc-induced proliferation of MCF7 breast 
cancer cells has been well documented [362, 363]. Hence, activation of such a 
transcription factor that has a wide array of targets could potentially lead to the changes 
in expression of miRNAs that are not cell cycle-relevant, but rather, targets of Myc. One 
could argue that a double thymidine block would abolish such biases, however, the 
addition of thymidine to cancer cell lines also has side effects depending on whether 
mismatch repair pathways are functional or not [364]. Hence we have used a combination 
of both synchronization techniques to obtain a list of miRNAs that are altered during the 
cell cycle irrespective of the method of synchronization across two different carcinoma 
cell lines. The use of different synchronization techniques could also explain the 
differences in dynamic expression of these miRNAs e.g. miR-3607-5p is expressed at 
high levels in G2-M phase of MCF7, whereas its expression is maximal at S-phase in 
HeLa cells. However, the expression of the miRNA is dynamic across the cell cycle and 
follow up analysis using real-time PCR-based validation could resolve such differences. 
Future studies on specific cancer cell types would benefit from a combination of 
synchronization techniques for the same cell line, eg. A comparison of estrogen and 
thymidine induced synchronization on MCF7 cells will help in delineating any 
methodology based bias. Another major limitation of the study is the absence of technical 
replicates for the miRNA-seq and microarray analysis. We attempt to overcome this 
through the use of two different biologically distinct cell lines and appropriate 
bioinformatics controls for the analysis, but further downstream validations are required 
to strengthen these findings. Given the tissues specific nature of a miRNA’s functional 
repression, the overlap of nine of the 21 (HeLa) and 17 (MCF7) dynamically expressed 
miRNAs between these two distinct cancer types suggests the use of cancer cell lines 
from different tissues will help to eliminate miRNAs that play tissue-specific roles and 
identify regulators of common processes such as the cell cycle 
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Analysis of TCGA data revealed that all the cell cycle-associated miRNAs, 
excepting mir-1234-5p and mir-3975-3p (where data was not available), are differentially 
expressed in most of the cancer types analysed. This is perhaps not surprising given that 
miRNAs that regulate the cell cycle are well known to be deregulated in cancers [173, 
365]. We also identified 4 miRNAs with a possible dual nature of either being oncogenic 
or tumour suppressive in different cell types. This result suggests that further research on 
multiple cancer types and patient cohorts is necessary to begin exploring miRNAs as 
therapeutic options and cannot be relied on their extensive characterization in one 
cell/cancer type.  
miRNAs could change with the different phases of the cell cycle if they are 
required to drive a major role in regulation of those particular phases or transitions. 
Alternatively, this could be a passenger effect of a cell cycle-dependent transcription 
factor, which regulates the expression of these miRNAs as a means of fine-tuning its 
function. In this scenario, the expression of the transcription factor would change during 
the different phases resulting in a concomitant change in the expression of the miRNA, 
which in turn could regulate key target mRNAs that are critical for a certain checkpoint. 
The miRNA may serve as a homeostatic monitor or feedback mechanism to ensure fine 
regulation of the changes in cell cycle phase. We explored these possibilities by the 
analysis of promoter regions of miRNAs that were cell cycle phase-dependent in both 
HeLa and MCF7 cells. This analysis revealed a list of potential regulating transcription 
factors that could play a role in their transactivation or repression. Interestingly, the 
transcription factor data (Appendix 3.7) shows binding of the dynamic miRNAs by a 
unique set of factors that are absent in the promoter regions of the stationary miRNAs 
including FOXM1, NRF1, E2F4 and E2F6, each of which plays an important role in cell 
cycle regulation [366-369]. In fact, E2F4 has a known role in the regulation of various 
miRNAs to regulate the cell cycle, including miR-17-92, mir-22 and Let-7a [370]. 
Regulation of target genes such as MYC through these miRNAs, enables E2F4 to play a 
major role in the repression of G0-G1 progression [370]. Hence, these miRNAs that the 
TFs are bound to could be intermediate factors that they control to regulate the expression 
of a large number of downstream proteins that ultimately result in changes in the cell 
cycle. Our analysis did not reveal a significant correlation when comparing stationary and 
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dynamic miRNAs potentially due to the small sample set.  A similar analysis done at the 
genome wide level, may be able to identify a correlation in the presence of cell cycle 
regulated TFs upstream of dynamically expressed miRNAs, which might provide a 
platform to study the role of these transcription factors in miRNA-mediated cell cycle 
control.  
In order to test whether these cell cycle-associated miRNAs actually play a role in 
cell cycle regulation or cancer, further functional assays have to be performed. Cell 
proliferation assays in response to overexpression and down regulation of these miRNAs 
will allow us to estimate their effect on a cell’s ability to survive and grow, followed by 
FACS analysis of the cell cycle to understand its significance on the cell cycle transitions. 
These results can be expanded further using studies to identify upstream regulators of 
these functional miRNAs, this could be done by knockdown or overexpression of TFs 
and observing its effects on the expression of the miRNA simultaneously monitoring the 
cells’ progression across the cell cycle phases using FACS. This would provide evidence 
if it is the target repression by the TF or miRNA or both that is causing downstream 
functional regulation. Direct interaction studies between transcription factors and the 
promoter regions of miRNAs fused to luciferase-expressing constructs will provide 
evidence for interaction and mode of regulation. Additional ChIP-seq or ChIP-qPCR 
experiments may also be performed across different phases of the cell cycle to confirm 
binding of specific TFs to the promoter regions of miRNAs in a phase-dependent manner. 
 Although these above mentioned miRNAs were singled out based on their 
dynamics across the cell cycle, this does not necessarily indicate a functional role in cell 
cycle progression. Hence the short-listed miRNAs would need to be studied further in the 
context of their target mRNAs using direct experimental approaches such as biotin pull-
down [37, 123, 299, 301, 371-377]. Target identification can be followed up with target-
specific characterization studies. These can be based on the targets, their specific 
functions or the pathways they belong to. Experiments to determine their function could 
involve target overexpression or inhibition followed by a measure of their effect on the 
biological pathway. Furthermore studies focusing on regulators of miRNA transcription, 
which are also responsible for the downstream signaling outcomes need to be performed. 
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What signals do these factors respond to and which of these are responsible for the 
activation and repression of specific miRNAs? Databases such as TransmiR attempt to 
consolidate all published TF-miRNA associations [378], however, computational tools 
that predict TF binding to miRNA promoter regions based on their binding consensus 
sequence would facilitate prediction of miRNA regulating factors and enable more 
comprehensive understanding and streamlined validations of signaling, both upstream 
and downstream of miRNAs. 

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5 General Discussion and Future Directions 
5.1 Summary of findings: 
Since their discovery in 1993, miRNAs have been recognized as crucial in diverse 
cellular and organismal processes, from development to cellular proliferation, and 
differentiation. There is still considerable effort invested in discovering new miRNAs, 
and the number of known miRNAs has grown substantially. In 2003, miRBase Release 2 
had 506 miRNA entries [379]. Now, miRBase V20 in 2013 contains 24521 miRNA loci 
[379, 380]. This indicates a relatively new and evolving field of research with the role of 
miRNAs still being explored in various cellular processes and disease states.  
This thesis aimed to identify and characterize the functional role of miRNAs with 
a cancer association, particularly breast cancer. We have done this by identifying targets 
of dysregulated miRNAs and elucidating their effect on key cellular processes. The 
introductory chapter discusses what we know about the mechanisms by which miRNAs 
are generated, their mode of action and known associations in cancer. Chapter two 
focuses on miR-182-5p and its role in the DNA Damage Repair pathway of breast cancer 
and Chapter three elucidates the role of miR-139-5p in cellular processes underlying 
breast tumor progression. Chapter four takes a more exploratory look at expression 
profiles of miRNAs across the different phases of cell cycle and their potential 
association with cancer. In the following sections, the work performed as part of this 
thesis and its contribution to major themes of miRNA research are discussed. 
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5.2 miRNAs and mRNA target interactions 
5.2.1 miRNAs act through multiple mRNA targets to exert a phenotypic effect 
 Since the discovery of miR-15 and miR-16 in the frequently lost regions of 
chronic lymphocytic leukemia patient samples [184], several miRNAs have been 
implicated in the initiation and progression of cancer. Initially the studies focused on 
finding ‘the target’ gene of the miRNA or the cluster, eg. let-7 was shown to down-
regulate RAS [192] and miR-17-5p down-regulated the expression of AIB1 in breast 
cancer [257] and, along with miR-20a, was able to regulate expression of E2F1 [381]. 
These studies typically relied on expensive loss/gain of function studies, and therefore 
assessing multiple targets was impractical. This was followed by development of 
bioinformatics tools, like TargetScan [82] and Pictar [382] which could predict targets of 
miRNAs based on known principles of miRNA targeting mechanisms. However, 
validation was still typically restricted to single genes or gene families, as was the case 
with the miR-182’s repression of FOXO3 and MITF in melanoma [302] and its cluster’s 
regulation of FOXO1 in breast cancer [253] were both considered sufficient to explain its 
role in tumorigenesis. 
siRNAs are another class of small RNAs which unlike miRNAs, can be 
exogenous (viral or transgene induced) [8] or endogenous (dsRNA, typically from 
repeats, pseudogenes) [383] in origin. However, siRNAs share the same silencing 
machinery as miRNAs, Dicer for cleavage [384] and Ago proteins within the silencing 
complex to regulate target genes [384, 385]. Transfection of different siRNAs resulted in 
unique gene expression profiles [386] specific to the siRNA. Twelve siRNAs against 
three genes generated 347 off-targeted genes [387] and >969 transcripts were 
dysregulated in response to six siRNAs against six genes HeLa cells [388]. This 
regulation extended to changes in protein levels of unintended targets [389]. Analysis of 
the off-target transcripts revealed sequence complementarity in their 3’UTR to the 5’end 
of the siRNAs [388]. Despite strong reliance on single target validations, several studies 
began to show differential expression of hundreds of genes in response to over-
expression of a single miRNA, using gene expression arrays [20, 390]. These findings 
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and similarities of siRNAs to miRNA targeting mechanisms suggested that miRNAs 
could target multiple genes to achieve their functional specificity and output.  
 With the increase in the number of bioinformatics software that consistently 
showed large numbers of predicted targets [82, 102, 104, 382, 391], more studies 
explored multiple candidates per miRNA. miR-181a could regulate T-cell sensitivity by 
targeting multiple phosphatases [392].  miR-31 could suppress metastasis by coordinated 
regulation of RhoA, integrin-alpha5 and radixin [236]. Using large numbers of luciferase 
assays, miR-17-5p was shown to target 26 binding sites across 21 genes [228]. A study 
[104] performing large scale validation of 226 target sites (44 predicted targets of miR-
375, 24 for miR-296 and 158 for miR-134) found 168 target sites with at least 30% 
repression in luciferase activity [104]. High-throughput sequencing of RNA isolated by 
crosslinking immunoprecipitation (HITS-CLIP) was applied to mouse brain, where the 
top twenty most abundant miRNAs had an average of 655 targets [302]. A more efficient 
cross-linking using photoactivatable nucleoside such as 4-thiouridine in the 
Photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation (PAR-
CLIP) was used to compare Ago2-IP on mock transfected and miR-124 and miR-7 
transfected Hek293 cells, identifying ~3000 and ~920 transcripts containing PAR-CLIP 
sequence read clusters [112]. Stable isotope labeling with amino acids in cell culture 
(SILAC), a high throughput analysis of changes in protein levels, showed 12 of 504 
quantified proteins to be repressed (2.4%) by over-expressing miR-1 in HeLa cells [393]. 
Although methods for high-throughput analysis of proteins are still limited, this study 
suggested that a single miRNA could regulate a substantial portion of the proteome.  
In this thesis, the biotin pull-down method described previously [123], but 
significantly modified to increase the specificity of the enrichment [394] was employed. 
This technique has been successfully used in several studies from this laboratory [37, 
299, 377] and others [123, 301, 371-375] to experimentally identify hundreds of target 
genes for miRNAs of interest. Furthermore several targets belonging to the functionally 
relevant pathways were validated using luciferase assays (validation rate of 87.5% for 
miR-182-5p and 83.3% for miR-139-5p), strengthening the validity of this approach. This 
finding supports the principle of concomitant suppression of targets underlying the same 
 128 
biological process by a miRNA to achieve a functional output, as shown before for miR-
31 (Valastyan, Benaich et al. 2009) and miR-17-5p [228, 236]. 
One of the biggest criticisms of all the high-throughput methods of target 
identification is the potentially high rate of false positives, clouding our understanding of 
the true number of miRNA targets. The CLIP based analysis by employing the AGO 
footprint to determine ‘genuine’ miRNA interactions result in <10% false positive rate 
[395]. Using analyses from biotin pull-down of several miRNAs, sufficient 
complementarity to account for ~80% of the biological targets can be identified [394]. 
Using RNAseq on the pulled down transcripts, at least a further 40% where the transcript 
structure is different to what is defined in RefSeq can be explained, suggesting a false 
positive rate of <10% [394] for this technique. Such low false positive rates with a high 
rate of ‘true-positive’ biologically relevant target identification make these techniques 
highly suited for miRNA characterization. 
Through the identification of multiple target mRNAs, this thesis has substantially 
added to what was previously known about the underlying biology of the miRNAs 
examined in this study. Upon response to double-strand DNA breaks, ATM 
phosphorylates CHEK2, which in turn phosphorylates several substrates including 
BRCA1, CDC25A, p53 and E2F1 (Stolz, Ertych et al. 2011). If BRCA1 were the only 
target of miR-182, as had been shown by Moskwa et. al. then its inhibition alone would 
be insufficient to interfere with homologous recombination (HR) pathway [293]. In fact, 
being one of the early responders to damage, CHEK2 which also phosphorylates BRCA1 
to regulate the double stranded repair mechanism [396] might play a crucial role, as it can 
activate other downstream regulators. Hence, by inhibiting a range of different proteins 
that play major roles in the response to DNA damage, including CHEK2, RAD17, ATF1 
and CREB5, TP53BP1, SMARCD3 and CDKN1B, miR-182 is able to effectively knock 
down the ability of the cell to respond to damage and undergo apoptosis. Similarly with 
miR-139-5p, although literature supported a perceived role underlying metastasis in other 
cancers [397, 398], this study first showed concomitant suppression of several targets, 
HRAS, NFKB1, PIK3CA, RAF, and RHOT1 (luciferase validation of binding sites) and 
protein level repression for HRAS, NFKB1, PIK3CA which belong to key signaling 
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networks underlying metastasis. This in fact has been shown to be the case in other 
metastasis related miRNAs like miR-31 and miR10b, which target gene regulatory 
networks to control progression of metastasis [399], making it abundantly clear that 
miRNAs target multiple genes to exert a particular phenotype. 
5.2.2 miRNAs target multiple pathways to exert a biological effect 
 
 Tumorigenesis is a multi-step process, which requires disruption of multiple 
processes and their underlying pathways for progression. This process is typically 
initiated by the acquisition of certain cellular traits or ‘hallmarks’ [400], such as 
sustaining proliferative signaling, avoiding immune destruction, and activating invasion 
and metastasis. Several miRNAs have now been linked to individual hallmarks [401], 
consistent with the hypothesis above that miRNAs regulate multiple members of the 
same pathway. Intriguingly, it is now becoming evident that miRNAs can be associated 
with more than one pathway (and more than one hallmark) to achieve the same biological 
outcome. 
Several in-silico approaches first suggested that miRNAs co-regulate multiple 
pathways to exert a biological affect in a given cancer type [402-404], followed by 
functional studies which supported this notion. miR-155 was shown to have oncogenic 
properties by promoting the proliferation of breast cancer cells through the targeting of 
TP53INP1 [405]. It also has a well-defined role in the promotion of tumor cell invasion 
and metastasis by the activation of an epithelial-to-mesenchymal transition (EMT) in 
breast cancer cells in cooperation with TGF-β [249]. Additionally, it also targets SOCS1 
leading to activation of the JAK-STAT pathway promoting inflammation [251]. Hence 
miR-155 is able to promote tumorigenesis through the modulation of three hallmarks and 
regulating targets with varied functions. Similarly, miR-21 is able to promote 
proliferation in breast cancers through the targeting of PCDC4 [406]; it is also able to 
induce their migratory properties [407] and enable anti-apoptotic functions [407]. 
Prior to the publication on miR-139-5p (Chapter three), only six targets had been 
identified in six different studies. FoxO1 (Hasseine et al. 2009), Rho-kinase2 (Wong et 
al. 2011), and c-Fos (Fan et al. 2012) in hepatocellular carcinoma, CXCR4 (Bao et al. 
2011) in gastric cancer cells, RAP1B (Guo et al. 2012), and Type I insulin-like growth 
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factor (Shen et al. 2012) in colorectal cancer. Chapter three dramatically expanded this 
cohort, and new targets include genes belonging to key signaling pathways underlying 
metastasis. Multiple separate pathways, including Wnt signalling, TGF-β pathway, PI3K 
lipid signaling and MAP kinase cascade were targeted by regulation of multiple genes. 
While this finding strengthened its association as an anti-invasive and anti-migratory 
miRNA, it also highlighted that an assumption that a miRNA only targets one pathway 
may be overly simplistic. miR-139-5p targeting of mRNAs in the Wnt pathway also 
suggests a potential role in tumour initiation and stemness [408], which is distinct from 
its function in inhibiting migration and invasion identified in our study.   
Subsequent to the publication on miR-182 (Chapter two), its association with 
breast cancer was expanded to genes and other pathways besides the DNA Damage and 
Repair pathway. Activation of miR-182 by β-catenin signaling, leads to increased 
invasiveness and metastasis by targeting RECK [409]. Another study showed miR-182’s 
repression of MIM (Missing in Metastasis) leading to increased motility and invasiveness 
by activating RhoA [410]. Knockdown of miR-182 led to activation of CBX7 a positive 
regulator of E-cadherin, which is involved in normal epithelial cell morphology and 
frequently lost in neoplasia [411]. In combination to the findings in Chapter two that 
miR-182 targets genes in the apoptosis pathway such as CDKN1B, BAX and BAK, these 
studies suggest that this miRNA can contribute to breast tumorigenesis by regulating 
target genes underlying distinct signaling pathways, which culminate in altering different 
phenotypic changes. 
Given that a single miRNA can target hundreds of genes in a given cancer type, 
this raises the question of whether repression of all targets contribute to a phenotypic 
change, or if only a subset do. GSEA performed on the targets of miR-182-5p revealed an 
enrichment of genes that play a role in the cell cycle, prompting us to carry out 
proliferation assays to test its role in cell cycle progression. However, these assays 
showed no changes in the cell proliferation levels in the presence of miR-182-5p 
expression. This highlights a limitation in GSEA based analysis, where the same set of 
genes are involved in several cellular processes leading to a ‘pseudo-enrichment’ of that 
function. Another contributing factor is the genuine ability of the miRNA to interact with 
these target genes based on sequence complementarity but does not always result in a 
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functional repression with a phenotypic output in every cell type. In such cases multiple 
miRNAs targeting the same genes or isomiRs that also target the same cohort along with 
the canonical form, together enrich for the ‘functional network’ of genes belonging to 
core pathways whose repression leads to a specific biological signal [37].  
5.2.3 The functional output of a miRNA is determined by the expression of its target 
genes 
miRNAs can exert oncogenic phenotypes across different cancer types by 
targeting the same mRNAs. An example of this is miR-21 targeting PDCD4 in breast 
[412], cervical [413], and colorectal cancers [414]. However, miRNAs can also exert the 
same phenotype by targeting a different cohort of genes depending on the cell model. For 
instance, miR-139 targets NR5A2 in esophageal squamous cell carcinomas to effectively 
impose anti-invasive properties [415]. It also inhibits the metastasis of laryngeal 
squamous carcinoma cells through the targeting of CXCR4 [397], and of hepatocellular 
carcinoma cells by the targeting of Wnt-TCF4 [416]. In another example, miR-155, a 
well studied oncogenic miRNA, promotes the proliferation of MCF-7 breast cancer cells 
through the targeting of TP53INP1 [405]. It also promotes the proliferation of MDA-MB-
231 breast cancer cells through the targeting of SOCS1 [251] and BT-474 breast cancer 
cells through its downstream targeting of FOXO3a [250].  
It is possible that common target mRNAs targeted by the miRNAs in different 
cell types were missed due to technical limitations and differences in the modes of target 
identification. In the case of miR-139, all studies except from this thesis, employed 
computational target predicting softwares, typically reliant on conservative miRNA-
target binding principles, leading to high number of false negatives. Another possible 
explanation is the differences in target mRNAs expressed between each cancer/cell type, 
such that a miRNA target expressed in one cell type might be absent in another. In 
Chapter three, we performed an analysis for overlap of previously validated target genes 
and found that 2 out of 5 genes (CXCR4 and RAP1B) were not expressed in MCF7 cells. 
Hence, miRNAs could regulate distinct mRNAs, depending on their levels of expression, 
to achieve similar outcomes across different cell types and conditions. 
An apparently paradoxical phenomenon is the ability of a single miRNA to 
potentially have both oncogenic and tumor suppressive functions across different tumor 
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types. Analysis of TCGA miRNA sequencing data in the Chapter four highlights several 
examples of miRNAs that are up-regulated in some cancer types, whilst down-regulated 
in others. These have the potential to be oncogenic or tumour suppressive, respectively, 
although this still needs to be experimentally tested. Of the nine miRNAs that were 
dynamic across the phases of the cell cycle, four showed this pattern. This suggests that 
apparently contradictory roles for miRNAs may be more common than currently 
appreciated. There are several examples already in the literature: miR-17-5p, miR-182 
and miR-21, amongst others, have been studied extensively and shown to have dual roles 
in different cancer types [157, 199, 218, 257, 299, 417]. If the function of a miRNA was 
largely dependent on the mRNAs that it targets, then it is conceivable that its phenotypic 
effects could vary significantly based on whether or not its targets are expressed. When 
expressed, the level of mRNA abundance and its fluctuation alters the ability of miRNA 
to regulate its target genes. The cell can employ various mechanisms, for instance, a 
transcription factor can increase the expression of mRNA, which is also a target of the 
miRNA, to levels at which translational repression is no longer effective, thereby altering 
its functional output. Expression patterns of a specific set of miRNA targets across 
different tumor types where the miRNA has contradictory effects may help understand 
the role of these dual functioning miRNAs.  
miR-182 has oncogenic potential in melanoma [302], endometrial cancer [356] 
and colon cancer [357], amongst other tumor types. However, its role is more akin to a 
tumour suppressor in lung [359] and gastric carcinomas [418]. Chapter two identified 
targets of miR-182, uncovering a broad regulation of the DNA damage response as 
discussed before. As a potential oncogene, it also targets inhibitors of the cell cycle such 
as such as CDKN1A, CDKN1B and RB [322] that will presumably prevent cell cycle 
progression in the event that errors in DNA replication are encountered. Contradictory to 
the above function, is that miR-182 also targets genes that are important for cell cycle 
progression such as CDK4/6, CDK2 and CDK7 [322]. Also opposing its role in the 
repression of DNA repair, is its ability to target BTRC, SKP1, SKP2, and the components 
of the SCF complex, which are suppressors of the DNA repair pathway. Although further 
analyses and experiments need to be directed to understanding how the targeting of such 
counter-intuitive mRNAs could still lead to the observed outcome, prior work on miR-
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17-5p suggests that up-regulation of mRNAs via transcription factors overcome the 
functional effects of miRNA targeting [228], and it seems reasonable to hypothesize that 
a similar mechanism is at play here. 
There are also instances where the same target mRNAs regulated by the same 
miRNAs exhibit different effects in multiple cancers. One example is NCOA3, a nuclear 
receptor co-activator known to promote cell proliferation, which is a target of miR-17-5p 
in HEK293T cells [228]. miR-17-5p also targets NCOA3 in breast cancer cells where it 
inhibits cell proliferation [257]. Perhaps the presence of functional estrogen receptor also 
a nuclear hormone receptor, in the breast cancer cells could alter the function of the co-
activator. Moreover, NCOA3 is a co-activator that is actively recruited to transcription 
factors to alter gene expression. Regulation of different target genes by these 
transcription factors could also result in differing phenotypes indirectly. Another 
possibility is the preferential ability of certain signaling pathways to confer oncogenic 
traits in certain cell types, while performing opposing functions in others. A good 
example of this scenario is the TGFβ pathway, which has a well-documented role in 
tumor progression and metastasis in breast cancers. However, TGFβ also plays a tumor-
suppressive role in colorectal and pancreatic cancers where deletions and loss-of-function 
mutations can be found in key proteins of the pathway [419, 420]. Hence a miRNA 
targeting key components of this pathway would bestow oncogenicity in colorectal and 
pancreatic tumors while displaying a tumor-suppressive role in breast cancer. Thus, like 
the individual phenotypic effects of a miRNA, the overall oncogenic or tumor-suppressor 
potential of a miRNA is a function of the mRNAs it targets. The involvement of large 
networks of genes ensures that phenotypic effects observed are a result of combinatorial 
outcomes of multiple signals and pathways making it evident that the function of a 
miRNA cannot be attributed to one target or one phenotype associated with a specific 
target. Hence, a rigorous experimental approach to identify and validate miRNA targets 
should constitute the first step towards understanding its function in a given cell type. 
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5.3 MicroRNAs in breast cancer 
5.3.1 Molecular heterogeneity of breast cancer 
There is no single dominant pathway which characterizes breast tumours, unlike 
colon cancers which are primarily driven by alterations in the Wnt signaling pathway 
[421] or pancreatic cancer which are driven by mutations in KRAS [422]. Breast cancer 
has been classified into approximately 20 major and 18 minor subtypes primarily by 
histology and morphological properties of the tumor at time of diagnosis [423]. However, 
around 70% of all breast tumours ultimately fall under the invasive ductal carcinoma not 
otherwise specified (IDC NOS) category or invasive lobular carcinoma (ILC) subtype 
[423], indicating that the classification system is not able to account for the wider 
heterogeneity of the disease and is thus of minimal prognostic value and clinical utility 
[423]. More recently, gene expression profiling enabled classification of breast cancers 
into five molecular subtypes: luminal A, luminal B, ERBB2, basal and normal-like [424, 
425]. Triple negative breast cancers (TNBCs), a subclass of the basal subtype, lack 
expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal 
growth factor receptor 2 (HER2). TNBCs account for around 15% of all invasive breast 
cancers and are associated with a higher probability of relapse and poorer overall survival 
in the first few years after diagnosis [426]. Stratification of TNBC patients using more 
reliable markers, based on dysregulated pathways would help to personalize treatment, 
possibly increasing efficacy. miRNAs being regulators of pathways, have the potential to 
be valuable therapeutic candidates, providing an avenue to be explored. 
5.3.2 miRNA expression signatures in breast cancers 
Expression profiling has enabled the identification of miRNAs that are 
differentially expressed between the five molecular subtypes of breast cancer with the 
same miRNAs able to distinguish luminal and basal subtypes in independent datasets 
[427]. Recent studies have identified a nine miRNAs signature that could differentiate 
ductal carcinoma in-situ (DCIS) from invasive breast cancers, this includes let-7d, miR-
210, and -221 which are up-regulated in the invasive transition, possibly regulating 
signaling pathways that are responsible for the progression of the cancers [428]. 
However, studies that stratify different subtypes of breast cancer using miRNA signatures 
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do so solely based on expression profiling, with very little or no insight into the targets 
and function of the specific miRNAs in that context. Perhaps this information is not 
necessary for the purposes of classification, however the same set of miRNAs may not be 
useful to classify a different cancer type due to their highly target dependent 
functionality. Hence, the interpretation of a miRNA signature may change based on 
which signaling pathways are active in a particular tumor. With the realization that breast 
cancers are very heterogeneous, it may be a futile exercise identifying a signature that 
works for a small set of tumors without understanding the biological functions of its 
composite miRNAs. One way to do this is to develop an understanding of the miRNA 
function based on accurate determination of its targets and what signaling pathways they 
regulate.  
The first two results chapters of this thesis explored the roles of miR-182-5p and 
miR-139-5p in breast cancer. The first study analyzed expression of miR-182-5p in 
different subtypes of breast cancer showing a consistent upregulation in all tumor 
subtypes, except the TNBC, which had more variability. From identification of targets, 
miR-182-5p was shown to regulate the homologous recombination (HR) pathway of 
DNA damage repair (DDR), targeting several key transcripts such as BRCA1 and 
CHEK2. Hence high expression of miR-182-5p, aside from BRCA mutations, could also 
be an indicator of a perturbation in the HR pathway. Similarly, expression of miR-139-5p 
was variable across the TNBC subtype, highlighting the heterogeneity present within this 
subtype. On a larger cohort of patient samples, it was frequently down-regulated in the 
most invasive subtypes and subsequent functional analysis showed its ability to regulate 
pathways that are important for cell migration and invasion that initiate the process of 
metastasis. Hence the loss of expression of this miRNA may be predictive of an activated 
MAPK, PI3K, TGF-beta or Wnt signaling pathway. This predictive power based on 
expression pattern of a miRNA could be used as a tool to decode intra- and inter-tumoral 
heterogeneity and understand the signaling pathways that are active in different subsets of 
carcinoma cells.   
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5.3.3 miRNA signatures could predict prognosis 
As discussed above, the widely used histological classification of breast cancers 
does not take into account the heterogeneity of the disease. The classification of breast 
cancers into the molecular subtypes requires gene expression profiling followed by data 
analysis, protocols that are usually not part of a diagnostic lab that analyses clinical tumor 
samples to provide a histological report to the physician. Such a setup would benefit from 
the use of a simple prognostic marker that would substitute for having to perform 
extensive transcriptome analyses but still provide information on pathways that are active 
in a particular tumor. This is now possible with miRNA signatures, which have been 
identified to segregate molecular subtypes of breast cancer as well as differentiate 
between the DCIS and IDC stages of tumor progression [427, 428]. miRNA expression 
has been associated with clinicopathological features such as ER positivity [429]. Such 
signatures have been reliably used to specifically identify ER, PR and HER2 status of 
breast cancers [430] and have also been used to stratify TNBCs based on predictability of 
overall survival and metastasis-free survival [431]. 
Presumed advantages for the use of miRNAs as diagnostics include their stability 
and ease of detection in serum [432], plasma [433] and even whole blood [434] of 
patients. Studies have compared expression of miRNA in the tumor to those in the serum, 
where only 7 out of the 20 oncomiRs highly expressed in the tumor are also present in the 
serum [429]. This represents about a third of overexpressed miRNAs, a level of non-
specificity, which may not be applicable for accurate diagnostic purposes. Circulating 
levels of miR-155 have shown promise in separating breast cancer patients from normal 
with expression levels in the serum dropping following chemotherapy or surgery [435]. 
However, the role of miR-155 in inflammation and immunity [436, 437] maybe a 
confounding factor in determining its prognostic value in this context. It might just be a 
‘side-effect’ of chemotherapy as opposed to a sign of tumour regression. Levels of 
circulating miR-182 are higher in breast cancer patients than in healthy controls [438]. 
Moreover, circulating levels of this miRNA also have utility as a prognostic marker as its 
levels in ER negative and PR negative patients are higher than those in ER positive and 
PR positive patients, respectively [438]. As observed in Chapter three, expression of 
miR-139-5p is known to be heterogeneous across the TNBC subtype of breast cancers. 
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Lower expression levels of miR-139-5p may be able to predict higher invasive potential 
and high propensity for metastasis, whose applicability could be extended to other cancer 
types such as squamous cell, cervical and hepatocellular carcinoma, where it has been 
shown to have similar anti-invasive and anti-migratory properties. Such techniques might 
provide easier and more feasible options to segregate between cancer subtypes in addition 
to histological procedures, however their utility in a clinical setting requires more studies 
to establish specificity and reliability before being considered as genuine biomarkers. 
5.3.4 Using miRNAs to direct therapy choices 
Therapy choice based on expression markers began with the uncovering of 
amplifications in the HER2 gene in 15% of breast cancers, tumors which were classified 
as having poor clinical prognosis are now treated with a monoclonal antibody against the 
HER2 receptor as neoadjuvant therapy, significantly increasing the overall survival and 
disease-free survival of patients that even harbor metastatic disease [439, 440]. The use 
of miRNAs as clinical tools (discussed above) could also enable a better selection of 
appropriate treatments based on the specific signaling pathways that are active in a 
particular cancer type. 
A directly translateable case would be miR-182-5p, whose expression impairs 
functioning of the HR pathway, and directly modulates the sensitivity of cells to PARP 
inhibitor therapy. miR-182-5p over-expression, to a certain extent, phenocopies the 
presence of a BRCA mutation. The incidence of BRCA mutation induced clinical breast 
cancer is around 5% of all breast cancers [441]. This subset of patients would be 
classified under the TNBC and could possibly receive neo-adjuvant chemotherapy 
followed by surgery. However, a similar proportion of patients, may not harbor a defect 
in the BRCA genes but have aberrant expression of miR-182. When gene expression data 
of tumors containing high levels of miR-182 expression from the TCGA are compared to 
those with BRCA1/2 mutations, there is almost no overlap: of the 98 patients with 
significant over-expression of miR-182, only a single patient also had a BRCA mutation, 
indicating that these two lesions rarely occur simultaneously in a tumor. Although 
diagnostic tools would have to encompass both these complementary scenarios when 
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being used to direct therapy, testing this miRNA would open up the treatment to a new 
group of patients previously thought not to respond.  
Similarly, expression levels of miR-139-5p could also be used to direct therapy. 
Current diagnostic tools monitor for expression of HER2 and EGFR as an indication of 
active MAPK and/or PI3K signaling which will then direct therapy towards the use of 
Trastuzumab or lapatinib [442]. However, the loss of miR-139-5p may also lead to 
activation of the MAPK and P13K pathway, which may not manifest as aberrant HER2 
or EGFR, but rather affect Ras, which is a downstream protein. Additionally, loss of 
miR-139 expression could potentially direct the use of anti-TGF-beta [443] and anti-Wnt 
therapy [444] using agents that are currently in development.  
This thesis has thus far explored how understanding the miRNA target repertoire 
could be useful when deciphering its functional role and to derive prognostic information 
for clinical utility. Another possible, but longer-term goal would be to use knowledge on 
miRNA function towards developing novel therapies. The outcomes observed from 
manipulating miRNAs experimentally make it highly appealing to design miRNA-based 
therapeutics. It is known that miRNAs are highly stable molecules which resist 
degradation by RNAses by being enclosed in exosomes and microvesicles [445]. miRNA 
mimics in the form of synthetic RNA duplexes or anti-miRs that reduce the levels of 
endogenous miRNAs have both been attempted as therapeutic tools [445, 446]. With the 
cost of high-throughput genomics decreasing significantly, personalized cancer medicine 
is now becoming a possible reality, where every cancer patient will receive tailored 
therapy that is specifically targeted to their disease. To match the speed of diagnostics, 
new avenues for drug development are also highly sought after and the pursuit of any 
viable avenue is warranted, especially miRNAs, which have a widespread effect on a 
whole signaling pathway as opposed to other inhibitors, which would only target nodes. 
Similar to siRNA and gene therapy, several key considerations need to be taken into 
account for miRNA-based therapy: (1) delivery of the mimic or anti-miR to the 
appropriate tissue, (2) vehicle of delivery, (3) minimal or no side-effects and (4) 
appropriate dosage levels without toxic effects are crucial. Administration of short 
hairpin RNAs in adult mice have resulted in long term adverse side-effects due to 
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saturation of their cellular processing pathways, also shared by miRNAs [447], such 
studies need to be performed with potential therapeutic miRNA mimics or anti-miRs for 
their potential as therapy to be inferred. 
5.4 Conclusions and Future Directions 
  
Findings from this thesis and other studies have shown that miRNAs act through 
multiple targets to exert a phenotypic effect, by targeting multiple genes of a single 
pathway and multiple pathways in a given cellular state. The functional output of a 
miRNA is determined by the expression of its target cohort in the given context, which 
can largely explain the multitude of roles a single miRNA is capable of. Results from this 
thesis have also been discussed in the context of breast cancer heterogeneity and how 
miRNA expression signatures and functional analysis can be applied to leverage a 
therapeutic benefit. 
Given the importance of miRNAs and subsequent characterization of their target 
genes, the need for accurate and high-throughput technologies to directly identify 
endogenous miRNA-target interactions still exists. A new technique to address this issue 
is crosslinking, ligation, and sequencing of hybrids (CLASH) [448], which combines 
immunoprecipitation of miRNA machinery (AGO protein) with interacting RNAs 
followed by partial hydrolysis, ligation, reverse transcription and sequencing. This 
technique has the advantage of identifying targets and their specific binding sites. Similar 
to other crosslinking techniques, this method relies on pulling down a component of the 
miRNA machinery to analyse miRNA-mRNA interactions, and currently requires tagged 
protein-RNA complexes, which limits its use to cell cultures. Delivery using viral vectors 
for primary cells or developing mouse models expressing tagged proteins will allow for 
more cell and animal models to be studied under different conditions. Another caveat is 
the low efficiency of RNA-RNA ligation which leads the chimeric reads to be less than 
2% of the total reads obtained from a library [449]. Optimization steps are required to 
stabilize and recover more RNA-RNA hybrids. This would enable identification of higher 
number of miRNA interactions. This protocol provides an avenue to identify novel target 
binding principles, novel targets and in real time analyse changes to miRNA targeting 
mechanisms in response to different conditions. 
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 Another direct future goal arising out of this thesis would be to explore the 
regulators of miRNAs. It is conceivable that miR-182-5p or other potential oncogenic 
miRNAs, could be induced to high levels as a consequence of a genetic aberration in its 
promoter or enhancer regions or even as a result of up-regulation of a transcription factor 
that could activate its transcription during the pathogenesis of breast cancer. This could 
be carried out by surveying its promoter region for binding of transcription factors that 
are elevated in breast cancer. Alternatively sequence data from TCGA or ICGC could be 
queried for alterations in the genomic regions, which could identify copy number changes 
to explain the dysregulation in the miRNA expression.  
Similarly, genomic or epigenomic alterations in a regulatory region that controls 
the transcription of miR-139-5p could result in its silencing across breast tumours. In 
fact, the promoter region of miR-139-5p has been reported to be silenced by EZH2-
induced H3K27me3 in hepatocellular carcinomas [450]. Similarly, CD44 and HER2 can 
induce deacetylation of the H3K9 mark leading to silencing of miR-139 in gastric cancer 
cells [451]. Similar mechanisms could be observed in breast cancer cells by carrying out 
methylation-specific PCR to detect DNA methylation of the promoter or ChIP-qPCR for 
silencing histone marks such as H3K27me3 or H3K9me3 at the promoter regions of miR-
139-5p. Alternatively, publicly available data from the NIH epigenomics roadmap that 
catalogues the epigenetic status of various cell types could be mined and analyzed to 
specifically identify regions of silencing in breast cancer cells. Independent of the role of 
upstream regulators in the context of miR-139-5p, it would be interesting to test whether 
expression of mir-139-5p induces a transition from a more mesenchymal morphology to 
an epithelial phenotype, a reverse EMT (or mesenchymal-to-epithelial transition; MET) 
in MDA-MB-231 cells. This would provide a mechanism by which miR-139-5p is able to 
alter the migratory, invasive and metastatic properties of these cells. Understanding the 
signals to which miRNAs and/or their upstream regulators respond, would enable a top to 
bottom delineation of signaling pathway that miRNAs are part of. 
 The level of dysregulation of individual miRNAs in cancer raises the question of 
whether they are drivers of cancer, or just bystanders. As has been shown in this thesis 
and several other studies in the last few years, dysregulation of miRNA expression and 
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their target repression has been implicated in tumorigenesis. miRNAs are also found in 
‘fragile loci’, which are frequently associated with cancer [449] and promote several 
phenotypes of cancer. However, high expression of miRNA does not always lead to 
biological significance. miR-21 is one of the most highly expressed miRNAs in normal 
liver tissue but has a subdued effect on target repression [376]. Very few miRNAs have 
been shown to be able to induce transformation: miR-17 [143] and miR-21 [157] are two 
examples. Mechanistic network analysis of general miRNA functions show they could 
either switch off target expression or in many cases try to maintain target expression 
within an optimal window suggesting a more modulatory effect than a driver effect for 
miRNAs [452, 453]. So is the regulation at the miRNA machinery level more relevant in 
the analysis of therapeutic benefits for cancer? Are individual subsets of miRNAs 
dysregulated only to fine tune processes in a cell? Regardless of the answer to these 
questions, their potential clinical utility in breast and other cancers as diagnostic, 
prognostic, and therapeutic biomarkers is not impacted, as an oncogenic function is not 
required for their application in this field. It is likely that miRNAs will continue to attract 
a lot of attention for their clinical potential in cancer and other diseases. 
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Supplementary Table 1: Significantly 
targets 
 
 
enriched probes, predicted to be miR-182 
 
 
 
 
 
Probe_ID Gene 
Symbol 
logFC Avg. 
Exp 
adj.P.
Value 
ILMN_1714083 KLHL8 -3.25 9.66 0.00 
ILMN_1711853 MED24 -2.81 10.59 0.00 
ILMN_1772455 HDAC3 -2.81 11.60 0.00 
ILMN_2252136 YWHAE -2.78 9.95 0.01 
ILMN_2358457 ATF4 -2.72 10.49 0.00 
ILMN_2189222 KLHL8 -2.71 10.47 0.00 
ILMN_1805800 RAB5A -2.61 10.03 0.00 
ILMN_1746171 H2AFY -2.60 11.25 0.00 
ILMN_1686254 FAM127B -2.55 10.69 0.00 
ILMN_2388272 MED24 -2.48 10.32 0.00 
ILMN_1809496 COPG2 -2.43 9.93 0.00 
ILMN_1723871 OTUB1 -2.31 9.63 0.00 
ILMN_1685625 UCP2 -2.30 9.20 0.00 
ILMN_1700690 VAT1 -2.30 9.80 0.00 
ILMN_2349006 USP21 -2.26 9.02 0.00 
ILMN_1658911 LOC647349 -2.25 9.88 0.00 
ILMN_1718354 INTS7 -2.25 9.15 0.00 
ILMN_1747460 TMEM184B -2.24 9.63 0.00 
ILMN_1696021 KPNA6 -2.23 10.40 0.00 
ILMN_1743939 C5orf24 -2.22 8.36 0.00 
ILMN_2396672 ABLIM1 -2.20 8.85 0.00 
ILMN_1752947 C17orf79 -2.19 10.19 0.00 
ILMN_1670931 PDS5A -2.18 9.76 0.00 
ILMN_1783806 DTNBP1 -2.16 8.57 0.00 
ILMN_2314140 PAX6 -2.14 8.67 0.00 
ILMN_1859946 n/a -2.13 10.44 0.00 
ILMN_1707336 ARPC4 -2.10 9.42 0.00 
ILMN_1758087 TAOK1 -2.09 8.85 0.00 
ILMN_1807873 SNX6 -2.08 9.71 0.00 
ILMN_2364131 TTPAL -2.08 9.74 0.00 
ILMN_1699496 PHF21A -2.08 10.14 0.00 
ILMN_1751444 NCAPG -2.06 11.25 0.00 
ILMN_1743034 KIF1B -2.05 8.65 0.00 
ILMN_1675612 BLCAP -2.05 9.35 0.00 
ILMN_1792672 POLR2D -2.05 10.33 0.00 
ILMN_2415926 THOC3 -2.04 10.75 0.00 
ILMN_2351638 BEX4 -2.03 11.30 0.00 
ILMN_1780887 USP21 -2.02 9.18 0.00 
ILMN_1683658 FKBP1A -2.01 11.28 0.00 
ILMN_2311537 HMGA1 -2.01 11.44 0.00 
ILMN_1728083 EIF4EBP2 -2.01 9.74 0.00 
ILMN_1694799 PIAS2 -2.01 9.03 0.00 
ILMN_1782403 PRR11 -2.00 8.52 0.00 
ILMN_2109197 EPB41L3 -1.99 10.24 0.00 
ILMN_2074258 BARD1 -1.98 10.01 0.00 
ILMN_1728845 SMARCD1 -1.97 11.82 0.00 
ILMN_1651819 GALNT11 -1.97 9.99 0.00 
ILMN_1723007 ZCCHC9 -1.97 11.17 0.00 
ILMN_1706990 ZNF271 -1.96 10.13 0.00 
ILMN_2311761 AP3S1 -1.96 9.84 0.00 
ILMN_2328433 NOL1 -1.95 9.01 0.00 
ILMN_1678235 KIAA1267 -1.95 9.43 0.00 
ILMN_1762835 HELZ -1.95 9.23 0.00 
ILMN_1688158 CYB5R4 -1.94 9.09 0.00 
ILMN_1760360 ZNF294 -1.94 9.58 0.00 
ILMN_2385097 NDRG3 -1.94 8.95 0.00 
ILMN_1722774 VPS72 -1.93 9.75 0.00 
ILMN_1783985 COQ6 -1.93 9.88 0.00 
ILMN_1711766 SKP1A -1.93 11.33 0.00 
ILMN_1679520 AGPAT1 -1.91 9.26 0.00 
ILMN_1669940 TMEM38B -1.89 9.89 0.00 
ILMN_1766435 WBP11 -1.87 12.39 0.00 
ILMN_2091792 ENTPD6 -1.87 9.52 0.00 
ILMN_1738424 CDC42 -1.87 10.44 0.00 
ILMN_2396813 C19orf62 -1.86 9.51 0.00 
ILMN_1812441 C17orf63 -1.86 9.70 0.00 
ILMN_1655165 RNF138 -1.85 10.44 0.00 
ILMN_1744442 TTPAL -1.85 8.93 0.00 
ILMN_1700546 ELOVL6 -1.85 8.79 0.00 
ILMN_1719471 MSH3 -1.85 10.07 0.00 
ILMN_1813246 LOC728554 -1.85 9.15 0.00 
ILMN_2399896 SEC31A -1.84 10.69 0.00 
ILMN_2370208 CMTM3 -1.84 8.66 0.00 
ILMN_1742981 TUBA1A -1.83 12.61 0.00 
ILMN_2352563 CLDND1 -1.83 10.80 0.00 
ILMN_1772302 MTHFS -1.83 10.78 0.00 
ILMN_1791332 ATP5O -1.83 13.53 0.00 
ILMN_2222008 KIFC1 -1.83 10.98 0.00 
ILMN_1793616 RNF38 -1.82 9.44 0.00 
ILMN_1753002 RAB2B -1.81 10.87 0.00 
ILMN_1785424 ABLIM1 -1.81 10.92 0.00 
ILMN_2283388 C20orf24 -1.79 11.96 0.00 
ILMN_1791002 SKP2 -1.79 9.70 0.00 
ILMN_1704793 LOC339344 -1.79 10.85 0.00 
ILMN_1654289 ELK1 -1.79 10.37 0.00 
ILMN_1678919 YOD1 -1.79 10.17 0.00 
ILMN_1790951 C19orf50 -1.78 10.31 0.00 
ILMN_2394250 PLEKHA1 -1.78 9.82 0.00 
ILMN_1690963 DDEF1 -1.78 10.33 0.00 
ILMN_1793360 APITD1 -1.78 10.55 0.00 
ILMN_1808587 ZFHX3 -1.78 8.73 0.00 
ILMN_1785635 BRD3 -1.77 10.19 0.00 
ILMN_1719039 UBE2G1 -1.77 9.81 0.00 
ILMN_2373779 COPS8 -1.76 9.03 0.00 
ILMN_1667670 SLC25A15 -1.76 9.54 0.00 
ILMN_2181125 NAPB -1.76 9.20 0.00 
ILMN_1680782 PATL1 -1.75 10.32 0.00 
ILMN_2100689 MAP2K4 -1.75 9.48 0.00 
ILMN_1911042 n/a -1.74 11.29 0.00 
ILMN_1706553 SMG7 -1.74 9.97 0.00 
ILMN_1720526 CENPN -1.74 11.18 0.00 
ILMN_2207393 CNOT3 -1.73 9.04 0.00 
ILMN_2371685 UBE2E1 -1.73 8.35 0.00 
ILMN_1691942 CCNI -1.73 13.30 0.00 
ILMN_1722066 ARMC1 -1.73 9.84 0.00 
ILMN_1711189 EXOSC10 -1.73 10.13 0.00 
ILMN_1688322 ADIPOR1 -1.73 10.23 0.00 
ILMN_1792712 LOC201725 -1.72 9.52 0.00 
ILMN_1798496 HOXB8 -1.72 10.97 0.00 
ILMN_2409793 MAZ -1.72 8.24 0.00 
ILMN_1673185 CPSF2 -1.72 9.41 0.00 
ILMN_1710326 CLDND1 -1.72 10.71 0.00 
ILMN_1758311 NET1 -1.72 11.41 0.00 
ILMN_1771019 MTMR4 -1.72 10.54 0.00 
ILMN_1734833 NBN -1.71 9.94 0.00 
ILMN_1656682 AZIN1 -1.71 11.12 0.00 
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ILMN_1807243 PRPF18 -1.71 9.01 0.00 
ILMN_1714622 TNRC6A -1.70 8.84 0.00 
ILMN_1700024 UST -1.70 8.63 0.00 
ILMN_2374244 DYRK2 -1.70 9.42 0.00 
ILMN_1732772 PPME1 -1.70 9.42 0.00 
ILMN_1727809 STK35 -1.69 8.46 0.00 
ILMN_1721116 USP10 -1.69 9.58 0.00 
ILMN_1720965 TULP4 -1.69 8.97 0.00 
ILMN_1724148 ORAI1 -1.69 8.22 0.00 
ILMN_1760143 ADRM1 -1.69 11.55 0.00 
ILMN_1781360 MPHOSPH6 -1.69 9.36 0.00 
ILMN_1697614 NHP2L1 -1.68 10.12 0.00 
ILMN_2333367 FKBP1A -1.67 9.33 0.00 
ILMN_1744308 DHX33 -1.66 9.71 0.00 
ILMN_2090397 ISG20L2 -1.66 10.36 0.00 
ILMN_1724293 KDELR2 -1.66 9.98 0.00 
ILMN_2155172 BXDC2 -1.66 11.05 0.00 
ILMN_1764415 ZNF585A -1.66 8.17 0.00 
ILMN_2077886 C1orf109 -1.66 9.62 0.00 
ILMN_1683609 UBE1 -1.65 11.97 0.00 
ILMN_1745813 KIAA1279 -1.65 10.80 0.00 
ILMN_1654262 ZMAT3 -1.65 8.29 0.00 
ILMN_2124951 RBMX -1.65 11.50 0.00 
ILMN_1770425 CDIPT -1.65 8.37 0.00 
ILMN_1655608 KLHL18 -1.64 8.39 0.00 
ILMN_1810488 NFYC -1.64 9.95 0.00 
ILMN_1727996 BAG4 -1.64 8.24 0.01 
ILMN_1755077 HEBP2 -1.64 11.78 0.00 
ILMN_1778917 CDK7 -1.64 9.27 0.00 
ILMN_1715416 NUP188 -1.64 9.96 0.00 
ILMN_1699695 TNFRSF21 -1.64 10.79 0.00 
ILMN_1700044 SAP130 -1.63 9.85 0.00 
ILMN_1917341 n/a -1.63 9.12 0.00 
ILMN_1752582 RAB5B -1.63 10.86 0.00 
ILMN_1790953 TBCB -1.63 11.01 0.00 
ILMN_1673369 SEPHS1 -1.63 9.74 0.00 
ILMN_1724497 ABI2 -1.63 9.30 0.00 
ILMN_1730433 CD2AP -1.62 8.40 0.00 
ILMN_1801928 YWHAZ -1.62 13.13 0.00 
ILMN_1810514 SLC25A44 -1.62 10.06 0.00 
ILMN_1728024 TUBG1 -1.62 10.10 0.00 
ILMN_1712687 PAK2 -1.62 9.60 0.00 
ILMN_1804798 BEXL1 -1.61 12.52 0.00 
ILMN_1704342 UBE3C -1.61 10.16 0.00 
ILMN_1752591 LEPROTL1 -1.61 10.53 0.00 
ILMN_1668507 DDAH1 -1.61 9.63 0.00 
ILMN_1693108 RUVBL1 -1.61 10.74 0.00 
ILMN_1689817 LCOR -1.61 9.24 0.00 
ILMN_1738229 NDRG3 -1.61 10.41 0.00 
ILMN_1775744 MRPS16 -1.61 10.47 0.00 
ILMN_1723185 ELOF1 -1.61 8.92 0.00 
ILMN_1737426 PCMTD1 -1.61 8.51 0.00 
ILMN_1706502 EIF2AK2 -1.61 10.83 0.00 
ILMN_1665423 ZFP91 -1.60 11.38 0.00 
ILMN_1671742 UPF3A -1.60 9.35 0.00 
ILMN_2173451 GPI -1.60 10.95 0.00 
ILMN_1783023 LOC285636 -1.60 10.88 0.00 
ILMN_1912737 n/a -1.60 8.40 0.00 
ILMN_1708858 CSNK1E -1.60 11.10 0.00 
ILMN_2089340 FAM127B -1.60 8.04 0.00 
ILMN_1815733 EIF5 -1.59 10.42 0.00 
ILMN_1815158 GPS2 -1.59 9.95 0.00 
ILMN_1790987 HUWE1 -1.59 8.96 0.00 
ILMN_1793671 TFDP2 -1.58 7.94 0.00 
ILMN_2359345 NET1 -1.58 8.01 0.00 
ILMN_1813834 PRMT6 -1.58 9.51 0.00 
ILMN_1757467 H1F0 -1.58 11.45 0.01 
ILMN_2415235 CSNK1E -1.57 12.82 0.00 
ILMN_1666004 WASL -1.57 10.11 0.00 
ILMN_1682180 VCPIP1 -1.57 8.52 0.00 
ILMN_2374865 ATF3 -1.57 9.49 0.00 
ILMN_1763260 HIF1A -1.57 8.28 0.00 
ILMN_2072603 MRPL14 -1.57 12.25 0.00 
ILMN_1806266 RAP1GDS1 -1.57 8.95 0.00 
ILMN_2106902 CHES1 -1.57 9.48 0.00 
ILMN_2070896 BMPR2 -1.56 9.03 0.00 
ILMN_2379130 IRAK1 -1.56 11.72 0.00 
ILMN_1667561 IFRD1 -1.56 9.10 0.00 
ILMN_1682264 WDR68 -1.56 10.87 0.00 
ILMN_1697597 KIAA0494 -1.55 9.29 0.00 
ILMN_1671257 DKC1 -1.55 12.31 0.00 
ILMN_1679800 BXDC2 -1.55 12.43 0.00 
ILMN_2320964 ADAR -1.55 10.19 0.00 
ILMN_1743397 PIGW -1.55 9.42 0.00 
ILMN_1745415 BBX -1.55 10.03 0.00 
ILMN_1680987 HAND1 -1.55 12.98 0.00 
ILMN_1789999 SLC30A7 -1.55 9.61 0.00 
ILMN_1753885 YTHDF1 -1.55 10.65 0.00 
ILMN_2055760 KIAA1715 -1.55 9.20 0.00 
ILMN_2393763 ARPC4 -1.54 9.23 0.00 
ILMN_2391551 C13orf23 -1.54 10.03 0.00 
ILMN_1669722 LRRC61 -1.54 8.07 0.00 
ILMN_1788203 HEY1 -1.54 11.59 0.00 
ILMN_1800975 PSME3 -1.54 11.27 0.00 
ILMN_1688639 FBXL2 -1.54 8.55 0.00 
ILMN_1743208 NEDD1 -1.54 7.89 0.00 
ILMN_1685763 WDR45L -1.54 9.47 0.00 
ILMN_2403458 SMARCB1 -1.53 9.62 0.00 
ILMN_2322552 NCKAP1 -1.53 9.25 0.00 
ILMN_2321485 PPP1R8 -1.53 8.73 0.00 
ILMN_1745686 MFHAS1 -1.53 8.10 0.00 
ILMN_1786328 WDR40A -1.53 9.80 0.00 
ILMN_1782579 IMMT -1.53 11.09 0.00 
ILMN_1754304 C6orf151 -1.53 8.83 0.00 
ILMN_1682938 ARF3 -1.53 9.65 0.00 
ILMN_1657754 RPAP2 -1.53 9.21 0.00 
ILMN_1806328 PDIK1L -1.53 9.17 0.00 
ILMN_1694259 TINP1 -1.52 11.97 0.00 
ILMN_1763694 RSPRY1 -1.52 10.30 0.00 
ILMN_1658847 MGC61598 -1.51 9.83 0.00 
ILMN_1783676 CCDC15 -1.51 8.28 0.00 
ILMN_1685574 TSC22D2 -1.51 8.81 0.00 
ILMN_1757636 C5orf35 -1.51 8.98 0.00 
ILMN_1656540 RUVBL1 -1.51 9.88 0.00 
ILMN_1669046 FOXQ1 -1.51 8.67 0.00 
ILMN_1703487 LMO4 -1.50 10.30 0.00 
ILMN_1781580 BRI3 -1.50 10.66 0.00 
ILMN_1657139 ADAT1 -1.50 8.61 0.00 
ILMN_1673069 DPP9 -1.50 9.17 0.00 
ILMN_1738491 SNX30 -1.50 8.76 0.00 
ILMN_1659895 MSN -1.50 10.14 0.00 
ILMN_1779374 AMMECR1 -1.50 10.00 0.00 
ILMN_1761531 SGPL1 -1.50 8.39 0.00 
ILMN_1708414 GNL3L -1.50 10.63 0.00 
ILMN_1789510 STIP1 -1.49 11.82 0.00 
ILMN_1774028 MTFR1 -1.49 10.14 0.00 
ILMN_2394242 AMMECR1 -1.49 8.60 0.00 
ILMN_1722718 BMP2 -1.49 8.92 0.00 
ILMN_1687782 RAD17 -1.49 8.06 0.00 
ILMN_2399627 AP1G1 -1.49 8.59 0.00 
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ILMN_1725612 NUP50 -1.49 9.40 0.00 
ILMN_2187487 HEATR5B -1.49 9.38 0.00 
ILMN_2325008 DHX40 -1.48 9.05 0.00 
ILMN_1729976 ZNF828 -1.48 10.78 0.00 
ILMN_1911605 n/a -1.48 8.90 0.00 
ILMN_1722811 CDKN1B -1.48 9.15 0.00 
ILMN_1701131 C2orf49 -1.48 9.32 0.00 
ILMN_1669394 EI24 -1.48 11.93 0.00 
ILMN_2330371 TATDN3 -1.48 9.10 0.00 
ILMN_1771884 ZNF45 -1.48 8.44 0.00 
ILMN_1673024 RBM15B -1.47 8.07 0.00 
ILMN_1713129 TTF1 -1.47 8.96 0.00 
ILMN_1720270 CDR2 -1.47 9.87 0.00 
ILMN_1654441 OAT -1.47 11.12 0.01 
ILMN_1727444 C16orf53 -1.47 9.84 0.00 
ILMN_1651705 CAT -1.47 8.94 0.00 
ILMN_2129388 KIAA1128 -1.47 8.59 0.00 
ILMN_1726359 NECAP1 -1.46 10.55 0.00 
ILMN_2374293 DYRK1A -1.46 9.15 0.00 
ILMN_1753345 SCAMP5 -1.46 8.56 0.00 
ILMN_1761797 CSTB -1.46 12.74 0.00 
ILMN_2321634 RAD17 -1.46 8.04 0.00 
ILMN_1750167 PRR3 -1.46 8.45 0.00 
ILMN_2181968 CBL -1.45 8.57 0.00 
ILMN_1674302 PPAT -1.45 10.50 0.00 
ILMN_1688404 ZMYM4 -1.45 10.26 0.00 
ILMN_1655497 EIF4B -1.45 12.26 0.00 
ILMN_1667432 HYAL3 -1.45 8.23 0.00 
ILMN_1710676 FBXO5 -1.45 10.49 0.00 
ILMN_1776260 LOC653505 -1.45 12.29 0.00 
ILMN_1771962 GLI3 -1.45 7.97 0.00 
ILMN_1767662 LASS6 -1.44 11.11 0.00 
ILMN_1812552 PHCA -1.44 8.63 0.00 
ILMN_1757272 THAP1 -1.44 8.48 0.00 
ILMN_1807042 MARCKS -1.44 12.60 0.00 
ILMN_1790100 C11orf82 -1.44 9.70 0.00 
ILMN_1759097 MLLT11 -1.44 11.49 0.00 
ILMN_1658472 APH1A -1.44 10.97 0.00 
ILMN_1741422 FUT8 -1.44 8.69 0.00 
ILMN_1675387 LIMS1 -1.44 8.54 0.00 
ILMN_1716552 ENAH -1.43 9.62 0.00 
ILMN_1659953 3-Sep -1.43 8.61 0.00 
ILMN_1738632 PRKAR1A -1.43 11.35 0.00 
ILMN_1759008 ZNF689 -1.43 11.09 0.00 
ILMN_1751898 C12orf4 -1.43 9.16 0.00 
ILMN_2414399 NME1 -1.43 10.64 0.01 
ILMN_1668270 ZDHHC18 -1.43 8.68 0.00 
ILMN_1742167 TUBA1C -1.42 14.30 0.00 
ILMN_1671326 EIF2C1 -1.42 8.95 0.00 
ILMN_2337941 COPS8 -1.42 11.01 0.00 
ILMN_1771964 GSTA4 -1.42 9.77 0.00 
ILMN_2243553 ZNF275 -1.42 9.40 0.00 
ILMN_1674282 PPARD -1.42 7.94 0.00 
ILMN_1705442 CMTM3 -1.42 10.51 0.00 
ILMN_1729175 FBXO3 -1.42 8.72 0.00 
ILMN_1796962 PPP3R1 -1.42 10.47 0.00 
ILMN_1795128 C13orf23 -1.42 9.74 0.00 
ILMN_1697503 DHX29 -1.42 9.24 0.00 
ILMN_1651936 SETD8 -1.41 9.24 0.00 
ILMN_1758906 GNA13 -1.41 10.39 0.00 
ILMN_1705515 UPF3A -1.41 9.48 0.00 
ILMN_1670383 PCDH7 -1.41 8.31 0.00 
ILMN_1695509 PTPN12 -1.41 8.46 0.00 
ILMN_1659415 MAP2K1IP1 -1.41 10.20 0.00 
ILMN_1672504 PDXK -1.41 10.78 0.00 
ILMN_1736510 FOXN2 -1.41 9.47 0.00 
ILMN_1795435 ZNF264 -1.40 8.31 0.00 
ILMN_1663486 TLK2 -1.40 9.67 0.00 
ILMN_1661491 SH3GL2 -1.40 9.18 0.00 
ILMN_2367020 SEC61G -1.40 13.36 0.00 
ILMN_1773066 CDKN2AIP -1.40 8.71 0.00 
ILMN_1684051 WASF2 -1.39 8.84 0.00 
ILMN_2312719 EXOSC9 -1.39 9.47 0.00 
ILMN_1837935 TNPO1 -1.39 9.38 0.00 
ILMN_1794588 DYRK2 -1.39 8.13 0.00 
ILMN_1769665 RAB5C -1.38 10.11 0.00 
ILMN_2374687 PTPN13 -1.38 8.60 0.00 
ILMN_1800837 CFDP1 -1.38 9.71 0.00 
ILMN_1801215 PDDC1 -1.38 8.36 0.00 
ILMN_1679655 WDR82 -1.37 10.57 0.00 
ILMN_1784602 CDKN1A -1.37 9.04 0.00 
ILMN_2374683 PTPN13 -1.37 8.71 0.00 
ILMN_1765574 TFAP2A -1.37 11.06 0.01 
ILMN_1753440 C4orf30 -1.37 9.33 0.00 
ILMN_1802894 VKORC1L1 -1.37 9.34 0.00 
ILMN_1682316 TRIM33 -1.37 10.79 0.00 
ILMN_1738173 METTL4 -1.36 8.06 0.00 
ILMN_2366177 IFT122 -1.35 7.89 0.00 
ILMN_1701269 ATP5C1 -1.35 12.44 0.00 
ILMN_2311089 BRCA1 -1.35 9.57 0.00 
ILMN_1723117 IPO9 -1.35 9.32 0.00 
ILMN_1732343 KIAA0999 -1.35 9.00 0.00 
ILMN_2106167 RAP1GDS1 -1.35 8.75 0.00 
ILMN_1665117 C6orf89 -1.35 7.83 0.00 
ILMN_1680955 AURKA -1.35 11.64 0.00 
ILMN_1815169 MCM5 -1.35 10.40 0.00 
ILMN_1703946 ADORA2B -1.35 10.27 0.00 
ILMN_1656427 C17orf39 -1.35 8.71 0.00 
ILMN_1803256 STOX2 -1.35 9.78 0.00 
ILMN_2404539 C20orf30 -1.35 11.97 0.00 
ILMN_2403006 TJP1 -1.34 8.88 0.00 
ILMN_1672940 ZNF562 -1.34 8.90 0.00 
ILMN_2346573 PSME3 -1.34 11.30 0.00 
ILMN_1813236 C6orf136 -1.34 9.59 0.00 
ILMN_1662166 PTK7 -1.34 8.43 0.00 
ILMN_2330267 ABCE1 -1.34 11.60 0.00 
ILMN_1692684 SMARCD2 -1.34 9.06 0.00 
ILMN_1676846 ABCE1 -1.34 11.54 0.00 
ILMN_1696383 POP4 -1.34 9.13 0.00 
ILMN_1770623 FAM58A -1.33 10.07 0.00 
ILMN_1701558 MAP1A -1.33 8.54 0.00 
ILMN_2096322 ADIPOR1 -1.33 9.78 0.00 
ILMN_1656676 ZYG11B -1.33 11.17 0.00 
ILMN_2324421 TXNRD1 -1.33 8.50 0.01 
ILMN_1902658 n/a -1.32 8.86 0.00 
ILMN_1775901 PHF5A -1.32 9.45 0.00 
ILMN_2057220 HRSP12 -1.32 8.78 0.01 
ILMN_1731184 MELK -1.32 9.62 0.00 
ILMN_1705871 DDHD2 -1.32 9.59 0.00 
ILMN_1687440 HIPK2 -1.32 9.09 0.00 
ILMN_1740216 ERCC3 -1.32 9.79 0.00 
ILMN_2365544 NOLA2 -1.32 11.39 0.00 
ILMN_1658624 UBXN6 -1.32 9.01 0.00 
ILMN_1689123 CCNK -1.32 10.44 0.00 
ILMN_2156267 EIF2AK1 -1.32 11.98 0.00 
ILMN_1809285 DCP1A -1.32 8.69 0.00 
ILMN_1652580 POLD1 -1.32 9.43 0.00 
ILMN_1724811 PARN -1.31 9.26 0.00 
ILMN_1755235 XPO6 -1.31 10.27 0.00 
ILMN_1709439 CHMP1A -1.31 9.83 0.00 
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ILMN_1695334 PYGO2 -1.31 8.03 0.00 
ILMN_2331636 ACACA -1.31 11.07 0.00 
ILMN_1732705 HCFC1 -1.31 12.60 0.00 
ILMN_1762615 FAM175B -1.31 10.36 0.00 
ILMN_2062381 LCOR -1.31 9.86 0.00 
ILMN_1812080 PARP16 -1.31 8.21 0.00 
ILMN_1782504 MTERFD1 -1.31 10.11 0.00 
ILMN_1762764 SH3BGRL2 -1.31 9.39 0.00 
ILMN_1803254 KIAA2010 -1.31 9.72 0.00 
ILMN_1754121 CSK -1.31 12.03 0.00 
ILMN_2361695 BAG5 -1.31 10.74 0.00 
ILMN_1705985 PIGA -1.31 10.54 0.00 
ILMN_1665538 SKP2 -1.30 12.43 0.00 
ILMN_2389013 ADRM1 -1.30 9.86 0.00 
ILMN_1800889 FIG4 -1.30 9.06 0.00 
ILMN_1708619 SEH1L -1.30 8.84 0.00 
ILMN_1651254 LPP -1.30 8.97 0.00 
ILMN_1728517 FNTB -1.30 9.42 0.01 
ILMN_1758750 EARS2 -1.29 9.14 0.00 
ILMN_1741356 PRICKLE1 -1.29 9.01 0.00 
ILMN_1786601 PLAGL2 -1.29 10.09 0.00 
ILMN_1717524 LIPT1 -1.29 8.60 0.00 
ILMN_2357438 AURKA -1.29 11.45 0.00 
ILMN_1659206 RARA -1.29 9.47 0.00 
ILMN_1672004 TOB1 -1.29 9.21 0.00 
ILMN_1654118 BCL2L1 -1.29 9.69 0.00 
ILMN_1676075 KLHL12 -1.29 8.57 0.00 
ILMN_1683300 BAX -1.29 8.05 0.00 
ILMN_1725485 RGS17 -1.29 8.75 0.00 
ILMN_1728984 PA2G4 -1.29 11.41 0.00 
ILMN_1676010 SP1 -1.29 9.38 0.00 
ILMN_2164081 KLHL12 -1.28 10.34 0.00 
ILMN_1806818 MCM3 -1.28 11.15 0.01 
ILMN_1702835 SH3BGRL -1.28 10.02 0.01 
ILMN_2061950 RABGAP1 -1.28 10.09 0.00 
ILMN_1779486 FAM126B -1.28 8.27 0.00 
ILMN_1741003 ANXA5 -1.28 11.83 0.00 
ILMN_1762725 EIF3EIP -1.28 12.70 0.00 
ILMN_2370296 ENAH -1.28 8.46 0.00 
ILMN_1721713 EXOSC9 -1.28 10.22 0.00 
ILMN_1771149 MRPL19 -1.28 9.21 0.00 
ILMN_1801923 ATF1 -1.28 8.08 0.00 
ILMN_2399622 AP1G1 -1.27 9.17 0.00 
ILMN_2175075 SFRS4 -1.27 12.21 0.00 
ILMN_1815723 NUP35 -1.27 8.46 0.00 
ILMN_1705032 SEH1L -1.27 8.21 0.00 
ILMN_1718672 NOLA2 -1.27 11.69 0.00 
ILMN_1708059 USP13 -1.27 8.84 0.00 
ILMN_1785926 ZNF621 -1.27 9.43 0.00 
ILMN_1704972 TRIM5 -1.27 8.14 0.00 
ILMN_1766951 MSX2 -1.27 8.31 0.00 
ILMN_1718071 AGTPBP1 -1.27 9.33 0.00 
ILMN_1679438 MLF1IP -1.27 8.90 0.00 
ILMN_1662161 TBC1D13 -1.26 9.22 0.00 
ILMN_1772690 OGFOD1 -1.26 9.66 0.00 
ILMN_1811195 ZNF211 -1.26 8.29 0.00 
ILMN_2047112 RP11-529I10.4 -1.26 10.00 0.00 
ILMN_2343105 LIPT1 -1.26 8.66 0.00 
ILMN_1788347 KIAA1737 -1.26 9.41 0.00 
ILMN_1691949 LOC728554 -1.26 13.13 0.00 
ILMN_1657857 TMEM14C -1.26 11.39 0.00 
ILMN_1775762 GNAI2 -1.26 9.51 0.00 
ILMN_1761844 ZCCHC17 -1.25 10.71 0.00 
ILMN_1731714 CREB5 -1.25 9.12 0.00 
ILMN_2170515 METTL11A -1.25 10.16 0.00 
ILMN_1790577 SLC35F2 -1.25 9.23 0.00 
ILMN_1780598 PIAS1 -1.25 9.43 0.00 
ILMN_1700231 IHPK1 -1.25 10.15 0.00 
ILMN_2400500 LASS2 -1.25 9.44 0.00 
ILMN_1716080 CBL -1.25 8.24 0.00 
ILMN_1806312 C20orf30 -1.25 12.31 0.00 
ILMN_1808196 GSTO1 -1.25 12.04 0.00 
ILMN_1754912 GLE1 -1.25 10.64 0.00 
ILMN_1724493 LYSMD2 -1.25 8.88 0.00 
ILMN_1680703 MRPS15 -1.25 12.03 0.00 
ILMN_1741585 SFMBT1 -1.24 8.30 0.00 
ILMN_1799104 SPAG9 -1.24 9.69 0.00 
ILMN_1761560 PHF13 -1.24 10.49 0.00 
ILMN_1802669 PPP3CB -1.24 10.03 0.00 
ILMN_2196097 PPP2CA -1.24 11.87 0.00 
ILMN_1765204 ST13 -1.24 10.95 0.00 
ILMN_1782459 OSBPL8 -1.24 9.39 0.01 
ILMN_1720422 G3BP2 -1.24 9.68 0.00 
ILMN_1786852 ZCCHC3 -1.24 8.78 0.00 
ILMN_1806937 C19orf62 -1.24 11.45 0.00 
ILMN_1712320 DDX50 -1.24 10.39 0.00 
ILMN_1742238 SET -1.24 11.72 0.00 
ILMN_1724825 PCBP2 -1.23 12.43 0.00 
ILMN_1718265 ATG5 -1.23 8.79 0.00 
ILMN_1680104 SLC35C1 -1.23 8.09 0.00 
ILMN_1652244 POPDC3 -1.23 8.00 0.00 
ILMN_2112402 PHF5A -1.23 11.82 0.00 
ILMN_2362122 AP3M1 -1.23 9.81 0.01 
ILMN_2249288 TIPRL -1.23 8.75 0.01 
ILMN_1703408 FZD3 -1.23 8.62 0.00 
ILMN_2093674 GMFB -1.23 11.75 0.00 
ILMN_1813400 CBR4 -1.23 9.82 0.00 
ILMN_2144116 CPSF2 -1.22 9.46 0.01 
ILMN_1713491 VAMP2 -1.22 8.67 0.00 
ILMN_1736939 UGCG -1.22 8.68 0.00 
ILMN_2149766 APPBP2 -1.22 10.21 0.00 
ILMN_2129015 AFF1 -1.22 8.01 0.00 
ILMN_1670353 RAD51AP1 -1.22 11.15 0.00 
ILMN_1812856 ZSWIM1 -1.22 9.86 0.00 
ILMN_2362457 ZDHHC16 -1.22 9.99 0.00 
ILMN_1666156 MORF4L2 -1.22 12.34 0.01 
ILMN_1708841 GOLPH3 -1.21 10.52 0.01 
ILMN_2387599 C20orf24 -1.21 13.24 0.00 
ILMN_2393254 CAPNS1 -1.21 9.53 0.00 
ILMN_1657153 ACTR3 -1.21 10.30 0.00 
ILMN_1809889 CCDC117 -1.21 11.00 0.00 
ILMN_1771627 ZMIZ1 -1.21 9.93 0.00 
ILMN_1674034 H2AFY -1.21 8.28 0.00 
ILMN_2128293 APIP -1.21 9.39 0.00 
ILMN_1683811 TNPO3 -1.20 9.68 0.00 
ILMN_1801348 GOT2 -1.20 12.61 0.00 
ILMN_1710873 ZNF330 -1.20 10.72 0.00 
ILMN_1736816 C13orf3 -1.20 8.90 0.00 
ILMN_1723158 NOL1 -1.20 12.03 0.00 
ILMN_2323979 WARS2 -1.20 8.82 0.00 
ILMN_1696870 TGFBRAP1 -1.20 8.54 0.00 
ILMN_1728514 BAG5 -1.20 8.70 0.00 
ILMN_2261784 CCNY -1.20 9.63 0.00 
ILMN_1708502 AFF4 -1.20 8.62 0.00 
ILMN_1772540 ATMIN -1.19 8.32 0.00 
ILMN_1685824 B4GALT5 -1.19 10.50 0.00 
ILMN_1773369 MRPL48 -1.19 10.04 0.00 
ILMN_1734742 ARHGDIA -1.19 11.44 0.00 
ILMN_1810805 HEATR5B -1.19 8.66 0.00 
ILMN_1715905 DSN1 -1.19 9.61 0.00 
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ILMN_1737380 BCAP29 -1.19 8.35 0.00 
ILMN_1651872 UBIAD1 -1.19 9.22 0.00 
ILMN_1686555 FYN -1.19 9.38 0.00 
ILMN_1701991 SYNJ1 -1.18 8.68 0.00 
ILMN_1651385 MFN2 -1.18 9.75 0.00 
ILMN_1785284 ALDH6A1 -1.18 9.37 0.00 
ILMN_1791097 RSBN1 -1.18 9.48 0.00 
ILMN_1798659 CCDC28A -1.18 10.21 0.00 
ILMN_1718285 HOXC8 -1.18 8.77 0.00 
ILMN_1701374 NUP35 -1.18 8.39 0.00 
ILMN_1660691 RAB31 -1.18 11.51 0.01 
ILMN_1666192 DCTN5 -1.18 10.56 0.00 
ILMN_1843198 n/a -1.18 10.30 0.00 
ILMN_1734254 ZNF770 -1.18 9.53 0.00 
ILMN_1807600 NPLOC4 -1.18 9.26 0.00 
ILMN_1746673 3-Sep -1.18 10.01 0.00 
ILMN_1727692 TRIT1 -1.18 9.88 0.00 
ILMN_1803005 MMACHC -1.18 9.54 0.00 
ILMN_1806017 PSME1 -1.18 11.58 0.00 
ILMN_1774844 MAPKAPK2 -1.18 7.83 0.00 
ILMN_2223350 C13orf1 -1.18 8.16 0.00 
ILMN_1708611 RDX -1.18 10.05 0.00 
ILMN_2402766 AFTPH -1.18 8.11 0.00 
ILMN_1768050 SCOC -1.17 10.91 0.00 
ILMN_1742379 IFT122 -1.17 8.41 0.00 
ILMN_1694323 GLE1 -1.17 7.86 0.00 
ILMN_1692056 HS3ST3A1 -1.17 10.64 0.00 
ILMN_1666050 TMUB1 -1.17 11.07 0.00 
ILMN_2398587 ZNRD1 -1.17 9.53 0.00 
ILMN_1775759 NRAS -1.17 9.18 0.00 
ILMN_1775008 NCAPD2 -1.17 10.57 0.00 
ILMN_1809818 PRCC -1.17 8.13 0.00 
ILMN_1735548 HIVEP1 -1.17 7.87 0.00 
ILMN_1789095 BMPR2 -1.17 8.78 0.00 
ILMN_1695276 MAPRE2 -1.17 10.98 0.00 
ILMN_1784785 COPS7B -1.17 10.45 0.00 
ILMN_1676899 YEATS2 -1.17 9.36 0.00 
ILMN_1738712 GPR180 -1.17 9.86 0.00 
ILMN_1753279 HNRNPA0 -1.17 11.55 0.01 
ILMN_1711703 C16orf70 -1.17 8.21 0.00 
ILMN_1796210 PPRC1 -1.17 10.59 0.00 
ILMN_1661636 ZMYM2 -1.17 8.95 0.00 
ILMN_1738657 SATB2 -1.17 9.71 0.00 
ILMN_1762972 CHD9 -1.16 9.56 0.00 
ILMN_1714335 RDH10 -1.16 9.40 0.00 
ILMN_1785107 NXT2 -1.16 8.77 0.01 
ILMN_1761808 MCFD2 -1.16 9.37 0.01 
ILMN_2404906 SGOL1 -1.16 8.58 0.00 
ILMN_2395236 CHEK2 -1.16 9.00 0.00 
ILMN_2404112 TRDMT1 -1.16 8.00 0.00 
ILMN_1811997 ZNF364 -1.16 10.17 0.01 
ILMN_1795228 ZFAND5 -1.16 11.05 0.00 
ILMN_1697559 G6PD -1.15 8.44 0.00 
ILMN_1656501 DUSP5 -1.15 8.60 0.00 
ILMN_1783709 RRAGA -1.15 11.56 0.00 
ILMN_1739876 RAB3GAP1 -1.15 10.88 0.00 
ILMN_1741054 SLC5A6 -1.15 10.85 0.00 
ILMN_1722894 ZNRD1 -1.15 9.46 0.00 
ILMN_1806106 GNL3 -1.15 10.86 0.00 
ILMN_1729980 RNF216 -1.15 9.45 0.00 
ILMN_1661337 SRM -1.15 11.51 0.00 
ILMN_1782385 POLR2A -1.15 11.46 0.00 
ILMN_1808501 SH3KBP1 -1.15 9.49 0.00 
ILMN_1652082 ELF4 -1.15 8.58 0.00 
ILMN_1659364 RFC5 -1.15 11.49 0.00 
ILMN_1738677 PRPF8 -1.15 12.10 0.00 
ILMN_1733863 FAM100A -1.15 8.69 0.00 
ILMN_2103295 TINP1 -1.15 12.98 0.00 
ILMN_1732725 SAPS3 -1.14 9.73 0.00 
ILMN_1678922 HERC4 -1.14 9.00 0.00 
ILMN_1790533 PHACTR2 -1.14 9.14 0.00 
ILMN_1775304 DNAJB1 -1.14 9.67 0.00 
ILMN_2307450 ZNF302 -1.14 10.08 0.00 
ILMN_1686235 GNPNAT1 -1.14 7.96 0.01 
ILMN_2102693 NUFIP2 -1.14 9.86 0.00 
ILMN_1717765 NUDT11 -1.14 9.74 0.00 
ILMN_2399264 6-Sep -1.14 8.39 0.00 
ILMN_1709101 AKAP13 -1.14 7.92 0.00 
ILMN_2052208 GADD45A -1.14 9.77 0.00 
ILMN_2172969 STXBP6 -1.14 8.01 0.01 
ILMN_2095840 MYST3 -1.14 10.08 0.00 
ILMN_2166384 IPO5 -1.13 9.40 0.01 
ILMN_1763634 PEX14 -1.13 8.82 0.00 
ILMN_1812191 C12orf57 -1.13 11.77 0.00 
ILMN_1689318 NUAK1 -1.13 9.51 0.00 
ILMN_1812776 FBXO28 -1.13 9.44 0.00 
ILMN_2139100 SHISA5 -1.13 11.01 0.00 
ILMN_1742069 ZSWIM5 -1.13 8.42 0.00 
ILMN_1658464 GTF3A -1.13 11.86 0.01 
ILMN_1682197 NFXL1 -1.13 9.19 0.00 
ILMN_2111187 ELOVL6 -1.13 10.69 0.00 
ILMN_1865764 n/a -1.13 8.50 0.01 
ILMN_1773906 NCOA4 -1.13 12.66 0.00 
ILMN_1754660 ZCCHC24 -1.13 8.67 0.00 
ILMN_2377430 AGPAT2 -1.13 9.55 0.00 
ILMN_1742456 OSTF1 -1.13 9.08 0.00 
ILMN_1768197 ROD1 -1.13 10.92 0.00 
ILMN_1744138 CHCHD7 -1.12 9.28 0.00 
ILMN_1736340 ANGEL2 -1.12 10.40 0.00 
ILMN_1679092 RAB9B -1.12 8.32 0.00 
ILMN_1682799 STAMBPL1 -1.12 9.31 0.00 
ILMN_1800225 PPARG -1.12 9.75 0.00 
ILMN_1737611 VAMP1 -1.12 10.14 0.01 
ILMN_1679838 WBP5 -1.12 11.84 0.00 
ILMN_2097858 KIAA1737 -1.12 9.57 0.00 
ILMN_1703053 ZFP91 -1.12 7.98 0.00 
ILMN_1814165 SSBP3 -1.12 7.94 0.00 
ILMN_1657771 CRTC2 -1.12 7.91 0.00 
ILMN_1716766 CEBPG -1.12 9.74 0.00 
ILMN_1677432 SRGAP1 -1.11 8.19 0.00 
ILMN_1652521 MTMR9 -1.11 9.03 0.00 
ILMN_2301083 UBE2C -1.11 12.58 0.00 
ILMN_2373495 H2AFY -1.11 14.22 0.00 
ILMN_1803476 KCTD20 -1.11 9.96 0.00 
ILMN_1741148 ALDOA -1.11 12.85 0.00 
ILMN_1691432 PRDM4 -1.11 9.59 0.00 
ILMN_2318685 ABHD12 -1.11 8.00 0.00 
ILMN_1676745 ZNF142 -1.11 8.95 0.00 
ILMN_1764186 LOC146517 -1.11 9.12 0.00 
ILMN_1764871 PIGP -1.11 11.23 0.00 
ILMN_1661622 TBC1D7 -1.11 10.41 0.00 
ILMN_2380801 FYN -1.11 8.13 0.00 
ILMN_2225348 ZNF805 -1.11 8.13 0.00 
ILMN_1713143 MRPL3 -1.10 12.60 0.00 
ILMN_1656826 SH3RF1 -1.10 8.51 0.00 
ILMN_2109526 CSNK2A1P -1.10 8.84 0.00 
ILMN_2097793 ZBTB4 -1.10 9.21 0.00 
ILMN_1758673 SLC44A1 -1.10 8.43 0.01 
ILMN_2135709 C8orf47 -1.10 8.37 0.00 
ILMN_1658143 RFC3 -1.10 9.38 0.01 
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ILMN_1692962 CTDSP2 -1.10 10.20 0.00 
ILMN_2189605 FAM122B -1.10 9.52 0.00 
ILMN_1765060 FBXO34 -1.10 9.34 0.00 
ILMN_1805225 LPCAT3 -1.10 8.86 0.00 
ILMN_1766222 LARP5 -1.09 10.24 0.00 
ILMN_1744949 RHOBTB3 -1.09 11.23 0.00 
ILMN_1739032 TMEM70 -1.09 8.09 0.00 
ILMN_1672128 ATF4 -1.09 14.17 0.00 
ILMN_2386355 CSNK2A1 -1.09 9.08 0.01 
ILMN_1777526 MED20 -1.09 11.46 0.00 
ILMN_1656145 GOT1 -1.09 11.24 0.00 
ILMN_1800512 HMOX1 -1.09 10.09 0.00 
ILMN_1669635 NUP85 -1.09 11.09 0.00 
ILMN_1776216 TMEM32 -1.09 11.77 0.00 
ILMN_1772692 DICER1 -1.09 9.39 0.00 
ILMN_1788961 PPP2R2A -1.09 10.73 0.00 
ILMN_1738027 BRCA1 -1.08 9.76 0.00 
ILMN_1657993 ADNP -1.08 9.45 0.01 
ILMN_1691499 TJP1 -1.08 10.25 0.00 
ILMN_1778255 FARSA -1.08 9.59 0.00 
ILMN_1679195 C20orf24 -1.08 13.25 0.00 
ILMN_2115696 USP42 -1.08 9.99 0.00 
ILMN_1706957 BMPR1A -1.08 9.05 0.00 
ILMN_2227573 GSTO1 -1.08 12.63 0.00 
ILMN_1777449 IFT74 -1.08 8.68 0.00 
ILMN_1719103 UBE2CBP -1.08 7.89 0.00 
ILMN_1856861 n/a -1.08 8.07 0.00 
ILMN_1671885 MLF2 -1.08 10.46 0.00 
ILMN_2075927 STK40 -1.08 10.53 0.01 
ILMN_1699859 GNPAT -1.08 10.15 0.00 
ILMN_2403906 ARFIP1 -1.08 9.97 0.00 
ILMN_1713380 EIF2B2 -1.08 11.05 0.00 
ILMN_1736548 PHACTR4 -1.07 10.82 0.00 
ILMN_1726108 LASS2 -1.07 10.09 0.00 
ILMN_2128428 DAB2 -1.07 8.79 0.00 
ILMN_1723020 MAP3K1 -1.07 9.27 0.00 
ILMN_1804329 TUSC2 -1.07 8.41 0.00 
ILMN_1807106 LDHA -1.07 13.93 0.00 
ILMN_2356890 MRPL42 -1.07 9.02 0.00 
ILMN_1700695 SLC44A1 -1.07 10.99 0.00 
ILMN_1713756 GLUD1 -1.07 11.35 0.01 
ILMN_1811648 DCAKD -1.07 10.80 0.00 
ILMN_1654697 ZNF280B -1.06 8.28 0.00 
ILMN_1694075 GADD45A -1.06 8.70 0.00 
ILMN_1794349 XYLB -1.06 8.20 0.00 
ILMN_2147306 PNRC2 -1.06 11.06 0.00 
ILMN_1742578 MKLN1 -1.06 9.87 0.00 
ILMN_1685774 LOC647340 -1.06 13.41 0.00 
ILMN_1862018 ATXN7L3 -1.06 9.48 0.00 
ILMN_1684594 USP24 -1.06 9.88 0.00 
ILMN_1686152 GGA2 -1.05 9.95 0.00 
ILMN_1691575 SNX2 -1.05 10.96 0.00 
ILMN_2263718 SPAG9 -1.05 10.60 0.00 
ILMN_1763265 CHMP1B -1.05 9.20 0.00 
ILMN_1663605 RNF123 -1.05 8.84 0.01 
ILMN_1732300 POLR2C -1.05 8.81 0.00 
ILMN_1748697 LIN28B -1.05 11.27 0.01 
ILMN_1653404 NKIRAS2 -1.05 9.15 0.01 
ILMN_1655117 WDR19 -1.05 9.56 0.00 
ILMN_2335669 ZC3H14 -1.05 9.19 0.00 
ILMN_1727271 WARS -1.05 9.66 0.00 
ILMN_1813275 DUSP22 -1.05 11.11 0.00 
ILMN_2209027 RPS26 -1.05 12.61 0.00 
ILMN_1841334 n/a -1.04 8.54 0.00 
ILMN_1730294 INO80C -1.04 10.52 0.00 
ILMN_2222074 PTPN12 -1.04 9.17 0.00 
ILMN_2397024 SPOP -1.04 11.57 0.00 
ILMN_2313926 CDC42SE2 -1.04 9.23 0.00 
ILMN_2392674 PRR3 -1.04 8.26 0.00 
ILMN_1748591 ODC1 -1.04 12.28 0.00 
ILMN_2100693 MAP2K4 -1.04 7.90 0.00 
ILMN_1657683 C1orf198 -1.04 9.34 0.00 
ILMN_1695585 RPS26L -1.04 13.82 0.01 
ILMN_1758412 COPS7A -1.04 11.54 0.00 
ILMN_1764945 AP3D1 -1.04 10.13 0.00 
ILMN_1804812 ANAPC1 -1.04 10.69 0.00 
ILMN_2323526 WAC -1.03 10.20 0.00 
ILMN_2390114 AP3D1 -1.03 10.27 0.00 
ILMN_1794470 ANKFY1 -1.03 9.18 0.00 
ILMN_1666761 PPP2R5E -1.03 10.39 0.01 
ILMN_1746856 RAB21 -1.03 8.94 0.00 
ILMN_1766359 GATAD2B -1.03 8.46 0.00 
ILMN_1787410 EIF6 -1.03 11.34 0.00 
ILMN_1711381 RFC3 -1.03 7.98 0.00 
ILMN_1673215 PCBP1 -1.03 12.82 0.00 
ILMN_1876924 WNK1 -1.03 10.10 0.00 
ILMN_1769118 9-Sep -1.03 12.69 0.00 
ILMN_1761260 COBLL1 -1.03 9.15 0.01 
ILMN_1758250 TRAFD1 -1.03 8.94 0.00 
ILMN_1681081 AGPAT2 -1.03 8.27 0.01 
ILMN_2181445 BCL2L13 -1.03 10.65 0.00 
ILMN_1779264 PSMG1 -1.03 11.04 0.00 
ILMN_1673682 GATAD2A -1.03 11.42 0.00 
ILMN_2108938 FNBP4 -1.02 10.76 0.00 
ILMN_1692121 USO1 -1.02 10.57 0.00 
ILMN_1795905 ZBTB4 -1.02 8.25 0.00 
ILMN_1744628 FDX1L -1.02 9.54 0.01 
ILMN_1714383 TPD52L1 -1.02 9.04 0.00 
ILMN_1827736 n/a -1.02 10.73 0.00 
ILMN_1682783 TUG1 -1.02 11.89 0.00 
ILMN_1669599 DENND4C -1.02 8.25 0.00 
ILMN_1756898 COQ9 -1.02 10.37 0.00 
ILMN_1765860 DOCK11 -1.02 8.70 0.01 
ILMN_2200636 KIAA1267 -1.02 10.30 0.00 
ILMN_1813938 CHCHD4 -1.02 10.79 0.00 
ILMN_1787705 ATP6V1B2 -1.02 11.61 0.00 
ILMN_1802615 CDK6 -1.02 10.18 0.00 
ILMN_1726554 IREB2 -1.02 9.44 0.00 
ILMN_1708203 OTUD4 -1.02 8.83 0.00 
ILMN_2234229 PRMT6 -1.02 10.57 0.00 
ILMN_2053921 CAPZB -1.02 8.48 0.00 
ILMN_1669931 TM9SF3 -1.02 9.55 0.00 
ILMN_1761031 PTPDC1 -1.02 8.11 0.00 
ILMN_2380946 EIF4G2 -1.02 13.45 0.00 
ILMN_1798108 C6orf211 -1.01 8.06 0.00 
ILMN_1664909 LOC729351 -1.01 7.99 0.00 
ILMN_1705908 RPL7L1 -1.01 11.74 0.01 
ILMN_2413141 C6orf162 -1.01 8.19 0.00 
ILMN_1671809 DUSP22 -1.01 9.68 0.00 
ILMN_1659099 ROCK2 -1.01 8.62 0.01 
ILMN_1743711 LOC650215 -1.01 10.19 0.00 
ILMN_2312732 DPP8 -1.01 8.26 0.00 
ILMN_2045911 FBXO28 -1.01 9.74 0.00 
ILMN_2337655 WARS -1.01 10.43 0.00 
ILMN_1748651 PSMB3 -1.01 13.68 0.00 
ILMN_1730645 TMEFF2 -1.01 7.89 0.00 
ILMN_1681703 FOXO3 -1.01 11.50 0.01 
ILMN_1721729 PPARBP -1.01 9.50 0.01 
ILMN_1709474 ALMS1 -1.01 7.97 0.00 
ILMN_1800993 CLUAP1 -1.00 8.13 0.00 
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ILMN_1685978 ATPIF1 -1.00 8.67 0.00 
ILMN_1799289 MRPL55 -1.00 9.86 0.00 
ILMN_2090105 TAGLN2 -1.00 11.23 0.00 
ILMN_1803060 MAML1 -1.00 7.90 0.00 
ILMN_1804479 MRPL18 -1.00 11.29 0.01 
ILMN_1724052 LOC730051 -1.00 7.90 0.00 
ILMN_2391355 STAMBP -1.00 9.26 0.00 
ILMN_1769869 PIP5K1A -1.00 7.83 0.00 
ILMN_1799642 TRIM24 -1.00 9.78 0.00 
ILMN_1675577 C14orf172 -1.00 8.39 0.00 
ILMN_1784227 MCRS1 -1.00 11.75 0.00 
ILMN_1793729 C15orf39 -1.00 9.47 0.00 
ILMN_2337923 TPD52L1 -1.00 9.05 0.00 
ILMN_1745116 ABHD12 -1.00 7.86 0.00 
ILMN_2346727 MTUS1 -1.00 7.79 0.00 
ILMN_1659544 STX3 -1.00 9.22 0.01 
ILMN_1800871 RAB6A -1.00 8.31 0.00 
ILMN_1658884 ATP11B -1.00 7.78 0.00 
ILMN_2132161 KIF18A -1.00 8.51 0.00 
ILMN_1774949 PIGP -1.00 9.05 0.00 
ILMN_2038776 TXN -1.00 14.39 0.00 
ILMN_1802642 TOM1L1 -0.99 7.99 0.00 
ILMN_1799604 OCIAD1 -0.99 11.54 0.01 
ILMN_1736481 SECISBP2 -0.99 9.14 0.00 
ILMN_2189668 NUDT11 -0.99 10.05 0.00 
ILMN_2171461 ZNF322A -0.99 8.11 0.00 
ILMN_1743456 ZCCHC14 -0.99 9.48 0.00 
ILMN_2398388 APH1A -0.99 9.17 0.01 
ILMN_1664440 TP53BP1 -0.99 9.52 0.01 
ILMN_1797342 FNBP1 -0.99 10.27 0.00 
ILMN_1653871 NAMPT -0.99 8.00 0.00 
ILMN_1691119 RNF122 -0.99 7.87 0.00 
ILMN_1728676 KIAA0196 -0.99 10.45 0.01 
ILMN_2214098 BIVM -0.99 9.61 0.00 
ILMN_1708906 C2orf29 -0.99 12.03 0.01 
ILMN_1763436 SETX -0.99 7.83 0.00 
ILMN_2124471 SLC36A1 -0.99 8.25 0.00 
ILMN_1799128 SLC30A9 -0.99 10.42 0.00 
ILMN_1732176 AGPAT2 -0.99 8.62 0.00 
ILMN_1758049 NFIA -0.99 7.90 0.00 
ILMN_1727309 FAM82A2 -0.99 9.81 0.01 
ILMN_1733421 PRKCQ -0.98 9.89 0.00 
ILMN_1657873 XPO4 -0.98 10.09 0.00 
ILMN_2396956 AKAP13 -0.98 9.28 0.00 
ILMN_1681590 LARP1 -0.98 9.87 0.00 
ILMN_1779886 TBC1D14 -0.98 10.02 0.00 
ILMN_2357577 PRKAA1 -0.98 9.54 0.00 
ILMN_2083567 PHLPPL -0.98 8.13 0.01 
ILMN_1721842 RYBP -0.98 9.72 0.01 
ILMN_1669070 MIPEP -0.98 8.69 0.00 
ILMN_1652735 RFXAP -0.98 8.54 0.00 
ILMN_1753467 SAMD4B -0.98 8.19 0.00 
ILMN_2176768 SEPHS1 -0.98 10.93 0.00 
ILMN_1793203 SMCR7L -0.98 10.71 0.00 
ILMN_1739749 B3GALT6 -0.98 9.13 0.00 
ILMN_2081883 IQCK -0.97 8.87 0.00 
ILMN_1666306 SRRD -0.97 8.86 0.00 
ILMN_1704665 GPM6B -0.97 9.78 0.00 
ILMN_1666372 ATP5H -0.97 12.99 0.00 
ILMN_1664560 DYRK1A -0.97 8.96 0.00 
ILMN_1693323 C6orf162 -0.97 8.08 0.00 
ILMN_1785406 NAP1L3 -0.97 8.41 0.00 
ILMN_1725300 MLL3 -0.97 8.51 0.01 
ILMN_2353697 MIZF -0.97 8.49 0.00 
ILMN_1705310 VEZF1 -0.97 10.52 0.00 
ILMN_1695432 TPST2 -0.96 8.57 0.00 
ILMN_1691425 LDOC1L -0.96 9.54 0.00 
ILMN_1750029 GABPA -0.96 8.35 0.01 
ILMN_1805990 BAK1 -0.96 8.52 0.00 
ILMN_1811489 OXSR1 -0.96 10.24 0.01 
ILMN_1659285 PSMG1 -0.96 11.37 0.00 
ILMN_1677396 NDFIP2 -0.96 11.74 0.01 
ILMN_1778444 FKBP5 -0.96 9.49 0.00 
ILMN_2336109 L3MBTL2 -0.96 10.22 0.00 
ILMN_1773741 GOLGA5 -0.96 9.56 0.00 
ILMN_2312296 PCBP2 -0.96 13.41 0.00 
ILMN_2311518 TROVE2 -0.96 11.23 0.01 
ILMN_1666122 HEG1 -0.96 8.02 0.00 
ILMN_1663042 SDC4 -0.95 7.77 0.00 
ILMN_2124769 YBX1 -0.95 12.70 0.00 
ILMN_2245305 ABHD12 -0.95 8.49 0.00 
ILMN_2088612 XPO4 -0.95 9.24 0.00 
ILMN_1666049 NUP214 -0.95 9.01 0.00 
ILMN_1788783 TRAM2 -0.95 8.90 0.01 
ILMN_1767848 PCMTD2 -0.95 8.84 0.00 
ILMN_1784037 ZBTB40 -0.95 8.60 0.01 
ILMN_2297710 PLEKHB2 -0.95 8.71 0.00 
ILMN_1752810 LARP6 -0.95 9.42 0.00 
ILMN_1736575 TRIM28 -0.95 10.48 0.00 
ILMN_1786036 GPATCH2 -0.95 7.93 0.00 
ILMN_1660840 FAM152A -0.95 10.27 0.00 
ILMN_2327795 RERE -0.95 8.44 0.00 
ILMN_1734096 DCLRE1A -0.95 9.33 0.00 
ILMN_1698968 ASXL2 -0.95 9.37 0.00 
ILMN_1771224 C18orf24 -0.94 8.63 0.00 
ILMN_2358842 PCBP4 -0.94 8.86 0.00 
ILMN_1806778 UBE2E1 -0.94 12.46 0.00 
ILMN_2106227 KIAA2026 -0.94 7.86 0.00 
ILMN_2158242 SHOC2 -0.94 8.37 0.00 
ILMN_1676005 KPNA1 -0.94 9.72 0.00 
ILMN_2169856 C12orf43 -0.94 9.16 0.01 
ILMN_1745962 FBXO7 -0.94 10.14 0.00 
ILMN_1791478 MTPN -0.94 10.75 0.00 
ILMN_1665357 EPS15 -0.94 8.21 0.00 
ILMN_1738420 TMEM201 -0.94 8.29 0.00 
ILMN_2208495 LASS5 -0.94 8.76 0.01 
ILMN_1803180 PRDX6 -0.94 12.71 0.00 
ILMN_1722533 KATNAL1 -0.94 8.14 0.00 
ILMN_2317348 APTX -0.94 9.76 0.00 
ILMN_1807540 CBARA1 -0.94 9.09 0.00 
ILMN_1661039 MRPL30 -0.94 7.96 0.00 
ILMN_2230683 CDCA7L -0.94 8.52 0.01 
ILMN_1657624 NSFL1C -0.94 9.27 0.00 
ILMN_1759801 DPP8 -0.93 8.71 0.00 
ILMN_1726752 APTX -0.93 8.64 0.00 
ILMN_1761519 EIF4G2 -0.93 13.02 0.00 
ILMN_1704446 SLC6A10P -0.93 8.78 0.00 
ILMN_1662839 PLEKHA1 -0.93 10.21 0.00 
ILMN_1763828 MTF1 -0.93 8.68 0.00 
ILMN_2248589 DHX40 -0.93 10.98 0.00 
ILMN_1724540 CART1 -0.93 8.60 0.01 
ILMN_1774974 CLUAP1 -0.93 7.80 0.01 
ILMN_2328972 DNMT3B -0.93 8.78 0.00 
ILMN_2117987 TFDP1 -0.93 11.89 0.01 
ILMN_2328378 OSBPL3 -0.93 8.46 0.00 
ILMN_1711919 SCYL2 -0.92 9.02 0.00 
ILMN_1672135 ZNF615 -0.92 8.58 0.00 
ILMN_1754235 SLC35C2 -0.92 8.16 0.00 
ILMN_1674506 MED23 -0.92 8.71 0.01 
ILMN_2405031 TRIM24 -0.92 7.99 0.00 
 174 
ILMN_1747775 STX2 -0.92 9.72 0.01 
ILMN_1699208 NAP1L1 -0.92 12.18 0.01 
ILMN_1769473 SETD2 -0.92 9.83 0.01 
ILMN_1736796 RB1CC1 -0.92 9.96 0.00 
ILMN_2290204 ARHGAP28 -0.92 7.87 0.00 
ILMN_2327860 MAL -0.92 7.79 0.00 
ILMN_1698487 SDHD -0.92 10.62 0.01 
ILMN_1679880 THOC6 -0.92 8.86 0.01 
ILMN_1775243 LOC646766 -0.92 14.02 0.01 
ILMN_1714278 C9orf30 -0.92 8.95 0.00 
ILMN_1692486 ZNRD1 -0.91 10.03 0.01 
ILMN_1677953 OGFOD1 -0.91 9.81 0.00 
ILMN_1802831 MTMR12 -0.91 7.91 0.01 
ILMN_1665510 ERRFI1 -0.91 9.98 0.00 
ILMN_1777584 KARS -0.91 9.75 0.01 
ILMN_1714990 DBT -0.91 9.68 0.00 
ILMN_1716400 FOXM1 -0.91 9.22 0.00 
ILMN_1788738 ZNRF3 -0.91 7.89 0.00 
ILMN_2117223 ROD1 -0.91 10.63 0.00 
ILMN_2367743 TUBG1 -0.91 11.98 0.00 
ILMN_1745811 TDRD3 -0.91 8.01 0.00 
ILMN_2192620 LOC90379 -0.91 8.80 0.00 
ILMN_1712774 IRS4 -0.91 8.22 0.01 
ILMN_1742147 UBL4A -0.91 9.63 0.01 
ILMN_1733627 NEDD4L -0.91 8.20 0.00 
ILMN_1814573 FTSJD1 -0.91 8.49 0.00 
ILMN_1710738 RC3H2 -0.91 8.71 0.00 
ILMN_2089656 C1orf107 -0.91 8.24 0.00 
ILMN_2144088 FDFT1 -0.91 12.48 0.01 
ILMN_1686097 TOP2A -0.90 12.26 0.01 
ILMN_1688526 ARL5A -0.90 11.83 0.01 
ILMN_1726783 RNASEH1 -0.90 10.00 0.00 
ILMN_1814966 PIAS3 -0.90 7.83 0.00 
ILMN_2404049 RBM38 -0.90 9.01 0.01 
ILMN_1682336 MASTL -0.90 8.96 0.00 
ILMN_1844692 FOXO3 -0.90 9.97 0.01 
ILMN_1747016 CEP55 -0.90 10.20 0.01 
ILMN_1669905 DCP2 -0.90 11.42 0.01 
ILMN_1687743 BTBD7 -0.90 8.93 0.01 
ILMN_1802380 RERE -0.90 9.43 0.00 
ILMN_1662852 IQCK -0.90 7.85 0.00 
ILMN_2364384 PPARG -0.90 7.80 0.00 
ILMN_1748916 C18orf55 -0.89 9.61 0.01 
ILMN_1760849 NETO2 -0.89 10.52 0.00 
ILMN_1671895 ZNF613 -0.89 8.23 0.01 
ILMN_1743104 RBM4B -0.89 9.69 0.00 
ILMN_1755352 TUB -0.89 9.12 0.00 
ILMN_1764803 SMU1 -0.89 8.14 0.00 
ILMN_1769566 ATG3 -0.89 10.03 0.00 
ILMN_1711089 DNAJC21 -0.89 7.97 0.00 
ILMN_1722858 PPP2CA -0.89 13.39 0.01 
ILMN_1745798 GTF2F2 -0.89 10.92 0.00 
ILMN_1785179 UBE2G2 -0.89 10.28 0.00 
ILMN_1775170 MT1X -0.89 11.17 0.01 
ILMN_2381753 G3BP2 -0.89 11.28 0.00 
ILMN_1741264 MRPS33 -0.88 11.59 0.00 
ILMN_1692651 PHB -0.88 11.54 0.00 
ILMN_1736002 COPS5 -0.88 11.98 0.01 
ILMN_1773459 SOX11 -0.88 8.47 0.01 
ILMN_1730048 C7orf26 -0.88 9.68 0.00 
ILMN_1774083 TRIAP1 -0.88 10.02 0.01 
ILMN_2335319 KCNG3 -0.88 7.75 0.00 
ILMN_1714216 TSC2 -0.88 8.83 0.00 
ILMN_1760890 SEPN1 -0.88 9.79 0.01 
ILMN_1770412 AHCYL1 -0.88 11.21 0.01 
ILMN_2288232 PHKB -0.88 8.54 0.01 
ILMN_2224031 CETN3 -0.88 9.41 0.00 
ILMN_1667213 DFFA -0.88 10.27 0.01 
ILMN_2294274 S100PBP -0.88 8.18 0.00 
ILMN_1679891 NAF1 -0.88 8.52 0.00 
ILMN_1667319 LPPR2 -0.87 8.19 0.01 
ILMN_1808374 SNTB2 -0.87 9.44 0.00 
ILMN_1737833 ATN1 -0.87 8.58 0.01 
ILMN_1757347 C22orf9 -0.87 7.77 0.00 
ILMN_1779381 SEC61A2 -0.87 8.61 0.00 
ILMN_1781099 ISY1 -0.87 9.85 0.00 
ILMN_1762787 RNF26 -0.87 9.28 0.00 
ILMN_2215631 OTUD6B -0.87 8.93 0.00 
ILMN_1684321 CYB5B -0.87 12.37 0.00 
ILMN_1669424 LOC646531 -0.87 13.58 0.01 
ILMN_1778991 NFIB -0.87 8.60 0.01 
ILMN_2313158 MBNL1 -0.87 8.40 0.00 
ILMN_1749081 AUTS2 -0.87 10.32 0.00 
ILMN_1663195 MCM7 -0.87 13.44 0.01 
ILMN_1798886 NUDT21 -0.87 10.10 0.01 
ILMN_1799516 DNAJC9 -0.87 11.84 0.01 
ILMN_2403889 PRMT5 -0.87 10.78 0.01 
ILMN_2358041 NBN -0.87 7.72 0.01 
ILMN_1716272 KBTBD8 -0.87 8.84 0.00 
ILMN_1666305 CDKN3 -0.86 9.88 0.01 
ILMN_1739586 FEZ2 -0.86 10.58 0.00 
ILMN_1725043 ADAL -0.86 8.10 0.01 
ILMN_1772527 C12orf44 -0.86 9.89 0.01 
ILMN_1765578 TIPARP -0.86 8.69 0.00 
ILMN_1686136 NSD1 -0.86 7.95 0.00 
ILMN_1746276 EPC1 -0.86 7.72 0.00 
ILMN_1762224 HPS3 -0.86 7.77 0.00 
ILMN_2223903 PPIC -0.86 10.49 0.00 
ILMN_1656316 ZMYM3 -0.85 8.69 0.00 
ILMN_1705876 NAP1L1 -0.85 9.80 0.00 
ILMN_1767542 THAP10 -0.85 9.29 0.00 
ILMN_1679797 ADARB1 -0.85 9.20 0.01 
ILMN_1699476 RPE -0.85 9.13 0.01 
ILMN_2403946 FEZ2 -0.85 9.71 0.01 
ILMN_1697529 RNF10 -0.85 8.35 0.01 
ILMN_1719097 C18orf8 -0.85 9.54 0.00 
ILMN_1763409 LRRC8D -0.85 8.09 0.00 
ILMN_1727134 KLHDC5 -0.85 9.07 0.00 
ILMN_1772876 ZNF395 -0.85 9.12 0.00 
ILMN_2335718 HNRNPAB -0.85 12.41 0.01 
ILMN_1749641 FBXO3 -0.85 8.41 0.01 
ILMN_1799814 WDR57 -0.85 10.77 0.01 
ILMN_1683950 SNX11 -0.85 9.54 0.01 
ILMN_2387799 PDPK1 -0.85 9.79 0.01 
ILMN_1810797 WASF3 -0.85 8.93 0.01 
ILMN_1805826 BIVM -0.85 9.45 0.00 
ILMN_2225974 GCLM -0.85 8.01 0.00 
ILMN_1714444 KLF12 -0.85 8.36 0.00 
ILMN_1797813 SUZ12 -0.85 12.50 0.00 
ILMN_1740395 RAVER1 -0.84 9.40 0.00 
ILMN_1781526 PPP1R8 -0.84 8.20 0.01 
ILMN_1732489 SLC10A7 -0.84 8.45 0.01 
ILMN_1682232 MIER1 -0.84 9.19 0.01 
ILMN_1692260 MAFG -0.84 7.97 0.01 
ILMN_1737211 ZNF585A -0.84 7.88 0.00 
ILMN_1754839 DHX15 -0.84 11.66 0.01 
ILMN_1674662 C15orf42 -0.84 8.74 0.00 
ILMN_1763104 TRAF4 -0.84 7.65 0.00 
ILMN_2127624 UBE2CBP -0.84 8.23 0.00 
ILMN_2096405 WDR37 -0.84 9.16 0.01 
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ILMN_1691567 GNPDA2 -0.84 8.23 0.00 
ILMN_2192281 CARD8 -0.84 8.38 0.00 
ILMN_1656186 SLC41A1 -0.84 8.41 0.00 
ILMN_1748438 POLR2G -0.84 12.09 0.01 
ILMN_1763091 C14orf43 -0.84 8.80 0.00 
ILMN_1683450 CDCA5 -0.84 11.96 0.00 
ILMN_1743829 ATXN2 -0.84 10.71 0.00 
ILMN_1696485 HNRNPAB -0.84 11.24 0.01 
ILMN_1699015 H3F3A -0.84 13.94 0.01 
ILMN_2080637 ZBTB44 -0.84 7.95 0.00 
ILMN_1707156 LRRFIP2 -0.84 9.13 0.01 
ILMN_2346460 NARG2 -0.83 8.00 0.00 
ILMN_1699703 ARCN1 -0.83 11.13 0.01 
ILMN_1710962 TMEM97 -0.83 12.24 0.01 
ILMN_1815121 PLAGL1 -0.83 7.80 0.00 
ILMN_1706376 OSBP -0.83 11.02 0.01 
ILMN_1734288 DUSP18 -0.83 8.16 0.00 
ILMN_1668283 HYAL2 -0.83 8.48 0.01 
ILMN_1690223 CNTNAP2 -0.83 10.10 0.01 
ILMN_1658677 DTX3 -0.83 7.60 0.00 
ILMN_1693259 PDCD6IP -0.83 9.20 0.01 
ILMN_1726421 METTL9 -0.83 8.42 0.00 
ILMN_1664776 EFR3A -0.83 9.78 0.01 
ILMN_1720844 SSX2IP -0.83 8.28 0.01 
ILMN_1775937 DDB1 -0.83 13.48 0.01 
ILMN_1659189 C9orf89 -0.83 8.58 0.00 
ILMN_1794956 BBS9 -0.82 8.10 0.00 
ILMN_1767015 BCORL1 -0.82 7.97 0.01 
ILMN_2157951 STX6 -0.82 9.06 0.00 
ILMN_2142284 SLC25A43 -0.82 8.67 0.00 
ILMN_1807177 KIAA1797 -0.82 8.50 0.00 
ILMN_1699598 AP2M1 -0.82 10.09 0.00 
ILMN_1667453 MIZF -0.82 8.46 0.00 
ILMN_1741331 C14orf108 -0.82 9.03 0.01 
ILMN_1677765 LRP8 -0.82 8.37 0.00 
ILMN_1662719 GPBP1L1 -0.82 8.34 0.00 
ILMN_1749014 ACLY -0.82 11.75 0.01 
ILMN_1744046 DIAPH2 -0.82 8.48 0.01 
ILMN_1653797 C6orf62 -0.82 10.41 0.01 
ILMN_2174805 CD300LG -0.82 7.84 0.01 
ILMN_1745946 CCDC5 -0.82 8.82 0.01 
ILMN_2175474 MTRF1L -0.82 10.06 0.00 
ILMN_1699676 C14orf147 -0.81 8.76 0.01 
ILMN_1802397 GNA11 -0.81 9.54 0.01 
ILMN_1669252 CUL2 -0.81 10.19 0.01 
ILMN_1792314 ACTR1A -0.81 10.85 0.01 
ILMN_1691736 ST6GALNAC6 -0.81 8.80 0.00 
ILMN_1678546 PEX11B -0.81 9.61 0.00 
ILMN_1754547 R3HDM1 -0.81 8.16 0.00 
ILMN_1717477 PSD3 -0.81 8.13 0.00 
ILMN_1746375 CSNK2A1P -0.81 8.51 0.01 
ILMN_2180866 RPS26L1 -0.81 13.94 0.01 
ILMN_1700660 RNF135 -0.81 8.65 0.01 
ILMN_1696591 RB1 -0.81 7.75 0.01 
ILMN_2324375 CHCHD7 -0.80 7.89 0.01 
ILMN_1675674 UBE4B -0.80 9.53 0.01 
ILMN_1726025 ASXL1 -0.80 9.28 0.01 
ILMN_1726289 C12orf35 -0.80 7.80 0.00 
ILMN_1731518 LOC201164 -0.80 8.49 0.00 
ILMN_2355168 MGST1 -0.80 10.26 0.01 
ILMN_1703617 AHSA1 -0.80 11.34 0.00 
ILMN_1762407 CABLES2 -0.80 8.04 0.01 
ILMN_1687538 ETS1 -0.80 8.37 0.01 
ILMN_1720233 CCDC49 -0.80 8.63 0.01 
ILMN_1751645 OR3A4 -0.80 7.74 0.01 
ILMN_1784238 SEC22B -0.79 9.09 0.01 
ILMN_2187533 FAM130A1 -0.79 8.09 0.01 
ILMN_1797585 MYO1B -0.79 7.95 0.00 
ILMN_2182531 C18orf55 -0.79 10.72 0.01 
ILMN_1808860 STX5 -0.79 8.51 0.01 
ILMN_1665554 BRF2 -0.79 9.10 0.01 
ILMN_1736650 JMJD2A -0.79 7.71 0.01 
ILMN_1739297 GALNT4 -0.79 7.86 0.01 
ILMN_1686194 SDCCAG10 -0.79 10.44 0.01 
ILMN_1807016 LHX2 -0.79 9.11 0.01 
ILMN_1709549 PLEKHM1 -0.79 8.11 0.00 
ILMN_2058468 BACH2 -0.79 7.95 0.00 
ILMN_2061310 ZNF280C -0.79 8.88 0.00 
ILMN_1788988 THAP1 -0.79 7.62 0.00 
ILMN_1682727 JAZF1 -0.79 8.11 0.00 
ILMN_1694041 PDCL -0.79 7.81 0.00 
ILMN_1706901 HOXD13 -0.79 8.95 0.00 
ILMN_1757644 UBE2H -0.78 8.16 0.00 
ILMN_2220739 TMCO3 -0.78 8.74 0.01 
ILMN_1797367 TSC1 -0.78 8.44 0.01 
ILMN_1808590 GUCY1A3 -0.78 8.87 0.01 
ILMN_1803398 SRF -0.78 10.25 0.00 
ILMN_2133638 DULLARD -0.78 8.47 0.00 
ILMN_1709623 MAPK7 -0.78 8.92 0.00 
ILMN_2401618 MLX -0.78 8.06 0.01 
ILMN_1702279 KIF3B -0.78 8.51 0.00 
ILMN_1691892 TAGLN2 -0.78 9.09 0.01 
ILMN_2163306 FAM120A -0.78 11.60 0.00 
ILMN_1813389 MRPS7 -0.78 11.22 0.01 
ILMN_1733511 GOLGA3 -0.78 10.44 0.01 
ILMN_1726704 RSC1A1 -0.77 7.97 0.01 
ILMN_1760575 PTP4A1 -0.77 8.56 0.01 
ILMN_1741133 NME1 -0.77 14.52 0.01 
ILMN_1789233 VPS37C -0.77 10.88 0.01 
ILMN_2374249 DYRK2 -0.77 8.95 0.00 
ILMN_1681135 SPATA2 -0.77 7.75 0.00 
ILMN_1708805 NCOA3 -0.77 8.95 0.01 
ILMN_1777915 STX6 -0.77 8.67 0.01 
ILMN_1788878 MORN4 -0.77 8.03 0.01 
ILMN_1744649 PSMB5 -0.77 12.34 0.00 
ILMN_1697118 ARMC6 -0.77 8.63 0.01 
ILMN_1709114 MAP3K7IP1 -0.77 8.55 0.01 
ILMN_1800976 NFATC3 -0.77 7.90 0.00 
ILMN_1720311 SLC25A46 -0.77 9.40 0.00 
ILMN_1739454 USP34 -0.76 8.17 0.01 
ILMN_1741005 RG9MTD2 -0.76 8.02 0.01 
ILMN_1670096 NRBP1 -0.76 7.80 0.00 
ILMN_1696532 RBBP5 -0.76 8.59 0.01 
ILMN_1719064 KCTD10 -0.76 8.22 0.00 
ILMN_1759117 XK -0.76 7.81 0.01 
ILMN_1657679 VAV3 -0.76 7.76 0.01 
ILMN_1811972 MYCBP2 -0.76 10.02 0.01 
ILMN_1664168 SLC25A11 -0.76 9.08 0.01 
ILMN_1666208 C14orf106 -0.76 9.88 0.00 
ILMN_2225144 EIF4E3 -0.76 8.50 0.01 
ILMN_2057981 FAM164A -0.75 7.85 0.01 
ILMN_1738276 TMEM185A -0.75 9.02 0.01 
ILMN_1813423 NAT15 -0.75 7.88 0.01 
ILMN_1697117 TBP -0.75 9.77 0.01 
ILMN_1665205 ZNF260 -0.75 8.64 0.00 
ILMN_1698770 C5orf33 -0.75 8.02 0.00 
ILMN_1762932 CHMP2A -0.75 7.74 0.00 
ILMN_2167922 TRMT5 -0.75 13.30 0.01 
ILMN_1772722 MRPS33 -0.75 8.78 0.01 
ILMN_1800058 NKX2-5 -0.75 8.94 0.00 
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ILMN_1742230 BAZ1A -0.75 10.36 0.01 
ILMN_2354478 CYFIP2 -0.75 8.22 0.01 
ILMN_1806349 SLC6A8 -0.75 8.02 0.01 
ILMN_1787280 C1orf135 -0.75 9.78 0.01 
ILMN_1780188 B3GALNT2 -0.74 7.77 0.00 
ILMN_1751051 C7orf25 -0.74 8.43 0.00 
ILMN_2314007 TCF12 -0.74 8.53 0.01 
ILMN_1675472 LOC644799 -0.74 9.01 0.01 
ILMN_1758852 ENTPD7 -0.74 7.81 0.00 
ILMN_1679071 MTX3 -0.74 9.21 0.01 
ILMN_2069593 SFRS2IP -0.74 8.85 0.01 
ILMN_1750563 CERCAM -0.74 8.07 0.01 
ILMN_1793302 WDR4 -0.74 7.78 0.01 
ILMN_1789909 TBC1D9B -0.74 8.56 0.01 
ILMN_1759549 SRGAP2 -0.74 8.50 0.01 
ILMN_1709044 TGIF2 -0.74 8.59 0.01 
ILMN_2394571 FBXW11 -0.74 10.44 0.01 
ILMN_1717393 PTCHD1 -0.73 7.77 0.01 
ILMN_1761322 FHOD3 -0.73 8.89 0.00 
ILMN_1672843 FBXO8 -0.73 9.02 0.01 
ILMN_1666482 SP2 -0.73 8.60 0.01 
ILMN_1742450 TAPBP -0.73 8.60 0.00 
ILMN_1722726 RICS -0.73 8.25 0.00 
ILMN_1815705 LZTFL1 -0.72 8.96 0.00 
ILMN_1776522 RAG1AP1 -0.72 10.26 0.01 
ILMN_1722738 ROGDI -0.72 7.76 0.01 
ILMN_1801600 CCDC97 -0.72 9.50 0.01 
ILMN_1759513 RND3 -0.72 8.84 0.01 
ILMN_1781691 TRAK2 -0.72 8.92 0.01 
ILMN_1657436 FGFR1OP2 -0.72 7.89 0.01 
ILMN_1788135 APITD1 -0.72 7.94 0.01 
ILMN_1769601 MGC16169 -0.72 8.27 0.01 
ILMN_1670000 IQWD1 -0.71 10.24 0.01 
ILMN_2199022 SAP30BP -0.71 8.00 0.01 
ILMN_1792092 ZCCHC8 -0.71 8.60 0.01 
ILMN_2323418 KRIT1 -0.71 8.39 0.01 
ILMN_2063925 CTNNBL1 -0.71 9.72 0.01 
ILMN_2360028 NFATC3 -0.71 8.10 0.01 
ILMN_1689007 SFRS14 -0.71 7.98 0.00 
ILMN_1684034 STAT5B -0.71 8.27 0.01 
ILMN_1681591 PTPN1 -0.71 10.18 0.01 
ILMN_2387505 AP1B1 -0.71 7.65 0.01 
ILMN_1796772 ARHGAP28 -0.71 7.85 0.01 
ILMN_1671583 MKRN1 -0.71 11.70 0.01 
ILMN_2140700 CRIPAK -0.70 8.01 0.01 
ILMN_1672331 MAP3K7IP2 -0.70 7.91 0.01 
ILMN_1764166 BCKDHB -0.70 8.99 0.01 
ILMN_1733155 GIT1 -0.70 7.83 0.01 
ILMN_2065783 EXOC2 -0.70 8.51 0.01 
ILMN_1771620 SNRPB2 -0.70 10.20 0.01 
ILMN_1746031 RIMS4 -0.70 8.29 0.01 
ILMN_1658182 MEX3C -0.70 8.29 0.01 
ILMN_1709882 ICK -0.69 8.40 0.01 
ILMN_1727938 ZNF764 -0.69 7.62 0.00 
ILMN_2376833 ZNF200 -0.69 7.67 0.01 
ILMN_1761147 GABPB2 -0.68 8.47 0.01 
ILMN_1703132 LYRM2 -0.68 10.22 0.01 
ILMN_1671902 THUMPD3 -0.68 7.99 0.01 
ILMN_1809344 BTBD10 -0.68 8.61 0.01 
ILMN_1692272 TEX261 -0.68 8.80 0.01 
ILMN_2195703 PPARGC1B -0.68 7.72 0.01 
ILMN_1769478 LOC202051 -0.67 8.01 0.01 
ILMN_2363621 RBBP8 -0.67 10.85 0.01 
ILMN_1749848 SLC35F1 -0.67 9.23 0.01 
ILMN_1775939 SF3B2 -0.67 10.98 0.01 
ILMN_1663618 STAT3 -0.67 7.90 0.01 
ILMN_1703791 ANXA7 -0.67 10.81 0.01 
ILMN_1717809 RNF24 -0.67 7.68 0.01 
ILMN_1658494 C13orf15 -0.67 8.61 0.01 
ILMN_2278636 CUTL1 -0.66 8.79 0.01 
ILMN_2120210 RCAN2 -0.66 7.92 0.01 
ILMN_1789136 SERF2 -0.66 12.37 0.01 
ILMN_1666364 COQ10A -0.66 9.21 0.01 
ILMN_1680378 RBM45 -0.65 8.78 0.01 
ILMN_1727761 GMEB1 -0.65 8.48 0.01 
ILMN_1666739 RBM15 -0.64 10.08 0.01 
ILMN_1815718 BTRC -0.64 7.87 0.01 
ILMN_1658083 ABT1 -0.64 7.72 0.01 
ILMN_1793241 SRD5A1 -0.63 7.72 0.01 
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Supplementary Table 2: Functional Enrichment Analysis of genes predicted to be miR-182 
targets 
 
Category Function Function 
Annotation 
p-value Molecules 
Gene 
Expression 
transcription transcription 1.15E-11 ACTR3, AFF1, AFF4, AKAP13, ALX1, ATF1, ATF3, ATF4, ATN1, 
ATXN7L3, BACH2 (includes EG:60468), BAZ1A, BCL2L1, BMP2, 
BMPR2, BRCA1, BTRC, CBL, CCNK, CDK7, CDKN1A, CEBPG, 
CHMP1A, COPS5, CREB5, CRTC2, CSNK1E, CSRNP2, CTDSP2, CUX1, 
DAB2, DCAF6, DDB1, DHX15, ELF4, ELK1, EPC1, ERCC3, ETS1, 
FOXM1, FOXN2, FOXN3, FOXO3, GABPA, GABPB1, GATAD2A, GLI3, 
GPS2, GTF3A, HAND1, HCFC1, HEY1, HIF1A, HINFP, HIPK2, HMGA1, 
HOXD13, JAZF1, KAT6A, KLF12, LMO4, MAML1, MAP3K1, MAZ, 
MED1, MED23, MED24, MLX, MTERFD1, MTF1 (includes EG:17764), 
NCKAP1, NCOA3, NCOA4, NFATC3, NFIA, NFIB, NFYC, NKX2-5, 
NME1, NSD1, OTUB1, PA2G4, PAX6, PHF21A, PIAS1, PIAS2, PIAS3, 
PLAGL1, PLAGL2, POLR2A, POLR2C, POLR2D, POLR2G, PPARD, 
PPARG, PPARGC1B, PPP1R8, PRDM4, PRKAR1A, PRKCQ, PRMT6, 
PRPF8, PYGO2, R3HDM1, RARA, RB1, RBBP8, RNF10, RNF216, 
RUVBL1, SMARCB1, SMARCD1, SP1, SP2, SRF, STAT3, STAT5B, 
TAB1, TAB2, TAGLN2, TBP, TCF12, TFAP2A, TFDP1, TFDP2, TGIF2, 
THAP1, TRIM24, TRIM28, TROVE2, VEZF1, VPS72, WNK1, YBX1, 
ZFHX3, ZNF45 
Gene 
Expression 
transcription transcription of DNA 
endogenous promoter 
3.32E-11 AFF4, ALX1, ATF4, BMPR2, BRCA1, CCNK, CDK7, CEBPG, COPS5, 
CREB5, CSRNP2, CUX1, DCAF6, ELF4, ELK1, EPC1, ERCC3, ETS1, 
FOXM1, FOXO3, GABPA, GABPB1, GLI3, HAND1, HCFC1, HIF1A, 
HOXD13, JAZF1, KLF12, MAML1, MAZ, MED1, MED23, MTF1 
(includes EG:17764), NCOA3, NFATC3, NFYC, NKX2-5, PHF21A, 
PLAGL1, POLR2A, POLR2C, POLR2D, POLR2G, PPARD, PPARG, 
PPARGC1B, PRDM4, PRKAR1A, RARA, RBBP8, RUVBL1, SMARCB1, 
SMARCD1, SP1, SP2, SRF, STAT3, STAT5B, TBP, TCF12, TFDP1, 
TRIM24, TRIM28, TROVE2, VEZF1, VPS72, YBX1, ZFHX3 
Gene 
Expression 
transcription transcription of DNA 6.94E-07 ACTR3, AFF1, ATF1, ATF3, ATF4, ATXN7L3, CBL, CHMP1A, CREB5, 
CSRNP2, DAB2, ELK1, ETS1, FOXM1, FOXN2, FOXN3, FOXO3, 
GABPB1, GATAD2A, GLI3, HEY1, HIF1A, HINFP, HIPK2, HMGA1, 
KLF12, LMO4, MAZ, MED1, MED23, MED24, MLX, MTERFD1, MTF1 
(includes EG:17764), NFIB, NFYC, NKX2-5, NSD1, PA2G4, PAX6, 
PLAGL2, PPARD, PPARG, PRKCQ, PRMT6, RARA, RB1, SP1, SRF, 
STAT3, STAT5B, TBP, TCF12, TFDP1, THAP1, TRIM28, YBX1, ZFHX3, 
ZNF45 
Gene 
Expression 
transcription transcription of gene 1.37E-04 ACTR3, ATF1, ATN1, BAZ1A, CCNK, CDK7, DDB1, ERCC3, HCFC1, 
HIF1A, HIPK2, KAT6A, MAP3K1, MED1, NCOA3, NFIA, NFIB, NME1, 
POLR2A, PYGO2, RARA, RB1, SMARCB1, SP1, SRF, STAT3, TBP, 
TFAP2A, TGIF2 
Gene 
Expression 
transcription transcription of HIF-
1 response element 
7.88E-04 HIF1A, PLAGL2, SP1 
Gene 
Expression 
transcription initiation of 
transcription 
1.78E-03 AKAP13, DHX15, ERCC3, NCKAP1, RNF10, TBP 
Gene 
Expression 
transcription transcription of 
androgen-responsive 
element 
6.03E-03 PIAS1, PIAS2, PIAS3 
Gene 
Expression 
transcription transcription of 
cAMP response 
element 
1.01E-02 ATF4, CRTC2 
Gene 
Expression 
transcription transcription of HIV-
1 
1.93E-02 PPP1R8, SP1 
Gene 
Expression 
transcription transcription of 
synthetic promoter 
3.05E-02 ATF1, ATF3, BRCA1, CDKN1A, CUX1, DAB2, MAML1, MED1, NCOA3, 
NCOA4, OTUB1, PPARG, PRKCQ, PYGO2, RARA, RB1, RBBP8, STAT3, 
TAB2, TBP, TFDP1 
Gene 
Expression 
transcription transcription of E2F 
binding site 
3.10E-02 TFDP1, TFDP2 
Gene 
Expression 
transcription transcription of RNA 3.78E-02 SMARCB1, SP1, TBP 
Gene 
Expression 
activation activation of 
synthetic promoter 
1.53E-06 AKAP13, ASXL1, ATF1, ATF4, BMP2, BMPR2, BRCA1, BTRC, CBL, 
CDK7, DUSP22, ELK1, EPC1, ETS1, FKBP5, GNA13, HDAC3, HIF1A, 
JAZF1, LRRFIP2, MED1, MLX, MTF1 (includes EG:17764), NCOA3, 
NCOA4, NME1, PDPK1, PIAS1, PIAS2, PPARD, PPARG, PPARGC1B, 
PRKAR1A, PRKCQ, RARA, RB1, RFXAP, RNF216, SEPT9, SP1, 
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STAT5B, TAB1, TBP, TFAP2A, TSC1, TSC2, TXN 
Gene 
Expression 
activation activation of 
androgen-responsive 
element 
4.22E-04 BRCA1, FKBP5, FOXO3, PA2G4, PIAS1, PIAS2 
Gene 
Expression 
activation activation of AP2 
binding site 
9.22E-03 SP1, TFAP2A, YBX1 
Gene 
Expression 
activation activation of gene 2.79E-02 GABPA, NAP1L1, NKX2-5, PIAS1, PIAS3, SMARCB1, SP1, STAT3, TBP, 
TP53BP1, TXNRD1 
Gene 
Expression 
activation activation of ATF 
binding site 
3.10E-02 ELK1, SRF 
Gene 
Expression 
activation activation of p53 
consensus binding 
site 
4.47E-02 SP1, YBX1 
Gene 
Expression 
transactivatio
n 
transactivation 5.88E-04 AKAP13, ASXL1, BRCA1, BTRC, CDC42, CDK7, CRTC2, ELK1, ETS1, 
FOXM1, GABPA, GABPB1, GNA13, HDAC3, HIF1A, ISG20L2, JAZF1, 
LMO4, MAML1, MAZ, MCM5, MED1, MSX2, NAP1L1, NCOA3, 
NCOA4, NFATC3, NKX2-5, NME1, PIAS1, PIAS2, POLR2A, PPARD, 
PPARG, PRKCQ, RARA, SMARCB1, SP1, SRF, STAT3, STAT5B, TBP, 
TP53BP1, TXN 
Gene 
Expression 
transactivatio
n 
transactivation of 
PEA3/ets binding site 
1.01E-02 GABPA, GABPB1 
Gene 
Expression 
elongation elongation of RNA 1.09E-03 ADRM1, CDK7, ERCC3, GTF2F2, POLR2A, POLR2C, POLR2D, 
POLR2G, TBP 
Gene 
Expression 
repression repression of DNA 2.87E-03 ATF1, BRCA1, PIAS3, TFAP2A 
Gene 
Expression 
gene 
silencing 
gene silencing 3.60E-03 CHMP1A, TRIM24, TRIM33 
Gene 
Expression 
gene 
silencing 
gene silencing of 
gene 
1.93E-02 TRIM24, TRIM33 
Gene 
Expression 
expression expression of cAMP 
response element 
4.10E-03 ATF4, CRTC2, PRKAR1A, RB1 
Gene 
Expression 
expression expression of 
synthetic promoter 
7.80E-03 ATF1, ATF3, BMPR2, BRCA1, CDKN1A, CUX1, DAB2, HIF1A, HMGA1, 
MAML1, MED1, NCOA3, NCOA4, OTUB1, PPARG, PRKCQ, PYGO2, 
RARA, RB1, RBBP8, SOX11, STAT3, TAB2, TBP, TFDP1, TXN 
Gene 
Expression 
regulation regulation of Osf1 
binding site 
1.01E-02 SP1, SP2 
Gene 
Expression 
binding binding of p53 
consensus binding 
site 
3.03E-02 ANXA7, BRCA1, MED1 
Cell Cycle cell division 
process 
cell division process 1.46E-10 ACLY, ASXL1, ATF3, AURKA, BABAM1, BAX, BMP2, BRCA1, BTRC, 
C13orf15, CAT, CBL, CD2AP, CDC42, CDCA5, CDK6, CDK7, CDKN1A, 
CDKN1B, CDKN3, CEP55, CETN3, CHEK2, CHMP1A, COPS5, CSNK1E, 
CSNK2A1, CUL2, DDB1, DIAPH2, DSN1, DYRK2, EIF4G2, ELF4, 
ERCC3, ETS1, FBXO5, FOXM1, FOXN3, FOXO3, FYN, GADD45A, 
GNA13, GNAI2, GNL3, GPS2, HAUS1, HCFC1, HDAC3, HIF1A, HINFP, 
HIPK2, HMGA1, HMOX1, KIF3B, KIFC1, MAPK7, MASTL, MCM7, 
MELK, MPHOSPH6, NAMPT, NBN, NCAPD2, NCAPG (includes 
EG:64151), NCOA3, NEDD1, NEDD4L, NME1, NRAS, PA2G4, PCBP4, 
PDK3, PEX11B, PHB (includes EG:5245), PHF13, PIAS1, PLAGL1, 
POLD1, PPARG, PPP2R2A, PRCC, PRDM4, PRMT5, PSMB5, RAD17, 
RB1, RB1CC1, RBBP8, SEPT6, SEPT9, SETD8, SGOL1, SKA1, SKA3, 
SKP2, SMARCB1, SP1, STAT3, TFDP1, THAP1, TOP2A, TP53BP1, 
TPD52L1, TRIM33, TSC2, TUSC2, TXN, UBE2C, UBIAD1, VAV3, 
WNK1, YWHAE 
Cell Cycle cell division 
process 
cell division process 
of tumor cell lines 
4.69E-06 ASXL1, AURKA, BAX, BMP2, BRCA1, BTRC, CD2AP, CDC42, CDK6, 
CDKN1A, CDKN1B, CEP55, CHEK2, COPS5, CSNK2A1, FBXO5, 
FOXM1, FOXO3, FYN, GADD45A, GNAI2, GNL3, GPS2, HIF1A, 
HMGA1, HMOX1, KIFC1, MAPK7, MASTL, MCM7, MELK, NCAPD2, 
NCOA3, NEDD4L, PCBP4, PHB (includes EG:5245), PIAS1, PLAGL1, 
PPARG, PPP2R2A, RAD17, RB1, RB1CC1, RBBP8, SEPT6, SEPT9, SKP2, 
SMARCB1, SP1, STAT3, TOP2A, TP53BP1, TRIM33, TUSC2, VAV3, 
YWHAE 
Cell Cycle cell division 
process 
cell division process 
of chromosomes 
7.67E-06 AURKA, BRCA1, CDC42, CDK7, CDKN1A, CSNK1E, DSN1, DYRK2, 
HIF1A, NCAPD2, NCAPG (includes EG:64151), NME1, NRAS, PDK3, 
PHF13, SGOL1, SKA1, SKA3, TOP2A, UBIAD1, WNK1 
Cell Cycle cell division 
process 
cell division process 
of lung cancer cell 
lines 
1.17E-05 BRCA1, BTRC, CDKN1A, CDKN1B, CHEK2, FOXM1, HMOX1, MCM7, 
PCBP4, PIAS1, RAD17, RB1, TUSC2, YWHAE 
Cell Cycle cell division cell division process 1.27E-05 ASXL1, AURKA, BAX, BMP2, BRCA1, BTRC, CD2AP, CDC42, CDK6, 
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process of cell lines CDKN1A, CDKN1B, CEP55, CHEK2, COPS5, CSNK2A1, DDB1, FBXO5, 
FOXM1, FOXO3, FYN, GADD45A, GNAI2, GNL3, GPS2, HIF1A, HIPK2, 
HMGA1, HMOX1, KIFC1, MAPK7, MASTL, MCM7, MELK, NCAPD2, 
NCOA3, NEDD4L, NME1, PCBP4, PHB (includes EG:5245), PIAS1, 
PLAGL1, PPARG, PPP2R2A, RAD17, RB1, RB1CC1, RBBP8, SEPT6, 
SEPT9, SKP2, SMARCB1, SP1, STAT3, TFDP1, TOP2A, TP53BP1, 
TRIM33, TUSC2, VAV3, YWHAE 
Cell Cycle cell division 
process 
cell division process 
of eukaryotic cells 
5.31E-05 ASXL1, AURKA, BAX, BMP2, BRCA1, BTRC, C13orf15, CD2AP, 
CDC42, CDK6, CDKN1A, CDKN1B, CEP55, CHEK2, COPS5, CSNK2A1, 
DDB1, FBXO5, FOXM1, FOXO3, FYN, GADD45A, GNAI2, GNL3, GPS2, 
HIF1A, HIPK2, HMGA1, HMOX1, KIFC1, MAPK7, MASTL, MCM7, 
MELK, NBN, NCAPD2, NCOA3, NEDD4L, NME1, PCBP4, PHB (includes 
EG:5245), PIAS1, PLAGL1, PPARG, PPP2R2A, RAD17, RB1, RB1CC1, 
RBBP8, SEPT6, SEPT9, SKP2, SMARCB1, SP1, STAT3, TFDP1, TOP2A, 
TP53BP1, TRIM33, TUSC2, TXN, VAV3, YWHAE 
Cell Cycle cell division 
process 
arrest in cell division 
process of lung 
cancer cell lines 
8.29E-05 BRCA1, BTRC, CDKN1A, CDKN1B, CHEK2, PCBP4, PIAS1, RB1, 
TUSC2, YWHAE 
Cell Cycle cell division 
process 
cell division process 
of cervical cancer 
cell lines 
2.00E-04 ASXL1, AURKA, CD2AP, CDC42, CDKN1B, CEP55, CSNK2A1, FBXO5, 
FOXM1, GNAI2, KIFC1, MAPK7, MASTL, NCAPD2, NEDD4L, 
PPP2R2A, RB1, SEPT6, SEPT9, TOP2A, VAV3 
Cell Cycle cell division 
process 
arrest in cell division 
process 
9.60E-04 AURKA, BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CDKN3, 
CHEK2, CUL2, DDB1, EIF4G2, FBXO5, FOXM1, FOXO3, GADD45A, 
GNL3, GPS2, HIPK2, MASTL, MELK, NBN, PA2G4, PCBP4, PIAS1, 
PLAGL1, PPARG, PPP2R2A, RB1, RB1CC1, SEPT9, SGOL1, SKP2, 
SMARCB1, SP1, TP53BP1, TUSC2, YWHAE 
Cell Cycle cell division 
process 
entry into cell 
division process of 
cell lines 
1.06E-03 AURKA, CDKN1A, CDKN1B, FOXM1, HMOX1, MAPK7, NCAPD2, 
NCOA3, RB1, SKP2, SMARCB1 
Cell Cycle cell division 
process 
arrest in cell division 
process of bone 
cancer cell lines 
1.21E-03 CDC42, CDKN1A, FOXM1, GNL3, GPS2, PLAGL1, RB1, TP53BP1 
Cell Cycle cell division 
process 
entry into cell 
division process of 
eukaryotic cells 
1.24E-03 AURKA, C13orf15, CDKN1A, CDKN1B, CHEK2, FOXM1, HMOX1, 
MAPK7, NCAPD2, NCOA3, RB1, SKP2, SMARCB1 
Cell Cycle cell division 
process 
cell division process 
of carcinoma cell 
lines 
1.77E-03 BRCA1, CDKN1A, CDKN1B, CHEK2, FOXM1, HMOX1, MCM7, RAD17, 
RB1 
Cell Cycle cell division 
process 
arrest in cell division 
process of tumor cell 
lines 
2.20E-03 AURKA, BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, 
FBXO5, FOXM1, FOXO3, GADD45A, GNL3, GPS2, MASTL, MELK, 
PCBP4, PIAS1, PLAGL1, PPARG, PPP2R2A, RB1, RB1CC1, SMARCB1, 
SP1, TP53BP1, TUSC2, YWHAE 
Cell Cycle cell division 
process 
delay in cell division 
process 
2.22E-03 AURKA, BAX, BRCA1, CDC42, CDKN1A, CHEK2, FOXM1, NCOA3, 
TFDP1, TOP2A 
Cell Cycle cell division 
process 
entry into cell 
division process of 
cervical cancer cell 
lines 
2.43E-03 AURKA, CDKN1B, FOXM1, MAPK7, NCAPD2 
Cell Cycle cell division 
process 
delay in cell division 
process of cell lines 
2.74E-03 AURKA, BAX, BRCA1, CDC42, CDKN1A, CHEK2, NCOA3, TFDP1, 
TOP2A 
Cell Cycle cell division 
process 
entry into cell 
division process of 
tumor cell lines 
2.74E-03 AURKA, CDKN1B, FOXM1, HMOX1, MAPK7, NCAPD2, RB1, SKP2, 
SMARCB1 
Cell Cycle cell division 
process 
arrest in cell division 
process of fibroblasts 
2.87E-03 CDKN1A, GADD45A, NBN, SKP2 
Cell Cycle cell division 
process 
arrest in cell division 
process of eukaryotic 
cells 
3.08E-03 AURKA, BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, 
DDB1, FBXO5, FOXM1, FOXO3, GADD45A, GNL3, GPS2, HIPK2, 
MASTL, MELK, NBN, PCBP4, PIAS1, PLAGL1, PPARG, PPP2R2A, RB1, 
RB1CC1, SKP2, SMARCB1, SP1, TP53BP1, TUSC2, YWHAE 
Cell Cycle cell division 
process 
delay in cell division 
process of epithelial 
cell lines 
3.49E-03 CHEK2, TFDP1 
Cell Cycle cell division 
process 
arrest in cell division 
process of cell lines 
4.75E-03 AURKA, BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, 
DDB1, FBXO5, FOXM1, FOXO3, GADD45A, GNL3, GPS2, HIPK2, 
MASTL, MELK, PCBP4, PIAS1, PLAGL1, PPARG, PPP2R2A, RB1, 
RB1CC1, SMARCB1, SP1, TP53BP1, TUSC2, YWHAE 
Cell Cycle cell division 
process 
cell division process 
of skin cancer cell 
lines 
6.03E-03 BAX, CDKN1A, CDKN1B 
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Cell Cycle cell division 
process 
cell division process 
of fibroblast cell lines 
6.58E-03 CDKN1A, CDKN1B, NCOA3, RB1, SMARCB1 
Cell Cycle cell division 
process 
exit from cell 
division process of 
colon cancer cell 
lines 
9.22E-03 CDKN1A, CDKN1B, FOXO3 
Cell Cycle cell division 
process 
cell division process 
of bone cancer cell 
lines 
9.23E-03 CDC42, CDK6, CDKN1A, FOXM1, GNL3, GPS2, PLAGL1, RB1, 
TP53BP1 
Cell Cycle cell division 
process 
cell division process 
of epithelial cell lines 
1.23E-02 CDKN1B, CHEK2, DDB1, FBXO5, HIPK2, NME1, TFDP1 
Cell Cycle cell division 
process 
cell division process 
of endothelial cell 
lines 
1.32E-02 CDKN1B, FOXM1, SEPT9 
Cell Cycle cell division 
process 
cell division process 
of pancreatic cancer 
cell lines 
1.56E-02 COPS5, FOXM1, HMGA1, STAT3 
Cell Cycle cell division 
process 
exit from cell 
division process of 
tumor cell lines 
1.56E-02 CDKN1A, CDKN1B, FOXO3, MASTL 
Cell Cycle cell division 
process 
arrest in cell division 
process of colon 
cancer cell lines 
2.03E-02 BRCA1, CDKN1A, CDKN1B, CHEK2, GADD45A, PPARG 
Cell Cycle cell division 
process 
arrest in cell division 
process of normal 
cells 
2.29E-02 CDKN1A, GADD45A, NBN, RB1, SKP2, SP1 
Cell Cycle cell division 
process 
cell division process 
of connective tissue 
cells 
2.29E-02 CDKN1A, CHEK2, GADD45A, NBN, SKP2, TXN 
Cell Cycle cell division 
process 
arrest in cell division 
process of fibroblast 
cell lines 
2.38E-02 CDKN1A, CDKN1B, SMARCB1 
Cell Cycle cell division 
process 
delay in cell division 
process of tumor cell 
lines 
2.42E-02 AURKA, BAX, BRCA1, CDC42, CDKN1A, NCOA3, TOP2A 
Cell Cycle cell division 
process 
cell division process 
of colon cancer cell 
lines 
2.55E-02 BRCA1, CDK6, CDKN1A, CDKN1B, CHEK2, FOXO3, GADD45A, 
PPARG, RAD17 
Cell Cycle cell division 
process 
exit from cell 
division process 
2.97E-02 CDKN1A, CDKN1B, FOXO3, MASTL, PPARG 
Cell Cycle cell division 
process 
entry into cell 
division process of 
smooth muscle cells 
3.10E-02 C13orf15, MAPK7 
Cell Cycle cell division 
process 
arrest in cell division 
process of embryonic 
cell lines 
3.25E-02 CDKN1B, DDB1, FBXO5, HIPK2 
Cell Cycle cell division 
process 
cell division process 
of embryonic cell 
lines 
4.29E-02 CDKN1B, DDB1, FBXO5, HIPK2, TFDP1 
Cell Cycle cell division 
process 
arrest in cell division 
process of epithelial 
cell lines 
4.38E-02 CDKN1B, DDB1, FBXO5, HIPK2 
Cell Cycle cell division 
process 
entry into cell 
division process of 
normal cells 
4.38E-02 C13orf15, CDKN1A, CHEK2, MAPK7 
Cell Cycle cell stage cell stage 4.75E-09 AURKA, BABAM1, BAX, BMP2, BRCA1, BTRC, C13orf15, CBL, 
CD2AP, CDC42, CDCA5, CDK6, CDKN1A, CDKN1B, CDKN3, CEP55, 
CHEK2, CHMP1A, COPS5, CUL2, DDB1, DIAPH2, ELF4, FBXO5, 
FOXM1, FOXN3, FOXO3, FYN, GADD45A, GNA13, GNAI2, GNL3, 
GPS2, HAUS1, HDAC3, HIF1A, HINFP, HMGA1, HMOX1, KIFC1, 
MAPK7, MASTL, MPHOSPH6, NBN, NCAPD2, NCOA3, NEDD4L, 
NME1, PCBP4, PHF13, PIAS1, POLD1, PPARG, PPP2R2A, PRMT5, 
RAD17, RB1, RB1CC1, RBBP8, SEPT6, SEPT9, SETD8, SGOL1, SKA1, 
SKA3, SKP2, SMARCB1, SP1, TFDP1, THAP1, TIPRL, TOP2A, TP53BP1, 
TPD52L1, TRIM33, TUSC2, TXN, UBE2C, VAV3, YWHAE 
Cell Cycle cell stage cell stage of cell lines 2.29E-06 AURKA, BAX, BMP2, BRCA1, BTRC, CD2AP, CDC42, CDK6, CDKN1A, 
CDKN1B, CEP55, CHEK2, COPS5, DDB1, FBXO5, FOXM1, FOXO3, 
GADD45A, GNAI2, GNL3, GPS2, HIF1A, HMGA1, HMOX1, KIFC1, 
MAPK7, MASTL, NCAPD2, NCOA3, NEDD4L, NME1, PCBP4, PIAS1, 
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PPARG, PPP2R2A, RAD17, RB1, RB1CC1, RBBP8, SEPT6, SEPT9, SKP2, 
SMARCB1, SP1, TFDP1, TOP2A, TP53BP1, TUSC2, VAV3, YWHAE 
Cell Cycle cell stage cell stage of tumor 
cell lines 
2.67E-06 AURKA, BAX, BMP2, BRCA1, BTRC, CD2AP, CDC42, CDK6, CDKN1A, 
CDKN1B, CEP55, CHEK2, COPS5, FBXO5, FOXM1, FOXO3, GADD45A, 
GNAI2, GNL3, GPS2, HIF1A, HMGA1, HMOX1, KIFC1, MAPK7, 
MASTL, NCAPD2, NCOA3, NEDD4L, PCBP4, PIAS1, PPP2R2A, RAD17, 
RB1, RB1CC1, RBBP8, SEPT6, SEPT9, SKP2, SMARCB1, SP1, TOP2A, 
TP53BP1, TUSC2, VAV3, YWHAE 
Cell Cycle cell stage cell stage of 
eukaryotic cells 
5.33E-06 AURKA, BAX, BMP2, BRCA1, BTRC, C13orf15, CD2AP, CDC42, CDK6, 
CDKN1A, CDKN1B, CEP55, CHEK2, COPS5, DDB1, FBXO5, FOXM1, 
FOXO3, GADD45A, GNAI2, GNL3, GPS2, HIF1A, HMGA1, HMOX1, 
KIFC1, MAPK7, MASTL, NBN, NCAPD2, NCOA3, NEDD4L, NME1, 
PCBP4, PIAS1, PPARG, PPP2R2A, RAD17, RB1, RB1CC1, RBBP8, 
SEPT6, SEPT9, SKP2, SMARCB1, SP1, TFDP1, TOP2A, TP53BP1, 
TUSC2, VAV3, YWHAE 
Cell Cycle cell stage cell stage of lung 
cancer cell lines 
1.29E-05 BRCA1, BTRC, CDKN1A, CDKN1B, CHEK2, FOXM1, HMOX1, PCBP4, 
PIAS1, RB1, TUSC2, YWHAE 
Cell Cycle cell stage entry into cell stage 
of eukaryotic cells 
2.71E-04 AURKA, C13orf15, CDKN1A, CDKN1B, CHEK2, FOXM1, HMOX1, 
MAPK7, NCAPD2, NCOA3, RB1, SKP2, SMARCB1 
Cell Cycle cell stage cell stage of cervical 
cancer cell lines 
3.93E-04 AURKA, CD2AP, CDC42, CDKN1B, CEP55, FBXO5, FOXM1, GNAI2, 
KIFC1, MAPK7, MASTL, NCAPD2, NEDD4L, PPP2R2A, SEPT6, SEPT9, 
TOP2A, VAV3 
Cell Cycle cell stage entry into cell stage 
of cell lines 
4.37E-04 AURKA, CDKN1A, CDKN1B, FOXM1, HMOX1, MAPK7, NCAPD2, 
NCOA3, RB1, SKP2, SMARCB1 
Cell Cycle cell stage arrest in cell stage 1.25E-03 BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, DDB1, 
FBXO5, FOXM1, FOXO3, GADD45A, GNL3, GPS2, MASTL, NBN, 
PCBP4, PIAS1, PPP2R2A, RB1, RB1CC1, SEPT9, SGOL1, SKP2, 
SMARCB1, SP1, TP53BP1, TUSC2 
Cell Cycle cell stage entry into cell stage 
of tumor cell lines 
1.51E-03 AURKA, CDKN1B, FOXM1, HMOX1, MAPK7, NCAPD2, RB1, SKP2, 
SMARCB1 
Cell Cycle cell stage entry into cell stage 
of cervical cancer 
cell lines 
2.43E-03 AURKA, CDKN1B, FOXM1, MAPK7, NCAPD2 
Cell Cycle cell stage arrest in cell stage of 
tumor cell lines 
3.01E-03 BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, FBXO5, 
FOXM1, FOXO3, GADD45A, GNL3, GPS2, MASTL, PCBP4, PIAS1, 
PPP2R2A, RB1, RB1CC1, SMARCB1, SP1, TP53BP1, TUSC2 
Cell Cycle cell stage arrest in cell stage of 
eukaryotic cells 
3.47E-03 BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, DDB1, 
FBXO5, FOXM1, FOXO3, GADD45A, GNL3, GPS2, MASTL, NBN, 
PCBP4, PIAS1, PPP2R2A, RB1, RB1CC1, SKP2, SMARCB1, SP1, 
TP53BP1, TUSC2 
Cell Cycle cell stage cell stage of 
endothelial cell lines 
6.03E-03 CDKN1B, FOXM1, SEPT9 
Cell Cycle cell stage cell stage of normal 
cells 
6.57E-03 BMP2, C13orf15, CDKN1A, CHEK2, GADD45A, MAPK7, NBN, NME1, 
RB1, SKP2, SP1 
Cell Cycle cell stage arrest in cell stage of 
cell lines 
7.45E-03 BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, DDB1, 
FBXO5, FOXM1, FOXO3, GADD45A, GNL3, GPS2, MASTL, PCBP4, 
PIAS1, PPP2R2A, RB1, RB1CC1, SMARCB1, SP1, TP53BP1, TUSC2 
Cell Cycle cell stage cell stage of 
carcinoma cell lines 
1.01E-02 BRCA1, CDKN1B, CHEK2, FOXM1, HMOX1, RB1 
Cell Cycle cell stage cell stage of 
epithelial cell lines 
1.18E-02 CDKN1B, CHEK2, DDB1, FBXO5, NME1, TFDP1 
Cell Cycle cell stage entry into cell stage 
of normal cells 
1.56E-02 C13orf15, CDKN1A, CHEK2, MAPK7 
Cell Cycle cell stage delay in cell stage 1.76E-02 BRCA1, CDC42, CDKN1A, CHEK2, FOXM1, NCOA3, TOP2A 
Cell Cycle cell stage cell stage of 
epithelial cells 
3.03E-02 NME1, RB1, SP1 
Cell Cycle cell stage exit from cell stage 
of tumor cell lines 
3.03E-02 CDKN1A, FOXO3, MASTL 
Cell Cycle cell stage entry into cell stage 
of smooth muscle 
cells 
3.10E-02 C13orf15, MAPK7 
Cell Cycle cell stage cell stage of smooth 
muscle cells 
3.78E-02 BMP2, C13orf15, MAPK7 
Cell Cycle cell stage delay in cell stage of 
eukaryotic cells 
4.36E-02 BRCA1, CDC42, CDKN1A, CHEK2, NCOA3, TOP2A 
Cell Cycle cell cycle 
progression 
cell cycle progression 7.67E-06 ACLY, ATF3, AURKA, BAX, BMP2, BRCA1, BTRC, CAT, CBL, CDC42, 
CDCA5, CDK6, CDKN1A, CDKN1B, CDKN3, CHEK2, CSNK2A1, CUL2, 
EIF4G2, ETS1, FBXO5, FOXM1, FOXO3, FYN, GADD45A, GNA13, 
GPS2, HAUS1, HCFC1, HDAC3, HIPK2, HMOX1, MAPK7, MASTL, 
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MELK, NAMPT, NBN, NCAPD2, PA2G4, PHB (includes EG:5245), 
PHF13, PLAGL1, PPARG, PRDM4, PRMT5, PSMB5, RB1, SEPT9, 
SGOL1, SKA1, SKA3, SKP2, SMARCB1, STAT3, TFDP1, THAP1, 
TOP2A, TRIM33, TSC2, TXN, UBE2C, YWHAE 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of 
eukaryotic cells 
1.70E-03 AURKA, BRCA1, BTRC, CDKN1A, CDKN1B, FOXM1, FOXO3, 
GADD45A, HIPK2, MELK, PLAGL1, PPARG, RB1, SKP2, SMARCB1, 
YWHAE 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression 
2.23E-03 AURKA, BRCA1, BTRC, CDKN1A, CDKN1B, CDKN3, CUL2, EIF4G2, 
FOXM1, FOXO3, GADD45A, HIPK2, MELK, NBN, PA2G4, PLAGL1, 
PPARG, RB1, SKP2, SMARCB1, YWHAE 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of cell 
lines 
3.19E-03 AURKA, BRCA1, BTRC, CDKN1A, CDKN1B, FOXM1, FOXO3, HIPK2, 
MELK, PLAGL1, PPARG, RB1, SMARCB1, YWHAE 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of 
squamous cell 
carcinoma cell lines 
3.49E-03 AURKA, FOXO3 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of tumor 
cell lines 
5.01E-03 AURKA, BRCA1, CDKN1A, CDKN1B, FOXM1, FOXO3, MELK, 
PLAGL1, PPARG, RB1, SMARCB1, YWHAE 
Cell Cycle cell cycle 
progression 
cell cycle progression 
of cell lines 
5.09E-03 AURKA, BAX, BRCA1, BTRC, CDK6, CDKN1A, CDKN1B, CSNK2A1, 
FOXM1, FOXO3, HIPK2, HMOX1, MELK, PHB (includes EG:5245), 
PLAGL1, PPARG, RB1, SMARCB1, STAT3, TFDP1, YWHAE 
Cell Cycle cell cycle 
progression 
delay in cell cycle 
progression of cell 
lines 
5.65E-03 AURKA, BAX, CDKN1A, TFDP1 
Cell Cycle cell cycle 
progression 
cell cycle progression 
of eukaryotic cells 
7.41E-03 AURKA, BAX, BRCA1, BTRC, CDK6, CDKN1A, CDKN1B, CSNK2A1, 
FOXM1, FOXO3, GADD45A, HIPK2, HMOX1, MELK, PHB (includes 
EG:5245), PLAGL1, PPARG, RB1, SKP2, SMARCB1, STAT3, TFDP1, 
YWHAE 
Cell Cycle cell cycle 
progression 
cell cycle progression 
of tumor cell lines 
8.84E-03 AURKA, BAX, BRCA1, CDK6, CDKN1A, CDKN1B, CSNK2A1, FOXM1, 
FOXO3, HMOX1, MELK, PHB (includes EG:5245), PLAGL1, PPARG, 
RB1, SMARCB1, STAT3, YWHAE 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of 
fibroblasts 
1.01E-02 CDKN1A, SKP2 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of skin 
cancer cell lines 
1.01E-02 CDKN1A, CDKN1B 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of lung 
cancer cell lines 
1.32E-02 CDKN1A, RB1, YWHAE 
Cell Cycle cell cycle 
progression 
cell cycle progression 
of fibroblast cell lines 
1.81E-02 CDKN1A, RB1, SMARCB1 
Cell Cycle cell cycle 
progression 
cell cycle progression 
of lung cancer cell 
lines 
2.31E-02 CDKN1A, HMOX1, RB1, YWHAE 
Cell Cycle cell cycle 
progression 
delay in cell cycle 
progression of tumor 
cell lines 
3.03E-02 AURKA, BAX, CDKN1A 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of colon 
cancer cell lines 
3.10E-02 CDKN1A, PPARG 
Cell Cycle cell cycle 
progression 
cell cycle progression 
of colon cancer cell 
lines 
3.78E-02 CDK6, CDKN1A, PPARG 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of breast 
cancer cell lines 
3.79E-02 BRCA1, FOXM1, FOXO3, RB1 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of bone 
cancer cell lines 
4.47E-02 PLAGL1, RB1 
Cell Cycle cell cycle 
progression 
arrest in cell cycle 
progression of 
fibroblast cell lines 
4.47E-02 CDKN1A, SMARCB1 
Cell Cycle cell cycle 
progression 
delay in cell cycle 
progression of 
lymphoblastoid cell 
lines 
4.47E-02 BAX, CDKN1A 
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Cell Cycle cytokinesis cytokinesis of cell 
lines 
1.05E-05 CD2AP, CEP55, GNAI2, KIFC1, MASTL, NEDD4L, NME1, SEPT6, 
SEPT9, TOP2A, VAV3 
Cell Cycle cytokinesis cytokinesis of 
cervical cancer cell 
lines 
2.90E-05 CD2AP, CEP55, GNAI2, KIFC1, MASTL, NEDD4L, SEPT6, SEPT9, 
VAV3 
Cell Cycle cytokinesis cytokinesis of tumor 
cell lines 
5.15E-05 CD2AP, CEP55, GNAI2, KIFC1, MASTL, NEDD4L, SEPT6, SEPT9, 
TOP2A, VAV3 
Cell Cycle cytokinesis cytokinesis 5.98E-05 AURKA, CD2AP, CDKN1A, CEP55, DIAPH2, GNAI2, KIFC1, MASTL, 
NEDD4L, NME1, SEPT6, SEPT9, SETD8, TOP2A, VAV3 
Cell Cycle M phase M phase of cervical 
cancer cell lines 
2.05E-05 CD2AP, CDC42, CEP55, GNAI2, KIFC1, MASTL, NCAPD2, NEDD4L, 
SEPT6, SEPT9, TOP2A, VAV3 
Cell Cycle M phase M phase 4.27E-05 AURKA, CD2AP, CDC42, CDKN1A, CEP55, DIAPH2, FBXO5, GNAI2, 
KIFC1, MASTL, MPHOSPH6, NCAPD2, NEDD4L, NME1, SEPT6, 
SEPT9, SETD8, SKA1, TOP2A, VAV3 
Cell Cycle M phase M phase of cell lines 4.99E-05 CD2AP, CDC42, CEP55, FBXO5, GNAI2, KIFC1, MASTL, NCAPD2, 
NEDD4L, NME1, SEPT6, SEPT9, TOP2A, VAV3 
Cell Cycle M phase M phase of tumor 
cell lines 
1.28E-04 CD2AP, CDC42, CEP55, FBXO5, GNAI2, KIFC1, MASTL, NCAPD2, 
NEDD4L, SEPT6, SEPT9, TOP2A, VAV3 
Cell Cycle M phase M phase of epithelial 
cell lines 
1.01E-02 FBXO5, NME1 
Cell Cycle interphase interphase 2.56E-05 BABAM1, BAX, BMP2, BRCA1, BTRC, C13orf15, CDC42, CDCA5, 
CDK6, CDKN1A, CDKN1B, CDKN3, CHEK2, CHMP1A, COPS5, CUL2, 
DDB1, ELF4, FOXM1, FOXN3, FOXO3, GADD45A, GNL3, GPS2, 
HINFP, HMGA1, HMOX1, MASTL, NBN, NCOA3, PCBP4, PIAS1, 
POLD1, PPARG, PPP2R2A, RAD17, RB1, RB1CC1, RBBP8, SKP2, 
SMARCB1, SP1, TFDP1, TP53BP1, TPD52L1, TUSC2 
Cell Cycle interphase interphase of lung 
cancer cell lines 
6.56E-05 BRCA1, BTRC, CDKN1A, CDKN1B, CHEK2, HMOX1, PCBP4, PIAS1, 
RB1, TUSC2 
Cell Cycle interphase arrest in interphase of 
lung cancer cell lines 
3.37E-04 BRCA1, BTRC, CDKN1A, CDKN1B, CHEK2, PCBP4, PIAS1, TUSC2 
Cell Cycle interphase interphase of cell 
lines 
4.76E-04 BAX, BMP2, BRCA1, BTRC, CDC42, CDK6, CDKN1A, CDKN1B, 
CHEK2, COPS5, DDB1, FOXM1, FOXO3, GADD45A, GNL3, GPS2, 
HMGA1, HMOX1, MASTL, NCOA3, PCBP4, PIAS1, PPARG, PPP2R2A, 
RAD17, RB1, RB1CC1, RBBP8, SKP2, SMARCB1, SP1, TFDP1, 
TP53BP1, TUSC2 
Cell Cycle interphase interphase of tumor 
cell lines 
5.06E-04 BAX, BMP2, BRCA1, BTRC, CDC42, CDK6, CDKN1A, CDKN1B, 
CHEK2, COPS5, FOXM1, FOXO3, GADD45A, GNL3, GPS2, HMGA1, 
HMOX1, MASTL, NCOA3, PCBP4, PIAS1, PPP2R2A, RAD17, RB1, 
RB1CC1, RBBP8, SKP2, SMARCB1, SP1, TP53BP1, TUSC2 
Cell Cycle interphase interphase of 
eukaryotic cells 
5.31E-04 BAX, BMP2, BRCA1, BTRC, C13orf15, CDC42, CDK6, CDKN1A, 
CDKN1B, CHEK2, COPS5, DDB1, FOXM1, FOXO3, GADD45A, GNL3, 
GPS2, HMGA1, HMOX1, MASTL, NBN, NCOA3, PCBP4, PIAS1, 
PPARG, PPP2R2A, RAD17, RB1, RB1CC1, RBBP8, SKP2, SMARCB1, 
SP1, TFDP1, TP53BP1, TUSC2 
Cell Cycle interphase arrest in interphase of 
eukaryotic cells 
1.48E-03 BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, DDB1, 
FOXM1, FOXO3, GADD45A, GNL3, GPS2, MASTL, NBN, PCBP4, 
PIAS1, PPP2R2A, RB1, RB1CC1, SKP2, SMARCB1, SP1, TP53BP1, 
TUSC2 
Cell Cycle interphase arrest in interphase of 
tumor cell lines 
1.48E-03 BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, FOXM1, 
FOXO3, GADD45A, GNL3, GPS2, MASTL, PCBP4, PIAS1, PPP2R2A, 
RB1, RB1CC1, SMARCB1, SP1, TP53BP1, TUSC2 
Cell Cycle interphase arrest in interphase of 
bone cancer cell lines 
1.51E-03 CDC42, CDKN1A, FOXM1, GNL3, GPS2, RB1, TP53BP1 
Cell Cycle interphase interphase of bone 
cancer cell lines 
1.73E-03 CDC42, CDK6, CDKN1A, FOXM1, GNL3, GPS2, RB1, TP53BP1 
Cell Cycle interphase interphase of 
fibroblast cell lines 
1.91E-03 CDKN1A, CDKN1B, NCOA3, SMARCB1 
Cell Cycle interphase arrest in interphase of 
cell lines 
3.40E-03 BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, CHEK2, DDB1, 
FOXM1, FOXO3, GADD45A, GNL3, GPS2, MASTL, PCBP4, PIAS1, 
PPP2R2A, RB1, RB1CC1, SMARCB1, SP1, TP53BP1, TUSC2 
Cell Cycle interphase interphase of 
fibroblasts 
5.26E-03 CDKN1A, CHEK2, GADD45A, NBN, SKP2 
Cell Cycle interphase interphase of normal 
cells 
5.83E-03 C13orf15, CDKN1A, CHEK2, GADD45A, NBN, RB1, SKP2, SP1 
Cell Cycle interphase arrest in interphase of 
normal cells 
9.86E-03 CDKN1A, GADD45A, NBN, RB1, SP1 
Cell Cycle interphase arrest in interphase of 
fibroblasts 
1.32E-02 CDKN1A, GADD45A, NBN 
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Cell Cycle interphase interphase of 
carcinoma cell lines 
1.67E-02 BRCA1, CDKN1B, CHEK2, HMOX1, RB1 
Cell Cycle interphase arrest in interphase of 
endothelial cell lines 
1.93E-02 CDKN1B, FOXM1 
Cell Cycle interphase entry into interphase 
of fibroblasts 
1.93E-02 CDKN1A, CHEK2 
Cell Cycle interphase interphase of 
pancreatic cancer cell 
lines 
2.38E-02 COPS5, FOXM1, HMGA1 
Cell Cycle interphase interphase of colon 
cancer cell lines 
2.95E-02 BRCA1, CDKN1A, CDKN1B, CHEK2, FOXO3, GADD45A, RAD17 
Cell Cycle interphase arrest in interphase of 
colon cancer cell 
lines 
2.97E-02 BRCA1, CDKN1A, CDKN1B, CHEK2, GADD45A 
Cell Cycle interphase interphase of prostate 
cancer cell lines 
3.25E-02 CDKN1B, NCOA3, SKP2, SP1 
Cell Cycle interphase interphase of 
epithelial cell lines 
3.79E-02 CDKN1B, CHEK2, DDB1, TFDP1 
Cell Cycle G1 phase G1 phase 4.93E-05 BAX, BMP2, BRCA1, BTRC, CDC42, CDCA5, CDK6, CDKN1A, 
CDKN1B, CDKN3, CHEK2, COPS5, CUL2, ELF4, FOXM1, GADD45A, 
GNL3, GPS2, HINFP, HMGA1, NBN, NCOA3, PIAS1, RB1, RB1CC1, 
SKP2, SP1, TFDP1, TUSC2 
Cell Cycle G1 phase G1 phase of tumor 
cell lines 
7.53E-04 BAX, BMP2, BRCA1, BTRC, CDC42, CDK6, CDKN1A, CDKN1B, 
COPS5, FOXM1, GNL3, GPS2, HMGA1, NCOA3, PIAS1, RB1, RB1CC1, 
SKP2, SP1, TUSC2 
Cell Cycle G1 phase G1 phase of cell lines 7.68E-04 BAX, BMP2, BRCA1, BTRC, CDC42, CDK6, CDKN1A, CDKN1B, 
CHEK2, COPS5, FOXM1, GNL3, GPS2, HMGA1, NCOA3, PIAS1, RB1, 
RB1CC1, SKP2, SP1, TFDP1, TUSC2 
Cell Cycle G1 phase G1 phase of bone 
cancer cell lines 
1.86E-03 CDC42, CDK6, CDKN1A, FOXM1, GNL3, GPS2, RB1 
Cell Cycle G1 phase arrest in G1 phase of 
bone cancer cell lines 
3.49E-03 CDC42, CDKN1A, FOXM1, GNL3, GPS2, RB1 
Cell Cycle G1 phase G1 phase of skin 
cancer cell lines 
3.49E-03 BAX, CDKN1B 
Cell Cycle G1 phase arrest in G1 phase of 
tumor cell lines 
3.81E-03 BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, FOXM1, GNL3, 
GPS2, PIAS1, RB1, RB1CC1, SP1, TUSC2 
Cell Cycle G1 phase arrest in G1 phase of 
lung cancer cell lines 
4.15E-03 BRCA1, BTRC, CDKN1A, PIAS1, TUSC2 
Cell Cycle G1 phase arrest in G1 phase of 
eukaryotic cells 
6.92E-03 BMP2, BRCA1, BTRC, CDC42, CDKN1A, CDKN1B, FOXM1, GNL3, 
GPS2, PIAS1, RB1, RB1CC1, SKP2, SP1, TUSC2 
Cell Cycle G1 phase arrest in G1 phase of 
epithelial cells 
1.01E-02 RB1, SP1 
Cell Cycle G1 phase arrest in G1 phase of 
tumor cells 
1.93E-02 CDKN1A, SKP2 
Cell Cycle G1 phase G1 phase of 
epithelial cell lines 
2.38E-02 CDKN1B, CHEK2, TFDP1 
Cell Cycle G1 phase G1 phase of prostate 
cancer cell lines 
3.78E-02 CDKN1B, NCOA3, SP1 
Cell Cycle G1/S phase 
transition 
G1/S phase transition 8.50E-05 CDC42, CDCA5, CDKN1A, CDKN1B, CDKN3, CHEK2, COPS5, CUL2, 
ELF4, FOXM1, GADD45A, HINFP, HMGA1, NBN, NCOA3, RB1, 
RB1CC1, TFDP1 
Cell Cycle G1/S phase 
transition 
G1/S phase transition 
of pancreatic cancer 
cell lines 
3.49E-03 COPS5, HMGA1 
Cell Cycle G1/S phase 
transition 
G1/S phase transition 
of cell lines 
6.37E-03 CDC42, CDKN1A, CDKN1B, CHEK2, COPS5, FOXM1, HMGA1, 
NCOA3, RB1CC1, TFDP1 
Cell Cycle G1/S phase 
transition 
G1/S phase transition 
of tumor cell lines 
2.42E-02 CDC42, CDKN1A, CDKN1B, COPS5, FOXM1, HMGA1, NCOA3, 
RB1CC1 
Cell Cycle G1/S phase 
transition 
G1/S phase transition 
of epithelial cell lines 
3.10E-02 CHEK2, TFDP1 
Cell Cycle ploidy ploidy 4.37E-04 AURKA, CDK7, CDKN1A, CSNK1E, DYRK2, HIF1A, NME1, PDK3, 
TOP2A, UBIAD1, WNK1 
Cell Cycle ploidy ploidy of cell lines 2.42E-03 CDK7, CDKN1A, CSNK1E, DYRK2, NME1, PDK3, UBIAD1, WNK1 
Cell Cycle mitosis mitosis 4.81E-04 AURKA, BMP2, BRCA1, CBL, CDC42, CDCA5, CDKN1A, CDKN1B, 
FBXO5, FOXM1, FYN, GNA13, HAUS1, HDAC3, MAPK7, MASTL, 
NCAPD2, PHF13, PRMT5, RB1, SEPT9, SGOL1, SKA1, SKA3, THAP1, 
TOP2A, TRIM33, TXN, UBE2C, YWHAE 
Cell Cycle mitosis mitosis of cell lines 3.39E-03 AURKA, BMP2, BRCA1, CDKN1A, CDKN1B, FBXO5, FOXM1, MAPK7, 
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MASTL, SEPT9, TOP2A, YWHAE 
Cell Cycle mitosis mitosis of breast cell 
lines 
3.60E-03 CDKN1A, CDKN1B, SEPT9 
Cell Cycle mitosis entry into mitosis of 
cell lines 
9.81E-03 AURKA, CDKN1A, CDKN1B, MAPK7 
Cell Cycle mitosis entry into mitosis of 
breast cell lines 
1.01E-02 CDKN1A, CDKN1B 
Cell Cycle mitosis mitosis of tumor cell 
lines 
1.25E-02 AURKA, BMP2, BRCA1, CDKN1A, FBXO5, FOXM1, MAPK7, MASTL, 
TOP2A, YWHAE 
Cell Cycle mitosis mitosis of lung 
cancer cell lines 
1.93E-02 FOXM1, YWHAE 
Cell Cycle mitosis exit from mitosis of 
tumor cell lines 
3.10E-02 CDKN1A, MASTL 
Cell Cycle checkpoint 
control 
checkpoint control 6.46E-04 CHEK2, DDB1, ERCC3, MCM7, PRCC, RAD17, RB1, RBBP8, TP53BP1 
Cell Cycle checkpoint 
control 
checkpoint control of 
tumor cell lines 
2.87E-03 CHEK2, MCM7, RAD17, TP53BP1 
Cell Cycle S phase entry into S phase of 
eukaryotic cells 
1.28E-03 C13orf15, CDKN1A, CDKN1B, CHEK2, FOXM1, HMOX1, NCOA3, RB1, 
SKP2, SMARCB1 
Cell Cycle S phase entry into S phase of 
cell lines 
2.84E-03 CDKN1A, CDKN1B, FOXM1, HMOX1, NCOA3, RB1, SKP2, SMARCB1 
Cell Cycle S phase S phase of fibroblasts 5.65E-03 CDKN1A, CHEK2, NBN, SKP2 
Cell Cycle S phase initiation of S phase 
of breast cancer cell 
lines 
1.01E-02 CDKN1A, CDKN1B 
Cell Cycle S phase entry into S phase of 
tumor cell lines 
1.01E-02 CDKN1B, FOXM1, HMOX1, RB1, SKP2, SMARCB1 
Cell Cycle S phase S phase of normal 
cells 
1.19E-02 C13orf15, CDKN1A, CHEK2, NBN, SKP2 
Cell Cycle S phase S phase 1.20E-02 C13orf15, CDKN1A, CDKN1B, CHEK2, CHMP1A, FOXM1, FOXO3, 
HMOX1, NBN, NCOA3, POLD1, PPARG, RB1, SKP2, SMARCB1 
Cell Cycle S phase S phase of eukaryotic 
cells 
1.29E-02 C13orf15, CDKN1A, CDKN1B, CHEK2, FOXM1, FOXO3, HMOX1, NBN, 
NCOA3, PPARG, RB1, SKP2, SMARCB1 
Cell Cycle S phase entry into S phase of 
breast cell lines 
1.93E-02 CDKN1A, CDKN1B 
Cell Cycle S phase entry into S phase of 
fibroblast cell lines 
1.93E-02 NCOA3, SMARCB1 
Cell Cycle S phase entry into S phase of 
prostate cancer cell 
lines 
1.93E-02 CDKN1B, SKP2 
Cell Cycle S phase initiation of S phase 
of eukaryotic cells 
2.38E-02 CDKN1A, CDKN1B, SKP2 
Cell Cycle S phase entry into S phase of 
lung cancer cell lines 
3.10E-02 HMOX1, RB1 
Cell Cycle S phase re-entry into S phase 
of eukaryotic cells 
3.78E-02 CDKN1A, PPARG, SKP2 
Cell Cycle S phase entry into S phase of 
carcinoma cell lines 
4.47E-02 HMOX1, RB1 
Cell Cycle S phase entry into S phase of 
cervical cancer cell 
lines 
4.47E-02 CDKN1B, FOXM1 
Cell Cycle S phase exit from S phase of 
colon cancer cell 
lines 
4.47E-02 CDKN1A, FOXO3 
Cell Cycle DNA 
damage 
checkpoint 
DNA damage 
checkpoint 
1.78E-03 CHEK2, FOXN3, HINFP, NBN, RAD17, TIPRL 
Cell Cycle endoreduplic
ation 
endoreduplication 1.88E-03 CDKN1A, NRAS, RB1 
Cell Cycle endoreduplic
ation 
endoreduplication of 
cells 
1.01E-02 CDKN1A, RB1 
Cell Cycle segregation segregation of 
chromosomes 
2.22E-03 BRCA1, CDC42, DSN1, NCAPD2, NCAPG (includes EG:64151), PHF13, 
SGOL1, SKA1, SKA3, TOP2A 
Cell Cycle G2 phase G2 phase 2.97E-03 BABAM1, BAX, BRCA1, CDKN1A, CHEK2, DDB1, FOXM1, FOXN3, 
GADD45A, MASTL, NBN, PCBP4, PPP2R2A, RAD17, RBBP8, TP53BP1, 
TPD52L1 
Cell Cycle G2 phase G2 phase of colon 
cancer cell lines 
3.21E-03 BRCA1, CDKN1A, CHEK2, GADD45A, RAD17 
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Cell Cycle G2 phase arrest in G2 phase of 
colon cancer cell 
lines 
4.10E-03 BRCA1, CDKN1A, CHEK2, GADD45A 
Cell Cycle G2 phase G2 phase of tumor 
cell lines 
4.14E-03 BAX, BRCA1, CDKN1A, CHEK2, FOXM1, GADD45A, MASTL, PCBP4, 
PPP2R2A, RAD17, RBBP8, TP53BP1 
Cell Cycle G2 phase G2 phase of cell lines 4.19E-03 BAX, BRCA1, CDKN1A, CHEK2, DDB1, FOXM1, GADD45A, MASTL, 
PCBP4, PPP2R2A, RAD17, RBBP8, TP53BP1 
Cell Cycle G2 phase arrest in G2 phase of 
bone cancer cell lines 
6.03E-03 CDKN1A, FOXM1, TP53BP1 
Cell Cycle G2 phase arrest in G2 phase of 
cell lines 
1.63E-02 BRCA1, CDKN1A, CHEK2, DDB1, FOXM1, GADD45A, MASTL, PCBP4, 
PPP2R2A, TP53BP1 
Cell Cycle G2 phase arrest in G2 phase of 
tumor cell lines 
1.82E-02 BRCA1, CDKN1A, CHEK2, FOXM1, GADD45A, MASTL, PCBP4, 
PPP2R2A, TP53BP1 
Cell Cycle G2 phase arrest in G2 phase of 
lung cancer cell lines 
2.38E-02 BRCA1, CHEK2, PCBP4 
Cell Cycle G2/M phase arrest in G2/M phase 
of bone cancer cell 
lines 
3.49E-03 FOXM1, TP53BP1 
Cell Cycle G2/M phase G2/M phase of tumor 
cell lines 
2.03E-02 BRCA1, CHEK2, FOXM1, RAD17, RBBP8, TP53BP1 
Cell Cycle G2/M phase G2/M phase 2.65E-02 BABAM1, BRCA1, CHEK2, FOXM1, NBN, RAD17, RBBP8, TP53BP1 
Cell Cycle G2/M phase arrest in G2/M phase 
of tumor cell lines 
4.38E-02 BRCA1, CHEK2, FOXM1, TP53BP1 
Cell Cycle S phase 
checkpoint 
control 
S phase checkpoint 
control of carcinoma 
cell lines 
3.49E-03 MCM7, RAD17 
Cell Cycle S phase 
checkpoint 
control 
S phase checkpoint 
control of lung 
cancer cell lines 
3.49E-03 MCM7, RAD17 
Cell Cycle S phase 
checkpoint 
control 
S phase checkpoint 
control of tumor cell 
lines 
6.03E-03 MCM7, RAD17, TP53BP1 
Cell Cycle senescence senescence of cells 4.41E-03 ACLY, BRCA1, CAT, CDKN1A, CDKN1B, CHEK2, CSNK2A1, NAMPT, 
PSMB5, RB1, SMARCB1 
Cell Cycle senescence senescence of 
eukaryotic cells 
8.63E-03 ACLY, BRCA1, CAT, CDKN1A, CHEK2, CSNK2A1, NAMPT, PSMB5, 
RB1, SMARCB1 
Cell Cycle senescence senescence of breast 
cell lines 
3.10E-02 CDKN1A, RB1 
Cell Cycle senescence senescence of normal 
cells 
3.25E-02 BRCA1, CAT, CDKN1A, CSNK2A1 
Cell Cycle G0/G1 phase 
transition 
arrest in G0/G1 phase 
transition of 
fibroblast cell lines 
1.01E-02 CDKN1A, CDKN1B 
Cell Cycle G0/G1 phase 
transition 
arrest in G0/G1 phase 
transition of tumor 
cell lines 
4.38E-02 CDKN1A, CDKN1B, FOXO3, SMARCB1 
Cell Cycle prometaphas
e 
prometaphase 2.38E-02 CDC42, KIFC1, MASTL 
Cell Cycle anaphase anaphase 3.03E-02 NCAPD2, SKA1, TOP2A 
Cell Cycle anaphase anaphase of cervical 
cancer cell lines 
3.10E-02 NCAPD2, TOP2A 
Cell Cycle antiproliferat
ive response 
antiproliferative 
response of tumor 
cell lines 
4.47E-02 ASXL1, CDKN1B 
Post-
Translational 
Modification 
ubiquitinatio
n 
ubiquitination 1.22E-07 ATG3 (includes EG:171415), BAG5, BRCA1, BTRC, CBL, CUL2, DDB1, 
FBXL2, FBXO3, FBXO7, FBXW11, FKBP1A, HUWE1, IRAK1, 
LOC728622/SKP1, NDFIP2, OTUB1, PRICKLE1, RNF115, RNF135, 
TBC1D7, TRIM24, TRIM33, TSC1, UBE2C, UBE2E1, UBE2H, UBE3C, 
UBE4B, USP21 
Post-
Translational 
Modification 
ubiquitinatio
n 
ubiquitination of 
protein 
2.84E-07 ATG3 (includes EG:171415), BAG5, BRCA1, BTRC, CBL, CUL2, DDB1, 
FBXL2, FBXO3, FBXO7, FBXW11, FKBP1A, HUWE1, IRAK1, 
LOC728622/SKP1, NDFIP2, PRICKLE1, RNF115, RNF135, TBC1D7, 
TRIM24, TRIM33, TSC1, UBE2C, UBE2E1, UBE2H, UBE3C, UBE4B, 
USP21 
Post-
Translational 
Modification 
moiety 
attachment 
moiety attachment of 
protein 
3.18E-04 ATG3 (includes EG:171415), BAG5, BMP2, BMPR1A, BRCA1, BTRC, 
CBL, CDK6, CUL2, DAB2, DDB1, DYRK2, EIF2AK2, EPB41L3, FBXL2, 
FBXO3, FBXO7, FBXW11, FKBP1A, FNTB, FUT8, FYN, GMFB, 
HUWE1, ICK, IRAK1, LOC728622/SKP1, MAPKAPK2, NDFIP2, OXSR1, 
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PAK2, PRICKLE1, PRKAA1, RARA, RNF115, RNF135, SIK3, SLC35C1, 
TBC1D7, TLK2, TPST2, TRIM24, TRIM33, TSC1, UBE2C, UBE2E1, 
UBE2H, UBE3C, UBE4B, USP21, UST, WNK1 
Post-
Translational 
Modification 
modification modification of 
protein 
3.27E-04 APH1A, ATG3 (includes EG:171415), BAG4, BAG5, BMP2, BMPR1A, 
BRCA1, BTRC, CBL, CDK6, CTDNEP1, CTDSP2, CUL2, DAB2, DDB1, 
DNAJB1, DYRK2, EIF2AK2, EPB41L3, FBXL2, FBXO3, FBXO7, 
FBXW11, FKBP1A, FNTB, FUT8, FYN, GMFB, HDAC3, HUWE1, ICK, 
IRAK1, LOC728622/SKP1, MAPKAPK2, MCRS1, NDFIP2, NFYC, 
OXSR1, PAK2, PPME1, PPP2CA, PPP2R2A, PRICKLE1, PRKAA1, 
RARA, RNF115, RNF135, SEPHS1, SIK3, SLC35C1, TBC1D7, TLK2, 
TPST2, TRIM24, TRIM33, TSC1, UBE2C, UBE2E1, UBE2H, UBE3C, 
UBE4B, UBL4A, USP10, USP21, UST, WNK1 
Post-
Translational 
Modification 
activation activation of Protein 
kinase 
1.01E-02 CRIPAK, PAK2, PDPK1, RB1, TAB2, TRAF4 
Post-
Translational 
Modification 
heterodimeri
zation 
heterodimerization of 
protein 
1.93E-02 BAK1, BAX 
Post-
Translational 
Modification 
methylation methylation of basic 
amino acid 
3.10E-02 PRMT5, PRMT6 
Post-
Translational 
Modification 
methylation methylation of 
glutamine family 
amino acid 
3.10E-02 PRMT5, PRMT6 
Post-
Translational 
Modification 
sulfation sulfation of protein 3.10E-02 TPST2, UST 
Cell Death cell death cell death 4.88E-07 ABCE1, ACACA, ADNP, ADRM1, AGPAT2, AHSA1, AKAP13, ANXA7, 
APH1A, APIP, ARHGDIA, ATF1, ATF3, ATG5, ATMIN, ATN1, ATXN2, 
AURKA, B4GALT5, BACH2 (includes EG:60468), BAG4, BAG5, BAK1, 
BARD1, BAX, BCL2L1, BCL2L13, BLCAP, BMP2, BRCA1, BTRC, 
CABLES2, CAPNS1, CARD8, CAT, CDC42, CDK6, CDKN1A, CDKN1B, 
CERS5, CHEK2, COPS5, CSNK1E, CSNK2A1, CTNNBL1, CYFIP2 
(includes EG:26999), DAB2, DFFA, DNAJB1, DNMT3B, DUSP22, 
EIF2AK2, EIF4G2, ELK1, ERCC3, ETS1, EXOC2, FDFT1, FKBP1A, 
FKBP5, FOXM1, FOXO3, GABPA, GABPB1, GADD45A, GMEB1, GPS2, 
GTF2F2, HAUS1, HDAC3, HEY1, HIF1A, HIPK2, HMGA1, HMOX1, 
HUWE1, IMMT, LIMS1, MAML1, MAP2K4, MAP3K1, MAPK7, MED1, 
MELK, MFN2, MSN, MT1X, MTMR9, NAMPT, NBN, NCKAP1, NCOA3, 
NET1, NKX2-5, NME1, NRAS, NUAK1, ODC1, OGFOD1, PAK2, PCBP2, 
PDCD6IP, PDPK1, PHB (includes EG:5245), PIAS1, PLAGL1, POLR2A, 
PPARD, PPARG, PPP2CA, PPP2R2A, PPP3R1, PRKAA1, PRKAR1A, 
PRKCQ, PSME3, PTPN13, RARA, RB1, RB1CC1, RBM4B, RDX, RND3, 
RNF216, RRAGA, RYBP, SAP30BP, SEC61G, SET, SGPL1, SH3RF1, 
SKP2, SMARCB1, SP1, STAT3, STAT5B, TCF12, TFAP2A, TFDP1, 
THAP1, TNFRSF21, TOP2A, TPD52L1, TRAF4, TRIAP1, TRIM24, 
TRIM28, TSC2, TTF1, TUBA1A, TXN, TXNRD1, UBE2C, UBE4B, UCP2, 
UGCG, VAV3, YBX1, YWHAE, YWHAZ, ZMYM2 
Cell Death cell death cell death of tumor 
cell lines 
2.38E-06 ABCE1, ACACA, ADNP, ADRM1, AGPAT2, AHSA1, ARHGDIA, ATF1, 
ATF3, ATG5, ATMIN, AURKA, BACH2 (includes EG:60468), BAK1, 
BARD1, BAX, BCL2L1, BCL2L13, BMP2, BRCA1, BTRC, CABLES2, 
CAPNS1, CARD8, CAT, CDC42, CDK6, CDKN1A, CDKN1B, CERS5, 
CHEK2, CSNK2A1, DAB2, DFFA, DNAJB1, EIF2AK2, EIF4G2, ELK1, 
ETS1, EXOC2, FDFT1, FKBP1A, FKBP5, FOXO3, GABPA, GADD45A, 
GPS2, HDAC3, HIF1A, HIPK2, HMGA1, HMOX1, HUWE1, IMMT, 
LIMS1, MAML1, MAP2K4, MAPK7, MELK, MSN, MT1X, MTMR9, 
NAMPT, NCOA3, NME1, NRAS, NUAK1, OGFOD1, PAK2, PCBP2, 
PDCD6IP, PDPK1, PHB (includes EG:5245), PIAS1, PLAGL1, PPARD, 
PPARG, PPP2CA, PPP2R2A, PRKAA1, PRKAR1A, PTPN13, RARA, RB1, 
RBM4B, RDX, SEC61G, SH3RF1, SKP2, SP1, STAT3, TFAP2A, 
TNFRSF21, TOP2A, TRAF4, TRIAP1, TRIM28, TSC2, TTF1, TUBA1A, 
TXN, UBE2C, UCP2, UGCG, YBX1, YWHAE, YWHAZ 
Cell Death cell death cell death of cell lines 7.73E-06 ABCE1, ACACA, ADNP, ADRM1, AGPAT2, AHSA1, ARHGDIA, ATF1, 
ATF3, ATG5, ATMIN, AURKA, BACH2 (includes EG:60468), BAG4, 
BAK1, BARD1, BAX, BCL2L1, BCL2L13, BMP2, BRCA1, BTRC, 
CABLES2, CAPNS1, CARD8, CAT, CDC42, CDK6, CDKN1A, CDKN1B, 
CERS5, CHEK2, CSNK2A1, DAB2, DFFA, DNAJB1, EIF2AK2, EIF4G2, 
ELK1, ETS1, EXOC2, FDFT1, FKBP1A, FKBP5, FOXO3, GABPA, 
GADD45A, GPS2, HDAC3, HIF1A, HIPK2, HMGA1, HMOX1, HUWE1, 
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IMMT, LIMS1, MAML1, MAP2K4, MAPK7, MELK, MSN, MT1X, 
MTMR9, NAMPT, NBN, NCOA3, NME1, NRAS, NUAK1, OGFOD1, 
PAK2, PCBP2, PDCD6IP, PDPK1, PHB (includes EG:5245), PIAS1, 
PLAGL1, PPARD, PPARG, PPP2CA, PPP2R2A, PPP3R1, PRKAA1, 
PRKAR1A, PRKCQ, PTPN13, RARA, RB1, RBM4B, RDX, RNF216, 
SEC61G, SGPL1, SH3RF1, SKP2, SP1, STAT3, STAT5B, TCF12, 
TFAP2A, TFDP1, TNFRSF21, TOP2A, TRAF4, TRIAP1, TRIM28, TSC2, 
TTF1, TUBA1A, TXN, UBE2C, UCP2, UGCG, YBX1, YWHAE, YWHAZ 
Cell Death cell death cell death of 
eukaryotic cells 
3.42E-05 ABCE1, ACACA, ADNP, ADRM1, AGPAT2, AHSA1, APIP, ARHGDIA, 
ATF1, ATF3, ATG5, ATMIN, ATXN2, AURKA, B4GALT5, BACH2 
(includes EG:60468), BAG4, BAG5, BAK1, BARD1, BAX, BCL2L1, 
BCL2L13, BMP2, BRCA1, BTRC, CABLES2, CAPNS1, CARD8, CAT, 
CDC42, CDK6, CDKN1A, CDKN1B, CERS5, CHEK2, COPS5, CSNK2A1, 
DAB2, DFFA, DNAJB1, DNMT3B, EIF2AK2, EIF4G2, ELK1, ETS1, 
EXOC2, FDFT1, FKBP1A, FKBP5, FOXO3, GABPA, GADD45A, GPS2, 
GTF2F2, HDAC3, HIF1A, HIPK2, HMGA1, HMOX1, HUWE1, IMMT, 
LIMS1, MAML1, MAP2K4, MAPK7, MELK, MFN2, MSN, MT1X, 
MTMR9, NAMPT, NBN, NCOA3, NKX2-5, NME1, NRAS, NUAK1, 
OGFOD1, PAK2, PCBP2, PDCD6IP, PDPK1, PHB (includes EG:5245), 
PIAS1, PLAGL1, PPARD, PPARG, PPP2CA, PPP2R2A, PPP3R1, 
PRKAA1, PRKAR1A, PRKCQ, PTPN13, RARA, RB1, RBM4B, RDX, 
RND3, RNF216, SEC61G, SET, SGPL1, SH3RF1, SKP2, SP1, STAT3, 
STAT5B, TCF12, TFAP2A, TFDP1, TNFRSF21, TOP2A, TRAF4, TRIAP1, 
TRIM28, TSC2, TTF1, TUBA1A, TXN, UBE2C, UCP2, UGCG, YBX1, 
YWHAE, YWHAZ 
Cell Death cell death cell death of cervical 
cancer cell lines 
1.68E-04 ADRM1, ATG5, BAK1, BAX, BCL2L1, CAT, CDKN1A, CDKN1B, 
CSNK2A1, EIF2AK2, EIF4G2, EXOC2, GADD45A, IMMT, LIMS1, MSN, 
MTMR9, NME1, OGFOD1, PAK2, PCBP2, PDCD6IP, PDPK1, PPP2R2A, 
RB1, SEC61G, TFAP2A, TNFRSF21, TOP2A, TSC2, TXN, UCP2 
Cell Death cell death cell death of bone 
cancer cell lines 
1.90E-04 ATG5, ATMIN, BAX, BMP2, BRCA1, CABLES2, CAPNS1, CDK6, 
CDKN1A, ETS1, GPS2, HMGA1, HUWE1, PIAS1, PLAGL1, PRKAA1, 
RB1, TRAF4 
Cell Death cell death cell death of colon 
cancer cell lines 
1.07E-03 AHSA1, ATF3, ATMIN, BAK1, BAX, BCL2L1, CDKN1A, CDKN1B, 
CHEK2, ETS1, EXOC2, FOXO3, GABPA, GADD45A, HDAC3, HIPK2, 
HMGA1, LIMS1, MAML1, NUAK1, PPARD, PPARG, TRIAP1, UBE2C, 
YWHAE 
Cell Death cell death cell death of 
unspecified cell lines 
1.91E-03 BAX, BCL2L1, HMOX1, PPP2CA 
Cell Death cell death cell death of 
fibrosarcoma cell 
lines 
2.38E-03 BAX, BCL2L1, CDKN1A, LIMS1, NAMPT, PDPK1, TOP2A, TRIM28, 
YBX1 
Cell Death cell death cell death of tumor 
cells 
3.05E-03 ATXN2, B4GALT5, BAX, BCL2L1, BRCA1, CARD8, CAT, CDKN1A, 
CDKN1B, DNMT3B, HIF1A, HMOX1, NCOA3, PPP2CA, RARA, STAT3, 
TFAP2A, TXN 
Cell Death cell death cell death of cancer 
cells 
1.21E-02 ATXN2, B4GALT5, BAX, BCL2L1, BRCA1, CAT, CDKN1A, CDKN1B, 
DNMT3B, HMOX1, NCOA3, RARA, TFAP2A, TXN 
Cell Death cell death cell death of 
neuroblastoma cell 
lines 
1.71E-02 ADNP, ATG5, BAK1, BCL2L1, CAT, CDC42, CDKN1A, DNAJB1, 
EIF2AK2, FKBP1A, TUBA1A, TXN, UGCG 
Cell Death cell death cell death of muscle 
cells 
1.76E-02 APIP, BCL2L1, BMP2, CAT, NKX2-5, RB1, STAT3 
Cell Death cell death cell death of breast 
cancer cell lines 
1.76E-02 ARHGDIA, ATG5, BAK1, BARD1, BAX, BCL2L1, BCL2L13, BRCA1, 
CDC42, CDKN1A, CERS5, DAB2, ELK1, EXOC2, FOXO3, GADD45A, 
HIF1A, NCOA3, PHB (includes EG:5245), PPARG, PTPN13, SH3RF1, SP1, 
TFAP2A, UGCG 
Cell Death cell death cell death of prostate 
cancer cell lines 
2.89E-02 ABCE1, ACACA, BAK1, BAX, BCL2L1, BMP2, BRCA1, CAT, FDFT1, 
FOXO3, GADD45A, HIF1A, NCOA3, RB1, STAT3, TXN 
Cell Death cell death cell death of 
epithelial cell lines 
3.06E-02 ATG5, BAG4, BAX, BCL2L1, CAT, CDC42, EIF2AK2, HIPK2, MAP2K4, 
NAMPT, PAK2, PIAS1, PPARD, PPARG, PPP3R1, PRKAA1, RNF216, 
SGPL1, TCF12 
Cell Death cell death cell death of skin cell 
lines 
3.10E-02 BAK1, CAT 
Cell Death apoptosis apoptosis 1.37E-06 ABCE1, ACACA, AGPAT2, AHSA1, AKAP13, ANXA7, APH1A, APIP, 
ARHGDIA, ATF1, ATF3, ATG5, ATMIN, ATN1, ATXN2, AURKA, 
B4GALT5, BACH2 (includes EG:60468), BAK1, BARD1, BAX, BCL2L1, 
BCL2L13, BLCAP, BMP2, BRCA1, BTRC, CABLES2, CAPNS1, CARD8, 
CAT, CDC42, CDK6, CDKN1A, CDKN1B, CHEK2, COPS5, CSNK1E, 
CSNK2A1, CTNNBL1, CYFIP2 (includes EG:26999), DAB2, DFFA, 
DNAJB1, DNMT3B, DUSP22, EIF2AK2, EIF4G2, ERCC3, ETS1, EXOC2, 
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FKBP1A, FKBP5, FOXO3, GABPA, GABPB1, GADD45A, GMEB1, GPS2, 
HAUS1, HDAC3, HEY1, HIF1A, HIPK2, HMGA1, HMOX1, HUWE1, 
IMMT, LIMS1, MAP2K4, MAP3K1, MAPK7, MED1, MELK, MFN2, 
MSN, MTMR9, NAMPT, NBN, NCKAP1, NCOA3, NET1, NKX2-5, 
NME1, NRAS, ODC1, OGFOD1, PAK2, PCBP2, PDCD6IP, PDPK1, PHB 
(includes EG:5245), PIAS1, PLAGL1, POLR2A, PPARD, PPARG, 
PPP2CA, PPP2R2A, PPP3R1, PRKAA1, PRKAR1A, PRKCQ, PSME3, 
PTPN13, RARA, RB1, RB1CC1, RBM4B, RND3, RNF216, RYBP, 
SAP30BP, SEC61G, SET, SGPL1, SH3RF1, SKP2, SMARCB1, STAT3, 
STAT5B, TCF12, TFAP2A, THAP1, TNFRSF21, TOP2A, TPD52L1, 
TRAF4, TRIAP1, TRIM24, TRIM28, TSC2, TTF1, TXN, UBE4B, UGCG, 
VAV3, YBX1, YWHAE, YWHAZ 
Cell Death apoptosis apoptosis of tumor 
cell lines 
1.78E-05 ABCE1, ACACA, AGPAT2, AHSA1, ARHGDIA, ATF1, ATF3, ATG5, 
ATMIN, AURKA, BACH2 (includes EG:60468), BAK1, BARD1, BAX, 
BCL2L1, BCL2L13, BMP2, BRCA1, BTRC, CABLES2, CAPNS1, CARD8, 
CAT, CDC42, CDK6, CDKN1A, CDKN1B, CHEK2, CSNK2A1, DAB2, 
DFFA, DNAJB1, EIF2AK2, EIF4G2, ETS1, EXOC2, FKBP5, FOXO3, 
GABPA, GADD45A, GPS2, HDAC3, HIF1A, HIPK2, HMGA1, HMOX1, 
HUWE1, IMMT, LIMS1, MAP2K4, MAPK7, MELK, MSN, MTMR9, 
NCOA3, NME1, NRAS, OGFOD1, PAK2, PCBP2, PDCD6IP, PDPK1, PHB 
(includes EG:5245), PIAS1, PLAGL1, PPARD, PPARG, PPP2CA, 
PPP2R2A, PRKAA1, PRKAR1A, PTPN13, RARA, RB1, RBM4B, SEC61G, 
SH3RF1, SKP2, STAT3, TNFRSF21, TOP2A, TRAF4, TRIAP1, TRIM28, 
TSC2, TTF1, TXN, UGCG, YBX1, YWHAE, YWHAZ 
Cell Death apoptosis apoptosis of cell lines 3.69E-05 ABCE1, ACACA, AGPAT2, AHSA1, ARHGDIA, ATF1, ATF3, ATG5, 
ATMIN, AURKA, BACH2 (includes EG:60468), BAK1, BARD1, BAX, 
BCL2L1, BCL2L13, BMP2, BRCA1, BTRC, CABLES2, CAPNS1, CARD8, 
CAT, CDC42, CDK6, CDKN1A, CDKN1B, CHEK2, CSNK2A1, DAB2, 
DFFA, DNAJB1, EIF2AK2, EIF4G2, ETS1, EXOC2, FKBP5, FOXO3, 
GABPA, GADD45A, GPS2, HDAC3, HIF1A, HIPK2, HMGA1, HMOX1, 
HUWE1, IMMT, LIMS1, MAP2K4, MAPK7, MELK, MSN, MTMR9, 
NBN, NCOA3, NME1, NRAS, OGFOD1, PAK2, PCBP2, PDCD6IP, 
PDPK1, PHB (includes EG:5245), PIAS1, PLAGL1, PPARD, PPARG, 
PPP2CA, PPP2R2A, PPP3R1, PRKAA1, PRKAR1A, PRKCQ, PTPN13, 
RARA, RB1, RBM4B, RNF216, SEC61G, SGPL1, SH3RF1, SKP2, STAT3, 
STAT5B, TCF12, TNFRSF21, TOP2A, TRAF4, TRIAP1, TRIM28, TSC2, 
TTF1, TXN, UGCG, YBX1, YWHAE, YWHAZ 
Cell Death apoptosis apoptosis of cervical 
cancer cell lines 
5.43E-05 ATG5, BAK1, BAX, BCL2L1, CAT, CDKN1A, CDKN1B, CSNK2A1, 
EIF2AK2, EIF4G2, EXOC2, GADD45A, IMMT, LIMS1, MSN, MTMR9, 
NME1, OGFOD1, PAK2, PCBP2, PDCD6IP, PDPK1, PPP2R2A, RB1, 
SEC61G, TNFRSF21, TSC2, TXN 
Cell Death apoptosis apoptosis of bone 
cancer cell lines 
7.25E-05 ATG5, ATMIN, BAX, BMP2, BRCA1, CABLES2, CAPNS1, CDK6, 
CDKN1A, ETS1, GPS2, HUWE1, PIAS1, PLAGL1, PRKAA1, RB1, 
TRAF4 
Cell Death apoptosis apoptosis of 
eukaryotic cells 
1.89E-04 ABCE1, ACACA, AGPAT2, AHSA1, ARHGDIA, ATF1, ATF3, ATG5, 
ATMIN, ATXN2, AURKA, B4GALT5, BACH2 (includes EG:60468), 
BAK1, BARD1, BAX, BCL2L1, BCL2L13, BMP2, BRCA1, BTRC, 
CABLES2, CAPNS1, CARD8, CAT, CDC42, CDK6, CDKN1A, CDKN1B, 
CHEK2, COPS5, CSNK2A1, DAB2, DFFA, DNAJB1, DNMT3B, 
EIF2AK2, EIF4G2, ETS1, EXOC2, FKBP5, FOXO3, GABPA, GADD45A, 
GPS2, HDAC3, HIF1A, HIPK2, HMGA1, HMOX1, HUWE1, IMMT, 
LIMS1, MAP2K4, MAPK7, MELK, MSN, MTMR9, NAMPT, NBN, 
NCOA3, NKX2-5, NME1, NRAS, OGFOD1, PAK2, PCBP2, PDCD6IP, 
PDPK1, PHB (includes EG:5245), PIAS1, PLAGL1, PPARD, PPARG, 
PPP2CA, PPP2R2A, PPP3R1, PRKAA1, PRKAR1A, PRKCQ, PTPN13, 
RARA, RB1, RBM4B, RND3, RNF216, SEC61G, SET, SGPL1, SH3RF1, 
SKP2, STAT3, STAT5B, TCF12, TFAP2A, TNFRSF21, TOP2A, TRAF4, 
TRIAP1, TRIM28, TSC2, TTF1, TXN, UGCG, YBX1, YWHAE, YWHAZ 
Cell Death apoptosis apoptosis of 
lymphoma cell lines 
2.44E-03 ARHGDIA, BACH2 (includes EG:60468), BCL2L1, BMP2, CARD8, CAT, 
CDKN1A, CHEK2, EIF2AK2, MSN, PPARG, RARA, STAT3, UGCG, 
YWHAZ 
Cell Death apoptosis apoptosis of colon 
cancer cell lines 
2.72E-03 AHSA1, ATF3, ATMIN, BAK1, BAX, BCL2L1, CDKN1A, CHEK2, ETS1, 
EXOC2, FOXO3, GABPA, GADD45A, HDAC3, HIPK2, HMGA1, LIMS1, 
PPARD, PPARG, TRIAP1, YWHAE 
Cell Death apoptosis apoptosis of tumor 
cells 
3.90E-03 ATXN2, B4GALT5, BAX, BCL2L1, BRCA1, CAT, CDKN1A, CDKN1B, 
DNMT3B, HIF1A, NCOA3, PPP2CA, RARA, STAT3, TFAP2A, TXN 
Cell Death apoptosis apoptosis of 
unspecified cell lines 
6.03E-03 BAX, BCL2L1, PPP2CA 
Cell Death apoptosis apoptosis of cancer 8.24E-03 ATXN2, B4GALT5, BAX, BCL2L1, BRCA1, CAT, CDKN1A, CDKN1B, 
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cells DNMT3B, NCOA3, RARA, TFAP2A, TXN 
Cell Death apoptosis apoptosis of glioma 
cells 
9.81E-03 B4GALT5, BCL2L1, CAT, CDKN1B 
Cell Death apoptosis apoptosis of 
fibrosarcoma cell 
lines 
1.08E-02 BAX, BCL2L1, CDKN1A, LIMS1, PDPK1, TRIM28, YBX1 
Cell Death apoptosis apoptosis of prostate 
cancer cells 
1.93E-02 NCOA3, RARA 
Cell Death apoptosis apoptosis of 
carcinoma cell lines 
2.91E-02 BAK1, BAX, BCL2L1, CDKN1B, FOXO3, HMGA1, PRKAR1A, RB1, 
RBM4B, SKP2, TTF1, YBX1 
Cell Death apoptosis apoptosis of lung 
cancer cell lines 
3.03E-02 BAK1, BAX, BCL2L1, CDKN1A, CDKN1B, FOXO3, GADD45A, HIPK2, 
PPP2CA, RB1, SKP2, TRIAP1, TTF1, YBX1 
Cell Death apoptosis apoptosis of prostate 
cancer cell lines 
4.37E-02 ABCE1, ACACA, BAK1, BAX, BCL2L1, BMP2, BRCA1, CAT, FOXO3, 
GADD45A, HIF1A, NCOA3, RB1, STAT3 
Cell Death apoptosis apoptosis of 
sympathetic neuron 
4.47E-02 BAX, BCL2L1 
Cell Death survival survival of breast 
cancer cell lines 
7.52E-04 BCL2L1, BRCA1, CDKN1A, FKBP5, FOXM1, HMGA1, KIFC1, MED1, 
PTPN13, RB1CC1, STAT3, UGCG 
Cell Death survival survival of 
lymphoblastoid cell 
lines 
9.22E-03 BAX, CDKN1A, NBN 
Cell Death survival survival of tumor cell 
lines 
1.32E-02 AKAP13, BAX, BCL2L1, BRCA1, CAT, CDK6, CDKN1A, CDKN1B, 
CHEK2, DUSP22, DUSP5, FKBP5, FOXM1, GLUD1, HDAC3, HMGA1, 
HMOX1, KIFC1, LAMTOR3, MAP3K1, MED1, MTMR12, NBN, NRAS, 
NUAK1, PPAT, PPP1R8, PPP2CA, PRKAA1, PRKCQ, PTPN13, RB1CC1, 
STAT3, TRIM28, TXN, UGCG 
Cell Death survival survival of cell lines 4.38E-02 AKAP13, BAX, BCL2L1, BRCA1, CAT, CDK6, CDKN1A, CDKN1B, 
CHEK2, DUSP22, DUSP5, FKBP5, FOXM1, GLUD1, HDAC3, HMGA1, 
HMOX1, KIFC1, LAMTOR3, MAP3K1, MED1, MGST1, MTMR12, NBN, 
NRAS, NUAK1, PPAT, PPP1R8, PPP2CA, PRKAA1, PRKCQ, PTPN13, 
RB1CC1, STAT3, TRIM28, TXN, UGCG 
Cell Death survival survival of 
fibrosarcoma cell 
lines 
4.47E-02 NRAS, TRIM28 
Cell Death cell viability cell viability of 
lymphoma cell lines 
1.32E-02 CAT, HMOX1, RARA 
Cell Death cell viability cell viability of 
cancer cells 
1.93E-02 BMP2, HMOX1 
Cell Death colony 
survival 
colony survival of 
tumor cell lines 
1.56E-02 BCL2L1, CDKN1A, CHEK2, RB1CC1 
Cell Death colony 
survival 
colony survival of 
colon cancer cell 
lines 
1.93E-02 CDKN1A, CHEK2 
Cell Death necrosis necrosis of 
lymphoma cell lines 
3.10E-02 CAT, CDKN1A 
Cancer colon cancer colon cancer 2.31E-06 ACLY, AKAP13, ARHGDIA, ATF3, AURKA, BAK1, BAX, BMP2, CAT, 
CDCA5, CDK7, CDKN1A, CDKN1B, CDKN3, CEP55, CHMP1A, 
CNTNAP2, DUSP5, EIF2AK2, EXOSC9, FKBP1A, GNA11, HAND1, 
HDAC3, HUWE1, KIFC1, LRP8, MCM3, MCM5, MELK, MLF1IP, MSH3, 
MT1X, NKX2-5, NRAS, ODC1, PDPK1, POLD1, PPARG, PPPDE1, 
RUVBL1, SET, SRD5A1, STIP1, STXBP6, TMEM97, TPD52L1, TRIAP1, 
TUBA1A, TUBA1C, TUBG1, UBA1, YWHAE 
Cancer central 
nervous 
system 
tumor 
central nervous 
system tumor 
2.64E-04 B4GALT5, CDCA7L, CDK6, CDK7, CDKN1B, ELK1, FDFT1, FKBP1A, 
FNTB, GNA13, HDAC3, HIF1A, HIPK2, MARCKS, MLL3, POLD1, 
PPARG, PSMB5, RARA, RB1, SEC61G, SOX11, TAOK1, TOP2A, 
TUBA1A, TUBA1C, TUBG1, UBE2C, VAV3 
Cancer colon tumor colon tumor 2.70E-04 ACLY, ARHGDIA, AURKA, CAT, HAND1, HDAC3, HUWE1, LRP8, 
PDPK1, POLD1, PPARG, PPPDE1, STIP1, TMEM97, TUBG1, UBA1, 
YWHAE 
Cancer lung 
adenocarcino
ma 
lung adenocarcinoma 3.59E-04 ALDOA, CDCA5, DICER1, EIF2C1, FOXM1, FOXO3, GPI, LDHA, 
NRAS, POLR2A, SMEK1, SRM, UBE2C 
Cancer lung tumor lung tumor 3.71E-04 ALDOA, BAX, BCL2L1, CDCA5, CDKN1A, CDKN1B, CERS2, CERS5, 
DICER1, EIF2C1, FOXM1, FOXO3, GPI, HUWE1, LDHA, NRAS, PDPK1, 
POLR2A, PSMB5, RB1, SEC61G, SMEK1, SRM, TOP2A, TUBA1A, 
TUBA1C, TUBG1, UBE2C, YWHAE 
Cancer colon 
carcinoma 
colon carcinoma 4.29E-04 ACLY, ARHGDIA, CAT, HAND1, HDAC3, HUWE1, LRP8, PDPK1, 
POLD1, PPARG, PPPDE1, STIP1, TMEM97, TUBG1, UBA1, YWHAE 
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Cancer transformatio
n 
transformation of 
cells 
4.78E-04 AURKA, BCL2L1, BMP2, BRCA1, CAT, CDKN1A, CDKN1B, HMGA1, 
HYAL2, NCOA3, NRAS, ODC1, SEPT9, SKP2, STAT3, TBP 
Cancer tumor tumor 4.83E-04 ABI2, ACLY, ADARB1, ADORA2B, AGPAT2, AHCYL1, ALDOA, 
ANXA5, ARHGDIA, AURKA, B4GALT5, BAK1, BAX, BCL2L1, BMP2, 
BMPR1A, BMPR2, BRF2, C13orf15, C6orf211, CAT, CBL, CCDC28A, 
CDCA5, CDCA7L, CDK6, CDK7, CDKN1A, CDKN1B, CDKN3, CEBPG, 
CERS2, CERS5, CETN3, CHEK2, COBLL1, COPS5, CUX1, DAB2, 
DDHD2, DICER1, DKC1, DYRK2, EIF2AK1, EIF2AK2, EIF2C1, EIF4B, 
ELK1, EPS15, ETS1, FDFT1, FKBP1A, FNTB, FOXM1, FOXN2, FOXO3, 
FYN, FZD3, GADD45A, GLUD1, GNA13, GNAI2, GOLGA5, GPI, 
GPM6B, GSTO1, HAND1, HDAC3, HEY1, HIF1A, HIPK2, HMGA1, 
HPS3, HS3ST3A1, HUWE1, KIF1B, KRIT1, LDHA, LOC728622/SKP1, 
LRP8, LTN1, MARCKS, MBNL1, MCM5, MCM7, MGST1, MIPEP, 
MLF1IP, MLL3, MLX, MSH3, MSX2, MT1X, MTUS1, NCAPG (includes 
EG:64151), NCOA3, NCOA4, NETO2, NFYC, NKX2-5, NME1, NRAS, 
NUP50, ODC1, PA2G4, PDPK1, POLD1, POLR2A, PPARD, PPARG, 
PPP3CB, PPPDE1, PRCC, PRDX6, PRKAR1A, PRKCQ, PRPF8, PSMB5, 
RARA, RB1, RBM4B, RCAN2, ROCK2, RPE, SDHD, SEC22B, SEC31A, 
SEC61G, SKP2, SMARCB1, SMEK1, SOX11, SRD5A1, SRM, STAMBP, 
STAT3, STAT5B, STIP1, STK35, STX3, STXBP6, TAOK1, TFAP2A, 
TFDP2, TMEM97, TNPO3, TOM1L1, TOP2A, TRIM24, TRIM33, TSC1, 
TSC2, TUBA1A, TUBA1C, TUBG1, TXN, UBA1, UBE2C, UGCG, VAV3, 
WDR19, WNK1, YWHAE, YWHAZ, ZMYM2 
Cancer tuberous 
sclerosis 
tuberous sclerosis 7.02E-04 FKBP1A, HMOX1, TSC1, TSC2 
Cancer head and 
neck cancer 
head and neck cancer 7.71E-04 AURKA, B4GALT5, BRCA1, CDC42, CDCA7L, CDK6, CDKN1A, 
CDKN1B, ELK1, EPS15, ETS1, FDFT1, FKBP1A, FNTB, FYN, GNA13, 
GOLGA5, HDAC3, HIF1A, HIPK2, HUWE1, LDHA, LMO4, LRRC8D, 
MARCKS, MLL3, NCOA4, NRAS, PAK2, PPARD, PPARG, PRKAR1A, 
PSMB5, RB1, SEC61G, SET, SOX11, STAT5B, TAOK1, TMEM38B, 
TOP2A, TRIM24, TRIM33, TUBA1A, TUBA1C, TUBG1, UBE2C, VAV3 
Cancer sarcoma sarcoma 8.78E-04 CDK6, CDK7, CDKN1A, CHEK2, FDFT1, FKBP1A, FNTB, FOXM1, 
FYN, HDAC3, HIPK2, HMGA1, POLD1, PPARG, PSMB5, RARA, RB1, 
SMARCB1, STK35, TAOK1, TOP2A, TUBA1A, TUBA1C, TUBG1, 
UBE2C, WNK1 
Cancer soft tissue 
sarcoma 
soft tissue sarcoma 8.86E-04 CDK6, CDKN1A, FKBP1A, FNTB, FOXM1, FYN, HDAC3, HMGA1, 
PPARG, RB1, SMARCB1, TOP2A, TUBA1A, TUBA1C, TUBG1, UBE2C 
Cancer colorectal 
cancer 
colorectal cancer 9.26E-04 ACLY, AKAP13, ARHGDIA, ATF3, AURKA, BAK1, BAX, BEX4, BMP2, 
CAT, CDCA5, CDK7, CDKN1A, CDKN1B, CDKN3, CEP55, CHMP1A, 
CNTNAP2, COBLL1, DUSP5, EIF2AK1, EIF2AK2, ENAH, EPB41L3, 
ERRFI1, EXOSC9, FBXL2, FKBP1A, FNTB, GNA11, HAND1, HDAC3, 
HIF1A, HMOX1, HUWE1, KIFC1, LDHA, LRP8, MCM3, MCM5, MELK, 
MLF1IP, MSH3, MT1X, NCAPG (includes EG:64151), NFYC, NKX2-5, 
NRAS, NUAK1, ODC1, PDPK1, POLD1, PPARD, PPARG, PPP3CB, 
PPPDE1, PSMB5, RAB31, RUVBL1, SEPT9, SET, SRD5A1, SSBP3, 
STIP1, STK35, STXBP6, TAOK1, TFDP1, TMEFF2, TMEM97, TOP2A, 
TPD52L1, TRIAP1, TUBA1A, TUBA1C, TUBG1, UBA1, UBE2C, WARS, 
YWHAE, ZNF200 
Cancer brain cancer brain cancer 1.07E-03 B4GALT5, BAX, CDCA7L, CDK6, CDKN1B, ELK1, FKBP1A, FNTB, 
GNA13, HIF1A, HIPK2, MARCKS, MLL3, PPARG, PSMB5, RB1, 
SEC61G, SMARCB1, SOX11, TAOK1, TOP2A, TUBA1A, TUBA1C, 
TUBG1, UBE2C, VAV3 
Cancer digestive 
organ tumor 
digestive organ 
tumor 
1.20E-03 ACLY, ARHGDIA, AURKA, BAX, CAT, CCDC28A, CDKN1A, CDKN1B, 
CDKN3, COBLL1, COPS5, EIF2AK2, EPS15, FKBP1A, FNTB, FYN, 
GLUD1, GSTO1, HAND1, HDAC3, HIF1A, HUWE1, LRP8, MLF1IP, 
MLL3, MSH3, MSX2, MTUS1, NCAPG (includes EG:64151), PA2G4, 
PDPK1, POLD1, PPARG, PPP3CB, PPPDE1, PRCC, PRKCQ, PSMB5, 
RARA, RB1, SEC31A, STIP1, TFDP2, TMEM97, TOP2A, TUBA1A, 
TUBA1C, TUBG1, TXN, UBA1, UBE2C, YWHAE 
Cancer colorectal 
carcinoma 
colorectal carcinoma 1.32E-03 ACLY, ARHGDIA, CAT, COBLL1, FNTB, HAND1, HDAC3, HUWE1, 
LRP8, PDPK1, POLD1, PPARG, PPP3CB, PPPDE1, STIP1, TMEM97, 
TUBG1, UBA1, UBE2C, YWHAE 
Cancer tumorigenesi
s 
tumorigenesis 1.32E-03 ABI2, ACLY, ACTR3, ADARB1, ADORA2B, AGPAT2, AHCYL1, 
AKAP13, ALDOA, ANXA5, ARHGDIA, ASXL1, ATF3, ATP5C1, 
AURKA, B4GALT5, BAG4, BAK1, BARD1, BAX, BCL2L1, BEX4, 
BMP2, BMPR1A, BMPR2, BRCA1, BRF2, BTRC, C13orf15, C18orf8, 
C6orf211, CAT, CBL, CCDC28A, CDC42, CDCA5, CDCA7L, CDK6, 
CDK7, CDKN1A, CDKN1B, CDKN3, CEBPG, CEP55, CERS2, CERS5, 
CETN3, CHEK2, CHMP1A, CNTNAP2, COBLL1, COPS5, CSNK1E, 
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CUX1, DAB2, DDHD2, DIAPH2, DICER1, DKC1, DOCK11, DUSP5, 
DYRK2, EI24, EIF2AK1, EIF2AK2, EIF2C1, EIF4B, EIF5, ELK1, 
ELOVL6, ENAH, EPB41L3, EPS15, ERRFI1, ETS1, EXOSC9, FBXL2, 
FDFT1, FGFR1OP2, FHOD3, FKBP1A, FNTB, FOXM1, FOXN2, FOXO3, 
FYN, FZD3, G3BP2, GADD45A, GLUD1, GNA11, GNA13, GNAI2, 
GOLGA5, GOT1, GPI, GPM6B, GSTO1, GUCY1A3, HAND1, HDAC3, 
HEY1, HIF1A, HIPK2, HMGA1, HMOX1, HPS3, HS3ST3A1, HUWE1, 
KDELR2, KIF1B, KIFC1, KRIT1, LDHA, LMO4, LOC728622/SKP1, LPP, 
LRP8, LRRC8D, LTN1, MAL, MAP3K1, MAPK7, MARCKS, MBNL1, 
MCM3, MCM5, MCM7, MELK, MGST1, MIPEP, MLF1IP, MLL3, MLX, 
MSH3, MSX2, MT1X, MTUS1, NAMPT, NBN, NCAPG (includes 
EG:64151), NCOA3, NCOA4, NETO2, NFYC, NKX2-5, NME1, NRAS, 
NSD1, NUAK1, NUP214, NUP50, ODC1, PA2G4, PAK2, PDCD6IP, 
PDPK1, PHB (includes EG:5245), PLAGL2, POLD1, POLR2A, PPARD, 
PPARG, PPAT, PPP2CA, PPP3CB, PPP3R1, PPPDE1, PRCC, PRDX6, 
PRKAR1A, PRKCQ, PRPF8, PSD3, PSMB5, PTP4A1, PTPN1, RAB31, 
RARA, RB1, RB1CC1, RBBP8, RBM15, RBM4B, RCAN2, RND3, 
ROCK2, RPE, RUVBL1, SDHD, SEC22B, SEC31A, SEC61G, SEPT9, SET, 
SKP2, SLC35C1, SMARCB1, SMEK1, SOX11, SRD5A1, SRM, SSBP3, 
STAMBP, STAT3, STAT5B, STIP1, STK35, STX3, STXBP6, SUZ12, 
TAOK1, TFAP2A, TFDP1, TFDP2, TGIF2, TMEFF2, TMEM38B, 
TMEM97, TNPO3, TOM1L1, TOP2A, TPD52L1, TRIAP1, TRIM24, 
TRIM33, TSC1, TSC2, TUBA1A, TUBA1C, TUBG1, TXN, UBA1, 
UBE2C, UGCG, VAV3, WARS, WDR19, WNK1, YEATS2, YWHAE, 
YWHAZ, ZBTB4, ZBTB40, ZFHX3, ZMYM2, ZNF200 
Cancer colorectal 
tumor 
colorectal tumor 1.40E-03 ACLY, ARHGDIA, AURKA, CAT, COBLL1, FNTB, HAND1, HDAC3, 
HUWE1, LRP8, PDPK1, POLD1, PPARG, PPP3CB, PPPDE1, STIP1, 
TMEM97, TUBA1A, TUBA1C, TUBG1, UBA1, UBE2C, YWHAE 
Cancer neuroepitheli
al tumor 
neuroepithelial tumor 1.53E-03 B4GALT5, CDK6, CDK7, CDKN1B, ELK1, FKBP1A, GNA13, HIF1A, 
HIPK2, MARCKS, MLL3, PPARG, RARA, RB1, SEC61G, SOX11, 
TAOK1, TOP2A, UBE2C, VAV3 
Cancer head and 
neck tumor 
head and neck tumor 1.70E-03 AURKA, B4GALT5, CDCA7L, CDK6, CDKN1B, ELK1, EPS15, ETS1, 
FKBP1A, FNTB, GNA13, GOLGA5, HDAC3, HIF1A, HIPK2, HUWE1, 
LDHA, MARCKS, MLL3, NCOA4, NRAS, PPARD, PPARG, PRKAR1A, 
PSMB5, RB1, SEC61G, SOX11, STAT5B, TAOK1, TOP2A, TRIM24, 
TRIM33, TUBA1A, TUBA1C, TUBG1, UBE2C, VAV3 
Cancer acute 
myeloid 
leukemia 
acute myeloid 
leukemia 
1.86E-03 ASXL1, CBL, FKBP1A, FNTB, FYN, HDAC3, LPP, NRAS, NSD1, 
NUP214, PDPK1, PLAGL2, POLD1, PPAT, PSMB5, RARA, RBM15, 
STAT3, TOP2A 
Cancer myosarcoma myosarcoma 2.01E-03 CDKN1A, FKBP1A, FOXM1, FYN, HMGA1, SMARCB1, TOP2A, 
TUBA1A, TUBA1C, TUBG1, UBE2C 
Cancer brain tumor brain tumor 2.07E-03 B4GALT5, CDCA7L, CDK6, CDKN1B, ELK1, FKBP1A, FNTB, GNA13, 
HIF1A, HIPK2, MARCKS, MLL3, PPARG, RB1, SEC61G, SOX11, 
TAOK1, TOP2A, TUBA1A, TUBA1C, TUBG1, UBE2C, VAV3 
Cancer lung 
carcinoma 
lung carcinoma 2.38E-03 ALDOA, CDCA5, DICER1, EIF2C1, FOXM1, FOXO3, GPI, HUWE1, 
LDHA, NRAS, POLR2A, RB1, SEC61G, SMEK1, SRM, TOP2A, 
TUBA1A, TUBA1C, TUBG1, UBE2C, YWHAE 
Cancer gastrointestin
al tumor 
gastrointestinal tumor 2.44E-03 BAX, CCDC28A, COBLL1, FKBP1A, FYN, HDAC3, MSH3, PA2G4, 
PRCC, PRKCQ, SEC31A, TFDP2, TMEM97, TOP2A, TUBA1A, TUBA1C, 
TUBG1, UBE2C 
Cancer lymphocytic 
leukemia 
lymphocytic 
leukemia 
2.51E-03 BAK1, BAX, BCL2L1, CDK6, CDK7, CDKN1A, FNTB, FOXO3, FYN, 
HDAC3, NRAS, POLD1, PPAT, PPP3CB, PPP3R1, PSMB5, RARA, RB1, 
STAT3, TOP2A, TUBA1A, TUBA1C, TUBG1 
Cancer stomach 
tumor 
stomach tumor 2.66E-03 BAX, CCDC28A, COBLL1, FKBP1A, MSH3, PA2G4, PRCC, SEC31A, 
TFDP2, TMEM97, TOP2A, TUBA1A, TUBA1C, TUBG1, UBE2C 
Cancer neoplasia neoplasia 2.70E-03 ABI2, ACLY, ACTR3, ADARB1, ADORA2B, AGPAT2, AHCYL1, 
AKAP13, ALDOA, ANXA5, ARHGDIA, ASXL1, ATF3, ATP5C1, 
AURKA, B4GALT5, BAG4, BAK1, BARD1, BAX, BCL2L1, BEX4, 
BMP2, BMPR1A, BMPR2, BRCA1, BRF2, BTRC, C13orf15, C18orf8, 
C6orf211, CAT, CBL, CCDC28A, CDC42, CDCA5, CDCA7L, CDK6, 
CDK7, CDKN1A, CDKN1B, CDKN3, CEP55, CERS2, CERS5, CETN3, 
CHEK2, CHMP1A, CNTNAP2, COBLL1, COPS5, CUX1, DAB2, DDHD2, 
DIAPH2, DICER1, DOCK11, DUSP5, DYRK2, EI24, EIF2AK1, EIF2AK2, 
EIF2C1, EIF4B, EIF5, ELK1, ELOVL6, ENAH, EPB41L3, EPS15, ERRFI1, 
ETS1, EXOSC9, FBXL2, FDFT1, FGFR1OP2, FHOD3, FKBP1A, FNTB, 
FOXM1, FOXN2, FOXO3, FYN, FZD3, G3BP2, GADD45A, GLUD1, 
GNA11, GNA13, GNAI2, GOLGA5, GOT1, GPI, GSTO1, GUCY1A3, 
HAND1, HDAC3, HEY1, HIF1A, HIPK2, HMGA1, HMOX1, HPS3, 
HS3ST3A1, HUWE1, KIF1B, KIFC1, LDHA, LMO4, LOC728622/SKP1, 
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LPP, LRP8, LRRC8D, LTN1, MAL, MAP3K1, MAPK7, MARCKS, 
MBNL1, MCM3, MCM5, MCM7, MELK, MGST1, MIPEP, MLF1IP, 
MLL3, MSH3, MSX2, MT1X, NAMPT, NBN, NCAPG (includes 
EG:64151), NCOA3, NCOA4, NFYC, NKX2-5, NME1, NRAS, NSD1, 
NUAK1, NUP214, NUP50, ODC1, PA2G4, PAK2, PDPK1, PHB (includes 
EG:5245), PLAGL2, POLD1, POLR2A, PPARD, PPARG, PPAT, PPP2CA, 
PPP3CB, PPP3R1, PPPDE1, PRCC, PRKAR1A, PRKCQ, PRPF8, PSD3, 
PSMB5, PTP4A1, PTPN1, RAB31, RARA, RB1, RB1CC1, RBBP8, 
RBM15, RBM4B, RCAN2, RND3, ROCK2, RPE, RUVBL1, SDHD, 
SEC22B, SEC31A, SEC61G, SEPT9, SET, SKP2, SLC35C1, SMARCB1, 
SMEK1, SOX11, SRD5A1, SRM, SSBP3, STAMBP, STAT3, STAT5B, 
STIP1, STK35, STX3, STXBP6, SUZ12, TAOK1, TFAP2A, TFDP1, 
TFDP2, TGIF2, TMEFF2, TMEM38B, TMEM97, TNPO3, TOM1L1, 
TOP2A, TPD52L1, TRIAP1, TRIM24, TRIM33, TSC1, TSC2, TUBA1A, 
TUBA1C, TUBG1, TXN, UBA1, UBE2C, UGCG, VAV3, WARS, WDR19, 
WNK1, YEATS2, YWHAE, YWHAZ, ZBTB4, ZBTB40, ZFHX3, ZMYM2, 
ZNF200 
Cancer endocrine 
gland tumor 
endocrine gland 
tumor 
3.26E-03 BMP2, BMPR1A, BMPR2, CDKN1A, COPS5, ETS1, FKBP1A, GNAI2, 
GOLGA5, HIF1A, HUWE1, MLL3, MSX2, NCOA4, NRAS, PPARD, 
PPARG, PRKAR1A, SDHD, TOP2A, TRIM24, TRIM33 
Cancer adenocarcino
ma 
adenocarcinoma 3.33E-03 AGPAT2, ALDOA, C13orf15, CDCA5, DAB2, DICER1, EIF2C1, ETS1, 
FDFT1, FKBP1A, FOXM1, FOXN2, FOXO3, FZD3, GOLGA5, GPI, 
HIF1A, HPS3, LDHA, LOC728622/SKP1, LRP8, NCOA4, NRAS, 
POLR2A, PPARG, PPP3CB, PRKAR1A, PSMB5, SMEK1, SRM, TRIM24, 
TRIM33, TUBA1A, TUBA1C, TUBG1, UBE2C, VAV3 
Cancer urinary tract 
tumor 
urinary tract tumor 4.56E-03 AGPAT2, AURKA, FKBP1A, HIF1A, NRAS, RB1, TOP2A, TSC1, 
TUBA1A, TUBA1C, TUBG1, UBE2C 
Cancer mantle cell 
lymphoma 
mantle cell 
lymphoma 
4.56E-03 CDK6, CDK7, FKBP1A, FNTB, POLD1, PSMB5, TOP2A 
Cancer cancer cancer 4.93E-03 ABI2, ACLY, ACTR3, ADARB1, ADORA2B, AGPAT2, AHCYL1, 
AKAP13, ALDOA, ANXA5, ARHGDIA, ASXL1, ATF3, ATP5C1, 
AURKA, B4GALT5, BAG4, BAK1, BARD1, BAX, BCL2L1, BEX4, 
BMP2, BMPR1A, BMPR2, BRCA1, BRF2, BTRC, C13orf15, C18orf8, 
C6orf211, CAT, CBL, CCDC28A, CDC42, CDCA5, CDCA7L, CDK6, 
CDK7, CDKN1A, CDKN1B, CDKN3, CEP55, CERS2, CERS5, CETN3, 
CHEK2, CHMP1A, CNTNAP2, COBLL1, COPS5, CUX1, DAB2, DDHD2, 
DICER1, DOCK11, DUSP5, DYRK2, EI24, EIF2AK1, EIF2AK2, EIF2C1, 
EIF4B, EIF5, ELK1, ELOVL6, ENAH, EPB41L3, EPS15, ERRFI1, ETS1, 
EXOSC9, FBXL2, FDFT1, FHOD3, FKBP1A, FNTB, FOXM1, FOXN2, 
FOXO3, FYN, FZD3, G3BP2, GADD45A, GLUD1, GNA11, GNA13, 
GNAI2, GOLGA5, GOT1, GPI, GSTO1, GUCY1A3, HAND1, HDAC3, 
HEY1, HIF1A, HIPK2, HMGA1, HMOX1, HPS3, HS3ST3A1, HUWE1, 
KIF1B, KIFC1, LDHA, LMO4, LOC728622/SKP1, LPP, LRP8, LRRC8D, 
LTN1, MAL, MAP3K1, MAPK7, MARCKS, MBNL1, MCM3, MCM5, 
MCM7, MELK, MGST1, MIPEP, MLF1IP, MLL3, MSH3, MSX2, MT1X, 
NAMPT, NBN, NCAPG (includes EG:64151), NCOA3, NCOA4, NFYC, 
NKX2-5, NME1, NRAS, NSD1, NUAK1, NUP214, NUP50, ODC1, PA2G4, 
PAK2, PDPK1, PHB (includes EG:5245), PLAGL2, POLD1, POLR2A, 
PPARD, PPARG, PPAT, PPP2CA, PPP3CB, PPP3R1, PPPDE1, PRCC, 
PRKAR1A, PRKCQ, PRPF8, PSD3, PSMB5, PTP4A1, PTPN1, RAB31, 
RARA, RB1, RB1CC1, RBM15, RBM4B, RCAN2, RND3, ROCK2, RPE, 
RUVBL1, SEC22B, SEC31A, SEC61G, SEPT9, SET, SKP2, SLC35C1, 
SMARCB1, SMEK1, SOX11, SRD5A1, SRM, SSBP3, STAMBP, STAT3, 
STAT5B, STIP1, STK35, STX3, STXBP6, SUZ12, TAOK1, TFAP2A, 
TFDP1, TFDP2, TGIF2, TMEFF2, TMEM38B, TMEM97, TNPO3, 
TOM1L1, TOP2A, TPD52L1, TRIAP1, TRIM24, TRIM33, TSC1, 
TUBA1A, TUBA1C, TUBG1, TXN, UBA1, UBE2C, UGCG, VAV3, 
WARS, WDR19, WNK1, YEATS2, YWHAE, YWHAZ, ZBTB4, ZBTB40, 
ZFHX3, ZMYM2, ZNF200 
Cancer retinoblasto
ma 
retinoblastoma 5.26E-03 CDK6, CDK7, RARA, RB1, TOP2A 
Cancer infection infection of tumor 
cell lines 
5.36E-03 AP1B1, AP2M1, ARHGAP32, ASXL2, BRCA1, CBL, CDC42, CLDND1, 
CRIPAK, CRTC2, DDX50, DHX33, DNAJB1, EPS15, ERCC3, FBXW11, 
GABPB1, GOLPH3, HUWE1, INTS7, ISG20L2, LRRC8D, MED20, 
MPHOSPH6, NRBP1, NUP85 (includes EG:287830), PIP5K1A, PPP2R2A, 
PRKAA1, RAB5A, RAB6A, RB1CC1, RIMS4, RNF216, RNF26, SEC61G, 
STIP1, STX5, SYNJ1, TAOK1, TFDP2, TNPO3, TRIM5, TRMT5, 
UBE2E1, WASF2, WNK1, ZNRD1 
Cancer infection infection of cervical 2.26E-02 AP2M1, ARHGAP32, ASXL2, BRCA1, CDC42, CLDND1, CRIPAK, 
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cancer cell lines CRTC2, DDX50, DHX33, DNAJB1, ERCC3, FBXW11, GABPB1, 
GOLPH3, HUWE1, INTS7, ISG20L2, LRRC8D, MED20, MPHOSPH6, 
NRBP1, NUP85 (includes EG:287830), PPP2R2A, PRKAA1, RAB5A, 
RAB6A, RB1CC1, RIMS4, RNF26, SEC61G, STIP1, STX5, TAOK1, 
TFDP2, TNPO3, TRMT5, UBE2E1, WNK1, ZNRD1 
Cancer non-hodgkin 
lymphoma 
non-hodgkin 
lymphoma 
5.63E-03 CDK6, CDK7, EIF2AK1, FKBP1A, FNTB, FYN, GADD45A, HDAC3, 
ODC1, POLD1, PPARG, PSMB5, RARA, TAOK1, TOP2A, TUBA1A, 
TUBA1C, TUBG1, YWHAZ 
Cancer disease disease of tumor cell 
lines 
5.65E-03 AP1B1, AP2M1, ARHGAP32, ASXL2, BRCA1, CBL, CDC42, CDKN1A, 
CLDND1, CRIPAK, CRTC2, DDX50, DHX33, DNAJB1, EPS15, ERCC3, 
ETS1, FBXW11, FYN, GABPB1, GOLPH3, HMOX1, HUWE1, INTS7, 
ISG20L2, LRRC8D, MED20, MPHOSPH6, NME1, NRBP1, NUP85 
(includes EG:287830), PDCD6IP, PIP5K1A, PPP2R2A, PRKAA1, 
PRKAR1A, RAB5A, RAB6A, RB1CC1, RIMS4, RNF216, RNF26, 
SEC61G, STIP1, STX5, SYNJ1, TAOK1, TFDP2, TNPO3, TRIM5, TRMT5, 
UBE2E1, WASF2, WNK1, ZNRD1 
Cancer disease disease of cervical 
cancer cell lines 
1.93E-02 AP2M1, ARHGAP32, ASXL2, BRCA1, CDC42, CLDND1, CRIPAK, 
CRTC2, DDX50, DHX33, DNAJB1, ERCC3, FBXW11, GABPB1, 
GOLPH3, HUWE1, INTS7, ISG20L2, LRRC8D, MED20, MPHOSPH6, 
NRBP1, NUP85 (includes EG:287830), PDCD6IP, PPP2R2A, PRKAA1, 
RAB5A, RAB6A, RB1CC1, RIMS4, RNF26, SEC61G, STIP1, STX5, 
TAOK1, TFDP2, TNPO3, TRMT5, UBE2E1, WNK1, ZNRD1 
Cancer disease disease of hepatoma 
cell lines 
4.23E-02 AP1B1, CBL, EPS15, PIP5K1A, RAB5A, SYNJ1, WASF2 
Cancer bladder 
tumor 
bladder tumor 5.83E-03 AURKA, RB1, TOP2A, TSC1, TUBA1A, TUBA1C, TUBG1, UBE2C 
Cancer gastric 
carcinoma 
gastric carcinoma 5.97E-03 BAX, CCDC28A, COBLL1, MSH3, PA2G4, PRCC, SEC31A, TFDP2, 
TMEM97, TOP2A, UBE2C 
Cancer leukemia leukemia 6.33E-03 ADORA2B, ASXL1, BAK1, BAX, BCL2L1, CBL, CDK6, CDK7, 
CDKN1A, EIF2AK2, FKBP1A, FNTB, FOXO3, FYN, HDAC3, LPP, 
NRAS, NSD1, NUP214, PDPK1, PLAGL2, POLD1, PPAT, PPP3CB, 
PPP3R1, PSMB5, RARA, RB1, RBM15, STAT3, TOP2A, TUBA1A, 
TUBA1C, TUBG1 
Cancer glioma glioma 6.53E-03 B4GALT5, CDK6, CDKN1B, ELK1, FKBP1A, GNA13, HIPK2, MARCKS, 
MLL3, PPARG, RB1, SEC61G, SOX11, TAOK1, TOP2A, UBE2C, VAV3 
Cancer early-onset 
breast cancer 
early-onset breast 
cancer 
6.58E-03 BARD1, BRCA1, CHEK2, EI24, RB1CC1 
Cancer lung cancer lung cancer 7.00E-03 ALDOA, AURKA, BAX, BCL2L1, BTRC, CDCA5, CDK6, CDKN1A, 
CDKN1B, CERS2, CERS5, CHEK2, DICER1, EIF2AK1, EIF2C1, FDFT1, 
FKBP1A, FNTB, FOXM1, FOXO3, FYN, GPI, GUCY1A3, HDAC3, 
HIF1A, HIPK2, HUWE1, LDHA, NRAS, PDPK1, POLR2A, PPARG, 
PSMB5, RARA, RB1, SEC61G, SMEK1, SRM, STK35, TAOK1, TOP2A, 
TUBA1A, TUBA1C, TUBG1, UBE2C, WNK1, YWHAE 
Cancer benign tumor benign tumor 7.07E-03 ABI2, ADARB1, AHCYL1, ALDOA, ANXA5, CBL, CDKN1B, CEBPG, 
CETN3, DKC1, DYRK2, FDFT1, FKBP1A, FNTB, FYN, GPM6B, 
HUWE1, KIF1B, KRIT1, LTN1, MGST1, MLX, NETO2, NUP50, PPARD, 
PPARG, PPP3CB, PRDX6, PRPF8, RCAN2, RPE, SDHD, SEC22B, 
STAMBP, STX3, STXBP6, TNPO3, TOP2A, TSC2, TUBA1A, TUBA1C, 
TUBG1, UGCG 
Cancer lymphoma lymphoma 7.20E-03 CDK6, CDK7, CDKN1A, CDKN1B, EIF2AK1, FKBP1A, FNTB, FYN, 
GADD45A, HDAC3, ODC1, POLD1, PPARG, PSMB5, RARA, TAOK1, 
TOP2A, TUBA1A, TUBA1C, TUBG1, YWHAZ 
Cancer heart and 
pleura tumor 
heart and pleura 
tumor 
7.21E-03 FYN, PRKAR1A, RARA, TOP2A, TUBA1A, TUBA1C, TUBG1 
Cancer diffuse B-
cell 
lymphoma 
diffuse B-cell 
lymphoma 
7.42E-03 CDK6, CDK7, FKBP1A, FNTB, FYN, POLD1, PSMB5, TOP2A, YWHAZ 
Cancer hematologic 
cancer 
hematologic cancer 8.87E-03 ADORA2B, ASXL1, BAK1, BAX, BCL2L1, CBL, CDK6, CDK7, 
CDKN1A, CHEK2, EIF2AK2, FDFT1, FKBP1A, FNTB, FOXO3, FYN, 
HDAC3, LPP, NRAS, NSD1, NUP214, PDPK1, PLAGL2, POLD1, PPAT, 
PPP3CB, PPP3R1, PSMB5, RARA, RB1, RBM15, STAT3, TOP2A, 
TUBA1A, TUBA1C, TUBG1 
Cancer malignant 
tumor 
malignant tumor 9.22E-03 ACLY, ADORA2B, AGPAT2, ALDOA, ARHGDIA, AURKA, BAK1, 
BAX, BMP2, BMPR1A, BMPR2, BRF2, C13orf15, C6orf211, CAT, 
CCDC28A, CDCA5, CDCA7L, CDK6, CDK7, CDKN1A, CDKN1B, 
CDKN3, CHEK2, COBLL1, COPS5, CUX1, DAB2, DDHD2, DICER1, 
EIF2AK1, EIF2AK2, EIF2C1, EIF4B, EPS15, ETS1, FDFT1, FKBP1A, 
FNTB, FOXM1, FOXN2, FOXO3, FYN, FZD3, GADD45A, GLUD1, 
GOLGA5, GPI, GSTO1, HAND1, HDAC3, HEY1, HIF1A, HIPK2, 
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HMGA1, HPS3, HS3ST3A1, HUWE1, KIF1B, LDHA, LOC728622/SKP1, 
LRP8, MBNL1, MCM5, MCM7, MIPEP, MLF1IP, MLL3, MSH3, MSX2, 
MT1X, NCAPG (includes EG:64151), NCOA3, NCOA4, NFYC, NKX2-5, 
NME1, NRAS, ODC1, PA2G4, PDPK1, POLD1, POLR2A, PPARD, 
PPARG, PPP3CB, PPPDE1, PRCC, PRKAR1A, PSMB5, RARA, RB1, 
RBM4B, RCAN2, ROCK2, SEC31A, SEC61G, SKP2, SMARCB1, SMEK1, 
SRD5A1, SRM, STAT3, STAT5B, STIP1, STK35, TAOK1, TFAP2A, 
TFDP2, TMEM97, TOP2A, TRIM24, TRIM33, TUBA1A, TUBA1C, 
TUBG1, TXN, UBA1, UBE2C, VAV3, WDR19, WNK1, YWHAE, 
YWHAZ, ZMYM2 
Cancer myeloprolife
rative 
disorder 
myeloproliferative 
disorder 
9.53E-03 ASXL1, BMPR2, CBL, FDFT1, FKBP1A, FNTB, FOXO3, FYN, HDAC3, 
LPP, NRAS, NSD1, NUP214, PDPK1, PLAGL2, POLD1, PPAT, PSMB5, 
RARA, RBM15, STAT3, TOP2A 
Cancer hereditary 
gingival 
fibromatosis 
hereditary gingival 
fibromatosis 
9.81E-03 RB1, RBBP8, TFDP1, TFDP2 
Cancer angiolipoma angiolipoma 1.01E-02 FKBP1A, TSC2 
Cancer epithelial 
tumor 
epithelial tumor 1.01E-02 AGPAT2, RB1 
Cancer extra-adrenal 
paraganglio
ma 
extra-adrenal 
paraganglioma 
1.01E-02 FKBP1A, SDHD 
Cancer liver tumor liver tumor 1.10E-02 AURKA, CDKN1A, CDKN1B, CDKN3, EIF2AK2, FKBP1A, GLUD1, 
GSTO1, HUWE1, MLF1IP, NCAPG (includes EG:64151), PDPK1, POLD1, 
RARA, TOP2A, TUBA1A, TUBA1C, TUBG1, TXN, UBE2C 
Cancer gastric 
cancer 
gastric cancer 1.15E-02 BAK1, BAX, BRCA1, CCDC28A, CDKN1A, COBLL1, FKBP1A, FOXM1, 
HDAC3, MAL, MSH3, NAMPT, PA2G4, PHB (includes EG:5245), PRCC, 
PSMB5, SEC31A, TFDP2, TMEM97, TOP2A, TUBA1A, TUBA1C, 
TUBG1, UBE2C 
Cancer hepatocellula
r carcinoma 
hepatocellular 
carcinoma 
1.21E-02 AURKA, CDKN1A, CDKN1B, CDKN3, EIF2AK2, FKBP1A, GLUD1, 
GSTO1, HUWE1, MLF1IP, NCAPG (includes EG:64151), POLD1, RARA, 
TOP2A, TUBA1A, TUBA1C, TUBG1, TXN, UBE2C 
Cancer carcinoma carcinoma 1.46E-02 ACLY, ADORA2B, AGPAT2, ALDOA, ARHGDIA, AURKA, BAK1, 
BAX, BMP2, BMPR1A, BMPR2, BRF2, C13orf15, C6orf211, CAT, 
CCDC28A, CDCA5, CDKN1A, CDKN1B, CDKN3, COBLL1, COPS5, 
CUX1, DAB2, DDHD2, DICER1, EIF2AK2, EIF2C1, EIF4B, EPS15, ETS1, 
FDFT1, FKBP1A, FNTB, FOXM1, FOXN2, FOXO3, FYN, FZD3, GLUD1, 
GOLGA5, GPI, GSTO1, HAND1, HDAC3, HIF1A, HPS3, HS3ST3A1, 
HUWE1, LDHA, LOC728622/SKP1, LRP8, MBNL1, MCM5, MCM7, 
MIPEP, MLF1IP, MLL3, MSH3, MSX2, MT1X, NCAPG (includes 
EG:64151), NCOA4, NFYC, NKX2-5, NRAS, ODC1, PA2G4, PDPK1, 
POLD1, POLR2A, PPARD, PPARG, PPP3CB, PPPDE1, PRCC, PRKAR1A, 
PSMB5, RARA, RB1, RBM4B, RCAN2, ROCK2, SEC31A, SEC61G, 
SMEK1, SRD5A1, SRM, STAT5B, STIP1, TFDP2, TMEM97, TOP2A, 
TRIM24, TRIM33, TUBA1A, TUBA1C, TUBG1, TXN, UBA1, UBE2C, 
VAV3, WDR19, YWHAE, ZMYM2 
Cancer bladder 
cancer 
bladder cancer 1.65E-02 ADORA2B, AURKA, BRCA1, CDKN1A, FKBP1A, FNTB, HDAC3, 
ODC1, PSMB5, RARA, RB1, STAT3, TOP2A, TSC1, TUBA1A, TUBA1C, 
TUBG1, UBE2C 
Cancer small-cell 
carcinoma 
small-cell carcinoma 2.03E-02 CDCA5, RB1, TUBA1A, TUBA1C, TUBG1, YWHAE 
Cancer thyroid gland 
tumor 
thyroid gland tumor 2.43E-02 ETS1, GOLGA5, HUWE1, NCOA4, NRAS, PPARD, PPARG, PRKAR1A, 
TOP2A, TRIM24, TRIM33 
Cancer testicular 
cancer 
testicular cancer 2.55E-02 FKBP1A, GNAI2, LDHA, RARA, RB1, TOP2A, TUBA1A, TUBA1C, 
TUBG1 
Cancer rhabdomyosa
rcoma 
rhabdomyosarcoma 2.58E-02 FKBP1A, FYN, SMARCB1, TUBA1A, TUBA1C, TUBG1 
Cancer large-cell 
lymphoma 
large-cell lymphoma 2.68E-02 FKBP1A, FYN, POLD1, TUBA1A, TUBA1C, TUBG1, YWHAZ 
Cancer thyroid 
cancer 
thyroid cancer 2.89E-02 CDKN1B, ETS1, FKBP1A, GOLGA5, HUWE1, MCM7, NCOA4, NRAS, 
PPARD, PPARG, PRKAR1A, STAT3, TOP2A, TRIM24, TRIM33 
Cancer type M3 
acute 
myeloid 
leukemia 
type M3 acute 
myeloid leukemia 
3.03E-02 POLD1, RARA, TOP2A 
Cancer Kaposi's 
sarcoma 
Kaposi's sarcoma 3.38E-02 RARA, TOP2A, TUBA1A, TUBA1C, TUBG1 
Cancer B-cell 
leukemia 
B-cell leukemia 3.38E-02 BAK1, BAX, BCL2L1, CDK6, CDK7, CDKN1A, FYN, HDAC3, NRAS, 
POLD1, PSMB5, RARA, STAT3, TOP2A 
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Cancer benign nerve 
tumor 
benign nerve tumor 3.88E-02 CDKN1B, FKBP1A, FNTB, KIF1B, KRIT1, SDHD, TOP2A 
Cancer medulloblast
oma 
medulloblastoma 3.95E-02 CDCA7L, CDK6, TOP2A, TUBA1A, TUBA1C, TUBG1 
Cancer malignant 
cutaneous 
melanoma 
malignant cutaneous 
melanoma 
4.33E-02 CDK6, CDK7, FKBP1A, FNTB, FYN, HDAC3, PSMB5, RARA, TUBA1A, 
TUBA1C, TUBG1 
Cancer chronic B-
cell leukemia 
chronic B-cell 
leukemia 
4.39E-02 BAK1, BAX, BCL2L1, CDK6, CDK7, CDKN1A, FYN, HDAC3, POLD1, 
PSMB5, RARA, STAT3, TOP2A 
Gastrointesti
nal Disease 
colon cancer colon cancer 2.31E-06 ACLY, AKAP13, ARHGDIA, ATF3, AURKA, BAK1, BAX, BMP2, CAT, 
CDCA5, CDK7, CDKN1A, CDKN1B, CDKN3, CEP55, CHMP1A, 
CNTNAP2, DUSP5, EIF2AK2, EXOSC9, FKBP1A, GNA11, HAND1, 
HDAC3, HUWE1, KIFC1, LRP8, MCM3, MCM5, MELK, MLF1IP, MSH3, 
MT1X, NKX2-5, NRAS, ODC1, PDPK1, POLD1, PPARG, PPPDE1, 
RUVBL1, SET, SRD5A1, STIP1, STXBP6, TMEM97, TPD52L1, TRIAP1, 
TUBA1A, TUBA1C, TUBG1, UBA1, YWHAE 
Gastrointesti
nal Disease 
colon tumor colon tumor 2.70E-04 ACLY, ARHGDIA, AURKA, CAT, HAND1, HDAC3, HUWE1, LRP8, 
PDPK1, POLD1, PPARG, PPPDE1, STIP1, TMEM97, TUBG1, UBA1, 
YWHAE 
Gastrointesti
nal Disease 
colon 
carcinoma 
colon carcinoma 4.29E-04 ACLY, ARHGDIA, CAT, HAND1, HDAC3, HUWE1, LRP8, PDPK1, 
POLD1, PPARG, PPPDE1, STIP1, TMEM97, TUBG1, UBA1, YWHAE 
Gastrointesti
nal Disease 
colorectal 
cancer 
colorectal cancer 9.26E-04 ACLY, AKAP13, ARHGDIA, ATF3, AURKA, BAK1, BAX, BEX4, BMP2, 
CAT, CDCA5, CDK7, CDKN1A, CDKN1B, CDKN3, CEP55, CHMP1A, 
CNTNAP2, COBLL1, DUSP5, EIF2AK1, EIF2AK2, ENAH, EPB41L3, 
ERRFI1, EXOSC9, FBXL2, FKBP1A, FNTB, GNA11, HAND1, HDAC3, 
HIF1A, HMOX1, HUWE1, KIFC1, LDHA, LRP8, MCM3, MCM5, MELK, 
MLF1IP, MSH3, MT1X, NCAPG (includes EG:64151), NFYC, NKX2-5, 
NRAS, NUAK1, ODC1, PDPK1, POLD1, PPARD, PPARG, PPP3CB, 
PPPDE1, PSMB5, RAB31, RUVBL1, SEPT9, SET, SRD5A1, SSBP3, 
STIP1, STK35, STXBP6, TAOK1, TFDP1, TMEFF2, TMEM97, TOP2A, 
TPD52L1, TRIAP1, TUBA1A, TUBA1C, TUBG1, UBA1, UBE2C, WARS, 
YWHAE, ZNF200 
Gastrointesti
nal Disease 
digestive 
organ tumor 
digestive organ 
tumor 
1.20E-03 ACLY, ARHGDIA, AURKA, BAX, CAT, CCDC28A, CDKN1A, CDKN1B, 
CDKN3, COBLL1, COPS5, EIF2AK2, EPS15, FKBP1A, FNTB, FYN, 
GLUD1, GSTO1, HAND1, HDAC3, HIF1A, HUWE1, LRP8, MLF1IP, 
MLL3, MSH3, MSX2, MTUS1, NCAPG (includes EG:64151), PA2G4, 
PDPK1, POLD1, PPARG, PPP3CB, PPPDE1, PRCC, PRKCQ, PSMB5, 
RARA, RB1, SEC31A, STIP1, TFDP2, TMEM97, TOP2A, TUBA1A, 
TUBA1C, TUBG1, TXN, UBA1, UBE2C, YWHAE 
Gastrointesti
nal Disease 
colorectal 
carcinoma 
colorectal carcinoma 1.32E-03 ACLY, ARHGDIA, CAT, COBLL1, FNTB, HAND1, HDAC3, HUWE1, 
LRP8, PDPK1, POLD1, PPARG, PPP3CB, PPPDE1, STIP1, TMEM97, 
TUBG1, UBA1, UBE2C, YWHAE 
Gastrointesti
nal Disease 
colorectal 
tumor 
colorectal tumor 1.40E-03 ACLY, ARHGDIA, AURKA, CAT, COBLL1, FNTB, HAND1, HDAC3, 
HUWE1, LRP8, PDPK1, POLD1, PPARG, PPP3CB, PPPDE1, STIP1, 
TMEM97, TUBA1A, TUBA1C, TUBG1, UBA1, UBE2C, YWHAE 
Gastrointesti
nal Disease 
gastrointestin
al tumor 
gastrointestinal tumor 2.44E-03 BAX, CCDC28A, COBLL1, FKBP1A, FYN, HDAC3, MSH3, PA2G4, 
PRCC, PRKCQ, SEC31A, TFDP2, TMEM97, TOP2A, TUBA1A, TUBA1C, 
TUBG1, UBE2C 
Gastrointesti
nal Disease 
stomach 
tumor 
stomach tumor 2.66E-03 BAX, CCDC28A, COBLL1, FKBP1A, MSH3, PA2G4, PRCC, SEC31A, 
TFDP2, TMEM97, TOP2A, TUBA1A, TUBA1C, TUBG1, UBE2C 
Gastrointesti
nal Disease 
gastric 
carcinoma 
gastric carcinoma 5.97E-03 BAX, CCDC28A, COBLL1, MSH3, PA2G4, PRCC, SEC31A, TFDP2, 
TMEM97, TOP2A, UBE2C 
Gastrointesti
nal Disease 
liver tumor liver tumor 1.10E-02 AURKA, CDKN1A, CDKN1B, CDKN3, EIF2AK2, FKBP1A, GLUD1, 
GSTO1, HUWE1, MLF1IP, NCAPG (includes EG:64151), PDPK1, POLD1, 
RARA, TOP2A, TUBA1A, TUBA1C, TUBG1, TXN, UBE2C 
Gastrointesti
nal Disease 
gastric 
cancer 
gastric cancer 1.15E-02 BAK1, BAX, BRCA1, CCDC28A, CDKN1A, COBLL1, FKBP1A, FOXM1, 
HDAC3, MAL, MSH3, NAMPT, PA2G4, PHB (includes EG:5245), PRCC, 
PSMB5, SEC31A, TFDP2, TMEM97, TOP2A, TUBA1A, TUBA1C, 
TUBG1, UBE2C 
Gastrointesti
nal Disease 
hepatocellula
r carcinoma 
hepatocellular 
carcinoma 
1.21E-02 AURKA, CDKN1A, CDKN1B, CDKN3, EIF2AK2, FKBP1A, GLUD1, 
GSTO1, HUWE1, MLF1IP, NCAPG (includes EG:64151), POLD1, RARA, 
TOP2A, TUBA1A, TUBA1C, TUBG1, TXN, UBE2C 
Genetic 
Disorder 
colon cancer colon cancer 2.31E-06 ACLY, AKAP13, ARHGDIA, ATF3, AURKA, BAK1, BAX, BMP2, CAT, 
CDCA5, CDK7, CDKN1A, CDKN1B, CDKN3, CEP55, CHMP1A, 
CNTNAP2, DUSP5, EIF2AK2, EXOSC9, FKBP1A, GNA11, HAND1, 
HDAC3, HUWE1, KIFC1, LRP8, MCM3, MCM5, MELK, MLF1IP, MSH3, 
MT1X, NKX2-5, NRAS, ODC1, PDPK1, POLD1, PPARG, PPPDE1, 
RUVBL1, SET, SRD5A1, STIP1, STXBP6, TMEM97, TPD52L1, TRIAP1, 
TUBA1A, TUBA1C, TUBG1, UBA1, YWHAE 
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Genetic 
Disorder 
colon tumor colon tumor 2.70E-04 ACLY, ARHGDIA, AURKA, CAT, HAND1, HDAC3, HUWE1, LRP8, 
PDPK1, POLD1, PPARG, PPPDE1, STIP1, TMEM97, TUBG1, UBA1, 
YWHAE 
Genetic 
Disorder 
lung 
adenocarcino
ma 
lung adenocarcinoma 3.59E-04 ALDOA, CDCA5, DICER1, EIF2C1, FOXM1, FOXO3, GPI, LDHA, 
NRAS, POLR2A, SMEK1, SRM, UBE2C 
Genetic 
Disorder 
lung tumor lung tumor 3.71E-04 ALDOA, BAX, BCL2L1, CDCA5, CDKN1A, CDKN1B, CERS2, CERS5, 
DICER1, EIF2C1, FOXM1, FOXO3, GPI, HUWE1, LDHA, NRAS, PDPK1, 
POLR2A, PSMB5, RB1, SEC61G, SMEK1, SRM, TOP2A, TUBA1A, 
TUBA1C, TUBG1, UBE2C, YWHAE 
Genetic 
Disorder 
colon 
carcinoma 
colon carcinoma 4.29E-04 ACLY, ARHGDIA, CAT, HAND1, HDAC3, HUWE1, LRP8, PDPK1, 
POLD1, PPARG, PPPDE1, STIP1, TMEM97, TUBG1, UBA1, YWHAE 
Genetic 
Disorder 
tuberous 
sclerosis 
tuberous sclerosis 7.02E-04 FKBP1A, HMOX1, TSC1, TSC2 
Genetic 
Disorder 
acute 
myeloid 
leukemia 
acute myeloid 
leukemia 
1.86E-03 ASXL1, CBL, FKBP1A, FNTB, FYN, HDAC3, LPP, NRAS, NSD1, 
NUP214, PDPK1, PLAGL2, POLD1, PPAT, PSMB5, RARA, RBM15, 
STAT3, TOP2A 
Genetic 
Disorder 
lung 
carcinoma 
lung carcinoma 2.38E-03 ALDOA, CDCA5, DICER1, EIF2C1, FOXM1, FOXO3, GPI, HUWE1, 
LDHA, NRAS, POLR2A, RB1, SEC61G, SMEK1, SRM, TOP2A, 
TUBA1A, TUBA1C, TUBG1, UBE2C, YWHAE 
Genetic 
Disorder 
ataxia with 
oculomotor 
apraxia 
ataxia with 
oculomotor apraxia 
3.49E-03 APTX, SETX 
Genetic 
Disorder 
Huntington's 
disease 
Huntington's disease 3.67E-03 AHCYL1, ALDH6A1, ATP5C1, ATP5O, ATP6V1B2, B4GALT5, BAX, 
CYFIP2 (includes EG:26999), DUSP5, FDFT1, FOXN3, GIT1, GPI, 
GTF3A, HMOX1, LDHA, MAP2K4, METTL9, MFN2, MLF2, MT1X, 
NDRG3, NME1, OSBPL8, PCDH7, PDCL, PPARG, PPARGC1B, PPRC1, 
PRDX6, RAB5A, RAB6A, RERE, RHOBTB3, ROCK2, SCAMP5, SCOC, 
SDC4, SEPHS1, SEPT6, SRD5A1, SRM, SSX2IP, SYNJ1, TBP, TRAK2, 
USP13, VAMP1, VAMP2, WNK1, YWHAZ, ZBTB44 
Genetic 
Disorder 
early-onset 
breast cancer 
early-onset breast 
cancer 
6.58E-03 BARD1, BRCA1, CHEK2, EI24, RB1CC1 
Genetic 
Disorder 
lung cancer lung cancer 7.00E-03 ALDOA, AURKA, BAX, BCL2L1, BTRC, CDCA5, CDK6, CDKN1A, 
CDKN1B, CERS2, CERS5, CHEK2, DICER1, EIF2AK1, EIF2C1, FDFT1, 
FKBP1A, FNTB, FOXM1, FOXO3, FYN, GPI, GUCY1A3, HDAC3, 
HIF1A, HIPK2, HUWE1, LDHA, NRAS, PDPK1, POLR2A, PPARG, 
PSMB5, RARA, RB1, SEC61G, SMEK1, SRM, STK35, TAOK1, TOP2A, 
TUBA1A, TUBA1C, TUBG1, UBE2C, WNK1, YWHAE 
Genetic 
Disorder 
hereditary 
gingival 
fibromatosis 
hereditary gingival 
fibromatosis 
9.81E-03 RB1, RBBP8, TFDP1, TFDP2 
Genetic 
Disorder 
Charcot-
Marie-Tooth 
disease type 
2A1 
Charcot-Marie-Tooth 
disease type 2A1 
1.01E-02 KIF1B, MFN2 
Genetic 
Disorder 
type 1A 
maple syrup 
urine disease 
type 1A maple syrup 
urine disease 
1.93E-02 BCKDHB, DBT 
Genetic 
Disorder 
lymphangiol
eiomyomatos
is 
lymphangioleiomyo
matosis 
2.38E-02 FKBP1A, TSC1, TSC2 
Genetic 
Disorder 
type M3 
acute 
myeloid 
leukemia 
type M3 acute 
myeloid leukemia 
3.03E-02 POLD1, RARA, TOP2A 
Cellular 
Movement 
cytokinesis cytokinesis of cell 
lines 
1.05E-05 CD2AP, CEP55, GNAI2, KIFC1, MASTL, NEDD4L, NME1, SEPT6, 
SEPT9, TOP2A, VAV3 
Cellular 
Movement 
cytokinesis cytokinesis of 
cervical cancer cell 
lines 
2.90E-05 CD2AP, CEP55, GNAI2, KIFC1, MASTL, NEDD4L, SEPT6, SEPT9, 
VAV3 
Cellular 
Movement 
cytokinesis cytokinesis of tumor 
cell lines 
5.15E-05 CD2AP, CEP55, GNAI2, KIFC1, MASTL, NEDD4L, SEPT6, SEPT9, 
TOP2A, VAV3 
Cellular 
Movement 
cytokinesis cytokinesis 5.98E-05 AURKA, CD2AP, CDKN1A, CEP55, DIAPH2, GNAI2, KIFC1, MASTL, 
NEDD4L, NME1, SEPT6, SEPT9, SETD8, TOP2A, VAV3 
Cellular 
Movement 
invasion invasion of tumor 
cell lines 
5.48E-03 ASAP1, ATF1, ATF3, CAT, CBL, CDC42, CDKN1B, CSK, DAB2, 
DIAPH2, DNMT3B, ETS1, FOXM1, GPI, HIF1A, HIPK2, HMGA1, 
HMOX1, MAPKAPK2, MARCKS, NCOA3, NME1, NUAK1, PA2G4, 
PPARG, PRKAA1, RND3, SDC4, SEPT9, SKP2, SP1, STAT3, TAB1, 
TFAP2A, TJP1 
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Cellular 
Movement 
invasion invasion of cell lines 6.80E-03 ASAP1, ATF1, ATF3, CAT, CBL, CDC42, CDKN1B, CSK, DAB2, 
DIAPH2, DNMT3B, ETS1, FOXM1, GPI, HIF1A, HIPK2, HMGA1, 
HMOX1, MAPKAPK2, MARCKS, NCOA3, NME1, NUAK1, OTUB1, 
PA2G4, PPARG, PRKAA1, RND3, SDC4, SEPT9, SKP2, SP1, STAT3, 
TAB1, TFAP2A, TJP1 
Cellular 
Movement 
invasion invasion of cells 1.03E-02 ASAP1, ATF1, ATF3, B4GALT5, CAT, CBL, CDC42, CDKN1B, CSK, 
DAB2, DIAPH2, DNMT3B, ETS1, FKBP1A, FOXM1, GPI, HIF1A, HIPK2, 
HMGA1, HMOX1, MAPKAPK2, MARCKS, NCOA3, NME1, NUAK1, 
OTUB1, PA2G4, PIP5K1A, PPARG, PRKAA1, RND3, SDC4, SEPT9, 
SKP2, SP1, STAT3, TAB1, TFAP2A, TJP1 
Cellular 
Movement 
invasion invasion of 
eukaryotic cells 
1.19E-02 ASAP1, ATF1, ATF3, B4GALT5, CAT, CBL, CDC42, CDKN1B, CSK, 
DAB2, DIAPH2, DNMT3B, ETS1, FKBP1A, FOXM1, GPI, HIF1A, HIPK2, 
HMGA1, HMOX1, MAPKAPK2, MARCKS, NCOA3, NME1, NUAK1, 
OTUB1, PA2G4, PPARG, PRKAA1, RND3, SDC4, SEPT9, SKP2, SP1, 
STAT3, TAB1, TFAP2A, TJP1 
Cellular 
Movement 
invasion invasion of colon 
cancer cell lines 
1.23E-02 ATF3, CSK, HIF1A, HIPK2, NME1, NUAK1, STAT3 
Cellular 
Movement 
invasion invasion of bladder 
cancer cell lines 
3.03E-02 CAT, DAB2, MAPKAPK2 
Infectious 
Disease 
infection infection of cell lines 1.30E-04 AKAP13, AP1B1, AP2M1, ARHGAP32, ASXL2, ATMIN, ATXN2, 
BRCA1, C19orf50, CBL, CDC42, CLDND1, CRIPAK, CRTC2, DCP2, 
DDX50, DHX15, DHX33, DNAJB1, EPS15, ERCC3, EXOSC10, FBXW11, 
GABPB1, GATAD2A, GOLPH3, HUWE1, INTS7, ISG20L2, KARS, 
KAT6A, LRRC8D, MED20, MPHOSPH6, MT1X, NCKAP1, NRBP1, 
NUDT11, NUP214, NUP50, NUP85 (includes EG:287830), OSBPL3, 
PCBP2, PIP5K1A, POLR2A, POLR2C, PPP2R2A, PPP2R5E, PRKAA1, 
PRPF8, R3HDM1, RAB5A, RAB6A, RB1CC1, RIMS4, RNF10, RNF216, 
RNF26, SAP30BP, SEC61G, SF3B2, STIP1, STX5, SYNJ1, TAGLN2, 
TAOK1, TFDP2, TNPO3, TRIM5, TRMT5, UBE2C, UBE2E1, UBE2H, 
WASF2, WNK1, YBX1, ZCCHC17, ZNRD1 
Infectious 
Disease 
infection infection by virus 2.10E-04 AKAP13, AP1B1, AP2M1, ARHGAP32, ASXL2, ATMIN, ATXN2, 
BRCA1, C19orf50, CBL, CDC42, CLDND1, CRIPAK, CRTC2, DCP2, 
DDX50, DHX15, DHX33, DNAJB1, EPS15, ERCC3, EXOSC10, FBXW11, 
FDFT1, GABPB1, GATAD2A, GOLPH3, HUWE1, INTS7, ISG20L2, 
KARS, KAT6A, LRRC8D, MED20, MPHOSPH6, MT1X, NCKAP1, 
NRBP1, NUDT11, NUP214, NUP50, NUP85 (includes EG:287830), 
OSBPL3, PCBP2, PIP5K1A, POLD1, POLR2A, POLR2C, PPARG, 
PPP2R2A, PPP2R5E, PPP3CB, PPP3R1, PRKAA1, PRPF8, R3HDM1, 
RAB5A, RAB6A, RARA, RB1CC1, RIMS4, RNF10, RNF216, RNF26, 
SAP30BP, SEC61G, SF3B2, STIP1, STX5, SYNJ1, TAGLN2, TAOK1, 
TFDP2, TNPO3, TOP2A, TRIM5, TRMT5, TUBA1A, TUBA1C, TUBG1, 
UBE2C, UBE2E1, UBE2H, UGCG, WASF2, WNK1, YBX1, ZCCHC17, 
ZNRD1 
Infectious 
Disease 
infection infection by 
lentivirus 
5.17E-04 AKAP13, AP2M1, ARHGAP32, ASXL2, ATMIN, ATXN2, BRCA1, 
C19orf50, CLDND1, CRIPAK, CRTC2, DCP2, DDX50, DHX15, DHX33, 
DNAJB1, ERCC3, EXOSC10, FBXW11, FDFT1, GABPB1, GATAD2A, 
GOLPH3, HUWE1, INTS7, ISG20L2, KARS, KAT6A, LRRC8D, MED20, 
MPHOSPH6, MT1X, NCKAP1, NRBP1, NUDT11, NUP214, NUP50, 
NUP85 (includes EG:287830), OSBPL3, POLD1, POLR2A, POLR2C, 
PPARG, PPP2R2A, PPP2R5E, PPP3CB, PPP3R1, PRKAA1, PRPF8, 
R3HDM1, RAB6A, RARA, RB1CC1, RIMS4, RNF10, RNF216, RNF26, 
SAP30BP, SEC61G, SF3B2, STIP1, STX5, TAGLN2, TAOK1, TFDP2, 
TNPO3, TOP2A, TRIM5, TRMT5, TUBA1A, TUBA1C, TUBG1, UBE2C, 
UBE2E1, UBE2H, UGCG, WNK1, YBX1, ZCCHC17, ZNRD1 
Infectious 
Disease 
infection infection by HIV 7.39E-04 AKAP13, AP2M1, ARHGAP32, ASXL2, ATMIN, ATXN2, BRCA1, 
C19orf50, CLDND1, CRIPAK, CRTC2, DCP2, DDX50, DHX15, DHX33, 
DNAJB1, ERCC3, EXOSC10, FBXW11, FDFT1, GABPB1, GATAD2A, 
GOLPH3, HUWE1, INTS7, ISG20L2, KARS, KAT6A, LRRC8D, MED20, 
MPHOSPH6, MT1X, NCKAP1, NRBP1, NUDT11, NUP214, NUP50, 
NUP85 (includes EG:287830), OSBPL3, POLD1, POLR2A, POLR2C, 
PPARG, PPP2R2A, PPP2R5E, PPP3CB, PPP3R1, PRKAA1, PRPF8, 
R3HDM1, RAB6A, RARA, RB1CC1, RIMS4, RNF10, RNF216, RNF26, 
SAP30BP, SEC61G, SF3B2, STIP1, STX5, TAGLN2, TAOK1, TFDP2, 
TNPO3, TOP2A, TRMT5, TUBA1A, TUBA1C, TUBG1, UBE2C, UBE2E1, 
UBE2H, UGCG, WNK1, YBX1, ZCCHC17, ZNRD1 
Infectious 
Disease 
infection infection by HIV-1 7.82E-04 AKAP13, AP2M1, ARHGAP32, ASXL2, ATMIN, ATXN2, BRCA1, 
C19orf50, CLDND1, CRIPAK, CRTC2, DCP2, DDX50, DHX15, DHX33, 
DNAJB1, ERCC3, EXOSC10, FBXW11, GABPB1, GATAD2A, GOLPH3, 
HUWE1, INTS7, ISG20L2, KARS, KAT6A, LRRC8D, MED20, 
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MPHOSPH6, MT1X, NCKAP1, NRBP1, NUDT11, NUP214, NUP50, 
NUP85 (includes EG:287830), OSBPL3, POLR2A, POLR2C, PPP2R2A, 
PPP2R5E, PRKAA1, PRPF8, R3HDM1, RAB6A, RB1CC1, RIMS4, RNF10, 
RNF216, RNF26, SAP30BP, SEC61G, SF3B2, STIP1, STX5, TAGLN2, 
TAOK1, TFDP2, TNPO3, TRMT5, UBE2C, UBE2E1, UBE2H, WNK1, 
YBX1, ZCCHC17, ZNRD1 
Infectious 
Disease 
infection infection of kidney 
cell lines 
3.23E-03 AKAP13, ATMIN, ATXN2, C19orf50, DCP2, DHX15, EXOSC10, 
GATAD2A, KARS, KAT6A, MT1X, NCKAP1, NUDT11, NUP214, 
NUP50, OSBPL3, PCBP2, POLR2A, POLR2C, PPP2R5E, PRPF8, 
R3HDM1, RNF10, RNF216, SAP30BP, SF3B2, TAGLN2, TNPO3, UBE2C, 
UBE2H, YBX1, ZCCHC17 
Infectious 
Disease 
infection infection of tumor 
cell lines 
5.36E-03 AP1B1, AP2M1, ARHGAP32, ASXL2, BRCA1, CBL, CDC42, CLDND1, 
CRIPAK, CRTC2, DDX50, DHX33, DNAJB1, EPS15, ERCC3, FBXW11, 
GABPB1, GOLPH3, HUWE1, INTS7, ISG20L2, LRRC8D, MED20, 
MPHOSPH6, NRBP1, NUP85 (includes EG:287830), PIP5K1A, PPP2R2A, 
PRKAA1, RAB5A, RAB6A, RB1CC1, RIMS4, RNF216, RNF26, SEC61G, 
STIP1, STX5, SYNJ1, TAOK1, TFDP2, TNPO3, TRIM5, TRMT5, 
UBE2E1, WASF2, WNK1, ZNRD1 
Infectious 
Disease 
infection infection by Dengue 
virus 2 
1.96E-02 AP1B1, CBL, EPS15, PIP5K1A, RAB5A, SYNJ1, WASF2 
Infectious 
Disease 
infection infection of cervical 
cancer cell lines 
2.26E-02 AP2M1, ARHGAP32, ASXL2, BRCA1, CDC42, CLDND1, CRIPAK, 
CRTC2, DDX50, DHX33, DNAJB1, ERCC3, FBXW11, GABPB1, 
GOLPH3, HUWE1, INTS7, ISG20L2, LRRC8D, MED20, MPHOSPH6, 
NRBP1, NUP85 (includes EG:287830), PPP2R2A, PRKAA1, RAB5A, 
RAB6A, RB1CC1, RIMS4, RNF26, SEC61G, STIP1, STX5, TAOK1, 
TFDP2, TNPO3, TRMT5, UBE2E1, WNK1, ZNRD1 
Infectious 
Disease 
infectious 
disorder 
infectious disorder of 
embryonic cell lines 
2.30E-03 AKAP13, ATMIN, ATXN2, C19orf50, DCP2, DHX15, EXOSC10, 
GATAD2A, KARS, KAT6A, MT1X, NCKAP1, NUDT11, NUP214, 
NUP50, OSBPL3, PCBP2, POLR2A, POLR2C, PPP2R5E, PRPF8, 
R3HDM1, RNF10, RNF216, SAP30BP, SF3B2, TAGLN2, TNPO3, UBE2C, 
UBE2H, YBX1, ZCCHC17 
Infectious 
Disease 
infectious 
disorder 
infectious disorder of 
epithelial cell lines 
2.30E-03 AKAP13, ATMIN, ATXN2, C19orf50, DCP2, DHX15, EXOSC10, 
GATAD2A, KARS, KAT6A, MT1X, NCKAP1, NUDT11, NUP214, 
NUP50, OSBPL3, PCBP2, POLR2A, POLR2C, PPP2R5E, PRPF8, 
R3HDM1, RNF10, RNF216, SAP30BP, SF3B2, TAGLN2, TNPO3, UBE2C, 
UBE2H, YBX1, ZCCHC17 
Infectious 
Disease 
keratoconjun
ctivitis sicca 
keratoconjunctivitis 
sicca 
2.87E-03 HYAL2, HYAL3, PPP3CB, PPP3R1 
 
 
Supplementary Table 3: Functional Enrichment Analysis of genes predicted to be miR-182 
targets 
 
 
Ingenuity Canonical 
Pathways 
 -log(p-
value) 
Ratio* Sig** Molecules 
Cell Cycle: G2/M 
DNA Damage 
Checkpoint Regulation 
4.54E+00 2.29E-01 > 4SD  GADD45A,YWHAE,CDK7,CDKN1A,YWHAZ,TOP2A,BTRC,BRCA1,LOC728
622/SKP1,CHEK2,SKP2 (includes EG:27401) 
Role of BRCA1 in 
DNA Damage 
Response 
4.07E+00 2.03E-01 > 4SD  RB1,ATF1 (includes 
EG:100040260),GADD45A,CDKN1A,BARD1,RBBP8,SMARCD2,RFC5,BRCA
1,CHEK2,RFC3,NBN 
Hereditary Breast 
Cancer Signaling 
3.97E+00 1.50E-01 > 4SD  NRAS,POLR2D,TUBG1,BARD1,CDK6,SMARCD2,RFC5,NBN,POLR2G,RB1,P
OLR2C,POLR2A,HDAC3,GADD45A,CDKN1A,BRCA1,CHEK2,RFC3 
Cyclins and Cell Cycle 
Regulation 
3.83E+00 1.61E-01 > 4SD  TFDP1,PA2G4,PPP2CA,PPP2R2A,CDK7,CDK6,LOC728622/SKP1,SKP2 
(includes EG:27401),RB1,HDAC3,CDKN1A,BTRC,PPP2R5E,CDKN1B 
Molecular 
Mechanisms of Cancer 
3.76E+00 1.03E-01 > 4SD  MAP2K4,FYN,CDC42,PA2G4,BMP2,TAB2,GNA11,BMPR2,HIF1A,RB1,LAMT
OR3,BMPR1A,GNA13,BRCA1,HIPK2,TAB1,CHEK2,PAK2,PRKCQ,NRAS,TF
DP1,CDK6,AURKA,BAX,BAK1,APH1A,NBN,GNAI2,BCL2L1,CBL,RND3,CD
KN1A,FZD3,CDKN1B,ELK1,FNBP1,PRKAR1A 
Role of CHK Proteins 
in Cell Cycle 
Checkpoint Control 
3.27E+00 2.29E-01 > 4SD  RAD17 (includes EG:19356),CDKN1A,TLK2,RFC5,BRCA1,CHEK2,RFC3,NBN 
Protein Ubiquitination 
Pathway 
3.12E+00 1.08E-01 > 4SD  PSMB3,USP21,USP24,UBE2H,ANAPC1/LOC100286979,USO1,USP13,USP42,
USP10,DNAJB1,BRCA1,NEDD4L,PSMB5,MED20,DNAJC9,UBE4B,LOC72862
2/SKP1,SKP2 (includes 
EG:27401),UBE2G2,DNAJC21,PSME1,CBL,CUL2,UBE2G1,BTRC,UBA1,USP3
4,UBE2E1,UBE2C 
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ATM Signaling 3.09E+00 1.85E-01 > 4SD  MAP2K4,GADD45A,CDKN1A,ATF4,TP53BP1,TLK2,CREB5,BRCA1,CHEK2,
NBN 
Aryl Hydrocarbon 
Receptor Signaling 
3.08E+00 1.28E-01 > 4SD  MGST1,TFDP1,MED1 (includes 
EG:19014),GSTA4,CDK6,BAX,GSTO1,NCOA3,RB1,SP1,RARA,NFIA,CDKN1
A,NFIB,CDKN1B,CHEK2,ALDH6A1,MCM7 
Cell Cycle: G1/S 
Checkpoint Regulation 
2.96E+00 1.69E-01 > 4SD  RB1,HDAC3,TFDP1,PA2G4,CDKN1A,CDK6,BTRC,CDKN1B,LOC728622/SKP
1,SKP2 (includes EG:27401) 
Clathrin-mediated 
Endocytosis Signaling 
2.63E+00 1.14E-01 > 4SD  AP2M1,EPS15,RAB5A,CDC42,RAB5B,SH3GL2,AP1B1,CD2AP,CBL,ACTR3,
WASL,PPP3CB,SYNJ1,PPP3R1,RAB5C,ARPC4,CSNK2A1,DAB2,SH3KBP1 
14-3-3-mediated 
Signaling 
2.58E+00 1.30E-01 > 2SD MAP2K4,TSC1,PRKCQ,NRAS,YWHAE,TUBG1,YWHAZ,BAX,TUBA1A,CBL,
TSC2,TUBA1C,CDKN1B,PDCD6IP,ELK1 
Glutamate Metabolism 2.41E+00 2.00E-01 > 3SD EARS2,GNPNAT1,GLUD1,GOT1,GCLM,GOT2,PPAT 
Cell Cycle Control of 
Chromosomal 
Replication 
2.37E+00 2.00E-01 > 4SD  MCM5,MCM3,CDK7,CDK6,CHEK2,MCM7 
NRF2-mediated 
Oxidative Stress 
Response 
2.34E+00 1.06E-01 > 4SD  MAP2K4,MGST1,PRKCQ,NRAS,DNAJC9,GSTA4,MAP3K1,GSTO1,TXNRD1,
MAFG,DNAJC21,HMOX1,STIP1,CAT,ATF4,MAPK7,DNAJB1,TXN (includes 
EG:116484),GCLM,FKBP5 
Hypoxia Signaling in 
the Cardiovascular 
System 
2.34E+00 1.52E-01 > 4SD  UBE2G2,UBE2H,COPS5,UBE2G1,ATF4,HIF1A,CREB5,LDHA,UBE2E1,UBE2
C 
Androgen Signaling 2.24E+00 1.08E-01 > 4SD  PRKCQ,POLR2D,CDK7,GNA11,TBP,POLR2G,GNAI2,POLR2A,POLR2C,ERC
C3,NCOA4,GNA13,DNAJB1,PRKAR1A 
Glucocorticoid 
Receptor Signaling 
2.23E+00 9.39E-02 > 3SD MAP2K4,POLR2D,NFATC3,GTF2F2,SMARCD2,POLR2C,POLR2A,PPP3CB,P
PP3R1,FOXO3,PRKAA1,FKBP5,STAT5B,TAB1,NRAS,MED1 (includes 
EG:19014),CDK7,MAP3K1,TBP,STAT3,NCOA3,POLR2G,BCL2L1,ERCC3,CD
KN1A,ELK1 
PI3K Signaling in B 
Lymphocytes 
2.13E+00 1.15E-01 > 4SD  FYN,ATF3,NRAS,ATF1 (includes EG:100040260),NFATC3,IRS4 (includes 
EG:16370),PDPK1,CBL,PPP3CB,PPP3R1,VAV3,FOXO3,ATF4,PLEKHA1,ELK
1 
Rac Signaling 2.12E+00 1.11E-01 > 4SD  MAP2K4,ABI2,PAK2,NRAS,CDC42,MAP3K1,PIP5K1A,ACTR3,CYFIP2,ARPC
4,SH3RF1,ELK1,NCKAP1 
PI3K/AKT Signaling 2.10E+00 1.09E-01 > 4SD  TSC1,NRAS,YWHAE,PPP2CA,PPP2R2A,LIMS1,YWHAZ,PDPK1,BCL2L1,TS
C2,CDKN1A,FOXO3,CDKN1B,PPP2R5E 
Estrogen Receptor 
Signaling 
2.10E+00 1.12E-01 > 2SD MED23,NRAS,POLR2D,MED20,GTF2F2,MED1 (includes 
EG:19014),CDK7,TBP,NCOA3,POLR2G,POLR2A,HDAC3,POLR2C,ERCC3,M
ED24 
Polyamine Regulation 
in Colon Cancer 
2.09E+00 2.08E-01 > 4SD  PPARG,PSME1,AZIN1,PSME3,ODC1 
p53 Signaling 2.07E+00 1.26E-01 > 3SD BCL2L1,RB1,PLAGL1,GADD45A,MED1 (includes 
EG:19014),CDKN1A,CCNK,GNL3,BAX,HIPK2,BRCA1,CHEK2 
mTOR Signaling 2.07E+00 1.10E-01 > 2SD TSC1,PRKCQ,NRAS,PPP2CA,PPP2R2A,PDPK1,FKBP1A,HIF1A,HMOX1,RND
3,EIF4G2,TSC2,PRKAA1,PPP2R5E,FNBP1,EIF4B 
RAR Activation 2.05E+00 1.05E-01 > 4SD  MAP2K4,NSD1,PRKCQ,TRIM24,RDH10,MED1 (includes 
EG:19014),CDK7,BMP2,CSK,MAP3K1,SMARCD2,PDPK1,RARA,ERCC3,CSN
K2A1,MAPKAPK2,STAT5B,PRKAR1A 
ERK5 Signaling 2.03E+00 1.45E-01 > 4SD  NRAS,YWHAE,FOXO3,YWHAZ,ATF4,GNA13,MAPK7,CREB5,WNK1 
T Cell Receptor 
Signaling 
1.96E+00 1.18E-01 > 1SD MAP2K4,FYN,PRKCQ,NRAS,CBL,PPP3CB,NFATC3,CSK,VAV3,PPP3R1,MA
P3K1,ELK1 
Nicotinate and 
Nicotinamide 
Metabolism 
1.96E+00 1.25E-01 > 3SD MAP2K4,PAK2,PRKCQ,CDK7,PRKAA1,CDK6,DUSP18,NAMPT,MAPK7,EIF
2AK2,IRAK1,DYRK1A 
RAN Signaling 1.90E+00 2.22E-01 > 4SD  KPNA6,TNPO1,KPNA1,IPO5 
Mismatch Repair in 
Eukaryotes 
1.90E+00 2.00E-01 > 4SD  MSH3 (includes EG:17686),RFC5,POLD1,RFC3 
Nucleotide Excision 
Repair Pathway 
1.81E+00 1.71E-01 > 4SD  POLR2G,POLR2A,POLR2D,POLR2C,CDK7,ERCC3 
Regulation of IL-2 
Expression in 
Activated and Anergic 
T Lymphocytes 
1.79E+00 1.19E-01 > 3SD MAP2K4,FYN,NRAS,PPP3CB,NFATC3,VAV3,PPP3R1,MAP3K1,TOB1,ELK1 
Antiproliferative Role 
of TOB in T Cell 
Signaling 
1.78E+00 1.92E-01 > 4SD  RB1,TOB1,CDKN1B,LOC728622/SKP1,SKP2 (includes EG:27401) 
Prostate Cancer 
Signaling 
1.75E+00 1.11E-01 > 4SD  RB1,NRAS,TFDP1,PA2G4,SRD5A1,CDKN1A,ATF4,PDPK1,CDKN1B,CREB5 
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Cardiomyocyte 
Differentiation via 
BMP Receptors 
1.72E+00 2.11E-01 > 4SD  NKX2-5,BMPR1A,BMP2,BMPR2 
B Cell Receptor 
Signaling 
1.68E+00 1.01E-01 > 2SD MAP2K4,ETS1,PRKCQ,NRAS,CDC42,NFATC3,CSK,MAP3K1,CREB5,BCL2L
1,PPP3CB,PPP3R1,VAV3,ATF4,ELK1 
Small Cell Lung 
Cancer Signaling 
1.63E+00 1.07E-01 > 4SD  BCL2L1,PIAS3,RB1,TFDP1,PA2G4,TRAF4,CDK6,CDKN1B,SKP2 (includes 
EG:27401) 
Toll-like Receptor 
Signaling 
1.62E+00 1.37E-01 > 4SD  MAP2K4,MAP3K1,TAB2,EIF2AK2,ELK1,TAB1,IRAK1 
 
 
Supplementary Table 4: Genes involved in the ‘DNA Damage Response’, identified as 
significantly enriched in our miR-182 biotinylated pull-down 
 
Gene Symbol Log2 FC adj. P-value  Functional summary References 
ATF1 -1.27 0.0003 Belongs to the CREB family of transcription factors, which in 
response to growth factor/other stress signals activates expression of 
proto-oncogenes and cell cycle related genes 
Meyer and Habener 1993;  
ATF4 -1.09 0.0028 Belongs to the CREB/ATF family of DNA binding proteins that 
contain leucine zipper regions. It is known to interact with several 
general transcription factors such as TFIIB and TBP and acts as a 
potent transcriptional activator. 
Liang and Hai 1997; Fung, 
Liu et al. 2007; 
BARD1 -1.98 0.0002 Partners with BRCA1 to regulate transcription, cell cycle progression 
and maintenance of X chromosome inactivation; mutant cell lines 
with defective BARD1 exhibit genome instability and defective HR-
mediated DNA repair 
Scully and Livingston 2000; 
Ganesan, Silver et al. 2002; 
Moynahan, Chiu et al. 1999; 
Scully, Ganesan et al. 1999; 
BRCA1 -1.08 0.0011 Mutations in BRCA1 predispose to breast cancer. BRCA1 deficiency 
activates the DNA damage response, causing growth arrest and, in 
some cases, apoptosis. 
Deng 2006; 
BTRC -0.64 0.0085 Is part of the E3 ubiquitin ligase complex and binding of BTRC 
results in ubiquitination and subsequent proteasomal degradation of 
its substrates. In response to DNA damage, it degrades Cdc25A 
leading to an intra-S-phase delay in the cell cycle. 
Busino, Donzelli et al. 2003; 
CDK6 -1.01 0.0013 Along with CDK4, is known to phosphorylate Rb, preventing 
quiescence, senescence and cell differentiation. Upon DNA damage, 
failure to inhibit these CDKs by p16 or p21 leads to accumulation of 
mutations and genomic instability. 
Harper, Elledge et al. 1995; 
Shapiro, Edwards et al. 
1998; 
CDK7 -1.63 0.0002 Identified as the catalytic subunit of the CDK-activating kinase 
(CAK) complex that includes cyclin H and MAT1. It is also a 
component of the general transcription factor TFIIH. 
Roy, Adamczewski et al. 
1994; Kaldis 1999; 
CDKN1A -1.373 0.001 Regulates cell cycle, apoptosis and transcription in response to DNA 
Damage 
Dotto 2000; Coqueret 2003; 
CDKN1B -1.48 0.0003 CDKN1B controls cell cycle progression at the G1 checkpoint by 
inhibiting the cyclin E-CDK2 and cyclin D-CDK4 complexes. This 
occurs through the activation of Rb, which leads to a G1 arrest. 
Polyak, Lee et al. 1994; 
CHEK2 -1.159 0.0009 Protein kinase activated in response to DNA damage, plays a crucial 
role in cell cycle arrest. Phosphorylates and activates BRCA1, 
thereby regulating DNA Damage Response pathway 
Matsuoka, Huang et al. 
1998; Lee, Collins et al. 
2000 
CREB5 -1.25 0.0005 A member of the CREB/ATF family of DNA-binding proteins that 
binds to the cAMP response element as a homodimer or as a 
heterodimer with c-Jun, functioning as a transactivator. 
Zu, Maekawa et al. 1993; 
GADD45a -1.139 0.001 Activated upon exposure of cells to UV, ionizing radiation and 
alkylating agents; plays a major role in maintenance of genomic 
integrity and in control of centrosome duplication. 
Papathanasiou, Kerr et al. 
1991; Hollander and 
Fornace 2002; 
HDAC3 -2.8 0.00006 Is a class I histone deacetylase which represses transcription when 
recruited to a gene promoter. It is required for efficient DNA repair 
and genomic stability. 
Bhaskara, Knutson et al. 
2010; 
MAP2K4 -1.74 0.0002 Also known as MEK4, this serine/threonine kinase is a direct 
activator of MAP kinases and has been shown to activate JNK1, 
JNK2 and p38 in response to environmental stress or mitogenic 
stimuli. 
Lin, Minden et al. 1995; 
NBN -1.71 0.0007 It is a component of the MRN complex that governs cellular response 
to DNA damage. Its N-terminus binds ?H2AX, and is believed to 
recruit the MRN complex to the proximity of the DNA double-strand 
break. Also known as NBS1. 
Zhang, Zhou et al. 2006; 
NRAS -1.17 0.0007 It is a member of the Ras family of proteins that have GTPase 
activity. Mutations in this gene have been associated with several 
cancers and Noonan syndrome. 
Colicelli 2004; 
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PA2G4 -1.28 0.0036 It is an RNA-binding protein involved in growth regulation. It 
interacts with the ErbB3 receptor and modulates cell signaling. It 
also binds Rb and inhibits E2F1-mediated transcription. 
Yoo, Wang et al. 2000; Xia, 
Cheng et al. 2001; 
POLR2A -1.15 0.0042 These are four subunits of the 12-component eukaryotic DNA-
directed RNA polymerase II that catalyzes the transcription of DNA 
to mRNA. BRCA1 is known to interact with RNA polymerase II and 
regulate gene transcription. 
Myer and Young 1998; 
Starita and Parvin 2003; 
POLR2C -1.05 0.0013 These are four subunits of the 12-component eukaryotic DNA-
directed RNA polymerase II that catalyzes the transcription of DNA 
to mRNA. BRCA1 is known to interact with RNA polymerase II and 
regulate gene transcription. 
Myer and Young 1998; 
Starita and Parvin 2003; 
POLR2D -2.04 0.0001 These are four subunits of the 12-component eukaryotic DNA-
directed RNA polymerase II that catalyzes the transcription of DNA 
to mRNA. BRCA1 is known to interact with RNA polymerase II and 
regulate gene transcription. 
Myer and Young 1998; 
Starita and Parvin 2003; 
POLR2G -0.83 0.0051 These are four subunits of the 12-component eukaryotic DNA-
directed RNA polymerase II that catalyzes the transcription of DNA 
to mRNA. BRCA1 is known to interact with RNA polymerase II and 
regulate gene transcription. 
Myer and Young 1998; 
Starita and Parvin 2003; 
PPP2CA -0.88 0.0088 These are subunits of the Serine/threonine-protein phosphatase 2A 
(PP2A) family. The dynamic equilibrium that is maintained between 
PP2A and the CDKs controls phosphorylation of the RB family of 
proteins. PPP2R5E is part of a sub-family that is important in the 
DNA damage-induced stabilization of TP53.  
Li, Cai et al. 2007; Mumby 
2007; 
PPP2R2A -1.08 0.0018 These are subunits of the Serine/threonine-protein phosphatase 2A 
(PP2A) family. The dynamic equilibrium that is maintained between 
PP2A and the CDKs controls phosphorylation of the RB family of 
proteins. PPP2R5E is part of a sub-family that is important in the 
DNA damage-induced stabilization of TP53.  
Li, Cai et al. 2007; Mumby 
2007; 
PPP2R5E -1.03 0.009 These are subunits of the Serine/threonine-protein phosphatase 2A 
(PP2A) family. The dynamic equilibrium that is maintained between 
PP2A and the CDKs controls phosphorylation of the RB family of 
proteins. PPP2R5E is part of a sub-family that is important in the 
DNA damage-induced stabilization of TP53.  
Li, Cai et al. 2007; Mumby 
2007; 
RAD17 -1.45 0.0004 A cell cycle checkpoint gene that is bound to chromatin prior to 
DNA damage. Upon damage, it is phosphorylated by ATR, after 
which it recruits the RAD1-RAD9a-HUS1 complex to chromatin 
inducing cell cycle G2 arrest 
Rauen, Burtelow et al. 2000; 
Bao, Tibbetts et al. 2001; 
RB1 -0.805 0.008 Induces cell cycle arrest at the G1/S checkpoint upon DNA Damage; 
important for an intra-S-phase arrest in response to DNA damage by 
cisplatin inducing genotoxic stress 
Harrington, Bruce et al. 
1998; Knudsen, Booth et al. 
2000; 
RBBP8 -0.67 0.0067 Also known as CtIP. Associates with BRCA1 and is thought to 
regulate BRCA1-dependent transcriptional regulation, DNA repair 
and cell cycle checkpoint control. 
Jhanwar-Uniyal 2003; Yun 
and Hiom 2009; 
Replication 
Factor C 
(RFC3, 5) 
-1.147 0.0007 RFC is a 5-subunit containing clamp loader, which aids in PCNA 
assembly onto primed DNA for its replication. 
Waga and Stillman 1998; 
Hubscher, Maga et al. 2002; 
Garg and Burgers 2005; 
SKP1 -1.92 0.0002 Is also a component of the E3 ubiquitin ligase complex and the SCF 
complex (that includes BTRC), which is responsible for degradation 
of Cdc25A and cell cycle delay. 
Donzelli, Squatrito et al. 
2002; 
SKP2 -1.79 0.0001 Member of the F-box protein family that form a part of the SCF 
complex that is known to promote proteasomal degradation of 
p27kip1/CDKN1B in the S and G2 phases of the cell cycle. 
Carrano, Eytan et al. 1999; 
SMARCD2 -1.342 0.0005 Is a component of the human SWI/SNF-like chromatin-remodeling 
protein complexes which possess tumour suppressive activity, with 
recurrent mutations of its different subunits present in various 
cancers 
Wilson and Roberts 2011; 
TFDP1 -0.92 0.0064 Also known as DP1, this family of transcription factors 
heterodimerize with E2F proteins and enhance their DNA-binding 
ability, resulting in increased transcription of E2F target genes 
involved in cell cycle progression. 
Helin, Wu et al. 1993; 
TLK2 -1.39 0.0005 Member of the Tousled-like kinase family of serine/threonine kinases 
that are involved in the regulation of chromatin assembly. 
Sillje and Nigg 2001; 
TOP2A -0.9 0.009 A DNA topoisomerase that is involved in chromosome condensation 
and regulation of torsional stress during DNA transcription and 
replication. 
Watt and Hickson 1994; 
TP53BP1 -0.99 0.0052 It is a DNA-damage response factor involved in both homologous 
recombination and nonhomologous end joining. It is also known to 
be an activator of p53. 
Wang, Matsuoka et al. 2002; 
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TUBG1 -0.91 0.0022 A member of the tubulin family of proteins that are localized to the 
centrosome where they mediate microtubule formation, nucleation 
and are hence required for cell cycle progression. 
Zheng, Jung et al. 1991; 
YWHAE -2.77 0.0083 These belong to the 14-3-3 family of signal transducers that function 
in several points of the G1S and G2M transition by modulating the 
function of several proteins such as Cdc25. 
Hermeking and Benzinger 
2006; 
YWHAZ -1.62 0.0014 These belong to the 14-3-3 family of signal transducers that function 
in several points of the G1S and G2M transition by modulating the 
function of several proteins such as Cdc25. 
Hermeking and Benzinger 
2006; 
 
Supplementary Table 5: Sample information for human breast cancer patient samples used in 
the miR-182 q-PCR screening analysis 
 
Sample ID Invasive Type Size Grade Breast cancer Subtype Lymph Node Metastasis 
Q075 Invasive Ductal Carcinoma of No Special Type 43 3 Triple Negative N/A 
Q087 Invasive Ductal Carcinoma of No Special Type 28 2 HER2 Positive Positive 
Q132 Invasive Ductal Carcinoma of No Special Type 17 3 Luminal Positive 
Q151 Invasive Ductal Carcinoma of No Special Type 3 3 Triple Negative Negative 
Q173 Invasive Ductal Carcinoma of No Special Type 28 3 HER2 Positive Negative 
Q179 Invasive Ductal Carcinoma of No Special Type 20 3 HER2 Positive Positive 
Q184 Invasive Ductal Carcinoma of No Special Type 38 2 Triple Negative Negative 
Q214 Normal N/A N/A N/A N/A 
Q215 Normal N/A N/A N/A N/A 
Q218 Invasive Ductal Carcinoma of No Special Type 30 3 Triple Negative Negative 
Q222 Invasive Ductal Carcinoma of No Special Type 13 3 Triple Negative Positive 
Q227 Invasive Ductal Carcinoma of No Special Type 30 3 Triple Negative Positive 
Q230 Invasive Ductal Carcinoma of No Special Type 15 3 Triple Negative Negative 
Q232 Invasive Ductal Carcinoma of No Special Type 30 3 Luminal Positive 
Q234 Invasive Ductal Carcinoma of No Special Type 12 3 Triple Negative N/A 
Q240 Invasive Ductal Carcinoma of No Special Type 50 2 Luminal Positive 
Q248 Mixed ductolobular 16 2 Luminal Negative 
Q251 Normal N/A N/A N/A N/A 
Q254 Mixed ductolobular 130 2 Luminal Positive 
Q261 Normal N/A N/A N/A N/A 
Q268 Invasive Ductal Carcinoma of No Special Type 21 3 Triple Negative Negative 
Q279 Invasive Ductal Carcinoma of No Special Type 40 3 Triple Negative Positive 
Q281 Invasive Ductal Carcinoma of No Special Type 45 3 Triple Negative Negative 
Q293 Normal N/A N/A N/A N/A 
Q304 Normal N/A N/A N/A N/A 
Q307 Normal N/A N/A N/A N/A 
Q311 Invasive Ductal Carcinoma of No Special Type 45 3 HER2 Positive Positive 
Q356 Mixed ductolobular 60 3 Luminal Positive 
Q359 Invasive Ductal Carcinoma of No Special Type 45 3 Luminal Negative 
Q381 Invasive Lobular Carcinoma 12 1 N/A Negative 
Q382 Invasive Ductal Carcinoma of No Special Type 21 3 Luminal Positive 
Q407 Invasive Ductal Carcinoma of No Special Type 30 3 Triple Negative Positive 
Q437 Invasive Ductal Carcinoma of No Special Type 17 3 Triple Negative Positive 
Q441 Invasive Ductal Carcinoma of No Special Type 15 3 Triple Negative Negative 
Q453 Invasive Lobular Carcinoma 39 2 N/A Negative 
Q486 Invasive Ductal Carcinoma of No Special Type 45 3 Triple Negative Positive 
Q488 Invasive Ductal Carcinoma of No Special Type 75 3 Luminal Positive 
Q506 Invasive Ductal Carcinoma of No Special Type 20 3 Triple Negative Negative 
Q509 Invasive Ductal Carcinoma of No Special Type 25 3 Triple Negative Positive 
Q517 Invasive Lobular Carcinoma 19 2 N/A Positive 
Q543 Mixed ductolobular 40 3 Triple Negative Positive 
 
 
Supplementary Table 6: Primer sequences 
 
Oligo Name Sequence  Use 
miR-182_pos 5’-UUUGGCAAUGGUAGAACUCACACU-Biotin (C6 leave 
blankr arm)-3’ 
biotinylated miRNA for pull-down 
miR-182_neg 5’-UGUGAGUUCUACCAUUGCCAUAAG-3’ passenger strand of miRNA for pull-down 
CHEK2_fwd AGTGGTGGGGAATAAACGCC Real time analysis of gene expression 
CHEK2_rev TCTGGCTTTAAGTCACGGTGTA Real time analysis of gene expression 
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TP53_fwd CCAGGGCAGCTACGGTTTC Real time analysis of gene expression 
TP53_rev CTCCGTCATGTGCTGTGACTG Real time analysis of gene expression 
BRCA1_fwd ACAAATACTCATGCCAGCTCATT Real time analysis of gene expression 
BRCA1_rev GGCTCCTTGCTAAGCCAGG Real time analysis of gene expression 
ATMIN_fwd GTGCACATGCGGCTGTCCCT Real time analysis of gene expression 
ATMIN_rev TGGGTCCCTGTGTTCTGCAGGT Real time analysis of gene expression 
FOXO1_fwd CTCGGCGGGCTGGAAGAATTCA Real time analysis of gene expression 
FOXO1_rev TGTTGTTGTCCATGGATGCAGCTC Real time analysis of gene expression 
ATF1_fwd AGATACACGGGGCAGAAAAGG Real time analysis of gene expression 
ATF1_rev TCCGCTGCTAGTCTGATAGATG Real time analysis of gene expression 
miR-182_fwd GATTCAGCTAGCGGCCGCCTGCAGGAAGGACCTTGTCGCA Forward primer to amplify miR-182 from 
genomic DNA 
miR-182_rev GGAAACAAGCTTTGTCACTTCCAGCTGCACCTGCCCTC Reverse primer to amplify miR-182 hairpin 
from genomic DNA 
MAX_fwd CTAGTGTGTGTGTGGGGGGGACTCGGCTTGTTGTTGTCGGT
GACTTCCCCCTCCCCTTCA 
Top strand of luciferase construct with binding 
site  
MAX_rev TCGATGAAGGGGAGGGGGAAGTCACCGACAACAACAAGC
CGAGTCCCCCCCACACACACA 
Bottom strand of luciferase construct 
PRKAG1_fwd CTAGACAGATTGGCACCTATGCCAATATTGCTATGGTTCGC
ACTACCACCCCCGTCTATG 
Top strand of luciferase construct with binding 
site  
PRKAG1_rev TCGACATAGACGGGGGTGGTAGTGCGAACCATAGCAATAT
TGGCATAGGTGCCAATCTGT 
Bottom strand of luciferase construct 
SMARCD3_fwd CTAGAGATTCCCCAGCGCCTCACAGCCCTGCTATTGCCCCC
TGACCCAATTGTCATCAAC 
Top strand of luciferase construct with binding 
site  
SMARCD3_rev TCGAGTTGATGACAATTGGGTCAGGGGGCAATAGCAGGGC
TGTGAGGCGCTGGGGAATCT 
Bottom strand of luciferase construct 
EIF4G2_fwd CTAGTCGTTCCTAATGAATAAAAATCAAGTGCCAAAGCTTC
AGCCCCAGATAACTATGAT 
Top strand of luciferase construct with binding 
site  
EIF4G2_rev TCGAATCATAGTTATCTGGGGCTGAAGCTTTGGCACTTGAT
TTTTATTCATTAGGAACGA 
Bottom strand of luciferase construct 
CASP7_fwd CTAGTGTTTTGGCTTTATGTGCAAAATCTGTTATAGCTTTA
AAATATATCTGGAACTTTT 
Top strand of luciferase construct with binding 
site  
CASP7_rev TCGAAAAAGTTCCAGATATATTTTAAAGCTATAACAGATTT
TGCACATAAAGCCAAAACA 
Bottom strand of luciferase construct 
PRKCD_fwd CTAGAGTGTCTGAGGTGACCGTGGGTGTGTCGGTGCTGGC
CGAGCGCTGCAAGAAGAACA 
Top strand of luciferase construct with binding 
site  
PRKCD_rev TCGATGTTCTTCTTGCAGCGCTCGGCCAGCACCGACACACC
CACGGTCACCTCAGACACT 
Bottom strand of luciferase construct 
FKBP1A_fwd CTAGAGCACCATTTATGAGTCTCAAGTTTTATTATTGCAAT
AAAAGTGCTTTATGCCGGC 
Top strand of luciferase construct with binding 
site  
FKBP1A_rev TCGAGCCGGCATAAAGCACTTTTATTGCAATAATAAAACTT
GAGACTCATAAATGGTGCT 
Bottom strand of luciferase construct 
CHEK2_fwd CTAGATATCCAGCTCCTCTACCAGCACGATGCCAAACTCCA
GCCAGTCCTCTCACTCCAG 
Top strand of luciferase construct with binding 
site  
CHEK2_rev TCGACTGGAGTGAGAGGACTGGCTGGAGTTTGGCATCGTG
CTGGTAGAGGAGCTGGATAT 
Bottom strand of luciferase construct 
PDPK1_fwd CTAGAGAAGCTGTATTTCGGCCTTAGTTATGCCAAAAATGG
AGAACTACTTAAATATATT 
Top strand of luciferase construct with binding 
site  
PDPK1_rev TCGAAATATATTTAAGTAGTTCTCCATTTTTGGCATAACTA
AGGCCGAAATACAGCTTCT 
Bottom strand of luciferase construct 
CDKN1B_fwd CTAGTTTGTAATGTGTGAAAAAGATGCCAATTATTGTTACA
CATTAAGTAATCAATAAAG 
Top strand of luciferase construct with binding 
site  
CDKN1B_rev TCGACTTTATTGATTACTTAATGTGTAACAATAATTGGCAT
CTTTTTCACACATTACAAA 
Bottom strand of luciferase construct 
RBPJ_fwd CTAGGGAGTTGAAAAATGGAAGAATTATTTGCCAAAAGAG
GAGGACAAAAGATAATATGC 
Top strand of luciferase construct with binding 
site  
RBPJ_rev TCGAGCATATTATCTTTTGTCCTCCTCTTTTGGCAAATAATT
CTTCCATTTTTCAACTCC 
Bottom strand of luciferase construct 
PRKAG2_fwd CTAGAAGCCCTGATCCTCACACCAGCAGGTGCCAAACAAA
AGGAGACAGAAACGGAGTGA 
Top strand of luciferase construct with binding 
site  
PRKAG2_rev TCGATCACTCCGTTTCTGTCTCCTTTTGTTTGGCACCTGCTG
GTGTGAGGATCAGGGCTT 
Bottom strand of luciferase construct 
NFKBIB_fwd CTAGCGACCCCCGCCCCGTGTGATTTGTTTCATTGTTAATA
TAATTTCCAGTTTAATAAA 
Top strand of luciferase construct with binding 
site  
NFKBIB_rev TCGATTTATTAAACTGGAAATTATATTAACAATGAAACAA
ATCACACGGGGCGGGGGTCG 
Bottom strand of luciferase construct 
ATF1_fwd CTAGCTAAATTTTCTAAATAACCAATAGTTGCCAATCTAAA
TGGCAGAGAAGATGAAATT 
Top strand of luciferase construct with binding 
site  
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ATF1_rev TCGAAATTTCATCTTCTCTGCCATTTAGATTGGCAACTATT
GGTTATTTAGAAAATTTAG 
Bottom strand of luciferase construct 
BARD1_fwd CTAGAGCAGGCTCAACAGAGAACAGCTGTTGCCAAAGCTG
TTTGATGGATGCTACTTCTA 
Top strand of luciferase construct with binding 
site  
BARD1_rev TCGATAGAAGTAGCATCCATCAAACAGCTTTGGCAACAGC
TGTTCTCTGTTGAGCCTGCT 
Bottom strand of luciferase construct 
CREB5_fwd CTAGAGCTGAAGTGGGGGGTAAGGCCAAATTGCCAACACT
TGTTAAAAGATTAATACTCT 
Top strand of luciferase construct with binding 
site  
CREB5_rev TCGAAGAGTATTAATCTTTTAACAAGTGTTGGCAATTTGGC
CTTACCCCCCACTTCAGCT 
Bottom strand of luciferase construct 
RAD17_fwd CTAGGTGTATAAAGTGTGTTTGAACATTATGCCAAATATCA
AGATGTGAAGGACTAATTC 
Top strand of luciferase construct with binding 
site  
RAD17_rev TCGAGAATTAGTCCTTCACATCTTGATATTTGGCATAATGT
TCAAACACACTTTATACAC 
Bottom strand of luciferase construct 
TP53BP1_fwd CTAGCAAGGGTTGTGTCTTCAAAAGGAAATGCCAAAAAAA
GAATGCTCAGAAGCTATGGA 
Top strand of luciferase construct with binding 
site  
TP53BP1_rev TCGATCCATAGCTTCTGAGCATTCTTTTTTTGGCATTTCCTT
TTGAAGACACAACCCTTG 
Bottom strand of luciferase construct 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. APPENDIX  
 
Supplementary Material for Chapter 3 
 
  
 207 
 
Supplementary Table 1: Sample information for human breast cancer patient 
samples used in the miR-139-5p q-PCR screening analysis 
 
 
 
 
Supplementary Table 2: Significantly enriched probes, predicted to be miR-139-5p 
targets 
 
probe_ID geneSymbol logFC Avg 
Exp 
adj.P.
Value 
ILMN_2087528 CPSF3 -5.47 12.19 0.00 
ILMN_1668179 HNRNPF -5.37 10.39 0.00 
ILMN_2278636 CUTL1 -4.03 11.91 0.00 
ILMN_2328972 DNMT3B -3.89 10.55 0.00 
ILMN_1752249 FAM38A -4.10 12.58 0.00 
ILMN_1676010 SP1 -4.38 11.82 0.00 
ILMN_1653828 CHFR -3.83 12.07 0.00 
ILMN_1705746 LSG1 -4.67 11.48 0.00 
ILMN_1746408 MIDN -4.60 13.00 0.00 
ILMN_1663444 LIN7B -4.26 10.98 0.00 
ILMN_2157435 DYNLRB1 -3.40 13.56 0.00 
ILMN_1756999 RBL2 -4.42 10.53 0.00 
ILMN_1794692 DNMT3B -3.26 9.90 0.00 
ILMN_1658053 DYNLRB1 -3.18 12.99 0.00 
ILMN_1766762 DYNLRB1 -2.83 11.34 0.00 
ILMN_1659845 KIAA0355 -4.77 10.49 0.00 
ILMN_2095840 MYST3 -3.44 11.38 0.00 
ILMN_2307450 ZNF302 -3.63 11.88 0.00 
ILMN_1756402 TMEM177 -3.50 11.23 0.00 
ILMN_1662038 LARGE -3.14 11.56 0.00 
Sample ID Invasive Type Size Grade Breast cancer Subtype Lymph Node Metastasis 
Q075 Invasive Ductal Carcinoma of No Special Type 43 3 Triple Negative N/A 
Q087 Invasive Ductal Carcinoma of No Special Type 28 2 HER2 Positive Positive 
Q132 Invasive Ductal Carcinoma of No Special Type 17 3 Luminal Positive 
Q151 Invasive Ductal Carcinoma of No Special Type 3 3 Triple Negative Negative 
Q173 Invasive Ductal Carcinoma of No Special Type 28 3 HER2 Positive Negative 
Q179 Invasive Ductal Carcinoma of No Special Type 20 3 HER2 Positive Positive 
Q184 Invasive Ductal Carcinoma of No Special Type 38 2 Triple Negative Negative 
Q214 Normal N/A N/A N/A N/A 
Q215 Normal N/A N/A N/A N/A 
Q218 Invasive Ductal Carcinoma of No Special Type 30 3 Triple Negative Negative 
Q222 Invasive Ductal Carcinoma of No Special Type 13 3 Triple Negative Positive 
Q227 Invasive Ductal Carcinoma of No Special Type 30 3 Triple Negative Positive 
Q230 Invasive Ductal Carcinoma of No Special Type 15 3 Triple Negative Negative 
Q232 Invasive Ductal Carcinoma of No Special Type 30 3 Luminal Positive 
Q234 Invasive Ductal Carcinoma of No Special Type 12 3 Triple Negative N/A 
Q240 Invasive Ductal Carcinoma of No Special Type 50 2 Luminal Positive 
Q248 Mixed ductolobular 16 2 Luminal Negative 
Q251 Normal N/A N/A N/A N/A 
Q254 Mixed ductolobular 130 2 Luminal Positive 
Q261 Normal N/A N/A N/A N/A 
Q268 Invasive Ductal Carcinoma of No Special Type 21 3 Triple Negative Negative 
Q279 Invasive Ductal Carcinoma of No Special Type 40 3 Triple Negative Positive 
Q281 Invasive Ductal Carcinoma of No Special Type 45 3 Triple Negative Negative 
Q293 Normal N/A N/A N/A N/A 
Q304 Normal N/A N/A N/A N/A 
Q307 Normal N/A N/A N/A N/A 
Q311 Invasive Ductal Carcinoma of No Special Type 45 3 HER2 Positive Positive 
Q356 Mixed ductolobular 60 3 Luminal Positive 
Q359 Invasive Ductal Carcinoma of No Special Type 45 3 Luminal Negative 
Q381 Invasive Lobular Carcinoma 12 1 N/A Negative 
Q382 Invasive Ductal Carcinoma of No Special Type 21 3 Luminal Positive 
Q407 Invasive Ductal Carcinoma of No Special Type 30 3 Triple Negative Positive 
Q437 Invasive Ductal Carcinoma of No Special Type 17 3 Triple Negative Positive 
Q441 Invasive Ductal Carcinoma of No Special Type 15 3 Triple Negative Negative 
Q453 Invasive Lobular Carcinoma 39 2 N/A Negative 
Q486 Invasive Ductal Carcinoma of No Special Type 45 3 Triple Negative Positive 
Q488 Invasive Ductal Carcinoma of No Special Type 75 3 Luminal Positive 
Q506 Invasive Ductal Carcinoma of No Special Type 20 3 Triple Negative Negative 
Q509 Invasive Ductal Carcinoma of No Special Type 25 3 Triple Negative Positive 
Q517 Invasive Lobular Carcinoma 19 2 N/A Positive 
Q543 Mixed ductolobular 40 3 Triple Negative Positive 
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ILMN_1780773 LOC400027 -3.89 12.50 0.00 
ILMN_1754531 AP4E1 -3.68 11.72 0.00 
ILMN_2188204 ATG12 -3.11 12.90 0.00 
ILMN_1671933 CLCC1 -2.86 12.40 0.00 
ILMN_1723211 L2HGDH -2.54 10.63 0.00 
ILMN_1732410 SLC16A9 -3.42 10.08 0.00 
ILMN_1669696 ZNF792 -3.36 9.28 0.00 
ILMN_1703564 DYNLRB1 -3.73 12.38 0.00 
ILMN_1684594 USP24 -3.82 10.52 0.00 
ILMN_1736340 ANGEL2 -3.66 10.73 0.00 
ILMN_2320336 CLK3 -3.77 12.27 0.00 
ILMN_3307901 GAN -3.56 10.68 0.00 
ILMN_1664931 GTF2E2 -3.55 13.43 0.00 
ILMN_1658847 MGC61598 -3.48 12.73 0.00 
ILMN_2205050 PRKX -2.66 9.64 0.00 
ILMN_1800626 SESN1 -3.55 11.07 0.00 
ILMN_1719627 SLC27A3 -3.68 11.17 0.00 
ILMN_1788251 SNN -3.37 9.50 0.00 
ILMN_1697448 TXNIP -2.85 13.27 0.00 
ILMN_3307719 ZNF490 -3.90 9.64 0.00 
ILMN_1777061 ZSWIM6 -2.56 10.62 0.00 
ILMN_1786396 ZZEF1 -3.31 9.64 0.00 
ILMN_1665761 BCL11B -3.43 9.23 0.00 
ILMN_1672834 SSH2 -3.91 10.10 0.00 
ILMN_1785356 DENND5A -2.31 10.78 0.00 
ILMN_1662719 GPBP1L1 -2.94 10.42 0.00 
ILMN_1748831 PPP1R13B -2.84 11.29 0.00 
ILMN_1805992 KIAA1598 -2.76 12.26 0.00 
ILMN_1779376 GSK3B -3.06 13.53 0.00 
ILMN_1764177 JARID2 -2.69 10.95 0.00 
ILMN_2165867 DHCR7 -2.92 12.65 0.00 
ILMN_1693421 RPN2 -2.95 10.20 0.00 
ILMN_1805271 ZNF721 -3.21 12.06 0.00 
ILMN_3245413 DENND5A -2.23 10.09 0.00 
ILMN_1815626 DHCR7 -2.71 12.61 0.00 
ILMN_1735499 DCBLD2 -3.27 11.19 0.00 
ILMN_1782829 GLTSCR1 -3.83 9.90 0.00 
ILMN_1814282 ISG20L1 -2.37 12.34 0.00 
ILMN_1718297 EML4 -2.79 11.93 0.00 
ILMN_2339655 MAPK7 -2.00 8.70 0.00 
ILMN_1687567 CUX1 -2.79 8.95 0.00 
ILMN_1733690 AKAP7 -2.40 8.88 0.00 
ILMN_1696675 CES2 -3.14 10.02 0.00 
ILMN_1669905 DCP2 -2.81 12.38 0.00 
ILMN_2186061 PFKFB3 -3.43 11.11 0.00 
ILMN_1735360 SDAD1 -3.03 13.11 0.00 
ILMN_1705310 VEZF1 -2.64 13.00 0.00 
ILMN_1719064 KCTD10 -2.91 10.10 0.00 
ILMN_2374244 DYRK2 -2.54 13.03 0.00 
ILMN_1739222 ETV5 -4.30 11.25 0.00 
ILMN_1696311 IMPAD1 -3.52 11.07 0.00 
ILMN_1705985 PIGA -3.52 12.71 0.00 
ILMN_1682699 PBX2 -2.71 10.09 0.00 
ILMN_1747775 STX2 -3.14 10.86 0.00 
ILMN_2405602 OSBPL1A -2.88 11.45 0.00 
ILMN_2055760 KIAA1715 -3.07 10.77 0.00 
ILMN_1766094 MOSPD2 -3.17 11.31 0.00 
ILMN_1773865 HSPA5 -3.04 10.05 0.00 
ILMN_1786125 CCNA2 -3.07 12.72 0.00 
ILMN_1658425 DAG1 -2.87 10.91 0.00 
ILMN_2053567 FASTKD2 -2.71 9.99 0.00 
ILMN_1709623 MAPK7 -2.28 10.07 0.00 
ILMN_1798354 PAPOLA -2.71 12.53 0.00 
ILMN_1783350 PCNXL3 -2.97 11.47 0.00 
ILMN_1804562 SLC31A1 -4.04 10.79 0.00 
ILMN_1740819 STARD7 -2.71 13.67 0.00 
ILMN_1781479 SUV39H1 -3.12 11.78 0.00 
ILMN_1764549 UBE3A -2.59 11.45 0.00 
ILMN_2391141 UBE3A -2.34 11.11 0.00 
ILMN_2105983 XRCC5 -3.28 10.44 0.00 
ILMN_1730888 ZNF680 -2.22 10.76 0.00 
ILMN_1774604 PNKD -2.71 12.48 0.00 
ILMN_1907095 ONECUT2 -2.12 9.61 0.00 
ILMN_1674231 CHAF1B -3.30 10.90 0.00 
ILMN_1803745 SUOX -4.28 11.53 0.00 
ILMN_1670263 C1orf71 -2.76 11.22 0.00 
ILMN_1691432 PRDM4 -2.62 13.29 0.00 
ILMN_1760620 TMEM33 -2.91 9.00 0.00 
ILMN_1744023 MGC18216 -2.66 11.32 0.00 
ILMN_1797342 FNBP1 -2.71 11.36 0.00 
ILMN_1777881 TSPAN17 -2.28 13.10 0.00 
ILMN_2394027 CLK3 -3.52 10.38 0.00 
ILMN_2089073 ATP9A -2.38 13.81 0.00 
ILMN_1673898 ATG12 -3.10 9.71 0.00 
ILMN_1723481 CHST3 -1.76 8.34 0.00 
ILMN_3240321 AEN -2.68 11.37 0.00 
ILMN_1707175 NSD1 -2.12 8.85 0.00 
ILMN_1738821 GOLGA2 -2.15 9.28 0.00 
ILMN_2344216 STX2 -2.77 10.29 0.00 
ILMN_1709257 DSCR6 -2.16 11.17 0.00 
ILMN_1670124 LOC150223 -1.97 8.92 0.00 
ILMN_2404049 RBM38 -1.86 12.38 0.00 
ILMN_1711005 CDC25A -2.14 11.24 0.00 
ILMN_1775761 TSR1 -2.35 9.83 0.00 
ILMN_2206812 CCNJ -1.98 8.69 0.00 
ILMN_1741334 IKZF4 -2.11 8.67 0.00 
ILMN_1810712 ARHGEF12 -2.57 8.84 0.00 
ILMN_3238048 LOC730324 -2.72 11.44 0.00 
ILMN_1681304 PAN3 -2.73 11.27 0.00 
ILMN_1663532 RIC8B -1.89 10.25 0.00 
ILMN_1742705 SLC39A11 -2.48 9.65 0.00 
ILMN_1710078 TMEM181 -3.49 11.70 0.00 
ILMN_1676629 INSIG2 -2.63 10.01 0.00 
ILMN_1682864 SPSB3 -1.87 10.78 0.00 
ILMN_1664034 ZNF485 -3.34 10.59 0.00 
ILMN_1711543 C14orf169 -3.54 11.99 0.00 
ILMN_1775182 GSR -2.47 10.73 0.00 
ILMN_1760303 PIK3R1 -2.68 11.49 0.00 
ILMN_1660079 RNF44 -2.68 10.60 0.00 
ILMN_1803652 C9orf91 -2.20 11.22 0.00 
ILMN_2164081 KLHL12 -1.79 11.21 0.00 
ILMN_1814737 LNPEP -2.71 9.58 0.00 
ILMN_2126423 ZNF480 -2.24 11.45 0.00 
ILMN_1708081 LCLAT1 -3.70 10.25 0.00 
ILMN_2290118 MEGF9 -2.88 9.73 0.00 
ILMN_1807873 SNX6 -2.35 10.97 0.00 
ILMN_1801605 BIRC6 -2.44 9.61 0.00 
ILMN_2362681 CES2 -2.74 8.90 0.00 
ILMN_1673950 STBD1 -2.01 8.60 0.00 
ILMN_1730539 NPHP3 -2.34 8.61 0.00 
ILMN_1711894 MYB -2.81 12.69 0.00 
ILMN_1809484 TMOD3 -1.71 9.40 0.00 
ILMN_2256359 HSZFP36 -3.13 12.05 0.00 
ILMN_1705151 SF3A3 -2.20 11.43 0.00 
ILMN_1673682 GATAD2A -1.87 13.86 0.00 
ILMN_1763228 MEF2D -1.82 8.98 0.00 
ILMN_1712298 ANKRD46 -2.49 11.30 0.00 
ILMN_1755954 CPEB3 -2.48 9.69 0.00 
ILMN_1672660 MBP -3.21 10.26 0.00 
ILMN_2174127 DCBLD2 -3.11 11.68 0.00 
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ILMN_1654385 ASB13 -2.50 10.08 0.00 
ILMN_1717094 ZNF618 -1.53 9.12 0.00 
ILMN_1794588 DYRK2 -2.49 10.49 0.00 
ILMN_1738383 EEF2 -2.11 14.35 0.00 
ILMN_1735151 EIF5A2 -1.68 9.29 0.00 
ILMN_1700231 IP6K1 -1.75 10.16 0.00 
ILMN_1733155 GIT1 -2.79 11.24 0.00 
ILMN_2196569 NUP93 -1.87 10.37 0.00 
ILMN_1709479 YAP1 -2.48 9.47 0.00 
ILMN_2196337 C12orf11 -1.87 10.29 0.00 
ILMN_1746561 BCL2L2 -2.44 11.88 0.00 
ILMN_1776582 PDK3 -2.54 10.79 0.00 
ILMN_2076940 C1orf149 -1.85 9.38 0.00 
ILMN_1743747 RUSC1 -2.07 14.07 0.00 
ILMN_1851492  -2.25 12.06 0.00 
ILMN_1772588 C6orf97 -2.60 9.60 0.00 
ILMN_1726306 HMBS -2.54 12.19 0.00 
ILMN_1848552  -2.43 11.53 0.00 
ILMN_1743582 NUDT22 -2.63 11.11 0.00 
ILMN_2214197 TP53INP1 -2.73 9.34 0.00 
ILMN_1760441 MRPS5 -2.53 10.81 0.00 
ILMN_1715392 PRPF3 -2.37 12.30 0.00 
ILMN_1695961 CLK3 -2.25 8.74 0.00 
ILMN_1772876 ZNF395 -1.76 11.00 0.00 
ILMN_1781791 PRRG1 -1.96 9.10 0.00 
ILMN_1761531 SGPL1 -2.74 9.99 0.00 
ILMN_1783023 C5orf51 -1.79 11.93 0.00 
ILMN_1658834 ZC3H18 -2.54 9.49 0.00 
ILMN_1727970 ONECUT1 -1.99 8.80 0.00 
ILMN_1790973 CDS2 -3.62 9.89 0.00 
ILMN_1658351 FIS1 -2.47 12.75 0.00 
ILMN_2194627 GMCL1 -2.13 10.04 0.00 
ILMN_1847308  -2.89 11.18 0.00 
ILMN_2390162 PHF11 -2.41 11.22 0.00 
ILMN_1789599 NBL1 -2.12 12.48 0.00 
ILMN_2153495 WNT7B -2.41 10.17 0.00 
ILMN_1813635 KIAA1429 -2.71 9.95 0.00 
ILMN_2158242 SHOC2 -2.27 10.88 0.00 
ILMN_1782412 IRX2 -1.71 12.18 0.00 
ILMN_1706376 OSBP -2.48 11.82 0.00 
ILMN_1806828 MRI1 -2.80 9.44 0.00 
ILMN_1726064 PAK1IP1 -2.42 11.87 0.00 
ILMN_1782069 TRAK1 -2.70 10.60 0.00 
ILMN_1701131 C2orf49 -3.60 11.71 0.00 
ILMN_2383455 SUOX -3.87 9.87 0.00 
ILMN_2410965 MRI1 -2.67 10.54 0.00 
ILMN_1715069 TANK -2.86 10.94 0.00 
ILMN_2396272 PDCD4 -2.42 12.92 0.00 
ILMN_1723632 PIGC -2.26 12.36 0.00 
ILMN_1812580 YDJC -3.38 11.62 0.00 
ILMN_1727996 BAG4 -1.68 9.47 0.00 
ILMN_3199647 LOC645251 -1.92 8.98 0.00 
ILMN_1721170 GREB1 -1.85 11.40 0.00 
ILMN_1657550 MVD -3.26 10.25 0.00 
ILMN_2128770 CDR2L -1.93 12.12 0.00 
ILMN_1703852 EFNB2 -1.72 10.71 0.00 
ILMN_1862521  -1.70 8.69 0.00 
ILMN_1699989 BNIPL -1.62 8.97 0.00 
ILMN_2392189 CTDSPL -1.63 9.20 0.00 
ILMN_3245066 DENND4B -3.97 12.00 0.00 
ILMN_1743204 DUSP8 -2.87 10.15 0.00 
ILMN_1688246 LOC642852 -2.20 9.33 0.00 
ILMN_3187328 IP6K1 -1.83 10.15 0.00 
ILMN_1714622 TNRC6A -2.09 10.30 0.00 
ILMN_1708619 SEH1L -1.67 10.44 0.00 
ILMN_1786834 PRKX -2.11 8.96 0.00 
ILMN_1751615 COQ10B -1.64 12.82 0.00 
ILMN_1811579 HOMER3 -1.56 10.39 0.00 
ILMN_3186473 LCLAT1 -3.30 9.26 0.00 
ILMN_1779448 EFHD1 -2.22 11.89 0.00 
ILMN_1773427 KANK1 -1.97 9.26 0.00 
ILMN_1669064 ZNF823 -3.11 10.85 0.00 
ILMN_1820244  -3.37 10.15 0.00 
ILMN_2173294 FLJ10916 -2.09 10.13 0.00 
ILMN_1754130 TRIM52 -2.88 9.14 0.00 
ILMN_2337263 PKIB -2.30 14.25 0.00 
ILMN_2358784 ASB3 -2.74 10.46 0.00 
ILMN_2358783 ASB3 -1.99 9.38 0.00 
ILMN_1804820 ZNF431 -1.72 8.75 0.00 
ILMN_2311518 TROVE2 -1.84 12.58 0.00 
ILMN_2272074 TROVE2 -1.81 9.24 0.00 
ILMN_1737084 TXLNA -1.52 10.45 0.00 
ILMN_1768004 PDCD4 -1.65 8.64 0.00 
ILMN_1771957 MAN1B1 -1.66 10.54 0.00 
ILMN_1795285 PHF15 -1.44 10.47 0.00 
ILMN_1778173 AK3 -2.23 12.52 0.00 
ILMN_1732089 MRI1 -2.90 11.18 0.00 
ILMN_2374383 TSPAN17 -2.40 10.95 0.00 
ILMN_1782788 CSDA -1.54 14.71 0.00 
ILMN_1687884 ZNF2 -1.76 8.99 0.00 
ILMN_1682775 EDN1 -3.11 11.53 0.00 
ILMN_2408430 LARGE -2.51 9.38 0.00 
ILMN_1744713 PARK7 -2.80 13.91 0.00 
ILMN_1768743 FIP1L1 -1.69 9.99 0.00 
ILMN_1745112 FAM102A -1.82 12.55 0.00 
ILMN_2401779 FAM102A -1.63 12.61 0.00 
ILMN_1769637 RNMT -2.40 10.17 0.00 
ILMN_1751234 C1GALT1C
1 
-1.95 9.74 0.00 
ILMN_1804327 NAP1L4 -1.87 12.22 0.00 
ILMN_1688629 ZNF274 -2.04 10.54 0.00 
ILMN_1726842 TYW3 -2.05 9.48 0.00 
ILMN_1720373 SLC7A5 -1.78 14.58 0.00 
ILMN_1773751 HRAS -1.65 11.87 0.00 
ILMN_2367782 STARD7 -3.09 10.97 0.00 
ILMN_1815519 EPN2 -1.46 9.45 0.00 
ILMN_1712517 ZNF696 -1.97 9.96 0.00 
ILMN_1744665 EP300 -1.93 8.79 0.00 
ILMN_1678494 ZNF438 -1.55 8.66 0.00 
ILMN_1737715 OSR2 -1.76 11.09 0.00 
ILMN_3251207 TMEM19 -1.93 9.04 0.00 
ILMN_1719696 PLD1 -1.36 8.14 0.00 
ILMN_1690320 TTC23 -1.85 9.31 0.00 
ILMN_1693014 CEBPB -1.54 14.63 0.00 
ILMN_1792076 TRERF1 -1.90 9.07 0.00 
ILMN_3235593 ZNF841 -1.91 9.54 0.00 
ILMN_1794063 ANKRD27 -2.13 8.85 0.00 
ILMN_1784860 RFC3 -1.81 10.85 0.00 
ILMN_1706706 WDR68 -2.49 11.12 0.00 
ILMN_2122953 CISD1 -3.17 12.97 0.00 
ILMN_3246910 LOC100190
986 
-1.37 8.69 0.00 
ILMN_1670532 GMCL1 -1.94 10.05 0.00 
ILMN_2284591 OPA3 -1.90 10.08 0.00 
ILMN_1662316 VPS33A -2.16 9.37 0.00 
ILMN_2342240 MGAT2 -3.00 11.75 0.00 
ILMN_2331636 ACACA -1.85 10.14 0.00 
ILMN_1776723 PHF11 -2.48 11.45 0.00 
ILMN_1770244 CBX1 -2.21 8.76 0.00 
ILMN_3262345 HEATR7A -1.47 8.96 0.00 
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ILMN_1765829 NUFIP2 -1.85 10.17 0.00 
ILMN_1827736  -2.00 11.28 0.00 
ILMN_2293758 AKAP11 -1.39 10.06 0.00 
ILMN_1677292 C5orf30 -2.04 10.94 0.00 
ILMN_1691097 HSP90AA1 -2.98 13.28 0.00 
ILMN_1714854 MEAF6 -1.33 8.39 0.00 
ILMN_1680782 PATL1 -1.87 11.24 0.00 
ILMN_2352293 PRDM10 -1.73 8.95 0.00 
ILMN_1803045 TUBGCP5 -1.77 8.31 0.00 
ILMN_1741780 DUSP28 -2.24 10.07 0.00 
ILMN_1718718 MKKS -2.08 12.04 0.00 
ILMN_1722781 EGR3 -1.27 8.12 0.00 
ILMN_1831566  -1.55 8.55 0.00 
ILMN_1687107 RFWD3 -1.56 12.15 0.00 
ILMN_1789233 VPS37C -1.41 13.47 0.00 
ILMN_1832208  -2.93 11.71 0.00 
ILMN_1837935 TNPO1 -2.39 9.05 0.00 
ILMN_2405078 OSBPL8 -2.78 10.24 0.00 
ILMN_1777096 TDG -1.67 13.39 0.00 
ILMN_1793040 ADAMTSL5 -1.41 8.33 0.00 
ILMN_2132809 ARHGEF10 -1.85 9.88 0.00 
ILMN_2405009 NBL1 -2.23 11.75 0.00 
ILMN_1676062 DIP2C -2.06 9.52 0.00 
ILMN_3238058 LOC151162 -1.48 12.29 0.00 
ILMN_1735058 CHST12 -1.32 8.70 0.00 
ILMN_1678535 ESR1 -2.01 12.60 0.00 
ILMN_2386008 MPZL1 -2.59 10.33 0.00 
ILMN_2186626 ZNF485 -2.22 8.86 0.00 
ILMN_1682264 DCAF7 -2.08 12.52 0.00 
ILMN_1714170 SPSB1 -1.93 10.20 0.00 
ILMN_1758105 ZNF791 -1.71 10.36 0.00 
ILMN_2390416 BAT3 -1.59 10.23 0.00 
ILMN_2073543 C15orf63 -1.44 12.26 0.00 
ILMN_1676946 AP3M2 -1.53 9.95 0.00 
ILMN_1723971 SLC29A1 -2.54 9.76 0.00 
ILMN_1655068 TOM1L2 -1.72 8.52 0.00 
ILMN_1837428  -1.29 11.69 0.00 
ILMN_1674380 TRPC1 -2.02 8.45 0.00 
ILMN_1808356 FAM3A -1.56 13.13 0.00 
ILMN_1655206 ZBTB34 -1.91 9.80 0.00 
ILMN_1668535 JOSD1 -1.34 10.61 0.00 
ILMN_1726388 ACBD7 -1.44 9.10 0.00 
ILMN_1654392 KHNYN -2.84 9.93 0.00 
ILMN_1669201 ABCF2 -1.75 9.19 0.00 
ILMN_1670439 FYTTD1 -1.35 10.25 0.00 
ILMN_1673024 RBM15B -1.21 8.89 0.00 
ILMN_1746359 RERG -1.51 11.86 0.00 
ILMN_1666453 STK3 -1.95 11.51 0.00 
ILMN_1660111 UCHL3 -3.72 11.92 0.00 
ILMN_3243961 ZNF252 -2.00 12.07 0.00 
ILMN_1786852 ZCCHC3 -1.46 9.26 0.00 
ILMN_2122952 CISD1 -3.10 12.73 0.00 
ILMN_1709549 PLEKHM1 -2.19 8.67 0.00 
ILMN_1662161 TBC1D13 -1.26 9.74 0.00 
ILMN_1742578 MKLN1 -1.44 10.89 0.00 
ILMN_1659937 ZBTB24 -1.57 10.61 0.00 
ILMN_1809400 FAM49B -2.01 8.53 0.00 
ILMN_1789839 GTF3C1 -1.52 9.16 0.00 
ILMN_1666761 PPP2R5E -1.72 13.75 0.00 
ILMN_2097185 PUS3 -2.20 9.36 0.00 
ILMN_1787808 CEP63 -1.84 10.61 0.00 
ILMN_3237850 C5orf51 -1.73 11.57 0.00 
ILMN_1763666 ALDH3B2 -1.71 11.62 0.00 
ILMN_1760280 NXT1 -2.10 12.93 0.00 
ILMN_3244019 LOC647886 -1.62 8.49 0.00 
ILMN_1673966 POLR3F -2.25 10.66 0.00 
ILMN_1806804 USP14 -1.30 8.99 0.00 
ILMN_1761463 EFHD2 -3.13 12.80 0.00 
ILMN_1773063 OSBPL1A -1.52 9.10 0.00 
ILMN_1809894 TMEM117 -1.51 8.39 0.00 
ILMN_3247821 TMEM206 -2.18 9.11 0.00 
ILMN_1709132 ELP2 -1.76 10.53 0.00 
ILMN_1714384 PCCA -1.83 8.67 0.00 
ILMN_2217935 RFC1 -1.70 10.04 0.00 
ILMN_2230683 CDCA7L -1.93 9.03 0.00 
ILMN_1689868 TMEM80 -2.06 8.79 0.00 
ILMN_1672504 PDXK -2.41 12.71 0.00 
ILMN_2075440 PDIA3P -1.27 8.84 0.00 
ILMN_1724410 USP46 -2.56 9.34 0.00 
ILMN_3238751 PMS2L4 -1.13 11.77 0.00 
ILMN_2102693 NUFIP2 -1.64 10.00 0.00 
ILMN_1743499 POLDIP2 -2.43 10.18 0.00 
ILMN_1706434 LOC440359 -1.86 13.01 0.00 
ILMN_1889752  -1.98 9.75 0.00 
ILMN_1787256 HCN3 -1.18 8.08 0.00 
ILMN_1663664 MRPS10 -1.30 12.05 0.00 
ILMN_1718961 BNIP3L -1.58 9.37 0.00 
ILMN_1797341 ARID1A -2.08 9.83 0.00 
ILMN_1856861  -1.32 9.42 0.00 
ILMN_1815361 XIAP -1.32 8.13 0.00 
ILMN_1733042 BCAS1 -1.68 9.83 0.00 
ILMN_1756049 NT5DC3 -1.30 9.92 0.00 
ILMN_2397571 PIGC -2.07 9.84 0.00 
ILMN_1710738 RC3H2 -2.04 11.46 0.00 
ILMN_1689817 LCOR -1.25 10.00 0.00 
ILMN_3238006 LOC730323 -1.09 10.78 0.00 
ILMN_1708482 TMEM80 -1.82 8.96 0.00 
ILMN_1685602 TMEM41A -1.51 9.68 0.00 
ILMN_1784540 KBTBD2 -1.39 11.93 0.00 
ILMN_1783771 UBE2Z -2.07 10.54 0.00 
ILMN_1710427 VPS37B -1.63 10.47 0.00 
ILMN_1807031 C14orf28 -1.74 9.38 0.00 
ILMN_2060145 GRHL2 -2.19 10.87 0.00 
ILMN_1690442 C18orf45 -1.68 11.51 0.00 
ILMN_1768662 UCK2 -2.55 11.53 0.00 
ILMN_1694147 PUS3 -2.33 10.25 0.00 
ILMN_2252136 YWHAE -2.56 11.68 0.00 
ILMN_2046470 DAAM1 -1.36 9.59 0.00 
ILMN_2096191 AASDHPPT -1.14 9.09 0.00 
ILMN_1771824 DNAJC30 -1.04 8.46 0.00 
ILMN_2126706 LMNB1 -1.44 9.47 0.00 
ILMN_1720998 CA12 -1.55 11.38 0.00 
ILMN_2139816 GPSM2 -1.16 11.44 0.00 
ILMN_3224204 PSMG4 -1.35 11.50 0.00 
ILMN_1743316 FAM109A -1.17 8.70 0.00 
ILMN_1810436 DNAJC27 -1.94 10.07 0.00 
ILMN_1801443 TSKU -2.24 12.57 0.00 
ILMN_1706118 HN1L -2.24 9.92 0.00 
ILMN_1794677 TMC6 -1.44 9.97 0.00 
ILMN_1699703 ARCN1 -1.49 12.69 0.00 
ILMN_1704079 RBM38 -1.64 10.53 0.00 
ILMN_1762678 NMT1 -1.15 9.19 0.00 
ILMN_2106227 KIAA2026 -1.33 8.62 0.00 
ILMN_1709630 CCDC107 -1.06 8.15 0.00 
ILMN_1784630 KBTBD11 -1.47 8.20 0.00 
ILMN_1748432 ZNF525 -2.59 10.38 0.00 
ILMN_1777318 C9orf64 -1.89 10.21 0.00 
ILMN_3298694 TYW1B -1.34 10.00 0.00 
ILMN_1727809 STK35 -1.50 9.61 0.00 
ILMN_1702501 RPS6KA2 -1.15 8.31 0.00 
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ILMN_1703946 ADORA2B -2.20 9.01 0.00 
ILMN_1684591 ZNF434 -1.79 10.20 0.00 
ILMN_1803824 ZDHHC9 -1.15 12.43 0.00 
ILMN_1746314 EVI5 -1.50 9.52 0.00 
ILMN_1714108 TP53INP1 -3.14 10.77 0.00 
ILMN_2224143 MCM3 -1.73 12.60 0.00 
ILMN_2325112 C22orf40 -1.43 8.08 0.00 
ILMN_1743456 ZCCHC14 -1.15 10.05 0.00 
ILMN_1734231 DDOST -1.81 12.13 0.00 
ILMN_1713846 PPM1H -1.03 10.94 0.00 
ILMN_1841334  -1.49 10.79 0.00 
ILMN_1726520 TDP1 -1.47 8.87 0.00 
ILMN_2338997 PTP4A2 -1.15 14.04 0.00 
ILMN_2361570 SNX14 -1.40 9.37 0.00 
ILMN_1788738 ZNRF3 -1.25 8.10 0.00 
ILMN_1724658 BNIP3 -1.34 13.43 0.00 
ILMN_1792910 MNT -1.21 8.90 0.00 
ILMN_2144573 CTBS -1.65 9.09 0.00 
ILMN_1664921 PPP6C -2.17 14.02 0.00 
ILMN_2112493 DAP -1.73 12.19 0.00 
ILMN_1808789 MYO5C -1.25 12.24 0.00 
ILMN_1704383 TRIM37 -2.91 12.53 0.00 
ILMN_3240685 INO80D -1.47 10.15 0.00 
ILMN_1794333 POU2F1 -1.24 9.05 0.00 
ILMN_1813489 RAF1 -1.39 12.10 0.00 
ILMN_2221673 ASNSD1 -2.08 12.79 0.00 
ILMN_1772522 ZFP161 -1.69 10.13 0.00 
ILMN_1791067 TESK1 -1.47 11.26 0.00 
ILMN_1771333 CD47 -2.02 9.96 0.00 
ILMN_1798790 IL17RC -1.55 8.54 0.00 
ILMN_2181363 UBE3C -1.18 13.20 0.00 
ILMN_1702279 KIF3B -1.99 9.89 0.00 
ILMN_1702384 ZNF706 -1.06 9.78 0.00 
ILMN_1772123 ACACA -1.57 9.76 0.00 
ILMN_1794967 EIF4ENIF1 -1.16 9.06 0.00 
ILMN_1789436 C1orf218 -1.32 11.08 0.00 
ILMN_1794294 DSTN -1.45 9.94 0.00 
ILMN_1807515 CSTF2T -1.00 7.91 0.00 
ILMN_2339202 KTN1 -2.43 11.05 0.00 
ILMN_2392286 IP6K1 -1.64 9.74 0.00 
ILMN_1763208 ZNF10 -1.08 7.91 0.00 
ILMN_1764794 PSMB2 -3.34 13.03 0.00 
ILMN_2094776 CCNL1 -2.17 9.97 0.00 
ILMN_1733519 HMGB3 -1.32 10.15 0.00 
ILMN_2359789 RAC1 -1.38 14.30 0.00 
ILMN_1880983  -2.17 11.05 0.00 
ILMN_1683494 TMEM154 -1.53 9.35 0.00 
ILMN_1751258 NDUFA4 -2.37 13.22 0.00 
ILMN_1746012 MBD6 -1.25 11.49 0.00 
ILMN_1694686 KIAA0194 -2.53 10.36 0.00 
ILMN_1714159 LUZP1 -1.33 9.40 0.00 
ILMN_1802780 M160 -1.28 9.53 0.00 
ILMN_1704342 UBE3C -1.27 11.02 0.00 
ILMN_2342437 KLHL5 -2.71 9.94 0.00 
ILMN_1707326 TASP1 -1.90 8.57 0.00 
ILMN_1782057 ATP8B2 -1.04 9.11 0.00 
ILMN_2346831 MGAT2 -1.80 8.70 0.00 
ILMN_2081398 KIF3B -2.21 9.82 0.00 
ILMN_2212763 ICAM3 -1.37 11.64 0.00 
ILMN_1738579 VHL -1.39 12.83 0.00 
ILMN_1661599 DDIT4 -2.97 12.66 0.00 
ILMN_1663042 SDC4 -1.39 11.31 0.00 
ILMN_1701512 KIAA0391 -1.49 11.73 0.00 
ILMN_3241510 FBXO45 -1.29 9.36 0.00 
ILMN_1694759 C19orf42 -1.41 11.29 0.00 
ILMN_1673892 GK5 -1.09 9.14 0.00 
ILMN_3226769 LOC730074 -2.30 10.30 0.00 
ILMN_1677534 SCAP -1.16 10.41 0.00 
ILMN_2338963 SLC29A1 -2.25 8.87 0.00 
ILMN_2316918 PANK1 -1.90 10.44 0.00 
ILMN_1786606 LOC729764 -1.53 8.25 0.00 
ILMN_1660847 PFKFB3 -1.45 8.56 0.00 
ILMN_1656165 USP9X -1.70 10.50 0.00 
ILMN_1667476 LTBR -1.30 12.90 0.00 
ILMN_2083334 PMS2L5 -1.47 9.23 0.00 
ILMN_1715969 SLC25A37 -1.01 9.66 0.00 
ILMN_2159152 TP53TG3 -1.11 7.99 0.00 
ILMN_1664646 NSUN6 -1.05 8.27 0.00 
ILMN_1669599 DENND4C -1.43 10.55 0.00 
ILMN_1697153 ZDHHC17 -1.13 8.96 0.00 
ILMN_1797594 NFAT5 -1.48 8.78 0.00 
ILMN_2115669 SEMA4C -1.04 8.90 0.00 
ILMN_1765044 CUTC -2.79 11.02 0.00 
ILMN_2118472 C10orf58 -1.17 14.59 0.00 
ILMN_2043918 DLEU1 -2.50 10.33 0.00 
ILMN_2077886 C1orf109 -2.26 9.47 0.00 
ILMN_1691117 DNTTIP1 -2.78 11.20 0.00 
ILMN_1735275 WDSUB1 -1.77 9.91 0.00 
ILMN_3230435 LOC729086 -1.69 9.11 0.00 
ILMN_2096405 WDR37 -1.46 9.70 0.00 
ILMN_1796130 LOC221710 -1.66 10.44 0.00 
ILMN_2329914 SPRY1 -1.99 8.68 0.00 
ILMN_1765636 FLJ22184 -1.32 8.79 0.00 
ILMN_1740523 KTN1 -2.25 8.85 0.00 
ILMN_2399174 TRAK1 -1.54 8.89 0.00 
ILMN_1786470 C1orf74 -1.45 9.88 0.00 
ILMN_1802819 DEPDC1 -1.32 9.63 0.00 
ILMN_1741942 STX16 -1.32 12.50 0.00 
ILMN_1725969 RPP14 -1.04 8.10 0.00 
ILMN_1838320 ONECUT2 -1.36 9.57 0.00 
ILMN_1726786 TNRC6B -1.04 8.92 0.00 
ILMN_1741300 ZNF407 -1.15 8.52 0.00 
ILMN_2063586 CLIC4 -1.13 10.37 0.00 
ILMN_1774083 TRIAP1 -1.54 12.15 0.00 
ILMN_1734476 KIF2A -2.39 10.20 0.00 
ILMN_1750967 ZKSCAN3 -1.09 8.28 0.00 
ILMN_2054510 BCAS3 -1.31 11.62 0.00 
ILMN_2210482 MRPS34 -2.43 10.39 0.00 
ILMN_1804929 OXTR -1.54 9.13 0.00 
ILMN_1654287 ADCY9 -1.02 9.22 0.00 
ILMN_1674506 MED23 -1.04 8.18 0.00 
ILMN_3236428 TMEM170B -1.18 9.00 0.00 
ILMN_1810085 ABCF3 -1.73 8.77 0.00 
ILMN_1670901 COX10 -1.24 11.19 0.00 
ILMN_2325347 B3GALNT1 -1.60 12.72 0.00 
ILMN_1711109 TOM1L2 -1.11 8.12 0.00 
ILMN_2088124 TMEM154 -1.45 9.56 0.00 
ILMN_2246956 BCL2 -1.14 8.36 0.00 
ILMN_1797903 ZNF544 -1.01 12.10 0.00 
ILMN_1808202 C19orf22 -1.34 12.06 0.00 
ILMN_1673795 HSD17B4 -2.65 11.00 0.00 
ILMN_1758719 NEDD9 -1.19 8.10 0.00 
ILMN_1798210 E2F7 -1.29 9.65 0.00 
ILMN_1696827 PARS2 -1.12 8.25 0.00 
ILMN_2414014 RBM10 -1.79 12.42 0.00 
ILMN_1811373 FAM20B -1.33 12.71 0.00 
ILMN_2173004 RAB8B -2.14 9.30 0.00 
ILMN_1813625 TRIM25 -1.72 9.73 0.00 
ILMN_2387471 FLJ22184 -1.22 10.60 0.00 
ILMN_3237156 LOC100009 -1.11 8.15 0.00 
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ILMN_1760320 GNB1 -1.06 13.41 0.00 
ILMN_2255579 RAB37 -1.38 8.63 0.00 
ILMN_1686626 BAT1 -1.93 12.74 0.00 
ILMN_2122374 FAM49B -1.48 8.26 0.00 
ILMN_1803939 YIPF6 -1.43 11.42 0.00 
ILMN_1765520 MTIF2 -1.82 11.19 0.00 
ILMN_1768470 EIF4G1 -1.60 11.92 0.00 
ILMN_1699112 COPB1 -1.73 11.42 0.00 
ILMN_2373515 HSP90AA1 -1.01 14.81 0.00 
ILMN_1688755 AAK1 -1.88 9.26 0.00 
ILMN_2091792 ENTPD6 -1.51 10.71 0.00 
ILMN_1747183 GXYLT1 -1.83 10.13 0.00 
ILMN_1695719 EIF2C2 -1.09 13.39 0.00 
ILMN_2140974 TPM4 -1.72 10.58 0.00 
ILMN_1706687 KLHL5 -2.90 11.92 0.00 
ILMN_2053415 LDLR -1.18 12.04 0.00 
ILMN_1687315 RXRA -1.01 12.47 0.00 
ILMN_1721349 MAGT1 -1.21 11.95 0.00 
ILMN_1813191 LOC653080 -1.09 8.93 0.00 
ILMN_1746368 SELT -1.15 9.90 0.00 
ILMN_1754553 MED19 -1.53 10.16 0.00 
ILMN_2105966 SLC35A4 -2.20 11.42 0.00 
ILMN_1692168 UBE2Z -1.66 11.30 0.00 
ILMN_1714965 NFKB1 -1.31 11.79 0.00 
ILMN_1668822 BATF -1.72 11.11 0.00 
ILMN_1693410 BRI3BP -1.26 12.95 0.00 
ILMN_1789492 ZDHHC8 -1.47 10.14 0.00 
ILMN_2388975 CERK -1.25 8.46 0.00 
ILMN_2067709 TFB2M -1.96 9.42 0.00 
ILMN_1787567 TSC22D1 -2.52 11.87 0.00 
ILMN_1791106 HEATR6 -1.83 11.70 0.00 
ILMN_2194649 TADA1L -1.01 9.40 0.00 
ILMN_1683305 COMMD2 -2.15 11.22 0.00 
ILMN_1712320 DDX50 -1.03 10.13 0.00 
ILMN_1746465 FJX1 -1.59 9.40 0.00 
ILMN_1748770 CKAP5 -1.29 11.73 0.00 
ILMN_1774074 RXRB -1.48 9.27 0.00 
ILMN_3250585 KIAA0194 -2.67 10.43 0.00 
ILMN_1802973 ANAPC4 -1.85 10.41 0.00 
ILMN_1722239 TIMM8A -1.07 9.73 0.00 
ILMN_1802799 AKIRIN1 -1.13 11.34 0.00 
ILMN_2376625 VHL -1.39 9.37 0.00 
ILMN_2347349 CCNB1IP1 -1.68 11.61 0.00 
ILMN_3240541 EML2 -1.85 8.57 0.00 
ILMN_3305055 TP63 -1.96 9.63 0.00 
ILMN_1797534 RIOK1 -1.75 9.84 0.00 
ILMN_1708611 RDX -2.10 12.02 0.00 
ILMN_2136147 BCAS1 -1.42 9.53 0.00 
ILMN_1752394 CCNB1IP1 -1.59 10.64 0.00 
ILMN_1806607 SFN -1.49 11.19 0.00 
ILMN_1759495 XPO5 -1.44 10.29 0.00 
ILMN_2101832 LAPTM4B -1.77 13.29 0.00 
ILMN_1752226 P2RY11 -1.17 8.56 0.00 
ILMN_1699254 PLEKHH1 -1.55 8.99 0.00 
ILMN_1711878 ENOPH1 -1.58 12.65 0.00 
ILMN_2366703 SGK3 -2.11 10.85 0.00 
ILMN_1750008 SUPV3L1 -2.18 10.11 0.00 
ILMN_1801101 ZBTB48 -1.19 8.36 0.00 
ILMN_1718988 DAZAP2 -1.35 13.39 0.00 
ILMN_1664922 FLNB -1.73 10.27 0.00 
ILMN_1770719 KIAA0664 -1.96 9.75 0.00 
ILMN_2061950 RABGAP1 -1.38 12.02 0.00 
ILMN_1810832 ZNF343 -1.44 8.64 0.00 
ILMN_1653896 ATRIP -1.11 8.77 0.00 
ILMN_2064606 TBC1D2B -1.23 9.05 0.00 
ILMN_3228822 TMEM194A -1.19 11.21 0.00 
ILMN_1816244  -1.02 8.58 0.00 
ILMN_1781745 C9orf152 -1.79 11.00 0.00 
ILMN_1681641 DLEU1 -2.08 8.61 0.00 
ILMN_1772658 KIAA0947 -1.45 8.27 0.00 
ILMN_2243687 LAMP2 -1.24 10.18 0.00 
ILMN_2387919 PRKAG2 -1.22 9.43 0.00 
ILMN_1692219 RAB11FIP1 -1.12 10.58 0.00 
ILMN_2136455 C3orf64 -1.20 8.01 0.00 
ILMN_1767475 CERK -1.63 9.13 0.00 
ILMN_2381138 SEH1L -1.80 10.86 0.00 
ILMN_1666545 GCNT1 -1.61 9.96 0.00 
ILMN_2104830 ACP2 -1.10 9.19 0.00 
ILMN_1678504 RHOT1 -1.06 11.46 0.00 
ILMN_1749809 ZNF813 -1.02 8.42 0.00 
ILMN_1710092 ZBTB46 -1.86 8.89 0.00 
ILMN_1741005 RG9MTD2 -1.20 8.23 0.00 
ILMN_1811489 OXSR1 -1.52 11.76 0.00 
ILMN_2050790 C11orf52 -1.04 8.49 0.00 
ILMN_1778991 NFIB -1.08 12.05 0.00 
ILMN_1781151 ARMC8 -1.77 9.36 0.00 
ILMN_2161832 VPS37A -1.12 10.39 0.00 
ILMN_1693220 AKAP11 -1.12 9.44 0.00 
ILMN_1771903 NUP37 -1.77 11.35 0.00 
ILMN_1657631 STAP2 -2.38 9.18 0.00 
ILMN_1790136 C20orf20 -1.25 13.36 0.00 
ILMN_1705468 PIK3CA -1.12 8.07 0.00 
ILMN_2408946 PDE8A -1.26 8.50 0.00 
ILMN_1729650 PEX7 -1.04 9.45 0.00 
ILMN_1724309 FAM35A -1.01 7.93 0.00 
ILMN_1665455 DCUN1D3 -1.31 10.56 0.00 
ILMN_2404135 RIOK3 -1.14 11.21 0.00 
ILMN_1797693 BRI3BP -1.10 11.04 0.00 
ILMN_1741613 SERINC1 -1.29 9.63 0.00 
ILMN_1705814 KRT80 -1.28 14.64 0.00 
ILMN_1719392 FH -2.20 10.35 0.00 
ILMN_1773228 DLST -1.41 10.68 0.00 
ILMN_1711327 TRIM37 -2.37 10.64 0.00 
ILMN_1689908 ANKRD13A -1.47 9.79 0.00 
ILMN_3228595 LOC729768 -1.05 12.88 0.00 
ILMN_2044027 C20orf191 -1.48 9.94 0.00 
ILMN_1717799 PRKCE -1.07 8.04 0.00 
ILMN_1797933 MRPL17 -1.95 12.56 0.00 
ILMN_1765082 RBM10 -1.86 9.55 0.00 
ILMN_3248026 RBM27 -1.30 9.50 0.00 
ILMN_1739601 MSI1 -1.35 8.71 0.00 
ILMN_2123871 TMEM18 -1.27 8.88 0.00 
ILMN_1779517 RASEF -1.06 10.01 0.00 
ILMN_2352574 ZNF274 -1.44 8.99 0.00 
ILMN_2155322 ZNF652 -1.05 12.52 0.00 
ILMN_1797822 SEL1L3 -1.42 10.05 0.00 
ILMN_1748291 C1orf55 -1.04 9.31 0.00 
ILMN_1721713 EXOSC9 -1.08 10.05 0.00 
ILMN_1676322 C1orf172 -1.31 9.55 0.00 
ILMN_2116127 NPEPPS -1.82 9.75 0.00 
ILMN_2115696 USP42 -1.68 10.16 0.00 
ILMN_1798360 CXCR7 -1.28 12.03 0.00 
ILMN_2412807 DCTN1 -1.80 10.44 0.00 
ILMN_1664012 CANT1 -1.30 10.27 0.00 
ILMN_1706413 C1orf66 -1.10 8.86 0.00 
ILMN_2067708 TFB2M -2.15 10.12 0.00 
ILMN_1728626 WDR5 -1.04 10.22 0.00 
ILMN_1764813 B3GALTL -1.22 8.51 0.00 
ILMN_1655482 TRIM27 -1.46 9.17 0.00 
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ILMN_1694111 PNKP -1.83 10.41 0.00 
ILMN_3245057 ASAP1 -1.68 12.09 0.00 
ILMN_2128668 FOXJ3 -1.04 10.80 0.00 
ILMN_2038775 TUBB2A -1.95 9.58 0.00 
ILMN_1681829 ZNF606 -1.22 8.44 0.00 
ILMN_1652082 ELF4 -1.16 11.63 0.00 
ILMN_1676600 SEC24C -1.10 11.11 0.00 
ILMN_2096012 UHMK1 -1.15 10.32 0.00 
ILMN_1676075 KLHL12 -1.23 9.30 0.00 
ILMN_1846771  -1.00 7.98 0.00 
ILMN_1681118 CAPRIN2 -1.06 8.57 0.00 
ILMN_2384237 STAP2 -2.23 8.84 0.00 
ILMN_2366445 KRT80 -1.34 11.66 0.00 
ILMN_3240721 LOC645233 -1.13 9.51 0.00 
ILMN_1794470 ANKFY1 -1.18 9.61 0.00 
ILMN_1787251 DAAM1 -1.58 10.15 0.00 
ILMN_1797531 PRKAG2 -1.53 10.57 0.00 
ILMN_1849494  -1.07 10.09 0.00 
ILMN_1706246 CCT5 -1.16 9.73 0.00 
ILMN_1653180 TPM4 -1.79 10.68 0.00 
ILMN_1674024 IKZF5 -1.10 8.84 0.00 
ILMN_1784847 CREBZF -1.10 9.68 0.00 
ILMN_1680673 NT5DC1 -1.06 9.31 0.00 
ILMN_1799642 TRIM24 -1.60 9.49 0.00 
ILMN_3242540 CD163L1 -1.04 8.72 0.00 
ILMN_1753008 REXO1 -1.44 8.77 0.00 
ILMN_2361695 BAG5 -1.29 12.57 0.00 
ILMN_2382942 CA12 -1.04 9.24 0.00 
ILMN_1771411 ALG6 -1.08 9.11 0.00 
ILMN_1729051 MSH6 -1.03 11.01 0.00 
ILMN_1660533 RPN1 -1.05 13.21 0.00 
ILMN_2311826 USP6NL -1.11 9.26 0.00 
ILMN_1744395 LOC284371 -1.01 8.54 0.00 
ILMN_1658494 C13orf15 -1.46 8.91 0.00 
ILMN_1793563 DCTN1 -1.64 8.66 0.00 
ILMN_1706301 RET -1.08 9.98 0.00 
ILMN_1690963 ASAP1 -1.71 11.39 0.00 
ILMN_2363880 ALDH3B2 -1.02 9.87 0.00 
ILMN_1790650 C16orf63 -1.05 12.48 0.00 
ILMN_1798804 SRPK1 -1.08 10.84 0.00 
ILMN_1727574 ZNF827 -1.14 8.67 0.00 
ILMN_2383419 GMEB1 -1.01 8.71 0.00 
ILMN_1806818 MCM3 -1.42 9.42 0.00 
ILMN_1777526 MED20 -1.14 11.15 0.00 
ILMN_1738523 MYD88 -2.07 9.86 0.00 
ILMN_2397880 CSTF3 -2.34 10.22 0.00 
ILMN_2123567 SENP2 -1.05 11.44 0.00 
ILMN_1726755 COPS4 -1.27 9.76 0.00 
ILMN_1704253 C6orf106 -1.07 10.27 0.00 
ILMN_1674366 LHX4 -1.08 8.79 0.00 
ILMN_1696294 SNX6 -1.20 8.06 0.00 
ILMN_1705364 BAT3 -1.14 9.23 0.00 
ILMN_1741392 SLC25A20 -1.19 8.52 0.00 
ILMN_2119774 CYP2R1 -1.24 8.91 0.01 
ILMN_1694174 TRIM68 -1.32 8.60 0.01 
ILMN_1733931 PDCD6 -1.46 12.79 0.01 
ILMN_1797074 EMG1 -1.20 11.15 0.01 
ILMN_1700109 PTOV1 -2.54 12.23 0.01 
ILMN_1711270 SFRS14 -1.40 11.09 0.01 
ILMN_1770084 TACC1 -1.43 9.86 0.01 
ILMN_2371458 CXCR7 -1.45 10.62 0.01 
ILMN_2278433 LOC285074 -1.23 9.51 0.01 
ILMN_2175112 KCNS3 -1.69 9.83 0.01 
ILMN_1783497 PANK1 -1.25 8.53 0.01 
ILMN_1739450 NFE2L1 -1.46 10.51 0.01 
ILMN_1719883 CYP4F11 -1.02 8.18 0.01 
ILMN_1667711 HRASLS3 -1.20 10.61 0.01 
ILMN_1724207 IVD -1.05 8.33 0.01 
ILMN_2172174 NP -1.73 10.95 0.01 
ILMN_2377980 PPP1CA -1.67 10.59 0.01 
ILMN_3244286 TANC2 -1.07 10.19 0.01 
ILMN_1772700 TMEM18 -1.03 8.48 0.01 
ILMN_1677432 SRGAP1 -1.15 10.86 0.01 
ILMN_1742379 IFT122 -1.15 9.15 0.01 
ILMN_3245625 RFX7 -1.07 10.79 0.01 
ILMN_1793017 DGKQ -1.17 9.18 0.01 
ILMN_1675669 IBTK -1.11 10.30 0.01 
ILMN_1728224 OGFR -2.59 10.34 0.01 
ILMN_1746720 TTC39C -1.05 8.80 0.01 
ILMN_1774086 CBX3 -1.16 8.41 0.01 
ILMN_1677843 RAB24 -1.22 11.42 0.01 
ILMN_1672042 DOLPP1 -1.19 9.97 0.01 
ILMN_1785646 PMP22 -1.63 10.85 0.01 
ILMN_2110281 UFC1 -1.15 11.81 0.01 
ILMN_1772492 MCART1 -1.17 12.83 0.01 
ILMN_2193706 HRK -1.53 8.88 0.01 
ILMN_1766408 CBFB -1.13 10.83 0.01 
ILMN_1713706 ZNF786 -1.01 9.54 0.01 
ILMN_2246510 TSC1 -1.08 9.16 0.01 
ILMN_1792072 FUT4 -1.32 8.66 0.01 
ILMN_1686367 HSPA8 -1.62 13.54 0.01 
ILMN_1774161 ARL15 -1.12 8.06 0.01 
ILMN_1671885 MLF2 -1.45 11.94 0.01 
ILMN_1755235 XPO6 -1.20 11.51 0.01 
ILMN_1690122 CRKL -1.40 12.10 0.01 
ILMN_2370772 EIF4G1 -1.20 11.68 0.01 
ILMN_1758806 C21orf2 -1.12 8.81 0.01 
ILMN_1732296 ID3 -1.99 11.15 0.01 
ILMN_2384241 TGFBR2 -1.78 9.07 0.01 
ILMN_1724040 ANKRD57 -1.10 11.10 0.01 
ILMN_3200330 LOC399988 -1.59 12.47 0.01 
ILMN_1707475 UBE2E2 -1.19 11.98 0.01 
ILMN_1735553 MAP3K9 -1.11 8.30 0.01 
ILMN_1687375 ATP2A2 -1.13 9.21 0.01 
ILMN_1658950 LOC400890 -1.16 9.89 0.01 
ILMN_1793290 WDR60 -1.06 8.25 0.01 
ILMN_1739914 ZNF618 -1.01 8.10 0.01 
ILMN_1766010 YARS -1.93 12.15 0.01 
ILMN_2415170 VPS8 -1.50 8.78 0.01 
ILMN_3248975 PPP4C -1.32 13.06 0.01 
ILMN_1775579 ACAD9 -1.01 9.70 0.01 
ILMN_2062381 LCOR -1.08 9.29 0.01 
ILMN_1769787 SELO -1.53 8.51 0.01 
ILMN_1654653 KLC1 -1.24 11.29 0.01 
ILMN_1745784 ZNF324 -1.30 8.97 0.01 
ILMN_1680196 LAPTM4B -1.64 13.11 0.01 
ILMN_1749521 SLC35E3 -1.11 10.44 0.01 
ILMN_1790909 NFE2L2 -1.35 10.46 0.01 
ILMN_3233135 FAM178A -1.08 9.67 0.01 
ILMN_1809590 GINS2 -1.30 13.49 0.01 
ILMN_1795639 MGMT -1.95 11.17 0.01 
ILMN_1728514 BAG5 -1.07 10.05 0.01 
ILMN_1658835 CAV2 -1.86 8.94 0.01 
ILMN_1678268 VPS8 -1.15 9.64 0.01 
ILMN_1772821 KIAA1671 -1.17 9.83 0.01 
ILMN_1762835 HELZ -1.00 10.63 0.01 
ILMN_1658071 ATP1B1 -1.27 11.79 0.01 
ILMN_1709377 ZNF28 -1.01 8.50 0.01 
ILMN_3294365 LOC646993 -1.11 10.22 0.01 
ILMN_1661432 NUP43 -1.07 10.57 0.01 
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ILMN_1784602 CDKN1A -1.77 13.92 0.01 
ILMN_1761594 FAM35A -1.18 8.82 0.01 
ILMN_1803279 TMED5 -1.80 11.21 0.01 
ILMN_1909886  -1.31 8.19 0.01 
ILMN_1672884 MTFMT -1.30 9.45 0.01 
ILMN_1658160 FAM156A -1.12 8.58 0.01 
ILMN_1815610 SYT12 -1.19 8.81 0.01 
ILMN_1697864 CXorf38 -1.10 9.72 0.01 
ILMN_1762002 CSTF3 -2.19 8.99 0.01 
ILMN_1691436 BLVRA -1.96 10.45 0.01 
ILMN_1796464 WDR37 -1.08 8.61 0.01 
ILMN_1733615 MTF2 -1.06 8.82 0.01 
ILMN_3251506 ZNF69 -1.15 8.55 0.01 
ILMN_1759436 NOSIP -1.19 11.00 0.01 
ILMN_1672940 ZNF562 -1.17 11.20 0.01 
ILMN_1760954 DENR -1.15 12.93 0.01 
ILMN_1678619 DAK -1.07 8.37 0.01 
ILMN_3229033 LOC732360 -1.03 10.89 0.01 
ILMN_1746031 RIMS4 -1.36 8.71 0.01 
ILMN_2407824 ATP1B1 -1.13 12.54 0.01 
ILMN_2130635 FOXRED2 -1.02 10.54 0.01 
ILMN_2413084 HSPA8 -1.43 13.28 0.01 
ILMN_1720114 GMNN -1.66 9.19 0.01 
ILMN_1747020 SGK3 -1.04 9.40 0.01 
ILMN_1687495 SLC37A1 -1.37 10.71 0.02 
ILMN_1787345 FKBP11 -1.76 10.53 0.02 
ILMN_1718023 APEH -1.78 10.98 0.02 
ILMN_1742432 COBRA1 -1.21 11.22 0.02 
ILMN_2379718 RAB24 -1.08 10.14 0.02 
ILMN_1808587 ZFHX3 -1.34 10.93 0.02 
ILMN_1791873 COG1 -1.43 8.61 0.02 
ILMN_1744963 ERO1L -1.25 10.49 0.02 
ILMN_1681591 PTPN1 -1.04 12.70 0.02 
ILMN_2224031 CETN3 -1.01 10.48 0.02 
ILMN_1662438 SOD1 -1.14 14.12 0.02 
ILMN_1670130 ARID3A -1.20 10.38 0.02 
ILMN_1798308 AHSA2 -1.01 8.45 0.02 
ILMN_2364131 TTPAL -1.27 10.53 0.02 
ILMN_1690621 GPR98 -1.01 7.91 0.02 
ILMN_1747281 EVI5L -1.47 9.61 0.02 
ILMN_1700915 BMI1 -1.07 13.01 0.02 
ILMN_1800276 RCN1 -1.10 9.58 0.02 
ILMN_1721626 ARID5B -1.12 10.11 0.02 
ILMN_1724753 NIN -1.01 8.98 0.02 
ILMN_1726574 CACYBP -1.43 10.79 0.02 
ILMN_2368068 TCF20 -1.12 9.54 0.02 
ILMN_1798886 NUDT21 -1.13 9.00 0.02 
ILMN_2322996 EYA2 -1.05 8.83 0.02 
ILMN_1695827 PPP1CA -1.14 12.03 0.02 
ILMN_1718537 HPS6 -1.60 10.80 0.02 
ILMN_1655921 GTF2E1 -1.26 9.92 0.02 
ILMN_1798172 IPO4 -1.17 9.32 0.02 
ILMN_1726901 KLC1 -1.06 10.13 0.02 
ILMN_2366246 SEC23B -1.34 10.26 0.02 
ILMN_1781374 TUFT1 -1.33 11.32 0.02 
ILMN_1803464 PHTF1 -1.81 10.60 0.02 
ILMN_1743538 MLLT10 -1.07 8.89 0.02 
ILMN_1801121 SENP2 -1.26 9.75 0.02 
ILMN_3187852 KIAA1310 -1.28 11.93 0.02 
ILMN_3244110 FAM156B -1.01 9.01 0.02 
ILMN_1685415 HBP1 -1.01 9.43 0.02 
ILMN_3290261 LOC644877 -1.21 9.42 0.02 
ILMN_1693136 VTI1B -1.09 11.51 0.02 
ILMN_2131336 TMEM194 -1.07 9.57 0.02 
ILMN_1698231 RRM2B -1.12 8.28 0.02 
ILMN_1726245 TGFBR2 -1.50 9.14 0.02 
ILMN_1657483 SEC23B -1.17 10.83 0.02 
ILMN_1674859 LOC651576 -1.00 8.95 0.03 
ILMN_1744442 TTPAL -1.00 9.94 0.03 
ILMN_1745217 FLJ10081 -1.06 9.93 0.03 
ILMN_1859946  -1.05 12.65 0.03 
ILMN_1720829 ZFP36 -1.11 11.93 0.03 
ILMN_3281195 LOC440459 -1.06 8.21 0.03 
ILMN_1667893 TNS3 -1.40 8.48 0.03 
ILMN_1815874 NANS -1.57 10.70 0.03 
ILMN_2321634 RAD17 -1.01 8.72 0.03 
ILMN_1763523 HARS -1.01 11.63 0.03 
ILMN_1723480 BST2 -1.36 8.31 0.03 
ILMN_1750641 SRCAP -1.22 8.38 0.03 
ILMN_2166865 ENY2 -1.26 13.24 0.03 
ILMN_3306440 TMEM194A -1.09 10.05 0.03 
ILMN_1697420 TINF2 -1.17 9.58 0.04 
ILMN_2138801 TP73L -1.15 8.41 0.04 
ILMN_1772487 SFRS14 -1.32 9.34 0.04 
ILMN_1713266 FAM46C -1.05 10.57 0.04 
ILMN_1689007 SFRS14 -1.17 8.67 0.05 
ILMN_1657395 HMGCR -1.07 11.25 0.05 
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Supplementary Table 3: Functional Enrichment Analysis of genes predicted to be miR-
139-5p targets 
 
Ingenuity Canonical 
Pathways 
 -log10(p-
value) 
Ratio Molecules 
Glucocorticoid Receptor 
Signaling 
3.39E+00 7.94E-02 RAF1,PIK3CA,PIK3R1,RAC1,HRAS,GTF2E2,CEBPB (includes 
EG:1051),NFKB1,HSPA5,EP300,BCL2,TGFBR2,HSPA8,POU2F1,NFAT5,NCOR1P1,G
TF2E1,CDKN1A,PRKAG2,HSP90AA1,ESR1,CREBZF 
PI3K/AKT Signaling 3.35E+00 1.01E-01 RAF1,TSC1,PIK3CA,YWHAE,PIK3R1,HRAS,NFKB1,BCL2,CDKN1A,HSP90AA1,GS
K3B,PPP2R5E,SFN 
Cleavage and 
Polyadenylation of Pre-
mRNA 
3.09E+00 3.33E-01 PAPOLA,NUDT21,CPSF3,CSTF3 
p53 Signaling 3.08E+00 1.16E-01 PIK3CA,TP53INP1,TP63,PPP1R13B,PIK3R1,CDKN1A,RRM2B,GSK3B,SFN,BCL2,EP
300 
Prostate Cancer Signaling 3.08E+00 1.11E-01 RAF1,PIK3CA,PIK3R1,SUV39H1,CDKN1A,HSP90AA1,HRAS,GSK3B,NFKB1,BCL2 
mTOR Signaling 3.02E+00 9.59E-02 TSC1,PIK3CA,DDIT4,PIK3R1,RAC1,HRAS,EIF4G1,PLD1,RHOT1,PRKAG2,PRKCE,
PPP2R5E,RPS6KA2,FNBP1 
N-Glycan Biosynthesis 3.01E+00 1.67E-01 DOLPP1,RPN2,DDOST,MAN1B1,RPN1,MGAT2,FUT4 
Breast Cancer Regulation 
by Stathmin1 
2.97E+00 8.63E-02 ADCY9,RAF1,PIK3CA,ARHGEF12,PIK3R1,TUBB2A,RAC1,HRAS,GNB1,ARHGEF1
0,CDKN1A,PRKAG2,PRKCE,UHMK1,PPP2R5E,PPP1CA,PRKAR1A 
Melanocyte Development 
and Pigmentation 
Signaling 
2.87E+00 1.15E-01 ADCY9,RAF1,PIK3CA,PIK3R1,PRKAG2,HRAS,RPS6KA2,BCL2,PRKAR1A,EP300 
Chronic Myeloid 
Leukemia Signaling 
2.57E+00 9.80E-02 TGFBR2,RAF1,PIK3CA,RBL2 (includes 
EG:100331892),CRKL,PIK3R1,SUV39H1,CDKN1A,HRAS,NFKB1 
14-3-3-mediated 
Signaling 
2.40E+00 9.57E-02 RAF1,TSC1,PIK3CA,YWHAE,PIK3R1,TUBB2A,YAP1 (includes 
EG:10413),PRKCE,HRAS,GSK3B,SFN 
Ovarian Cancer Signaling 2.35E+00 8.70E-02 RAF1,PIK3CA,EDN1,PIK3R1,WNT7B,SUV39H1,MSH6,PRKAG2,HRAS,GSK3B,BCL
2,PRKAR1A 
HGF Signaling 2.34E+00 9.80E-02 RAF1,MAP3K9,ELF4,PIK3CA,CRKL,PIK3R1,CDKN1A,RAC1,PRKCE,HRAS 
P2Y Purigenic Receptor 
Signaling Pathway 
2.34E+00 9.02E-02 ADCY9,GNB1,RAF1,PPAN,PIK3CA,PIK3R1,PRKAG2,PRKCE,HRAS,NFKB1,PRKA
R1A 
Renal Cell Carcinoma 
Signaling 
2.33E+00 1.13E-01 RAF1,PIK3CA,PIK3R1,RAC1,HRAS,FH,VHL,EP300 
Aryl Hydrocarbon 
Receptor Signaling 
2.30E+00 8.51E-02 CCNA2,ALDH3B2,SP1,CDKN1A,HSP90AA1,NFIB,RXRB,RXRA,NFKB1,NFE2L2,ES
R1,EP300 
Protein Ubiquitination 
Pathway 
2.27E+00 7.06E-02 USP24,UCHL3,USP14,MED20,DNAJC27,USP9X,BIRC6,HSPA5,UBE3A,XIAP,HSPA
8,ANAPC4,PSMB2,USP42,HSP90AA1,UBE2E2,USP46,DNAJC30,VHL 
Prolactin Signaling 2.18E+00 1.04E-01 RAF1,PIK3CA,SP1,PIK3R1,PRKCE,HRAS,CEBPB (includes EG:1051),EP300 
Pancreatic 
Adenocarcinoma 
Signaling 
2.16E+00 8.77E-02 TGFBR2,RAF1,PIK3CA,PIK3R1,SUV39H1,CDKN1A,RAC1,NFKB1,PLD1,BCL2 
Insulin Receptor 
Signaling 
2.12E+00 8.73E-02 RAF1,TSC1,PIK3CA,CRKL,PIK3R1,PTPN1,PRKAG2,HRAS,GSK3B,PPP1CA,PRKAR
1A 
Biosynthesis of Steroids 2.12E+00 1.90E-01 MVD,DHCR7,COX10 (includes EG:1352),HMGCR 
Estrogen-Dependent 
Breast Cancer Signaling 
2.11E+00 1.08E-01 PIK3CA,SP1,PIK3R1,HRAS,NFKB1,HSD17B4,ESR1 
Renin-Angiotensin 
Signaling 
2.11E+00 8.93E-02 ADCY9,RAF1,PIK3CA,PIK3R1,RAC1,PRKAG2,PRKCE,HRAS,NFKB1,PRKAR1A 
PTEN Signaling 2.11E+00 8.33E-02 TGFBR2,RAF1,PIK3CA,PIK3R1,CDKN1A,RAC1,HRAS,GSK3B,NFKB1,BCL2 
Role of CHK Proteins in 
Cell Cycle Checkpoint 
Control 
2.10E+00 1.43E-01 RAD17 (includes EG:19356),CDKN1A,RFC1,CDC25A,RFC3 
Xenobiotic Metabolism 
Signaling 
2.08E+00 6.95E-02 RAF1,MAP3K9,PIK3CA,MGMT,PIK3R1,HRAS,CHST12,CES2,NFKB1,EP300,ALDH
3B2,CHST3,HSP90AA1,PRKCE,MAPK7,PPP2R5E,RXRA,NFE2L2 
HMGB1 Signaling 2.04E+00 9.28E-02 PIK3CA,SP1,RHOT1,KAT6A,PIK3R1,RAC1,HRAS,NFKB1,FNBP1 
Molecular Mechanisms of 
Cancer 
2.02E+00 6.13E-02 ADCY9,RAF1,PIK3CA,ARHGEF12,SUV39H1,PIK3R1,RAC1,HRAS,NFKB1,XIAP,EP
300,BCL2,TGFBR2,ARHGEF10,RHOT1,CDKN1A,PRKAG2,PRKCE,GSK3B,FNBP1,P
RKAR1A,CDC25A 
Ceramide Signaling 2.01E+00 9.76E-02 RAF1,PIK3CA,PIK3R1,HRAS,CERK,PPP2R5E,NFKB1,BCL2 
RAR Activation 1.96E+00 7.60E-02 ADCY9,NSD1,PIK3CA,TRIM24,PIK3R1,RAC1,NFKB1,EP300,PRKAG2,PRKCE,RXR
B,RXRA,PRKAR1A 
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Cardiac Î²-adrenergic 
Signaling 
1.93E+00 8.03E-02 PDE8A,ADCY9,GNB1,PKIB,PRKAG2,PPP2R5E,PPP1CA,ATP2A2,AKAP7,AKAP11,P
RKAR1A 
Non-Small Cell Lung 
Cancer Signaling 
1.93E+00 9.59E-02 RAF1,PIK3CA,PIK3R1,SUV39H1,HRAS,RXRB,RXRA 
EIF2 Signaling 1.89E+00 8.79E-02 RAF1,PIK3CA,PIK3R1,HRAS,EIF2C2,GSK3B,EIF4G1,PPP1CA 
Phospholipase C 
Signaling 
1.87E+00 6.58E-02 ADCY9,RAF1,ARHGEF12,RAC1,HRAS,NFKB1,PLD1,EP300,GNB1,ARHGEF10,NFA
T5,RHOT1,MEF2D,PRKCE,PPP1CA,FNBP1 
Macropinocytosis 
Signaling 
1.83E+00 9.21E-02 ANKFY1,PIK3CA,PIK3R1,USP6NL,RAC1,PRKCE,HRAS 
p70S6K Signaling 1.82E+00 8.20E-02 RAF1,PIK3CA,YWHAE,EEF2,PIK3R1,PRKCE,HRAS,PPP2R5E,SFN,PLD1 
TR/RXR Activation 1.80E+00 8.99E-02 PIK3CA,LDLR,PIK3R1,ACACA,RXRB,RXRA,SYT12,EP300 
PPARÎ±/RXRÎ± 
Activation 
1.76E+00 7.27E-02 ADCY9,TGFBR2,RAF1,MED23,CKAP5,PRKAG2,HSP90AA1,HRAS,RXRA,NFKB1,P
RKAR1A,EP300 
Role of NFAT in Cardiac 
Hypertrophy 
1.75E+00 6.95E-02 ADCY9,RAF1,PIK3CA,PIK3R1,HRAS,EP300,GNB1,TGFBR2,MEF2D,PRKAG2,PRK
CE,GSK3B,PRKAR1A 
IL-3 Signaling 1.73E+00 9.59E-02 RAF1,PIK3CA,CRKL,PIK3R1,RAC1,PRKCE,HRAS 
Small Cell Lung Cancer 
Signaling 
1.73E+00 8.33E-02 PIK3CA,PIK3R1,SUV39H1,RXRB,RXRA,NFKB1,BCL2 
GNRH Signaling 1.71E+00 7.63E-02 ADCY9,RAF1,MAP3K9,RAC1,PRKAG2,PRKCE,HRAS,MAPK7,NFKB1,PRKAR1A 
Role of BRCA1 in DNA 
Damage Response 
1.71E+00 1.02E-01 RBL2 (includes EG:100331892),POU2F1,CDKN1A,MSH6,RFC1,RFC3 
IL-17 Signaling 1.70E+00 9.46E-02 PIK3CA,PIK3R1,IL17RC,HRAS,CEBPB (includes EG:1051),GSK3B,NFKB1 
Melanoma Signaling 1.67E+00 1.14E-01 RAF1,PIK3CA,PIK3R1,CDKN1A,HRAS 
LPS-stimulated MAPK 
Signaling 
1.67E+00 8.86E-02 RAF1,PIK3CA,PIK3R1,RAC1,PRKCE,HRAS,NFKB1 
fMLP Signaling in 
Neutrophils 
1.67E+00 7.69E-02 GNB1,RAF1,PIK3CA,NFAT5,PIK3R1,RAC1,PRKCE,HRAS,NFKB1 
Mismatch Repair in 
Eukaryotes 
1.67E+00 1.50E-01 MSH6,RFC1,RFC3 
Cardiac Hypertrophy 
Signaling 
1.65E+00 6.58E-02 ADCY9,RAF1,MAP3K9,PIK3CA,PIK3R1,HRAS,EP300,TGFBR2,GNB1,RHOT1,MEF
2D,PRKAG2,GSK3B,FNBP1,PRKAR1A 
Myc Mediated Apoptosis 
Signaling 
1.64E+00 1.00E-01 PIK3CA,YWHAE,PIK3R1,HRAS,SFN,BCL2 
Glioblastoma Multiforme 
Signaling 
1.63E+00 7.01E-02 RAF1,TSC1,PIK3CA,RHOT1,PIK3R1,WNT7B,CDKN1A,RAC1,HRAS,GSK3B,FNBP1 
*Ratio of miR-139 targets in the pathway to the total number of genes in the pathway 
 
 
Supplementary Table 4: Transcripts per million for miRNAs assessed by small RNA 
sequencing 
 
miRNA (tpm) MDA-MB-
231 
MCF7 
hsa-let-7a-1-3p 345.9848459 394.8470919 
hsa-let-7a-1-5p 6435.318133 5227.023407 
hsa-let-7a-1-amb 34.59848459 112.8134548 
hsa-let-7a-2-3p 518.9772688 0 
hsa-let-7a-2-5p 6539.113587 5678.277226 
hsa-let-7a-2-amb 34.59848459 0 
hsa-let-7a-3-3p 276.7878767 282.0336371 
hsa-let-7a-3-5p 5985.537833 5358.639104 
hsa-let-7b-3p 449.7802996 451.2538193 
hsa-let-7b-5p 1107.151507 1522.98164 
hsa-let-7b-amb 0 18.80224247 
hsa-let-7c-3p 69.19696917 56.40672742 
hsa-let-7c-5p 899.5605992 1052.925578 
hsa-let-7d-3p 795.7651455 1203.343518 
hsa-let-7d-5p 1107.151507 1767.410792 
hsa-let-7e-3p 311.3863613 244.4291521 
hsa-let-7e-5p 899.5605992 1015.321093 
hsa-let-7e-amb 103.7954538 18.80224247 
hsa-let-7f-1-3p 172.9924229 733.2874564 
hsa-let-7f-1-5p 1003.356053 1767.410792 
hsa-let-7f-2-3p 69.19696917 112.8134548 
hsa-let-7f-2-5p 1003.356053 1673.39958 
hsa-let-7g-3p 622.7727226 376.0448494 
hsa-let-7g-5p 2248.901498 1222.145761 
hsa-let-7g-amb 34.59848459 0 
hsa-let-7i-3p 380.5833305 319.638122 
hsa-let-7i-5p 1902.916652 1428.970428 
hsa-miR-1-1-3p 34.59848459 0 
hsa-miR-1-2-3p 34.59848459 0 
hsa-miR-100-3p 138.3939383 0 
hsa-miR-100-5p 6400.719648 37.60448494 
hsa-miR-101-1-3p 726.5681763 2275.071339 
hsa-miR-101-1-5p 103.7954538 18.80224247 
hsa-miR-101-2-3p 899.5605992 2444.291521 
hsa-miR-101-2-5p 0 75.20896989 
hsa-miR-103a-1-3p 14981.14383 9156.692084 
hsa-miR-103a-1-5p 138.3939383 131.6156973 
hsa-miR-103a-2-3p 15742.31049 9607.945903 
hsa-miR-103a-2-5p 207.5909075 300.8358795 
hsa-miR-103a-2-amb 0 18.80224247 
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hsa-miR-105-1-3p 34.59848459 0 
hsa-miR-105-1-5p 34.59848459 37.60448494 
hsa-miR-105-2-3p 34.59848459 0 
hsa-miR-105-2-5p 34.59848459 37.60448494 
hsa-miR-106a-5p 345.9848459 658.0784865 
hsa-miR-106b-3p 5016.780265 3835.657464 
hsa-miR-106b-5p 1556.931806 3760.448494 
hsa-miR-106b-amb 207.5909075 94.01121236 
hsa-miR-107-3p 13493.40899 8272.986688 
hsa-miR-107-5p 138.3939383 112.8134548 
hsa-miR-10a-3p 34.59848459 0 
hsa-miR-10a-5p 622.7727226 169.2201822 
hsa-miR-10a-amb 69.19696917 0 
hsa-miR-10b-5p 0 37.60448494 
hsa-miR-1178-5p 0 18.80224247 
hsa-miR-1179-5p 0 18.80224247 
hsa-miR-1180-3p 242.1893921 300.8358795 
hsa-miR-1180-5p 0 37.60448494 
hsa-miR-1181-5p 69.19696917 18.80224247 
hsa-miR-122-5p 34.59848459 0 
hsa-miR-1224-3p 0 56.40672742 
hsa-miR-1224-5p 0 150.4179398 
hsa-miR-1226-5p 34.59848459 56.40672742 
hsa-miR-1226-amb 0 37.60448494 
hsa-miR-1227-3p 138.3939383 225.6269097 
hsa-miR-1228-3p 242.1893921 18.80224247 
hsa-miR-1228-5p 34.59848459 0 
hsa-miR-1229-3p 553.5757534 770.8919413 
hsa-miR-1233-1-3p 34.59848459 18.80224247 
hsa-miR-1233-2-3p 34.59848459 18.80224247 
hsa-miR-1234-5p 172.9924229 1034.123336 
hsa-miR-1236-3p 103.7954538 37.60448494 
hsa-miR-1237-3p 276.7878767 131.6156973 
hsa-miR-1244-1-5p 0 18.80224247 
hsa-miR-1244-2-5p 0 18.80224247 
hsa-miR-1244-3-5p 0 18.80224247 
hsa-miR-1246-5p 69.19696917 56.40672742 
hsa-miR-1247-3p 0 37.60448494 
hsa-miR-1247-5p 0 620.4740016 
hsa-miR-1248-5p 103.7954538 150.4179398 
hsa-miR-1249-3p 0 94.01121236 
hsa-miR-1250-5p 0 37.60448494 
hsa-miR-1251-3p 0 18.80224247 
hsa-miR-1254-1-3p 311.3863613 300.8358795 
hsa-miR-1254-1-5p 242.1893921 695.6829715 
hsa-miR-1254-2-5p 207.5909075 526.4627892 
hsa-miR-1254-2-amb 34.59848459 37.60448494 
hsa-miR-1255a-3p 34.59848459 94.01121236 
hsa-miR-1255a-5p 0 18.80224247 
hsa-miR-1256-5p 0 18.80224247 
hsa-miR-1257-3p 0 18.80224247 
hsa-miR-1257-5p 242.1893921 150.4179398 
hsa-miR-125a-3p 484.3787842 488.8583043 
hsa-miR-125a-5p 2456.492406 5640.672742 
hsa-miR-125b-1-3p 1591.530291 0 
hsa-miR-125b-1-5p 17368.43926 2669.918431 
hsa-miR-125b-1-amb 69.19696917 0 
hsa-miR-125b-2-3p 103.7954538 1109.332306 
hsa-miR-125b-2-5p 17472.23472 2632.313946 
hsa-miR-126-3p 345.9848459 977.7166085 
hsa-miR-126-5p 138.3939383 188.0224247 
hsa-miR-1260a-5p 484.3787842 582.8695166 
hsa-miR-1260b-5p 34.59848459 188.0224247 
hsa-miR-1261-5p 0 18.80224247 
hsa-miR-1266-3p 34.59848459 18.80224247 
hsa-miR-1266-5p 103.7954538 206.8246672 
hsa-miR-1267-5p 34.59848459 0 
hsa-miR-1268a-3p 345.9848459 131.6156973 
hsa-miR-1268a-5p 1937.515137 169.2201822 
hsa-miR-1268a-amb 0 18.80224247 
hsa-miR-1268b-3p 0 56.40672742 
hsa-miR-1268b-5p 2283.499983 357.242607 
hsa-miR-1269a-3p 34.59848459 75.20896989 
hsa-miR-1269b-5p 172.9924229 0 
hsa-miR-127-3p 34.59848459 0 
hsa-miR-1270-1-5p 276.7878767 0 
hsa-miR-1270-2-5p 276.7878767 0 
hsa-miR-1271-3p 103.7954538 0 
hsa-miR-1271-5p 242.1893921 0 
hsa-miR-1273a-3p 3044.666644 2218.664612 
hsa-miR-1273a-5p 380.5833305 413.6493344 
hsa-miR-1273a-amb 172.9924229 150.4179398 
hsa-miR-1273c-3p 0 37.60448494 
hsa-miR-1273c-5p 172.9924229 75.20896989 
hsa-miR-1273d-3p 484.3787842 357.242607 
hsa-miR-1273d-5p 103.7954538 112.8134548 
hsa-miR-1273d-amb 207.5909075 206.8246672 
hsa-miR-1273e-3p 1037.954538 733.2874564 
hsa-miR-1273e-5p 345.9848459 188.0224247 
hsa-miR-1273e-amb 345.9848459 131.6156973 
hsa-miR-1273f-3p 69.19696917 37.60448494 
hsa-miR-1273f-5p 345.9848459 94.01121236 
hsa-miR-1273f-amb 276.7878767 131.6156973 
hsa-miR-1273g-3p 1383.939383 940.1121236 
hsa-miR-1273g-5p 103.7954538 94.01121236 
hsa-miR-1275-5p 276.7878767 37.60448494 
hsa-miR-1276-5p 0 18.80224247 
hsa-miR-1277-5p 0 18.80224247 
hsa-miR-1277-amb 34.59848459 0 
hsa-miR-1278-3p 0 37.60448494 
hsa-miR-128-1-3p 761.1666609 1466.574913 
hsa-miR-128-1-5p 34.59848459 75.20896989 
hsa-miR-128-2-3p 657.3712071 1334.959215 
hsa-miR-1280-5p 34.59848459 0 
hsa-miR-1283-1-5p 0 56.40672742 
hsa-miR-1283-2-3p 69.19696917 18.80224247 
hsa-miR-1283-2-5p 0 56.40672742 
hsa-miR-1284-3p 0 94.01121236 
hsa-miR-1284-5p 0 56.40672742 
hsa-miR-1285-1-3p 138.3939383 1165.739033 
hsa-miR-1285-1-5p 34.59848459 376.0448494 
hsa-miR-1285-1-amb 276.7878767 131.6156973 
hsa-miR-1285-2-3p 138.3939383 1090.530063 
hsa-miR-1285-2-5p 138.3939383 94.01121236 
hsa-miR-1285-2-amb 0 18.80224247 
hsa-miR-1286-3p 0 37.60448494 
hsa-miR-1286-5p 0 18.80224247 
hsa-miR-1287-3p 34.59848459 37.60448494 
hsa-miR-1287-5p 138.3939383 112.8134548 
hsa-miR-1289-1-5p 34.59848459 0 
hsa-miR-129-1-3p 0 18.80224247 
hsa-miR-129-1-5p 0 18.80224247 
hsa-miR-129-2-3p 69.19696917 75.20896989 
hsa-miR-129-2-5p 0 37.60448494 
hsa-miR-1290-3p 69.19696917 0 
hsa-miR-1291-5p 0 37.60448494 
hsa-miR-1292-3p 34.59848459 0 
hsa-miR-1292-5p 242.1893921 131.6156973 
hsa-miR-1293-3p 34.59848459 112.8134548 
hsa-miR-1293-5p 34.59848459 75.20896989 
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hsa-miR-1293-amb 0 18.80224247 
hsa-miR-1294-3p 69.19696917 131.6156973 
hsa-miR-1294-5p 34.59848459 0 
hsa-miR-1296-3p 69.19696917 0 
hsa-miR-1296-5p 2075.909075 338.4403645 
hsa-miR-1297-3p 34.59848459 394.8470919 
hsa-miR-1301-3p 311.3863613 1993.037702 
hsa-miR-1301-5p 69.19696917 338.4403645 
hsa-miR-1302-8-amb 0 37.60448494 
hsa-miR-1303-3p 34.59848459 75.20896989 
hsa-miR-1303-5p 657.3712071 1372.5637 
hsa-miR-1304-3p 207.5909075 131.6156973 
hsa-miR-1304-5p 103.7954538 75.20896989 
hsa-miR-1306-3p 242.1893921 37.60448494 
hsa-miR-1306-5p 345.9848459 188.0224247 
hsa-miR-1307-3p 1799.121198 1579.388368 
hsa-miR-1307-5p 968.7575684 714.4852139 
hsa-miR-130a-3p 2767.878767 75.20896989 
hsa-miR-130a-5p 2387.295436 0 
hsa-miR-130a-amb 34.59848459 0 
hsa-miR-130b-3p 1418.537868 1579.388368 
hsa-miR-130b-5p 242.1893921 94.01121236 
hsa-miR-132-3p 518.9772688 75.20896989 
hsa-miR-132-5p 207.5909075 56.40672742 
hsa-miR-132-amb 34.59848459 0 
hsa-miR-1322-3p 34.59848459 18.80224247 
hsa-miR-133a-1-3p 0 37.60448494 
hsa-miR-133a-2-3p 0 37.60448494 
hsa-miR-1343-3p 138.3939383 112.8134548 
hsa-miR-1343-5p 34.59848459 18.80224247 
hsa-miR-135a-1-5p 0 112.8134548 
hsa-miR-135a-2-5p 0 112.8134548 
hsa-miR-135b-3p 69.19696917 0 
hsa-miR-135b-5p 69.19696917 94.01121236 
hsa-miR-137-3p 34.59848459 0 
hsa-miR-137-5p 34.59848459 0 
hsa-miR-138-1-3p 1868.318168 0 
hsa-miR-138-1-5p 57295.09048 0 
hsa-miR-138-2-3p 0 18.80224247 
hsa-miR-138-2-5p 56257.13594 18.80224247 
hsa-miR-139-3p 207.5909075 0 
hsa-miR-139-5p 311.3863613 131.6156973 
hsa-miR-140-3p 2352.696952 1635.795095 
hsa-miR-140-5p 103.7954538 94.01121236 
hsa-miR-140-amb 34.59848459 0 
hsa-miR-141-3p 103.7954538 2068.246672 
hsa-miR-141-5p 0 282.0336371 
hsa-miR-141-amb 0 244.4291521 
hsa-miR-142-3p 103.7954538 0 
hsa-miR-142-5p 103.7954538 0 
hsa-miR-143-3p 34.59848459 56.40672742 
hsa-miR-144-5p 0 37.60448494 
hsa-miR-145-5p 34.59848459 75.20896989 
hsa-miR-146a-5p 9030.204477 0 
hsa-miR-146b-5p 69.19696917 169.2201822 
hsa-miR-147b-3p 276.7878767 18.80224247 
hsa-miR-147b-5p 0 37.60448494 
hsa-miR-148a-3p 345.9848459 545.2650317 
hsa-miR-148a-5p 34.59848459 37.60448494 
hsa-miR-148b-3p 172.9924229 620.4740016 
hsa-miR-148b-5p 207.5909075 958.9143661 
hsa-miR-149-3p 0 75.20896989 
hsa-miR-149-5p 449.7802996 2857.940856 
hsa-miR-149-amb 0 18.80224247 
hsa-miR-150-3p 0 18.80224247 
hsa-miR-150-5p 0 18.80224247 
hsa-miR-151a-3p 74248.34792 36382.33918 
hsa-miR-151a-5p 4601.59845 3572.42607 
hsa-miR-151b-3p 3978.825727 3177.578978 
hsa-miR-152-3p 276.7878767 545.2650317 
hsa-miR-152-5p 0 18.80224247 
hsa-miR-153-1-3p 34.59848459 0 
hsa-miR-153-1-5p 34.59848459 0 
hsa-miR-153-2-3p 34.59848459 0 
hsa-miR-1537-3p 34.59848459 0 
hsa-miR-1538-3p 34.59848459 0 
hsa-miR-1538-5p 34.59848459 18.80224247 
hsa-miR-15a-3p 380.5833305 263.2313946 
hsa-miR-15a-5p 1280.14393 1635.795095 
hsa-miR-15b-3p 415.181815 883.7053962 
hsa-miR-15b-5p 4221.01512 5509.057044 
hsa-miR-16-1-3p 103.7954538 94.01121236 
hsa-miR-16-1-5p 2525.689375 6919.22523 
hsa-miR-16-2-3p 345.9848459 394.8470919 
hsa-miR-16-2-5p 2387.295436 6731.202805 
hsa-miR-17-3p 761.1666609 244.4291521 
hsa-miR-17-5p 4463.204512 2745.127401 
hsa-miR-181a-1-3p 484.3787842 282.0336371 
hsa-miR-181a-1-5p 2318.098467 3440.810372 
hsa-miR-181a-2-3p 518.9772688 0 
hsa-miR-181a-2-5p 588.174238 1203.343518 
hsa-miR-181a-2-amb 1522.333322 2275.071339 
hsa-miR-181b-1-3p 415.181815 244.4291521 
hsa-miR-181b-1-5p 2145.106044 2519.500491 
hsa-miR-181b-1-amb 1453.136353 1128.134548 
hsa-miR-181b-2-3p 69.19696917 18.80224247 
hsa-miR-181b-2-5p 3010.068159 3121.17225 
hsa-miR-181c-3p 207.5909075 112.8134548 
hsa-miR-181c-5p 207.5909075 94.01121236 
hsa-miR-181d-3p 138.3939383 18.80224247 
hsa-miR-181d-5p 1072.553022 244.4291521 
hsa-miR-182-3p 34.59848459 188.0224247 
hsa-miR-182-5p 1280.14393 6693.59832 
hsa-miR-182-amb 0 18.80224247 
hsa-miR-183-3p 103.7954538 639.276244 
hsa-miR-183-5p 553.5757534 2688.720673 
hsa-miR-184-3p 0 37.60448494 
hsa-miR-184-5p 0 18.80224247 
hsa-miR-185-3p 0 56.40672742 
hsa-miR-185-5p 380.5833305 1504.179398 
hsa-miR-186-3p 34.59848459 56.40672742 
hsa-miR-186-5p 311.3863613 526.4627892 
hsa-miR-187-3p 69.19696917 18.80224247 
hsa-miR-188-3p 103.7954538 75.20896989 
hsa-miR-188-5p 5431.96208 5885.101894 
hsa-miR-18a-3p 311.3863613 56.40672742 
hsa-miR-18a-5p 1383.939383 413.6493344 
hsa-miR-18b-5p 276.7878767 37.60448494 
hsa-miR-1908-3p 69.19696917 150.4179398 
hsa-miR-1908-5p 172.9924229 56.40672742 
hsa-miR-1909-3p 69.19696917 18.80224247 
hsa-miR-1909-5p 138.3939383 18.80224247 
hsa-miR-190a-3p 0 18.80224247 
hsa-miR-190a-5p 0 37.60448494 
hsa-miR-191-3p 276.7878767 244.4291521 
hsa-miR-191-5p 3217.659067 4963.792013 
hsa-miR-1910-3p 138.3939383 507.6605467 
hsa-miR-1910-5p 172.9924229 714.4852139 
hsa-miR-1911-3p 0 18.80224247 
hsa-miR-1911-5p 0 56.40672742 
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hsa-miR-1913-3p 0 56.40672742 
hsa-miR-1913-5p 34.59848459 56.40672742 
hsa-miR-1914-3p 138.3939383 112.8134548 
hsa-miR-1914-5p 172.9924229 94.01121236 
hsa-miR-1915-3p 34.59848459 601.6717591 
hsa-miR-1915-5p 242.1893921 244.4291521 
hsa-miR-192-3p 172.9924229 131.6156973 
hsa-miR-192-5p 518.9772688 789.6941838 
hsa-miR-193a-3p 795.7651455 4174.097829 
hsa-miR-193a-5p 207.5909075 169.2201822 
hsa-miR-193b-3p 968.7575684 6975.631957 
hsa-miR-193b-5p 0 112.8134548 
hsa-miR-194-1-5p 69.19696917 150.4179398 
hsa-miR-194-2-3p 69.19696917 37.60448494 
hsa-miR-194-2-5p 103.7954538 225.6269097 
hsa-miR-195-3p 69.19696917 75.20896989 
hsa-miR-195-5p 207.5909075 470.0560618 
hsa-miR-196a-1-5p 34.59848459 56.40672742 
hsa-miR-196a-2-3p 0 56.40672742 
hsa-miR-196a-2-5p 34.59848459 75.20896989 
hsa-miR-197-3p 2594.886344 3252.787948 
hsa-miR-197-5p 69.19696917 75.20896989 
hsa-miR-1972-1-3p 138.3939383 188.0224247 
hsa-miR-1972-1-5p 0 75.20896989 
hsa-miR-1972-2-3p 138.3939383 188.0224247 
hsa-miR-1972-2-5p 0 75.20896989 
hsa-miR-1973-3p 0 37.60448494 
hsa-miR-1973-amb 69.19696917 18.80224247 
hsa-miR-1976-3p 103.7954538 18.80224247 
hsa-miR-1976-5p 34.59848459 0 
hsa-miR-199a-1-3p 34.59848459 56.40672742 
hsa-miR-199a-1-5p 34.59848459 18.80224247 
hsa-miR-199a-2-3p 34.59848459 56.40672742 
hsa-miR-199a-2-5p 34.59848459 18.80224247 
hsa-miR-199b-3p 34.59848459 56.40672742 
hsa-miR-199b-5p 34.59848459 112.8134548 
hsa-miR-19a-3p 380.5833305 451.2538193 
hsa-miR-19a-5p 69.19696917 0 
hsa-miR-19b-1-3p 761.1666609 1184.541276 
hsa-miR-19b-1-5p 69.19696917 56.40672742 
hsa-miR-19b-2-3p 830.3636301 1203.343518 
hsa-miR-200a-3p 138.3939383 958.9143661 
hsa-miR-200a-5p 69.19696917 225.6269097 
hsa-miR-200b-3p 172.9924229 996.518851 
hsa-miR-200b-5p 34.59848459 244.4291521 
hsa-miR-200c-3p 69.19696917 2763.929643 
hsa-miR-200c-5p 0 131.6156973 
hsa-miR-200c-amb 0 18.80224247 
hsa-miR-203-3p 0 2143.455642 
hsa-miR-203-5p 0 150.4179398 
hsa-miR-204-3p 34.59848459 0 
hsa-miR-204-5p 207.5909075 0 
hsa-miR-205-5p 172.9924229 206.8246672 
hsa-miR-20a-3p 415.181815 488.8583043 
hsa-miR-20a-5p 553.5757534 300.8358795 
hsa-miR-20b-5p 69.19696917 37.60448494 
hsa-miR-21-3p 1799.121198 3008.358795 
hsa-miR-21-5p 6435.318133 34784.14857 
hsa-miR-21-amb 0 18.80224247 
hsa-miR-210-3p 2975.469674 958.9143661 
hsa-miR-210-5p 311.3863613 56.40672742 
hsa-miR-211-5p 34.59848459 0 
hsa-miR-2110-3p 69.19696917 357.242607 
hsa-miR-2110-5p 207.5909075 263.2313946 
hsa-miR-2114-5p 0 37.60448494 
hsa-miR-2116-3p 0 56.40672742 
hsa-miR-212-3p 380.5833305 112.8134548 
hsa-miR-212-5p 69.19696917 37.60448494 
hsa-miR-214-3p 34.59848459 0 
hsa-miR-215-5p 172.9924229 432.4515769 
hsa-miR-216a-3p 34.59848459 0 
hsa-miR-216a-5p 34.59848459 0 
hsa-miR-216b-5p 69.19696917 0 
hsa-miR-217-5p 34.59848459 0 
hsa-miR-218-1-3p 138.3939383 0 
hsa-miR-218-1-5p 345.9848459 75.20896989 
hsa-miR-218-2-5p 311.3863613 75.20896989 
hsa-miR-219-1-3p 0 112.8134548 
hsa-miR-219-1-5p 0 37.60448494 
hsa-miR-22-3p 657.3712071 1184.541276 
hsa-miR-22-5p 138.3939383 56.40672742 
hsa-miR-221-3p 12801.4393 432.4515769 
hsa-miR-221-5p 726.5681763 37.60448494 
hsa-miR-222-3p 19513.54531 451.2538193 
hsa-miR-222-5p 2387.295436 56.40672742 
hsa-miR-224-3p 311.3863613 0 
hsa-miR-224-5p 553.5757534 0 
hsa-miR-2276-3p 0 282.0336371 
hsa-miR-2276-5p 0 225.6269097 
hsa-miR-2277-3p 207.5909075 94.01121236 
hsa-miR-2277-5p 34.59848459 56.40672742 
hsa-miR-2278-3p 0 18.80224247 
hsa-miR-2278-5p 172.9924229 150.4179398 
hsa-miR-2278-amb 0 56.40672742 
hsa-miR-2355-3p 0 56.40672742 
hsa-miR-2355-5p 34.59848459 75.20896989 
hsa-miR-23a-3p 10725.53022 13594.02131 
hsa-miR-23a-5p 242.1893921 56.40672742 
hsa-miR-23b-3p 8580.424177 11224.93876 
hsa-miR-23b-5p 380.5833305 169.2201822 
hsa-miR-23b-amb 0 18.80224247 
hsa-miR-23c-3p 484.3787842 752.0896989 
hsa-miR-24-1-3p 11901.8787 16658.78683 
hsa-miR-24-1-5p 380.5833305 526.4627892 
hsa-miR-24-2-3p 10275.74992 15493.0478 
hsa-miR-24-2-5p 657.3712071 1015.321093 
hsa-miR-25-3p 1349.340899 2613.511704 
hsa-miR-25-5p 172.9924229 300.8358795 
hsa-miR-2682-3p 103.7954538 0 
hsa-miR-2682-5p 69.19696917 0 
hsa-miR-26a-1-3p 172.9924229 37.60448494 
hsa-miR-26a-1-5p 1799.121198 6693.59832 
hsa-miR-26a-2-3p 34.59848459 112.8134548 
hsa-miR-26a-2-5p 1868.318168 6204.740016 
hsa-miR-26b-3p 172.9924229 338.4403645 
hsa-miR-26b-5p 2837.075736 6054.322076 
hsa-miR-27a-3p 9030.204477 10510.45354 
hsa-miR-27a-5p 276.7878767 131.6156973 
hsa-miR-27a-amb 2179.704529 94.01121236 
hsa-miR-27b-3p 7058.090856 8536.218082 
hsa-miR-27b-5p 242.1893921 300.8358795 
hsa-miR-27b-amb 34.59848459 18.80224247 
hsa-miR-28-3p 864.9621147 413.6493344 
hsa-miR-28-5p 276.7878767 376.0448494 
hsa-miR-296-3p 0 864.9031537 
hsa-miR-296-5p 0 244.4291521 
hsa-miR-2964a-5p 69.19696917 37.60448494 
hsa-miR-29a-3p 19271.35591 902.5076386 
hsa-miR-29a-5p 172.9924229 18.80224247 
hsa-miR-29b-1-3p 1660.72726 601.6717591 
 220 
hsa-miR-29b-1-5p 345.9848459 75.20896989 
hsa-miR-29b-2-3p 1764.522714 601.6717591 
hsa-miR-29b-2-5p 311.3863613 169.2201822 
hsa-miR-29c-3p 553.5757534 300.8358795 
hsa-miR-29c-5p 726.5681763 432.4515769 
hsa-miR-301a-3p 15915.30291 64811.3298 
hsa-miR-301a-5p 242.1893921 188.0224247 
hsa-miR-301b-3p 1764.522714 1560.586125 
hsa-miR-301b-5p 103.7954538 37.60448494 
hsa-miR-3064-3p 0 75.20896989 
hsa-miR-3064-5p 34.59848459 18.80224247 
hsa-miR-3065-3p 103.7954538 75.20896989 
hsa-miR-3065-5p 138.3939383 169.2201822 
hsa-miR-3074-3p 172.9924229 150.4179398 
hsa-miR-3074-5p 34.59848459 56.40672742 
hsa-miR-30a-3p 2629.484829 112.8134548 
hsa-miR-30a-5p 46327.37086 3986.075404 
hsa-miR-30b-3p 138.3939383 37.60448494 
hsa-miR-30b-5p 2075.909075 2481.896006 
hsa-miR-30c-1-3p 69.19696917 18.80224247 
hsa-miR-30c-1-5p 2075.909075 1109.332306 
hsa-miR-30c-2-3p 207.5909075 0 
hsa-miR-30c-2-5p 1868.318168 902.5076386 
hsa-miR-30c-2-amb 34.59848459 0 
hsa-miR-30d-3p 103.7954538 56.40672742 
hsa-miR-30d-5p 12836.03778 21096.11605 
hsa-miR-30e-3p 207.5909075 169.2201822 
hsa-miR-30e-5p 2664.083313 3534.821585 
hsa-miR-30e-amb 69.19696917 0 
hsa-miR-31-3p 0 18.80224247 
hsa-miR-31-5p 0 150.4179398 
hsa-miR-3116-1-5p 0 75.20896989 
hsa-miR-3116-2-5p 0 75.20896989 
hsa-miR-3127-3p 34.59848459 225.6269097 
hsa-miR-3127-5p 0 56.40672742 
hsa-miR-3128-5p 0 37.60448494 
hsa-miR-3130-1-3p 0 37.60448494 
hsa-miR-3130-1-5p 34.59848459 169.2201822 
hsa-miR-3130-2-3p 0 37.60448494 
hsa-miR-3130-2-5p 69.19696917 169.2201822 
hsa-miR-3131-5p 69.19696917 0 
hsa-miR-3135a-3p 138.3939383 56.40672742 
hsa-miR-3135a-5p 0 37.60448494 
hsa-miR-3135a-amb 0 18.80224247 
hsa-miR-3135b-3p 34.59848459 150.4179398 
hsa-miR-3136-5p 34.59848459 37.60448494 
hsa-miR-3138-3p 34.59848459 94.01121236 
hsa-miR-3138-5p 0 37.60448494 
hsa-miR-3139-5p 0 37.60448494 
hsa-miR-3143-3p 69.19696917 18.80224247 
hsa-miR-3143-5p 69.19696917 0 
hsa-miR-3143-amb 0 18.80224247 
hsa-miR-3144-3p 0 37.60448494 
hsa-miR-3145-5p 0 18.80224247 
hsa-miR-3146-3p 0 18.80224247 
hsa-miR-3149-3p 172.9924229 37.60448494 
hsa-miR-3149-amb 0 37.60448494 
hsa-miR-3150a-3p 0 18.80224247 
hsa-miR-3150a-5p 34.59848459 56.40672742 
hsa-miR-3155b-5p 0 18.80224247 
hsa-miR-3157-3p 0 37.60448494 
hsa-miR-3157-5p 69.19696917 56.40672742 
hsa-miR-3158-1-3p 34.59848459 18.80224247 
hsa-miR-3158-1-5p 0 112.8134548 
hsa-miR-3158-2-3p 34.59848459 18.80224247 
hsa-miR-3158-2-5p 0 112.8134548 
hsa-miR-3159-3p 553.5757534 1711.004065 
hsa-miR-3159-5p 0 18.80224247 
hsa-miR-3159-amb 0 37.60448494 
hsa-miR-3160-1-3p 0 18.80224247 
hsa-miR-3160-2-3p 0 18.80224247 
hsa-miR-3161-5p 0 56.40672742 
hsa-miR-3168-3p 34.59848459 0 
hsa-miR-3171-5p 0 18.80224247 
hsa-miR-3173-3p 0 37.60448494 
hsa-miR-3173-5p 69.19696917 112.8134548 
hsa-miR-3174-3p 0 37.60448494 
hsa-miR-3174-5p 34.59848459 56.40672742 
hsa-miR-3175-3p 34.59848459 56.40672742 
hsa-miR-3175-5p 34.59848459 37.60448494 
hsa-miR-3176-3p 69.19696917 507.6605467 
hsa-miR-3176-5p 0 18.80224247 
hsa-miR-3177-3p 207.5909075 206.8246672 
hsa-miR-3177-5p 0 18.80224247 
hsa-miR-3180-1-3p 34.59848459 18.80224247 
hsa-miR-3180-1-5p 0 56.40672742 
hsa-miR-3180-2-3p 34.59848459 18.80224247 
hsa-miR-3180-2-5p 0 56.40672742 
hsa-miR-3180-3-3p 34.59848459 18.80224247 
hsa-miR-3180-3-5p 0 56.40672742 
hsa-miR-3180-4-5p 34.59848459 18.80224247 
hsa-miR-3180-5-5p 34.59848459 18.80224247 
hsa-miR-3182-5p 34.59848459 225.6269097 
hsa-miR-3183-5p 103.7954538 56.40672742 
hsa-miR-3185-amb 0 18.80224247 
hsa-miR-3187-3p 691.9696917 1316.156973 
hsa-miR-3187-5p 69.19696917 18.80224247 
hsa-miR-3188-3p 0 37.60448494 
hsa-miR-3189-5p 0 18.80224247 
hsa-miR-3190-3p 34.59848459 37.60448494 
hsa-miR-3190-5p 0 18.80224247 
hsa-miR-3191-3p 34.59848459 0 
hsa-miR-3193-5p 0 18.80224247 
hsa-miR-3194-3p 0 18.80224247 
hsa-miR-3194-5p 622.7727226 658.0784865 
hsa-miR-3195-3p 34.59848459 263.2313946 
hsa-miR-3195-5p 69.19696917 18.80224247 
hsa-miR-3196-5p 415.181815 18.80224247 
hsa-miR-3197-3p 0 37.60448494 
hsa-miR-32-3p 103.7954538 188.0224247 
hsa-miR-32-5p 172.9924229 206.8246672 
hsa-miR-32-amb 172.9924229 75.20896989 
hsa-miR-3200-3p 242.1893921 206.8246672 
hsa-miR-3200-5p 0 131.6156973 
hsa-miR-320a-3p 7715.462063 6167.135531 
hsa-miR-320a-5p 103.7954538 0 
hsa-miR-320a-amb 69.19696917 18.80224247 
hsa-miR-320b-1-3p 2733.280282 2444.291521 
hsa-miR-320b-2-3p 2525.689375 2557.104976 
hsa-miR-320c-1-3p 1660.72726 2049.444429 
hsa-miR-320c-2-3p 1383.939383 1428.970428 
hsa-miR-320d-1-3p 0 37.60448494 
hsa-miR-320d-2-3p 0 56.40672742 
hsa-miR-320e-3p 138.3939383 282.0336371 
hsa-miR-323a-3p 0 18.80224247 
hsa-miR-324-3p 4670.795419 1146.936791 
hsa-miR-324-5p 6020.136318 2688.720673 
hsa-miR-324-amb 34.59848459 0 
hsa-miR-326-3p 864.9621147 1015.321093 
hsa-miR-326-5p 34.59848459 18.80224247 
 221 
hsa-miR-328-3p 1522.333322 545.2650317 
hsa-miR-328-amb 0 37.60448494 
hsa-miR-329-1-3p 0 37.60448494 
hsa-miR-329-2-3p 0 37.60448494 
hsa-miR-330-3p 1383.939383 883.7053962 
hsa-miR-330-5p 207.5909075 56.40672742 
hsa-miR-331-3p 1280.14393 3647.63504 
hsa-miR-331-5p 1210.946961 582.8695166 
hsa-miR-331-amb 0 37.60448494 
hsa-miR-335-3p 207.5909075 244.4291521 
hsa-miR-335-5p 103.7954538 376.0448494 
hsa-miR-337-5p 0 18.80224247 
hsa-miR-338-3p 0 94.01121236 
hsa-miR-338-5p 0 18.80224247 
hsa-miR-339-3p 1037.954538 4568.944921 
hsa-miR-339-5p 7646.265094 15173.40967 
hsa-miR-339-amb 0 18.80224247 
hsa-miR-33a-3p 242.1893921 169.2201822 
hsa-miR-33a-5p 69.19696917 94.01121236 
hsa-miR-33a-amb 553.5757534 37.60448494 
hsa-miR-33b-3p 3494.446943 2500.698249 
hsa-miR-33b-5p 415.181815 188.0224247 
hsa-miR-340-3p 138.3939383 206.8246672 
hsa-miR-340-5p 34.59848459 94.01121236 
hsa-miR-342-3p 553.5757534 33035.54002 
hsa-miR-342-5p 69.19696917 225.6269097 
hsa-miR-342-amb 0 75.20896989 
hsa-miR-345-3p 69.19696917 75.20896989 
hsa-miR-345-5p 2525.689375 5057.803225 
hsa-miR-346-3p 34.59848459 0 
hsa-miR-34a-3p 311.3863613 394.8470919 
hsa-miR-34a-5p 1314.742414 1165.739033 
hsa-miR-34a-amb 34.59848459 131.6156973 
hsa-miR-34b-3p 207.5909075 0 
hsa-miR-34b-5p 207.5909075 18.80224247 
hsa-miR-34c-3p 242.1893921 0 
hsa-miR-34c-5p 172.9924229 0 
hsa-miR-3545-3p 0 75.20896989 
hsa-miR-3605-3p 311.3863613 56.40672742 
hsa-miR-3605-5p 103.7954538 0 
hsa-miR-3605-amb 34.59848459 0 
hsa-miR-3607-3p 34.59848459 37.60448494 
hsa-miR-3607-5p 0 56.40672742 
hsa-miR-3607-amb 0 18.80224247 
hsa-miR-3609-3p 34.59848459 112.8134548 
hsa-miR-361-3p 380.5833305 676.880729 
hsa-miR-361-5p 449.7802996 789.6941838 
hsa-miR-3610-3p 34.59848459 18.80224247 
hsa-miR-3613-3p 34.59848459 1090.530063 
hsa-miR-3613-5p 0 188.0224247 
hsa-miR-3614-3p 69.19696917 18.80224247 
hsa-miR-3614-5p 69.19696917 94.01121236 
hsa-miR-3615-3p 415.181815 263.2313946 
hsa-miR-3616-3p 0 37.60448494 
hsa-miR-3617-3p 69.19696917 0 
hsa-miR-3617-5p 69.19696917 0 
hsa-miR-3619-3p 103.7954538 75.20896989 
hsa-miR-3619-5p 311.3863613 507.6605467 
hsa-miR-362-3p 103.7954538 263.2313946 
hsa-miR-362-5p 172.9924229 300.8358795 
hsa-miR-3620-3p 380.5833305 357.242607 
hsa-miR-3620-5p 34.59848459 0 
hsa-miR-3622a-3p 34.59848459 18.80224247 
hsa-miR-363-3p 0 18.80224247 
hsa-miR-3648-3p 588.174238 300.8358795 
hsa-miR-3648-5p 657.3712071 263.2313946 
hsa-miR-3648-amb 34.59848459 37.60448494 
hsa-miR-3651-3p 69.19696917 0 
hsa-miR-3652-5p 0 18.80224247 
hsa-miR-3652-amb 34.59848459 0 
hsa-miR-3653-5p 103.7954538 131.6156973 
hsa-miR-3656-3p 34.59848459 0 
hsa-miR-3657-5p 34.59848459 18.80224247 
hsa-miR-365a-3p 103.7954538 695.6829715 
hsa-miR-365a-5p 69.19696917 112.8134548 
hsa-miR-365b-3p 103.7954538 695.6829715 
hsa-miR-365b-5p 69.19696917 169.2201822 
hsa-miR-3661-5p 69.19696917 18.80224247 
hsa-miR-3663-3p 0 37.60448494 
hsa-miR-3664-3p 34.59848459 56.40672742 
hsa-miR-3664-5p 0 112.8134548 
hsa-miR-3665-5p 795.7651455 300.8358795 
hsa-miR-3676-3p 1037.954538 789.6941838 
hsa-miR-3676-5p 0 188.0224247 
hsa-miR-3676-amb 276.7878767 658.0784865 
hsa-miR-3677-3p 69.19696917 75.20896989 
hsa-miR-3677-5p 207.5909075 131.6156973 
hsa-miR-3679-3p 0 37.60448494 
hsa-miR-3679-5p 103.7954538 206.8246672 
hsa-miR-3680-1-3p 0 18.80224247 
hsa-miR-3680-1-5p 0 37.60448494 
hsa-miR-3680-2-3p 0 18.80224247 
hsa-miR-3680-2-5p 0 37.60448494 
hsa-miR-3681-3p 34.59848459 0 
hsa-miR-3681-5p 34.59848459 0 
hsa-miR-3682-5p 34.59848459 0 
hsa-miR-3683-5p 0 18.80224247 
hsa-miR-3687-3p 518.9772688 94.01121236 
hsa-miR-3687-5p 138.3939383 18.80224247 
hsa-miR-3687-amb 103.7954538 18.80224247 
hsa-miR-3688-1-5p 0 18.80224247 
hsa-miR-3688-2-5p 0 18.80224247 
hsa-miR-3688-2-amb 0 18.80224247 
hsa-miR-3691-3p 34.59848459 0 
hsa-miR-3691-5p 0 18.80224247 
hsa-miR-3692-5p 34.59848459 18.80224247 
hsa-miR-373-3p 34.59848459 0 
hsa-miR-374a-3p 69.19696917 37.60448494 
hsa-miR-374a-5p 69.19696917 206.8246672 
hsa-miR-374b-3p 69.19696917 131.6156973 
hsa-miR-374b-5p 242.1893921 1748.60855 
hsa-miR-374c-5p 0 131.6156973 
hsa-miR-375-3p 0 507.6605467 
hsa-miR-375-5p 0 112.8134548 
hsa-miR-376b-3p 0 18.80224247 
hsa-miR-376c-3p 0 18.80224247 
hsa-miR-378a-3p 22834.99983 42756.29938 
hsa-miR-378a-5p 242.1893921 206.8246672 
hsa-miR-378b-3p 0 169.2201822 
hsa-miR-378c-5p 22523.61347 42173.42986 
hsa-miR-378d-1-3p 22454.4165 41778.58277 
hsa-miR-378d-2-5p 22523.61347 42229.83659 
hsa-miR-378e-3p 172.9924229 488.8583043 
hsa-miR-378f-3p 69.19696917 75.20896989 
hsa-miR-378g-5p 34.59848459 112.8134548 
hsa-miR-378i-5p 103.7954538 56.40672742 
hsa-miR-383-3p 0 18.80224247 
hsa-miR-3908-3p 0 18.80224247 
hsa-miR-3909-3p 34.59848459 169.2201822 
hsa-miR-3909-5p 103.7954538 37.60448494 
 222 
hsa-miR-3909-amb 0 18.80224247 
hsa-miR-3911-5p 34.59848459 0 
hsa-miR-3912-3p 34.59848459 37.60448494 
hsa-miR-3913-1-3p 0 56.40672742 
hsa-miR-3913-1-5p 0 75.20896989 
hsa-miR-3913-2-3p 0 56.40672742 
hsa-miR-3913-2-5p 0 75.20896989 
hsa-miR-3916-5p 34.59848459 37.60448494 
hsa-miR-3917-3p 0 18.80224247 
hsa-miR-3917-5p 34.59848459 0 
hsa-miR-3917-amb 0 18.80224247 
hsa-miR-3922-5p 172.9924229 0 
hsa-miR-3926-1-5p 0 18.80224247 
hsa-miR-3927-5p 0 18.80224247 
hsa-miR-3928-3p 103.7954538 75.20896989 
hsa-miR-3928-5p 0 18.80224247 
hsa-miR-3929-3p 103.7954538 112.8134548 
hsa-miR-3929-5p 103.7954538 282.0336371 
hsa-miR-3929-amb 553.5757534 507.6605467 
hsa-miR-3934-5p 0 18.80224247 
hsa-miR-3935-3p 0 18.80224247 
hsa-miR-3939-3p 34.59848459 18.80224247 
hsa-miR-3940-3p 276.7878767 75.20896989 
hsa-miR-3940-5p 172.9924229 18.80224247 
hsa-miR-3943-5p 34.59848459 0 
hsa-miR-3944-3p 69.19696917 0 
hsa-miR-3944-5p 69.19696917 56.40672742 
hsa-miR-3960-3p 5950.939349 2575.907219 
hsa-miR-3960-5p 69.19696917 0 
hsa-miR-409-3p 0 18.80224247 
hsa-miR-421-3p 795.7651455 3403.205887 
hsa-miR-422a-5p 34.59848459 75.20896989 
hsa-miR-423-3p 3909.628758 2632.313946 
hsa-miR-423-5p 380.5833305 357.242607 
hsa-miR-424-3p 1280.14393 432.4515769 
hsa-miR-424-5p 1487.734837 2049.444429 
hsa-miR-425-3p 1245.545445 977.7166085 
hsa-miR-425-5p 2041.310591 7972.150808 
hsa-miR-4254-3p 0 18.80224247 
hsa-miR-4279-3p 276.7878767 225.6269097 
hsa-miR-4284-5p 1072.553022 2594.709461 
hsa-miR-4286-5p 1453.136353 282.0336371 
hsa-miR-429-3p 103.7954538 658.0784865 
hsa-miR-429-5p 0 18.80224247 
hsa-miR-4296-5p 34.59848459 0 
hsa-miR-4300-3p 0 18.80224247 
hsa-miR-4300-amb 0 94.01121236 
hsa-miR-4301-5p 207.5909075 300.8358795 
hsa-miR-4313-3p 0 18.80224247 
hsa-miR-4324-3p 138.3939383 94.01121236 
hsa-miR-4325-3p 0 56.40672742 
hsa-miR-4326-5p 34.59848459 0 
hsa-miR-4326-amb 138.3939383 0 
hsa-miR-4419a-3p 0 18.80224247 
hsa-miR-4419a-5p 242.1893921 112.8134548 
hsa-miR-4419a-amb 380.5833305 206.8246672 
hsa-miR-4419b-3p 103.7954538 37.60448494 
hsa-miR-4419b-amb 138.3939383 37.60448494 
hsa-miR-4420-3p 103.7954538 0 
hsa-miR-4421-3p 69.19696917 0 
hsa-miR-4421-amb 34.59848459 0 
hsa-miR-4422-5p 0 18.80224247 
hsa-miR-4423-5p 34.59848459 0 
hsa-miR-4424-3p 0 18.80224247 
hsa-miR-4428-3p 0 18.80224247 
hsa-miR-4429-5p 622.7727226 827.2986688 
hsa-miR-4430-3p 172.9924229 56.40672742 
hsa-miR-4430-amb 0 18.80224247 
hsa-miR-4435-1-3p 34.59848459 0 
hsa-miR-4435-1-5p 34.59848459 18.80224247 
hsa-miR-4435-2-3p 34.59848459 0 
hsa-miR-4435-2-5p 34.59848459 18.80224247 
hsa-miR-4440-3p 34.59848459 0 
hsa-miR-4440-5p 0 18.80224247 
hsa-miR-4443-5p 0 18.80224247 
hsa-miR-4444-1-3p 0 18.80224247 
hsa-miR-4444-2-3p 0 18.80224247 
hsa-miR-4446-3p 0 319.638122 
hsa-miR-4446-5p 0 94.01121236 
hsa-miR-4448-3p 34.59848459 37.60448494 
hsa-miR-4449-3p 0 37.60448494 
hsa-miR-4449-5p 276.7878767 206.8246672 
hsa-miR-4451-3p 0 18.80224247 
hsa-miR-4452-5p 0 18.80224247 
hsa-miR-4454-5p 207.5909075 112.8134548 
hsa-miR-4459-3p 34.59848459 18.80224247 
hsa-miR-4459-5p 69.19696917 94.01121236 
hsa-miR-4459-amb 103.7954538 94.01121236 
hsa-miR-4461-3p 276.7878767 545.2650317 
hsa-miR-4461-5p 69.19696917 0 
hsa-miR-4463-3p 0 18.80224247 
hsa-miR-4466-5p 345.9848459 131.6156973 
hsa-miR-4467-5p 0 18.80224247 
hsa-miR-4469-3p 34.59848459 0 
hsa-miR-4470-3p 0 18.80224247 
hsa-miR-4472-2-3p 34.59848459 37.60448494 
hsa-miR-4472-2-amb 0 18.80224247 
hsa-miR-4473-3p 0 37.60448494 
hsa-miR-4474-5p 0 18.80224247 
hsa-miR-4479-3p 103.7954538 56.40672742 
hsa-miR-448-3p 0 18.80224247 
hsa-miR-448-5p 0 18.80224247 
hsa-miR-4484-3p 138.3939383 526.4627892 
hsa-miR-4485-3p 1902.916652 1616.992853 
hsa-miR-4485-5p 726.5681763 470.0560618 
hsa-miR-4488-5p 172.9924229 0 
hsa-miR-4492-3p 0 37.60448494 
hsa-miR-4492-5p 34.59848459 37.60448494 
hsa-miR-4498-5p 0 18.80224247 
hsa-miR-449a-5p 207.5909075 18.80224247 
hsa-miR-449b-3p 34.59848459 0 
hsa-miR-449b-5p 103.7954538 18.80224247 
hsa-miR-449c-5p 138.3939383 18.80224247 
hsa-miR-4500-3p 0 18.80224247 
hsa-miR-4502-3p 34.59848459 0 
hsa-miR-4504-3p 0 18.80224247 
hsa-miR-4504-5p 34.59848459 0 
hsa-miR-4508-5p 0 18.80224247 
hsa-miR-450a-1-3p 34.59848459 0 
hsa-miR-450a-1-5p 103.7954538 413.6493344 
hsa-miR-450a-2-5p 103.7954538 413.6493344 
hsa-miR-450b-5p 34.59848459 56.40672742 
hsa-miR-4512-3p 0 56.40672742 
hsa-miR-4512-5p 484.3787842 770.8919413 
hsa-miR-4516-5p 138.3939383 37.60448494 
hsa-miR-4516-amb 0 56.40672742 
hsa-miR-4517-5p 0 18.80224247 
hsa-miR-4519-5p 34.59848459 0 
hsa-miR-451a-5p 0 37.60448494 
hsa-miR-451a-amb 0 37.60448494 
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hsa-miR-452-3p 138.3939383 0 
hsa-miR-452-5p 207.5909075 0 
hsa-miR-4521-3p 0 18.80224247 
hsa-miR-4521-5p 380.5833305 451.2538193 
hsa-miR-4523-5p 34.59848459 94.01121236 
hsa-miR-4525-3p 0 300.8358795 
hsa-miR-4525-5p 0 18.80224247 
hsa-miR-4526-3p 0 56.40672742 
hsa-miR-4532-5p 622.7727226 37.60448494 
hsa-miR-4536-1-3p 0 37.60448494 
hsa-miR-454-3p 588.174238 3534.821585 
hsa-miR-454-5p 138.3939383 188.0224247 
hsa-miR-455-3p 21347.26499 3722.844009 
hsa-miR-455-5p 380.5833305 94.01121236 
hsa-miR-4632-3p 34.59848459 0 
hsa-miR-4633-5p 0 18.80224247 
hsa-miR-4635-3p 0 18.80224247 
hsa-miR-4638-3p 138.3939383 94.01121236 
hsa-miR-4638-5p 0 18.80224247 
hsa-miR-4640-3p 34.59848459 37.60448494 
hsa-miR-4640-5p 0 75.20896989 
hsa-miR-4644-5p 0 18.80224247 
hsa-miR-4645-3p 0 18.80224247 
hsa-miR-4646-3p 34.59848459 56.40672742 
hsa-miR-4647-5p 69.19696917 0 
hsa-miR-4647-amb 0 18.80224247 
hsa-miR-4648-5p 0 37.60448494 
hsa-miR-4652-3p 0 56.40672742 
hsa-miR-4653-3p 0 18.80224247 
hsa-miR-4655-3p 0 37.60448494 
hsa-miR-4655-5p 0 37.60448494 
hsa-miR-4659a-3p 0 18.80224247 
hsa-miR-4659a-5p 0 37.60448494 
hsa-miR-466-3p 0 37.60448494 
hsa-miR-466-5p 0 18.80224247 
hsa-miR-4660-5p 0 18.80224247 
hsa-miR-4661-5p 34.59848459 18.80224247 
hsa-miR-4662a-5p 34.59848459 0 
hsa-miR-4664-3p 34.59848459 18.80224247 
hsa-miR-4664-5p 0 56.40672742 
hsa-miR-4665-3p 34.59848459 18.80224247 
hsa-miR-4667-3p 69.19696917 94.01121236 
hsa-miR-4667-5p 34.59848459 18.80224247 
hsa-miR-4669-3p 0 18.80224247 
hsa-miR-4673-5p 0 18.80224247 
hsa-miR-4674-5p 0 18.80224247 
hsa-miR-4676-3p 34.59848459 0 
hsa-miR-4676-5p 34.59848459 18.80224247 
hsa-miR-4677-3p 0 18.80224247 
hsa-miR-4683-3p 34.59848459 56.40672742 
hsa-miR-4685-3p 34.59848459 0 
hsa-miR-4687-3p 69.19696917 18.80224247 
hsa-miR-4689-5p 34.59848459 37.60448494 
hsa-miR-4690-3p 172.9924229 131.6156973 
hsa-miR-4691-3p 0 18.80224247 
hsa-miR-4695-3p 0 37.60448494 
hsa-miR-4698-5p 0 18.80224247 
hsa-miR-4700-5p 34.59848459 0 
hsa-miR-4701-5p 0 37.60448494 
hsa-miR-4706-5p 34.59848459 18.80224247 
hsa-miR-4707-3p 103.7954538 131.6156973 
hsa-miR-4707-5p 207.5909075 75.20896989 
hsa-miR-4707-amb 34.59848459 0 
hsa-miR-4708-3p 0 18.80224247 
hsa-miR-4708-5p 0 18.80224247 
hsa-miR-4710-5p 69.19696917 0 
hsa-miR-4713-5p 0 282.0336371 
hsa-miR-4714-3p 0 18.80224247 
hsa-miR-4714-5p 0 18.80224247 
hsa-miR-4715-amb 0 18.80224247 
hsa-miR-4717-3p 0 18.80224247 
hsa-miR-4717-5p 34.59848459 37.60448494 
hsa-miR-4720-5p 0 18.80224247 
hsa-miR-4721-5p 34.59848459 0 
hsa-miR-4722-3p 34.59848459 18.80224247 
hsa-miR-4723-3p 34.59848459 56.40672742 
hsa-miR-4723-5p 0 37.60448494 
hsa-miR-4724-5p 0 18.80224247 
hsa-miR-4725-3p 0 75.20896989 
hsa-miR-4725-5p 69.19696917 206.8246672 
hsa-miR-4726-3p 0 37.60448494 
hsa-miR-4726-5p 69.19696917 37.60448494 
hsa-miR-4728-3p 138.3939383 300.8358795 
hsa-miR-4730-5p 34.59848459 56.40672742 
hsa-miR-4731-3p 138.3939383 37.60448494 
hsa-miR-4731-5p 34.59848459 0 
hsa-miR-4732-5p 0 18.80224247 
hsa-miR-4733-5p 0 37.60448494 
hsa-miR-4737-amb 0 37.60448494 
hsa-miR-4738-3p 0 18.80224247 
hsa-miR-4741-3p 103.7954538 0 
hsa-miR-4741-5p 69.19696917 37.60448494 
hsa-miR-4742-3p 34.59848459 18.80224247 
hsa-miR-4742-5p 34.59848459 18.80224247 
hsa-miR-4743-5p 69.19696917 0 
hsa-miR-4745-3p 0 94.01121236 
hsa-miR-4745-5p 69.19696917 282.0336371 
hsa-miR-4746-3p 0 37.60448494 
hsa-miR-4746-5p 138.3939383 75.20896989 
hsa-miR-4747-3p 0 37.60448494 
hsa-miR-4748-5p 34.59848459 0 
hsa-miR-4749-3p 138.3939383 37.60448494 
hsa-miR-4749-5p 34.59848459 0 
hsa-miR-4750-5p 69.19696917 37.60448494 
hsa-miR-4754-3p 0 37.60448494 
hsa-miR-4756-3p 0 37.60448494 
hsa-miR-4756-5p 0 37.60448494 
hsa-miR-4757-3p 34.59848459 0 
hsa-miR-4757-5p 34.59848459 0 
hsa-miR-4758-3p 242.1893921 507.6605467 
hsa-miR-4758-5p 34.59848459 94.01121236 
hsa-miR-4758-amb 0 18.80224247 
hsa-miR-4760-3p 0 37.60448494 
hsa-miR-4762-5p 0 18.80224247 
hsa-miR-4763-3p 0 75.20896989 
hsa-miR-4763-5p 34.59848459 94.01121236 
hsa-miR-4765-5p 0 18.80224247 
hsa-miR-4767-5p 103.7954538 37.60448494 
hsa-miR-4769-3p 34.59848459 0 
hsa-miR-4783-3p 0 56.40672742 
hsa-miR-4786-3p 34.59848459 0 
hsa-miR-4787-3p 138.3939383 37.60448494 
hsa-miR-4787-5p 69.19696917 18.80224247 
hsa-miR-4789-3p 34.59848459 37.60448494 
hsa-miR-4791-5p 0 37.60448494 
hsa-miR-4795-5p 0 18.80224247 
hsa-miR-4797-5p 0 18.80224247 
hsa-miR-4798-5p 0 18.80224247 
hsa-miR-4799-5p 34.59848459 37.60448494 
hsa-miR-4800-3p 0 18.80224247 
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hsa-miR-4802-3p 0 18.80224247 
hsa-miR-4802-5p 0 18.80224247 
hsa-miR-483-3p 0 56.40672742 
hsa-miR-483-5p 0 75.20896989 
hsa-miR-484-5p 1660.72726 3440.810372 
hsa-miR-486-3p 138.3939383 18.80224247 
hsa-miR-486-5p 1210.946961 206.8246672 
hsa-miR-487b-3p 0 18.80224247 
hsa-miR-489-3p 3667.439366 60543.22076 
hsa-miR-489-5p 69.19696917 18.80224247 
hsa-miR-491-3p 69.19696917 18.80224247 
hsa-miR-491-5p 103.7954538 94.01121236 
hsa-miR-491-amb 34.59848459 0 
hsa-miR-492-3p 0 56.40672742 
hsa-miR-492-5p 0 56.40672742 
hsa-miR-494-3p 0 18.80224247 
hsa-miR-495-3p 0 18.80224247 
hsa-miR-497-3p 0 18.80224247 
hsa-miR-497-5p 207.5909075 300.8358795 
hsa-miR-5000-5p 0 18.80224247 
hsa-miR-5001-3p 34.59848459 37.60448494 
hsa-miR-5001-5p 0 56.40672742 
hsa-miR-5008-3p 103.7954538 150.4179398 
hsa-miR-5008-5p 69.19696917 75.20896989 
hsa-miR-500a-3p 138.3939383 338.4403645 
hsa-miR-500a-5p 207.5909075 357.242607 
hsa-miR-500b-3p 34.59848459 37.60448494 
hsa-miR-500b-5p 207.5909075 357.242607 
hsa-miR-501-3p 172.9924229 244.4291521 
hsa-miR-501-5p 345.9848459 451.2538193 
hsa-miR-5010-3p 0 18.80224247 
hsa-miR-5010-5p 34.59848459 0 
hsa-miR-502-3p 138.3939383 376.0448494 
hsa-miR-502-5p 138.3939383 282.0336371 
hsa-miR-503-3p 553.5757534 37.60448494 
hsa-miR-503-5p 6504.515102 1203.343518 
hsa-miR-504-3p 0 18.80224247 
hsa-miR-504-5p 0 75.20896989 
hsa-miR-505-3p 1037.954538 1165.739033 
hsa-miR-505-5p 172.9924229 357.242607 
hsa-miR-5087-3p 0 18.80224247 
hsa-miR-5090-3p 69.19696917 56.40672742 
hsa-miR-5090-5p 103.7954538 131.6156973 
hsa-miR-5094-5p 34.59848459 56.40672742 
hsa-miR-5095-3p 69.19696917 545.2650317 
hsa-miR-5095-5p 207.5909075 394.8470919 
hsa-miR-5096-3p 518.9772688 733.2874564 
hsa-miR-5096-5p 172.9924229 94.01121236 
hsa-miR-5096-amb 276.7878767 300.8358795 
hsa-miR-5100-3p 0 75.20896989 
hsa-miR-512-1-3p 0 18.80224247 
hsa-miR-512-1-5p 0 56.40672742 
hsa-miR-512-2-3p 0 18.80224247 
hsa-miR-512-2-5p 0 56.40672742 
hsa-miR-513b-5p 0 18.80224247 
hsa-miR-515-1-3p 0 37.60448494 
hsa-miR-515-2-3p 0 37.60448494 
hsa-miR-516a-1-3p 0 18.80224247 
hsa-miR-516a-2-3p 0 18.80224247 
hsa-miR-516b-1-3p 0 18.80224247 
hsa-miR-516b-2-3p 0 18.80224247 
hsa-miR-517a-3p 34.59848459 18.80224247 
hsa-miR-517b-3p 34.59848459 18.80224247 
hsa-miR-517c-3p 0 18.80224247 
hsa-miR-5187-5p 0 18.80224247 
hsa-miR-5189-3p 0 18.80224247 
hsa-miR-518a-1-3p 0 18.80224247 
hsa-miR-518a-1-5p 0 18.80224247 
hsa-miR-518a-2-3p 0 18.80224247 
hsa-miR-518a-2-5p 0 18.80224247 
hsa-miR-518b-3p 0 18.80224247 
hsa-miR-518c-3p 0 18.80224247 
hsa-miR-518e-3p 0 18.80224247 
hsa-miR-5196-3p 69.19696917 18.80224247 
hsa-miR-519a-1-3p 34.59848459 18.80224247 
hsa-miR-519a-1-5p 34.59848459 18.80224247 
hsa-miR-519a-2-3p 34.59848459 18.80224247 
hsa-miR-519a-2-5p 0 18.80224247 
hsa-miR-519b-3p 0 18.80224247 
hsa-miR-519c-3p 0 18.80224247 
hsa-miR-519d-3p 0 18.80224247 
hsa-miR-520b-5p 0 18.80224247 
hsa-miR-520d-3p 0 18.80224247 
hsa-miR-520d-5p 0 18.80224247 
hsa-miR-520f-3p 0 18.80224247 
hsa-miR-520g-3p 34.59848459 37.60448494 
hsa-miR-520g-5p 0 18.80224247 
hsa-miR-520h-3p 0 18.80224247 
hsa-miR-520h-5p 0 18.80224247 
hsa-miR-521-1-3p 34.59848459 18.80224247 
hsa-miR-521-2-3p 34.59848459 18.80224247 
hsa-miR-522-3p 0 18.80224247 
hsa-miR-525-3p 0 18.80224247 
hsa-miR-526b-3p 0 18.80224247 
hsa-miR-526b-5p 0 37.60448494 
hsa-miR-527-5p 0 18.80224247 
hsa-miR-532-3p 588.174238 1240.948003 
hsa-miR-532-5p 1037.954538 2105.851157 
hsa-miR-542-3p 103.7954538 658.0784865 
hsa-miR-542-5p 138.3939383 75.20896989 
hsa-miR-544b-3p 0 37.60448494 
hsa-miR-544b-5p 0 18.80224247 
hsa-miR-545-3p 138.3939383 112.8134548 
hsa-miR-545-5p 69.19696917 112.8134548 
hsa-miR-548a-1-3p 34.59848459 18.80224247 
hsa-miR-548a-2-3p 34.59848459 0 
hsa-miR-548a-2-5p 0 18.80224247 
hsa-miR-548a-3-3p 69.19696917 0 
hsa-miR-548aa-1-3p 311.3863613 564.0672742 
hsa-miR-548aa-2-3p 311.3863613 582.8695166 
hsa-miR-548ab-5p 0 37.60448494 
hsa-miR-548ac-5p 0 18.80224247 
hsa-miR-548ad-5p 0 75.20896989 
hsa-miR-548ae-1-3p 0 18.80224247 
hsa-miR-548ae-2-3p 0 18.80224247 
hsa-miR-548ag-2-3p 0 18.80224247 
hsa-miR-548ai-5p 0 56.40672742 
hsa-miR-548aj-1-3p 0 18.80224247 
hsa-miR-548aj-2-3p 0 18.80224247 
hsa-miR-548aj-2-5p 0 37.60448494 
hsa-miR-548ak-3p 0 37.60448494 
hsa-miR-548ak-5p 0 37.60448494 
hsa-miR-548al-3p 34.59848459 37.60448494 
hsa-miR-548am-3p 0 18.80224247 
hsa-miR-548am-5p 0 18.80224247 
hsa-miR-548an-3p 0 37.60448494 
hsa-miR-548ao-5p 34.59848459 0 
hsa-miR-548ap-3p 34.59848459 0 
hsa-miR-548aq-5p 34.59848459 0 
hsa-miR-548au-5p 0 37.60448494 
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hsa-miR-548aw-3p 0 18.80224247 
hsa-miR-548aw-5p 69.19696917 0 
hsa-miR-548b-3p 34.59848459 18.80224247 
hsa-miR-548b-5p 34.59848459 0 
hsa-miR-548c-3p 34.59848459 18.80224247 
hsa-miR-548c-5p 34.59848459 37.60448494 
hsa-miR-548d-1-3p 0 37.60448494 
hsa-miR-548d-2-3p 0 37.60448494 
hsa-miR-548d-2-5p 0 18.80224247 
hsa-miR-548e-3p 0 18.80224247 
hsa-miR-548f-1-5p 0 18.80224247 
hsa-miR-548f-2-3p 0 18.80224247 
hsa-miR-548f-3-3p 0 18.80224247 
hsa-miR-548g-5p 34.59848459 0 
hsa-miR-548h-2-3p 103.7954538 394.8470919 
hsa-miR-548h-3-3p 34.59848459 56.40672742 
hsa-miR-548h-4-3p 69.19696917 56.40672742 
hsa-miR-548i-1-3p 0 18.80224247 
hsa-miR-548i-1-5p 34.59848459 37.60448494 
hsa-miR-548i-2-3p 0 18.80224247 
hsa-miR-548i-2-5p 0 18.80224247 
hsa-miR-548i-3-3p 0 18.80224247 
hsa-miR-548i-3-5p 0 18.80224247 
hsa-miR-548i-4-5p 34.59848459 56.40672742 
hsa-miR-548j-5p 34.59848459 0 
hsa-miR-548n-3p 69.19696917 0 
hsa-miR-548o-2-3p 34.59848459 18.80224247 
hsa-miR-548o-2-5p 34.59848459 37.60448494 
hsa-miR-548o-3p 34.59848459 18.80224247 
hsa-miR-548p-3p 0 56.40672742 
hsa-miR-548q-5p 34.59848459 150.4179398 
hsa-miR-548t-3p 311.3863613 545.2650317 
hsa-miR-548t-5p 0 18.80224247 
hsa-miR-548v-3p 0 37.60448494 
hsa-miR-548v-5p 0 56.40672742 
hsa-miR-548w-3p 34.59848459 0 
hsa-miR-548w-5p 0 18.80224247 
hsa-miR-548z-3p 69.19696917 94.01121236 
hsa-miR-549-3p 34.59848459 0 
hsa-miR-549-5p 34.59848459 0 
hsa-miR-550a-1-3p 207.5909075 150.4179398 
hsa-miR-550a-1-5p 588.174238 1316.156973 
hsa-miR-550a-2-3p 207.5909075 150.4179398 
hsa-miR-550a-2-5p 588.174238 1316.156973 
hsa-miR-550a-3-3p 207.5909075 150.4179398 
hsa-miR-550a-3-5p 553.5757534 1109.332306 
hsa-miR-550b-1-5p 69.19696917 0 
hsa-miR-550b-2-5p 69.19696917 0 
hsa-miR-551a-3p 69.19696917 263.2313946 
hsa-miR-551b-3p 830.3636301 75.20896989 
hsa-miR-551b-5p 69.19696917 0 
hsa-miR-556-3p 0 18.80224247 
hsa-miR-556-5p 0 18.80224247 
hsa-miR-558-5p 69.19696917 75.20896989 
hsa-miR-5580-3p 0 18.80224247 
hsa-miR-5581-3p 0 56.40672742 
hsa-miR-5582-5p 34.59848459 18.80224247 
hsa-miR-5585-3p 103.7954538 94.01121236 
hsa-miR-5587-3p 0 112.8134548 
hsa-miR-5587-5p 34.59848459 56.40672742 
hsa-miR-559-3p 0 18.80224247 
hsa-miR-559-5p 0 18.80224247 
hsa-miR-564-3p 0 18.80224247 
hsa-miR-566-3p 415.181815 695.6829715 
hsa-miR-566-5p 138.3939383 94.01121236 
hsa-miR-566-amb 103.7954538 94.01121236 
hsa-miR-5684-3p 207.5909075 94.01121236 
hsa-miR-5684-5p 242.1893921 413.6493344 
hsa-miR-5689-3p 0 56.40672742 
hsa-miR-5689-5p 34.59848459 18.80224247 
hsa-miR-5690-5p 0 37.60448494 
hsa-miR-5691-5p 0 18.80224247 
hsa-miR-5692a-1-3p 0 37.60448494 
hsa-miR-5692a-2-3p 0 18.80224247 
hsa-miR-5695-3p 34.59848459 75.20896989 
hsa-miR-5696-3p 0 18.80224247 
hsa-miR-5699-3p 34.59848459 56.40672742 
hsa-miR-5699-5p 103.7954538 357.242607 
hsa-miR-570-3p 0 37.60448494 
hsa-miR-570-5p 0 56.40672742 
hsa-miR-5708-3p 172.9924229 188.0224247 
hsa-miR-572-3p 0 37.60448494 
hsa-miR-572-5p 0 18.80224247 
hsa-miR-573-5p 34.59848459 37.60448494 
hsa-miR-574-3p 7369.477217 3365.601402 
hsa-miR-574-5p 2145.106044 902.5076386 
hsa-miR-576-3p 0 18.80224247 
hsa-miR-576-5p 0 75.20896989 
hsa-miR-577-5p 34.59848459 18.80224247 
hsa-miR-579-3p 0 37.60448494 
hsa-miR-579-5p 69.19696917 56.40672742 
hsa-miR-582-3p 34.59848459 0 
hsa-miR-582-5p 103.7954538 37.60448494 
hsa-miR-584-3p 311.3863613 0 
hsa-miR-584-5p 622.7727226 0 
hsa-miR-584-amb 34.59848459 0 
hsa-miR-588-5p 69.19696917 18.80224247 
hsa-miR-589-3p 172.9924229 451.2538193 
hsa-miR-589-5p 103.7954538 131.6156973 
hsa-miR-590-3p 34.59848459 56.40672742 
hsa-miR-590-5p 138.3939383 545.2650317 
hsa-miR-590-amb 69.19696917 0 
hsa-miR-597-3p 0 37.60448494 
hsa-miR-597-5p 34.59848459 18.80224247 
hsa-miR-598-3p 345.9848459 244.4291521 
hsa-miR-598-5p 103.7954538 37.60448494 
hsa-miR-600-3p 34.59848459 0 
hsa-miR-602-5p 103.7954538 169.2201822 
hsa-miR-603-3p 34.59848459 0 
hsa-miR-603-5p 0 18.80224247 
hsa-miR-608-5p 0 18.80224247 
hsa-miR-609-5p 0 18.80224247 
hsa-miR-610-3p 34.59848459 0 
hsa-miR-610-5p 0 18.80224247 
hsa-miR-611-5p 0 18.80224247 
hsa-miR-611-amb 34.59848459 0 
hsa-miR-615-3p 276.7878767 733.2874564 
hsa-miR-615-5p 34.59848459 0 
hsa-miR-616-5p 34.59848459 56.40672742 
hsa-miR-618-5p 0 56.40672742 
hsa-miR-619-5p 1003.356053 1184.541276 
hsa-miR-622-3p 0 18.80224247 
hsa-miR-622-5p 0 56.40672742 
hsa-miR-624-3p 34.59848459 56.40672742 
hsa-miR-624-5p 138.3939383 169.2201822 
hsa-miR-625-3p 2006.712106 2519.500491 
hsa-miR-625-5p 34.59848459 131.6156973 
hsa-miR-627-3p 0 75.20896989 
hsa-miR-627-5p 34.59848459 75.20896989 
hsa-miR-628-3p 34.59848459 75.20896989 
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hsa-miR-628-5p 69.19696917 94.01121236 
hsa-miR-629-3p 207.5909075 244.4291521 
hsa-miR-629-5p 1280.14393 1955.433217 
hsa-miR-631-5p 0 37.60448494 
hsa-miR-632-3p 0 18.80224247 
hsa-miR-636-3p 138.3939383 244.4291521 
hsa-miR-636-5p 0 18.80224247 
hsa-miR-639-3p 0 18.80224247 
hsa-miR-639-5p 0 18.80224247 
hsa-miR-641-5p 103.7954538 112.8134548 
hsa-miR-642a-3p 69.19696917 18.80224247 
hsa-miR-642a-5p 34.59848459 0 
hsa-miR-642b-3p 34.59848459 18.80224247 
hsa-miR-643-3p 0 56.40672742 
hsa-miR-643-5p 0 18.80224247 
hsa-miR-644b-3p 138.3939383 94.01121236 
hsa-miR-651-5p 0 56.40672742 
hsa-miR-652-3p 1107.151507 3233.985705 
hsa-miR-652-5p 761.1666609 2030.642187 
hsa-miR-653-3p 0 225.6269097 
hsa-miR-653-5p 34.59848459 206.8246672 
hsa-miR-657-3p 0 18.80224247 
hsa-miR-659-3p 34.59848459 0 
hsa-miR-659-5p 34.59848459 18.80224247 
hsa-miR-660-3p 276.7878767 94.01121236 
hsa-miR-660-5p 172.9924229 394.8470919 
hsa-miR-662-3p 34.59848459 0 
hsa-miR-663a-3p 657.3712071 37.60448494 
hsa-miR-663a-5p 276.7878767 0 
hsa-miR-663a-amb 138.3939383 18.80224247 
hsa-miR-663b-3p 103.7954538 37.60448494 
hsa-miR-663b-5p 34.59848459 0 
hsa-miR-664-3p 138.3939383 94.01121236 
hsa-miR-664-5p 34.59848459 37.60448494 
hsa-miR-671-3p 588.174238 470.0560618 
hsa-miR-671-5p 1245.545445 1955.433217 
hsa-miR-675-3p 0 244.4291521 
hsa-miR-675-5p 0 206.8246672 
hsa-miR-676-3p 34.59848459 37.60448494 
hsa-miR-676-5p 0 18.80224247 
hsa-miR-7-1-3p 484.3787842 376.0448494 
hsa-miR-7-1-5p 553.5757534 1974.23546 
hsa-miR-7-2-3p 0 18.80224247 
hsa-miR-7-2-5p 449.7802996 1466.574913 
hsa-miR-7-3-5p 415.181815 1692.201822 
hsa-miR-708-5p 34.59848459 150.4179398 
hsa-miR-720-5p 4636.196935 1015.321093 
hsa-miR-744-3p 1314.742414 1334.959215 
hsa-miR-744-5p 449.7802996 996.518851 
hsa-miR-760-3p 553.5757534 507.6605467 
hsa-miR-760-5p 138.3939383 206.8246672 
hsa-miR-762-3p 34.59848459 37.60448494 
hsa-miR-766-3p 5155.174203 94.01121236 
hsa-miR-766-5p 69.19696917 0 
hsa-miR-769-3p 1418.537868 225.6269097 
hsa-miR-769-5p 657.3712071 507.6605467 
hsa-miR-874-3p 622.7727226 37.60448494 
hsa-miR-874-5p 207.5909075 0 
hsa-miR-877-3p 795.7651455 676.880729 
hsa-miR-877-5p 3252.257551 3666.437282 
hsa-miR-885-5p 34.59848459 18.80224247 
hsa-miR-887-3p 553.5757534 94.01121236 
hsa-miR-9-1-3p 0 112.8134548 
hsa-miR-9-1-5p 34.59848459 56.40672742 
hsa-miR-9-2-3p 0 112.8134548 
hsa-miR-9-2-5p 34.59848459 56.40672742 
hsa-miR-9-3-3p 0 112.8134548 
hsa-miR-9-3-5p 34.59848459 56.40672742 
hsa-miR-92a-1-3p 3736.636335 2406.687036 
hsa-miR-92a-1-5p 103.7954538 94.01121236 
hsa-miR-92a-2-3p 3252.257551 2162.257884 
hsa-miR-92b-3p 2664.083313 1993.037702 
hsa-miR-92b-5p 345.9848459 188.0224247 
hsa-miR-93-3p 553.5757534 1128.134548 
hsa-miR-93-5p 2525.689375 6373.960198 
hsa-miR-933-3p 69.19696917 18.80224247 
hsa-miR-934-3p 0 18.80224247 
hsa-miR-935-3p 138.3939383 112.8134548 
hsa-miR-937-3p 172.9924229 376.0448494 
hsa-miR-937-5p 69.19696917 37.60448494 
hsa-miR-938-5p 0 37.60448494 
hsa-miR-939-3p 69.19696917 37.60448494 
hsa-miR-939-5p 69.19696917 75.20896989 
hsa-miR-940-3p 4497.802996 7539.699231 
hsa-miR-940-5p 0 94.01121236 
hsa-miR-941-1-3p 1037.954538 1447.77267 
hsa-miR-941-1-5p 657.3712071 1015.321093 
hsa-miR-941-2-3p 1037.954538 1447.77267 
hsa-miR-941-2-5p 1037.954538 1447.77267 
hsa-miR-941-3-3p 1037.954538 1447.77267 
hsa-miR-941-3-5p 1037.954538 1447.77267 
hsa-miR-941-4-3p 1037.954538 1447.77267 
hsa-miR-941-4-5p 1037.954538 1447.77267 
hsa-miR-942-3p 69.19696917 75.20896989 
hsa-miR-942-5p 34.59848459 75.20896989 
hsa-miR-942-amb 0 18.80224247 
hsa-miR-943-3p 69.19696917 18.80224247 
hsa-miR-944-3p 0 18.80224247 
hsa-miR-944-5p 0 18.80224247 
hsa-miR-95-3p 34.59848459 188.0224247 
hsa-miR-96-3p 69.19696917 169.2201822 
hsa-miR-96-5p 103.7954538 1541.783883 
hsa-miR-98-3p 138.3939383 244.4291521 
hsa-miR-98-5p 934.1590838 996.518851 
hsa-miR-99a-3p 172.9924229 225.6269097 
hsa-miR-99a-5p 276.7878767 1203.343518 
hsa-miR-99b-3p 1349.340899 1109.332306 
hsa-miR-99b-5p 1972.113621 3027.161038 
 
Supplementary Table 5: Primer Sequences 
 
Oligo Name Sequence  Use 
mir139_Fwd_gDNA ATAGAAGGATCCACTGGCTTGGGAAGGGCGAGAGG  Forward primer to amplify miR-139-
5p from genomic DNA 
mir139_Rev_gDNA TTAAAGAAGCTTCCTGCCAGAGACCTTTCCTCCTCCCT Reverse primer to amplify miR-139-
5p from genomic DNA 
BMI1_fwd CTA GTT GTT ATT ACG CTG TTT TGT GAA CCT GTA GAA Top strand of luciferase construct 
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AAC AAG TGC TTT TTA TCT TGA AAT with binding site  
BMI1__rev AGC TAT TTC AAG ATA AAA AGC ACT TGT TTT CTA CAG 
GTT CAC AAA ACA GCG TAA TAA CAA 
Bottom strand of luciferase construct 
HRAS_fwd CTA GGC CCC GGC TGC ATG AGC TGC AAG TGT GTG CTC 
TCC TGA CGC AGG TGA GGG GGA CTC 
Top strand of luciferase construct 
with binding site  
HRAS_rev AGC TGA GTC CCC CTC ACC TGC GTC AGG AGA GCA 
CAC ACT TGC AGC TCA TGC AGC CGG GGC 
Bottom strand of luciferase construct 
NFKB1_fwd CTA GGG AAA ACA CTG TGA GGA TGG GAT CTG CAC 
TGT AAC TGC TGG ACC CAA GGA CAT GGT 
Top strand of luciferase construct 
with binding site  
NFKB1_rev AGC TAC CAT GTC CTT GGG TCC AGC AGT TAC AGT GCA 
GAT CCC ATC CTC ACA GTG TTT TCC 
Bottom strand of luciferase construct 
NFKB1_fwd CTA GGC CAT GAT GAG CAA TAG CCT GCC ATG TTT GCT 
GCT GCT GGT GGC CGC TGG GGC TGA 
Top strand of luciferase construct 
with binding site  
NFKB1_rev AGC TTC AGC CCC AGC GGC CAC CAG CAG CAG CAA 
ACA TGG CAG GCT ATT GCT CAT CAT GGC 
Bottom strand of luciferase construct 
PIK3CA_fwd CTA GAA GTA ATA AAA ATA ATT TTA AAC ACA CTG 
TAG TAA GAA ATG ACT GTT GGA AAA TTA 
Top strand of luciferase construct 
with binding site  
PIK3CA_rev AGC TTA ATT TTC CAA CAG TCA TTT CTT ACT ACA GTG 
TGT TTA AAA TTA TTT TTA TTA CTT 
Bottom strand of luciferase construct 
PRKCE_fwd CTA GTA TTG AAG GGA TGT GAC ATT ACC TCC TGT AGA 
TAT GCT AAC AGT GTT ATT CTT TCA 
Top strand of luciferase construct 
with binding site  
PRKCE_rev AGC TTG AAA GAA TAA CAC TGT TAG CAT ATC TAC 
AGG AGG TAA TGT CAC ATC CCT TCA ATA 
Bottom strand of luciferase construct 
RAF_fwd CTA GCC CCA TGC TCA AGG CCC AGC CTT CTG TAG ATG 
CGC AAG TGG ATG TTG ATG GTA GTA 
Top strand of luciferase construct 
with binding site  
RAF_rev AGC TTA CTA CCA TCA ACA TCC ACT TGC GCA TCT ACA 
GAA GGC TGG GCC TTG AGC ATG GGG 
Bottom strand of luciferase construct 
RAF_fwd CTA GAC TTG TGG CTA CAA ATT TCA TGA GCA CTG TAG 
CAC CAA AGT ACC TAC TAT GTG TGT 
Top strand of luciferase construct 
with binding site  
RAF_rev AGC TAC ACA CAT AGT AGG TAC TTT GGT GCT ACA GTG 
CTC ATG AAA TTT GTA GCC ACA AGT 
Bottom strand of luciferase construct 
RHOT1_fwd CTA GTC AAG TAT TTA AAT AAA TAA CTG CTG TGT ACT 
GTG ATC TTG AGT TCT TTT GTC ATC 
Top strand of luciferase construct 
with binding site  
RHOT1_fwd AGC TGA TGA CAA AAG AAC TCA AGA TCA CAG TAC 
ACA GCA GTT ATT TAT TTA AAT ACT TGA 
Bottom strand of luciferase construct 
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Appendix 3.1: Summary of miRNAs that play a significant role in regulation of the cell cycle 
 
 
miRNA Role in cell cycle Target Reference 
miR-15, 16 Regulates G1-S transition Cyclins D1, D3, E1, CDK6, CDC27, 
E2F3, WEE1 
[183, 316]  
Let-7b Cell cycle progression Cyclins D1, D2, D3, A, CDK4, 
CDK6, CDC25A, CDC34, Myc 
[454] 
miR-17 family Regulates G1-S transition E2F1, CDKN1A, Cyclin D1, 
MYCN, p21CIP1, Rb 
[258, 298] 
miR19a Regulates G1-S transition Cyclin D1 [455] 
miR-21 Regulates G1-S transition CDC25A [456] 
miR-24 Regulates cell cycle progression p16INK4a, E2F2 [365, 457] 
miR-25 G1-S transition P57Kip2 [458] 
miR-26a Regulates cell cycle progression Cyclins D2, E2 [459] 
miR-31 Regulates cell cycle progression P16INK4a, p19INK4d [460] 
miR-34a Regulates G1-S transition Cyclins D1, E2, CDK4, CDK6, 
E2F1, E2F3, Myc 
[188, 461] 
miR-100 Regulates mitosis PLK1 [462] 
miR-124a Regulates G1-S transition CDK6 [463] 
miR-125b Regulates G1-S checkpoint CDK6, CDC25A, E2F3, Cyclin A,  [464, 465] 
miR-128a Regulates G2-M transition WEE1 [466] 
miR-129 Regulates G1-S transition p21Cip1, CDK6 [467, 468] 
miR-137 Regulates G1-S transition CDK6 [463] 
miR-145 Enables p53 regulation of Myc Myc [469] 
miR-155 Regulates G2-M transition WEE1 [466] 
miR-181 family Regulates G1-S transition p27Kip1 [470] 
miR-210 Cell cycle regulation in ovarian cancer E2F3 [471] 
miR-221 Enables G1-S transition p27Kip1, p57Kip2  [164] 
miR-331 Blocks G1-S transition E2F1 [472] 
miR-322/424 Promotes cell cycle quiescence CDC25A [473] 
miR-449a/b Blocks G1-S transition CDC25A, CDK6 [474] 
miR-503 Promotes cell cycle quiescence CDC25A [473] 
miR-504 Blocks p53 mediates cell cycle arrest p53 [475] 
miR-516a Enables G2-M transition WEE1 [466] 
miR-1285 Enables cell cycle progression p53 [462] 
miR-1296 Regulates S phase MCM2 [476] 
miR-365b-3p Cell cycle progression p21, p27, cdc2, Cyclin D1, PAX6  [477] 
miR-142-3p Blocks G1-S progression CD133, ABCG2, Lgr5, CyclinD1 [478] 
miR-223 Induces G1-S block Ect2 [479] 
miR-200b Blocks cell cycle progression GATA4, CyclinD1 [479] 
miR-497-195 cluster Induce G1 arrest Cyclin E1, D3, CDC25A, CDK4 [480] 
miR-32 Promotes cell cycle progression PTEN [481] 
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Appendix 3.2: Depth of sequencing for the samples studied here. Numbers represent the 
number of tags aligned to miRBase derived pre-miRNA hairpins 
 
Cell line Synchronized Phase Effective Library Sizes 
MCF7  G1 733020.4316 
MCF7  S 787469.3512 
MCF7  G2M 817938.8817 
HeLa G1 445658.0818 
HeLa S 309720.9925 
HeLa G2M 873672.2233 
 
Appendix 3.3: List of hairpin miRNAs and their corresponding potential cross-mapping 
miRNAs 
miRNA Cross mapping miRNAs* 
mir-520f miR-520f,miR-519c-5p,miR-522-5p,miR-519a-
5p,miR-526b-3p,miR-520b,miR-520c-3p,miR-
523-5p,miR-519b-5p,miR-518e-5p 
mir-1269a miR-1269a,miR-1269b 
mir-23c miR-23c,miR-23b-3p 
mir-301b miR-301b,miR-301a-3p 
mir-320a miR-320a,miR-320c,miR-320b 
mir-3689c miR-3689c,miR-3689b-3p,miR-3689a-3p,miR-
3689b-5p,miR-3689a-5p,miR-3689e 
mir-378g miR-378g,miR-378c 
mir-4477a miR-4477a,miR-4477b 
mir-4477b miR-4477b,miR-4477a 
mir-449a miR-449a,miR-449b-5p 
mir-4662b miR-4662b,miR-4662a-3p,miR-4662a-5p 
mir-484 miR-484,miR-4270 
mir-548ac miR-548ac,miR-548ay-5p,miR-548d-5p,miR-
548az-5p 
mir-548ak miR-548ak,miR-548w,miR-548h-3p,miR-548z 
mir-548j miR-548j,miR-548ap-5p,miR-548q 
mir-548l miR-548l,miR-548p,miR-548am-3p,miR-548ah-
3p 
mir-548v miR-548v,miR-548ax, 
mir-5681b miR-5681b,miR-5681a, 
mir-5692b miR-5692b,miR-5692c, 
mir-598 miR-598,miR-1322, 
mir-548h-3 miR-548t-3p,miR-548ae,miR-548h-5p,miR-
548p,miR-548h-3p,miR-548aq-3p,miR-548am-
3p,miR-548aa,miR-548ah-3p,miR-548z,miR 
548aj-3p,miR-548az-3p,miR-548u 
mir-548am miR-548aj-5p,miR-548i,miR-548av-3p,miR-
548ay-5p,miR-548x-5p,miR-548d-5p,miR-548o-
5p,miR-548g-5p,miR-548au-5p,miR-548w,miR-
548p,miR-548c-5p,miR-548am-3p,miR-548aq-
3p,miR-548ar-5p,miR-548o-3p,miR-548as-
5p,miR-548ah-3p, 
mir-548c miR-548aj-5p,miR-548i,miR-548ay-5p,miR-548x-
5p,miR-548d-5p,miR-548o-5p,miR-548c-3p,miR-
548g-5p,miR-548au-5p,miR-548w,miR-548c-
5p,miR-548ar-5p,miR-548as-5p,miR-548am-5p, 
mir-548o-2 miR-548aj-5p,miR-548i,miR-548av-3p,miR-
548ay-5p,miR-548x-5p,miR-548d-5p,miR-548o-
5p,miR-548g-5p,miR-548au-5p,miR-548w,miR-
548am-3p,miR-548c-5p,miR-548ar-5p,miR-548o-
3p,miR-548as-5p,miR-548ah-3p,miR-548am-5p 
mir-548au miR-548au-5p,miR-548w,miR-548i,miR-548c-
5p,miR-548ar-5p,miR-548as-5p,miR-548ay-
5p,miR-548au-3p,miR-548d-5p,miR-548o-
5p,miR-548am-5p 
mir-548ae-
2 
miR-548aj-5p,miR-548aq-3p,miR-548ay-5p,miR-
548x-5p,miR-548x-3p,miR-548d-5p,miR-548az-
5p,miR-548ae,miR-548n,miR-548g-5p, 
mir-548aj-2 miR-548aj-5p,miR-548ay-5p,miR-548x-5p,miR-
548x-3p,miR-548d-5p,miR-548o-5p,miR-548g-
5p,miR-548au-5p,miR-548aq-3p,miR-548c-
5p,miR-548ar-5p,miR-548aj-3p,miR-548am-5p 
mir-548aq miR-548t-3p,miR-548ae,miR-548h-3p,miR-
548aq-3p,miR-548am-3p,miR-548aa,miR-548ah-
3p,miR-548z,miR-548aj-3p,miR-548az-3p,miR-
548u,miR-548aq-5p, 
mir-548ay miR-548aj-5p,miR-548ay-5p,miR-548x-5p,miR-
548d-5p,miR-548o-5p,miR-548ay-3p,miR-548g-
5p,miR-548au-5p,miR-548c-5p,miR-548ar-
5p,miR-548ab,miR-548b-5p,miR-548az-5p,miR-
548n,miR-548am-5p 
mir-548d-1 miR-548aj-5p,miR-548ay-5p,miR-548x-5p,miR-
548d-5p,miR-548o-5p,miR-548g-5p,miR-548au-
5p,miR-548d-3p,miR-548c-5p,miR-548ar-5p,miR-
548ab,miR-548b-5p,miR-548az-5p,miR-
548n,miR-548am-5p 
mir-548d-2 miR-548aj-5p,miR-548ay-5p,miR-548x-5p,miR-
548d-5p,miR-548o-5p,miR-548g-5p,miR-548au-
5p,miR-548d-3p,miR-548c-5p,miR-548ar-5p,miR-
548ab,miR-548b-5p,miR-548az-5p,miR-
548n,miR-548am-5p 
mir-548g miR-548aj-5p,miR-548ay-5p,miR-548x-5p,miR-
548d-5p,miR-548g-3p,miR-548o-5p,miR-548g-
5p,miR-548au-5p,miR-548c-5p,miR-548ar-
5p,miR-548am-5p 
mir-548x miR-548aj-5p,miR-548ay-5p,miR-548x-5p,miR-
548x-3p,miR-548d-5p,miR-548ae,miR-548o-
5p,miR-548g-5p,miR-548au-5p,miR-548aq-
3p,miR-548c-5p,miR-548ar-5p,miR-548aj-
3p,miR-548am-5p, 
mir-548al miR-548au-5p,miR-548aj-5p,miR-548c-5p,miR-
548ar-5p,miR-548y,miR-548x-5p,miR-548al,miR-
548o-5p,miR-548aq-5p,miR-548am-5p,miR-548g-
5p 
mir-520c miR-520f,miR-520e,miR-520c-5p,miR-519c-
5p,miR-522-5p,miR-526a,miR-519a-5p,miR-
518d-5p,miR-518f-5p,miR-526b-3p,miR-
520b,miR-526b-5p,miR-520c-3p,miR-523-
5p,miR-519b-5p,miR-518e-5p, 
mir-526a-1 miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-526b-5p,miR-518d-
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5p,miR-518f-3p,miR-518f-5p,miR-523-5p,miR-
519b-5p,miR-526b-3p,miR-518e-5p 
mir-520b miR-520e,miR-519c-5p,miR-522-5p,miR-519a-
5p,miR-520c-3p,miR-523-5p,miR-519b-5p,miR-
526b-3p,miR-518e-5p,miR-520b, 
mir-518e miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-518d-5p,miR-518f-
5p,miR-518e-3p,miR-523-5p,miR-519b-5p,miR-
518e-5p 
mir-519c miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-519c-3p,miR-518d-
5p,miR-518f-5p,miR-523-5p,miR-519b-5p,miR-
518e-5p 
mir-522 miR-522-3p,miR-520c-5p,miR-519c-5p,miR-522-
5p,miR-526a,miR-519a-5p,miR-518d-5p,miR-
518f-5p,miR-523-5p,miR-519b-5p,miR-518e-5p 
mir-523 miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-518d-5p,miR-518f-
5p,miR-523-3p,miR-523-5p,miR-519b-5p,miR-
518e-5p 
mir-526a-2 miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-518d-5p,miR-518f-
5p,miR-526b-5p,miR-523-5p,miR-519b-5p,miR-
518e-5p 
mir-519a-1 miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-519e-3p,miR-519a-
3p,miR-518d-5p,miR-518f-5p,miR-519b-3p,miR-
523-5p,miR-519b-5p,miR-518e-5p 
mir-519b miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-519a-3p,miR-518d-
5p,miR-518f-5p,miR-526b-3p,miR-519b-3p,miR-
523-5p,miR-519b-5p,miR-518e-5p 
mir-518f miR-518c-3p,miR-520c-5p,miR-519c-5p,miR-
522-5p,miR-526a,miR-519a-5p,miR-526b-
5p,miR-518d-5p,miR-518f-3p,miR-518f-5p,miR-
523-5p,miR-519b-5p,miR-518e-5p 
mir-518d miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-526b-5p,miR-518d-
5p,miR-518f-5p,miR-523-5p,miR-518d-3p,miR-
519b-5p,miR-518e-5p, 
let-7a-1 let-7a-5p,let-7f-2-3p,let-7c,let-7f-5p,let-7a-3p,let-
7e-5p, 
let-7a-2 let-7a-5p,let-7c,let-7a-2-3p,let-7f-5p,let-7e-5p 
let-7a-3 let-7a-5p,let-7f-2-3p,let-7c,let-7f-5p,let-7a-3p,let-
7e-5p, 
let-7b let-7b-3p,let-7c,let-7b-5p 
let-7c let-7a-5p,let-7c,let-7b-5p 
let-7d let-7d-3p,let-7d-5p, 
let-7e let-7a-5p,let-7e-3p,let-7e-5p 
let-7f-1 let-7a-5p,let-7f-1-3p,let-7f-5p 
let-7f-2 let-7a-5p,let-7f-2-3p,let-7f-5p,let-7a-3p, 
let-7g let-7g-3p,let-7g-5p, 
let-7i let-7i-3p,let-7i-5p, 
mir-1-1 miR-1 
mir-1-2 miR-1 
mir-100 miR-100-3p,miR-99a-5p,miR-100-5p 
mir-101-1 miR-101-3p,miR-101-5p, 
mir-101-2 miR-101-3p 
mir-103a-1 miR-103a-2-5p,miR-103a-3p,miR-107 
mir-103a-2 miR-103a-3p,miR-103a-2-5p,miR-107 
mir-103b-1 miR-103b 
mir-103b-2 miR-103b 
mir-105-1 miR-105-3p,miR-105-5p, 
mir-105-2 miR-105-3p,miR-105-5p, 
mir-106a miR-106a-5p,miR-106a-3p,miR-17-5p 
mir-106b miR-106b-3p,miR-106b-5p, 
mir-107 miR-103a-3p,miR-103a-2-5p,miR-107 
mir-10a miR-10b-5p,miR-10a-5p,miR-10a-3p 
mir-10b miR-10b-5p,miR-10b-3p,miR-10a-5p 
mir-1178 miR-1178-3p 
mir-1184-1 miR-1184 
mir-1184-2 miR-1184 
mir-1184-3 miR-1184 
mir-1185-1 miR-1185-5p,miR-1185-1-3p,miR-1185-2-3p 
mir-1185-2 miR-1185-5p,miR-1185-1-3p,miR-1185-2-3p 
mir-1207 miR-1207-5p 
mir-122 miR-122-5p,miR-122-3p, 
mir-1224 miR-1224-3p,miR-1224-5p, 
mir-1225 miR-1225-5p,miR-1225-3p, 
mir-1226 miR-1226-5p,miR-1226-3p, 
mir-1228 miR-1228-5p,miR-1228-3p, 
mir-1229 miR-1229-3p,miR-1229-5p, 
mir-1233-1 miR-1233-1-5p 
mir-1233-2 miR-1233-1-5p 
mir-1234 miR-1234-3p,miR-1234-5p, 
mir-1236 miR-1236-5p,miR-1236-3p, 
mir-1237 miR-1237-5p,miR-1237-3p, 
mir-1238 miR-1238-3p,miR-1238-5p, 
mir-124-1 miR-124-5p,miR-124-3p, 
mir-124-2 miR-124-5p,miR-124-3p, 
mir-124-3 miR-124-5p,miR-124-3p, 
mir-1244-1 miR-1244 
mir-1244-2 miR-1244 
mir-1244-3 miR-1244 
mir-1245b miR-1245b-5p,miR-1245b-3p, 
mir-1247 miR-1247-5p,miR-1247-3p, 
mir-1254-1 miR-1254 
mir-1254-2 miR-1254 
mir-1255b-
1 
miR-1255b-5p 
mir-1255b-
2 
miR-1255b-2-3p,miR-1255b-5p, 
mir-125a miR-125a-5p,miR-125a-3p, 
mir-125b-1 miR-125b-1-3p,miR-125b-5p, 
mir-125b-2 miR-125b-2-3p,miR-125b-5p, 
mir-126 miR-126-5p,miR-126-3p, 
mir-1269b miR-1269a,miR-1269b, 
mir-127 miR-127-3p,miR-127-5p, 
mir-1270-1 miR-1270 
mir-1270-2 miR-1270 
mir-1271 miR-1271-5p,miR-1271-3p, 
mir-1273g miR-1273g-3p,miR-1273g-5p, 
mir-1277 miR-1277-3p,miR-1277-5p, 
mir-128-1 miR-128 
mir-128-2 miR-128 
mir-1283-1 miR-1283 
mir-1283-2 miR-1283 
mir-1285-1 miR-1285-3p,miR-1285-5p, 
mir-1285-2 miR-1285-3p 
mir-1289-1 miR-1289 
mir-1289-2 miR-1289 
mir-129-1 miR-129-2-3p,miR-129-1-3p,miR-129-5p 
mir-129-2 miR-129-2-3p,miR-129-1-3p,miR-129-5p 
mir-1292 miR-1292-3p,miR-1292-5p, 
mir-1295b miR-1295b-5p,miR-1295b-3p, 
mir-1302-1 miR-1302 
mir-1302-
10 
miR-1302 
mir-1302-
11 
miR-1302 
mir-1302-2 miR-1302 
mir-1302-3 miR-1302 
mir-1302-4 miR-1302 
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mir-1302-5 miR-1302 
mir-1302-6 miR-1302 
mir-1302-7 miR-1302 
mir-1302-8 miR-1302 
mir-1302-9 miR-1302 
mir-1304 miR-1304-5p,miR-1304-3p, 
mir-1306 miR-1306-5p 
mir-1307 miR-1307-5p,miR-1307-3p, 
mir-130a miR-130a-5p,miR-130a-3p, 
mir-130b miR-130b-5p,miR-130b-3p, 
mir-132 miR-132-5p,miR-132-3p, 
mir-133a-1 miR-133a,miR-133b, 
mir-133a-2 miR-133a,miR-133b, 
mir-133b miR-133a,miR-133b, 
mir-135a-1 miR-135a-5p,miR-135b-5p,miR-135a-3p 
mir-135a-2 miR-135a-5p,miR-135b-5p, 
mir-135b miR-135b-3p,miR-135a-5p,miR-135b-5p 
mir-136 miR-136-3p,miR-136-5p, 
mir-138-1 miR-138-5p,miR-138-1-3p, 
mir-138-2 miR-138-5p,miR-138-2-3p, 
mir-139 miR-139-5p,miR-139-3p, 
mir-140 miR-140-3p,miR-140-5p, 
mir-141 miR-200a-3p,miR-141-3p,miR-141-5p 
mir-142 miR-142-3p,miR-142-5p, 
mir-143 miR-143-5p,miR-143-3p, 
mir-144 miR-144-5p,miR-144-3p, 
mir-145 miR-145-5p,miR-145-3p, 
mir-146a miR-146a-3p,miR-146a-5p, 
mir-146b miR-146b-3p,miR-146b-5p, 
mir-147a miR-147b,miR-147a, 
mir-148a miR-148a-3p,miR-148b-3p,miR-148a-5p 
mir-148b miR-148a-3p,miR-148b-5p,miR-148b-3p 
mir-149 miR-149-5p,miR-149-3p, 
mir-150 miR-150-5p,miR-150-3p, 
mir-151a miR-151a-5p,miR-151a-3p, 
mir-151b miR-151a-5p 
mir-153-1 miR-153 
mir-153-2 miR-153 
mir-154 miR-154-5p,miR-154-3p, 
mir-155 miR-155-5p,miR-155-3p, 
mir-15a miR-15a-3p,miR-15a-5p, 
mir-15b miR-15b-3p,miR-15b-5p, 
mir-16-1 miR-16-5p,miR-16-1-3p, 
mir-16-2 miR-16-2-3p,miR-16-5p, 
mir-17 miR-17-3p,miR-106a-5p,miR-17-5p 
mir-181a-1 miR-181a-5p,miR-181a-3p, 
mir-181a-2 miR-181a-5p,miR-181a-2-3p, 
mir-181b-1 miR-181b-5p,miR-181b-3p,miR-181d 
mir-181b-2 miR-181b-5p,miR-181d,miR-181b-3p 
mir-181c miR-181c-3p,miR-181c-5p, 
mir-181d miR-181b-5p,miR-181d, 
mir-182 miR-182-5p,miR-182-3p, 
mir-183 miR-183-3p,miR-183-5p, 
mir-185 miR-185-3p,miR-185-5p, 
mir-186 miR-186-5p,miR-186-3p, 
mir-187 miR-187-3p,miR-187-5p, 
mir-188 miR-188-5p,miR-188-3p, 
mir-18a miR-18b-5p,miR-18a-5p,miR-18a-3p 
mir-18b miR-18b-3p,miR-18b-5p,miR-18a-5p 
mir-1909 miR-1909-5p,miR-1909-3p, 
mir-191 miR-191-3p,miR-191-5p, 
mir-1911 miR-1911-5p,miR-1911-3p, 
mir-1914 miR-1914-5p,miR-1914-3p, 
mir-1915 miR-1915-5p,miR-1915-3p, 
mir-192 miR-192-5p,miR-192-3p, 
mir-193a miR-193a-3p,miR-193a-5p, 
mir-193b miR-193b-5p,miR-193b-3p, 
mir-194-1 miR-194-5p 
mir-194-2 miR-194-3p,miR-194-5p, 
mir-195 miR-195-3p,miR-195-5p, 
mir-196a-1 miR-196b-5p,miR-196a-5p, 
mir-196a-2 miR-196b-5p,miR-196a-3p,miR-196a-5p 
mir-196b miR-196b-5p,miR-196b-3p,miR-196a-5p 
mir-197 miR-197-3p,miR-197-5p, 
mir-1972-1 miR-1972 
mir-1972-2 miR-1972 
mir-199a-1 miR-199b-3p,miR-199a-3p,miR-199a-5p 
mir-199a-2 miR-199b-3p,miR-199a-3p,miR-199a-5p 
mir-199b miR-199b-3p,miR-199a-3p,miR-199b-5p 
mir-19a miR-19b-3p,miR-19a-3p,miR-19a-5p 
mir-19b-1 miR-19b-3p,miR-19b-2-5p,miR-19a-3p,miR-19b-
1-5p, 
mir-19b-2 miR-19b-3p,miR-19b-2-5p,miR-19a-3p,miR-19b-
1-5p, 
mir-200a miR-200a-3p,miR-141-3p,miR-200a-5p 
mir-200b miR-200b-5p,miR-200c-3p,miR-200b-3p 
mir-200c miR-200c-5p,miR-200b-3p,miR-200c-3p 
mir-202 miR-202-3p,miR-202-5p, 
mir-203a miR-203b-3p,miR-203a, 
mir-203b miR-203b-3p,miR-203b-5p, 
mir-204 miR-204-3p,miR-204-5p, 
mir-205 miR-205-5p,miR-205-3p, 
mir-20a miR-20a-3p,miR-20a-5p, 
mir-20b miR-20b-5p,miR-20b-3p, 
mir-21 miR-21-5p,miR-21-3p, 
mir-211 miR-211-5p,miR-211-3p, 
mir-2114 miR-2114-5p,miR-2114-3p, 
mir-2115 miR-2115-5p,miR-2115-3p, 
mir-2116 miR-2116-3p,miR-2116-5p, 
mir-212 miR-212-3p,miR-212-5p, 
mir-214 miR-214-3p,miR-214-5p, 
mir-216a miR-216a-5p,miR-216a-3p, 
mir-218-1 miR-218-5p,miR-218-1-3p, 
mir-218-2 miR-218-5p,miR-218-2-3p, 
mir-219-1 miR-219-1-3p,miR-219-5p, 
mir-219-2 miR-219-5p,miR-219-2-3p, 
mir-22 miR-22-3p,miR-22-5p, 
mir-221 miR-221-3p,miR-221-5p, 
mir-222 miR-222-5p,miR-222-3p, 
mir-223 miR-223-5p,miR-223-3p, 
mir-224 miR-224-3p,miR-224-5p, 
mir-2277 miR-2277-5p,miR-2277-3p, 
mir-2355 miR-2355-5p,miR-2355-3p, 
mir-23a miR-23a-5p,miR-23a-3p,miR-23b-3p 
mir-23b miR-23c,miR-23b-5p,miR-23a-3p,miR-23b-3p, 
mir-24-1 miR-24-1-5p,miR-24-3p, 
mir-24-2 miR-24-3p,miR-24-2-5p, 
mir-2467 miR-2467-3p,miR-2467-5p, 
mir-25 miR-25-3p,miR-25-5p, 
mir-2681 miR-2681-3p,miR-2681-5p, 
mir-2682 miR-2682-5p,miR-2682-3p, 
mir-26a-1 miR-26a-1-3p,miR-26a-5p, 
mir-26a-2 miR-26a-2-3p,miR-26a-5p, 
mir-26b miR-26b-3p,miR-26b-5p, 
mir-27a miR-27a-5p,miR-27b-3p,miR-27a-3p 
mir-27b miR-27b-3p,miR-27b-5p,miR-27a-3p 
mir-28 miR-28-5p,miR-28-3p, 
mir-296 miR-296-5p,miR-296-3p, 
mir-2964a miR-2964a-3p,miR-2964a-5p, 
mir-299 miR-299-5p,miR-299-3p, 
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mir-29a miR-29a-3p,miR-29a-5p,miR-29c-3p 
mir-29b-1 miR-29b-1-5p,miR-29b-3p, 
mir-29b-2 miR-29b-3p,miR-29b-2-5p, 
mir-29c miR-29a-3p,miR-29c-5p,miR-29c-3p 
mir-301a miR-301a-5p,miR-301b,miR-301a-3p 
mir-302a miR-302b-3p,miR-302c-3p,miR-302a-5p,miR-
302a-3p, 
mir-302b miR-302c-3p,miR-302b-3p,miR-302d-3p,miR-
302b-5p,miR-302a-3p 
mir-302c miR-302c-5p,miR-302b-3p,miR-302c-3p,miR-
302d-3p,miR-302a-3p 
mir-302d miR-302b-3p,miR-302c-3p,miR-302d-3p,miR-
302d-5p, 
mir-302e miR-302c-3p 
mir-3064 miR-3064-3p,miR-3064-5p, 
mir-3065 miR-3065-3p,miR-3065-5p, 
mir-3074 miR-3074-3p,miR-3074-5p, 
mir-30a miR-30e-5p,miR-30d-5p,miR-30e-3p,miR-30a-
3p,miR-30a-5p 
mir-30b miR-30b-5p,miR-30c-5p,miR-30b-3p 
mir-30c-1 miR-30b-5p,miR-30c-5p,miR-30c-1-3p 
mir-30c-2 miR-30b-5p,miR-30c-2-3p,miR-30c-5p 
mir-30d miR-30e-5p,miR-30d-5p,miR-30d-3p,miR-30a-5p, 
mir-30e miR-30e-5p,miR-30d-5p,miR-30a-5p,miR-30e-
3p,miR-30a-3p 
mir-31 miR-31-3p,miR-31-5p, 
mir-3116-1 miR-3116 
mir-3116-2 miR-3116 
mir-3117 miR-3117-5p,miR-3117-3p, 
mir-3118-1 miR-3118 
mir-3118-2 miR-3118 
mir-3118-3 miR-3118 
mir-3118-4 miR-3118 
mir-3118-5 miR-3118 
mir-3118-6 miR-3118 
mir-3119-1 miR-3119 
mir-3119-2 miR-3119 
mir-3120 miR-3120-5p,miR-3120-3p, 
mir-3121 miR-3121-5p,miR-3121-3p, 
mir-3124 miR-3124-5p,miR-3124-3p, 
mir-3126 miR-3126-5p,miR-3126-3p, 
mir-3127 miR-3127-3p,miR-3127-5p, 
mir-3129 miR-3129-5p,miR-3129-3p, 
mir-3130-1 miR-3130-5p,miR-3130-3p, 
mir-3130-2 miR-3130-5p,miR-3130-3p, 
mir-3136 miR-3136-3p,miR-3136-5p, 
mir-3140 miR-3140-5p,miR-3140-3p, 
mir-3144 miR-3144-5p,miR-3144-3p, 
mir-3145 miR-3145-5p,miR-3145-3p, 
mir-3150a miR-3150a-3p,miR-3150a-5p, 
mir-3150b miR-3150b-5p,miR-3150b-3p, 
mir-3152 miR-3152-3p,miR-3152-5p, 
mir-3156-1 miR-3156-3p,miR-3156-5p, 
mir-3156-2 miR-3156-3p,miR-3156-5p, 
mir-3156-3 miR-3156-3p,miR-3156-5p, 
mir-3157 miR-3157-5p,miR-3157-3p, 
mir-3158-1 miR-3158-5p,miR-3158-3p, 
mir-3158-2 miR-3158-5p,miR-3158-3p, 
mir-3160-1 miR-3160-5p,miR-3160-3p, 
mir-3160-2 miR-3160-5p,miR-3160-3p, 
mir-3162 miR-3162-5p,miR-3162-3p, 
mir-3173 miR-3173-3p,miR-3173-5p, 
mir-3177 miR-3177-5p,miR-3177-3p, 
mir-3179-1 miR-3179 
mir-3179-2 miR-3179 
mir-3179-3 miR-3179 
mir-3180-1 miR-3180,miR-3180-3p,miR-3180-5p 
mir-3180-2 miR-3180,miR-3180-3p,miR-3180-5p 
mir-3180-3 miR-3180,miR-3180-3p,miR-3180-5p 
mir-3180-4 miR-3180,miR-3180-3p, 
mir-3180-5 miR-3180,miR-3180-3p, 
mir-3184 miR-3184-3p,miR-3184-5p, 
mir-3186 miR-3186-3p,miR-3186-5p, 
mir-3187 miR-3187-3p,miR-3187-5p, 
mir-3189 miR-3189-5p,miR-3189-3p, 
mir-3190 miR-3190-5p,miR-3190-3p, 
mir-3191 miR-3191-5p,miR-3191-3p, 
mir-3194 miR-3194-5p,miR-3194-3p, 
mir-3198-1 miR-3198 
mir-3198-2 miR-3198 
mir-3199-1 miR-3199 
mir-3199-2 miR-3199 
mir-32 miR-32-3p,miR-32-5p, 
mir-3200 miR-3200-5p,miR-3200-3p, 
mir-3202-1 miR-3202 
mir-3202-2 miR-3202 
mir-320b-1 miR-320a,miR-320c,miR-320b 
mir-320b-2 miR-320a,miR-320c,miR-320b 
mir-320c-1 miR-320a,miR-320c,miR-320b 
mir-323a miR-323a-5p,miR-323a-3p, 
mir-323b miR-323b-3p,miR-323b-5p, 
mir-324 miR-324-3p,miR-324-5p, 
mir-329-1 miR-329 
mir-329-2 miR-329 
mir-330 miR-330-5p,miR-330-3p, 
mir-331 miR-331-3p,miR-331-5p, 
mir-335 miR-335-5p,miR-335-3p, 
mir-337 miR-337-5p,miR-337-3p, 
mir-338 miR-338-5p,miR-338-3p, 
mir-339 miR-339-5p,miR-339-3p, 
mir-33a miR-33a-3p,miR-33a-5p, 
mir-33b miR-33b-3p,miR-33b-5p, 
mir-340 miR-340-5p,miR-340-3p, 
mir-342 miR-342-3p,miR-342-5p, 
mir-345 miR-345-5p,miR-345-3p, 
mir-34a miR-34a-3p,miR-34a-5p, 
mir-34b miR-34b-3p,miR-34b-5p, 
mir-34c miR-34c-3p,miR-34c-5p, 
mir-3529 miR-3529-5p,miR-3529-3p, 
mir-3591 miR-3591-3p,miR-3591-5p, 
mir-3605 miR-3605-3p,miR-3605-5p, 
mir-3606 miR-3606-3p,miR-3606-5p, 
mir-3607 miR-3607-3p,miR-3607-5p, 
mir-361 miR-361-5p,miR-361-3p, 
mir-3613 miR-3613-3p,miR-3613-5p, 
mir-3614 miR-3614-3p,miR-3614-5p, 
mir-3616 miR-3616-5p,miR-3616-3p, 
mir-3617 miR-3617-5p,miR-3617-3p, 
mir-3619 miR-3619-5p,miR-3619-3p, 
mir-362 miR-362-3p,miR-362-5p, 
mir-3620 miR-3620-5p,miR-3620-3p, 
mir-3622a miR-3622a-3p,miR-3622a-5p, 
mir-3622b miR-3622b-3p,miR-3622b-5p, 
mir-363 miR-363-3p,miR-363-5p, 
mir-365a miR-365b-3p,miR-365a-3p,miR-365a-5p 
mir-365b miR-365b-3p,miR-365a-3p,miR-365b-5p 
mir-3663 miR-3663-3p,miR-3663-5p, 
mir-3664 miR-3664-3p,miR-3664-5p, 
mir-3667 miR-3667-5p,miR-3667-3p, 
mir-367 miR-367-3p,miR-367-5p, 
mir-3670-1 miR-3670 
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mir-3670-2 miR-3670 
mir-3675 miR-3675-5p,miR-3675-3p, 
mir-3676 miR-5100,miR-3676-3p, 
mir-3677 miR-3677-5p,miR-3677-3p, 
mir-3678 miR-3678-3p,miR-3678-5p, 
mir-3679 miR-3679-3p,miR-3679-5p, 
mir-3680-1 miR-3680-5p,miR-3680-3p, 
mir-3680-2 miR-3680-3p,miR-3680-5p, 
mir-3681 miR-3681-5p,miR-3681-3p, 
mir-3682 miR-3682-5p,miR-3682-3p, 
mir-3688-1 miR-3688-3p,miR-3688-5p, 
mir-3688-2 miR-3688-3p,miR-3688-5p, 
mir-3689a miR-3689c,miR-3689b-5p,miR-3689a-5p,miR-
3689b-3p,miR-3689e,miR-3689f, 
mir-3689b miR-3689c,miR-3689b-5p,miR-3689a-5p,miR-
3689b-3p,miR-3689e,miR-3689a-3p, 
mir-3689d-
1 
miR-3689d 
mir-3689d-
2 
miR-3689d 
mir-3689e miR-3689a-3p,miR-3689b-5p,miR-3689a-5p,miR-
3689e, 
mir-3689f miR-3689d,miR-3689f, 
mir-369 miR-369-5p,miR-369-3p, 
mir-3690-1 miR-3690 
mir-3690-2 miR-3690 
mir-3691 miR-3691-3p,miR-3691-5p, 
mir-3692 miR-3692-5p,miR-3692-3p, 
mir-371a miR-371a-3p,miR-371a-5p, 
mir-371b miR-371b-3p,miR-371b-5p, 
mir-373 miR-373-5p,miR-373-3p, 
mir-374a miR-374a-3p,miR-374a-5p, 
mir-374b miR-374c-3p,miR-374c-5p,miR-374b-3p,miR-
374b-5p, 
mir-374c miR-374c-5p,miR-374b-5p,miR-374c-3p 
mir-376a-1 miR-376a-5p,miR-376b-3p,miR-376a-3p 
mir-376a-2 miR-376a-2-5p,miR-376b-3p,miR-376a-3p 
mir-376b miR-376c-5p,miR-376b-5p,miR-376b-3p,miR-
376a-3p, 
mir-376c miR-376c-5p,miR-376b-5p,miR-376c-3p 
mir-377 miR-377-5p,miR-377-3p, 
mir-378a miR-378a-5p,miR-378a-3p,miR-378d,miR-
378i,miR-378c 
mir-378c miR-378a-3p,miR-378d,miR-378c 
mir-378d-1 miR-378a-3p,miR-378d,miR-378c 
mir-378d-2 miR-378a-3p,miR-378d,miR-378c 
mir-378i miR-378a-3p,miR-378i, 
mir-379 miR-411-3p,miR-379-5p,miR-379-3p 
mir-380 miR-380-5p,miR-380-3p, 
mir-381 miR-381-3p,miR-381-5p, 
mir-382 miR-382-5p,miR-382-3p, 
mir-3910-1 miR-3910 
mir-3910-2 miR-3910 
mir-3913-1 miR-3913-5p,miR-3913-3p, 
mir-3913-2 miR-3913-5p,miR-3913-3p, 
mir-3914-1 miR-3914 
mir-3914-2 miR-3914 
mir-3922 miR-3922-3p,miR-3922-5p, 
mir-3925 miR-3925-3p,miR-3925-5p, 
mir-3926-1 miR-3926 
mir-3926-2 miR-3926 
mir-3927 miR-3927-5p,miR-3927-3p, 
mir-3934 miR-3934-3p,miR-3934-5p, 
mir-3940 miR-3940-5p,miR-3940-3p, 
mir-3942 miR-3942-5p,miR-3942-3p, 
mir-3944 miR-3944-5p,miR-3944-3p, 
mir-409 miR-409-5p,miR-409-3p, 
mir-411 miR-411-5p,miR-379-3p,miR-411-3p 
mir-423 miR-423-3p,miR-423-5p, 
mir-424 miR-424-3p,miR-424-5p, 
mir-425 miR-425-3p,miR-425-5p, 
mir-4270 miR-484,miR-4270, 
mir-4290 miR-483-5p,miR-4290, 
mir-431 miR-431-3p,miR-431-5p, 
mir-432 miR-432-5p,miR-432-3p, 
mir-4323 miR-766-3p 
mir-4423 miR-4423-3p,miR-4423-5p, 
mir-4433 miR-4433-5p,miR-4433-3p, 
mir-4435-1 miR-4435 
mir-4435-2 miR-4435 
mir-4436b-
1 
miR-4436b-5p,miR-4436b-3p, 
mir-4436b-
2 
miR-4436b-5p,miR-4436b-3p, 
mir-4445 miR-4445-3p,miR-4445-5p, 
mir-4446 miR-4446-5p,miR-4446-3p, 
mir-4474 miR-4474-5p,miR-4474-3p, 
mir-4482 miR-4482-5p,miR-4482-3p, 
mir-449b miR-449a,miR-449b-3p,miR-449b-5p 
mir-449c miR-449c-3p,miR-449c-5p, 
mir-4509-1 miR-4509 
mir-4509-2 miR-4509 
mir-4509-3 miR-4509 
mir-450a-1 miR-450a-5p 
mir-450a-2 miR-450a-5p,miR-450a-3p, 
mir-450b miR-450b-3p,miR-450b-5p, 
mir-452 miR-452-3p,miR-452-5p, 
mir-4520a miR-4520a-3p,miR-4520a-5p,miR-4520b-5p,miR-
4520b-3p, 
mir-4520b miR-4520a-3p,miR-4520a-5p,miR-4520b-5p,miR-
4520b-3p, 
mir-4524a miR-4524a-5p,miR-4524a-3p, 
mir-4524b miR-4524b-3p,miR-4524b-5p, 
mir-4529 miR-4529-3p,miR-4529-5p, 
mir-4536-1 miR-4536-3p,miR-4536-5p, 
mir-4536-2 miR-4536-5p,miR-4536-3p, 
mir-454 miR-454-3p,miR-454-5p, 
mir-455 miR-455-5p,miR-455-3p, 
mir-4632 miR-4632-3p,miR-4632-5p, 
mir-4633 miR-4633-5p,miR-4633-3p, 
mir-4638 miR-4638-3p,miR-4638-5p, 
mir-4639 miR-4639-3p,miR-4639-5p, 
mir-4640 miR-4640-3p,miR-4640-5p, 
mir-4645 miR-4645-3p,miR-4645-5p, 
mir-4646 miR-4646-3p,miR-4646-5p, 
mir-4649 miR-4649-5p,miR-4649-3p, 
mir-4650-1 miR-4650-5p,miR-4650-3p, 
mir-4650-2 miR-4650-5p,miR-4650-3p, 
mir-4652 miR-4652-3p,miR-4652-5p, 
mir-4653 miR-4653-5p,miR-4653-3p, 
mir-4655 miR-4655-3p,miR-4655-5p, 
mir-4659a miR-4659a-3p,miR-4659b-3p,miR-4659a-5p 
mir-4659b miR-4659a-3p,miR-4659b-3p,miR-4659a-5p,miR-
4659b-5p, 
mir-4661 miR-4661-3p,miR-4661-5p, 
mir-4662a miR-4662b,miR-4662a-3p,miR-4662a-5p 
mir-4664 miR-4664-5p,miR-4664-3p, 
mir-4665 miR-4665-3p,miR-4665-5p, 
mir-4666a miR-4666a-5p,miR-4666a-3p, 
mir-4667 miR-4667-3p,miR-4667-5p, 
mir-4668 miR-4668-3p,miR-4668-5p, 
mir-4670 miR-4670-5p,miR-4670-3p, 
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mir-4671 miR-4671-5p,miR-4671-3p, 
mir-4676 miR-4676-5p,miR-4676-3p, 
mir-4677 miR-4677-5p,miR-4677-3p, 
mir-4679-1 miR-4679 
mir-4679-2 miR-4679 
mir-4680 miR-4680-5p,miR-4680-3p, 
mir-4684 miR-4684-5p,miR-4684-3p, 
mir-4685 miR-4685-5p,miR-4685-3p, 
mir-4687 miR-4687-3p,miR-4687-5p, 
mir-4690 miR-4690-3p,miR-4690-5p, 
mir-4691 miR-4691-5p,miR-4691-3p, 
mir-4693 miR-4693-5p,miR-4693-3p, 
mir-4694 miR-4694-3p,miR-4694-5p, 
mir-4695 miR-4695-3p,miR-4695-5p, 
mir-4697 miR-4697-5p,miR-4697-3p, 
mir-4699 miR-4699-5p,miR-4699-3p, 
mir-4700 miR-4700-3p,miR-4700-5p, 
mir-4701 miR-4701-3p,miR-4701-5p, 
mir-4703 miR-4703-3p,miR-4703-5p, 
mir-4704 miR-4704-3p,miR-4704-5p, 
mir-4707 miR-4707-3p,miR-4707-5p, 
mir-4708 miR-4708-3p,miR-4708-5p, 
mir-4709 miR-4709-5p,miR-4709-3p, 
mir-4711 miR-4711-5p 
mir-4712 miR-4712-5p,miR-4712-3p, 
mir-4713 miR-4713-3p,miR-4713-5p, 
mir-4714 miR-4714-3p,miR-4714-5p, 
mir-4715 miR-4715-3p,miR-4715-5p, 
mir-4716 miR-4716-5p,miR-4716-3p, 
mir-4717 miR-4717-3p,miR-4717-5p, 
mir-4720 miR-4720-3p,miR-4720-5p, 
mir-4722 miR-4722-3p,miR-4722-5p, 
mir-4723 miR-4723-3p,miR-4723-5p, 
mir-4724 miR-4724-3p,miR-4724-5p, 
mir-4725 miR-4725-5p,miR-4725-3p, 
mir-4726 miR-4726-3p,miR-4726-5p, 
mir-4727 miR-4727-5p,miR-4727-3p, 
mir-4728 miR-4728-5p,miR-4728-3p, 
mir-4731 miR-4731-3p,miR-4731-5p, 
mir-4732 miR-4732-3p,miR-4732-5p, 
mir-4733 miR-4733-5p,miR-4733-3p, 
mir-4735 miR-4735-5p,miR-4735-3p, 
mir-4738 miR-4738-5p,miR-4738-3p, 
mir-4740 miR-4740-5p,miR-4740-3p, 
mir-4742 miR-4742-5p,miR-4742-3p, 
mir-4743 miR-4743-3p,miR-4743-5p, 
mir-4745 miR-4745-5p,miR-4745-3p, 
mir-4746 miR-4746-3p,miR-4746-5p, 
mir-4747 miR-4747-5p,miR-4747-3p, 
mir-4749 miR-4749-5p 
mir-4750 miR-4750-5p,miR-4750-3p, 
mir-4753 miR-4753-5p,miR-4753-3p, 
mir-4755 miR-4755-3p,miR-4755-5p, 
mir-4756 miR-4756-3p,miR-4756-5p, 
mir-4757 miR-4757-3p,miR-4757-5p, 
mir-4758 miR-4758-3p,miR-4758-5p, 
mir-4760 miR-4760-5p,miR-4760-3p, 
mir-4761 miR-4761-5p,miR-4761-3p, 
mir-4762 miR-4762-5p,miR-4762-3p, 
mir-4763 miR-4763-3p,miR-4763-5p, 
mir-4764 miR-4764-3p,miR-4764-5p, 
mir-4766 miR-4766-5p,miR-4766-3p, 
mir-4768 miR-4768-5p,miR-4768-3p, 
mir-4769 miR-4769-3p,miR-4769-5p, 
mir-4771-1 miR-4771 
mir-4771-2 miR-4771 
mir-4772 miR-4772-5p,miR-4772-3p, 
mir-4773-1 miR-4773 
mir-4773-2 miR-4773 
mir-4774 miR-4774-5p,miR-4774-3p, 
mir-4776-1 miR-4776-5p,miR-4776-3p, 
mir-4776-2 miR-4776-5p,miR-4776-3p, 
mir-4777 miR-4777-5p,miR-4777-3p, 
mir-4778 miR-4778-3p,miR-4778-5p, 
mir-4781 miR-4781-3p,miR-4781-5p, 
mir-4782 miR-4782-5p,miR-4782-3p, 
mir-4783 miR-4783-3p,miR-4783-5p, 
mir-4786 miR-4786-5p,miR-4786-3p, 
mir-4787 miR-4787-5p,miR-4787-3p, 
mir-4789 miR-4789-5p,miR-4789-3p, 
mir-4790 miR-4790-3p,miR-4790-5p, 
mir-4793 miR-4793-3p,miR-4793-5p, 
mir-4795 miR-4795-5p,miR-4795-3p, 
mir-4796 miR-4796-5p,miR-4796-3p, 
mir-4797 miR-4797-5p,miR-4797-3p, 
mir-4798 miR-4798-3p,miR-4798-5p, 
mir-4799 miR-4799-5p,miR-4799-3p, 
mir-4800 miR-4800-3p,miR-4800-5p, 
mir-4802 miR-4802-5p,miR-4802-3p, 
mir-4804 miR-4804-5p,miR-4804-3p, 
mir-483 miR-483-3p,miR-483-5p,miR-4290 
mir-485 miR-485-5p,miR-485-3p, 
mir-486 miR-486-3p,miR-486-5p, 
mir-488 miR-488-5p,miR-488-3p, 
mir-490 miR-490-3p,miR-490-5p, 
mir-491 miR-491-3p,miR-491-5p, 
mir-493 miR-493-5p,miR-493-3p, 
mir-495 miR-495-3p,miR-495-5p, 
mir-497 miR-497-3p,miR-497-5p, 
mir-4999 miR-4999-5p,miR-4999-3p, 
mir-499a miR-499a-3p,miR-499a-5p, 
mir-499b miR-499b-3p,miR-499b-5p, 
mir-5000 miR-5000-5p,miR-5000-3p, 
mir-5001 miR-5001-5p,miR-5001-3p, 
mir-5002 miR-5002-3p,miR-5002-5p, 
mir-5003 miR-5003-3p,miR-5003-5p, 
mir-5004 miR-5004-3p,miR-5004-5p, 
mir-5006 miR-5006-3p,miR-5006-5p, 
mir-5007 miR-5007-3p,miR-5007-5p, 
mir-5008 miR-5008-3p,miR-5008-5p, 
mir-5009 miR-5009-3p,miR-5009-5p, 
mir-500a miR-501-3p,miR-502-3p,miR-500a-5p,miR-500a-
3p, 
mir-500b miR-500a-5p 
mir-501 miR-501-3p,miR-502-3p,miR-501-5p,miR-500a-
3p, 
mir-5010 miR-5010-5p,miR-5010-3p, 
mir-5011 miR-5011-5p,miR-5011-3p, 
mir-502 miR-502-5p,miR-501-3p,miR-502-3p,miR-500a-
3p, 
mir-503 miR-503-5p,miR-503-3p, 
mir-505 miR-505-3p,miR-505-5p, 
mir-506 miR-506-5p,miR-506-3p, 
mir-508 miR-508-3p,miR-508-5p, 
mir-5089 miR-5089-3p,miR-5089-5p, 
mir-509-1 miR-509-5p,miR-509-3p, 
mir-509-2 miR-509-5p,miR-509-3p, 
mir-509-3 miR-509-3-5p,miR-509-3p, 
mir-511-1 miR-511 
mir-511-2 miR-511 
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mir-512-1 miR-512-3p,miR-512-5p, 
mir-512-2 miR-512-3p,miR-512-5p, 
mir-513a-1 miR-513a-3p,miR-513b,miR-513c-3p 
mir-513a-2 miR-513a-3p,miR-513b,miR-513c-3p 
mir-513c miR-513c-5p,miR-513a-3p,miR-513c-3p 
mir-514a-1 miR-514a-5p,miR-514a-3p, 
mir-514a-2 miR-514a-5p,miR-514a-3p, 
mir-514a-3 miR-514a-5p,miR-514a-3p, 
mir-514b miR-514b-3p,miR-514b-5p, 
mir-515-1 miR-515-5p,miR-515-3p,miR-519e-5p 
mir-515-2 miR-515-5p,miR-515-3p,miR-519e-5p 
mir-516a-1 miR-520f,miR-516a-5p,miR-520c-3p,miR-526b-
3p,miR-520b 
mir-516a-2 miR-520f,miR-516a-5p,miR-526b-3p,miR-
520b,miR-520c-3p 
mir-516b-1 miR-520f,miR-526b-3p,miR-520b,miR-516b-
5p,miR-520c-3p 
mir-516b-2 miR-520f,miR-526b-3p,miR-520b,miR-516b-
5p,miR-520c-3p 
mir-517a miR-517-5p,miR-517b-3p,miR-517c-3p,miR-
517a-3p, 
mir-517b miR-517b-3p,miR-517c-3p,miR-517-5p,miR-
517a-3p, 
mir-517c miR-517-5p,miR-517b-3p,miR-517c-3p,miR-
517a-3p, 
mir-5187 miR-5187-3p,miR-5187-5p, 
mir-518a-1 miR-518a-3p,miR-527,miR-518a-5p 
mir-518a-2 miR-518a-3p,miR-527,miR-518a-5p 
mir-518b miR-519c-5p,miR-522-5p,miR-519a-5p,miR-
520a-5p,miR-518b,miR-523-5p,miR-519b-
5p,miR-518e-5p, 
mir-518c miR-520c-5p,miR-526a,miR-518d-5p,miR-518f-
5p,miR-518c-3p,miR-526b-5p,miR-518c-5p,miR-
518f-3p, 
mir-5195 miR-5195-5p,miR-5195-3p, 
mir-5196 miR-5196-3p,miR-5196-5p, 
mir-5197 miR-5197-3p,miR-5197-5p, 
mir-519a-2 miR-519c-5p,miR-522-5p,miR-519a-5p,miR-
519e-3p,miR-519a-3p,miR-519b-3p,miR-523-
5p,miR-519b-5p,miR-518e-5p 
mir-519d miR-519e-3p,miR-520g,miR-519d,miR-520h, 
mir-519e miR-519e-3p,miR-515-5p,miR-519a-3p,miR-
519d,miR-519e-5p 
mir-520a miR-520a-5p,miR-520a-3p, 
mir-520d miR-520d-5p,miR-520d-3p,miR-524-5p 
mir-520e miR-520f,miR-520e,miR-526b-3p,miR-520b,miR-
520c-3p 
mir-520g miR-519d,miR-520g,miR-520h 
mir-520h miR-520g,miR-519d,miR-520h 
mir-521-1 miR-521 
mir-521-2 miR-521 
mir-524 miR-524-5p,miR-524-3p, 
mir-525 miR-525-3p,miR-525-5p, 
mir-526b miR-520f,miR-520c-5p,miR-526a,miR-518d-
5p,miR-518f-5p,miR-526b-3p,miR-520b,miR-
526b-5p,miR-520c-3p 
mir-527 miR-520a-3p,miR-527,miR-518a-5p 
mir-532 miR-532-5p,miR-532-3p, 
mir-539 miR-539-3p,miR-539-5p, 
mir-541 miR-541-5p,miR-541-3p, 
mir-542 miR-542-5p,miR-542-3p, 
mir-545 miR-545-3p,miR-545-5p, 
mir-548a-1 miR-548aj-5p,miR-548a-3p,miR-548ay-5p,miR-
548x-5p,miR-548d-5p,miR-548g-5p,miR-548ar-
5p 
mir-548a-2 miR-548a-3p 
mir-548a-3 miR-548a-3p,miR-548a-5p, 
mir-548aa-
1 
miR-548t-3p,miR-548ap-3p,miR-548h-3p,miR-
548aq-3p,miR-548aa,miR-548z, 
mir-548aa-
2 
miR-548t-3p,miR-548ap-3p,miR-548h-3p,miR-
548aq-3p,miR-548aa,miR-548z, 
mir-548ab miR-548i,miR-548ab,miR-548ay-5p,miR-548d-
5p,miR-548n 
mir-548ad miR-548aj-5p,miR-548ay-5p,miR-548x-5p,miR-
548d-5p,miR-548g-5p,miR-548az-5p,miR-
548ad,miR-548n, 
mir-548ae-
1 
miR-548x-3p,miR-548ae,miR-548aq-3p 
mir-548ag-
1 
miR-548ag 
mir-548ag-
2 
miR-548ag 
mir-548ah miR-548av-3p,miR-548ah-5p,miR-548p,miR-
548aq-3p,miR-548am-3p,miR-548o-3p,miR-
548ah-3p,miR-548au-3p, 
mir-548ai miR-548aj-5p,miR-548ai,miR-548t-3p,miR-
548aa,miR-570-5p,miR-548x-5p,miR-548g-5p 
mir-548aj-1 miR-548x-3p,miR-548aq-3p,miR-548aj-3p 
mir-548an miR-548h-3p,miR-548an,miR-548z,miR-548ay-
5p,miR-548d-5p 
mir-548ao miR-548ao-3p,miR-548ao-5p, 
mir-548ap miR-548j,miR-548ap-5p,miR-548t-3p,miR-548ap-
3p,miR-548aa 
mir-548ar miR-548ay-5p,miR-548d-5p,miR-548ar-3p,miR-
548o-5p,miR-548au-5p,miR-548c-5p,miR-548ar-
5p,miR-548am-5p, 
mir-548as miR-548au-5p,miR-548i,miR-548c-5p,miR-548as-
5p,miR-548as-3p,miR-548o-5p,miR-548am-5p 
mir-548at miR-548at-3p,miR-548at-5p, 
mir-548av miR-548am-3p,miR-548o-3p,miR-548ah-3p 
mir-548ax miR-548g-3p,miR-548h-3p,miR-548ax,miR-548z, 
mir-548az miR-548ay-5p,miR-548d-5p,miR-548t-5p,miR-
548aq-3p,miR-548az-3p,miR-548az-5p, 
mir-548b miR-548ay-5p,miR-548d-5p,miR-548b-3p,miR-
548b-5p, 
mir-548f-1 miR-548aj-5p,miR-548x-5p,miR-548f,miR-548g-
3p,miR-548g-5p,miR-548aq-3p, 
mir-548f-2 miR-548t-3p,miR-548f,miR-548g-3p,miR-548aq-
3p,miR-548aa 
mir-548f-3 miR-548t-3p,miR-548f,miR-548g-3p,miR-548aq-
3p,miR-548aa 
mir-548f-4 miR-548aq-3p,miR-548ay-5p,miR-548f,miR-
548d-5p,miR-548g-3p 
mir-548f-5 miR-548f,miR-548g-3p, 
mir-548h-1 miR-548h-5p 
mir-548h-2 miR-548h-5p,miR-548t-3p,miR-548aa 
mir-548h-4 miR-548h-5p,miR-548h-3p,miR-548aq-3p,miR-
548t-3p,miR-548aa,miR-548z, 
mir-548h-5 miR-548h-5p 
mir-548i-1 miR-548i,miR-548k,miR-548o-5p,miR-548au-
5p,miR-548c-5p,miR-548ab,miR-548as-5p,miR-
548n,miR-548am-5p 
mir-548i-2 miR-548i,miR-548k,miR-548o-5p,miR-548au-
5p,miR-548c-5p,miR-548ab,miR-548as-5p,miR-
548n,miR-548am-5p 
mir-548i-3 miR-548au-5p,miR-548i,miR-548k,miR-548c-
5p,miR-548ab,miR-548as-5p,miR-548o-5p,miR-
548n,miR-548am-5p 
mir-548i-4 miR-548i,miR-548k,miR-548o-5p,miR-548au-
5p,miR-548c-5p,miR-548ab,miR-548as-5p,miR-
548n,miR-548am-5p 
mir-548k miR-548h-3p,miR-548i,miR-548k,miR-548z, 
mir-548n miR-548h-3p,miR-548ab,miR-548z,miR-548n, 
mir-548o miR-548av-3p,miR-548am-3p,miR-548o-3p,miR-
548ah-3p, 
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mir-548p miR-548av-3p,miR-548p,miR-548aq-3p,miR-
548am-3p,miR-548o-3p,miR-548ah-3p, 
mir-548q miR-548o-5p,miR-548au-5p,miR-548c-5p,miR-
548q,miR-548am-5p 
mir-548s miR-548aj-5p,miR-548s,miR-548x-5p,miR-548ar-
3p,miR-548g-5p,miR-548ar-5p,miR-548o-3p 
mir-548t miR-548ap-3p,miR-548h-3p,miR-548aq-3p,miR-
548t-3p,miR-548aa,miR-548z,miR-548az-5p,miR-
548t-5p, 
mir-548u miR-548aq-3p,miR-548u, 
mir-548w miR-548au-5p,miR-548w,miR-548t-3p,miR-548c-
5p,miR-548aa,miR-548ak,miR-548o-5p,miR-
548am-5p, 
mir-548x-2 miR-548ab,miR-548ay-5p,miR-548aj-3p,miR-
548x-3p,miR-548d-5p,miR-548ae,miR-548n 
mir-548y miR-548h-3p,miR-548t-3p,miR-548y,miR-
548aa,miR-548z 
mir-548z miR-548t-3p,miR-548h-3p,miR-548aq-3p,miR-
548aa,miR-548z 
mir-550a-1 miR-550a-5p,miR-550a-3p,miR-550a-3-5p 
mir-550a-2 miR-550a-3p,miR-550a-5p,miR-550a-3-5p 
mir-550a-3 miR-550a-3p,miR-550a-5p,miR-550a-3-5p 
mir-550b-1 miR-550b-3p,miR-550b-2-5p, 
mir-550b-2 miR-550b-3p,miR-550b-2-5p, 
mir-551b miR-551b-3p,miR-551b-5p, 
mir-556 miR-556-3p,miR-556-5p, 
mir-5571 miR-5571-5p,miR-5571-3p, 
mir-5579 miR-5579-3p,miR-5579-5p, 
mir-5580 miR-5580-3p,miR-5580-5p, 
mir-5581 miR-5581-5p,miR-5581-3p, 
mir-5582 miR-5582-5p,miR-5582-3p, 
mir-5583-1 miR-5583-5p,miR-5583-3p, 
mir-5583-2 miR-5583-5p,miR-5583-3p, 
mir-5584 miR-5584-5p,miR-5584-3p, 
mir-5585 miR-5585-5p,miR-5585-3p, 
mir-5586 miR-5586-5p,miR-5586-3p, 
mir-5587 miR-5587-3p 
mir-5588 miR-1234-5p,miR-5588-5p, 
mir-5589 miR-5589-3p,miR-5589-5p, 
mir-5590 miR-5590-5p,miR-5590-3p, 
mir-5591 miR-5591-3p,miR-5591-5p, 
mir-561 miR-561-5p,miR-561-3p, 
mir-5681a miR-5681b,miR-5681a, 
mir-5692a-
1 
miR-5692a 
mir-5692a-
2 
miR-5692a 
mir-5692c-
1 
miR-5692c,miR-5692b, 
mir-5692c-
2 
miR-5692b,miR-5692c, 
mir-570 miR-548aj-5p,miR-548ai,miR-570-5p,miR-548x-
5p,miR-570-3p,miR-548g-5p, 
mir-5701-1 miR-5701 
mir-5701-2 miR-5701 
mir-5708 miR-1972,miR-5708, 
mir-574 miR-574-3p,miR-574-5p, 
mir-576 miR-576-3p,miR-576-5p, 
mir-582 miR-582-3p,miR-582-5p, 
mir-584 miR-584-3p,miR-584-5p, 
mir-589 miR-589-3p,miR-589-5p, 
mir-590 miR-590-5p,miR-590-3p, 
mir-593 miR-593-3p,miR-593-5p, 
mir-6077-1 miR-6077 
mir-6077-2 miR-6077 
mir-6089-1 miR-6089 
mir-6089-2 miR-6089 
mir-615 miR-615-5p,miR-615-3p, 
mir-616 miR-616-5p,miR-616-3p, 
mir-624 miR-624-5p,miR-624-3p, 
mir-625 miR-625-5p,miR-625-3p, 
mir-628 miR-628-3p,miR-628-5p, 
mir-629 miR-629-3p,miR-629-5p, 
mir-642a miR-642a-3p,miR-642b-5p,miR-642a-5p,miR-
642b-3p, 
mir-642b miR-642a-3p,miR-642b-5p,miR-642a-5p,miR-
642b-3p, 
mir-6499 miR-6499-5p,miR-6499-3p, 
mir-6500 miR-6500-3p,miR-6500-5p, 
mir-6501 miR-6501-3p,miR-6501-5p, 
mir-6502 miR-6502-5p,miR-6502-3p, 
mir-6503 miR-6503-5p,miR-6503-3p, 
mir-6504 miR-6504-3p,miR-6504-5p, 
mir-6505 miR-6505-3p,miR-6505-5p, 
mir-6506 miR-6506-5p,miR-6506-3p, 
mir-6507 miR-6507-3p,miR-6507-5p, 
mir-6508 miR-6508-3p,miR-6508-5p, 
mir-6509 miR-6509-5p,miR-6509-3p, 
mir-6510 miR-6510-3p,miR-6510-5p, 
mir-6511a-
1 
miR-6511a-3p,miR-6511b-3p,miR-6511a-5p,miR-
6511b-5p, 
mir-6511a-
2 
miR-6511a-3p,miR-6511b-3p,miR-6511a-5p,miR-
6511b-5p, 
mir-6511a-
3 
miR-6511a-3p,miR-6511b-3p,miR-6511a-5p,miR-
6511b-5p, 
mir-6511a-
4 
miR-6511a-3p,miR-6511b-3p,miR-6511a-5p,miR-
6511b-5p, 
mir-6511b-
1 
miR-6511a-3p,miR-6511b-3p,miR-6511a-5p,miR-
6511b-5p, 
mir-6512 miR-6512-3p,miR-6512-5p, 
mir-6513 miR-6513-3p,miR-6513-5p, 
mir-6514 miR-6514-3p,miR-6514-5p, 
mir-6515 miR-6515-5p 
mir-652 miR-652-3p,miR-652-5p, 
mir-654 miR-654-5p,miR-654-3p, 
mir-659 miR-659-5p,miR-659-3p, 
mir-660 miR-660-3p,miR-660-5p, 
mir-664a miR-664a-3p,miR-664a-5p, 
mir-664b miR-664b-5p,miR-664b-3p, 
mir-671 miR-671-3p,miR-671-5p, 
mir-6715a miR-6715a-3p 
mir-6715b miR-6715b-3p,miR-6715b-5p, 
mir-6716 miR-6716-3p,miR-6716-5p, 
mir-6717 miR-6717-5p 
mir-6718 miR-6718-5p 
mir-6719 miR-6719-3p 
mir-6720 miR-6720-3p 
mir-6721 miR-6721-5p 
mir-6722 miR-6722-5p,miR-6722-3p, 
mir-6723 miR-6723-5p 
mir-6724 miR-6724-5p 
mir-675 miR-675-5p,miR-675-3p, 
mir-676 miR-676-3p,miR-676-5p, 
mir-7-1 miR-7-1-3p,miR-7-5p, 
mir-7-2 miR-7-5p,miR-7-2-3p, 
mir-7-3 miR-7-5p 
mir-708 miR-708-3p,miR-708-5p, 
mir-744 miR-744-3p,miR-744-5p, 
mir-758 miR-758-3p,miR-758-5p, 
mir-766 miR-766-5p,miR-766-3p, 
mir-767 miR-767-5p,miR-767-3p, 
mir-769 miR-769-5p,miR-769-3p, 
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mir-770 miR-770-5p 
mir-873 miR-873-3p,miR-873-5p, 
mir-875 miR-875-3p,miR-875-5p, 
mir-876 miR-876-5p,miR-876-3p, 
mir-877 miR-877-3p,miR-877-5p, 
mir-885 miR-885-5p,miR-885-3p, 
mir-888 miR-888-5p,miR-888-3p, 
mir-892a miR-892c-5p,miR-892a, 
mir-892c miR-892c-3p,miR-892c-5p, 
mir-9-1 miR-9-3p,miR-9-5p, 
mir-9-2 miR-9-3p,miR-9-5p, 
mir-9-3 miR-9-3p,miR-9-5p, 
mir-92a-1 miR-92a-1-5p,miR-92a-3p, 
mir-92a-2 miR-92a-3p,miR-92a-2-5p, 
mir-92b miR-92b-3p,miR-92b-5p, 
mir-93 miR-93-5p,miR-93-3p, 
mir-937 miR-937-5p,miR-937-3p, 
mir-939 miR-939-3p,miR-939-5p, 
mir-941-1 miR-941 
mir-941-2 miR-941 
mir-941-3 miR-941 
mir-941-4 miR-941 
mir-96 miR-96-3p,miR-96-5p 
mir-98 miR-98-5p,miR-98-3p 
mir-99a miR-99a-3p,miR-99a-5p,miR-100-5p 
mir-99b miR-99b-5p,miR-99b-3p 
 
Appendix 3.4: Expression of miRNAs that are dynamically expressed in HeLa and MCF7 
 
MCF7 HeLa 
miRNAs G1G0 phase S phase G2M phase S phase G2M phase G1G0 phase 
hsa-mir-760-3p 12.06232169 28.79623605 35.733373 12.76459039 7.19708252 27.45402352 
hsa-mir-6127-3p 3.454460851 25.28317998 19.35772214 12.76459039 6.063014107 19.19107957 
hsa-mir-579-3p 7.365254973 12.47976575 19.35772214 2.408168808 13.14185089 19.19107957 
hsa-mir-5095-3p 5.555220935 12.47976575 12.37378789 479.3479974 174.9908388 161.7271747 
hsa-mir-503-5p 144.5352125 346.4061392 232.2780811 27.75186474 61.85991073 21.86980984 
hsa-mir-491-5p 9.808235237 19.25054078 0 16.49929082 6.901533728 3.973776348 
hsa-mir-4731-3p 26.56664015 12.47976575 15.74945912 16.49929082 1.775285613 6.588626413 
hsa-mir-451a-5p 464.3984812 1160.405289 776.9126178 435.389122 8463.374391 539.6355981 
hsa-mir-4485 12.06232169 16.96932302 28.68844341 2959.069365 722.6413432 500.9612173 
hsa-mir-4472-2-5p 17.02352497 6.901533728 17.57739354 5.925868684 5.414978892 10.87801184 
hsa-mir-4461-3p 17.02352497 28.79623605 54.64718167 38.9366264 18.20469715 16.96932302 
hsa-mir-4319-5p 15.65182036 13.85899936 7.235712428 32.28203593 17.24268554 14.99714146 
hsa-mir-4275-5p 7.365254973 16.96932302 22.90389448 5.925868684 12.21531703 35.84572274 
hsa-mir-4263-3p 331.1870844 86.11761011 166.3979328 12.76459039 3.520423995 25.28317998 
hsa-mir-4254-3p 5.555220935 15.13217853 10.73942422 16.49929082 4.896212907 1.775285613 
hsa-mir-4251-3p 1.40533462 10.6139014 7.235712428 0 4.051036165 10.87801184 
hsa-mir-421-3p 1902.913564 792.5027497 1160.405289 1204.46625 504.4351209 1084.376865 
hsa-mir-3975-3p 7.365254973 55.12021658 133.6559941 3364.683276 1587.056643 29.27167894 
hsa-mir-3940-3p 1.40533462 10.6139014 19.35772214 182.5367191 90.56341406 222.9296522 
hsa-mir-3908-5p 672.1391295 742.0782567 1397.768541 32.28203593 9.502153338 14.99714146 
hsa-mir-3619-5p 21.63629357 12.47976575 38.46508822 56.73645198 10.87801184 19.19107957 
hsa-mir-3609-3p 21.63629357 12.47976575 26.91177318 683.6070318 144.5352125 149.3497026 
hsa-mir-3607-5p 454.9515476 454.9515476 2238.256233 3443.931007 1033.856472 776.9126178 
hsa-mir-338-3p 34.95775308 22.82050905 15.74945912 78.49640148 208.1918988 162.9516609 
hsa-mir-331-5p 75.83474817 40.45220884 85.35884686 27.75186474 16.15418281 6.588626413 
hsa-mir-3200-3p 17.02352497 20.6677871 9.234176338 12.76459039 5.414978892 8.946392223 
hsa-mir-3196-5p 121.8498074 36.26972128 216.8646298 2.408168808 5.414978892 45.64292002 
hsa-mir-3195-5p 184.6345363 42.85439231 101.1881681 9.436190194 3.520423995 12.76459039 
hsa-mir-3195-3p 306.4945739 156.4369552 358.2693807 0 3.520423995 21.86980984 
hsa-mir-3159-3p 7.365254973 21.86980984 26.91177318 890.5533074 316.8402022 423.525475 
hsa-mir-3149-3p 13.94242081 5.19250601 17.57739354 63.99197567 24.91730951 29.27167894 
hsa-mir-222-5p 3.454460851 10.6139014 5.925868684 27.75186474 24.91730951 61.6249153 
hsa-mir-211-3p 3.454460851 8.691102594 15.74945912 20.02993942 8.374487244 3.973776348 
hsa-mir-210-5p 13.94242081 5.19250601 9.234176338 5.925868684 7.19708252 16.96932302 
hsa-mir-20a-3p 12.06232169 27.36461335 24.77847397 12.76459039 75.83474817 82.95894747 
hsa-mir-192-3p 3.454460851 13.85899936 13.94242081 2.408168808 4.051036165 16.96932302 
hsa-mir-190a-3p 1.40533462 19.25054078 17.57739354 5.925868684 9.502153338 16.96932302 
hsa-mir-185-5p 1778.668825 2387.155083 629.5079415 49.26349562 78.27681935 109.3698654 
hsa-mir-15b-3p 88.85183792 427.0150708 341.4195047 85.73822848 326.0837354 365.8906818 
hsa-mir-15a-3p 52.80033202 173.8690146 195.7820947 23.83758649 57.93701336 48.89083798 
hsa-mir-1468-3p 12.06232169 5.19250601 7.235712428 121.8498074 22.97406628 35.84572274 
hsa-mir-143-3p 3.454460851 10.6139014 9.234176338 60.68458879 1058.414274 45.64292002 
hsa-mir-1304-3p 7.365254973 12.47976575 2.855975236 75.4163265 33.5467733 68.70001877 
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hsa-mir-1302-5-3p 23.99401305 10.6139014 13.94242081 12.76459039 5.414978892 10.87801184 
hsa-mir-1291-5p 12.06232169 10.6139014 5.925868684 0 3.520423995 12.76459039 
hsa-mir-1256-5p 13.94242081 23.99401305 7.235712428 2.408168808 7.19708252 31.17931184 
hsa-mir-1248-5p 21.63629357 49.67558037 49.0771668 186.3711373 8.85043643 14.99714146 
hsa-mir-1247-5p 45.04465007 86.11761011 96.68933084 116.394709 29.07284912 21.86980984 
hsa-mir-1246-5p 13.94242081 19.25054078 32.42511018 226.398542 15.05491872 35.84572274 
hsa-mir-1234-5p 6576.023125 2699.734622 5160.096806 1186.640347 497.4873137 1033.856472 
hsa-mir-1229-3p 21.63629357 6.901533728 22.90389448 16.49929082 5.414978892 3.973776348 
hsa-mir-1180-3p 5.555220935 22.82050905 22.90389448 153.3726355 51.4622954 57.82377913 
hsa-mir-106b-3p 273.2439111 140.4574015 301.6864157 589.3979019 275.6774351 381.1021305 
hsa-let-7d-5p 1445.121007 2323.808068 575.3725301 85.73822848 154.3847464 191.9831302 
hsa-let-7d-3p 205.7761542 216.8646298 82.52143755 70.86429081 12.21531703 48.89083798 
 
Appendix 3.5:  
(A) miRNAs previously shown to be cell cycle regulators with cyclic expression across cell 
cycle phases 
 
HeLa  S Phase G2M Phase G1G0 Phase 
hsa-mir-145-5p 1482.25 9497.91 1902.91 
hsa-mir-15a-5p 101.98 229.10 328.63 
hsa-mir-195-5p 80.23 197.63 339.01 
hsa-mir-331-3p 5597.73 2184.50 2534.57 
hsa-mir-424-5p 116.39 672.13 572.46 
MCF7  S Phase G2M Phase G1G0 Phase 
hsa-mir-200b-5p 65.44 127.81 141.45 
hsa-mir-503-5p 346.40 232.27 144.53 
 
(B) miRNAs previously shown to be cell cycle regulators but not cyclic in this study 
 
miRNAs MCF7_S  MCF7_G2M  MCF7_G1G0  HeLa_S  HeLa_G2M  HeLa_G1G0 
hsa-mir-17-5p 2604.81 2959.06 3047.68 16229.24 16229.24 17370.86 
hsa-mir-31-5p 68.28 80.89 103.20 53836.60 67962.10 67962.10 
hsa-mir-210-5p 13.94 5.19 9.23 5.925 7.19 16.96 
 
(C) Isomir analysis for miR-17-5p  
 
miRNA Start 
Position 
End 
Position 
MCF7
S  
MCF7 
G2M  
MCF7 
G1G0 
HeLa
S  
HeLa
G2M  
HeLa
G1G0 
Sum of reads mapping to mature miRNA - 
hsa-mir-17-5p 
14 37 247.69 331.74 314.87 2941.
10 
2697.3
0 
3197.9
3 
Sum of reads to mapping to isomirs  11-20 32-51 2212.4
3 
3053.52 2860.74 6088.
80 
10187.
75 
9481.7
0 
Sum of isomirs shorter than mature 
miRNA (in the 3' end) 
11-15 32-36 1812.2
1 
2341.60
18 
2158.98 2659.
90 
4869.7
2 
4473.3
0 
Sum of isomirs longer than mature 
miRNA (in the 3' end) 
11-20 38-51 302.26 514.57 491.84 2482.
00 
3780.4
2 
3629.4
0 
 
(D) miRNAs identified to be cyclic in the Zhou et. al (2009) 
 
miRNAs HeLa_S  HeLa_G2M  HeLa_G1G0 Potential 
to Cross-
hybridize? 
Dynamic across 
cross 
hybridizing 
miRNA? 
hsa-mir-19a-5p 0 5.414978892 6.588626413 yes yes 
hsa-mir-34b-5p 0 1.775285613 3.973776348 yes yes 
hsa-mir-34c-3p 0 0 0 yes yes 
hsa-mir-933-5p 2.408168808 4.051036165 6.588626413     
hsa-mir-329-3p 0 0 0 yes yes 
hsa-mir-519d-5p 0 0 0 yes yes 
hsa-mir-590-3p 2.408168808 29.07284912 61.6249153     
hsa-mir-618-5p 0 0 0     
hsa-mir-126-5p 32.28203593 563.2081695 123.698712     
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hsa-mir-147b-5p 0 1.775285613 1.775285613 yes yes 
hsa-mir-224-5p 2815.209335 2869.838662 2815.209335     
hsa-mir-299-5p 0 57.15177807 10.87801184     
hsa-mir-524-5p 0 0 0 yes yes 
hsa-mir-553-5p 0 0 0     
hsa-mir-582-5p 536.5001919 1832.812821 2184.505937     
hsa-mir-653-5p 0 0 0 yes yes 
has-mir-924-5p 0 0 0     
hsa-mir-34a-5p 1046.135373 1445.121007 1778.668825     
hsa-mir-30b-5p 4660.366383 4979.755206 3443.931007 yes yes 
hsa-mir-22-5p 273.2439111 200.6373135 219.6043546     
hsa-mir-510-5p 0 0 0 yes no 
has-let-7a 711.0180338 1102.727249 913.7149604 yes yes 
hsa-mir-21-5p 23844.11968 92303.10664 92303.10664     
hsa-mir-221-3p 968.038206 698.8089319 609.5658477     
hsa-mir-222-3p 1397.768541 905.7753959 1058.414274     
 
Appendix 3.6: List of miRNA probes and their corresponding potential cross-hybridizing 
miRNAs 
 
miRNAs Cross-hybridizing miRNAs* 
miR-453 miR-323a-5p,miR-323b-5p, 
miR-376b miR-376b-3p,miR-376a-3p,miR-376c-3p, 
miR-146a miR-146a-5p,miR-146b-5p, 
miR-582 miR-582-5p, 
miR-422b miR-378j,miR-378a-3p,miR-378d,miR-6128,miR-
378i,miR-378e,miR-378b,miR-422a,miR-
378g,miR-378f,miR-378h,miR-378c, 
miR-
520f_miR-
520c 
miR-519d,miR-520f,miR-520e,miR-519c-3p,miR-
519b-3p,miR-519e-3p,miR-519a-3p,miR-520c-
3p,miR-516a-3p,miR-520g,miR-516b-3p,miR-
520h,miR-526b-3p,miR-520b, 
miR-376a* miR-376c-5p,miR-376a-5p,miR-376a-2-5p, 
miR-510 miR-514a-5p,miR-510, 
miR-200b miR-200a-3p,miR-141-3p,miR-200b-3p,miR-200c-
3p, 
miR-30e-3p miR-30d-3p,miR-30e-3p,miR-30a-3p, 
miR-628 miR-628-3p, 
miR-520b miR-520f,miR-520e,miR-519e-3p,miR-520a-
3p,miR-519a-3p,miR-520g,miR-520d-3p,miR-523-
3p,miR-525-3p,miR-526b-3p,miR-518e-3p,miR-
520b,miR-518c-3p,miR-519d,miR-522-3p,miR-
519c-3p,miR-518b,miR-519b-3p,miR-517c-
3p,miR-520c-3p,miR-518f-3p,miR-518d-3p,miR-
516a-3p,miR-516b-3p,miR-520h,miR-524-3p, 
miR-147 miR-147b,miR-147a, 
miR-32 miR-32-5p, 
miR-642 miR-642b-5p,miR-642a-5p, 
miR-519c miR-520f,miR-520e,miR-519e-3p,miR-519a-
3p,miR-520g,miR-520d-3p,miR-526b-3p,miR-
520b,miR-519d,miR-518c-3p,miR-519c-3p,miR-
519b-3p,miR-517c-3p,miR-520c-3p,miR-518f-
3p,miR-520h, 
miR-16 miR-16-5p,miR-195-5p, 
miR-18b miR-18b-5p,miR-18a-5p,miR-20a-5p, 
miR-17-5p miR-20b-5p,miR-106b-5p,miR-20a-5p,miR-106a-
5p,miR-17-5p, 
miR-548d miR-548at-3p,miR-548av-3p,miR-548t-3p,miR-
548c-3p,miR-548ap-3p,miR-548h-3p,miR-548d-
3p,miR-548aq-3p,miR-548am-3p,miR-548b-
3p,miR-548aa,miR-548o-3p,miR-548ah-3p,miR-
548z, 
miR-525 miR-520d-5p,miR-520c-5p,miR-519c-5p,miR-522-
5p,miR-526a,miR-519a-5p,miR-520a-5p,miR-
518d-5p,miR-518f-5p,miR-526b-5p,miR-518c-
5p,miR-523-5p,miR-525-5p,miR-527,miR-518a-
5p,miR-524-5p,miR-519b-5p,miR-518e-5p, 
miR-513 miR-513a-5p,miR-513c-5p,miR-513b, 
miR-500 miR-501-3p,miR-502-3p,miR-500a-3p, 
miR-518e miR-520f,miR-519e-3p,miR-523-3p,miR-521,miR-
525-3p,miR-526b-3p,miR-518e-3p,miR-518c-
3p,miR-518b,miR-3158-5p,miR-518f-3p,miR-
518d-3p,miR-524-3p, 
miR-515-5p miR-520d-5p,miR-520c-5p,miR-526a,miR-520a-
5p,miR-515-5p,miR-518d-5p,miR-518f-5p,miR-
1283,miR-519e-5p,miR-525-5p,miR-527,miR-
518a-5p,miR-524-5p, 
miR-301 miR-301b,miR-301a-3p, 
miR-144 miR-144-3p, 
miR-125b miR-4324,miR-125b-5p, 
miR-338 miR-338-3p, 
miR-187 miR-187-3p, 
miR-384 miR-384, 
miR-574 miR-574-3p, 
miR-653 miR-24-2-5p,miR-4684-5p,miR-653, 
miR-302a miR-520e,miR-302b-3p,miR-302c-3p,miR-302d-
3p,miR-302a-3p, 
miR-491 miR-491-5p, 
miR-483 miR-483-3p, 
miR-625 miR-625-5p, 
miR-138 miR-138-5p, 
miR-126 miR-126-3p, 
miR-429 miR-429,miR-141-3p, 
let-7d let-7a-5p,miR-98-5p,let-7c,let-7b-5p,let-7f-5p,let-
7e-5p,let-7d-5p,let-7g-5p, 
miR-503 miR-503-5p, 
miR-29a miR-29b-3p,miR-29a-3p,miR-29c-3p, 
miR-488 miR-488-5p, 
miR-766 miR-766-3p,miR-4323, 
miR-192 miR-192-5p,miR-215, 
miR-570 miR-548av-3p,miR-548t-3p,miR-548ac,miR-548g-
3p,miR-570-3p,miR-548h-3p,miR-548aq-3p,miR-
548aa,miR-548z,miR-548aj-3p,miR-548az-3p,miR-
548ad, 
miR-105 miR-105-5p, 
let-7g let-7a-5p,miR-98-5p,let-7c,let-7i-5p,let-7b-5p,let-
7f-5p,let-7e-5p,let-7d-5p,let-7g-5p, 
miR-9 miR-9-5p, 
miR-517* miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-520a-5p,miR-518d-
5p,miR-517-5p,miR-518f-5p,miR-526b-5p,miR-
 241 
518c-5p,miR-523-5p,miR-525-5p,miR-519b-
5p,miR-518e-5p, 
miR-133a miR-133a,miR-133b, 
miR-155 miR-155-5p, 
miR-520g miR-520f,miR-520e,miR-519e-3p,miR-520a-
3p,miR-519a-3p,miR-520g,miR-520d-3p,miR-523-
3p,miR-521,miR-525-3p,miR-526b-3p,miR-518e-
3p,miR-520b,miR-519d,miR-518c-3p,miR-522-
3p,miR-518b,miR-519c-3p,miR-517b-3p,miR-
519b-3p,miR-517c-3p,miR-520c-3p,miR-518f-
3p,miR-518d-3p,miR-520h,miR-524-3p,miR-517a-
3p, 
miR-34b miR-34c-5p,miR-34b-5p, 
miR-616 miR-616-5p, 
miR-520d* miR-520d-5p,miR-520c-5p,miR-519c-5p,miR-522-
5p,miR-526a,miR-519a-5p,miR-520a-5p,miR-515-
5p,miR-518d-5p,miR-518f-5p,miR-1283,miR-519e-
5p,miR-523-5p,miR-525-5p,miR-527,miR-518a-
5p,miR-524-5p,miR-519b-5p,miR-518e-5p, 
miR-222 miR-222-3p, 
miR-181a miR-181b-5p,miR-181a-5p, 
miR-432 miR-432-5p, 
miR-92 miR-25-3p,miR-92b-3p,miR-92a-3p, 
miR-593 miR-593-5p, 
miR-518f* miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-520a-5p,miR-518d-
5p,miR-517-5p,miR-518f-5p,miR-526b-5p,miR-
518c-5p,miR-523-5p,miR-525-5p,miR-524-5p,miR-
519b-5p,miR-518e-5p, 
miR-151 miR-151a-3p, 
miR-208 miR-208b,miR-208a, 
miR-302c* miR-302c-5p, 
miR-526c miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-518d-5p,miR-518f-5p,miR-
526b-5p,miR-518c-5p,miR-523-5p,miR-519b-
5p,miR-518e-5p, 
miR-487a miR-487a,miR-487b, 
miR-221 miR-221-3p, 
miR-204 miR-211-5p,miR-204-5p, 
miR-195 miR-16-5p,miR-195-5p, 
miR-487b miR-487a,miR-487b, 
miR-96 miR-96-5p, 
miR-519d miR-520f,miR-520e,miR-519e-3p,miR-520a-
3p,miR-519a-3p,miR-520g,miR-521,miR-525-
3p,miR-526b-3p,miR-518e-3p,miR-520b,miR-
519d,miR-518c-3p,miR-522-3p,miR-518b,miR-
519c-3p,miR-517b-3p,miR-519b-3p,miR-517c-
3p,miR-520c-3p,miR-518f-3p,miR-518d-3p,miR-
520h,miR-517a-3p, 
miR-545 miR-421,miR-545-3p, 
miR-181d miR-181b-5p,miR-181d, 
miR-135b miR-135a-5p,miR-135b-5p, 
miR-214 miR-214-3p, 
miR-514 miR-514b-3p,miR-514a-3p, 
miR-377 miR-377-3p, 
miR-27b miR-27b-3p,miR-27a-3p, 
miR-548c miR-548av-3p,miR-548t-3p,miR-548a-3p,miR-
548ae,miR-548c-3p,miR-548ap-3p,miR-548h-
3p,miR-548d-3p,miR-548aq-3p,miR-548am-
3p,miR-548b-3p,miR-548aa,miR-548ah-3p,miR-
548z,miR-548aj-3p,miR-548az-3p,miR-548u, 
miR-549 miR-549a, 
miR-34c miR-34c-5p,miR-34b-5p, 
miR-520e miR-520f,miR-520e,miR-519e-3p,miR-520a-
3p,miR-519a-3p,miR-520g,miR-520d-3p,miR-525-
3p,miR-526b-3p,miR-520b,miR-519d,miR-519c-
3p,miR-519b-3p,miR-373-3p,miR-520c-3p,miR-
518f-3p,miR-518d-3p,miR-520h,miR-524-3p, 
miR-518d miR-520e,miR-520a-3p,miR-520g,miR-520d-
3p,miR-523-3p,miR-521,miR-525-3p,miR-526b-
3p,miR-518e-3p,miR-520b,miR-519d,miR-518c-
3p,miR-518a-3p,miR-518b,miR-520c-3p,miR-518f-
3p,miR-518d-3p,miR-520h,miR-524-3p, 
miR-139 miR-139-5p, 
miR-200a miR-200a-3p,miR-141-3p,miR-200c-3p,miR-200b-
3p, 
miR-30d miR-30e-5p,miR-30d-5p,miR-30a-5p, 
miR-629 miR-629-3p, 
miR-93 miR-93-5p, 
miR-193b miR-193b-3p, 
miR-371 miR-371a-3p, 
miR-27a miR-27b-3p,miR-27a-3p, 
miR-518c* miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-520a-5p,miR-518d-
5p,miR-518f-5p,miR-526b-5p,miR-518c-5p,miR-
523-5p,miR-525-5p,miR-519b-5p,miR-518e-5p, 
miR-590 miR-590-5p, 
miR-523 miR-519c-5p,miR-522-5p,miR-519a-5p,miR-523-
3p,miR-521,miR-525-3p,miR-526b-3p,miR-518e-
3p,miR-520b,miR-518c-3p,miR-518b,miR-520c-
3p,miR-523-5p,miR-518f-3p,miR-518d-3p,miR-
519b-5p,miR-524-3p,miR-518e-5p, 
let-7i let-7a-5p,miR-98-5p,let-7c,let-7i-5p,let-7b-5p,let-
7f-5p,let-7g-5p, 
miR-335 miR-335-5p, 
miR-422a miR-378g,miR-378f,miR-378h,miR-378a-3p,miR-
378d,miR-378i,miR-422a,miR-378c, 
miR-152 miR-148a-3p,miR-152,miR-148b-3p, 
miR-23b miR-23c,miR-23a-3p,miR-23b-3p, 
miR-363* miR-363-5p, 
miR-188 miR-188-5p, 
miR-101 miR-101-3p, 
miR-452 miR-452-5p, 
miR-339 miR-339-5p,miR-1233-3p, 
miR-539 miR-2355-3p,miR-539-5p, 
miR-28 miR-151a-5p,miR-28-5p, 
miR-342 miR-342-3p, 
miR-296 miR-296-5p, 
miR-33 miR-33a-5p,miR-33b-5p, 
miR-33b miR-33a-5p,miR-33b-5p, 
miR-519b miR-520f,miR-520e,miR-519e-3p,miR-519a-
3p,miR-526b-3p,miR-520b,miR-519d,miR-519c-
3p,miR-519b-3p,miR-517c-3p,miR-520c-3p, 
miR-31 miR-31-5p, 
miR-124a miR-124-3p, 
miR-526b miR-520c-5p,miR-519c-5p,miR-522-5p,miR-
526a,miR-519a-5p,miR-520a-5p,miR-518d-
5p,miR-518f-5p,miR-526b-5p,miR-518c-5p,miR-
523-5p,miR-525-5p,miR-519b-5p,miR-518e-5p, 
miR-99a miR-99b-5p,miR-99a-5p,miR-100-5p, 
miR-133b miR-133a,miR-133b, 
let-7b let-7a-5p,miR-98-5p,let-7c,let-7i-5p,let-7b-5p,let-
7f-5p,let-7e-5p,miR-4510,let-7d-5p,let-7g-5p, 
miR-544 miR-544a, 
miR-361 miR-361-5p, 
miR-520a miR-520f,miR-520e,miR-519e-3p,miR-520a-
3p,miR-519a-3p,miR-520g,miR-520d-3p,miR-
526b-3p,miR-518e-3p,miR-520b,miR-519d,miR-
522-3p,miR-520c-3p,miR-518d-3p,miR-520h,miR-
524-3p, 
miR-143 miR-143-3p, 
miR-199b miR-199b-5p,miR-199a-5p, 
miR-330 miR-330-3p, 
miR-136 miR-136-5p, 
miR-551a miR-551a,miR-551b-3p, 
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miR-615 miR-615-3p, 
miR-320 miR-320a,miR-320c,miR-4429,miR-320e,miR-
320d,miR-320b, 
miR-449 miR-449a,miR-449c-5p,miR-449b-5p, 
miR-223 miR-223-3p, 
miR-141 miR-200a-3p,miR-429,miR-141-3p,miR-200c-
3p,miR-200b-3p, 
miR-508 miR-508-3p, 
let-7a let-7a-5p,miR-98-5p,let-7c,miR-6129,let-7i-5p,let-
7b-5p,miR-6134,let-7f-5p,let-7e-5p,miR-4510,let-
7d-5p,let-7g-5p, 
miR-576 miR-576-5p, 
miR-378 miR-378a-5p, 
miR-518c miR-520f,miR-519e-3p,miR-520a-3p,miR-519a-
3p,miR-520g,miR-520d-3p,miR-523-3p,miR-
521,miR-525-3p,miR-526b-3p,miR-518e-3p,miR-
520b,miR-519d,miR-518c-3p,miR-522-3p,miR-
518b,miR-519c-3p,miR-520c-3p,miR-518f-3p,miR-
518d-3p,miR-520h,miR-524-3p, 
miR-526b* miR-520f,miR-520e,miR-519e-3p,miR-520a-
3p,miR-519a-3p,miR-520g,miR-520d-3p,miR-525-
3p,miR-526b-3p,miR-518e-3p,miR-520b,miR-
519d,miR-518c-3p,miR-522-3p,miR-518b,miR-
519c-3p,miR-519b-3p,miR-517c-3p,miR-520c-
3p,miR-518f-3p,miR-518d-3p,miR-520h, 
miR-190 miR-190a, 
miR-98 let-7a-5p,miR-98-5p,let-7c,let-7i-5p,let-7b-5p,let-
7f-5p,let-7e-5p,miR-4510,let-7d-5p,let-7g-5p, 
miR-203 miR-203b-3p,miR-203a, 
miR-302a* miR-302a-5p, 
miR-561 miR-561-3p, 
miR-191 miR-191-5p, 
miR-381 miR-300,miR-381-3p, 
miR-127 miR-127-3p, 
miR-519e* miR-520d-5p,miR-520c-5p,miR-526a,miR-520a-
5p,miR-515-5p,miR-518d-5p,miR-518f-5p,miR-
519e-5p,miR-525-5p,miR-527,miR-518a-5p,miR-
524-5p, 
miR-211 miR-211-5p,miR-204-5p, 
miR-181a* miR-181a-3p,miR-181c-3p,miR-181a-2-3p, 
miR-19b miR-19b-3p,miR-19a-3p, 
miR-432* miR-432-3p, 
miR-380-3p miR-379-3p,miR-380-3p, 
miR-194 miR-194-5p, 
miR-502 miR-502-5p,miR-500b,miR-500a-5p, 
miR-150 miR-150-5p, 
miR-30c miR-30b-5p,miR-30c-5p, 
miR-181c miR-181c-5p, 
miR-526a miR-520d-5p,miR-520c-5p,miR-519c-5p,miR-522-
5p,miR-526a,miR-519a-5p,miR-520a-5p,miR-
518d-5p,miR-517-5p,miR-518f-5p,miR-526b-
5p,miR-518c-5p,miR-523-5p,miR-525-5p,miR-
527,miR-518a-5p,miR-524-5p,miR-519b-5p,miR-
518e-5p, 
miR-451 miR-451a, 
miR-556 miR-556-5p, 
miR-374 miR-374c-5p,miR-374a-5p,miR-374b-5p, 
miR-18a miR-18b-5p,miR-18a-5p,miR-20a-5p, 
miR-205 miR-205-5p, 
miR-224 miR-224-5p, 
miR-769-5p miR-769-5p, 
miR-516-3p miR-520f,miR-516a-3p,miR-516b-3p, 
miR-659 miR-659-3p, 
miR-603 miR-548av-3p,miR-548t-3p,miR-548f,miR-548x-
3p,miR-548g-3p,miR-548ae,miR-548h-3p,miR-
548aq-3p,miR-548am-3p,miR-548aa,miR-548o-
3p,miR-548ah-3p,miR-548z,miR-548aj-3p,miR-
603,miR-548az-3p,miR-548u, 
miR-527 miR-520d-5p,miR-520c-5p,miR-519c-5p,miR-522-
5p,miR-526a,miR-519a-5p,miR-520a-5p,miR-
518d-5p,miR-518f-5p,miR-1283,miR-523-5p,miR-
525-5p,miR-527,miR-518a-5p,miR-524-5p,miR-
519b-5p,miR-518e-5p, 
miR-185 miR-4306,miR-185-5p, 
miR-423 miR-423-3p, 
miR-20b miR-93-5p,miR-20b-5p,miR-106b-5p,miR-20a-
5p,miR-106a-5p,miR-17-5p, 
miR-631 miR-631,miR-3913-3p, 
miR-331 miR-331-3p, 
miR-106a miR-20b-5p,miR-106b-5p,miR-20a-5p,miR-106a-
5p,miR-17-5p, 
miR-519a miR-520f,miR-519e-3p,miR-519a-3p,miR-526b-
3p,miR-520b,miR-519c-3p,miR-517b-3p,miR-
519b-3p,miR-517c-3p,miR-520c-3p,miR-517a-3p, 
miR-199a* miR-199b-3p,miR-199a-3p, 
miR-18a* miR-18a-3p,miR-18b-3p, 
miR-149 miR-149-5p, 
miR-516-5p miR-516a-5p,miR-516b-5p, 
miR-92b miR-25-3p,miR-92b-3p,miR-92a-3p, 
miR-130b miR-130a-3p,miR-130b-3p, 
miR-486 miR-486-5p, 
miR-542-5p miR-542-5p, 
miR-532 miR-532-5p, 
miR-663 miR-663a, 
miR-99b miR-99b-5p,miR-99a-5p,miR-100-5p, 
miR-519e miR-520f,miR-520e,miR-519e-3p,miR-520a-
3p,miR-519a-3p,miR-520g,miR-526b-3p,miR-515-
3p,miR-518e-3p,miR-520b,miR-519d,miR-522-
3p,miR-519c-3p,miR-517b-3p,miR-519b-3p,miR-
517c-3p,miR-520c-3p,miR-520h,miR-517a-3p, 
miR-550 miR-550b-3p,miR-550a-3p, 
miR-520a* miR-520d-5p,miR-520c-5p,miR-519c-5p,miR-522-
5p,miR-526a,miR-519a-5p,miR-520a-5p,miR-
518d-5p,miR-518f-5p,miR-526b-5p,miR-518c-
5p,miR-523-5p,miR-525-5p,miR-527,miR-518a-
5p,miR-524-5p,miR-519b-5p,miR-518e-5p, 
let-7e let-7a-5p,miR-98-5p,let-7c,let-7b-5p,let-7f-5p,miR-
6133,let-7e-5p,miR-4510,let-7d-5p,let-7g-5p, 
miR-499 miR-499b-5p,miR-499a-5p, 
miR-30a-5p miR-30e-5p,miR-30d-5p,miR-30a-5p, 
miR-520h miR-520f,miR-520e,miR-519e-3p,miR-520a-
3p,miR-519a-3p,miR-520g,miR-520d-3p,miR-523-
3p,miR-521,miR-525-3p,miR-526b-3p,miR-518e-
3p,miR-520b,miR-519d,miR-518c-3p,miR-522-
3p,miR-518b,miR-519c-3p,miR-517b-3p,miR-
519b-3p,miR-517c-3p,miR-520c-3p,miR-518f-
3p,miR-518d-3p,miR-520h,miR-524-3p,miR-517a-
3p, 
miR-758 miR-758-3p,miR-379-3p, 
miR-216 miR-216a-5p,miR-216b, 
miR-548a miR-548av-3p,miR-548t-3p,miR-548a-3p,miR-
548ac,miR-548ae,miR-548c-3p,miR-548h-3p,miR-
548aq-3p,miR-548am-3p,miR-548aa,miR-548ah-
3p,miR-548z,miR-548au-3p,miR-548aj-3p,miR-
548az-3p,miR-548u, 
miR-522 miR-520f,miR-519e-3p,miR-522-3p, 
miR-30e-5p miR-30e-5p,miR-30d-5p,miR-30a-5p, 
miR-10b miR-10b-5p,miR-10a-5p,miR-100-5p, 
let-7c let-7a-5p,miR-98-5p,let-7c,let-7i-5p,let-7b-5p,let-
7f-5p,miR-6130,let-7e-5p,miR-4510,let-7d-5p,let-
7g-5p, 
miR-431 miR-431-3p,miR-431-5p, 
miR-197 miR-197-3p, 
miR-520d miR-520f,miR-520d-3p, 
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miR-103 miR-103a-3p,miR-4289,miR-107, 
miR-202* miR-202-5p, 
miR-24 miR-24-3p, 
miR-518f miR-520f,miR-520e,miR-520g,miR-520d-3p,miR-
523-3p,miR-521,miR-525-3p,miR-526b-3p,miR-
518e-3p,miR-520b,miR-519d,miR-518c-3p,miR-
518b,miR-519c-3p,miR-519b-3p,miR-520c-
3p,miR-518f-3p,miR-518d-3p,miR-520h,miR-524-
3p, 
miR-100 miR-99b-5p,miR-10a-5p,miR-99a-5p,miR-100-5p, 
miR-660 miR-660-5p, 
miR-148a miR-148a-3p,miR-152,miR-148b-3p, 
miR-379 miR-379-5p, 
miR-367 miR-367-3p, 
miR-369-5p miR-369-5p, 
miR-7 miR-7-5p, 
miR-382 miR-382-5p,miR-323b-5p, 
miR-182 miR-182-5p,miR-183-5p, 
miR-30b miR-30b-5p,miR-30c-5p, 
miR-219 miR-219-5p, 
miR-345 miR-345-5p, 
miR-25 miR-25-3p,miR-92b-3p,miR-92a-3p, 
miR-424 miR-424-5p, 
miR-186 miR-186-5p, 
miR-506 miR-506-3p, 
miR-23a miR-23c,miR-23a-3p,miR-23b-3p, 
miR-302b miR-302b-3p,miR-302c-3p,miR-302d-3p,miR-
302a-3p, 
miR-181b miR-181b-5p,miR-181a-5p,miR-181d, 
miR-365 miR-365b-3p,miR-365a-3p, 
miR-449b miR-449a,miR-449c-5p,miR-449b-5p, 
miR-10a miR-10b-5p,miR-10a-5p,miR-99a-5p,miR-100-5p, 
miR-21 miR-21-5p, 
miR-199a miR-199b-5p,miR-199a-5p, 
miR-140 miR-140-5p, 
miR-302c miR-302b-3p,miR-302c-3p,miR-302d-3p,miR-
302a-3p, 
miR-655 miR-329,miR-655,miR-369-3p, 
miR-654 miR-654-5p, 
miR-485-5p miR-485-5p,miR-377-5p, 
miR-202 miR-202-3p, 
miR-548b miR-548t-3p,miR-548c-3p,miR-548h-3p,miR-548d-
3p,miR-548am-3p,miR-548b-3p,miR-548aa,miR-
548ah-3p,miR-548z, 
miR-501 miR-501-5p,miR-500a-5p, 
miR-606 miR-606, 
miR-146b miR-146a-5p,miR-146b-5p, 
miR-521 miR-523-3p,miR-521,miR-525-3p,miR-518e-
3p,miR-518c-3p,miR-518b,miR-517b-3p,miR-518f-
3p,miR-518d-3p,miR-524-3p,miR-517a-3p, 
miR-212 miR-212-3p,miR-132-3p, 
miR-30a-3p miR-30d-3p,miR-30e-3p,miR-30a-3p, 
miR-206 miR-206,miR-1, 
miR-329 miR-329,miR-655, 
miR-189 miR-24-2-5p,miR-24-1-5p, 
miR-196a miR-196b-5p,miR-196a-5p, 
miR-525* miR-520g,miR-523-3p,miR-521,miR-525-3p,miR-
526b-3p,miR-518e-3p,miR-520b,miR-519d,miR-
518c-3p,miR-518b,miR-520c-3p,miR-518f-3p,miR-
518d-3p,miR-520h,miR-524-3p, 
miR-107 miR-103a-3p,miR-4289,miR-107, 
miR-19a miR-19b-3p,miR-19a-3p, 
miR-128b miR-128, 
miR-411 miR-411-5p, 
miR-518a miR-520d-3p,miR-518a-3p,miR-518d-3p,miR-524-
3p, 
miR-15a miR-497-5p,miR-15a-5p,miR-15b-5p, 
miR-652 miR-652-3p, 
miR-323 miR-323b-3p,miR-323a-3p, 
miR-129 miR-129-5p, 
miR-193a miR-193a-3p,miR-193b-3p, 
miR-125a miR-125a-5p, 
miR-128a miR-128, 
miR-20a miR-93-5p,miR-20b-5p,miR-106b-5p,miR-20a-
5p,miR-106a-5p,miR-17-5p, 
miR-324-3p miR-18a-3p,miR-324-3p, 
miR-183 miR-182-5p,miR-183-5p, 
miR-1 miR-206,miR-1, 
miR-490 miR-490-3p, 
miR-376a miR-376b-3p,miR-376a-3p,miR-376c-3p, 
miR-455 miR-455-5p, 
miR-373 miR-520e,miR-373-3p,miR-302d-3p,miR-302a-3p, 
miR-200c miR-200a-3p,miR-141-3p,miR-200c-3p,miR-200b-
3p, 
miR-368 miR-376b-3p,miR-376a-3p,miR-376c-3p, 
miR-196b miR-196b-5p,miR-196a-5p, 
miR-126* miR-126-5p, 
miR-363 miR-363-3p, 
miR-337 miR-337-3p, 
miR-130a miR-130a-3p,miR-130b-3p, 
miR-145 miR-145-5p, 
miR-524* miR-520d-5p,miR-520c-5p,miR-519c-5p,miR-522-
5p,miR-526a,miR-519a-5p,miR-520a-5p,miR-515-
5p,miR-518d-5p,miR-518f-5p,miR-1283,miR-519e-
5p,miR-526b-5p,miR-523-5p,miR-525-5p,miR-
527,miR-518a-5p,miR-524-5p,miR-519b-5p,miR-
518e-5p, 
miR-148b miR-148a-3p,miR-152,miR-148b-3p, 
miR-767-5p miR-767-5p,miR-767-3p, 
miR-340 miR-340-3p, 
miR-373* miR-373-5p, 
miR-515-3p miR-519e-3p,miR-515-3p, 
miR-26b miR-26b-5p,miR-26a-5p, 
miR-106b miR-20b-5p,miR-106b-5p,miR-20a-5p,miR-106a-
5p,miR-17-5p, 
miR-518b miR-520f,miR-520e,miR-520g,miR-523-3p,miR-
521,miR-525-3p,miR-526b-3p,miR-518e-3p,miR-
520b,miR-519d,miR-518c-3p,miR-518b,miR-519b-
3p,miR-520c-3p,miR-518f-3p,miR-518d-3p,miR-
520h,miR-524-3p, 
miR-497 miR-497-5p,miR-15a-5p, 
let-7f let-7a-5p,miR-98-5p,let-7c,let-7i-5p,miR-1827,let-
7b-5p,let-7f-5p,miR-6130,let-7e-5p,miR-4510,let-
7d-5p,let-7g-5p, 
miR-369-3p miR-154-3p,miR-655,miR-369-3p, 
miR-524 miR-520a-3p,miR-523-3p,miR-521,miR-525-
3p,miR-518e-3p,miR-518c-3p,miR-518a-3p,miR-
518b,miR-518f-3p,miR-518d-3p,miR-524-3p, 
miR-509 miR-514a-3p,miR-509-3p, 
miR-
517a_miR-
517b 
miR-519e-3p,miR-519a-3p,miR-517b-3p,miR-
517c-3p,miR-517a-3p, 
miR-302d miR-302e,miR-302b-3p,miR-302c-3p,miR-
302f,miR-302d-3p,miR-302a-3p, 
miR-517c miR-520f,miR-519e-3p,miR-519a-3p,miR-526b-
3p,miR-520b,miR-519c-3p,miR-517b-3p,miR-
519b-3p,miR-517c-3p,miR-520c-3p,miR-517a-3p, 
miR-624 miR-624-5p, 
miR-218 miR-218-5p, 
miR-302b* miR-302d-5p,miR-302b-5p, 
miR-551b miR-551a,miR-551b-3p, 
miR-326 miR-1296, 
miR-362 miR-362-5p, 
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miR-15b miR-15a-5p,miR-15b-5p, 
miR-505 miR-214-5p,miR-505-3p, 
miR-154 miR-154-5p,miR-323b-5p, 
miR-662 miR-662,miR-1285-5p, 
miR-26a miR-26b-5p,miR-26a-5p, 
miR-122a miR-3591-5p,miR-122-5p, 
miR-495 miR-495-3p, 
miR-200a* miR-200a-5p, 
miR-29c miR-29b-3p,miR-29a-3p,miR-29c-3p, 
miR-132 miR-132-3p, 
miR-589 miR-589-3p, 
miR-215 miR-192-5p,miR-215, 
miR-154* miR-154-3p,miR-655,miR-369-3p, 
miR-512-5p miR-4287,miR-512-5p, 
miR-34a miR-34a-5p, 
miR-671 miR-671-5p, 
miR-584 miR-584-5p, 
miR-135a miR-135a-5p,miR-135b-5p, 
miR-29b miR-29b-3p,miR-29a-3p,miR-29c-3p, 
 
* miRNAs whose probes do not cross hybridize to other miRNAs have been removed from this list 
 
 
Appendix 3.7: Oscillating miRNAs in HeLa and MCF7 with upstream transcription 
factor binding sites for known cell cycle regulators  
 
(A) Phasic miRNAs 
 
miRNA Phasic 
HeLa 
Phasic 
MCF7 
Transcription 
Factor 
Cell 
Line 
Coordinates of TF 
binding 
Distance 
in kb* 
Score  H3K27ac H3K4me3 
hsa-let-7d-5p Y Y None       
hsa-mir-106b-3p Y Y HA-E2F1 HeLa chr7:99698107-
99698808 
6.5 1000 Y Y 
 MCF7 chr7:99698837-
99699404 
7.2 1000 Y Y 
CEBPB HeLa chr7:99699195-
99699466 
7.5 98 Y Y 
c-Myc MCF7 chr7:99698072-
99698341 
6.5 1000 Y Y 
 HeLa chr7:99698200-
99698533 
7 721 Y Y 
ELK4 HeLa chr7:99698207-
99698590 
6.6 711 Y Y 
E2F4 HeLa chr7:99698322-
99698661 
6.7 399 Y Y 
E2F6 HeLa chr7:99698363-
99698692 
6.7 508 Y Y 
E2F1 HeLa hr7:99698358-
99698633 
6.7 666 Y Y 
ELF1 MCF7 chr7:99697879-
99698803 
6.8 517 Y Y 
Ini1 HeLa chr7:99698933-
99699252 
7.3 806 Y Y 
USF2 HeLa chr7:99691270-
99691849 
0.1 534 Y Y 
chr7:99698962-
99699149 
7.3 1000 Y Y 
EGR1 MCF7 chr7:99697864-
99698720 
6.2 133 Y Y 
GATA3 MCF7 chr7:99697898-
99698749 
6.2 38 Y Y 
FOXM1 MCF7 chr7:99697898-
99698749 
6.2 65 Y Y 
JUND MCF7 chr7:99697893-
99699827 
6.2 111 Y Y 
MAX MCF7 chr7:99697805-
99699801 
6.3 958 Y Y 
SRF MCF7 chr7:99698005-
99699829 
6.5 79 Y Y 
Mxi1 HeLa chr7:99698205-
99698524 
6.6 469 Y Y 
HA-E2F1 MCF7 chr8:145634440-
145634623 
9 314 Y Y 
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hsa-mir-1234-5p Y Y  HeLa chr8:145634420-
145635112 
9 101 Y Y 
c-Myc MCF7 chr8:145634613-
145634882 
9.2 773 Y Y 
 HeLa chr8:145634462-
145635414 
9 110 Y Y 
NRF1 HeLa chr8:145634642-
145634891 
9.2 605 Y Y 
EGR1 MCF7 chr8:145634093-
145635025 
8.6 125 Y Y 
FOXM1 MCF7 chr8:145634462-
145635455 
9 39 Y Y 
JUND MCF7 chr8:145634185-
145635565 
8.8 57 Y Y 
MAX MCF7 chr8:145633899-
145635587 
8.5 357 Y Y 
 HeLa chr8:145634523-
145635011 
9.1 1000 Y Y 
SRF MCF7 chr8:145634405-
145635556 
9 36 Y Y 
ELK1 HeLa chr8:145634577-
145634982 
9.1 1000 Y Y 
INI1 HeLa chr8:145634416-
145635322 
9 242 Y Y 
GATA3 MCF7 chr8:145634302-
145635063 
8.9 45 Y Y 
E2F1 HeLa chr3:160118681-
160118956 
3.5 1000 Y Y 
hsa-mir-15b-3p Y Y HA-E2F1 HeLa chr3:160118655-
160118999 
3.5 581 Y Y 
 MCF7 chr3:160118655-
160118999 
3.5 563 Y Y 
CEBPB HeLa chr3:160118234-
160118489 
4.3 462 Y Y 
USF2 HeLa chr3:160119147-
160119350 
3.3 675 Y Y 
ELK1 HeLa chr3:160118704-
160118858 
3.7 483 Y Y 
E2F4 HeLa chr3:160116843-
160118337 
5.1 652 Y Y 
STAT1 HeLa chr3:160116725-
160117084 
5.2 356 Y Y 
GATA3 MCF7 chr3:160117179-
160117490 
5.1 528 Y Y 
MAX MCF7  chr3:160117156-
160118397 
5.3 38 Y Y 
NRF1 HeLa chr3:160117098-
160117519 
5.1 170 Y Y 
INI1 HeLa chr3:160116804-
160119025 
4.3 191 Y Y 
FOXM1 MCF7 chr3:160116778-
160117727 
4.3 37 Y Y 
Mxi1 HeLa chr3:160116855-
160117104 
4.2 413 Y Y 
SRF MCF7 chr3:160116769-
160117767 
4.3 31 Y Y 
ZNF143 HeLa chr3:160118184-
160118383 
4.2 1000 Y Y 
HA-E2F1 MCF7  chr22:20014263-
20014377 
6.4 461 Y N 
hsa-mir-185-5p Y Y STAT1 HeLa chr5:85913437-
85913814 
2.8 176 Y Y 
hsa-mir-3607-5p Y Y ELK4 HeLa chr5:85913453-
85913816 
2.8 414 Y Y 
HA-E2F1 MCF7 chr5:85913599-
85914048 
2.7 165 Y Y 
SRF MCF7 chr5:85913370-
85914409 
2.8 52 Y Y 
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ELK1 HeLa chr5:85913259-
85914252 
2.9 400 Y Y 
MAZ HeLa chr5:85913513-
85914365 
2.7 518 Y Y 
USF2 HeLa chr5:85913526-
85914008 
2.7 592 Y Y 
ZNF143 HeLa chr5:85913426-
85914130 
2.8 1000 Y Y 
GATA3 MCF7 chr5:85913055-
85914565 
3.2 498 Y Y 
c-Myc MCF7 chr5:85913702-
85914273 
2.5 1000 Y Y 
NR2F2 MCF7 chr5:85913539-
85914657 
2.8 89 Y Y 
ELF1 MCF7 chr5:85913352-
85914465 
2.8 691 Y Y 
ELK1 HeLa chr18:33161918-
33162077 
9.7 392 Y Y 
MAX HeLa chr18:33161918-
33162336 
9.7 501 Y Y 
hsa-mir-3975-3p Y Y c-Myc MCF7 chr18:33161972-
33162276 
9.7 706 Y Y 
CEBPB MCF7 chrX:73439724-
73440008 
1.6 371 Y N 
c-Myc MCF7 chr17:27188732-
27188736 
0.4 572 Y N 
hsa-mir-421-3p Y Y CEBPB  
 
MCF7 chrX:73439724 
-73440008 
1.6  371 Y N 
hsa-mir-451a-5p Y Y c-Myc MCF7 chr17:2718873 
2-27188736 
0.4 572 Y N 
 
(B) Non-Phasic miRNAs 
 
 
Non-phasic 
miRNAs 
Phasic 
HeLa 
Phasic 
MCF7 
Transcription 
Factor 
Cell 
Line 
Coordinates of 
TF binding 
Distance 
in kb 
Score H3K27ac H3K4me3 
hsa-mir-378a-3p N N c-Myc MCF7 chr5:149109767-
149109976 
2.6 378 Y Y 
 HeLa chr5:149109681-
149111585 
2.7 103 Y Y 
HA-E2F1 MCF7 chr5:149111386-
149112048 
1 389 Y Y 
 HeLa chr5:149110106-
149110555 
2.2 326 Y Y 
EGR1 MCF7 chr5:149109402-
149109963 
2.9 38 Y Y 
MAX MCF7 chr5:149109384-
149111983 
2.9 955 Y Y 
AP-2g HeLa chr5:149109618-
149110786 
2.7 103 Y Y 
ELK1 HeLa chr5:149110817-
149110865 
1.5 399 Y Y 
INI1 HeLa chr5:149109484-
149111954 
2.8 298 Y Y 
MAZ HeLa chr5:149109596-
149111360 
2.7 1000 Y Y 
USF2 HeLa chr5:149111201-
149111334 
1.2 410 Y Y 
ZNF143 HeLa chr5:149110545-
149110697 
1.8 390 Y Y 
hsa-mir-34a-5p N N None       
hsa-mir-186-5p N N None       
hsa-mir-484-5p N N PRDM1 HeLa chr16:15736345-
15736588 
0.8 116 Y Y 
STAT1 HeLa chr16:15736387-
15736746 
0.85 102 Y Y 
SMC3 HeLa chr16:15736485- 0.95 370 Y Y 
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15736762 
MAX MCF7 chr16:15736341-
15737714 
0.8 88 Y Y 
 HeLa chr16:15736276-
15737753 
0.75 1000 Y Y 
ELK1 HeLa chr16:15736380-
15737532 
0.85 570 Y Y 
MAZ HeLa chr16:15736308-
15737712 
0.75 1000 Y Y 
p300 HeLa chr16:15735947-
15736548 
1.1 384 Y Y 
USF2 HeLa chr16:15736281-
15736573 
0.75 395 Y Y 
ZNF143 HeLa chr16:15736459-
15737681 
0.95 1000 Y Y 
c-Myc MCF7 chr16:15736729-
15737158 
0.7 757 Y Y 
hsa-mir-505-3p N N HA-E2F1 HeLa chrX:139014150-
139014433 
7.8 252 Y Y 
MAX HeLa chrX:139013617-
139016005 
7.2 1000 Y Y 
 MCF7 chrX:139015632-
139016018 
9.2 33 Y Y 
ELK1 HeLa chrX:139014987-
139015808 
8.6 478 Y Y 
INI1 HeLa chrX:139013902-
139016316 
7.6 160 Y Y 
MAZ HeLa chrX:139014122-
139016025 
7.8 1000 Y Y 
ZNF143 HeLa chrX:139014055-
139014468 
7.7 435 Y Y 
c-Myc MCF7 chrX:139013493-
139013573 
7.1 583 Y Y 
 HeLa chrX:139015332-
139015677 
7.15 812 Y Y 
hsa-mir-222-3p N N SMC3 HeLa  chrX:45608826-
45609065 
4.4 659 Y N 
hsa-mir-18b-5p N N c-Myc MCF7 chrX:133306417-
133306486 
2.4 597 N Y 
hsa-mir-100-5p N N None       
hsa-mir-30d-5p N N STAT1 HeLa chr8:135822525-
135823208 
5.9 116 Y Y 
 
* Distance from miRNAs in Kilobases 
 
 
 
Appendix 3.8: List of molecular and cellular functions associated with TargetScan 
predicted targets of miR-3607-5p 
 
Category  p-value Molecules 
Tissue 
Morphology 
5.1E-07-
1.3E-02 
ABCD1,GLDN,VTI1A,FGF2,PIK3R1,BMP2,SSBP2,DICER1,MYH11,ATP2A2,MMP24,COL5A1,HMGB1,FOXO
3,MARCKS,SIGLEC1,TCF7L1,GDF11,APC,GNAI2,CCM2,GNAI3,GINS1,FOXO1,NDEL1,BMF,RASSF2,SNX1,
ARHGAP35,CAPRIN1,KDR,NDST1 
Cellular 
Development 
3E-05-
1.15E-02 
EPS8,FGF2,PIK3R1,TXLNA,BMP2,SSBP2,DICER1,MYH11,HSPA5,ATP2A2,TRPC3,SEMA3D,HMGB1,IKZF2,
FOXO3,ULK2,MAP3K2,SIGLEC1,CNOT6L,TCF7L1,TUSC3,PDE4D,NFE2L1,GDF11,APC,CCM2,GNAI2,EMP1
,COL1A1,FABP2,NDEL1,FOXO1,RASSF2,MBNL1,CAPRIN1,NUP98,KDR,NDST1,FZD7 
Cellular 
Growth and 
Proliferation 
3E-05-
1.15E-02 
FGF2,BMP2,PIK3R1,TXLNA,MYH11,DICER1,HSPA5,TRPC3,ATP2A2,IKZF2,HMGB1,FOXO3,MAP3K2,SIGL
EC1,SERTAD2,CNOT6L,TUSC3,PDE4D,GDF11,APC,GNAI2,EMP1,COL1A1,FOXO1,RSU1,CAPRIN1,SETBP1
,KDR,NUP98 
DNA 
Replication, 
Recombinati
on, and 
Repair 
3.45E-05-
1.29E-02 
ABCD1,GNAI2,GNAI3,HMGB1,RAB2A,HSPA5,PDE4D 
Cellular 3.55E-05- SLAIN2,EPS8,RAB2A,FGF2,TRIM9,BMP2,PIK3R1,MARK1,DICER1,MYH11,HSPA5,ATP2A2,COL5A1,HMG
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Function and 
Maintenance 
1.23E-02 B1,SEMA3D,FOXO3,MARCKS,NAPB,ULK2,SIGLEC1,SERTAD2,APC,GDF11,GNAI2,COL1A1,GNAI3,FOXO
1,NDEL1,BMF,SNX1,ARHGAP35,RSU1,KDR,FZD7 
Embryonic 
Development 
3.99E-05-
1.23E-02 
EPS8,FGF2,PIK3R1,BMP2,DICER1,MYH11,HSPA5,ATP2A2,COL5A1,SEMA3D,IKZF2,HMGB1,FOXO3,MAR
CKS,ULK2,TCF7L1,GDF11,ARL3,APC,EMP1,CCM2,GNAI3,COL1A1,FABP2,TENC1,GINS1,FOXO1,NDEL1,
RASSF2,SNX1,ARHGAP35,MBNL1,KDR,NDST1,FZD7 
Cellular 
Compromise 
4.19E-05-
6.5E-03 
FOXO1,FGF2,BMP2,FOXO3,DICER1,HSPA5,ATP2A2 
Tissue 
Development 
8.01E-05-
1.2E-02 
EPS8,FGF2,PIK3R1,BMP2,MYH11,DICER1,HSPA5,SDK1,ATP2A2,COL5A1,HMGB1,SEMA3D,FOXO3,MARC
KS,ULK2,TCF7L1,ARL3,GDF11,APC,GNAI2,CCM2,EMP1,GNAI3,COL1A1,FABP2,TENC1,GINS1,FOXO1,ND
EL1,RASSF2,ARHGAP35,MBNL1,KDR,NDST1 
Cell Cycle 8.47E-05-
1.17E-02 
EPS8,FGF2,BMP2,PIK3R1,SSBP2,ZNF655,DICER1,HMGB1,FOXO3,MARCKS,TFDP2,PFDN4,RAB11FIP3,MA
PK6,APC,ARL3,GDF11,GNAI2,EMP1,GNAI3,COL1A1,FOXO1,RASSF2,RSU1,KDR 
Cancer 9.3E-05-
1.23E-02 
EPS8,VTI1A,TRIM9,PIK3R1,SLC9A9,MYH15,MARK1,SSBP2,TMEM169,DICER1,HSPA5,ATP2A2,TOMM70A
,MMP24,HMGB1,IKZF2,ETF1,TFDP2,ANKFN1,NOVA1,FAM26E,ZC3H6,DNALI1,TUSC3,WWC3,APC,GDF11
,GINS1,SNX1,ARHGAP35,RSU1,CAPRIN1,AK2,NUP98,SETBP1,DPP10,IQSEC1,RREB1,FGF2,ARL4C,BMP2,
TXLNA,DGKB,ZNF655,MYH11,SDK1,KCNT2,FOXO3,DIP2B,ABHD2,CD109,MARCKS,BTBD3,WDR1,KPNA
3,SIGLEC1,MCMBP,SERTAD2,MAPK6,SLCO2A1,TCF7L1,PDE4D,INO80D,NFE2L1,GNAI2,CCM2,EMP1,CO
L1A1,TENC1,FOXO1,BMF,FAM13A,MBNL1,KDR,A1CF,FZD7 
Cellular 
Movement 
1.1E-04-
1.17E-02 
EPS8,FGF2,PIK3R1,BMP2,MARK1,DICER1,MYH11,HSPA5,HMGB1,FOXO3,ABHD2,MARCKS,RAB11FIP3,
MAP3K2,PDE4D,TUSC3,ARL3,APC,GNAI2,GNAI3,COL1A1,TENC1,FOXO1,NDEL1,ARHGAP35,KDR,NDST
1 
Cell 
Morphology 
1.12E-04-
1.23E-02 
SLAIN2,EPS8,FGF2,PIK3R1,BMP2,DICER1,HSPA5,TRPC3,COL5A1,HMGB1,SEMA3D,FOXO3,ULK2,GDF11,
APC,COL1A1,GNAI3,PHLPP2,FABP2,NDEL1,FOXO1,ARHGAP35,RSU1,KDR,NDST1 
Hematologic
al System 
Development 
and Function 
1.7E-04-
1.17E-02 
SIGLEC1,FGF2,PIK3R1,BMP2,SSBP2,DICER1,MYH11,PDE4D,ATP2A2,APC,NFE2L1,GNAI2,COL1A1,GNAI3
,HMGB1,FOXO1,IKZF2,RASSF2,BMF,FOXO3,KDR,NUP98,MAP3K2,FZD7 
Hematopoies
is 
1.7E-04-
8.49E-03 
FGF2,BMP2,PIK3R1,SSBP2,DICER1,MYH11,NFE2L1,GNAI2,FOXO1,BMF,RASSF2,FOXO3,NUP98,KDR 
Tumor 
Morphology 
2.49E-04-
6.5E-03 
FGF2,TXLNA,BMP2,DICER1,PDE4D,HSPA5,TUSC3,ATP2A2,APC,COL1A1,FOXO1,HMGB1,FOXO3,KDR 
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